By Xx NE
contrast xxx NE
, , NE
the xxx NE
MAP XXX protein_B
kinases xxx protein_E
ERK1 XXXd protein
and xxx NE
ERK2 XXXd protein
were xxx NE
fully xxx NE
activated xxx NE
by xx NE
TPA XXX NE
or xx NE
TCR XXX protein
stimulation xxx NE
and xxx NE
were xxx NE
not xxx NE
affected xxx NE
by xx NE
Ca2+ Xxd+ NE
, , NE
CD28 XXdd NE
, , NE
or xx NE
CsA XxX NE
. . NE

Hence Xxxx NE
, , NE
integration xxx NE
of xx NE
signals xxx NE
that xxx NE
lead xxx NE
to xx NE
T X NE
cell xxx NE
activation xxx NE
occurs xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
JNK XXX protein
activation xxx NE
. . NE

Inhibition Xxxx NE
of xx NE
rat xxx NE
splenocyte xxx NE
proliferation xxx NE
with xxx NE
methylprednisolone xxx NE
: : NE
in xx NE
vivo xxx NE
effect xxx NE
of xx NE
liposomal xxx NE
formulation xxx NE
. . NE

The Xxx NE
effect xxx NE
of xx NE
a x NE
liposomal xxx NE
formulation xxx NE
of xx NE
methylprednisolone xxx NE
( ( NE
MPL XXX NE
) ) NE
on xx NE
the xxx NE
inhibition xxx NE
of xx NE
lymphocyte xxx NE
proliferation xxx NE
in xx NE
spleen xxx cell_type_B
cells xxx cell_type_E
was xxx NE
investigated xxx NE
following xxx NE
IV XX NE
dosing xxx NE
in xx NE
rats xxx NE
. . NE

Liposomes Xxxx NE
do xx NE
not xxx NE
alter xxx NE
the xxx NE
suppressive xxx NE
action xxx NE
of xx NE
MPL XXX NE
when xxx NE
placed xxx NE
in xx NE
lymphocyte xxx cell_line_B
culture xxx cell_line_E
. . NE

Rat Xxx cell_type_B
splenocytes xxx cell_type_E
were xxx NE
found xxx NE
to xx NE
have xxx NE
greater xxx NE
sensitivity xxx NE
to xx NE
MPL XXX NE
(EC50 (XXdd NE
= = NE
7.9 d.d NE
nM) xX) NE
than xxx NE
do xx NE
human xxx cell_type_B
peripheral xxx cell_type_M
blood xxx cell_type_M
lymphocytes xxx cell_type_E
(EC50 (XXdd NE
= = NE
28 dd NE
nM) xX) NE
. . NE

In Xx NE
vivo xxx NE
studies xxx NE
in xx NE
rats xxx NE
utilized xxx NE
2 d NE
mg/kg xx/xx NE
IV XX NE
bolus xxx NE
doses xxx NE
of xx NE
liposomal xxx NE
MPL XXX NE
compared xxx NE
to xx NE
drug xxx NE
in xx NE
solution xxx NE
. . NE

Animals Xxxx NE
were xxx NE
sacrificed xxx NE
at xx NE
various xxx NE
times xxx NE
post-dosing xxx-xxx NE
until xxx NE
120 ddd NE
h x NE
, , NE
spleen xxx NE
was xxx NE
excised xxx NE
and xxx NE
, , NE
after xxx NE
incubation xxx NE
of xx NE
lymphocytes xxx cell_type
with xxx NE
PHA XXX protein
, , NE
splenocyte xxx NE
blastogenic xxx NE
responses xxx NE
were xxx NE
assessed xxx NE
by xx NE
measuring xxx NE
cellular xxx NE
incorporation xxx NE
of xx NE
3H-thymidine dX-xxx NE
. . NE

The Xxx NE
suppressive xxx NE
effect xxx NE
of xx NE
liposomal xxx NE
MPL XXX NE
in xx NE
comparison xxx NE
with xxx NE
free xxx NE
drug xxx NE
was xxx NE
significantly xxx NE
prolonged xxx NE
(> (> NE
120 ddd NE
h x NE
vs xx NE
< < NE
18 dd NE
h) x) NE
. . NE

Inhibition Xxxx NE
effects xxx NE
versus xxx NE
time xxx NE
were xxx NE
described xxx NE
by xx NE
a x NE
pharmacodynamic xxx NE
model xxx NE
using xxx NE
MPL XXX NE
concentrations xxx NE
in xx NE
plasma xxx cell_type
as xx NE
an xx NE
input xxx NE
function xxx NE
. . NE

A X NE
nonlinear xxx NE
relationship xxx NE
was xxx NE
found xxx NE
between xxx NE
suppression xxx NE
of xx NE
splenocyte xxx NE
proliferation xxx NE
and xxx NE
the xxx NE
concentration xxx NE
of xx NE
bound xxx NE
glucocorticoid xxx protein_B
receptors xxx protein_E
in xx NE
spleen xxx NE
. . NE

Only Xxxx NE
partial xxx NE
receptor xxx NE
occupancy xxx NE
accompanied xxx NE
complete xxx NE
lymphocyte xxx NE
suppression xxx NE
. . NE

The Xxx NE
suppression xxx NE
of xx NE
endogenous xxx NE
corticosterone xxx NE
in xx NE
plasma xxx cell_type
for xxx NE
both xxx NE
treatments xxx NE
was xxx NE
similar xxx NE
with xxx NE
values xxx NE
from xxx NE
L- X- NE
MPL XXX NE
rats xxx NE
returning xxx NE
to xx NE
baseline xxx NE
after xxx NE
24 dd NE
h x NE
. . NE

These Xxxx NE
results xxx NE
demonstrate xxx NE
enhanced xxx NE
efficacy xxx NE
of xx NE
local xxx NE
immunosuppression xxx NE
by xx NE
targeting xxx NE
spleen xxx NE
with xxx NE
liposomal xxx NE
MPL XXX NE
. . NE

Function Xxxx NE
of xx NE
NF-kappa XX-xxx DNA_B
B X DNA_M
/Rel /Xxx DNA_M
binding xxx DNA_M
sites xxx DNA_E
in xx NE
the xxx NE
major xxx DNA_B
histocompatibility xxx DNA_M
complex xxx DNA_M
class xxx DNA_M
II XX DNA_M
invariant xxx DNA_M
chain xxx DNA_M
promoter xxx DNA_E
is xx NE
dependent xxx NE
on xx NE
cell-specific xxx-xxx NE
binding xxx NE
of xx NE
different xxx NE
NF-kappa XX-xxx protein_B
B X protein_M
/Rel /Xxx protein_M
subunits xxx protein_E
. . NE

The Xxx NE
promoter xxx DNA
of xx NE
the xxx NE
human xxx NE
major xxx NE
histocompatibility xxx DNA_B
complex xxx DNA_M
class xxx DNA_M
II-associated XX-xxx DNA_M
invariant-chain xxx-xxx DNA_M
gene xxx DNA_E
( ( NE
Ii Xx DNA
) ) NE
contains xxx NE
two xxx NE
NF-kappa XX-xxx DNA_B
B X DNA_M
/Rel /Xxx DNA_M
binding xxx DNA_M
sites xxx DNA_E
located xxx NE
at xx NE
-109 -ddd DNA_B
to xx DNA_M
-118 -ddd DNA_E
( ( NE
Ii Xx DNA_B
kappa xxx DNA_M
B-1 X-d DNA_E
) ) NE
and xxx NE
-163 -ddd DNA_B
to xx DNA_M
-172 -ddd DNA_E
( ( NE
Ii Xx DNA_B
kappa xxx DNA_M
B-2 X-d DNA_E
) ) NE
from xxx NE
the xxx NE
transcription xxx NE
start xxx NE
site xxx NE
. . NE

We Xx NE
report xxx NE
here xxx NE
that xxx NE
the xxx NE
differential xxx NE
function xxx NE
of xx NE
each xxx NE
of xx NE
these xxx NE
NF-kappa XX-xxx DNA_B
B X DNA_M
/Rel /Xxx DNA_M
sites xxx DNA_E
in xx NE
several xxx NE
distinct xxx NE
cell xxx NE
types xxx NE
depends xxx NE
on xx NE
cell-specific xxx-xxx NE
binding xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_M
/Rel /Xxx protein_M
transcription xxx protein_M
factors xxx protein_E
. . NE

Ii Xx DNA_B
kappa xxx DNA_M
B-1 X-d DNA_E
is xx NE
a x NE
positive xxx DNA_B
regulatory xxx DNA_M
element xxx DNA_E
in xx NE
B-cell X-xxx cell_line_B
lines xxx cell_line_E
and xxx NE
in xx NE
the xxx NE
Ii-expressing Xx-xxx cell_line_B
T-cell X-xxx cell_line_M
line xxx cell_line_E
, , NE
H9 Xd cell_line
, , NE
but xxx NE
acts xxx NE
as xx NE
a x NE
negative xxx DNA_B
regulatory xxx DNA_M
element xxx DNA_E
in xx NE
myelomonocytic xxx cell_line_B
cell xxx cell_line_M
line xxx cell_line_M
and xxx cell_line_M
glia xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_E

In Xx NE
vivo xxx NE
protein-DNA xxx-XXX NE
contacts xxx NE
are xxx NE
detectable xxx NE
at xx NE
Ii Xx DNA_B
kappa xxx DNA_M
B-1 X-d DNA_E
in xx NE
cell xxx cell_line_B
lines xxx cell_line_E
in xx NE
which xxx NE
this xxx NE
site xxx NE
is xx NE
functional xxx NE
as xx NE
either xxx NE
a x NE
positive xxx DNA_B
regulator xxx DNA_M
or xx DNA_M
negative xxx DNA_M
regulator xxx DNA_E

Electrophoretic Xxxx NE
mobility xxx NE
supershift xxx NE
assays xxx NE
determine xxx NE
that xxx NE
members xxx NE
of xx NE
the xxx NE
NF-kappa XX-xxx protein_B
B X protein_M
/Rel /Xxx protein_M
family xxx protein_E
of xx NE
transcription xxx protein_B
factors xxx protein_E
can xxx NE
bind xxx NE
to xx NE
this xxx NE
site xxx NE
in xx NE
vitro xxx NE
and xxx NE
that xxx NE
DNA-binding XXX-xxx NE
complexes xxx NE
that xxx NE
contain xxx NE
p50 xdd NE
, , NE
p52 xdd NE
, , NE
p65 xdd NE
, , NE
and xxx NE
cRel xXxx NE
correlate xxx NE
with xxx NE
positive xxx NE
regulation xxx NE
whereas xxx NE
the xxx NE
presence xxx NE
of xx NE
p50 xdd NE
correlates xxx NE
with xxx NE
negative xxx NE
regulation xxx NE
. . NE

Ii Xx DNA_B
kappa xxx DNA_M
B-2 X-d DNA_E
is xx NE
a x NE
site xxx NE
of xx NE
positive xxx NE
regulation xxx NE
in xx NE
B-cell X-xxx cell_line_B
lines xxx cell_line_E
and xxx NE
a x NE
site xxx NE
of xx NE
negative xxx NE
regulation xxx NE
in xx NE
H9 Xd cell_line_B
T X cell_line_M
cells xxx cell_line_E
, , NE
myelomonocytic xxx cell_line_B
cell xxx cell_line_M
line xxx cell_line_M
and xxx cell_line_M
glial xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_E

In Xx NE
vivo xxx NE
occupancy xxx NE
of xx NE
this xxx NE
site xxx NE
is xx NE
observed xxx NE
only xxx NE
in xx NE
the xxx NE
H9 Xd cell_line_B
T-cell X-xxx cell_line_M
line xxx cell_line_E
. . NE

Again Xxxx NE
, , NE
in xx NE
vitro xxx NE
supershift xxx NE
studies xxx NE
indicate xxx NE
that xxx NE
the xxx NE
presence xxx NE
of xx NE
p50 xdd protein
, , NE
p52 xdd protein
, , NE
p65 xdd protein
, , NE
and xxx NE
cRel xXxx protein
correlates xxx NE
with xxx NE
positive xxx NE
function xxx NE
whereas xxx NE
the xxx NE
presence xxx NE
of xx NE
only xxx NE
p50 xdd protein
and xxx NE
p52 xdd protein
correlates xxx NE
with xxx NE
negative xxx NE
function xxx NE
. . NE

This Xxxx NE
differential xxx NE
binding xxx NE
of xx NE
specific xxx NE
NF-kappa XX-xxx protein_B
B X protein_M
/Rel /Xxx protein_M
subunits xxx protein_E
is xx NE
likely xxx NE
to xx NE
mediate xxx NE
the xxx NE
disparate xxx NE
functions xxx NE
of xx NE
these xxx NE
two xxx NE
NF-kappa XX-xxx DNA_B
B X DNA_M
/Rel /Xxx DNA_M
binding xxx DNA_M
sites xxx DNA_E
. . NE

Epstein-Barr Xxxx-Xxxx NE
virus xxx NE
( ( NE
EBV XXX NE
) ) NE
replicative xxx NE
gene xxx NE
expression xxx NE
in xx NE
tumour xxx NE
cells xxx NE
of xx NE
AIDS-related XXXX-xxx NE
non-Hodgkin's xxx-Xxxx'x NE
lymphoma xxx NE
in xx NE
relation xxx NE
to xx NE
CD4 XXd NE
cell xxx NE
number xxx NE
and xxx NE
antibody xxx NE
titres xxx NE
to xx NE
EBV XXX NE
. . NE

OBJECTIVE XXXXXXXXX NE
: : NE
To Xx NE
determine xxx NE
whether xxx NE
activation xxx NE
of xx NE
Epstein-Barr Xxxx-Xxxx NE
virus xxx NE
( ( NE
EBV XXX NE
) ) NE
replication xxx NE
in xx NE
tumour xxx NE
cells xxx NE
of xx NE
AIDS-related XXXX-xxx NE
non-Hodgkin's xxx-Xxxx'x NE
lymphoma xxx NE
( ( NE
ARNHL XXXXX NE
) ) NE
is xx NE
correlated xxx NE
with xxx NE
CD4+ XXd+ NE
cell xxx NE
counts xxx NE
and xxx NE
influences xxx NE
antibody xxx NE
response xxx NE
to xx NE
EBV XXX NE
[ [ NE
anti-Z xxx-X NE
Epstein-Barr Xxxx-Xxxx NE
replicative xxx NE
activator xxx NE
( ( NE
ZEBRA XXXXX NE
) ) NE
, , NE
anti-early xxx-xxx NE
antigen xxx NE
( ( NE
EA XX NE
) ) NE
, , NE
anti-viral xxx-xxx NE
capsid xxx NE
antigen xxx NE
( ( NE
VCA XXX NE
)] )] NE
. . NE

DESIGN XXXXXX NE
: : NE
Retrospective Xxxx NE
study xxx NE
based xxx NE
on xx NE
immunohistochemistry xxx NE
and xxx NE
in xx NE
situ xxx NE
hybridization xxx NE
to xx NE
detect xxx NE
EBV XXX NE
replicative xxx NE
gene xxx NE
products xxx NE
in xx NE
tissue xxx NE
samples xxx NE
from xxx NE
patients xxx NE
affected xxx NE
by xx NE
ARNHL XXXXX NE
and xxx NE
correlation xxx NE
with xxx NE
CD4+ XXd+ NE
cell xxx NE
counts xxx NE
and xxx NE
results xxx NE
of xx NE
EBV XXX NE
serology xxx NE
(including (xxx NE
anti- xxx- NE
ZEBRA XXXXX NE
activity xxx NE
) ) NE
in xx NE
sera xxx NE
from xxx NE
the xxx NE
same xxx NE
patients xxx NE
. . NE

METHODS XXXXXXX NE
: : NE
Seventeen Xxxx NE
out xxx NE
of xx NE
22 dd NE
cases xxx NE
of xx NE
ARNHL XXXXX NE
were xxx NE
selected xxx NE
for xxx NE
the xxx NE
presence xxx NE
of xx NE
EBV XXX NE
[ [ NE
Epstein-Barr Xxxx-Xxxx NE
early xxx NE
region xxx NE
(EBER) (XXXX) NE
RNA-positive XXX-xxx NE
] ] NE
. . NE

Immunohistochemistry Xxxx NE
was xxx NE
performed xxx NE
with xxx NE
anti- xxx- NE
ZEBRA XXXXX NE
, , NE
anti- xxx- NE
EA XX NE
-restricted -xxx NE
, , NE
anti- xxx- NE
VCA XXX NE
antibodies xxx NE
and xxx NE
in xx NE
situ xxx NE
hybridization xxx NE
with xxx NE
BHLF1/NotI XXXXd/XxxX NE
oligoprobes xxx NE
on xx NE
tumour xxx NE
samples xxx NE
. . NE

Results Xxxx NE
were xxx NE
statistically xxx NE
correlated xxx NE
with xxx NE
those xxx NE
of xx NE
CD4+ XXd+ NE
cell xxx NE
counts xxx NE
(17 (dd NE
out xxx NE
of xx NE
17) dd) NE
and xxx NE
with xxx NE
anti- xxx- NE
EBV XXX NE
antibody xxx NE
titres xxx NE
(13 (dd NE
out xxx NE
of xx NE
17) dd) NE
assessed xxx NE
using xxx NE
standard xxx NE
immunofluorescence xxx NE
method xxx NE
and xxx NE
enzyme-linked xxx-xxx NE
immunosorbent xxx NE
assay xxx NE
procedure xxx NE
using xxx NE
recombinant xxx protein_B
ZEBRA XXXXX protein_M
protein xxx protein_E
and xxx NE
synthetic xxx NE
peptides xxx NE
as xx NE
antigens xxx protein
. . NE

RESULTS XXXXXXX NE
: : NE
BZLF1 XXXXd protein
( ( NE
ZEBRA XXXXX protein
) ) NE
or xx NE
early xxx protein_B
gene xxx protein_M
products xxx protein_E
( ( NE
EA-R XX-X protein
and xxx NE
EA-D/BHLF1/NotI XX-X/XXXXd/XxxX protein
) ) NE
were xxx NE
detected xxx NE
in xx NE
a x NE
small xxx NE
proportion xxx NE
(< (< NE
0.01-5%) d.dd-d%) NE
of xx NE
tumour xxx cell_type_B
cells xxx cell_type_E
in xx NE
eight xxx NE
of xx NE
these xxx NE
17 dd NE
cases xxx NE
by xx NE
immunohistochemistry xxx NE
and xxx NE
in xx NE
situ xxx NE
hybridization xxx NE
. . NE

Demonstration Xxxx NE
of xx NE
replicative xxx NE
gene xxx NE
expression xxx NE
did xxx NE
not xxx NE
correlate xxx NE
with xxx NE
either xxx NE
low xxx NE
CD4+ XXd+ NE
cell xxx NE
counts xxx NE
(P (X NE
> > NE
0.05) d.dd) NE
or xx NE
anti- xxx- NE
EBV XXX NE
antibody xxx NE
titres xxx NE
(P (X NE
> > NE
0.05) d.dd) NE
. . NE

Anti- Xxxx- NE
ZEBRA XXXXX NE
activity xxx NE
was xxx NE
not xxx NE
significantly xxx NE
increased xxx NE
in xx NE
patients xxx NE
affected xxx NE
with xxx NE
ARNHL XXXXX NE
, , NE
the xxx NE
cells xxx NE
of xx NE
which xxx NE
expressed xxx NE
replicative xxx NE
gene xxx NE
products xxx NE
(P (X NE
> > NE
0.05) d.dd) NE
. . NE

CONCLUSION XXXXXXXXXX NE
: : NE
The Xxx NE
degree xxx NE
of xx NE
immunodeficiency xxx NE
does xxx NE
not xxx NE
clearly xxx NE
enhance xxx NE
replicative xxx NE
gene xxx NE
expression xxx NE
in xx NE
tumour xxx cell_type_B
cells xxx cell_type_E
of xx NE
ARNHL XXXXX NE
. . NE

EBV XXX NE
serology xxx NE
, , NE
including xxx NE
anti- xxx- NE
ZEBRA XXXXX NE
activity xxx NE
, , NE
is xx NE
not xxx NE
a x NE
reliable xxx NE
tool xxx NE
for xxx NE
predicting xxx NE
the xxx NE
occurrence xxx NE
of xx NE
such xxx NE
proliferations xxx NE
. . NE

Effects Xxxx NE
of xx NE
prostaglandin xxx protein_B
E2 Xd protein_E
on xx NE
Th0-type Xxd-xxx cell_line_B
human xxx cell_line_M
T X cell_line_M
cell xxx cell_line_M
clones xxx cell_line_E
: : NE
modulation xxx NE
of xx NE
functions xxx NE
of xx NE
nuclear xxx protein_B
proteins xxx protein_E
involved xxx NE
in xx NE
cytokine xxx NE
production xxx NE
. . NE

The Xxx NE
effects xxx NE
of xx NE
prostaglandin xxx protein_B
E2 Xd protein_E
( ( NE
PGE2 XXXd protein
) ) NE
on xx NE
cytokine xxx NE
production xxx NE
and xxx NE
proliferation xxx NE
of xx NE
the xxx NE
CD4+ XXd+ cell_line_B
human xxx cell_line_M
helper xxx cell_line_M
T X cell_line_M
cell xxx cell_line_M
clone xxx cell_line_M
SP-B21 XX-Xdd cell_line_E
were xxx NE
investigated xxx NE
. . NE

In Xx NE
cells xxx NE
stimulated xxx NE
with xxx NE
anti-CD3 xxx-XXd protein_B
mAb xXx protein_E
, , NE
PGE2 XXXd protein
inhibited xxx NE
cell xxx NE
proliferation xxx NE
and xxx NE
the xxx NE
production xxx NE
of xx NE
all xxx NE
the xxx NE
cytokines xxx protein
examined xxx NE
. . NE

Addition Xxxx NE
of xx NE
rIL-2 xXX-d protein
fully xxx NE
restored xxx NE
the xxx NE
proliferative xxx NE
response xxx NE
and xxx NE
partially xxx NE
restored xxx NE
the xxx NE
production xxx NE
of xx NE
IL-4 XX-d protein
and xxx NE
IL-5 XX-d protein
, , NE
but xxx NE
not xxx NE
that xxx NE
of xx NE
other xxx NE
cytokines xxx protein
. . NE

In Xx NE
contrast xxx NE
, , NE
in xx NE
cells xxx NE
stimulated xxx NE
with xxx NE
phorbol xxx NE
myristate xxx NE
acetate xxx NE
( ( NE
PMA XXX NE
) ) NE
/ / NE
A23187 Xddddd NE
, , NE
PGE2 XXXd NE
enhanced xxx NE
the xxx NE
production xxx NE
of xx NE
IL-4 XX-d NE
and xxx NE
IL-5 XX-d NE
, , NE
and xxx NE
only xxx NE
partially xxx NE
inhibited xxx NE
the xxx NE
production xxx NE
of xx NE
other xxx NE
cytokines xxx NE
. . NE

Therefore Xxxx NE
, , NE
the xxx NE
effects xxx NE
of xx NE
PGE2 XXXd protein
vary xxx NE
depending xxx NE
on xx NE
the xxx NE
mode xxx NE
of xx NE
T X NE
cell xxx NE
activation xxx NE
, , NE
and xxx NE
the xxx NE
IL-4 XX-d protein
and xxx NE
IL-5 XX-d protein
are xxx NE
regulated xxx NE
differently xxx NE
from xxx NE
other xxx NE
cytokines xxx protein
. . NE

In Xx NE
a x NE
mobility xxx NE
shift xxx NE
assay xxx NE
, , NE
only xxx NE
the xxx NE
NF-kappa XX-xxx NE
B X NE
( ( NE
p50 xdd NE
/p50 /xdd NE
) ) NE
homodimer xxx NE
was xxx NE
observed xxx NE
in xx NE
a x NE
complex xxx NE
formed xxx NE
with xxx NE
the xxx NE
kappa xxx NE
B X NE
sequence xxx NE
in xx NE
unstimulated xxx NE
SP-B21 XX-Xdd NE
cells xxx NE
. . NE

When Xxxx NE
cells xxx NE
were xxx NE
stimulated xxx NE
with xxx NE
anti-CD3 xxx-XXd protein_B
mAb xXx protein_E
or xx NE
PMA XXX NE
/A23187 /Xddddd NE
, , NE
a x NE
complex xxx NE
formation xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
( ( NE
p50 xdd NE
/p65 /xdd NE
) ) NE
heterodimer xxx NE
with xxx NE
the xxx NE
kappa xxx NE
B X NE
sequence xxx NE
was xxx NE
induced xxx NE
. . NE

Interestingly Xxxx NE
, , NE
PGE2 XXXd protein
or xx NE
di-butyryl xx-xxx NE
(Bt2) (Xxd) NE
cAMP xXXX NE
abolished xxx NE
the xxx NE
binding xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
( ( NE
p50 xdd NE
/p65 /xdd NE
) ) NE
heterodimer xxx NE
to xx NE
the xxx NE
kappa xxx NE
B X NE
sequence xxx NE
in xx NE
cells xxx NE
stimulated xxx NE
with xxx NE
anti-CD3 xxx-XXd NE
mAb xXx NE
but xxx NE
not xxx NE
with xxx NE
PMA XXX NE
/A23187 /Xddddd NE
. . NE

Our Xxx NE
results xxx NE
suggest xxx NE
that xxx NE
the xxx NE
target xxx NE
of xx NE
PGE2 XXXd NE
action xxx NE
is xx NE
a x NE
component xxx NE
in xx NE
the xxx NE
signal xxx NE
transduction xxx NE
pathway xxx NE
leading xxx NE
to xx NE
the xxx NE
activation xxx NE
of xx NE
protein xxx protein_B
kinase xxx protein_M
C X protein_E
. . NE

However Xxxx NE
, , NE
the xxx NE
inhibition xxx NE
of xx NE
the xxx NE
T X NE
cell xxx NE
activation xxx NE
signals xxx NE
by xx NE
PGE2 XXXd protein
is xx NE
selective xxx NE
. . NE

PGE2 XXXd protein
enhanced xxx NE
the xxx NE
complex xxx NE
formation xxx NE
with xxx NE
NF-AT XX-XX DNA_B
sequence xxx DNA_M
and xxx DNA_M
AP-1 XX-d DNA_M
sequence xxx DNA_M
and xxx DNA_M
CLE0 XXXd DNA_M
sequence xxx DNA_E
when xxx NE
the xxx NE
cells xxx NE
were xxx NE
activated xxx NE
by xx NE
either xxx NE
anti-CD3 xxx-XXd protein_B
mAb xXx protein_E
or xx NE
PMA XXX NE
/A23187 /Xddddd NE
stimulation xxx NE
. . NE

It Xx NE
seems xxx NE
therefore xxx NE
that xxx NE
PGE2 XXXd protein
, , NE
by xx NE
elevating xxx NE
cAMP xXXX NE
levels xxx NE
, , NE
interferes xxx NE
with xxx NE
the xxx NE
activation xxx NE
pathway xxx NE
for xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
but xxx NE
not xxx NE
for xxx NE
NF-AT XX-XX protein
, , NE
AP-1 XX-d protein
or xx NE
CLE0 XXXd protein_B
binding xxx protein_M
protein xxx protein_E
. . NE

Characterization Xxxx NE
of xx NE
NF(P) XX(X) protein
, , NE
the xxx NE
nuclear xxx protein_B
factor xxx protein_E
that xxx NE
interacts xxx NE
with xxx NE
the xxx NE
regulatory xxx NE
P X DNA_B
sequence xxx DNA_E
( ( NE
5'-CGAAAATTTCC-3' d'-XXXXXXXXXXX-d' NE
) ) NE
of xx NE
the xxx NE
human xxx DNA_B
interleukin-4 xxx-d DNA_M
gene xxx DNA_E
: : NE
relationship xxx NE
to xx NE
NF-kappa XX-xxx protein_B
B X protein_E
and xxx NE
NF-AT XX-XX protein
. . NE

The Xxx NE
P X DNA_B
sequence xxx DNA_E
of xx NE
the xxx NE
human xxx NE
interleukin-4 xxx-d NE
( ( NE
IL-4 XX-d NE
) ) NE
gene xxx NE
, , NE
which xxx NE
was xxx NE
defined xxx NE
as xx NE
a x NE
responsive xxx NE
element xxx NE
for xxx NE
phorbol xxx NE
12-myristate dd-xxx NE
13-acetate dd-xxx NE
and xxx NE
calcium xxx NE
ionophore xxx NE
( ( NE
A23187 Xddddd NE
) ) NE
in xx NE
Jurkat Xxxx NE
T X NE
cells xxx NE
, , NE
shares xxx NE
sequence xxx NE
similarity xxx NE
with xxx NE
the xxx NE
NF-kappa XX-xxx NE
B X NE
and xxx NE
the xxx NE
NF-AT XX-XX NE
binding xxx NE
sites xxx NE
. . NE

We Xx NE
examined xxx NE
whether xxx NE
NF(P) XX(X) protein
, , NE
a x NE
nuclear xxx protein_B
factor xxx protein_E
specific xxx NE
for xxx NE
the xxx NE
P X DNA_B
sequence xxx DNA_E
, , NE
is xx NE
related xxx NE
to xx NE
NF-kappa XX-xxx protein_B
B X protein_E
and xxx NE
NF-AT XX-XX protein
. . NE

NF-kappa XX-xxx protein_B
B X protein_E
( ( NE
P65 Xdd protein
or xx NE
P65/P50 Xdd/Xdd protein_B
heterodimer xxx protein_E
) ) NE
bound xxx NE
to xx NE
the xxx NE
P X DNA_B
sequence xxx DNA_E
in xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assays xxx NE
( ( NE
EMSA XXXX NE
) ) NE
and xxx NE
activated xxx NE
transcription xxx NE
through xxx NE
the xxx NE
P X DNA_B
sequence xxx DNA_E
when xxx NE
expression xxx DNA_B
plasmids xxx DNA_E
were xxx NE
cotransfected xxx NE
with xxx NE
P X NE
sequence xxx NE
-driven -xxx NE
reporter xxx NE
plasmids xxx NE
in xx NE
Jurkat Xxxx NE
T X NE
cells xxx NE
. . NE

In Xx NE
EMSAs XXXXx NE
, , NE
NF(P) XX(X) protein
binding xxx NE
was xxx NE
inhibited xxx NE
by xx NE
the xxx NE
unlabeled xxx DNA_B
NF-AT XX-XX DNA_M
binding xxx DNA_M
site xxx DNA_E
but xxx NE
not xxx NE
by xx NE
the xxx NE
unlabeled xxx DNA_B
AP1 XXd DNA_M
binding xxx DNA_M
site xxx DNA_E
and xxx NE
purified xxx protein_B
NF-AT XX-XX protein_E
contained xxx NE
an xx NE
activity xxx NE
that xxx NE
bound xxx NE
to xx NE
the xxx NE
P X DNA_B
sequence xxx DNA_E
. . NE

Both Xxxx NE
mobility xxx NE
shift xxx NE
and xxx NE
sequence xxx NE
specificity xxx NE
of xx NE
NF-AT XX-XX protein
were xxx NE
similar xxx NE
to xx NE
those xxx NE
of xx NE
NF(P) XX(X) protein
and xxx NE
only xxx NE
a x NE
small xxx NE
amount xxx NE
of xx NE
P65 Xdd protein
was xxx NE
detected xxx NE
in xx NE
NF(P) XX(X) protein
in xx NE
crude xxx NE
nuclear xxx NE
extracts xxx NE
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
the xxx NE
component(s) xxx(x) NE
of xx NE
NF-AT XX-XX protein
has xxx NE
the xxx NE
potential xxx NE
to xx NE
reconstitute xxx NE
NF(P) XX(X) protein
whereas xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
alone xxx NE
cannot xxx NE
account xxx NE
for xxx NE
NF(P) XX(X) protein
in xx NE
crude xxx NE
extracts xxx NE
. . NE

Unlike Xxxx NE
NF-AT XX-XX protein
, , NE
NF(P) XX(X) protein
does xxx NE
not xxx NE
contain xxx NE
AP1 XXd protein
as xx NE
its xxx NE
DNA XXX protein_B
binding xxx protein_M
component xxx protein_E
. . NE

Activation Xxxx NE
of xx NE
early xxx NE
growth xxx NE
response xxx NE
1 d NE
gene xxx NE
transcription xxx NE
and xxx NE
pp90rsk xxddxxx protein
during xxx NE
induction xxx NE
of xx NE
monocytic xxx NE
differentiation xxx NE
. . NE

The Xxx NE
present xxx NE
work xxx NE
has xxx NE
studied xxx NE
mechanisms xxx NE
responsible xxx NE
for xxx NE
induction xxx NE
of xx NE
early xxx NE
growth xxx NE
response xxx NE
1 d NE
(EGR-1) (XXX-d) NE
gene xxx NE
expression xxx NE
during xxx NE
monocytic xxx NE
differentiation xxx NE
of xx NE
U-937 X-ddd cell_line_B
myeloid xxx cell_line_M
leukemia xxx cell_line_M
cells xxx cell_line_E
. . NE

Differentiation Xxxx NE
of xx NE
U-937 X-ddd cell_line_B
cells xxx cell_line_E
with xxx NE
12-O-tetradecanoylphorbol-13-acetate dd-X-xxx-dd-xxx NE
( ( NE
TPA XXX NE
) ) NE
, , NE
an xx NE
activator xxx NE
of xx NE
the xxx NE
serine/threonine xxx/xxx protein_B
protein xxx protein_M
kinase xxx protein_M
C X protein_E
, , NE
was xxx NE
associated xxx NE
with xxx NE
transcriptional xxx NE
activation xxx NE
of xx NE
EGR-1 XXX-d DNA_B
promoter-reporter xxx-xxx DNA_M
constructs xxx DNA_E
. . NE

The Xxx NE
EGR-1 XXX-d DNA_B
promoter xxx DNA_E
contains xxx NE
six xxx NE
CC(A/T)6GG XX(X/X)dXX DNA_B
(CArG) (XXxX) DNA_M
motifs xxx DNA_E
. . NE

The Xxx NE
two xxx NE
5'-most d'-xxx DNA_B
distal xxx DNA_M
CArG XXxX DNA_M
sequences xxx DNA_E
conferred xxx NE
TPA XXX NE
inducibility xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
there xxx NE
was xxx NE
little xxx NE
effect xxx NE
of xx NE
TPA XXX NE
on xx NE
EGR-1 XXX-d NE
transcription xxx NE
in xx NE
a x NE
TPA XXX NE
-resistant -xxx NE
U-937 X-ddd NE
cell xxx NE
variant xxx NE
, , NE
designated xxx NE
TUR XXX NE
. . NE

Treatment Xxxx NE
of xx NE
both xxx NE
U-937 X-ddd cell_line
and xxx NE
TUR XXX cell_line_B
cells xxx cell_line_E
with xxx NE
okadaic xxx NE
acid xxx NE
, , NE
an xx NE
inhibitor xxx NE
of xx NE
serine/threonine xxx/xxx NE
protein xxx NE
phosphatases xxx NE
serine/threonine xxx/xxx protein_B
protein xxx protein_M
phosphatase xxx protein_M
1 d protein_M
and xxx protein_M
serine/threonine xxx/xxx protein_M
protein xxx protein_M
phosphatase xxx protein_M
2A dX protein_E
1 d NE
monocytic xxx NE
differentiation xxx NE
and xxx NE
EGR-1 XXX-d NE
transcription xxx NE
through xxx NE
the xxx NE
5'-most d'-xxx DNA_B
CArG XXxX DNA_M
element xxx DNA_E
. . NE

Since Xxxx NE
these xxx NE
findings xxx NE
supported xxx NE
the xxx NE
involvement xxx NE
of xx NE
serine xxx NE
/threonine /xxx NE
protein xxx NE
phosphorylation xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
EGR-1 XXX-d NE
expression xxx NE
, , NE
we xx NE
studied xxx NE
activation xxx NE
of xx NE
the xxx NE
40S ddX NE
ribosomal xxx NE
protein xxx NE
S6 Xd NE
serine xxx NE
/threonine /xxx NE
kinases xxx NE
, , NE
pp70S6K xxddXdX NE
and xxx NE
pp90rsk xxddxxx NE
. . NE

Although Xxxx NE
both xxx NE
kinases xxx NE
participate xxx NE
in xx NE
regulating xxx NE
cell xxx NE
growth xxx NE
, , NE
there xxx NE
was xxx NE
no xx NE
detectable xxx NE
activation xxx NE
of xx NE
pp70S6K xxddXdX protein
during xxx NE
TPA-induced XXX-xxx NE
monocytic xxx NE
differentiation xxx NE
or xx NE
okadaic xxx NE
acid-induced xxx-xxx NE
monocytic xxx NE
differentiation xxx NE

Moreover Xxxx NE
, , NE
rapamycin xxx NE
, , NE
an xx NE
inhibitor xxx NE
of xx NE
pp70S6K xxddXdX NE
activation xxx NE
, , NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
induction xxx NE
of xx NE
EGR-1 XXX-d NE
expression xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
analysis xxx NE
of xx NE
pp90rsk xxddxxx NE
activity xxx NE
by xx NE
phosphorylation xxx NE
of xx NE
a x NE
peptide xxx NE
derived xxx NE
from xxx NE
S6 Xd protein_B
protein xxx protein_E
demonstrated xxx NE
stimulation xxx NE
of xx NE
this xxx NE
kinase xxx protein
in xx NE
TPA-treated XXX-xxx cell_line_B
U-937 X-ddd cell_line_M
cell xxx cell_line_M
and xxx cell_line_M
not xxx cell_line_M
TPA-treated XXX-xxx cell_line_M
TUR XXX cell_line_M
cell xxx cell_line_E

Okadaic Xxxx NE
acid xxx NE
treatment xxx NE
of xx NE
both xxx NE
cell xxx NE
types xxx NE
was xxx NE
associated xxx NE
with xxx NE
activation xxx NE
of xx NE
pp90rsk xxddxxx protein
. . NE

Antioxidants Xxxx NE
inhibit xxx NE
monocyte xxx NE
adhesion xxx NE
by xx NE
suppressing xxx NE
nuclear xxx NE
factor-kappa xxx-xxx NE
B X NE
mobilization xxx NE
and xxx NE
induction xxx NE
of xx NE
vascular xxx protein_B
cell xxx protein_M
adhesion xxx protein_M
molecule-1 xxx-d protein_E
in xx NE
endothelial xxx cell_type_B
cells xxx cell_type_E
stimulated xxx NE
to xx NE
generate xxx NE
radicals xxx NE
. . NE

Cell Xxxx NE
adhesion xxx NE
to xx NE
endothelial xxx cell_type_B
cells xxx cell_type_E
stimulated xxx protein_B
by xx protein_M
tumor xxx protein_M
necrosis xxx protein_M
factor-alpha xxx-xxx protein_E
( ( NE
TNF XXX protein
) ) NE
is xx NE
due xxx NE
to xx NE
induction xxx NE
of xx NE
surface xxx protein_B
receptors xxx protein_E
, , NE
such xxx NE
as xx NE
vascular xxx protein_B
cell xxx protein_M
adhesion xxx protein_M
molecule-1 xxx-d protein_E
( ( NE
VCAM-1 XXXX-d protein
) ) NE
. . NE

The Xxx NE
antioxidant xxx NE
pyrrolidine xxx NE
dithiocarbamate xxx NE
( ( NE
PDTC XXXX NE
) ) NE
specifically xxx NE
inhibits xxx NE
activation xxx NE
of xx NE
nuclear xxx protein_B
factor-kappa xxx-xxx protein_M
B X protein_E
( ( NE
NF-kappa XX-xxx protein_B
B X protein_E
) ) NE
. . NE

Since Xxxx NE
kappa xxx DNA_B
B X DNA_M
motifs xxx DNA_E
are xxx NE
present xxx NE
in xx NE
VCAM-1 XXXX-d NE
and xxx NE
intercellular xxx NE
adhesion xxx NE
molecule-1 xxx-d NE
( ( NE
ICAM-1 XXXX-d NE
) ) NE
promoters xxx NE
, , NE
we xx NE
used xxx NE
PDTC XXXX NE
to xx NE
study xxx NE
the xxx NE
regulatory xxx NE
mechanisms xxx NE
of xx NE
VCAM-1 XXXX-d NE
and xxx NE
ICAM-1 XXXX-d NE
induction xxx NE
and xxx NE
subsequent xxx NE
monocyte xxx NE
adhesion xxx NE
in xx NE
TNF-treated XXX-xxx NE
human xxx NE
umbilical xxx NE
vein xxx NE
endothelial xxx NE
cells xxx NE
( ( NE
HUVECs XXXXXx NE
) ) NE
. . NE

PDTC XXXX NE
or xx NE
N-acetylcysteine X-xxx NE
dose xxx NE
dependently xxx NE
reduced xxx NE
TNF-induced XXX-xxx protein_B
VCAM-1 XXXX-d protein_E
but xxx NE
not xxx NE
ICAM-1 XXXX-d protein_B
surface xxx protein_M
protein xxx protein_E
(also (xxx NE
in xx NE
human xxx cell_type_B
umbilical xxx cell_type_M
arterial xxx cell_type_M
endothelial xxx cell_type_M
cells xxx cell_type_E
) ) NE
and xxx NE
mRNA xXXX NE
expression xxx NE
(by (xx NE
70% dd% NE
at xx NE
100 ddd NE
mumol/L xxx/X NE
PDTC XXXX NE
) ) NE
in xx NE
HUVECs XXXXXx cell_line
as xx NE
assessed xxx NE
by xx NE
flow xxx NE
cytometry xxx NE
and xxx NE
polymerase xxx NE
chain xxx NE
reaction xxx NE
. . NE

Gel-shift Xxx-xxx NE
analysis xxx NE
in xx NE
HUVECs XXXXXx cell_line
demonstrated xxx NE
that xxx NE
PDTC XXXX NE
prevented xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
mobilization xxx NE
by xx NE
TNF XXX protein
, , NE
suggesting xxx NE
that xxx NE
only xxx NE
VCAM-1 XXXX-d NE
induction xxx NE
was xxx NE
controlled xxx NE
by xx NE
NF-kappa XX-xxx protein_B
B X protein_E
. . NE

Since Xxxx NE
HUVECs XXXXXx cell_line
released xxx NE
superoxide xxx NE
anions xxx NE
in xx NE
response xxx NE
to xx NE
TNF XXX NE
, , NE
and xxx NE
H2O2 XdXd NE
induces xxx NE
VCAM-1 XXXX-d protein
, , NE
PDTC XXXX NE
may xxx NE
act xxx NE
as xx NE
a x NE
radical xxx NE
scavenger xxx NE
. . NE

Although Xxxx NE
ICAM-1 XXXX-d protein
induction xxx NE
was xxx NE
unaffected xxx NE
, , NE
inhibitors xxx NE
of xx NE
NADPH XXXXX protein_B
oxidase xxx protein_E
( ( NE
apocynin xxx NE
) ) NE
or xx NE
cytochrome xxx protein_B
P-450 X-ddd protein_E
( ( NE
SKF525a XXXdddx NE
) ) NE
suppressed xxx NE
VCAM-1 XXXX-d protein
induction xxx NE
by xx NE
TNF XXX NE
, , NE
revealing xxx NE
that xxx NE
several xxx NE
radical-generating xxx-xxx NE
systems xxx NE
are xxx NE
involved xxx NE
in xx NE
its xxx NE
regulation xxx NE
. . NE

PDTC XXXX NE
, , NE
apocynin xxx NE
, , NE
or xx NE
SKF525a XXXdddx NE
decreased xxx NE
adhesion xxx NE
of xx NE
monocytic xxx cell_line_B
U937 Xddd cell_line_M
cells xxx cell_line_E
to xx NE
TNF-treated XXX-xxx cell_line_B
HUVECs XXXXXx cell_line_E
(by (xx NE
75% dd% NE
at xx NE
100 ddd NE
mumol/L xxx/X NE
PDTC XXXX NE
) ) NE
. . NE

Inhibition Xxxx NE
by xx NE
anti- xxx- NE
VCAM-1 XXXX-d NE
monoclonal xxx NE
antibody xxx NE
1G11 dXdd NE
indicated xxx NE
that xxx NE
U937 Xddd NE
adhesion xxx NE
was xxx NE
VCAM-1 XXXX-d NE
dependent xxx NE
and xxx NE
suppression xxx NE
by xx NE
antioxidants xxx NE
was xxx NE
due xxx NE
to xx NE
reduced xxx NE
VCAM-1 XXXX-d NE
induction xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Displacement Xxxx NE
of xx NE
an xx NE
E-box-binding X-xxx-xxx protein_B
repressor xxx protein_E
by xx NE
basic xxx protein_B
helix-loop-helix xxx-xxx-xxx protein_M
proteins xxx protein_E
: : NE
implications xxx NE
for xxx NE
B-cell X-xxx NE
specificity xxx NE
of xx NE
the xxx NE
immunoglobulin xxx DNA_B
heavy-chain xxx-xxx DNA_M
enhancer xxx DNA_E
. . NE

The Xxx NE
activity xxx NE
of xx NE
the xxx NE
immunoglobulin xxx DNA_B
heavy-chain xxx-xxx DNA_M
(IgH) (XxX) DNA_M
enhancer xxx DNA_E
is xx NE
restricted xxx NE
to xx NE
B X cell_type_B
cells xxx cell_type_E
, , NE
although xxx NE
it xx NE
binds xxx NE
both xxx NE
B-cell-restricted X-xxx-xxx protein_B
transcription xxx protein_M
factor xxx protein_M
and xxx protein_M
ubiquitous xxx protein_M
transcription xxx protein_M
factor xxx protein_E

Activation Xxxx NE
of xx NE
the xxx NE
enhancer xxx DNA
in xx NE
non- xxx- NE
B X NE
cells xxx NE
upon xxx NE
overexpression xxx NE
of xx NE
the xxx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
(bHLH) (xXXX) NE
protein xxx NE
E2A XdX NE
appears xxx NE
to xx NE
be xx NE
mediated xxx NE
not xxx NE
only xxx NE
by xx NE
the xxx NE
binding xxx NE
of xx NE
E2A XdX NE
to xx NE
its xxx NE
cognate xxx NE
E X NE
box xxx NE
but xxx NE
also xxx NE
by xx NE
the xxx NE
resulting xxx NE
displacement xxx NE
of xx NE
a x NE
repressor xxx NE
from xxx NE
that xxx NE
same xxx NE
site xxx NE
. . NE

We Xx NE
have xxx NE
identified xxx NE
a x NE
"two-handed" "xxx-xxx" protein_B
zinc xxx protein_M
finger xxx protein_M
protein xxx protein_E
, , NE
denoted xxx NE
ZEB XXX protein
, , NE
the xxx NE
DNA-binding XXX-xxx NE
specificity xxx NE
of xx NE
which xxx NE
mimics xxx NE
that xxx NE
of xx NE
the xxx NE
cellular xxx protein_B
repressor xxx protein_E
. . NE

By Xx NE
employing xxx NE
a x NE
derivative xxx NE
E X DNA_B
box xxx DNA_E
that xxx NE
binds xxx NE
ZEB XXX protein
but xxx NE
not xxx NE
E2A XdX protein
, , NE
we xx NE
have xxx NE
shown xxx NE
that xxx NE
the xxx NE
repressor xxx protein
is xx NE
active xxx NE
in xx NE
B X cell_type_B
cells xxx cell_type_E
and xxx NE
the xxx NE
IgH XxX DNA_B
enhancer xxx DNA_E
is xx NE
silenced xxx NE
in xx NE
the xxx NE
absence xxx NE
of xx NE
binding xxx NE
competition xxx NE
by xx NE
bHLH xXXX protein_B
proteins xxx protein_E
. . NE

Hence Xxxx NE
, , NE
we xx NE
propose xxx NE
that xxx NE
a x NE
necessary xxx NE
prerequisite xxx NE
of xx NE
enhancer xxx NE
activity xxx NE
is xx NE
the xxx NE
B-cell-specific X-xxx-xxx NE
displacement xxx NE
of xx NE
a x NE
ZEB XXX NE
-like -xxx NE
repressor xxx NE
by xx NE
bHLH xXXX NE
proteins xxx NE
. . NE

Inhibition Xxxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
by xx NE
sodium xxx NE
salicylate xxx NE
and xxx NE
aspirin xxx NE
[see [xxx NE
comments] xxx] NE

The Xxx NE
transcription xxx protein_B
factor xxx protein_E
nuclear xxx NE
factor-kappa xxx-xxx NE
B X NE
( ( NE
NF-kappa XX-xxx protein_B
B X protein_E
) ) NE
is xx NE
critical xxx NE
for xxx NE
the xxx NE
inducible xxx NE
expression xxx NE
of xx NE
multiple xxx NE
cellular xxx DNA_B
gene xxx DNA_M
and xxx DNA_M
viral xxx DNA_M
gene xxx DNA_E
adhesion xxx NE
molecules xxx NE
. . NE

The Xxx NE
anti-inflammatory xxx-xxx NE
drugs xxx NE
sodium xxx NE
salicylate xxx NE
and xxx NE
aspirin xxx NE
inhibited xxx NE
the xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
, , NE
which xxx NE
further xxx NE
explains xxx NE
the xxx NE
mechanism xxx NE
of xx NE
action xxx NE
of xx NE
these xxx NE
drugs xxx NE
. . NE

This Xxxx NE
inhibition xxx NE
prevented xxx NE
the xxx NE
degradation xxx NE
of xx NE
the xxx NE
NF-kappa XX-xxx protein_B
B X protein_M
inhibitor xxx protein_E
, , NE
I X protein_B
kappa xxx protein_M
B X protein_E
, , NE
and xxx NE
therefore xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
was xxx NE
retained xxx NE
in xx NE
the xxx NE
cytosol xxx NE
. . NE

Sodium Xxxx NE
salicylate xxx NE
and xxx NE
aspirin xxx NE
also xxx NE
inhibited xxx NE
NF-kappa XX-xxx NE
B X NE
-dependent -xxx NE
transcription xxx NE
from xxx NE
the xxx NE
Ig Xx NE
kappa xxx NE
enhancer xxx NE
and xxx NE
the xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
(HIV) (XXX) NE
long xxx NE
terminal xxx NE
repeat xxx NE
( ( NE
LTR XXX NE
) ) NE
in xx NE
transfected xxx NE
T X NE
cells xxx NE
. . NE

Effects Xxxx NE
of xx NE
the xxx NE
antisense xxx NE
myb xxx NE
expression xxx NE
on xx NE
hemin- xxx- NE
induced xxx NE
erythroid xxx NE
differentiation xxx NE
and xxx NE
erythropoietin- xxx- NE
induced xxx NE
erythroid xxx NE
differentiation xxx NE
of xx NE
K562 Xddd cell_line_B
cells xxx cell_line_E
. . NE

In Xx NE
order xxx NE
to xx NE
elucidate xxx NE
the xxx NE
role xxx NE
of xx NE
c-myb x-xxx DNA_B
gene xxx DNA_E
in xx NE
erythroid xxx NE
differentiation xxx NE
of xx NE
K562 Xddd cell_line_B
cell xxx cell_line_E
induced xxx NE
by xx NE
hemin xxx protein
( ( NE
Hm Xx protein
) ) NE
and xxx NE
erythropoietin xxx protein
( ( NE
Epo Xxx protein
) ) NE
, , NE
we xx NE
constructed xxx NE
recombinant xxx DNA_B
plasmid xxx DNA_E
that xxx NE
could xxx NE
produce xxx NE
antisense xxx RNA_B
myb xxx RNA_M
RNA XXX RNA_E
after xxx NE
induction xxx NE
with xxx NE
dexamethasone xxx NE
. . NE

During Xxxx NE
treatment xxx NE
with xxx NE
Hm Xx protein
, , NE
K562 Xddd cell_line_B
cells xxx cell_line_E
constitutively xxx NE
expressed xxx NE
c-myb x-xxx RNA_B
mRNA xXXX RNA_E
, , NE
and xxx NE
50% dd% NE
of xx NE
them xxx NE
began xxx NE
to xx NE
synthesize xxx NE
hemoglobin xxx protein
( ( NE
Hb Xx protein
) ) NE
. . NE

Expression Xxxx NE
of xx NE
antisense xxx RNA_B
myb xxx RNA_M
RNA XXX RNA_E
reduced xxx NE
the xxx NE
amount xxx NE
of xx NE
c-myb x-xxx RNA_B
mRNA xXXX RNA_E
, , NE
and xxx NE
the xxx NE
percentage xxx NE
of xx NE
Hb Xx NE
-synthesizing -xxx NE
cells xxx NE
was xxx NE
decreased xxx NE
to xx NE
20% dd% NE
. . NE

In Xx NE
the xxx NE
presence xxx NE
of xx NE
Epo Xxx protein
, , NE
c-myb x-xxx RNA_B
mRNA xXXX RNA_E
declined xxx NE
and xxx NE
20% dd% NE
of xx NE
K562 Xddd cell_line_B
cells xxx cell_line_E
synthesized xxx NE
Hb Xx protein
regardless xxx NE
of xx NE
antisense xxx RNA_B
myb xxx RNA_M
RNA XXX RNA_E
expression xxx NE
. . NE

It Xx NE
is xx NE
suggested xxx NE
that xxx NE
constitutive xxx NE
expression xxx NE
of xx NE
c-myb x-xxx RNA_B
mRNA xXXX RNA_E
is xx NE
necessary xxx NE
for xxx NE
Hm Xx NE
-induced -xxx NE
differentiation xxx NE
, , NE
and xxx NE
that xxx NE
a x NE
decrease xxx NE
in xx NE
the xxx NE
amount xxx NE
of xx NE
c-myb x-xxx NE
mRNA xXXX NE
induced xxx NE
by xx NE
antisense xxx NE
myb xxx NE
RNA XXX NE
expression xxx NE
suppresses xxx NE
Hm Xx NE
-induced -xxx NE
differentiation xxx NE
. . NE

The Xxx NE
amount xxx NE
of xx NE
c-myb x-xxx RNA_B
mRNA xXXX RNA_E
in xx NE
K562 Xddd cell_line_B
cells xxx cell_line_E
was xxx NE
reduced xxx NE
during xxx NE
the xxx NE
differentiation xxx NE
induced xxx NE
by xx NE
Epo Xxx protein
. . NE

Expression Xxxx NE
of xx NE
GATA-1 XXXX-d RNA_B
mRNA xXXX RNA_E
was xxx NE
almost xxx NE
constant xxx NE
during xxx NE
Hm Xx NE
-induced -xxx NE
differentiation xxx NE
, , NE
but xxx NE
increased xxx NE
during xxx NE
Epo Xxx NE
treatment xxx NE
. . NE

It Xx NE
is xx NE
supposed xxx NE
that xxx NE
the xxx NE
mechanism xxx NE
of xx NE
Hm Xx NE
-induced -xxx NE
differentiation xxx NE
is xx NE
distinguished xxx NE
from xxx NE
that xxx NE
of xx NE
Epo Xxx NE
-induced -xxx NE
differentiation xxx NE
in xx NE
K562 Xddd NE
cells xxx NE
. . NE

Prenatal Xxxx NE
immune xxx NE
challenge xxx NE
alters xxx NE
the xxx NE
hypothalamic-pituitary-adrenocortical xxx-xxx-xxx NE
axis xxx NE
in xx NE
adult xxx NE
rats xxx NE
. . NE

We Xx NE
investigated xxx NE
whether xxx NE
non-abortive xxx-xxx NE
maternal xxx NE
infections xxx NE
would xxx NE
compromise xxx NE
fetal xxx NE
brain xxx NE
development xxx NE
and xxx NE
alter xxx NE
hypothalamic-pituitary-adrenocortical xxx-xxx-xxx NE
(HPA) (XXX) NE
axis xxx NE
functioning xxx NE
when xxx NE
adult xxx NE
. . NE

To Xx NE
study xxx NE
putative xxx NE
teratogenic xxx NE
effects xxx NE
of xx NE
a x NE
T X NE
cell-mediated xxx-xxx NE
immune xxx NE
response xxx NE
versus xxx NE
an xx NE
endotoxic xxx NE
challenge xxx NE
, , NE
10-d-pregnant dd-x-xxx NE
rats xxx NE
received xxx NE
a x NE
single xxx NE
intraperitoneal xxx NE
injection xxx NE
of xx NE
5 d NE
x x NE
10(8) dd(d) NE
human xxx cell_type_B
red xxx cell_type_M
blood xxx cell_type_M
cells xxx cell_type_E
( ( NE
HRBC XXXX cell_type
) ) NE
or xx NE
gram-negative xxx-xxx NE
bacterial xxx NE
endotoxin xxx NE
( ( NE
Escherichia Xxxx NE
coli xxx NE
LPS XXX NE
: : NE
30 dd NE
micrograms/kg) xxx/xx) NE
. . NE

The Xxx NE
adult xxx NE
male xxx NE
progeny xxx NE
(3 (d NE
mo xx NE
old) xxx) NE
of xx NE
both xxx NE
experimental xxx NE
groups xxx NE
showed xxx NE
increased xxx NE
basal xxx NE
plasma xxx NE
corticosterone xxx NE
levels xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
after xxx NE
novelty xxx NE
stress xxx NE
the xxx NE
HRBC XXXX cell_type
group xxx NE
, , NE
but xxx NE
not xxx NE
the xxx NE
LPS XXX cell_line_B
group xxx cell_line_E
, , NE
showed xxx NE
increased xxx NE
ACTH XXXX NE
and xxx NE
corticosterone xxx NE
levels xxx NE
. . NE

Both Xxxx NE
groups xxx NE
showed xxx NE
substantial xxx NE
decreases xxx NE
in xx NE
mineralocorticoid xxx NE
(MR) (XX) NE
and xxx NE
mineralocorticoid xxx NE
receptor xxx NE
(MR) (XX) NE
level xxx NE
and xxx NE
glucocorticoid xxx NE
receptor xxx NE
(GR) (XX) NE
level xxx NE
in xx NE
the xxx NE
hippocampus xxx NE
, , NE
a x NE
limbic xxx NE
brain xxx NE
structure xxx NE
critical xxx NE
for xxx NE
HPA XXX NE
axis xxx NE
regulation xxx NE
, , NE
whereas xxx NE
GR XX NE
concentrations xxx NE
in xx NE
the xxx NE
hypothalamus xxx NE
were xxx NE
unchanged xxx NE
and xxx NE
in xx NE
anterior xxx NE
pituitary xxx NE
were xxx NE
slightly xxx NE
increased xxx NE
. . NE

HRBC XXXX cell_type
and xxx NE
LPS XXX NE
indeed xxx NE
stimulated xxx NE
the xxx NE
maternal xxx NE
immune xxx NE
system xxx NE
as xx NE
revealed xxx NE
by xx NE
specific xxx NE
anti- xxx- NE
HRBC XXXX NE
antibody xxx NE
production xxx NE
and xxx NE
enhanced xxx NE
IL-1 XX-d NE
beta xxx NE
mRNA xXXX NE
expression xxx NE
in xx NE
splenocytes xxx NE
, , NE
respectively xxx NE
. . NE

This Xxxx NE
study xxx NE
demonstrates xxx NE
that xxx NE
a x NE
T X NE
cell-mediated xxx-xxx NE
immune xxx NE
response xxx NE
as xx NE
well xxx NE
as xx NE
an xx NE
endotoxic xxx NE
challenge xxx NE
during xxx NE
pregnancy xxx NE
can xxx NE
induce xxx NE
anomalies xxx NE
in xx NE
HPA XXX NE
axis xxx NE
function xxx NE
in xx NE
adulthood xxx NE
. . NE

Clinically Xxxx NE
, , NE
it xx NE
may xxx NE
be xx NE
postulated xxx NE
that xxx NE
disturbed xxx NE
fetal xxx NE
brain xxx NE
development xxx NE
due xxx NE
to xx NE
prenatal xxx NE
immune xxx NE
challenge xxx NE
increases xxx NE
the xxx NE
vulnerability xxx NE
to xx NE
develop xxx NE
mental xxx NE
illness xxx NE
involving xxx NE
inadequate xxx NE
responses xxx NE
to xx NE
stress xxx NE
. . NE

A X NE
low xxx NE
NM23.H1 XXdd.Xd NE
gene xxx NE
expression xxx NE
identifying xxx NE
high xxx NE
malignancy xxx NE
human xxx NE
melanomas xxx NE
. . NE

The Xxx NE
NM23 XXdd DNA_B
gene xxx DNA_E
has xxx NE
been xxx NE
proposed xxx NE
as xx NE
a x NE
metastasis-suppressor xxx-xxx DNA_B
gene xxx DNA_E
, , NE
and xxx NE
its xxx NE
use xxx NE
has xxx NE
been xxx NE
suggested xxx NE
as xx NE
prognostic xxx NE
factor xxx NE
. . NE

NM23 XXdd protein
was xxx NE
identified xxx NE
in xx NE
a x NE
system xxx NE
of xx NE
murine xxx cell_line_B
melanoma xxx cell_line_M
cell xxx cell_line_M
lines xxx cell_line_E
, , NE
in xx NE
which xxx NE
an xx NE
inverse xxx NE
relationship xxx NE
was xxx NE
found xxx NE
between xxx NE
NM23 XXdd NE
expression xxx NE
and xxx NE
metastatic xxx NE
ability xxx NE
. . NE

In Xx NE
a x NE
human xxx NE
malignant xxx NE
melanoma xxx NE
study xxx NE
NM23 XXdd NE
expression xxx NE
was xxx NE
found xxx NE
to xx NE
be xx NE
significantly xxx NE
lower xxx NE
in xx NE
metastases xxx NE
that xxx NE
developed xxx NE
less xxx NE
than xxx NE
24 dd NE
months xxx NE
after xxx NE
diagnosis xxx NE
of xx NE
the xxx NE
primary xxx NE
tumours xxx NE
. . NE

The Xxx NE
present xxx NE
paper xxx NE
studies xxx NE
the xxx NE
expression xxx NE
of xx NE
the xxx NE
NM23 XXdd NE
.H1 .Xd NE
gene xxx NE
in xx NE
cell xxx NE
lines xxx NE
which xxx NE
derive xxx NE
from xxx NE
primary xxx NE
or xx NE
metastatic xxx NE
human xxx NE
malignant xxx NE
melanomas xxx NE
in xx NE
relation xxx NE
to xx NE
staging xxx NE
, , NE
infiltration xxx NE
degree xxx NE
, , NE
lymphocytic xxx NE
infiltration xxx NE
, , NE
cell xxx NE
morphology xxx NE
, , NE
cell xxx NE
pigmentation xxx NE
, , NE
karyotype xxx NE
, , NE
and xxx NE
disease-free xxx-xxx NE
survival xxx NE
. . NE

The Xxx NE
level xxx NE
of xx NE
mRNA xXXX NE
expression xxx NE
of xx NE
the xxx NE
NM23 XXdd DNA_B
gene xxx DNA_E
is xx NE
significantly xxx NE
lower xxx NE
in xx NE
cell xxx cell_line_B
lines xxx cell_line_E
that xxx NE
derive xxx NE
from xxx NE
more xxx NE
infiltrating xxx NE
primary xxx NE
melanomas xxx NE
than xxx NE
in xx NE
cell xxx cell_line_B
lines xxx cell_line_E
obtained xxx NE
from xxx NE
less xxx NE
infiltrating xxx NE
tumours xxx NE
. . NE

Moreover Xxxx NE
, , NE
cell xxx cell_line_B
lines xxx cell_line_E
derived xxx NE
from xxx NE
tumours xxx NE
of xx NE
patients xxx NE
with xxx NE
a x NE
disease-free xxx-xxx NE
survival xxx NE
of xx NE
more xxx NE
than xxx NE
24 dd NE
months xxx NE
(24-58 (dd-dd NE
months) xxx) NE
express xxx NE
the xxx NE
NM23 XXdd DNA_B
gene xxx DNA_E
at xx NE
higher xxx NE
levels xxx NE
than xxx NE
cell xxx cell_line_B
lines xxx cell_line_E
obtained xxx NE
from xxx NE
melanomas xxx NE
of xx NE
patients xxx NE
with xxx NE
a x NE
disease-free xxx-xxx NE
survival xxx NE
of xx NE
less xxx NE
than xxx NE
24 dd NE
months xxx NE
(6-15 (d-dd NE
months) xxx) NE
. . NE

Activation Xxxx NE
of xx NE
a x NE
novel xxx NE
serine xxx protein
/threonine /xxx NE
kinase xxx NE
that xxx NE
phosphorylates xxx NE
c-Fos x-Xxx protein
upon xxx NE
stimulation xxx NE
of xx NE
T X cell_type_B
lymphocyte xxx cell_type_M
and xxx cell_type_M
B X cell_type_M
lymphocyte xxx cell_type_E
cytokine xxx NE
receptors xxx NE
. . NE

Ligation Xxxx NE
of xx NE
Ag Xx protein_B
receptors xxx protein_E
in xx NE
T X cell_type_B
lymphocyte xxx cell_type_M
and xxx cell_type_M
B X cell_type_M
lymphocyte xxx cell_type_E
T X NE
initiates xxx NE
signal xxx NE
transduction xxx NE
cascades xxx NE
which xxx NE
alter xxx NE
the xxx NE
expression xxx NE
of xx NE
genes xxx NE
that xxx NE
regulate xxx NE
cellular xxx NE
proliferation xxx NE
and xxx NE
differentiation xxx NE
. . NE

The Xxx NE
transmission xxx NE
of xx NE
signals xxx NE
from xxx NE
the xxx NE
membrane xxx NE
to xx NE
the xxx NE
nucleus xxx NE
is xx NE
mediated xxx NE
principally xxx NE
through xxx NE
the xxx NE
action xxx NE
of xx NE
protein xxx protein_B
tyrosine xxx protein_M
kinase xxx protein_M
and xxx protein_M
protein xxx protein_M
serine/threonine xxx/xxx protein_M
kinase xxx protein_E

We Xx NE
have xxx NE
identified xxx NE
and xxx NE
characterized xxx NE
a x NE
novel xxx NE
serine xxx NE
/threonine /xxx NE
kinase xxx NE
that xxx NE
phosphorylated xxx NE
the xxx NE
proto-oncogene xxx-xxx NE
product xxx NE
, , NE
c-Fos x-Xxx NE
, , NE
and xxx NE
is xx NE
termed xxx NE
Fos Xxx NE
kinase xxx NE
. . NE

Fos Xxx protein_B
kinase xxx protein_E
was xxx NE
rapidly xxx NE
activated xxx NE
after xxx NE
ligation xxx NE
of xx NE
the xxx NE
CD3 XXd protein_B
receptor xxx protein_M
and xxx protein_M
CD2 XXd protein_M
receptor xxx protein_E
in xx NE
Jurkat Xxxx cell_line
and xxx NE
normal xxx cell_type_B
human xxx cell_type_M
T X cell_type_M
lymphocytes xxx cell_type_E
and xxx NE
in xx NE
response xxx NE
to xx NE
IL-6 XX-d protein
and xxx NE
anti-IgM xxx-XxX protein
in xx NE
the xxx NE
human xxx cell_line_B
B X cell_line_M
cell xxx cell_line_M
lines xxx cell_line_E
AF10 XXdd NE
and xxx NE
Ramos Xxxx cell_line
, , NE
respectively xxx NE
. . NE

The Xxx NE
phorbol xxx NE
ester xxx NE
, , NE
PMA XXX NE
, , NE
was xxx NE
also xxx NE
a x NE
potent xxx NE
inducer xxx NE
of xx NE
Fos Xxx protein_B
kinase xxx protein_E
activity xxx NE
in xx NE
all xxx NE
of xx NE
the xxx NE
above xxx NE
populations xxx NE
, , NE
suggesting xxx NE
that xxx NE
PKC XXX protein
plays xxx NE
a x NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
this xxx NE
enzyme xxx protein
. . NE

Fos Xxx protein_B
kinase xxx protein_E
phosphorylates xxx NE
c-Fos x-Xxx protein
at xx NE
a x NE
site xxx NE
near xxx NE
the xxx NE
C-terminus X-xxx protein
, , NE
as xx NE
well xxx NE
as xx NE
a x NE
peptide xxx NE
derived xxx NE
from xxx NE
this xxx NE
region xxx NE
( ( NE
residues xxx protein_B
359-370 ddd-ddd protein_E
, , NE
RKGSSSNEPSSD XXXXXXXXXXXX protein
) ) NE
, , NE
and xxx NE
Fos Xxx NE
peptide xxx NE
competitively xxx NE
inhibited xxx NE
c-Fos x-Xxx protein
phosphorylation xxx NE
. . NE

Fos Xxx protein_B
kinase xxx protein_E
was xxx NE
shown xxx NE
to xx NE
be xx NE
distinct xxx NE
from xxx NE
other xxx NE
identified xxx NE
serine xxx NE
/threonine /xxx NE
kinases xxx NE
, , NE
including xxx NE
protein xxx NE
kinase xxx NE
A X NE
, , NE
protein xxx NE
kinase xxx NE
C X NE
, , NE
casein xxx NE
kinase xxx NE
II XX NE
, , NE
MAP XXX NE
kinases xxx NE
, , NE
p70S6K xddXdX NE
and xxx NE
p90RSK xddXXX NE
. . NE

Fos Xxx protein_B
kinase xxx protein_E
was xxx NE
purified xxx NE
by xx NE
anion xxx NE
exchange xxx NE
chromatography xxx NE
and xxx NE
exhibited xxx NE
an xx NE
apparent xxx NE
M(r) X(x) NE
= = NE
65,000 dd,ddd NE
and xxx NE
isoelectric xxx NE
point xxx NE
= = NE
6.1 d.d NE
. . NE

Fos Xxx protein_B
kinase xxx protein_E
may xxx NE
play xxx NE
a x NE
role xxx NE
in xx NE
transcriptional xxx NE
regulation xxx NE
through xxx NE
its xxx NE
capacity xxx NE
to xx NE
phosphorylate xxx NE
c-Fos x-Xxx protein
at xx NE
a x NE
site xxx NE
required xxx NE
for xxx NE
expression xxx NE
of xx NE
the xxx NE
transcriptional xxx NE
transrepressive xxx NE
activity xxx NE
of xx NE
this xxx NE
molecule xxx NE
. . NE

Moreover Xxxx NE
, , NE
its xxx NE
rapid xxx NE
activation xxx NE
suggests xxx NE
it xx NE
may xxx NE
have xxx NE
a x NE
wider xxx NE
role xxx NE
within xxx NE
signal xxx NE
transduction xxx NE
cascades xxx NE
in xx NE
lymphocytes xxx cell_type
. . NE

Antigenic Xxxx NE
specificities xxx NE
of xx NE
human xxx NE
CD4+ XXd+ NE
T-cell X-xxx NE
clones xxx NE
recovered xxx NE
from xxx NE
recurrent xxx NE
genital xxx NE
herpes xxx NE
simplex xxx NE
virus xxx NE
type xxx NE
2 d NE
lesions xxx NE
. . NE

Lesions Xxxx NE
resulting xxx NE
from xxx NE
recurrent xxx NE
genital xxx NE
herpes xxx NE
simplex xxx NE
virus xxx NE
( ( NE
HSV XXX NE
) ) NE
infection xxx NE
are xxx NE
characterized xxx NE
by xx NE
infiltration xxx NE
of xx NE
CD4+ XXd+ NE
lymphocytes xxx NE
. . NE

We Xx NE
have xxx NE
investigated xxx NE
the xxx NE
antigenic xxx NE
specificity xxx NE
of xx NE
47 dd NE
HSV-specific XXX-xxx cell_line_B
CD4+ XXd+ cell_line_M
T-cell X-xxx cell_line_M
clones xxx cell_line_E
recovered xxx NE
from xxx NE
the xxx NE
HSV-2 XXX-d NE
buttock xxx NE
lesion xxx NE
and xxx NE
HSV-2 XXX-d NE
thigh xxx NE
lesion xxx NE
of xx NE
five xxx NE
patients xxx NE
. . NE

Clones Xxxx NE
with xxx NE
proliferative xxx NE
responses xxx NE
to xx NE
recombinant xxx protein_B
truncated xxx protein_M
glycoprotein xxx protein_M
B X protein_E
( ( NE
gB xX protein
) ) NE
or xx NE
gD xX protein
of xx NE
HSV-2 XXX-d NE
or xx NE
purified xxx NE
natural xxx NE
gC xX NE
of xx NE
HSV-2 XXX-d NE
comprised xxx NE
a x NE
minority xxx NE
of xx NE
the xxx NE
total xxx NE
number xxx NE
of xx NE
HSV-specific XXX-xxx cell_line_B
clones xxx cell_line_E
isolated xxx NE
from xxx NE
lesions xxx NE
. . NE

The Xxx NE
gC2-specific xXd-xxx cell_line_B
CD4+ XXd+ cell_line_M
clone xxx cell_line_M
and xxx cell_line_M
gD2-specific xXd-xxx cell_line_M
CD4+ XXd+ cell_line_M
clone xxx cell_line_E
had xxx NE
cytotoxic xxx NE
activity xxx NE
. . NE

The Xxx NE
approximate xxx NE
locations xxx NE
of xx NE
the xxx NE
HSV-2 XXX-d NE
genes xxx NE
encoding xxx NE
HSV-2 XXX-d NE
type-specific xxx-xxx NE
CD4+ XXd+ protein_B
antigens xxx protein_E
have xxx NE
been xxx NE
determined xxx NE
by xx NE
using xxx NE
HSV-1 XXX-d NE
x x NE
HSV-2 XXX-d NE
intertypic xxx NE
recombinant xxx NE
virus xxx NE
and xxx NE
include xxx NE
the xxx NE
approximate xxx NE
map xxx NE
regions xxx NE
0.30 d.dd NE
to xx NE
0.46 d.dd NE
, , NE
0.59 d.dd NE
to xx NE
0.67 d.dd NE
, , NE
0.67 d.dd NE
to xx NE
0.73 d.dd NE
, , NE
and xxx NE
0.82 d.dd NE
to xx NE
1.0 d.d NE
units xxx NE
. . NE

The Xxx NE
antigenic xxx NE
specificity xxx NE
of xx NE
an xx NE
HLA XXX cell_line_B
DQ2-restricted, XXd-xxx, cell_line_M
HSV-2 XXX-d cell_line_M
type-specific xxx-xxx cell_line_M
T-cell X-xxx cell_line_M
clone xxx cell_line_E
was xxx NE
mapped xxx NE
to xx NE
amino xxx NE
acids xxx NE
425 ddd NE
to xx NE
444 ddd NE
of xx NE
VP16 XXdd NE
of xx NE
HSV-2 XXX-d NE
by xx NE
sequential xxx NE
use xxx NE
of xx NE
an xx NE
intertypic xxx NE
recombinant xxx NE
virus xxx NE
containing xxx NE
VP16 XXdd NE
of xx NE
HSV-2 XXX-d NE
in xx NE
an xx NE
HSV-1 XXX-d NE
background xxx NE
, , NE
recombinant xxx NE
VP16 XXdd NE
fusion xxx NE
proteins xxx NE
, , NE
and xxx NE
synthetic xxx NE
peptides xxx NE
. . NE

Each Xxxx NE
of xx NE
the xxx NE
remaining xxx NE
four xxx NE
patients xxx NE
also xxx NE
yielded xxx NE
at xx NE
least xxx NE
one xxx NE
type-specific xxx-xxx cell_line_B
T-cell X-xxx cell_line_M
clone xxx cell_line_E
reactive xxx NE
with xxx NE
an xx NE
HSV-2 XXX-d NE
epitope xxx NE
mapping xxx NE
to xx NE
approximately xxx NE
0.67 d.dd NE
to xx NE
0.73 d.dd NE
map xxx NE
units xxx NE
. . NE

The Xxx NE
antigenic xxx NE
specificities xxx NE
of xx NE
lesion-derived xxx-xxx cell_line_B
CD4+ XXd+ cell_line_M
T-cell X-xxx cell_line_M
clones xxx cell_line_E
are xxx NE
quite xxx NE
diverse xxx NE
and xxx NE
include xxx NE
at xx NE
least xxx NE
10 dd NE
epitopes xxx NE
. . NE

Human Xxxx cell_line_B
T-cell X-xxx cell_line_M
clones xxx cell_line_E
reactive xxx NE
with xxx NE
gC xX protein
and xxx NE
VP16 XXdd protein
are xxx NE
reported xxx NE
here xxx NE
for xxx NE
the xxx NE
first xxx NE
time xxx NE
. . NE

Marked Xxxx NE
basophilia xxx NE
in xx NE
acute xxx NE
promyelocytic xxx NE
leukaemia xxx NE
treated xxx NE
with xxx NE
all-trans xxx-xxx NE
retinoic xxx NE
acid xxx NE
: : NE
molecular xxx NE
analysis xxx NE
of xx NE
the xxx NE
cell xxx NE
origin xxx NE
of xx NE
the xxx NE
basophils xxx cell_type
. . NE

We Xx NE
report xxx NE
a x NE
patient xxx NE
with xxx NE
acute xxx NE
promyelocytic xxx NE
leukaemia xxx NE
who xxx NE
developed xxx NE
marked xxx NE
basophilia xxx NE
during xxx NE
all-trans xxx-xxx NE
retinoic xxx NE
acid xxx NE
treatment xxx NE
. . NE

We Xx NE
studied xxx NE
genomic xxx DNA_B
DNA XXX DNA_E
and xxx NE
RNA XXX RNA
extracted xxx NE
from xxx NE
the xxx NE
patient's xxx'x NE
peripheral xxx cell_type_B
leucocytes xxx cell_type_E
in xx NE
order xxx NE
to xx NE
determine xxx NE
the xxx NE
origin xxx NE
of xx NE
the xxx NE
basophils xxx cell_type
. . NE

The Xxx NE
RAR XXX protein_B
alpha xxx protein_E
rearranged xxx NE
band xxx NE
in xx NE
the xxx NE
Southern Xxxx NE
blot xxx NE
analysis xxx NE
and xxx NE
a x NE
chimaeric xxx protein_B
product xxx protein_E
of xx NE
PML-RAR XXX-XXX protein_B
alpha xxx protein_E
by xx NE
polymerase xxx NE
chain xxx NE
reaction xxx NE
were xxx NE
strongly xxx NE
visible xxx NE
before xxx NE
ATRA XXXX NE
treatment xxx NE
, , NE
but xxx NE
at xx NE
the xxx NE
time xxx NE
of xx NE
maximal xxx NE
basophilia xxx NE
both xxx NE
of xx NE
them xxx NE
were xxx NE
markedly xxx NE
diminished xxx NE
. . NE

These Xxxx NE
findings xxx NE
suggest xxx NE
that xxx NE
the xxx NE
basophils xxx cell_type
which xxx NE
appeared xxx NE
during xxx NE
the xxx NE
ATRA XXXX NE
treatment xxx NE
are xxx NE
reactive xxx NE
in xx NE
nature xxx NE
rather xxx NE
than xxx NE
a x NE
leukaemic xxx cell_line_B
clone xxx cell_line_E
. . NE

Activation Xxxx NE
of xx NE
the xxx NE
interleukin xxx DNA_B
6 d DNA_M
gene xxx DNA_E
by xx NE
Mycobacterium Xxxx NE
tuberculosis xxx NE
or xx NE
lipopolysaccharide xxx NE
is xx NE
mediated xxx NE
by xx NE
nuclear xxx protein_B
factors xxx protein_M
NF-IL6 XX-XXd protein_E
and xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
[published [xxx NE
erratum xxx NE
appears xxx NE
in xx NE
Proc Xxxx NE
Natl Xxxx NE
Acad Xxxx NE
Sci Xxx NE
U X NE
S X NE
A X NE
1995 dddd NE
Apr Xxx NE
11;92(8):3632] dd;dd(d):dddd] NE

The Xxx NE
host xxx NE
response xxx NE
to xx NE
Mycobacterium Xxxx NE
tuberculosis xxx NE
includes xxx NE
granuloma xxx NE
formation xxx NE
at xx NE
sites xxx NE
of xx NE
infection xxx NE
and xxx NE
systemic xxx NE
symptoms xxx NE
. . NE

Cytokines Xxxx protein
have xxx NE
been xxx NE
identified xxx NE
by xx NE
immunohistochemistry xxx NE
in xx NE
granulomas xxx NE
in xx NE
animal xxx NE
models xxx NE
of xx NE
bacillus xxx NE
Calmette-Guerin Xxxx-Xxxx NE
(BCG) (XXX) NE
infection xxx NE
and xxx NE
are xxx NE
released xxx NE
by xx NE
mononuclear xxx cell_type_B
phagocytes xxx cell_type_E
upon xxx NE
stimulation xxx NE
by xx NE
mycobacterial xxx NE
proteins xxx NE
. . NE

In Xx NE
this xxx NE
regard xxx NE
, , NE
the xxx NE
cytokine xxx protein
interleukin xxx protein_B
6 d protein_E
( ( NE
IL-6 XX-d protein
) ) NE
may xxx NE
play xxx NE
a x NE
role xxx NE
in xx NE
the xxx NE
clinical xxx NE
manifestations xxx NE
and xxx NE
pathological xxx NE
events xxx NE
of xx NE
tuberculosis xxx protein_B
infection xxx protein_E
. . NE

We Xx NE
have xxx NE
demonstrated xxx NE
that xxx NE
lipoarabinomannan xxx protein
( ( NE
LAM XXX protein
) ) NE
from xxx NE
the xxx NE
mycobacterial xxx NE
cell xxx NE
wall xxx NE
, , NE
which xxx NE
was xxx NE
virtually xxx NE
devoid xxx NE
of xx NE
lipopolysaccharide xxx NE
( ( NE
LPS XXX NE
) ) NE
, , NE
stimulated xxx NE
mononuclear xxx cell_type_B
phagocytes xxx cell_type_E
to xx NE
release xxx NE
IL-6 XX-d protein
in xx NE
a x NE
dose-response xxx-xxx NE
manner xxx NE
. . NE

LAM XXX protein
and xxx NE
LPS XXX NE
were xxx NE
potent xxx NE
inducers xxx NE
of xx NE
IL-6 XX-d NE
gene xxx NE
expression xxx NE
in xx NE
peripheral xxx cell_type_B
blood xxx cell_type_M
monocytes xxx cell_type_E
. . NE

Both Xxxx NE
LAM XXX protein
-and -xxx NE
LPS XXX NE
-inducible -xxx NE
IL-6 XX-d NE
promoter xxx NE
activity xxx NE
was xxx NE
localized xxx NE
to xx NE
a x NE
DNA XXX NE
fragment xxx NE
, , NE
positions xxx NE
-158 -ddd NE
to xx NE
-49 -dd NE
, , NE
by xx NE
deletion xxx NE
analysis xxx NE
and xxx NE
chloramphenicol xxx NE
acetyltransferase xxx NE
assay xxx NE
. . NE

Two Xxx NE
nuclear xxx protein_B
factor xxx protein_M
NF-IL6 XX-XXd protein_E
(positions (xxx NE
-153 -ddd DNA_B
to xx DNA_M
-145 -ddd DNA_E
and xxx NE
-83 -dd NE
to xx NE
-75) -dd) NE
and xxx NE
one xxx NE
nuclear xxx DNA_B
factor xxx DNA_M
NF-kappa XX-xxx DNA_M
B X DNA_M
(positions (xxx DNA_M
-72 -dd DNA_M
to xx DNA_M
-63) -dd) DNA_M
motifs xxx DNA_E
are xxx NE
present xxx NE
within xxx NE
this xxx NE
fragment xxx NE
. . NE

Site-directed Xxxx-xxx NE
mutagenesis xxx NE
of xx NE
one xxx NE
or xx NE
more xxx NE
of xx NE
these xxx NE
motifs xxx NE
within xxx NE
the xxx NE
IL-6 XX-d protein
promoter xxx NE
demonstrated xxx NE
that xxx NE
each xxx NE
has xxx NE
positive xxx NE
regulatory xxx NE
activity xxx NE
and xxx NE
that xxx NE
they xxx NE
could xxx NE
act xxx NE
in xx NE
a x NE
function- xxx- NE
and xxx NE
orientation-independent xxx-xxx NE
manner xxx NE
. . NE

Deletion Xxxx NE
of xx NE
all xxx NE
three xxx NE
elements xxx NE
abolished xxx NE
inducibility xxx NE
of xx NE
IL-6 XX-d DNA_B
promoter xxx DNA_E
activity xxx NE
by xx NE
both xxx NE
LAM XXX protein
and xxx NE
LPS XXX NE
. . NE

We Xx NE
conclude xxx NE
that xxx NE
the xxx NE
NF-IL6 XX-XXd DNA_B
site xxx DNA_M
and xxx DNA_M
NF-kappa XX-xxx DNA_M
B X DNA_M
site xxx DNA_E
mediate xxx NE
IL-6 XX-d NE
induction xxx NE
in xx NE
response xxx NE
to xx NE
both xxx NE
LPS XXX NE
and xxx NE
LAM XXX protein
, , NE
acting xxx NE
as xx NE
bacterial xxx DNA_B
response xxx DNA_M
element xxx DNA_M
or xx DNA_M
mycobacterial xxx DNA_M
response xxx DNA_M
element xxx DNA_E

Regulation Xxxx NE
of xx NE
CD14 XXdd NE
expression xxx NE
during xxx NE
monocytic xxx NE
differentiation xxx NE
induced xxx NE
with xxx NE
1 d NE
alpha,25-dihydroxyvitamin xxx,dd-xxx NE
D3 Xd NE
. . NE

CD14 XXdd protein
, , NE
a x NE
monocyte/macrophage xxx/xxx protein_B
receptor xxx protein_E
for xxx NE
the xxx NE
complex xxx NE
of xx NE
LPS XXX NE
and xxx NE
LPS XXX protein_B
binding xxx protein_M
protein xxx protein_E
, , NE
is xx NE
a x NE
differentiation xxx NE
marker xxx NE
for xxx NE
the xxx NE
monocyte/macrophage xxx/xxx cell_type_B
lineage xxx cell_type_E
. . NE

We Xx NE
have xxx NE
analyzed xxx NE
the xxx NE
regulation xxx NE
of xx NE
CD14 XXdd NE
expression xxx NE
during xxx NE
1 d NE
alpha,25-dihydroxyvitamin xxx,dd-xxx NE
D3 Xd NE
(VitD3)-induced (XxxXd)-xxx NE
monocytic xxx NE
differentiation xxx NE
. . NE

Using Xxxx NE
FACS XXXX NE
, , NE
Northern Xxxx NE
blotting xxx NE
, , NE
and xxx NE
nuclear xxx NE
run-on xxx-xx NE
analyses xxx NE
, , NE
we xx NE
demonstrate xxx NE
that xxx NE
the xxx NE
up-regulation xx-xxx NE
of xx NE
CD14 XXdd NE
expression xxx NE
during xxx NE
monocytic xxx NE
cell xxx NE
maturation xxx NE
is xx NE
regulated xxx NE
mainly xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
gene xxx NE
transcription xxx NE
, , NE
and xxx NE
that xxx NE
new xxx NE
protein xxx NE
synthesis xxx NE
is xx NE
required xxx NE
for xxx NE
CD14 XXdd NE
induction xxx NE
. . NE

We Xx NE
have xxx NE
recently xxx NE
cloned xxx NE
the xxx NE
CD14 XXdd DNA_B
5' d' DNA_M
upstream xxx DNA_M
sequence xxx DNA_E
and xxx NE
demonstrated xxx NE
its xxx NE
tissue-specific xxx-xxx NE
promoter xxx NE
activity xxx NE
. . NE

Using Xxxx NE
stable xxx NE
transfection xxx NE
of xx NE
the xxx NE
monocytoid xxx cell_line_B
U937 Xddd cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
with xxx NE
a x NE
series xxx NE
of xx NE
deletion xxx NE
mutants xxx NE
of xx NE
the xxx NE
CD14 XXdd DNA_B
5' d' DNA_M
upstream xxx DNA_M
sequence xxx DNA_E
coupled xxx NE
to xx NE
a x NE
reporter xxx NE
gene xxx NE
construct xxx NE
, , NE
we xx NE
show xxx NE
that xxx NE
bp xx DNA_B
-128 -ddd DNA_M
to xx DNA_M
-70 -dd DNA_E
is xx NE
the xxx NE
critical xxx NE
region xxx NE
for xxx NE
the xxx NE
induction xxx NE
of xx NE
CD14 XXdd NE
expression xxx NE
. . NE

This Xxxx NE
region xxx NE
contains xxx NE
two xxx NE
binding xxx DNA_B
sites xxx DNA_E
for xxx NE
the xxx NE
Sp1 Xxd protein_B
transcription xxx protein_M
factor xxx protein_E
. . NE

A X NE
3-bp d-xx NE
mutation xxx NE
at xx NE
the xxx NE
distal xxx NE
Sp1-binding Xxd-xxx DNA_B
site xxx DNA_E
not xxx NE
only xxx NE
eliminates xxx NE
Sp1 Xxd NE
interaction xxx NE
, , NE
but xxx NE
also xxx NE
abolishes xxx NE
most xxx NE
of xx NE
the xxx NE
VitD3 XxxXd NE
induction xxx NE
of xx NE
CD14 XXdd NE
expression xxx NE
. . NE

Electrophoretic Xxxx NE
mobility xxx NE
shift xxx NE
analysis xxx NE
does xxx NE
not xxx NE
detect xxx NE
a x NE
direct xxx NE
interaction xxx NE
of xx NE
the xxx NE
CD14 XXdd protein
distal xxx NE
Sp1-binding Xxd-xxx DNA_B
site xxx DNA_E
with xxx NE
the xxx NE
vitamin xxx protein_B
D3 Xd protein_M
receptor xxx protein_E
and xxx NE
its xxx NE
partner xxx NE
, , NE
the xxx NE
retinoid xxx protein_B
X X protein_M
receptor xxx protein_E
. . NE

These Xxxx NE
data xxx NE
demonstrate xxx NE
that xxx NE
VitD3 XxxXd NE
induces xxx NE
CD14 XXdd protein
indirectly xxx NE
through xxx NE
some xxx NE
intermediary xxx protein_B
factor xxx protein_E
, , NE
and xxx NE
suggest xxx NE
a x NE
critical xxx NE
role xxx NE
for xxx NE
Sp1 Xxd protein
in xx NE
this xxx NE
process xxx NE
. . NE

DNA-binding XXX-xxx NE
and xxx NE
transcriptional xxx NE
regulatory xxx NE
properties xxx NE
of xx NE
hepatic xxx NE
leukemia xxx NE
factor xxx NE
( ( NE
HLF XXX NE
) ) NE
and xxx NE
the xxx NE
t(17;19) x(dd;dd) NE
acute xxx NE
lymphoblastic xxx NE
leukemia xxx NE
chimera xxx NE
E2A- XdX- NE
HLF XXX NE
. . NE

The Xxx NE
t(17;19) x(dd;dd) NE
translocation xxx NE
in xx NE
acute xxx NE
lymphoblastic xxx NE
leukemias xxx NE
results xxx NE
in xx NE
creation xxx NE
of xx NE
E2A- XdX- NE
hepatic xxx NE
leukemia xxx NE
factor xxx NE
( ( NE
HLF XXX NE
) ) NE
chimeric xxx NE
proteins xxx NE
that xxx NE
contain xxx NE
the xxx NE
DNA-binding XXX-xxx NE
and xxx NE
protein xxx NE
dimerization xxx NE
domains xxx NE
of xx NE
the xxx NE
basic xxx NE
leucine xxx NE
zipper xxx NE
(bZIP) (xXXX) NE
protein xxx NE
HLF XXX NE
fused xxx NE
to xx NE
a x NE
portion xxx NE
of xx NE
E2A XdX NE
proteins xxx NE
with xxx NE
transcriptional xxx NE
activation xxx NE
properties xxx NE
. . NE

An Xx NE
in xx NE
vitro xxx NE
binding xxx NE
site xxx NE
selection xxx NE
procedure xxx NE
was xxx NE
used xxx NE
to xx NE
determine xxx NE
DNA XXX NE
sequences xxx NE
preferentially xxx NE
bound xxx NE
by xx NE
wild-type xxx-xxx protein_B
HLF XXX protein_E
and xxx NE
chimeric xxx NE
E2A- XdX- NE
HLF XXX NE
proteins xxx NE
isolated xxx NE
from xxx NE
various xxx NE
t(17;19)-bearing x(dd;dd)-xxx NE
leukemias xxx NE
. . NE

All Xxx NE
were xxx NE
found xxx NE
to xx NE
selectively xxx NE
bind xxx NE
the xxx NE
consensus xxx DNA_B
sequence xxx DNA_E
5'-GTTACGTAAT-3' d'-XXXXXXXXXX-d' NE
with xxx NE
high xxx NE
affinity xxx NE
. . NE

Wild-type Xxxx-xxx NE
and xxx NE
chimeric xxx protein_B
HLF XXX protein_M
proteins xxx protein_E
also xxx NE
bound xxx NE
closely xxx NE
related xxx NE
sites xxx NE
identified xxx NE
previously xxx NE
for xxx NE
bZIP xXXX protein_B
proteins xxx protein_E
of xx NE
both xxx NE
the xxx NE
proline xxx NE
-and -xxx NE
acidic xxx NE
amino xxx NE
acid-rich xxx-xxx NE
( ( NE
PAR XXX NE
) ) NE
and xxx NE
C/EBP X/XXX NE
subfamilies xxx NE
; ; NE
however xxx NE
, , NE
E2A- XdX- NE
HLF XXX NE
proteins xxx NE
were xxx NE
significantly xxx NE
less xxx NE
tolerant xxx NE
of xx NE
certain xxx NE
deviations xxx NE
from xxx NE
the xxx NE
HLF XXX NE
consensus xxx NE
binding xxx NE
site xxx NE
. . NE

These Xxxx NE
differences xxx NE
were xxx NE
directly xxx NE
attributable xxx NE
to xx NE
loss xxx NE
of xx NE
an xx NE
HLF XXX DNA_B
ancillary xxx DNA_M
DNA-binding XXX-xxx DNA_M
domain xxx DNA_E
in xx NE
all xxx NE
E2A- XdX- NE
HLF XXX NE
chimeras xxx NE
and xxx NE
were xxx NE
further xxx NE
exacerbated xxx NE
by xx NE
a x NE
zipper xxx NE
mutation xxx NE
in xx NE
one xxx NE
isolate xxx NE
. . NE

Both Xxxx NE
wild-type xxx-xxx protein
and xxx NE
chimeric xxx protein_B
HLF XXX protein_M
proteins xxx protein_E
displayed xxx NE
transcriptional xxx NE
activator xxx NE
properties xxx NE
HLF XXX DNA_B
consensus xxx DNA_M
binding xxx DNA_M
site xxx DNA_M
or xx DNA_M
C/EBP X/XXX DNA_M
consensus xxx DNA_M
binding xxx DNA_M
site xxx DNA_E
lymphoid xxx NE
and xxx NE
lymphoid xxx cell_type_B
cell xxx cell_type_M
and xxx cell_type_M
nonlymphoid xxx cell_type_M
cell xxx cell_type_E
reporter xxx NE
genes xxx NE
containing xxx NE
HLF XXX NE
or xx DNA
C/EBP X/XXX NE
consensus xxx NE
binding xxx NE
sites xxx NE
. . NE

But Xxx NE
on xx NE
reporter xxx DNA_B
genes xxx DNA_E
with xxx NE
nonoptimal xxx DNA_B
binding xxx DNA_M
sites xxx DNA_E
, , NE
their xxx NE
transcriptional xxx NE
properties xxx NE
diverged xxx NE
and xxx NE
E2A- XdX- NE
HLF XXX NE
competitively xxx NE
inhibited xxx NE
activation xxx NE
by xx NE
wild-type xxx-xxx NE
PAR XXX NE
proteins xxx NE
. . NE

These Xxxx NE
findings xxx NE
establish xxx NE
a x NE
spectrum xxx NE
of xx NE
binding xxx NE
site-specific xxx-xxx NE
transcriptional xxx NE
properties xxx NE
for xxx NE
E2A- XdX- NE
HLF XXX NE
which xxx NE
may xxx NE
preferentially xxx NE
activate xxx NE
expression xxx NE
of xx NE
select xxx NE
subordinate xxx NE
genes xxx NE
as xx NE
a x NE
homodimer xxx NE
and xxx NE
potentially xxx NE
antagonize xxx NE
expression xxx NE
of xx NE
others xxx NE
through xxx NE
heteromeric xxx NE
interactions xxx NE
. . NE

ZAP-70 XXX-dd protein_B
tyrosine xxx protein_M
kinase xxx protein_E
, , NE
CD45 XXdd protein
, , NE
and xxx NE
T X protein_B
cell xxx protein_M
receptor xxx protein_E
involvement xxx NE
in xx NE
UV-induced XX-xxx NE
T X NE
cell xxx NE
signal xxx NE
transduction xxx NE
and xxx NE
H2O2-induced XdXd-xxx NE
T X NE
cell xxx NE
signal xxx NE
transduction xxx NE

Several Xxxx NE
mammalian xxx NE
responses xxx NE
to xx NE
UV XX NE
irradiation xxx NE
, , NE
including xxx NE
the xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
, , NE
are xxx NE
believed xxx NE
to xx NE
involve xxx NE
tyrosine xxx NE
phosphorylation xxx NE
. . NE

UV XX NE
irradiation xxx NE
and xxx NE
H2O2 XdXd NE
treatment xxx NE
of xx NE
T X cell_type_B
lymphocytes xxx cell_type_E
induce xxx NE
protein xxx NE
tyrosine xxx NE
phosphorylation xxx NE
and xxx NE
Ca2+ Xxd+ NE
signals xxx NE
similar xxx NE
to xx NE
those xxx NE
observed xxx NE
following xxx NE
biological xxx NE
stimulation xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
role xxx NE
of xx NE
cell xxx NE
surface xxx NE
molecules xxx NE
in xx NE
these xxx NE
responses xxx NE
. . NE

Normal Xxxx NE
T X cell_type_B
lymphocytes xxx cell_type_E
whose xxx NE
surface xxx NE
expression xxx NE
of xx NE
CD3 XXd protein
was xxx NE
depleted xxx NE
showed xxx NE
impaired xxx NE
UV-induced XX-xxx NE
tyrosine xxx NE
phosphorylation xxx NE
and xxx NE
Ca2+ Xxd+ NE
signals xxx NE
. . NE

Similarly Xxxx NE
, , NE
Jurkat Xxxx cell_line_B
T X cell_line_M
cell xxx cell_line_M
lines xxx cell_line_E
deficient xxx NE
in xx NE
CD3 XXd NE
expression xxx NE
or xx NE
CD45 XXdd NE
expression xxx NE
also xxx NE
gave xxx NE
impaired xxx NE
UV XX NE
responses xxx NE
. . NE

However Xxxx NE
, , NE
all xxx NE
these xxx NE
cell xxx NE
types xxx NE
still xxx NE
gave xxx NE
strong xxx NE
Ca2+ Xxd+ NE
and xxx NE
tyrosine xxx NE
phosphorylation xxx NE
responses xxx NE
to xx NE
H2O2 XdXd NE
. . NE

The Xxx NE
T X NE
cell xxx NE
tyrosine xxx NE
kinase xxx protein_B
ZAP-70 XXX-dd protein_E
was xxx NE
found xxx NE
to xx NE
be xx NE
highly xxx NE
responsive xxx NE
to xx NE
UV XX NE
and xxx NE
H2O2 XdXd NE
treatment xxx NE
. . NE

ZAP-70 XXX-dd NE
responsiveness xxx NE
to xx NE
UV XX NE
required xxx NE
expression xxx NE
of xx NE
both xxx NE
CD3 XXd protein
and xxx NE
CD45 XXdd protein
, , NE
whereas xxx NE
only xxx NE
CD3 XXd protein
was xxx NE
required xxx NE
for xxx NE
the xxx NE
response xxx NE
to xx NE
H2O2 XdXd NE
. . NE

UV XX NE
-induced -xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
was xxx NE
blocked xxx NE
by xx NE
CD3 XXd NE
depletion xxx NE
, , NE
indicating xxx NE
the xxx NE
importance xxx NE
of xx NE
such xxx NE
cell xxx NE
surface xxx NE
molecules xxx NE
in xx NE
biological xxx NE
responses xxx NE
to xx NE
UV XX NE
. . NE

In Xx NE
nonlymphoid xxx cell_type_B
cells xxx cell_type_E
, , NE
the xxx NE
epidermal xxx protein_B
growth xxx protein_M
factor xxx protein_M
receptor xxx protein_E
displayed xxx NE
increased xxx NE
tyrosine xxx NE
phosphorylation xxx NE
within xxx NE
seconds xxx NE
of xx NE
UV XX NE
irradiation xxx NE
. . NE

These Xxxx NE
results xxx NE
suggest xxx NE
that xxx NE
UV XX NE
-induced -xxx NE
signal xxx NE
transduction xxx NE
is xx NE
mediated xxx NE
via xxx NE
cell xxx NE
surface xxx NE
receptors xxx NE
that xxx NE
normally xxx NE
respond xxx NE
to xx NE
biological xxx NE
stimulation xxx NE
, , NE
whereas xxx NE
H2O2 XdXd NE
is xx NE
able xxx NE
to xx NE
partially xxx NE
bypass xxx NE
this xxx NE
requirement xxx NE
. . NE

Inhibition Xxxx NE
of xx NE
the xxx NE
differentiation xxx NE
of xx NE
human xxx cell_line_B
myeloid xxx cell_line_M
cell xxx cell_line_M
lines xxx cell_line_E
by xx NE
redox xxx NE
changes xxx NE
induced xxx NE
through xxx NE
glutathione xxx NE
depletion xxx NE
. . NE

We Xx NE
have xxx NE
investigated xxx NE
the xxx NE
effect xxx NE
of xx NE
redox xxx NE
changes xxx NE
in xx NE
vivo xxx NE
on xx NE
the xxx NE
differentiation xxx NE
of xx NE
two xxx NE
human xxx cell_line_B
myeloid xxx cell_line_M
cell xxx cell_line_M
lines xxx cell_line_E
, , NE
HL-60 XX-dd cell_line
and xxx NE
KG-1 XX-d cell_line
. . NE

The Xxx NE
glutathione xxx NE
-depleting -xxx NE
agent xxx NE
diethyl xxx NE
maleate xxx NE
( ( NE
DEM XXX NE
) ) NE
prevented xxx NE
the xxx NE
development xxx NE
of xx NE
differentiated xxx NE
features xxx NE
in xx NE
response xxx NE
to xx NE
phorbol xxx NE
esters xxx NE
, , NE
including xxx NE
adherence xxx NE
of xx NE
the xxx NE
cells xxx NE
to xx NE
plastic xxx NE
surfaces xxx NE
and xxx NE
repression xxx NE
of xx NE
the xxx NE
myeloperoxidase xxx DNA_B
gene xxx DNA_M
and xxx DNA_M
CD34 XXdd DNA_M
gene xxx DNA_E

Moreover Xxxx NE
, , NE
DEM XXX NE
abolished xxx NE
phorbol xxx NE
12-myristate dd-xxx NE
13-acetate dd-xxx NE
-induced -xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factors xxx NE
AP-1 XX-d NE
and xxx NE
Egr-1 Xxx-d NE
, , NE
suggesting xxx NE
that xxx NE
inhibition xxx NE
of xx NE
differentiation xxx NE
may xxx NE
be xx NE
due xxx NE
, , NE
at xx NE
least xxx NE
in xx NE
part xxx NE
, , NE
to xx NE
redox xxx NE
modifications xxx NE
of xx NE
these xxx NE
proteins xxx NE
. . NE

Lipopolysaccharide Xxxx NE
induction xxx NE
of xx NE
tissue xxx NE
factor xxx NE
gene xxx NE
expression xxx NE
in xx NE
monocytic xxx cell_type_B
cells xxx cell_type_E
is xx NE
mediated xxx NE
by xx NE
binding xxx NE
of xx NE
c-Rel/p65 x-Xxx/xdd protein_B
heterodimers xxx protein_E
to xx NE
a x NE
kappa xxx DNA_B
B-like X-xxx DNA_M
site xxx DNA_E
. . NE

Exposure Xxxx NE
of xx NE
monocytic xxx cell_type_B
cells xxx cell_type_E
to xx NE
bacterial xxx NE
lipopolysaccharide xxx NE
( ( NE
LPS XXX NE
) ) NE
activates xxx NE
the xxx NE
NF-kappa XX-xxx protein_B
B X protein_M
/Rel /Xxx protein_M
family xxx protein_E
of xx NE
proteins xxx NE
and xxx NE
leads xxx NE
to xx NE
the xxx NE
rapid xxx NE
induction xxx NE
of xx NE
inflammatory xxx protein_B
gene xxx protein_M
products xxx protein_E
, , NE
including xxx NE
tissue xxx protein_B
factor xxx protein_E
( ( NE
TF XX protein
) ) NE
. . NE

TF XX protein
is xx NE
the xxx NE
primary xxx NE
cellular xxx NE
initiator xxx NE
of xx NE
the xxx NE
coagulation xxx NE
protease xxx NE
cascades xxx NE
. . NE

Here Xxxx NE
we xx NE
report xxx NE
the xxx NE
characterization xxx NE
of xx NE
a x NE
nuclear xxx protein_B
complex xxx protein_E
from xxx NE
human xxx NE
monocytic xxx cell_type_B
cells xxx cell_type_E
that xxx NE
bound xxx NE
to xx NE
a x NE
kappa xxx DNA_B
B-like X-xxx DNA_M
site xxx DNA_E
, , NE
5'-CGGAGTTTCC-3' d'-XXXXXXXXXX-d' DNA
, , NE
in xx NE
the xxx NE
5'-flanking d'-xxx DNA_B
region xxx DNA_E
of xx NE
the xxx NE
human xxx DNA_B
TF XX DNA_M
gene xxx DNA_E
. . NE

This Xxxx NE
nuclear xxx protein_B
complex xxx protein_E
was xxx NE
activated xxx NE
by xx NE
LPS XXX NE
with xxx NE
kinetics xxx NE
that xxx NE
preceded xxx NE
induction xxx NE
of xx NE
the xxx NE
TF XX DNA_B
gene xxx DNA_E
. . NE

In Xx NE
vitro xxx NE
binding xxx NE
studies xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
TF XX DNA_B
site xxx DNA_E
bound xxx NE
translated xxx NE
c-Rel x-Xxx protein_B
homodimer xxx protein_M
and xxx protein_M
p65 xdd protein_M
homodimer xxx protein_E
but xxx NE
not xxx NE
p50/p65 xdd/xdd protein_B
heterodimers xxx protein_E
or xx NE
p50 xdd protein_B
homodimers xxx protein_E
. . NE

Base-pair Xxxx-xxx NE
substitutions xxx NE
in xx NE
the xxx NE
TF XX DNA_B
site xxx DNA_E
indicated xxx NE
that xxx NE
the xxx NE
presence xxx NE
of xx NE
a x NE
cytosine xxx NE
at xx NE
position xxx protein_B
1 d protein_E
precluded xxx NE
binding xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
. . NE

In Xx NE
fact xxx NE
, , NE
under xxx NE
low-ionic-strength xxx-xxx-xxx NE
conditions xxx NE
, , NE
the xxx NE
TF XX protein_B
complex xxx protein_E
did xxx NE
not xxx NE
migrate xxx NE
with xxx NE
translated xxx NE
p50/p65 xdd/xdd protein_B
dimers xxx protein_E
but xxx NE
instead xxx NE
comigrated xxx NE
with xxx NE
c-Rel x-Xxx NE
/p65 /xdd NE
dimers xxx NE
. . NE

Antibodies Xxxx NE
against xxx NE
the xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
and xxx NE
Rel Xxx NE
proteins xxx NE
and xxx NE
UV XX NE
cross-linking xxx-xxx NE
studies xxx NE
revealed xxx NE
the xxx NE
presence xxx NE
of xx NE
c-Rel x-Xxx NE
and xxx NE
p65 xdd NE
and xxx NE
the xxx NE
absence xxx NE
of xx NE
p50 xdd NE
in xx NE
the xxx NE
TF XX NE
complex xxx NE
and xxx NE
further xxx NE
showed xxx NE
that xxx NE
c-Rel x-Xxx NE
/ / NE
p65 xdd NE
heterodimers xxx NE
selectively xxx NE
bound xxx NE
to xx NE
the xxx NE
TF XX NE
kappa xxx NE
B-like X-xxx NE
site xxx NE
. . NE

Functional Xxxx NE
studies xxx NE
indicated xxx NE
that xxx NE
the xxx NE
TF XX DNA_B
site xxx DNA_E
conferred xxx NE
LPS XXX NE
inducibility xxx NE
on xx NE
a x NE
heterologous xxx DNA_B
promoter xxx DNA_E
and xxx NE
was xxx NE
transactivated xxx NE
by xx NE
c-Rel x-Xxx protein
or xx NE
p65 xdd protein
. . NE

Taken Xxxx NE
together xxx NE
, , NE
our xxx NE
results xxx NE
demonstrated xxx NE
that xxx NE
binding xxx NE
of xx NE
c-Rel x-Xxx NE
/ / NE
p65 xdd NE
heterodimers xxx NE
to xx NE
a x NE
novel xxx NE
kappa xxx NE
B-like X-xxx NE
site xxx NE
mediated xxx NE
LPS XXX NE
induction xxx NE
of xx NE
TF XX NE
gene xxx NE
expression xxx NE
in xx NE
monocytic xxx NE
cells xxx NE
. . NE

Inhibition Xxxx NE
of xx NE
T X NE
cell xxx NE
activation xxx NE
by xx NE
the xxx NE
extracellular xxx protein_B
matrix xxx protein_M
protein xxx protein_E
tenascin xxx protein
. . NE

Tenascin Xxxx protein
( ( NE
TN XX protein
) ) NE
is xx NE
an xx NE
extracellular xxx protein_B
matrix xxx protein_M
protein xxx protein_E
that xxx NE
is xx NE
expressed xxx NE
widely xxx NE
in xx NE
the xxx NE
fetus xxx NE
and xxx NE
sparingly xxx NE
in xx NE
the xxx NE
adult xxx NE
, , NE
but xxx NE
reappears xxx NE
at xx NE
high xxx NE
levels xxx NE
in xx NE
certain xxx NE
areas xxx NE
of xx NE
tissue xxx NE
insult xxx NE
such xxx NE
as xx NE
tumor xxx NE
matrices xxx NE
and xxx NE
sites xxx NE
of xx NE
wound xxx NE
healing xxx NE
. . NE

We Xx NE
show xxx NE
here xxx NE
that xxx NE
soluble xxx NE
TN XX protein
inhibits xxx NE
proliferation xxx NE
of xx NE
human xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
in xx NE
response xxx NE
to xx NE
alpha xxx protein_B
CD3 XXd protein_M
Ab Xx protein_E
co-immobilized xx-xxx NE
with xxx NE
the xxx NE
extracellular xxx protein_B
matrix xxx protein_M
protein xxx protein_E
fibronectin xxx protein
( ( NE
FN XX protein
) ) NE
. . NE

TN XX protein
also xxx NE
inhibits xxx NE
proliferation xxx NE
driven xxx NE
by xx NE
alpha xxx NE
CD3 XXd NE
/IL-2 /XX-d NE
or xx NE
by xx NE
phorbol xxx NE
ester/IL-2 xxx/XX-d NE
, , NE
and xxx NE
it xx NE
prevents xxx NE
high xxx NE
level xxx NE
induction xxx NE
of xx NE
IL-2R XX-dX NE
. . NE

The Xxx NE
presence xxx NE
of xx NE
TN XX protein
in xx NE
culture xxx NE
medium xxx NE
does xxx NE
not xxx NE
detectably xxx NE
alter xxx NE
the xxx NE
pattern xxx NE
of xx NE
tyrosine xxx NE
phosphorylation xxx NE
resulting xxx NE
from xxx NE
T X NE
cell xxx NE
triggering xxx NE
with xxx NE
alpha xxx protein_B
CD3 XXd protein_E
, , NE
but xxx NE
at xx NE
later xxx NE
time xxx NE
points xxx NE
prevents xxx NE
the xxx NE
appearance xxx NE
of xx NE
functional xxx NE
NF-AT1 XX-XXd NE
transcription xxx NE
factor xxx NE
complexes xxx NE
in xx NE
T X NE
cell xxx NE
nuclear xxx NE
extracts xxx NE
. . NE

These Xxxx NE
findings xxx NE
are xxx NE
consistent xxx NE
with xxx NE
the xxx NE
postulated xxx NE
role xxx NE
for xxx NE
TN XX protein
as xx NE
a x NE
natural xxx NE
antagonist xxx NE
to xx NE
FN XX protein
action xxx NE
, , NE
and xxx NE
suggest xxx NE
that xxx NE
T X NE
cell xxx NE
responses xxx NE
occurring xxx NE
at xx NE
tissue xxx NE
sites xxx NE
in xx NE
which xxx NE
TN XX protein
is xx NE
expressed xxx NE
could xxx NE
be xx NE
influenced xxx NE
by xx NE
its xxx NE
presence xxx NE
. . NE

Human Xxxx protein_B
immunodeficiency xxx protein_M
virus xxx protein_M
type xxx protein_M
1 d protein_M
Nef Xxx protein_M
protein xxx protein_E
down-regulates xxx-xxx NE
transcription xxx protein_B
factors xxx protein_E
NF-kappa XX-xxx protein_B
B X protein_E
and xxx NE
AP-1 XX-d protein
in xx NE
human xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
in xx NE
vitro xxx NE
after xxx NE
T-cell X-xxx NE
receptor xxx NE
stimulation xxx NE
. . NE

Human Xxxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
( ( NE
HIV-1 XXX-d NE
) ) NE
negative xxx protein_B
factor xxx protein_E
( ( NE
Nef Xxx protein
) ) NE
has xxx NE
been xxx NE
shown xxx NE
to xx NE
down-regulate xxx-xxx NE
the xxx NE
transcription xxx protein_B
factors xxx protein_E
NF-kappa XX-xxx protein_B
B X protein_E
and xxx NE
AP-1 XX-d protein
in xx NE
vitro xxx NE
. . NE

To Xx NE
define xxx NE
the xxx NE
mechanism xxx NE
of xx NE
action xxx NE
of xx NE
the xxx NE
Nef Xxx protein
protein xxx NE
, , NE
the xxx NE
signal xxx NE
transduction xxx NE
pathways xxx NE
which xxx NE
may xxx NE
be xx NE
affected xxx NE
in xx NE
T X cell_type_B
cells xxx cell_type_E
by xx NE
constitutive xxx NE
expression xxx NE
of xx NE
the xxx NE
nef xxx NE
gene xxx NE
were xxx NE
examined xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
T X cell_type_B
cells xxx cell_type_E
with xxx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
, , NE
interleukin-1 xxx-d NE
, , NE
or xx NE
lipopolysaccharide xxx NE
resulted xxx NE
in xx NE
the xxx NE
recruitment xxx NE
of xx NE
transcriptional xxx NE
factors xxx NE
to xx NE
a x NE
similar xxx NE
level xxx NE
whether xxx NE
or xx NE
not xxx NE
the xxx NE
cells xxx NE
expressed xxx NE
the xxx NE
nef xxx NE
gene xxx NE
. . NE

On Xx NE
the xxx NE
other xxx NE
hand xxx NE
, , NE
stimulation xxx NE
of xx NE
T X cell_type_B
cells xxx cell_type_E
by xx NE
mitogens xxx NE
or xx NE
antibodies xxx NE
to xx NE
the xxx NE
T-cell X-xxx NE
receptor xxx NE
(TCR)- (XXX)- NE
CD3 XXd protein
complex xxx NE
resulted xxx NE
in xx NE
the xxx NE
down-regulation xxx-xxx NE
of xx NE
transcriptional xxx NE
factors xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
and xxx NE
AP-1 XX-d protein
in xx NE
cells xxx NE
expressing xxx NE
the xxx NE
nef xxx NE
gene xxx NE
compared xxx NE
with xxx NE
cells xxx NE
not xxx NE
expressing xxx NE
the xxx NE
nef xxx NE
gene xxx NE
. . NE

Because Xxxx NE
the xxx NE
Nef Xxx protein
protein xxx NE
does xxx NE
not xxx NE
affect xxx NE
the xxx NE
surface xxx NE
expression xxx NE
of xx NE
the xxx NE
CD3 XXd protein
-TCR -XXX NE
complex xxx NE
, , NE
we xx NE
conclude xxx NE
that xxx NE
the xxx NE
Nef Xxx protein
protein xxx NE
down-regulates xxx-xxx NE
the xxx NE
transcriptional xxx NE
factors xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
and xxx NE
AP-1 XX-d protein
in xx NE
T X cell_type_B
cells xxx cell_type_E
in xx NE
vitro xxx NE
through xxx NE
an xx NE
effect xxx NE
on xx NE
the xxx NE
TCR-dependent XXX-xxx NE
signal xxx NE
transduction xxx NE
pathway xxx NE
. . NE

Effects Xxxx NE
of xx NE
alpha-lipoic xxx-xxx NE
acid xxx NE
and xxx NE
dihydrolipoic xxx NE
acid xxx NE
on xx NE
expression xxx NE
of xx NE
proto-oncogene xxx-xxx DNA_B
c-fos x-xxx DNA_E
. . NE

The Xxx NE
transcription xxx protein_B
factor xxx protein_E
AP-1 XX-d protein
is xx NE
an xx NE
important xxx NE
human xxx NE
mediator xxx NE
of xx NE
the xxx NE
cellular xxx NE
response xxx NE
to xx NE
serum xxx NE
, , NE
growth xxx protein_B
factors xxx protein_E
, , NE
and xxx NE
phorbol xxx NE
esters xxx NE
such xxx NE
as xx NE
12-O-tetradecanoyl-phorbol-13 dd-X-xxx-xxx-dd NE
acetate xxx NE
( ( NE
TPA XXX NE
) ) NE
. . NE

The Xxx NE
AP-1 XX-d protein
complex xxx NE
consists xxx NE
of xx NE
distinct xxx NE
protein xxx protein_B
heterodimers xxx protein_E
encoded xxx NE
by xx NE
the xxx NE
proto-oncogene xxx-xxx DNA_B
c-fos x-xxx DNA_E
and xxx NE
c-jun x-xxx RNA_B
mRNA xXXX RNA_E
whose xxx NE
gene xxx NE
expression xxx NE
can xxx NE
be xx NE
induced xxx NE
by xx NE
TPA XXX NE
, , NE
cyclic xxx NE
AMP XXX NE
and xxx NE
growth xxx protein_B
factors xxx protein_E
. . NE

Recent Xxxx NE
findings xxx NE
suggest xxx NE
an xx NE
involvement xxx NE
of xx NE
reactive xxx NE
oxygen xxx NE
species xxx NE
in xx NE
the xxx NE
pathway xxx NE
of xx NE
TPA XXX NE
and xxx NE
protein xxx protein_B
kinase xxx protein_M
C X protein_E
leading xxx NE
to xx NE
expression xxx NE
of xx NE
c-fos x-xxx RNA_B
mRNA xXXX RNA_M
and xxx RNA_M
c-jun x-xxx RNA_M
mRNA xXXX RNA_E

To Xx NE
investigate xxx NE
the xxx NE
role xxx NE
of xx NE
reactive xxx NE
oxygen xxx NE
species xxx NE
we xx NE
studied xxx NE
the xxx NE
effects xxx NE
of xx NE
alpha-lipoic xxx-xxx NE
acid xxx NE
and xxx NE
dihydrolipoic xxx NE
acid xxx NE
( ( NE
natural xxx NE
thiol xxx NE
antioxidants xxx NE
) ) NE
on xx NE
the xxx NE
expression xxx NE
of xx NE
c-fos x-xxx RNA_B
mRNA xXXX RNA_E
in xx NE
human xxx cell_line_B
Jurkat Xxxx cell_line_M
T X cell_line_M
cells xxx cell_line_E
. . NE

When Xxxx NE
cells xxx NE
were xxx NE
preincubated xxx NE
with xxx NE
dihydrolipoic xxx NE
acid xxx NE
(0.2 (d.d NE
mM) xX) NE
the xxx NE
expression xxx NE
of xx NE
c-fos x-xxx RNA_B
mRNA xXXX RNA_E
was xxx NE
suppressed xxx NE
at xx NE
30 dd NE
min xxx NE
after xxx NE
stimulation xxx NE
of xx NE
TPA XXX NE
(0.5 (d.d NE
microM) xxxX) NE
whereas xxx NE
in xx NE
the xxx NE
case xxx NE
of xx NE
preincubation xxx NE
of xx NE
alpha-lipoic xxx-xxx NE
acid xxx NE
(0.2 (d.d NE
microM) xxxX) NE
, , NE
the xxx NE
expression xxx NE
was xxx NE
enhanced xxx NE
at xx NE
30 dd NE
min xxx NE
. . NE

These Xxxx NE
studies xxx NE
support xxx NE
the xxx NE
idea xxx NE
that xxx NE
superoxide xxx NE
anion xxx NE
radical xxx NE
plays xxx NE
a x NE
role xxx NE
in xx NE
the xxx NE
expression xxx NE
of xx NE
c-fos x-xxx RNA_B
mRNA xXXX RNA_E
. . NE

Appraisal Xxxx NE
of xx NE
potential xxx NE
therapeutic xxx NE
index xxx NE
of xx NE
antioxidants xxx NE
on xx NE
the xxx NE
basis xxx NE
of xx NE
their xxx NE
in xx NE
vitro xxx NE
effects xxx NE
on xx NE
HIV XXX NE
replication xxx NE
in xx NE
monocytes xxx cell_type
and xxx NE
interleukin xxx NE
2 d NE
-induced -xxx NE
lymphocyte xxx NE
proliferation xxx NE
. . NE

Antioxidant Xxxx NE
molecules xxx NE
have xxx NE
been xxx NE
suggested xxx NE
to xx NE
be xx NE
of xx NE
therapeutic xxx NE
value xxx NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
HIV XXX NE
-infected -xxx NE
patients xxx NE
. . NE

To Xx NE
evaluate xxx NE
this xxx NE
possibility xxx NE
, , NE
we xx NE
examined xxx NE
in xx NE
vitro xxx NE
the xxx NE
effects xxx NE
of xx NE
two xxx NE
types xxx NE
of xx NE
antioxidant xxx NE
molecules xxx NE
in xx NE
terms xxx NE
of xx NE
inhibition xxx NE
of xx NE
HIV XXX NE
replication xxx NE
in xx NE
monocytes xxx cell_type
, , NE
one xxx NE
of xx NE
the xxx NE
main xxx NE
reservoirs xxx NE
of xx NE
HIV XXX NE
, , NE
and xxx NE
also xxx NE
in xx NE
terms xxx NE
of xx NE
modulation xxx NE
of xx NE
the xxx NE
immune xxx NE
competence xxx NE
as xx NE
measured xxx NE
by xx NE
PBMC XXXX NE
proliferation xxx NE
. . NE

We Xx NE
tested xxx NE
the xxx NE
effects xxx NE
of xx NE
BHA XXX NE
, , NE
a x NE
phenolic, xxx, NE
lipid-soluble, xxx-xxx, NE
chain-breaking xxx-xxx NE
antioxidant xxx NE
, , NE
and xxx NE
NAC XXX NE
, , NE
a x NE
known xxx NE
glutathione xxx NE
precursor xxx NE
with xxx NE
some xxx NE
direct xxx NE
free-radical xxx-xxx NE
scavenging xxx NE
properties xxx NE
as xx NE
well xxx NE
, , NE
on xx NE
the xxx NE
regulation xxx NE
of xx NE
HIV XXX NE
-1 -d NE
expression xxx NE
in xx NE
latently xxx NE
infected xxx NE
U1 Xd NE
cells xxx NE
and xxx NE
in xx NE
productively xxx NE
and xxx NE
chronically xxx NE
infected xxx NE
U937 Xddd NE
cells xxx NE
. . NE

Both Xxxx NE
antioxidants xxx NE
inhibited xxx NE
TNF-induced XXX-xxx NE
NF-kappa XX-xxx NE
B X NE
activity xxx NE
or xx NE
PMA-induced XXX-xxx NE
NF-kappa XX-xxx NE
B X NE
activity xxx NE
U1 Xd NE
cells xxx NE
, , NE
as xx NE
well xxx NE
as xx NE
the xxx NE
sustained xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
activity xxx NE
permanently xxx NE
induced xxx NE
by xx NE
the xxx NE
virus xxx NE
itself xxx NE
in xx NE
chronically xxx NE
HIV XXX NE
-infected -xxx NE
U937 Xddd cell_line_B
cells xxx cell_line_E
. . NE

This Xxxx NE
resulted xxx NE
in xx NE
only xxx NE
a x NE
partial xxx NE
inhibition xxx NE
of xx NE
TNF- XXX- NE
induced xxx NE
HIV XXX NE
replication xxx NE
or xx NE
PMA- XXX- NE
induced xxx NE
HIV XXX NE
replication xxx NE
U1 Xd NE
cells xxx NE
, , NE
and xxx NE
no xx NE
detectable xxx NE
effect xxx NE
on xx NE
HIV XXX NE
replication xxx NE
in xx NE
chronically xxx cell_line_B
infected xxx cell_line_M
U937 Xddd cell_line_M
cells xxx cell_line_E
. . NE

This Xxxx NE
may xxx NE
be xx NE
the xxx NE
first xxx NE
limitation xxx NE
to xx NE
potential xxx NE
antiviral xxx NE
effects xxx NE
of xx NE
antioxidant xxx NE
therapies xxx NE
. . NE

Another Xxxx NE
limitation xxx NE
is xx NE
that xxx NE
antioxidant xxx NE
concentrations xxx NE
high xxx NE
enough xxx NE
to xx NE
block xxx NE
NK-kappa XX-xxx NE
B X NE
activation xxx NE
were xxx NE
shown xxx NE
to xx NE
have xxx NE
a x NE
suppressive xxx NE
effect xxx NE
on xx NE
immune xxx NE
functions xxx NE
in xx NE
vitro xxx NE
, , NE
because xxx NE
NAC XXX NE
and xxx NE
BHA XXX NE
blocked xxx NE
IL-2 XX-d NE
-induced -xxx NE
PBMC XXXX NE
proliferation xxx NE
. . NE

These Xxxx NE
data xxx NE
warrant xxx NE
prudence xxx NE
in xx NE
the xxx NE
design xxx NE
of xx NE
antioxidant-based xxx-xxx NE
therapies xxx NE
aimed xxx NE
at xx NE
suppressing xxx NE
HIV XXX NE
replication xxx NE
. . NE

Isolation Xxxx NE
and xxx NE
characterization xxx NE
of xx NE
gelatinase xxx NE
granules xxx NE
from xxx NE
human xxx cell_type_B
neutrophils xxx cell_type_E
. . NE

We Xx NE
recently xxx NE
confirmed xxx NE
the xxx NE
existence xxx NE
of xx NE
gelatinase xxx NE
granules xxx NE
as xx NE
a x NE
subpopulation xxx NE
of xx NE
peroxidase-negative xxx-xxx NE
granules xxx NE
by xx NE
double-labeling xxx-xxx NE
immunogold xxx NE
electron xxx NE
microscopy xxx NE
on xx NE
intact xxx NE
cells xxx NE
and xxx NE
by xx NE
subcellular xxx NE
fractionation xxx NE
. . NE

Further Xxxx NE
characterization xxx NE
of xx NE
gelatinase xxx NE
granules xxx NE
has xxx NE
been xxx NE
hampered xxx NE
by xx NE
poor xxx NE
separation xxx NE
of xx NE
specific xxx NE
and xxx NE
gelatinase xxx NE
granules xxx NE
on xx NE
both xxx NE
two-layer xxx-xxx NE
Percoll Xxxx NE
gradients xxx NE
and xxx NE
sucrose xxx NE
gradients xxx NE
. . NE

We Xx NE
have xxx NE
developed xxx NE
a x NE
three-layer xxx-xxx NE
Percoll Xxxx NE
density xxx NE
gradient xxx NE
that xxx NE
allows xxx NE
separation xxx NE
of xx NE
the xxx NE
different xxx NE
granules xxx NE
and xxx NE
vesicles xxx NE
from xxx NE
human xxx cell_type_B
neutrophils xxx cell_type_E
; ; NE
in xx NE
particular xxx NE
, , NE
it xx NE
allows xxx NE
separation xxx NE
of xx NE
specific xxx NE
and xxx NE
gelatinase xxx NE
granules xxx NE
. . NE

This Xxxx NE
allows xxx NE
us xx NE
to xx NE
characterize xxx NE
these xxx NE
two xxx NE
granule xxx NE
populations xxx NE
with xxx NE
regard xxx NE
to xx NE
their xxx NE
content xxx NE
of xx NE
membrane xxx protein_B
proteins xxx protein_E
, , NE
which xxx NE
become xxx NE
incorporated xxx NE
into xxx NE
the xxx NE
plasma xxx NE
membrane xxx NE
during xxx NE
exocytosis xxx NE
. . NE

We Xx NE
found xxx NE
that xxx NE
gelatinase xxx NE
granules xxx NE
, , NE
defined xxx NE
as xx NE
peroxidase-negative xxx-xxx NE
granules xxx NE
containing xxx NE
gelatinase xxx protein
but xxx NE
lacking xxx NE
lactoferrin xxx protein
, , NE
contain xxx NE
50% dd% NE
of xx NE
total xxx NE
cell xxx NE
gelatinase xxx protein
, , NE
with xxx NE
the xxx NE
remaining xxx NE
residing xxx NE
in xx NE
specific xxx NE
granules xxx NE
. . NE

Furthermore Xxxx NE
, , NE
we xx NE
found xxx NE
that xxx NE
20% dd% NE
to xx NE
25% dd% NE
of xx NE
both xxx NE
the xxx NE
adhesion xxx protein_B
protein xxx protein_M
Mac-1 Xxx-d protein_E
and xxx NE
the xxx NE
NADPH-oxidase XXXXX-xxx protein_B
component xxx protein_M
cytochrome xxx protein_E
b558 xddd protein
is xx NE
localized xxx NE
in xx NE
gelatinase xxx NE
granules xxx NE
. . NE

Although Xxxx NE
no xx NE
qualitative xxx NE
difference xxx NE
was xxx NE
observed xxx NE
between xxx NE
specific xxx NE
granules xxx NE
and xxx NE
gelatinase xxx NE
granules xxx NE
with xxx NE
respect xxx NE
to xx NE
cytochrome xxx protein_B
b558 xddd protein_E
and xxx NE
Mac-1 Xxx-d protein
, , NE
stimulation xxx NE
of xx NE
the xxx NE
neutrophil xxx cell_type
with xxx NE
FMLP XXXX protein
resulted xxx NE
in xx NE
a x NE
selective xxx NE
mobilization xxx NE
of xx NE
the xxx NE
least xxx NE
dense xxx NE
peroxidase-negative xxx-xxx NE
granules xxx NE
, , NE
ie xx NE
, , NE
gelatinase xxx NE
granules xxx NE
, , NE
which xxx NE
, , NE
in xx NE
concert xxx NE
with xxx NE
secretory xxx NE
vesicles xxx NE
, , NE
furnish xxx NE
the xxx NE
plasma xxx NE
membrane xxx NE
with xxx NE
Mac-1 Xxx-d protein
and xxx NE
cytochrome xxx protein_B
b558 xddd protein_E
. . NE

This Xxxx NE
shows xxx NE
that xxx NE
gelatinase xxx NE
granules xxx NE
are xxx NE
functionally xxx NE
important xxx NE
relative xxx NE
to xx NE
specific xxx NE
granules xxx NE
in xx NE
mediating xxx NE
early xxx NE
inflammatory xxx NE
responses xxx NE
. . NE

Regulation Xxxx NE
of xx NE
interleukin-2 xxx-d NE
receptor xxx NE
alpha xxx NE
chain xxx NE
expression xxx NE
and xxx NE
nuclear xxx NE
factor.kappa xxx.xxx NE
B X NE
activation xxx NE
by xx NE
protein xxx protein_B
kinase xxx protein_M
C X protein_E
in xx NE
T X cell_type_B
lymphocytes xxx cell_type_E
. . NE

Autocrine Xxxx NE
role xxx NE
of xx NE
tumor xxx protein_B
necrosis xxx protein_M
factor xxx protein_M
alpha xxx protein_E
. . NE

The Xxx NE
regulation xxx NE
of xx NE
interleukin-2 xxx-d NE
receptor xxx NE
alpha xxx NE
chain xxx NE
( ( NE
IL-2R XX-dX NE
alpha xxx NE
) ) NE
expression xxx NE
and xxx NE
nuclear xxx NE
factor xxx NE
(NF) (XX) NE
activation xxx NE
by xx NE
protein xxx NE
kinase xxx NE
C X NE
( ( NE
PKC XXX NE
) ) NE
in xx NE
resting xxx NE
T X NE
cells xxx NE
, , NE
has xxx NE
been xxx NE
studied xxx NE
. . NE

Treatment Xxxx NE
of xx NE
human xxx NE
resting xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
with xxx NE
phorbol xxx NE
esters xxx NE
strongly xxx NE
induced xxx NE
the xxx NE
expression xxx NE
of xx NE
IL-2R XX-dX protein_B
alpha xxx protein_E
and xxx NE
the xxx NE
activation xxx NE
of xx NE
NF.kappa XX.xxx protein_B
B X protein_E
. . NE

This Xxxx NE
activation xxx NE
was xxx NE
due xxx NE
to xx NE
the xxx NE
translocation xxx NE
of xx NE
p65 xdd protein
and xxx NE
c-Rel x-Xxx protein
NF.kappa XX.xxx protein_B
B X protein_E
proteins xxx NE
from xxx NE
cytoplasmic xxx NE
stores xxx NE
to xx NE
the xxx NE
nucleus xxx NE
, , NE
where xxx NE
they xxx NE
bound xxx NE
the xxx NE
kappa xxx DNA_B
B X DNA_M
sequence xxx DNA_E
of xx NE
the xxx NE
IL-2R XX-dX DNA_B
alpha xxx DNA_M
promoter xxx DNA_E
either xxx NE
as xx NE
p50.p65 xdd.xdd protein
or xx NE
as xx NE
p50 xdd NE
. . NE
c-Rel x-Xxx NE
heterodimers xxx NE
. . NE

Interestingly Xxxx NE
, , NE
all xxx NE
of xx NE
those xxx NE
events xxx NE
were xxx NE
largely xxx NE
indirect xxx NE
and xxx NE
mediated xxx NE
by xx NE
endogenously xxx NE
secreted xxx NE
tumor xxx protein_B
necrosis xxx protein_M
factor xxx protein_M
alpha xxx protein_E
( ( NE
TNF XXX protein_B
alpha xxx protein_E
) ) NE
, , NE
as xx NE
they xxx NE
were xxx NE
strongly xxx NE
inhibited xxx NE
by xx NE
a x NE
neutralizing xxx NE
anti- xxx- NE
TNF XXX NE
alpha xxx NE
monoclonal xxx NE
antibody xxx NE
. . NE

Furthermore Xxxx NE
, , NE
cyclosporin xxx NE
A X NE
, , NE
which xxx NE
blocked xxx NE
TNF XXX NE
alpha xxx NE
production xxx NE
induced xxx NE
by xx NE
PKC XXX protein
, , NE
strongly xxx NE
inhibited xxx NE
IL-2R XX-dX NE
alpha xxx NE
and xxx NE
NF.kappa XX.xxx NE
B X NE
activation xxx NE
. . NE

The Xxx NE
addition xxx NE
of xx NE
either xxx NE
TNF XXX protein_B
alpha xxx protein_E
or xx NE
IL-2 XX-d protein
partially xxx NE
recovered xxx NE
cyclosporin xxx NE
A X NE
-induced -xxx NE
IL-2R XX-dX protein_B
alpha xxx protein_E
inhibition xxx NE
, , NE
but xxx NE
only xxx NE
TNF XXX protein_B
alpha xxx protein_E
completely xxx NE
recovered xxx NE
NF.kappa XX.xxx protein_B
B X protein_E
activation xxx NE
. . NE

Those Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
, , NE
in xx NE
resting xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
, , NE
PKC XXX protein
activation xxx NE
has xxx NE
only xxx NE
a x NE
triggering xxx NE
role xxx NE
, , NE
whereas xxx NE
the xxx NE
endogenously xxx NE
secreted xxx NE
TNF XXX protein_B
alpha xxx protein_E
plays xxx NE
an xx NE
essential xxx NE
role xxx NE
in xx NE
the xxx NE
quantitative xxx NE
control xxx NE
of xx NE
the xxx NE
expression xxx NE
of xx NE
IL-2R XX-dX protein_B
alpha xxx protein_E
chain xxx NE
or xx NE
NF.kappa XX.xxx NE
B X NE
activation xxx NE
. . NE

Superantigens Xxxx protein
activate xxx NE
HIV-1 XXX-d NE
gene xxx NE
expression xxx NE
in xx NE
monocytic xxx cell_type_B
cells xxx cell_type_E
. . NE

Binding Xxxx NE
of xx NE
superantigens xxx NE
to xx NE
MHC XXX protein_B
class xxx protein_M
II XX protein_M
molecules xxx protein_E
results xxx NE
in xx NE
transduction xxx NE
of xx NE
biochemical xxx NE
signals xxx NE
leading xxx NE
to xx NE
cellular xxx NE
activation xxx NE
and xxx NE
gene xxx NE
expression xxx NE
. . NE

We Xx NE
demonstrate xxx NE
that xxx NE
the xxx NE
staphylococcal xxx protein_B
superantigens xxx protein_E
toxic xxx protein_B
shock xxx protein_M
syndrome xxx protein_M
toxin-1 xxx-d protein_E
( ( NE
TSST-1 XXXX-d protein
) ) NE
and xxx NE
staphylococcal xxx protein_B
enterotoxin xxx protein_M
A X protein_E
( ( NE
SEA XXX protein
) ) NE
activate xxx NE
HIV-1 XXX-d NE
-LTR -XXX NE
-driven -xxx NE
transcription xxx NE
of xx NE
chloramphenicol xxx NE
acetyl xxx NE
transferase xxx NE
in xx NE
the xxx NE
human xxx NE
monocytic xxx NE
cell xxx NE
line xxx NE
THP-1 XXX-d NE
. . NE

Induction Xxxx NE
of xx NE
HIV-1 XXX-d NE
- - NE
LTR XXX NE
-driven -xxx NE
transcription xxx NE
in xx NE
THP-1 XXX-d NE
cells xxx NE
by xx NE
superantigens xxx NE
was xxx NE
associated xxx NE
with xxx NE
the xxx NE
induction xxx NE
of xx NE
nuclear xxx NE
factor-kappa xxx-xxx NE
B X NE
DNA-binding XXX-xxx NE
activity xxx NE
. . NE

Superantigens Xxxx protein
also xxx NE
increased xxx NE
viral xxx NE
protein xxx NE
secretion xxx NE
from xxx NE
the xxx NE
granulocyte-macrophage xxx-xxx NE
colony-stimulating xxx-xxx NE
factor xxx NE
-pretreated -xxx NE
chronically xxx NE
infected xxx NE
human xxx NE
monocytic xxx NE
cell xxx NE
line xxx NE
U1 Xd NE
. . NE

Induction Xxxx NE
of xx NE
HIV-1 XXX-d NE
gene xxx NE
expression xxx NE
in xx NE
monocytic xxx cell_type_B
cells xxx cell_type_E
by xx NE
superantigens xxx protein
occurred xxx NE
via xxx NE
tumor xxx NE
necrosis xxx NE
factor-alpha-dependent xxx-xxx-xxx NE
mechanism xxx NE
and xxx NE
tumor xxx NE
necrosis xxx NE
factor-alpha-independent xxx-xxx-xxx NE
mechanism xxx NE

Our Xxx NE
results xxx NE
suggest xxx NE
that xxx NE
superantigens xxx protein
and xxx NE
other xxx NE
MHC XXX protein_B
class xxx protein_M
II XX protein_M
ligands xxx protein_E
may xxx NE
activate xxx NE
HIV-1 XXX-d NE
gene xxx NE
expression xxx NE
in xx NE
monocytes/macrophages xxx/xxx cell_type
. . NE

Mitogen Xxxx NE
activation xxx NE
of xx NE
human xxx cell_type_B
peripheral xxx cell_type_M
T X cell_type_M
lymphocytes xxx cell_type_E
induces xxx NE
the xxx NE
formation xxx NE
of xx NE
new xxx NE
cyclic xxx NE
AMP XXX NE
response xxx NE
element-binding xxx-xxx NE
protein xxx NE
nuclear xxx NE
complexes xxx NE
. . NE

A X NE
large xxx NE
body xxx NE
of xx NE
evidence xxx NE
indicates xxx NE
that xxx NE
experimental xxx NE
agents xxx NE
which xxx NE
raise xxx NE
cellular xxx NE
cAMP xXXX NE
levels xxx NE
inhibit xxx NE
T X NE
cell xxx NE
growth xxx NE
and xxx NE
division xxx NE
. . NE

By Xx NE
contrast xxx NE
, , NE
many xxx NE
studies xxx NE
have xxx NE
reported xxx NE
that xxx NE
mitogen xxx NE
activation xxx NE
of xx NE
T X cell_type_B
cells xxx cell_type_E
increases xxx NE
cAMP xXXX NE
levels xxx NE
, , NE
implying xxx NE
a x NE
positive xxx NE
physiological xxx NE
role xxx NE
for xxx NE
cAMP xXXX NE
in xx NE
the xxx NE
activation xxx NE
process xxx NE
. . NE

In Xx NE
the xxx NE
present xxx NE
study xxx NE
we xx NE
demonstrate xxx NE
that xxx NE
mitogen xxx NE
activation xxx NE
of xx NE
human xxx cell_type_B
peripheral xxx cell_type_M
T X cell_type_M
lymphocytes xxx cell_type_E
induces xxx NE
nuclear xxx NE
factors xxx NE
that xxx NE
form xxx NE
complexes xxx NE
with xxx NE
cyclic xxx protein_B
AMP XXX protein_M
response xxx protein_M
element-binding xxx-xxx protein_M
protein xxx protein_E
( ( NE
CREB XXXX protein
) ) NE
. . NE

Four Xxxx NE
complexes xxx NE
are xxx NE
identified xxx NE
by xx NE
the xxx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
, , NE
two xxx NE
of xx NE
which xxx NE
are xxx NE
induced xxx NE
by xx NE
mitogen xxx NE
activation xxx NE
. . NE

All Xxx NE
four xxx NE
complexes xxx NE
contain xxx NE
CREB XXXX protein
and xxx NE
are xxx NE
bound xxx NE
to xx NE
the xxx NE
cAMP xXXX NE
response xxx NE
element xxx NE
( ( NE
CRE XXX NE
) ) NE
core xxx NE
sequence xxx NE
( ( NE
TGACGTCA XXXXXXXX NE
) ) NE
, , NE
as xx NE
indicated xxx NE
by xx NE
antibody xxx NE
and xxx NE
oligonucleotide xxx NE
competition xxx NE
experiments xxx NE
. . NE

Binding Xxxx NE
of xx NE
the xxx NE
four xxx NE
complexes xxx NE
to xx NE
CRE XXX DNA
is xx NE
prevented xxx NE
by xx NE
dephosphorylation xxx NE
of xx NE
nuclear xxx NE
extracts xxx NE
and xxx NE
is xx NE
restored xxx NE
by xx NE
rephosphorylation xxx NE
with xxx NE
cAMP xXXX NE
-dependent -xxx NE
protein xxx NE
kinase xxx NE
or xx NE
endogenous xxx NE
kinases xxx NE
. . NE

Similar Xxxx NE
complexes xxx NE
are xxx NE
detected xxx NE
in xx NE
nuclear xxx NE
extracts xxx NE
of xx NE
Jurkat Xxxx cell_line_B
cells xxx cell_line_E
. . NE

Mitogen Xxxx NE
induction xxx NE
of xx NE
the xxx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
complexes xxx NE
is xx NE
not xxx NE
accounted xxx NE
for xxx NE
by xx NE
protein xxx NE
phosphorylation xxx NE
or xx NE
by xx NE
induction xxx NE
of xx NE
CREB XXXX NE
. . NE

Rather Xxxx NE
, , NE
the xxx NE
data xxx NE
indicate xxx NE
that xxx NE
mitogen xxx NE
increases xxx NE
the xxx NE
levels xxx NE
of xx NE
a x NE
nuclear xxx NE
factor(s) xxx(x) NE
that xxx NE
dimerizes xxx NE
with xxx NE
CREB XXXX protein
. . NE

Induction Xxxx NE
of xx NE
new xxx NE
CREB XXXX NE
complexes xxx NE
implies xxx NE
a x NE
physiological xxx NE
role xxx NE
for xxx NE
cAMP xXXX NE
in xx NE
mitogen xxx NE
activation xxx NE
of xx NE
T X NE
lymphocytes xxx NE
. . NE

Alpha-tocopherol Xxxx-xxx NE
inhibits xxx NE
agonist-induced xxx-xxx NE
monocytic xxx NE
cell xxx NE
adhesion xxx NE
to xx NE
cultured xxx cell_line_B
human xxx cell_line_M
endothelial xxx cell_line_M
cells xxx cell_line_E
. . NE

Antioxidants Xxxx NE
have xxx NE
been xxx NE
proposed xxx NE
to xx NE
be xx NE
anti-atherosclerotic xxx-xxx NE
agents xxx NE
; ; NE
however xxx NE
, , NE
the xxx NE
mechanisms xxx NE
underlying xxx NE
their xxx NE
beneficial xxx NE
effects xxx NE
are xxx NE
poorly xxx NE
understood xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
effect xxx NE
of xx NE
alpha-tocopherol xxx-xxx NE
( ( NE
alpha-tcp xxx-xxx NE
) ) NE
on xx NE
one xxx NE
cellular xxx NE
event xxx NE
in xx NE
atherosclerotic xxx NE
plaque xxx NE
development xxx NE
, , NE
monocyte xxx NE
adhesion xxx NE
to xx NE
stimulated xxx cell_type_B
endothelial xxx cell_type_M
cells xxx cell_type_E
( ( NE
ECs XXx cell_type
) ) NE
. . NE

Human Xxxx NE
umbilical xxx NE
vein xxx NE
ECs XXx cell_type
were xxx NE
pretreated xxx NE
with xxx NE
alpha-tcp xxx-xxx NE
before xxx NE
stimulation xxx NE
with xxx NE
known xxx NE
agonists xxx NE
of xx NE
monocyte xxx NE
adhesion xxx NE
: : NE
IL-1 XX-d protein
(10 (dd NE
ng/ml) xx/xx) NE
, , NE
LPS XXX NE
(10 (dd NE
ng/ml) xx/xx) NE
, , NE
thrombin xxx protein
(30 (dd NE
U/ml) X/xx) NE
, , NE
or xx NE
PMA XXX NE
(10 (dd NE
nM) xX) NE
. . NE

Agonist-induced Xxxx-xxx NE
monocytic xxx NE
cell xxx NE
adhesion xxx NE
, , NE
but xxx NE
not xxx NE
basal xxx NE
adhesion xxx NE
, , NE
was xxx NE
inhibited xxx NE
in xx NE
a x NE
time- xxx- NE
and xxx NE
concentration-dependent xxx-xxx NE
manner xxx NE
by xx NE
alpha-tcp xxx-xxx NE
. . NE

The Xxx NE
IC50 XXdd NE
of xx NE
alpha-tcp xxx-xxx NE
on xx NE
an xx NE
IL-1 XX-d NE
-induced -xxx NE
response xxx NE
was xxx NE
45 dd NE
microM xxxX NE
. . NE

The Xxx NE
inhibition xxx NE
correlated xxx NE
with xxx NE
a x NE
decrease xxx NE
in xx NE
steady xxx NE
state xxx NE
levels xxx NE
of xx NE
E-selectin X-xxx RNA_B
mRNA xXXX RNA_E
and xxx NE
cell xxx NE
surface xxx NE
expression xxx NE
of xx NE
E-selectin X-xxx protein
which xxx NE
is xx NE
consistent xxx NE
with xxx NE
the xxx NE
ability xxx NE
of xx NE
a x NE
monoclonal xxx protein_B
antibody xxx protein_E
to xx NE
E-selectin X-xxx protein
to xx NE
inhibit xxx NE
monocytic xxx NE
cell xxx NE
adhesion xxx NE
in xx NE
this xxx NE
system xxx NE
. . NE

Probucol Xxxx NE
(50 (dd NE
microM) xxxX) NE
and xxx NE
N-acetylcysteine X-xxx NE
(20 (dd NE
mM) xX) NE
also xxx NE
inhibited xxx NE
agonist-induced xxx-xxx NE
monocytic xxx NE
cell xxx NE
adhesion xxx NE
; ; NE
whereas xxx NE
, , NE
several xxx NE
other xxx NE
antioxidants xxx NE
had xxx NE
no xx NE
significant xxx NE
effect xxx NE
. . NE

Protein Xxxx protein_B
kinase xxx protein_M
C X protein_E
( ( NE
PKC XXX protein
) ) NE
does xxx NE
not xxx NE
appear xxx NE
to xx NE
play xxx NE
a x NE
role xxx NE
in xx NE
the xxx NE
alpha-tcp xxx-xxx NE
effect xxx NE
since xxx NE
no xx NE
suppression xxx NE
of xx NE
phosphorylation xxx NE
of xx NE
PKC XXX protein
substrates xxx NE
was xxx NE
observed xxx NE
. . NE

Activation Xxxx NE
of xx NE
the xxx NE
transcription xxx protein_B
factor xxx protein_E
NF-kappa XX-xxx protein_B
B X protein_E
is xx NE
reported xxx NE
to xx NE
be xx NE
necessary xxx NE
but xxx NE
not xxx NE
sufficient xxx NE
for xxx NE
E-selectin X-xxx protein
expression xxx NE
in xx NE
EC XX cell_line
. . NE

Electrophoretic Xxxx NE
mobility xxx NE
shift xxx NE
assays xxx NE
failed xxx NE
to xx NE
show xxx NE
an xx NE
alpha-tcp xxx-xxx NE
-induced -xxx NE
decrease xxx NE
in xx NE
activation xxx NE
of xx NE
this xxx NE
transcription xxx NE
factor xxx NE
after xxx NE
cytokine xxx NE
stimulation xxx NE
. . NE

It Xx NE
has xxx NE
been xxx NE
hypothesized xxx NE
that xxx NE
alpha-tcp xxx-xxx NE
acts xxx NE
as xx NE
an xx NE
anti-atherosclerotic xxx-xxx NE
molecule xxx NE
by xx NE
inhibiting xxx NE
generation xxx NE
of xx NE
oxidized xxx NE
LDL XXX NE
--a --x NE
putative xxx NE
triggering xxx NE
molecule xxx NE
in xx NE
the xxx NE
atherosclerotic xxx NE
process xxx NE
. . NE

Our Xxx NE
results xxx NE
point xxx NE
to xx NE
a x NE
novel xxx NE
alternative xxx NE
mechanism xxx NE
of xx NE
action xxx NE
of xx NE
alpha-tcp xxx-xxx NE
. . NE

Central Xxxx NE
nervous xxx NE
system xxx NE
-derived -xxx NE
cells xxx NE
express xxx NE
a x NE
kappa xxx NE
B-binding X-xxx NE
activity xxx NE
that xxx NE
enhances xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
transcription xxx NE
in xx NE
vitro xxx NE
and xxx NE
facilitates xxx NE
TAR XXX NE
-independent -xxx NE
transactivation xxx NE
by xx NE
Tat Xxx NE
. . NE

The Xxx NE
Tat Xxx protein_B
protein xxx protein_E
of xx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
( ( NE
HIV-1 XXX-d NE
) ) NE
is xx NE
a x NE
potent xxx NE
activator xxx NE
of xx NE
long xxx NE
terminal xxx NE
repeat xxx NE
-directed -xxx NE
transcription xxx NE
. . NE

While Xxxx NE
in xx NE
most xxx NE
cell xxx NE
types xxx NE
, , NE
activation xxx NE
requires xxx NE
interaction xxx NE
of xx NE
Tat Xxx NE
with xxx NE
the xxx NE
unusual xxx NE
transcription xxx DNA_B
element xxx DNA_E
TAR XXX DNA
, , NE
astrocytic xxx cell_type_B
glial xxx cell_type_M
cells xxx cell_type_E
support xxx NE
TAR XXX NE
-independent -xxx NE
transactivation xxx NE
of xx NE
HIV-1 XXX-d NE
transcription xxx NE
by xx NE
Tat Xxx NE
. . NE

This Xxxx NE
alternative xxx NE
pathway xxx NE
of xx NE
Tat Xxx NE
activation xxx NE
is xx NE
mediated xxx NE
by xx NE
the xxx NE
viral xxx DNA_B
enhancer xxx DNA_E
, , NE
a x NE
kappa xxx NE
B X NE
domain xxx NE
capable xxx NE
of xx NE
binding xxx NE
the xxx NE
prototypical xxx NE
form xxx NE
of xx NE
the xxx NE
transcription xxx protein_B
factor xxx protein_E
nuclear xxx NE
factor xxx NE
kappa xxx NE
B X NE
( ( NE
NF-kappa XX-xxx protein_B
B X protein_E
) ) NE
present xxx NE
in xx NE
many xxx NE
cell xxx NE
types xxx NE
, , NE
including xxx NE
T X cell_type_B
lymphocytes xxx cell_type_E
. . NE

Tat Xxx protein
transactivation xxx NE
mediated xxx NE
by xx NE
the xxx NE
kappa xxx DNA_B
B X DNA_M
domain xxx DNA_E
is xx NE
sufficient xxx NE
to xx NE
allow xxx NE
replication xxx NE
of xx NE
TAR XXX NE
-deleted -xxx NE
mutant xxx NE
HIV-1 XXX-d NE
in xx NE
astrocytes xxx NE
. . NE

The Xxx NE
present xxx NE
study xxx NE
demonstrates xxx NE
the xxx NE
existence xxx NE
of xx NE
kappa xxx protein_B
B-specific X-xxx protein_M
binding xxx protein_M
factors xxx protein_E
present xxx NE
in xx NE
human xxx cell_type_B
glial xxx cell_type_M
astrocytes xxx cell_type_E
that xxx NE
differ xxx NE
from xxx NE
prototypical xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
. . NE

The Xxx NE
novel xxx NE
astrocyte-derived xxx-xxx NE
kappa xxx NE
B-binding X-xxx NE
activity xxx NE
is xx NE
retained xxx NE
on xx NE
an xx NE
HIV-1 XXX-d NE
Tat Xxx NE
affinity xxx NE
column xxx NE
, , NE
while xxx NE
prototypical xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
from xxx NE
Jurkat Xxxx cell_line_B
T X cell_line_M
cells xxx cell_line_E
is xx NE
not xxx NE
. . NE

In Xx NE
vitro xxx NE
transcription xxx NE
studies xxx NE
demonstrate xxx NE
that xxx NE
astrocyte-derived xxx-xxx protein_B
kappa xxx protein_M
B-binding X-xxx protein_M
factors xxx protein_E
activate xxx NE
transcription xxx NE
of xx NE
the xxx NE
HIV-1 XXX-d DNA_B
long xxx DNA_M
terminal xxx DNA_M
repeat xxx DNA_E
and xxx NE
that xxx NE
this xxx NE
activation xxx NE
is xx NE
dependent xxx NE
on xx NE
the xxx NE
kappa xxx DNA_B
B X DNA_M
domain xxx DNA_E
. . NE

Moreover Xxxx NE
, , NE
TAR XXX NE
-independent -xxx NE
transactivation xxx NE
of xx NE
HIV-1 XXX-d NE
transcription xxx NE
is xx NE
reproduced xxx NE
in xx NE
vitro xxx NE
in xx NE
an xx NE
astrocyte xxx NE
factor-dependent xxx-xxx NE
manner xxx NE
which xxx NE
correlates xxx NE
with xxx NE
kappa xxx NE
B-binding X-xxx NE
activity xxx NE
. . NE

The Xxx NE
importance xxx NE
of xx NE
the xxx NE
central xxx NE
nervous xxx NE
system xxx NE
-enriched -xxx NE
kappa xxx NE
B X NE
transcription xxx NE
factor xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
HIV-1 XXX-d NE
expression xxx NE
is xx NE
discussed xxx NE
. . NE

Human Xxxx protein_B
interleukin-13 xxx-dd protein_E
activates xxx NE
the xxx NE
interleukin-4-dependent xxx-d-xxx protein_B
transcription xxx protein_M
factor xxx protein_E
NF-IL4 XX-XXd protein
sharing xxx NE
a x NE
DNA XXX protein_B
binding xxx protein_M
motif xxx protein_E
with xxx NE
an xx NE
interferon-gamma-induced xxx-xxx-xxx protein_B
nuclear xxx protein_M
binding xxx protein_M
factor xxx protein_E
. . NE

The Xxx NE
effects xxx NE
of xx NE
interleukin-13 xxx-dd protein
( ( NE
IL-13 XX-dd protein
) ) NE
and xxx NE
interleukin-4 xxx-d protein
( ( NE
IL-4 XX-d protein
) ) NE
on xx NE
cellular xxx NE
functions xxx NE
were xxx NE
shown xxx NE
to xx NE
be xx NE
quite xxx NE
similar xxx NE
. . NE

We Xx NE
provide xxx NE
evidence xxx NE
that xxx NE
in xx NE
monocytes xxx NE
as xx NE
well xxx NE
as xx NE
in xx NE
T X cell_type_B
lymphocytes xxx cell_type_E
both xxx NE
IL-4 XX-d protein
and xxx NE
IL-13 XX-dd protein
activate xxx NE
the xxx NE
same xxx NE
recently xxx NE
identified xxx NE
transcription xxx protein_B
factor xxx protein_E
NF-IL4 XX-XXd protein
which xxx NE
binds xxx NE
to xx NE
the xxx NE
specific xxx DNA_B
responsive xxx DNA_M
element xxx DNA_M
IL-4RE XX-dXX DNA_E
. . NE

In Xx NE
addition xxx NE
, , NE
we xx NE
show xxx NE
that xxx NE
a x NE
nuclear xxx protein_B
factor xxx protein_E
activated xxx NE
by xx NE
interferon-gamma xxx-xxx NE
also xxx NE
interacts xxx NE
with xxx NE
the xxx NE
IL-4RE XX-dXX DNA
. . NE

It Xx NE
differs xxx NE
from xxx NE
NF-IL4 XX-XXd protein
in xx NE
the xxx NE
electrophoretic xxx NE
mobility xxx NE
of xx NE
the xxx NE
complex xxx NE
with xxx NE
DNA XXX NE
, , NE
in xx NE
its xxx NE
DNA-binding XXX-xxx NE
specificity xxx NE
and xxx NE
in xx NE
the xxx NE
proteins xxx NE
interacting xxx NE
with xxx NE
the xxx NE
DNA XXX DNA_B
sequence xxx DNA_E
. . NE

Sensitivity Xxxx NE
against xxx NE
various xxx NE
enzyme xxx NE
inhibitors xxx NE
suggests xxx NE
that xxx NE
components xxx NE
of xx NE
the xxx NE
signal xxx NE
transduction xxx NE
pathway xxx NE
are xxx NE
shared xxx NE
by xx NE
all xxx NE
three xxx NE
cytokines xxx protein
. . NE

Encephalomyocarditis Xxxx NE
virus xxx NE
internal xxx NE
ribosomal xxx NE
entry xxx NE
site xxx NE
RNA-protein XXX-xxx NE
interactions xxx NE
. . NE

Translational Xxxx NE
initiation xxx NE
of xx NE
encephalomyocarditis xxx NE
virus xxx NE
( ( NE
EMCV XXXX NE
) ) NE
mRNA xXXX NE
occurs xxx NE
by xx NE
ribosomal xxx NE
entry xxx NE
into xxx NE
the xxx NE
5' d' NE
nontranslated xxx NE
region xxx NE
of xx NE
the xxx NE
EMCV XXXX NE
mRNA xXXX NE
, , NE
rather xxx NE
than xxx NE
by xx NE
ribosomal xxx NE
scanning xxx NE
. . NE

Internal Xxxx NE
ribosomal xxx NE
binding xxx NE
requires xxx NE
a x NE
cis-acting xxx-xxx DNA_B
element xxx DNA_E
termed xxx NE
the xxx NE
internal xxx DNA_B
ribosomal xxx DNA_M
entry xxx DNA_M
site xxx DNA_E
( ( NE
IRES XXXX DNA
) ) NE
. . NE

IRES XXXX DNA_B
elements xxx DNA_E
have xxx NE
been xxx NE
proposed xxx NE
to xx NE
be xx NE
involved xxx NE
in xx NE
the xxx NE
translation xxx NE
of xx NE
picornavirus xxx RNA_B
mRNAs xXXXx RNA_E
and xxx NE
some xxx NE
cellular xxx RNA_B
mRNAs xXXXx RNA_E
. . NE

Internal Xxxx NE
ribosome xxx NE
binding xxx NE
likely xxx NE
requires xxx NE
the xxx NE
interaction xxx NE
of xx NE
trans-acting xxx-xxx protein_B
factors xxx protein_E
that xxx NE
recognize xxx NE
both xxx NE
the xxx NE
mRNA xXXX RNA
and xxx NE
the xxx NE
ribosomal xxx protein_B
complex xxx protein_E
. . NE

Five Xxxx NE
cellular xxx protein_B
proteins xxx protein_E
( ( NE
p52 xdd protein
, , NE
p57 xdd protein
, , NE
p70 xdd protein
, , NE
p72 xdd protein
, , NE
and xxx NE
p100 xddd protein
) ) NE
cross-link xxx-xxx NE
the xxx NE
EMCV XXXX NE
IRES XXXX DNA
or xx NE
fragments xxx NE
of xx NE
the xxx NE
IRES XXXX DNA
. . NE

For Xxx NE
one xxx NE
of xx NE
these xxx NE
proteins xxx NE
, , NE
p57 xdd protein
, , NE
binding xxx NE
to xx NE
the xxx NE
IRES XXXX DNA
correlates xxx NE
with xxx NE
translation xxx NE
. . NE

Recently Xxxx NE
, , NE
p57 xdd protein
was xxx NE
identified xxx NE
to xx NE
be xx NE
very xxx NE
similar xxx NE
, , NE
if xx NE
not xxx NE
identical xxx NE
, , NE
to xx NE
polypyrimidine xxx protein_B
tract-binding xxx-xxx protein_M
protein xxx protein_E
. . NE

On Xx NE
the xxx NE
basis xxx NE
of xx NE
cross-linking xxx-xxx NE
results xxx NE
with xxx NE
21 dd NE
different xxx NE
EMCV XXXX DNA_B
IRES XXXX DNA_M
fragments xxx DNA_E
and xxx NE
cytoplasmic xxx NE
HeLa XxXx NE
extract xxx NE
or xx NE
rabbit xxx NE
reticulocyte xxx NE
lysate xxx NE
as xx NE
the xxx NE
source xxx NE
of xx NE
polypeptides xxx NE
, , NE
consensus xxx DNA_B
binding xxx DNA_M
sites xxx DNA_E
for xxx NE
p52 xdd protein
, , NE
p57 xdd protein
, , NE
p70 xdd protein
, , NE
and xxx NE
p100 xddd protein
are xxx NE
proposed xxx NE
. . NE

It Xx NE
is xx NE
suggested xxx NE
that xxx NE
each xxx NE
of xx NE
these xxx NE
proteins xxx NE
recognizes xxx NE
primarily xxx NE
a x NE
structural xxx NE
feature xxx NE
of xx NE
the xxx NE
RNA XXX RNA
rather xxx NE
than xxx NE
a x NE
specific xxx NE
sequence xxx NE
. . NE

A X NE
novel xxx NE
heterodimerization xxx protein_B
partner xxx protein_E
for xxx NE
thyroid xxx protein_B
hormone xxx protein_M
receptor xxx protein_E
. . NE

Peroxisome Xxxx protein_B
proliferator-activated xxx-xxx protein_M
receptor xxx protein_E
. . NE

Retinoid-like Xxxx-xxx protein_B
receptors xxx protein_E
play xxx NE
a x NE
central xxx NE
role xxx NE
in xx NE
hormonal xxx NE
responses xxx NE
by xx NE
forming xxx NE
heterodimers xxx protein
with xxx NE
other xxx NE
nuclear xxx protein_B
hormone xxx protein_M
receptors xxx protein_E
. . NE

In Xx NE
this xxx NE
study xxx NE
we xx NE
have xxx NE
identified xxx NE
the xxx NE
peroxisome xxx protein_B
proliferator-activated xxx-xxx protein_M
receptor xxx protein_E
( ( NE
PPAR XXXX protein
) ) NE
as xx NE
a x NE
new xxx NE
thyroid xxx NE
hormone xxx NE
receptor xxx NE
( ( NE
THR XXX NE
) ) NE
auxiliary xxx NE
nuclear xxx NE
protein xxx NE
, , NE
heterodimerizing xxx NE
with xxx NE
THR XXX NE
in xx NE
solution xxx NE
. . NE

Although Xxxx NE
these xxx NE
heterodimers xxx protein
do xx NE
not xxx NE
recognize xxx NE
a x NE
classical xxx NE
thyroid xxx DNA_B
hormone xxx DNA_M
response xxx DNA_M
element xxx DNA_E
( ( NE
TRE XXX DNA
) ) NE
characterized xxx NE
by xx NE
direct xxx DNA_B
repeat xxx DNA_E
separated xxx NE
by xx NE
four xxx NE
nucleotides xxx NE
( ( NE
DR+4 XX+d DNA
) ) NE
, , NE
PPAR XXXX protein
behaves xxx NE
as xx NE
a x NE
dominant xxx NE
negative xxx NE
regulator xxx NE
of xx NE
thyroid xxx NE
hormone xxx NE
( ( NE
TH XX NE
) ) NE
action xxx NE
. . NE

However Xxxx NE
, , NE
a x NE
TH XX NE
-dependent -xxx NE
positive xxx NE
effect xxx NE
is xx NE
elicited xxx NE
by xx NE
selective xxx NE
interaction xxx NE
of xx NE
the xxx NE
THR XXX NE
beta- xxx- NE
PPAR XXXX NE
but xxx NE
not xxx NE
the xxx NE
THR XXX NE
alpha- xxx- NE
PPAR XXXX NE
heterodimer xxx NE
with xxx NE
a x NE
novel xxx NE
TRE XXX NE
( ( NE
DR+2 XX+d NE
) ) NE
. . NE

The Xxx NE
critical xxx NE
region xxx NE
of xx NE
THR XXX protein
beta xxx NE
was xxx NE
mapped xxx NE
to xx NE
3 d NE
amino xxx NE
acids xxx NE
in xx NE
the xxx NE
distal xxx protein_B
box xxx protein_E
of xx NE
the xxx NE
DNA XXX protein_B
binding xxx protein_M
domain xxx protein_E
. . NE

Hence Xxxx NE
, , NE
PPAR XXXX protein
can xxx NE
positively xxx NE
or xx NE
negatively xxx NE
influence xxx NE
TH XX NE
action xxx NE
depending xxx NE
on xx NE
TRE XXX NE
structure xxx NE
and xxx NE
THR XXX protein_B
isotype xxx protein_E
. . NE

Comparison Xxxx NE
of xx NE
retinoic xxx NE
acid xxx NE
and xxx NE
phorbol xxx NE
myristate xxx NE
acetate xxx NE
as xx NE
inducers xxx NE
of xx NE
monocytic xxx NE
differentiation xxx NE
. . NE

Several Xxxx NE
human xxx cell_line_B
myeloid xxx cell_line_M
leukemia xxx cell_line_M
cell xxx cell_line_M
lines xxx cell_line_E
growing xxx NE
in xx NE
vitro xxx NE
can xxx NE
be xx NE
induced xxx NE
to xx NE
differentiate xxx NE
to xx NE
more xxx NE
mature xxx NE
monocyte/macrophage-like xxx/xxx-xxx cell_type_B
cells xxx cell_type_E
by xx NE
treatment xxx NE
with xxx NE
protein xxx NE
kinase xxx NE
C X NE
-activating -xxx NE
phorbol xxx NE
esters xxx NE
, , NE
such xxx NE
as xx NE
PMA XXX NE
. . NE

In Xx NE
addition xxx NE
to xx NE
PMA XXX NE
, , NE
cells xxx NE
of xx NE
the xxx NE
THP-1 XXX-d cell_line_B
myeloid xxx cell_line_M
leukemia xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
acquire xxx NE
macrophage-like xxx-xxx NE
characteristics xxx NE
after xxx NE
treatment xxx NE
with xxx NE
all-trans xxx-xxx NE
retinoic xxx NE
acid xxx NE
( ( NE
RA XX NE
) ) NE
. . NE

To Xx NE
analyze xxx NE
the xxx NE
signal xxx NE
transduction xxx NE
mechanisms xxx NE
induced xxx NE
by xx NE
RA XX NE
, , NE
we xx NE
first xxx NE
compared xxx NE
the xxx NE
effects xxx NE
of xx NE
PMA XXX NE
and xxx NE
RA XX NE
on xx NE
the xxx NE
expression xxx NE
of xx NE
genes xxx NE
which xxx NE
are xxx NE
known xxx NE
to xx NE
be xx NE
regulated xxx NE
during xxx NE
monocytic xxx NE
differentiation xxx NE
. . NE

Both Xxxx NE
RA XX NE
and xxx NE
PMA XXX NE
effectively xxx NE
down-regulated xxx-xxx NE
c-myc x-xxx NE
expression xxx NE
, , NE
while xxx NE
c-myb x-xxx NE
expression xxx NE
decreased xxx NE
only xxx NE
after xxx NE
PMA XXX NE
treatment xxx NE
. . NE

Expression Xxxx NE
of xx NE
the xxx NE
beta xxx DNA_B
2-integrin d-xxx DNA_M
genes xxx DNA_E
, , NE
CD11a XXddx DNA
and xxx NE
CD11b XXddx DNA
, , NE
was xxx NE
clearly xxx NE
increased xxx NE
after xxx NE
both xxx NE
of xx NE
these xxx NE
treatments xxx NE
. . NE

Their Xxxx NE
effects xxx NE
on xx NE
the xxx NE
src-family xxx-xxx DNA_B
tyrosine xxx DNA_M
kinase xxx DNA_M
genes xxx DNA_E
were xxx NE
different xxx NE
: : NE
hck xxx NE
expression xxx NE
was xxx NE
similarly xxx NE
induced xxx NE
by xx NE
these xxx NE
agents xxx NE
but xxx NE
lyn xxx NE
expression xxx NE
was xxx NE
stronger xxx NE
and xxx NE
more xxx NE
rapid xxx NE
after xxx NE
RA XX NE
treatment xxx NE
. . NE

RA XX NE
also xxx NE
enhanced xxx NE
lyn xxx NE
mRNA xXXX NE
production xxx NE
rapidly xxx NE
in xx NE
HL-60 XX-dd cell_line
, , NE
indicating xxx NE
that xxx NE
the xxx NE
activation xxx NE
of xx NE
lyn xxx NE
gene xxx NE
expression xxx NE
is xx NE
common xxx NE
in xx NE
monocytic xxx NE
maturation xxx NE
and xxx NE
granulocytic xxx NE
maturation xxx NE
of xx NE
myeloid xxx cell_type_B
leukemia xxx cell_type_M
cells xxx cell_type_E
. . NE

To Xx NE
examine xxx NE
whether xxx NE
the xxx NE
AP-1 XX-d NE
enhancer xxx NE
activity xxx NE
is xx NE
involved xxx NE
in xx NE
RA XX NE
-induced -xxx NE
monocytic xxx NE
differentiation xxx NE
, , NE
THP-1 XXX-d cell_line_B
cells xxx cell_line_E
were xxx NE
transiently xxx NE
transfected xxx NE
with xxx NE
a x NE
chloramphenicol xxx NE
acetyl xxx NE
transferase xxx NE
( ( NE
CAT XXX NE
)-reporter )-xxx NE
gene xxx NE
containing xxx NE
5 d NE
copies xxx NE
of xx NE
the xxx NE
AP-1 XX-d NE
binding xxx NE
sites xxx NE
. . NE

In Xx NE
contrast xxx NE
to xx NE
PMA XXX NE
, , NE
RA XX NE
did xxx NE
not xxx NE
induce xxx NE
any xxx NE
CAT XXX NE
activity xxx NE
in xx NE
these xxx NE
cells xxx NE
, , NE
thus xxx NE
suggesting xxx NE
that xxx NE
the xxx NE
RA XX NE
-induced -xxx NE
changes xxx NE
in xx NE
the xxx NE
expression xxx NE
of xx NE
those xxx NE
genes xxx NE
described xxx NE
above xxx NE
were xxx NE
not xxx NE
dependent xxx NE
on xx NE
the xxx NE
AP-1 XX-d NE
enhancer xxx NE
activity xxx NE
. . NE

An Xx NE
active xxx NE
v-abl x-xxx protein_B
protein xxx protein_M
tyrosine xxx protein_M
kinase xxx protein_E
blocks xxx NE
immunoglobulin xxx NE
light-chain xxx-xxx NE
gene xxx NE
rearrangement xxx NE
. . NE

Lymphoid Xxxx cell_type_B
cells xxx cell_type_E
transformed xxx NE
by xx NE
Abelson Xxxx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
have xxx NE
provided xxx NE
one xxx NE
of xx NE
the xxx NE
classic xxx NE
models xxx NE
for xxx NE
study xxx NE
of xx NE
early xxx NE
B-cell X-xxx NE
development xxx NE
and xxx NE
immunoglobulin xxx NE
rearrangement xxx NE
. . NE

Most Xxxx NE
of xx NE
these xxx NE
cells xxx NE
have xxx NE
rearranged xxx NE
their xxx NE
heavy-chain xxx-xxx DNA_B
locus xxx DNA_E
but xxx NE
not xxx NE
their xxx NE
light xxx DNA_B
chain xxx DNA_M
genes xxx DNA_E
, , NE
suggesting xxx NE
that xxx NE
an xx NE
active xxx NE
v-abl x-xxx protein_B
protein xxx protein_E
interferes xxx NE
with xxx NE
this xxx NE
differentiation xxx NE
step xxx NE
. . NE

To Xx NE
test xxx NE
this xxx NE
hypothesis xxx NE
, , NE
light-chain xxx-xxx DNA_B
gene xxx DNA_M
structure xxx DNA_E
was xxx NE
examined xxx NE
in xx NE
pre-B xxx-X cell_line_B
cells xxx cell_line_E
transformed xxx NE
by xx NE
temperature-sensitive xxx-xxx NE
mutants xxx NE
of xx NE
the xxx NE
Abelson Xxxx NE
virus xxx NE
and xxx NE
in xx NE
derivatives xxx NE
that xxx NE
survive xxx NE
at xx NE
the xxx NE
nonpermissive xxx NE
temperature xxx NE
because xxx NE
they xxx NE
express xxx NE
a x NE
human xxx DNA_B
BCL-2 XXX-d DNA_M
gene xxx DNA_E
. . NE

Our Xxx NE
studies xxx NE
reveal xxx NE
that xxx NE
inactivation xxx NE
of xx NE
the xxx NE
v-abl x-xxx protein_B
protein xxx protein_M
tyrosine xxx protein_M
kinase xxx protein_E
triggers xxx NE
high-frequency xxx-xxx NE
rearrangement xxx NE
of xx NE
kappa xxx DNA_B
light-chain xxx-xxx DNA_M
gene xxx DNA_M
and xxx DNA_M
lambda xxx DNA_M
light-chain xxx-xxx DNA_M
gene xxx DNA_E

These Xxxx NE
events xxx NE
are xxx NE
accompanied xxx NE
by xx NE
marked xxx NE
increases xxx NE
in xx NE
the xxx NE
expression xxx NE
of xx NE
RAG-1 XXX-d RNA_B
and xxx RNA_M
RAG-2 XXX-d RNA_M
RNAs XXXx RNA_E
. . NE

These Xxxx NE
increases xxx NE
occur xxx NE
in xx NE
the xxx NE
absence xxx NE
of xx NE
protein xxx NE
synthesis xxx NE
but xxx NE
are xxx NE
dependent xxx NE
on xx NE
inactivation xxx NE
of xx NE
the xxx NE
v-abl x-xxx protein_B
protein xxx protein_M
tyrosine xxx protein_M
kinase xxx protein_E
. . NE

As Xx NE
documented xxx NE
in xx NE
the xxx NE
accompanying xxx NE
paper xxx NE
(Klug (Xxxx NE
et xx NE
al. xx. NE
, , NE
this xxx NE
issue) xxx) NE
, , NE
an xx NE
active xxx NE
v-abl x-xxx protein_B
protein xxx protein_E
also xxx NE
suppresses xxx NE
the xxx NE
activity xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
/rel /xxx NE
and xxx NE
expression xxx NE
controlled xxx NE
by xx NE
the xxx NE
kappa xxx NE
intron xxx NE
enhancer xxx NE
. . NE

Together Xxxx NE
these xxx NE
data xxx NE
demonstrate xxx NE
that xxx NE
the xxx NE
v-abl x-xxx protein_B
protein xxx protein_E
specifically xxx NE
interferes xxx NE
with xxx NE
light-chain xxx-xxx NE
gene xxx NE
rearrangement xxx NE
by xx NE
suppressing xxx NE
at xx NE
least xxx NE
two xxx NE
pathways xxx NE
essential xxx NE
for xxx NE
this xxx NE
stage xxx NE
of xx NE
B-cell X-xxx NE
differentiation xxx NE
and xxx NE
suggest xxx NE
that xxx NE
tyrosine xxx NE
phosphorylation xxx NE
is xx NE
important xxx NE
in xx NE
regulating xxx NE
RAG XXX NE
gene xxx NE
expression xxx NE
. . NE

Calcium Xxxx NE
signalling xxx NE
in xx NE
T X cell_type_B
cells xxx cell_type_E
stimulated xxx NE
by xx NE
a x NE
cyclophilin xxx protein_B
B-binding X-xxx protein_M
protein xxx protein_E
. . NE

The Xxx NE
immunosuppressant xxx NE
drug xxx NE
cyclosporin xxx NE
A X NE
blocks xxx NE
a x NE
calcium xxx NE
-dependent -xxx NE
signal xxx NE
from xxx NE
the xxx NE
T-cell X-xxx NE
receptor xxx NE
( ( NE
TCR XXX NE
) ) NE
that xxx NE
normally xxx NE
leads xxx NE
to xx NE
T-cell X-xxx NE
activation xxx NE
. . NE

When Xxxx NE
bound xxx NE
to xx NE
cyclophilin xxx protein
, , NE
cyclosporin xxx NE
A X NE
binds xxx NE
and xxx NE
inactivates xxx NE
the xxx NE
key xxx NE
signalling xxx NE
intermediate xxx NE
calcineurin xxx protein
. . NE

To Xx NE
identify xxx NE
potential xxx NE
cellular xxx NE
homologues xxx NE
of xx NE
cyclosporin xxx NE
A X NE
that xxx NE
might xxx NE
regulate xxx NE
calcium xxx NE
signalling xxx NE
, , NE
we xx NE
have xxx NE
cloned xxx NE
human xxx NE
genes xxx NE
encoding xxx NE
cyclophilin xxx protein_B
B-binding-proteins X-xxx-xxx protein_E
using xxx NE
the xxx NE
yeast xxx NE
two-hybrid xxx-xxx NE
system xxx NE
. . NE

One Xxx NE
gene xxx NE
product xxx NE
, , NE
when xxx NE
overexpressed xxx NE
in xx NE
Jurkat Xxxx cell_line_B
T X cell_line_M
cells xxx cell_line_E
, , NE
specifically xxx NE
induced xxx NE
transcription xxx NE
from xxx NE
the xxx NE
interleukin-2 xxx-d DNA_B
enhancer xxx DNA_E
, , NE
by xx NE
activating xxx NE
the xxx NE
T-cell-specific X-xxx-xxx protein_B
transcription xxx protein_M
factors xxx protein_E
NF-AT XX-XX protein
and xxx NE
NF-IL2A XX-XXdX protein
. . NE

This Xxxx NE
protein xxx NE
, , NE
termed xxx NE
calcium xxx NE
-signal -xxx NE
modulating xxx NE
cyclophilin xxx NE
ligand xxx NE
( ( NE
CAML XXXX NE
) ) NE
, , NE
acts xxx NE
downstream xxx NE
of xx NE
the xxx NE
TCR XXX NE
and xxx NE
upstream xxx NE
of xx NE
calcineurin xxx NE
by xx NE
causing xxx NE
an xx NE
influx xxx NE
of xx NE
calcium xxx NE
. . NE

CAML XXXX protein
appears xxx NE
to xx NE
be xx NE
a x NE
new xxx NE
participant xxx NE
in xx NE
the xxx NE
calcium xxx NE
-signal -xxx NE
transduction xxx NE
pathway xxx NE
, , NE
implicating xxx NE
cyclophilin xxx NE
B X NE
in xx NE
calcium xxx NE
signalling xxx NE
, , NE
even xxx NE
in xx NE
the xxx NE
absence xxx NE
of xx NE
cyclosporin xxx NE
. . NE

Expression Xxxx NE
and xxx NE
genomic xxx NE
configuration xxx NE
of xx NE
GM-CSF XX-XXX protein
, , NE
IL-3 XX-d protein
, , NE
M-CSF X-XXX protein_B
receptor xxx protein_E
( ( NE
C-FMS X-XXX protein
) ) NE
, , NE
early xxx DNA_B
growth xxx DNA_M
response xxx DNA_M
gene-1 xxx-d DNA_E
( ( NE
EGR-1 XXX-d DNA
) ) NE
and xxx NE
M-CSF X-XXX DNA_B
genes xxx DNA_E
in xx NE
primary xxx NE
myelodysplastic xxx NE
syndromes xxx NE
. . NE

Peripheral Xxxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
from xxx NE
seventeen xxx NE
patients xxx NE
with xxx NE
primary xxx NE
myelodysplastic xxx NE
syndromes xxx NE
( ( NE
MDS XXX NE
) ) NE
in xx NE
advanced xxx NE
stage xxx NE
were xxx NE
enriched xxx NE
for xxx NE
blasts xxx cell_type
and xxx NE
tested xxx NE
for xxx NE
(1) (d) NE
karyotype xxx NE
, , NE
(2) (d) NE
genomic xxx NE
configuration xxx NE
and xxx NE
(3) (d) NE
expression xxx NE
of xx NE
IL-3 XX-d DNA_B
gene xxx DNA_M
and xxx DNA_M
GM-CSF XX-XXX DNA_M
gene xxx DNA_M
and xxx DNA_M
FMS XXX DNA_M
gene xxx DNA_M
and xxx DNA_M
EGR-1 XXX-d DNA_M
gene xxx DNA_E
which xxx NE
are xxx NE
all xxx NE
located xxx NE
on xx NE
the xxx NE
long xxx DNA_B
arm xxx DNA_M
of xx DNA_M
chromosome xxx DNA_M
5 d DNA_E
. . NE

The Xxx NE
expression xxx NE
of xx NE
the xxx NE
M-CSF X-XXX DNA_B
gene xxx DNA_E
, , NE
that xxx NE
has xxx NE
been xxx NE
recently xxx NE
reassigned xxx NE
to xx NE
the xxx NE
short xxx DNA_B
arm xxx DNA_M
of xx DNA_M
chromosome xxx DNA_M
1 d DNA_E
( ( NE
lp xx DNA
) ) NE
, , NE
was xxx NE
also xxx NE
investigated xxx NE
. . NE

Aims Xxxx NE
of xx NE
the xxx NE
study xxx NE
were xxx NE
to xx NE
(1) (d) NE
assess xxx NE
the xxx NE
potential xxx NE
role xxx NE
of xx NE
the xxx NE
expression xxx NE
of xx NE
these xxx NE
genes xxx NE
in xx NE
the xxx NE
maintenance xxx NE
and xxx NE
expansion xxx NE
of xx NE
the xxx NE
neoplastic xxx cell_line_B
clones xxx cell_line_E
and xxx NE
(2) (d) NE
search xxx NE
for xxx NE
constitutional xxx NE
losses xxx NE
or xx NE
rearrangements xxx NE
of xx NE
one xxx NE
allele xxx DNA
followed xxx NE
by xx NE
a x NE
deletion xxx NE
of xx NE
the xxx NE
second xxx NE
allele xxx DNA
of xx NE
the xxx NE
same xxx NE
genes xxx NE
in xx NE
the xxx NE
leukemic xxx cell_type_B
cells xxx cell_type_E
. . NE

The Xxx NE
latter xxx NE
issue xxx NE
was xxx NE
investigated xxx NE
by xx NE
comparing xxx NE
, , NE
in xx NE
8 d NE
cases xxx NE
, , NE
constitutive xxx DNA_B
DNA XXX DNA_E
from xxx NE
skin xxx cell_type_B
fibroblasts xxx cell_type_E
with xxx NE
leukemic xxx DNA_B
DNA XXX DNA_E
. . NE

Eleven Xxxx NE
of xx NE
the xxx NE
17 dd NE
patients xxx NE
had xxx NE
abnormal xxx NE
karyotypes xxx NE
. . NE

The Xxx NE
M-CSF X-XXX DNA_B
gene xxx DNA_E
was xxx NE
expressed xxx NE
in xx NE
6 d NE
cases xxx NE
and xxx NE
the xxx NE
FMS XXX DNA
and xxx NE
the xxx NE
EGR-1 XXX-d DNA_B
genes xxx DNA_E
were xxx NE
expressed xxx NE
in xx NE
2 d NE
of xx NE
the xxx NE
latter xxx NE
cases xxx NE
. . NE

An Xx NE
autocrine xxx NE
mechanism xxx NE
of xx NE
growth xxx NE
could xxx NE
be xx NE
hypothesized xxx NE
only xxx NE
for xxx NE
the xxx NE
2 d NE
patients xxx NE
whose xxx NE
cells xxx NE
expressed xxx NE
both xxx NE
the xxx NE
M-CSF X-XXX DNA_B
gene xxx DNA_M
and xxx DNA_M
FMS XXX DNA_M
gene xxx DNA_E

No Xx NE
germline xxx NE
changes xxx NE
or xx NE
rearrangements xxx NE
were xxx NE
observed xxx NE
in xx NE
any xxx NE
of xx NE
the xxx NE
genes xxx NE
studied xxx NE
. . NE

Thus Xxxx NE
, , NE
deregulation xxx NE
of xx NE
genes xxx NE
encoding xxx NE
for xxx NE
certain xxx NE
hemopoietic xxx protein_B
growth xxx protein_M
factors xxx protein_E
or xx NE
receptors xxx NE
does xxx NE
not xxx NE
seem xxx NE
to xx NE
represent xxx NE
a x NE
major xxx NE
mechanism xxx NE
of xx NE
MDS XXX NE
progression xxx NE
. . NE

A X NE
novel xxx NE
human xxx DNA_B
homeobox xxx DNA_M
gene xxx DNA_E
distantly xxx NE
related xxx NE
to xx NE
proboscipedia xxx DNA
is xx NE
expressed xxx NE
in xx NE
lymphoid xxx NE
tissue xxx NE
and xxx NE
pancreatic xxx NE
tissue xxx NE

A X NE
novel xxx NE
human xxx DNA_B
homeobox xxx DNA_M
gene xxx DNA_E
, , NE
HB9 XXd DNA
, , NE
was xxx NE
isolated xxx NE
from xxx NE
a x NE
cDNA xXXX DNA_B
library xxx DNA_E
prepared xxx NE
from xxx NE
in xx NE
vitro xxx cell_type_B
stimulated xxx cell_type_M
human xxx cell_type_M
tonsil xxx cell_type_M
B X cell_type_M
lymphocytes xxx cell_type_E
and xxx NE
from xxx NE
a x NE
human xxx DNA_B
genomic xxx DNA_M
library xxx DNA_E
. . NE

The Xxx NE
HB9 XXd DNA_B
gene xxx DNA_E
is xx NE
composed xxx NE
of xx NE
3 d NE
exons xxx DNA
spread xxx NE
over xxx NE
6 d NE
kilobases xxx NE
of xx NE
DNA XXX NE
. . NE

An Xx NE
open xxx DNA_B
reading xxx DNA_M
frame xxx DNA_E
of xx NE
1206 dddd NE
nucleotides xxx NE
is xx NE
in xx NE
frame xxx NE
with xxx NE
a x NE
diverged xxx DNA_B
homeodomain xxx DNA_E
. . NE

The Xxx NE
predicted xxx NE
HB9 XXd protein_B
protein xxx protein_E
has xxx NE
a x NE
molecular xxx NE
mass xxx NE
of xx NE
41 dd NE
kilodaltons xxx NE
and xxx NE
is xx NE
enriched xxx NE
for xxx NE
alanine xxx NE
, , NE
glycine xxx NE
, , NE
and xxx NE
leucine xxx NE
. . NE

The Xxx NE
HB9 XXd DNA_B
homeodomain xxx DNA_E
is xx NE
most xxx NE
similar xxx NE
to xx NE
that xxx NE
of xx NE
the xxx NE
Drosophila Xxxx DNA_B
melanogaster xxx DNA_M
homeobox xxx DNA_M
gene xxx DNA_E
proboscipedia xxx DNA
. . NE

Northern Xxxx NE
blot xxx NE
analysis xxx NE
of xx NE
poly(A) xxx(X) RNA_B
RNA XXX RNA_E
purified xxx NE
from xxx NE
the xxx NE
human xxx cell_line_B
B X cell_line_M
cell xxx cell_line_M
line xxx cell_line_M
RPMI XXXX cell_line_M
8226 dddd cell_line_E
and xxx NE
from xxx NE
activated xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
revealed xxx NE
a x NE
major xxx RNA_B
mRNA xXXX RNA_M
transcript xxx RNA_E
of xx NE
2.2 d.d NE
kilobases xxx NE
. . NE

Similar Xxxx NE
analysis xxx NE
of xx NE
poly(A) xxx(X) RNA_B
RNA XXX RNA_E
from xxx NE
a x NE
variety xxx NE
of xx NE
adult xxx NE
tissues xxx NE
demonstrated xxx NE
HB9 XXd DNA
transcripts xxx NE
in xx NE
pancreas xxx NE
, , NE
small xxx NE
intestine xxx NE
, , NE
and xxx NE
colon xxx NE
. . NE

Reverse Xxxx NE
transcriptase-polymerase xxx-xxx NE
chain xxx NE
reaction xxx NE
was xxx NE
used xxx NE
to xx NE
examine xxx NE
HB9 XXd RNA_B
RNA XXX RNA_M
transcripts xxx RNA_E
in xx NE
hematopoietic xxx cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
. . NE

HB9 XXd RNA_B
RNA XXX RNA_M
transcripts xxx RNA_E
were xxx NE
most xxx NE
prevalent xxx NE
in xx NE
several xxx NE
human xxx cell_line_B
B X cell_line_M
cell xxx cell_line_M
lines xxx cell_line_E
and xxx NE
K562 Xddd cell_line_B
cells xxx cell_line_E
. . NE

In Xx NE
addition xxx NE
, , NE
transcripts xxx NE
were xxx NE
detected xxx NE
in xx NE
RNA XXX NE
prepared xxx NE
from xxx NE
tonsil xxx cell_type_B
B X cell_type_M
cells xxx cell_type_E
and xxx NE
in xx NE
situ xxx NE
hybridization xxx NE
studies xxx NE
localized xxx NE
them xxx NE
in xx NE
the xxx NE
germinal xxx NE
center xxx NE
region xxx NE
of xx NE
adult xxx NE
tonsil xxx NE
. . NE

These Xxxx NE
findings xxx NE
suggest xxx NE
the xxx NE
involvement xxx NE
of xx NE
HB9 XXd DNA
in xx NE
regulating xxx NE
gene xxx NE
transcription xxx NE
in xx NE
lymphoid xxx NE
tissue xxx NE
and xxx NE
pancreatic xxx NE
tissue xxx NE

Human Xxxx protein_B
immunodeficiency xxx protein_M
virus xxx protein_M
type xxx protein_M
1 d protein_M
Tat Xxx protein_E
upregulates xxx NE
interleukin-2 xxx-d NE
secretion xxx NE
in xx NE
activated xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
. . NE

Dysregulation Xxxx NE
of xx NE
cytokines xxx protein
secreted xxx NE
by xx NE
T X cell_type_B
cells xxx cell_type_E
may xxx NE
play xxx NE
an xx NE
important xxx NE
role xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
AIDS XXXX NE
. . NE

To Xx NE
investigate xxx NE
the xxx NE
effects xxx NE
of xx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
( ( NE
HIV-1 XXX-d NE
) ) NE
Tat Xxx NE
on xx NE
interleukin-2 xxx-d NE
( ( NE
IL-2 XX-d NE
) ) NE
expression xxx NE
, , NE
we xx NE
used xxx NE
IL-2 XX-d NE
promoter xxx NE
-chloramphenicol -xxx NE
acetyltransferase xxx NE
constructs xxx NE
and xxx NE
IL-2 XX-d NE
-secreting -xxx NE
Jurkat Xxxx NE
T X NE
cells xxx NE
as xx NE
a x NE
model xxx NE
system xxx NE
. . NE

Transient Xxxx NE
expression xxx NE
of xx NE
HIV-1 XXX-d protein_B
Tat Xxx protein_E
induced xxx NE
a x NE
five- xxx- NE
to xx NE
eightfold xxx NE
increase xxx NE
in xx NE
IL-2 XX-d NE
promoter xxx NE
activity xxx NE
in xx NE
Jurkat Xxxx cell_line_B
T X cell_line_M
cells xxx cell_line_E
stimulated xxx NE
with xxx NE
phytohemagglutinin xxx protein
and xxx NE
phorbol xxx NE
myristate xxx NE
acetate xxx NE
. . NE

IL-2 XX-d protein
secretion xxx NE
was xxx NE
increased xxx NE
more xxx NE
than xxx NE
twofold xxx NE
in xx NE
both xxx NE
Jurkat Xxxx cell_line_B
T X cell_line_M
cells xxx cell_line_E
and xxx NE
primary xxx cell_line_B
T X cell_line_M
cells xxx cell_line_E
stimulated xxx NE
by xx NE
extracellular xxx protein_B
HIV-1 XXX-d protein_M
Tat Xxx protein_M
protein xxx protein_E
. . NE

Analysis Xxxx NE
of xx NE
mRNA xXXX RNA
suggested xxx NE
that xxx NE
Tat Xxx NE
exerts xxx NE
its xxx NE
effect xxx NE
on xx NE
IL-2 XX-d protein
primarily xxx NE
at xx NE
the xxx NE
transcriptional xxx NE
level xxx NE
. . NE

The Xxx NE
NF-kappa XX-xxx DNA_B
B X DNA_M
site xxx DNA_E
at xx NE
positions xxx NE
-206 -ddd DNA_B
to xx DNA_M
-195 -ddd DNA_E
of xx NE
the xxx NE
IL-2 XX-d DNA_B
promoter xxx DNA_E
was xxx NE
required xxx NE
but xxx NE
not xxx NE
sufficient xxx NE
for xxx NE
the xxx NE
Tat Xxx NE
effect xxx NE
. . NE

The Xxx NE
Tat Xxx NE
-mediated -xxx NE
increase xxx NE
in xx NE
IL-2 XX-d NE
promoter xxx NE
activity xxx NE
could xxx NE
selectively xxx NE
be xx NE
blocked xxx NE
by xx NE
antisense xxx NE
tat xxx NE
or-unlike xx-xxx NE
the xxx NE
analogous xxx NE
effect xxx NE
of xx NE
human xxx NE
T-cell X-xxx NE
lymphotropic xxx NE
virus xxx NE
type xxx NE
1 d NE
Tax Xxx NE
-by -xx NE
cyclosporin xxx NE
A X NE
. . NE

The Xxx NE
observed xxx NE
increase xxx NE
in xx NE
IL-2 XX-d protein
levels xxx NE
might xxx NE
facilitate xxx NE
virus xxx NE
spread xxx NE
from xxx NE
or xx NE
to xx NE
T X cell_type_B
cells xxx cell_type_E
. . NE

Furthermore Xxxx NE
, , NE
it xx NE
might xxx NE
contribute xxx NE
to xx NE
the xxx NE
hypergammaglobulinemia xxx NE
or xx NE
, , NE
together xxx NE
with xxx NE
other xxx NE
cytokines xxx protein
found xxx NE
to xx NE
be xx NE
dysregulated xxx NE
, , NE
the xxx NE
T-helper X-xxx NE
cell xxx NE
dysfunctions xxx NE
observed xxx NE
in xx NE
AIDS XXXX NE
patients xxx NE
. . NE

Activation Xxxx NE
of xx NE
nuclear xxx protein_B
factor xxx protein_M
kappa xxx protein_M
B X protein_E
in xx NE
human xxx cell_type_B
lymphoblastoid xxx cell_type_M
cells xxx cell_type_E
by xx NE
low-dose xxx-xxx NE
ionizing xxx NE
radiation xxx NE
. . NE

Nuclear Xxxx protein_B
factor xxx protein_M
kappa xxx protein_M
B X protein_E
( ( NE
NF-kappa XX-xxx protein_B
B X protein_E
) ) NE
is xx NE
a x NE
pleiotropic xxx protein_B
transcription xxx protein_M
factor xxx protein_E
which xxx NE
is xx NE
involved xxx NE
in xx NE
the xxx NE
transcriptional xxx NE
regulation xxx NE
of xx NE
several xxx NE
specific xxx NE
genes xxx NE
. . NE

Recent Xxxx NE
reports xxx NE
demonstrated xxx NE
that xxx NE
ionizing xxx NE
radiation xxx NE
in xx NE
the xxx NE
dose xxx NE
range xxx NE
of xx NE
2-50 d-dd NE
Gy Xx NE
results xxx NE
in xx NE
expression xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
in xx NE
human xxx cell_line_B
KG-1 XX-d cell_line_M
myeloid xxx cell_line_M
leukemia xxx cell_line_M
cells xxx cell_line_E
and xxx NE
human xxx cell_type_B
B-lymphocyte X-xxx cell_type_M
precursor xxx cell_type_M
cells xxx cell_type_E
; ; NE
the xxx NE
precise xxx NE
mechanism xxx NE
involved xxx NE
and xxx NE
the xxx NE
significance xxx NE
are xxx NE
not xxx NE
yet xxx NE
known xxx NE
. . NE

The Xxx NE
present xxx NE
report xxx NE
demonstrates xxx NE
that xxx NE
even xxx NE
lower xxx NE
doses xxx NE
of xx NE
ionizing xxx NE
radiation xxx NE
, , NE
0.25-2.0 d.dd-d.d NE
Gy Xx NE
, , NE
are xxx NE
capable xxx NE
of xx NE
inducing xxx NE
expression xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
in xx NE
EBV-transformed XXX-xxx cell_line_B
244B dddX cell_line_M
human xxx cell_line_M
lymphoblastoid xxx cell_line_M
cells xxx cell_line_E
. . NE

These Xxxx NE
results xxx NE
are xxx NE
in xx NE
a x NE
dose xxx NE
range xxx NE
where xxx NE
the xxx NE
viability xxx NE
of xx NE
the xxx NE
cells xxx NE
remains xxx NE
very xxx NE
high xxx NE
. . NE

After Xxxx NE
exposure xxx NE
to xx NE
137Cs dddXx NE
gamma xxx NE
rays xxx NE
at xx NE
a x NE
dose xxx NE
rate xxx NE
of xx NE
1.17 d.dd NE
Gy/min Xx/xxx NE
, , NE
a x NE
maximum xxx NE
in xx NE
expression xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
was xxx NE
seen xxx NE
at xx NE
8 d NE
h x NE
after xxx NE
a x NE
0.5-Gy d.d-Xx NE
exposure xxx NE
. . NE

Time-course Xxxx-xxx NE
studies xxx NE
revealed xxx NE
a x NE
biphasic xxx NE
time-dependent xxx-xxx NE
expression xxx NE
after xxx NE
0.5-, d.d-, NE
1- d- NE
and xxx NE
2-Gy d-Xx NE
exposures xxx NE
. . NE

However Xxxx NE
, , NE
for xxx NE
each xxx NE
time xxx NE
examined xxx NE
, , NE
the xxx NE
expression xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
was xxx NE
maximum xxx NE
after xxx NE
the xxx NE
0.5-Gy d.d-Xx NE
exposure xxx NE
. . NE

The Xxx NE
expression xxx NE
of xx NE
the xxx NE
p50 xdd protein_B
NF-kappa XX-xxx protein_M
B X protein_M
subunit xxx protein_M
and xxx protein_M
p65 xdd protein_M
NF-kappa XX-xxx protein_M
B X protein_M
subunit xxx protein_E
was xxx NE
also xxx NE
shown xxx NE
to xx NE
be xx NE
regulated xxx NE
differentially xxx NE
after xxx NE
exposures xxx NE
to xx NE
1.0 d.d NE
and xxx NE
2.0 d.d NE
Gy Xx NE
. . NE

Alternative Xxxx NE
splicing xxx NE
of xx NE
RNA XXX RNA_B
transcripts xxx RNA_E
encoded xxx NE
by xx NE
the xxx NE
murine xxx DNA_B
p105 xddd DNA_M
NF-kappa XX-xxx DNA_M
B X DNA_M
gene xxx DNA_E
generates xxx NE
I X protein_B
kappa xxx protein_M
B X protein_M
gamma xxx protein_M
isoforms xxx protein_E
with xxx NE
different xxx NE
inhibitory xxx NE
activities xxx NE
. . NE

The Xxx NE
gene xxx NE
encoding xxx NE
the xxx NE
105-kDa ddd-xXx NE
protein xxx NE
( ( NE
p105 xddd NE
) ) NE
precursor xxx NE
of xx NE
the xxx NE
p50 xdd NE
subunit xxx NE
of xx NE
transcription xxx NE
factor xxx NE
NF-kappa XX-xxx NE
B X NE
also xxx NE
encodes xxx NE
a x NE
p70 xdd NE
I X NE
kappa xxx NE
B X NE
protein xxx NE
, , NE
I X NE
kappa xxx NE
B X NE
gamma xxx NE
, , NE
which xxx NE
is xx NE
identical xxx NE
to xx NE
the xxx NE
C-terminal X-xxx NE
607 ddd NE
amino xxx NE
acids xxx NE
of xx NE
p105 xddd NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
alternative xxx NE
RNA XXX NE
splicing xxx NE
generates xxx NE
I X protein_B
kappa xxx protein_M
B X protein_M
gamma xxx protein_M
isoforms xxx protein_E
with xxx NE
properties xxx NE
different xxx NE
from xxx NE
those xxx NE
of xx NE
p70 xdd protein
. . NE

One Xxx NE
63-kDa dd-xXx protein_B
isoform xxx protein_E
, , NE
termed xxx NE
I X protein_B
kappa xxx protein_M
B X protein_M
gamma-1 xxx-d protein_E
, , NE
which xxx NE
lacks xxx NE
59 dd NE
amino xxx NE
acids xxx NE
C-terminal X-xxx NE
to xx NE
ankyrin xxx protein_B
repeat xxx protein_M
7 d protein_E
, , NE
has xxx NE
a x NE
novel xxx NE
35-amino dd-xxx protein_B
acid xxx protein_M
C X protein_M
terminus xxx protein_E
encoded xxx NE
by xx NE
an xx NE
alternative xxx DNA_B
reading xxx DNA_M
frame xxx DNA_E
of xx NE
the xxx NE
p105 xddd DNA_B
gene xxx DNA_E
. . NE

A X NE
55-kDa dd-xXx protein_B
isoform xxx protein_E
, , NE
I X protein_B
kappa xxx protein_M
B X protein_M
gamma-2 xxx-d protein_E
, , NE
lacks xxx NE
the xxx NE
190 ddd protein_B
C-terminal X-xxx protein_M
amino xxx protein_M
acids xxx protein_E
of xx NE
p70 xdd protein
I X protein_B
kappa xxx protein_M
B X protein_M
gamma xxx protein_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
p70 xdd protein
I X protein_B
kappa xxx protein_M
B X protein_M
gamma xxx protein_E
, , NE
which xxx NE
is xx NE
a x NE
cytoplasmic xxx protein_B
protein xxx protein_E
, , NE
I X protein_B
kappa xxx protein_M
B X protein_M
gamma-1 xxx-d protein_E
is xx NE
found xxx NE
in xx NE
both xxx NE
the xxx NE
cytoplasm xxx NE
and xxx NE
nucleus xxx NE
, , NE
whereas xxx NE
I X protein_B
kappa xxx protein_M
B X protein_M
gamma-2 xxx-d protein_E
is xx NE
predominantly xxx NE
nuclear xxx NE
. . NE

The Xxx NE
I X protein_B
kappa xxx protein_M
B X protein_M
gamma xxx protein_M
isoforms xxx protein_E
also xxx NE
display xxx NE
differences xxx NE
in xx NE
specificity xxx NE
and xxx NE
affinity xxx NE
for xxx NE
Rel Xxx NE
/ / NE
NF-kappa XX-xxx NE
B X NE
proteins xxx NE
. . NE

While Xxxx NE
p70 xdd protein
I X NE
kappa xxx NE
B X NE
gamma xxx NE
inhibits xxx NE
p50-mediated xdd-xxx NE
transactivation xxx NE
and xxx NE
p65-mediated xdd-xxx NE
transactivation xxx NE
and xxx NE
c-Rel-mediated x-Xxx-xxx NE
transactivation xxx NE
DNA XXX NE
binding xxx NE
, , NE
both xxx NE
I X protein_B
kappa xxx protein_M
B X protein_M
gamma-1 xxx-d protein_E
and xxx NE
I X protein_B
kappa xxx protein_M
B X protein_M
gamma-2 xxx-d protein_E
are xxx NE
specific xxx NE
for xxx NE
p50 xdd protein
and xxx NE
have xxx NE
different xxx NE
affinities xxx NE
for xxx NE
this xxx NE
subunit xxx NE
. . NE

The Xxx NE
absence xxx NE
in xx NE
I X protein_B
kappa xxx protein_M
B X protein_M
gamma-1 xxx-d protein_E
and xxx NE
I X protein_B
kappa xxx protein_M
B X protein_M
gamma-2 xxx-d protein_E
of xx NE
a x NE
protein xxx DNA_B
kinase xxx DNA_M
A X DNA_M
site xxx DNA_E
whose xxx NE
phosphorylation xxx NE
modulates xxx NE
p70 xdd protein
I X protein_B
kappa xxx protein_M
B X protein_M
gamma xxx protein_E
inhibitory xxx NE
activity xxx NE
suggests xxx NE
that xxx NE
alternative xxx NE
RNA XXX NE
splicing xxx NE
may xxx NE
be xx NE
used xxx NE
to xx NE
generate xxx NE
I X protein_B
kappa xxx protein_M
B X protein_M
gamma xxx protein_M
isoforms xxx protein_E
that xxx NE
respond xxx NE
differently xxx NE
to xx NE
intracellular xxx NE
signals xxx NE
. . NE

Structure Xxxx NE
and xxx NE
expression xxx NE
of xx NE
the xxx NE
human xxx DNA_B
GATA3 XXXXd DNA_M
gene xxx DNA_E
. . NE

GATA3 XXXXd protein
, , NE
a x NE
member xxx NE
of xx NE
the xxx NE
GATA XXXX protein_B
family xxx protein_E
that xxx NE
is xx NE
abundantly xxx NE
expressed xxx NE
in xx NE
the xxx NE
T-lymphocyte X-xxx cell_type_B
lineage xxx cell_type_E
, , NE
is xx NE
thought xxx NE
to xx NE
participate xxx NE
in xx NE
T-cell X-xxx NE
receptor xxx NE
gene xxx NE
activation xxx NE
through xxx NE
binding xxx NE
to xx NE
enhancers xxx DNA
. . NE

To Xx NE
understand xxx NE
GATA3 XXXXd NE
gene xxx NE
regulation xxx NE
, , NE
we xx NE
cloned xxx NE
the xxx NE
human xxx DNA_B
gene xxx DNA_E
and xxx NE
the xxx NE
5' d' DNA_B
end xxx DNA_E
of xx NE
the xxx NE
mouse xxx DNA_B
GATA3 XXXXd DNA_M
gene xxx DNA_E
. . NE

We Xx NE
show xxx NE
that xxx NE
the xxx NE
human xxx DNA_B
GATA3 XXXXd DNA_M
gene xxx DNA_E
contains xxx NE
six xxx NE
exons xxx DNA
distributed xxx NE
over xxx NE
17 dd NE
kb xx NE
of xx NE
DNA XXX NE
. . NE

The Xxx NE
two xxx NE
human xxx protein_B
GATA3 XXXXd protein_M
zinc xxx protein_M
fingers xxx protein_E
are xxx NE
encoded xxx NE
by xx NE
two xxx NE
separate xxx NE
exons xxx DNA
highly xxx NE
conserved xxx NE
with xxx NE
those xxx NE
of xx NE
GATA1 XXXXd protein
, , NE
but xxx NE
no xx NE
other xxx NE
structural xxx NE
homologies xxx NE
between xxx NE
these xxx NE
two xxx NE
genes xxx NE
can xxx NE
be xx NE
found xxx NE
. . NE

The Xxx NE
human xxx DNA_B
GATA3 XXXXd DNA_M
transcription xxx DNA_M
unit xxx DNA_M
and xxx DNA_M
mouse xxx DNA_M
GATA3 XXXXd DNA_M
transcription xxx DNA_M
unit xxx DNA_E
start xxx NE
at xx NE
a x NE
major xxx DNA_B
initiation xxx DNA_M
site xxx DNA_E
. . NE

The Xxx NE
promoter xxx NE
sequence xxx NE
analysis xxx NE
of xx NE
these xxx NE
two xxx NE
genes xxx NE
revealed xxx NE
that xxx NE
they xxx NE
are xxx NE
embedded xxx NE
within xxx NE
a x NE
CpG XxX DNA_B
island xxx DNA_E
and xxx NE
share xxx NE
structural xxx NE
features xxx NE
often xxx NE
found xxx NE
in xx NE
the xxx NE
promoters xxx DNA
of xx NE
housekeeping xxx DNA_B
genes xxx DNA_E
. . NE

Finally Xxxx NE
, , NE
we xx NE
show xxx NE
that xxx NE
a x NE
DNA XXX DNA_B
fragment xxx DNA_E
containing xxx NE
the xxx NE
human xxx DNA_B
GATA3 XXXXd DNA_M
transcription xxx DNA_M
unit xxx DNA_E
, , NE
3 d DNA_B
kb xx DNA_M
upstream xxx DNA_E
from xxx NE
the xxx NE
initiation xxx DNA_B
site xxx DNA_E
and xxx NE
4 d DNA_B
kb xx DNA_M
downstream xxx DNA_E
from xxx NE
the xxx NE
polyadenylation xxx DNA_B
site xxx DNA_E
, , NE
displays xxx NE
T-cell X-xxx NE
specificity xxx NE
. . NE

Characterization Xxxx NE
of xx NE
the xxx NE
human xxx DNA_B
gene xxx DNA_E
encoding xxx NE
LBR XXX protein
, , NE
an xx NE
integral xxx protein_B
protein xxx protein_E
of xx NE
the xxx NE
nuclear xxx NE
envelope xxx NE
inner xxx NE
membrane xxx NE
. . NE

We Xx NE
have xxx NE
characterized xxx NE
the xxx NE
human xxx DNA_B
gene xxx DNA_E
encoding xxx NE
LBR XXX protein
, , NE
an xx NE
integral xxx protein_B
protein xxx protein_E
of xx NE
the xxx NE
nuclear xxx NE
envelope xxx NE
inner xxx NE
membrane xxx NE
. . NE

Restriction Xxxx NE
mapping xxx NE
shows xxx NE
that xxx NE
the xxx NE
transcription xxx DNA_B
unit xxx DNA_E
spans xxx NE
approximately xxx NE
35 dd NE
kilobases xxx NE
. . NE

A X NE
transcription xxx NE
start xxx NE
site xxx NE
is xx NE
located xxx NE
approximately xxx NE
4 d NE
kilobases xxx NE
5' d' NE
to xx NE
the xxx NE
translation xxx DNA_B
initiation xxx DNA_M
codon xxx DNA_E
, , NE
and xxx NE
an xx NE
RNA XXX NE
splice xxx NE
of xx NE
3863 dddd NE
bases xxx NE
occurs xxx NE
in xx NE
the xxx NE
5'-untranslated d'-xxx DNA_B
region xxx DNA_E
to xx NE
generate xxx NE
mature xxx RNA_B
HeLa XxXx RNA_M
cell xxx RNA_M
mRNA xXXX RNA_E
. . NE

5' d' NE
to xx NE
the xxx NE
identified xxx NE
transcription xxx DNA_B
start xxx DNA_M
site xxx DNA_E
are xxx NE
two xxx NE
CCAAT XXXXX DNA_B
sequences xxx DNA_E
and xxx NE
potential xxx DNA_B
recognition xxx DNA_M
sites xxx DNA_E
for xxx NE
several xxx NE
transcription xxx protein_B
factors xxx protein_E
including xxx NE
Sp1 Xxd protein
, , NE
AP-1 XX-d protein
, , NE
AP-2 XX-d protein
, , NE
and xxx NE
NF-kB XX-xX protein
. . NE

There Xxxx NE
are xxx NE
13 dd NE
protein xxx NE
coding xxx NE
exons xxx DNA
in xx NE
the xxx NE
LBR XXX DNA_B
gene xxx DNA_E
. . NE

LBR XXX protein
's 'x NE
nucleoplasmic xxx protein_B
domain xxx protein_E
is xx NE
encoded xxx NE
by xx NE
exons xxx DNA_B
1-4 d-d DNA_E
, , NE
and xxx NE
its xxx NE
hydrophobic xxx protein_B
domain xxx protein_E
, , NE
with xxx NE
eight xxx NE
putative xxx NE
transmembrane xxx protein_B
segments xxx protein_E
, , NE
is xx NE
encoded xxx NE
by xx NE
exons xxx DNA_B
5-13 d-dd DNA_E
. . NE

The Xxx NE
hydrophobic xxx protein_B
domain xxx protein_E
is xx NE
homologous xxx NE
to xx NE
three xxx NE
yeast xxx NE
polypeptides xxx NE
, , NE
suggesting xxx NE
that xxx NE
this xxx NE
higher xxx DNA_B
eukaryotic xxx DNA_M
gene xxx DNA_E
could xxx NE
have xxx NE
evolved xxx NE
from xxx NE
recombination xxx NE
between xxx NE
a x NE
gene xxx NE
that xxx NE
encoded xxx NE
a x NE
soluble xxx protein_B
nuclear xxx protein_M
protein xxx protein_E
and xxx NE
a x NE
membrane xxx DNA_B
protein xxx DNA_M
gene xxx DNA_E
similar xxx NE
to xx NE
those xxx NE
in xx NE
yeast xxx NE
. . NE

These Xxxx NE
results xxx NE
are xxx NE
the xxx NE
first xxx NE
to xx NE
demonstrate xxx NE
the xxx NE
structural xxx NE
organization xxx NE
of xx NE
a x NE
vertebrate xxx DNA_B
gene xxx DNA_E
encoding xxx NE
an xx NE
integral xxx protein_B
membrane xxx protein_M
protein xxx protein_E
of xx NE
the xxx NE
nuclear xxx NE
envelope xxx NE
that xxx NE
may xxx NE
be xx NE
a x NE
member xxx NE
of xx NE
a x NE
family xxx NE
of xx NE
polypeptides xxx NE
conserved xxx NE
in xx NE
evolution xxx NE
. . NE

Retinoic Xxxx NE
acid-induced xxx-xxx NE
expression xxx NE
of xx NE
CD38 XXdd protein_B
antigen xxx protein_E
in xx NE
myeloid xxx cell_type_B
cells xxx cell_type_E
is xx NE
mediated xxx NE
through xxx NE
retinoic xxx protein_B
acid xxx protein_M
receptor-alpha xxx-xxx protein_E
. . NE

CD38 XXdd protein
is xx NE
a x NE
leukocyte xxx protein_B
differentiation xxx protein_M
antigen xxx protein_E
that xxx NE
has xxx NE
been xxx NE
thought xxx NE
to xx NE
be xx NE
a x NE
phenotypic xxx NE
marker xxx NE
of xx NE
different xxx NE
subpopulations xxx NE
of xx NE
T- X- cell_type_B
lymphocyte xxx cell_type_M
and xxx cell_type_M
B- X- cell_type_M
lymphocyte xxx cell_type_E

In Xx NE
myeloid xxx cell_type_B
cells xxx cell_type_E
, , NE
CD38 XXdd protein
is xx NE
expressed xxx NE
during xxx NE
early xxx NE
stages xxx NE
of xx NE
differentiation xxx NE
. . NE

Virtually Xxxx NE
no xx NE
information xxx NE
is xx NE
available xxx NE
on xx NE
regulation xxx NE
and xxx NE
functions xxx NE
of xx NE
CD38 XXdd protein
. . NE

Recently Xxxx NE
we xx NE
reported xxx NE
that xxx NE
all-trans-retinoic xxx-xxx-xxx NE
acid xxx NE
( ( NE
ATRA XXXX NE
) ) NE
is xx NE
a x NE
potent xxx NE
and xxx NE
highly xxx NE
specific xxx NE
inducer xxx NE
of xx NE
CD38 XXdd NE
expression xxx NE
in xx NE
human xxx cell_type_B
promyelocytic xxx cell_type_M
leukemia xxx cell_type_M
cells xxx cell_type_E
. . NE

Here Xxxx NE
we xx NE
report xxx NE
that xxx NE
ATRA XXXX NE
-induced -xxx NE
expression xxx NE
of xx NE
CD38 XXdd NE
antigen xxx NE
in xx NE
myeloid xxx NE
cells xxx NE
is xx NE
mediated xxx NE
through xxx NE
retinoic xxx NE
acid-alpha xxx-xxx NE
receptor xxx NE
( ( NE
RAR XXX NE
alpha xxx NE
) ) NE
. . NE

ATRA XXXX NE
failed xxx NE
to xx NE
induce xxx NE
CD38 XXdd NE
expression xxx NE
in xx NE
a x NE
mutant xxx cell_line_B
subclone xxx cell_line_E
of xx NE
the xxx NE
HL-60 XX-dd cell_line_B
myeloid xxx cell_line_M
leukemia xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
(designated (xxx NE
HL-60R XX-ddX cell_line
) ) NE
that xxx NE
is xx NE
relatively xxx NE
resistant xxx NE
to xx NE
ATRA XXXX NE
-induced -xxx NE
granulocytic xxx NE
differentiation xxx NE
. . NE

Retroviral Xxxx NE
vector-mediated xxx-xxx NE
transduction xxx NE
of xx NE
RA XX protein_B
receptor xxx protein_E
( ( NE
RAR XXX protein_B
alpha xxx protein_E
) ) NE
into xxx NE
this xxx NE
HL-60R XX-ddX cell_line_B
subclone xxx cell_line_E
completely xxx NE
restored xxx NE
the xxx NE
sensitivity xxx NE
of xx NE
these xxx NE
cells xxx NE
to xx NE
ATRA XXXX NE
in xx NE
terms xxx NE
of xx NE
their xxx NE
ability xxx NE
to xx NE
express xxx NE
CD38 XXdd protein
. . NE

In Xx NE
contrast xxx NE
, , NE
CD38 XXdd NE
expression xxx NE
was xxx NE
not xxx NE
inducible xxx NE
by xx NE
ATRA XXXX NE
in xx NE
HL-60R XX-ddX cell_line_B
cells xxx cell_line_E
, , NE
transfected xxx NE
with xxx NE
a x NE
functional xxx NE
RAR XXX protein_B
beta xxx protein_E
, , NE
RAR XXX protein_B
gamma xxx protein_E
, , NE
or xx NE
RXR XXX protein_B
alpha xxx protein_M
receptor xxx protein_E
. . NE

Induction Xxxx NE
of xx NE
CD38 XXdd protein
in xx NE
acute xxx cell_type_B
promyelocytic xxx cell_type_M
leukemia xxx cell_type_M
cell xxx cell_type_M
and xxx cell_type_M
acute xxx cell_type_M
myeloblastic xxx cell_type_M
leukemia xxx cell_type_M
cell xxx cell_type_E
was xxx NE
independent xxx NE
of xx NE
ATRA XXXX NE
-induced -xxx NE
cytodifferentiation xxx NE
. . NE

Following Xxxx NE
culture xxx NE
with xxx NE
ATRA XXXX NE
, , NE
increased xxx NE
CD38 XXdd NE
protein xxx NE
levels xxx NE
were xxx NE
also xxx NE
observed xxx NE
in xx NE
normal xxx cell_type_B
CD34+ XXdd+ cell_type_M
bone xxx cell_type_M
marrow xxx cell_type_M
cells xxx cell_type_E
, , NE
but xxx NE
not xxx NE
on xx NE
normal xxx cell_type_B
circulating xxx cell_type_M
granulocytes xxx cell_type_E
. . NE

From Xxxx NE
these xxx NE
results xxx NE
, , NE
we xx NE
conclude xxx NE
that xxx NE
CD38 XXdd protein
is xx NE
ATRA XXXX NE
inducible xxx NE
in xx NE
myeloid xxx cell_type_B
leukemia xxx cell_type_M
cells xxx cell_type_E
and xxx NE
normal xxx cell_type_B
CD34+ XXdd+ cell_type_M
bone xxx cell_type_M
marrow xxx cell_type_M
cells xxx cell_type_E
. . NE

This Xxxx NE
effect xxx NE
is xx NE
independent xxx NE
of xx NE
differentiation xxx NE
and xxx NE
is xx NE
mediated xxx NE
by xx NE
RAR XXX protein_B
alpha xxx protein_E
in xx NE
HL-60 XX-dd cell_type_B
cells xxx cell_type_E
, , NE
suggesting xxx NE
a x NE
similar xxx NE
role xxx NE
for xxx NE
RAR XXX protein_B
alpha xxx protein_E
in xx NE
CD38 XXdd NE
expression xxx NE
in xx NE
other xxx NE
hematopoietic xxx cell_type_B
cells xxx cell_type_E
. . NE

Some Xxxx NE
antioxidants xxx NE
inhibit xxx NE
, , NE
in xx NE
a x NE
co-ordinate xx-xxx NE
fashion xxx NE
, , NE
the xxx NE
production xxx NE
of xx NE
tumor xxx protein_B
necrosis xxx protein_M
factor-alpha xxx-xxx protein_E
, , NE
IL-beta XX-xxx protein
, , NE
and xxx NE
IL-6 XX-d protein
by xx NE
human xxx cell_type_B
peripheral xxx cell_type_M
blood xxx cell_type_M
mononuclear xxx cell_type_M
cells xxx cell_type_E
. . NE

Some Xxxx NE
antioxidants xxx NE
, , NE
including xxx NE
butylated xxx NE
hydroxyanisole xxx NE
( ( NE
BHA XXX NE
) ) NE
, , NE
tetrahydropapaveroline xxx NE
( ( NE
THP XXX NE
) ) NE
, , NE
nordihydroguiauretic xxx NE
acid xxx NE
, , NE
and xxx NE
10,11-dihydroxyaporphine dd,dd-xxx NE
( ( NE
DHA XXX NE
) ) NE
, , NE
were xxx NE
found xxx NE
to xx NE
be xx NE
potent xxx NE
inhibitors xxx NE
of xx NE
the xxx NE
production xxx NE
of xx NE
tumor xxx protein_B
necrosis xxx protein_M
factor xxx protein_M
(TNF)-alpha (XXX)-xxx protein_E
, , NE
IL-1 XX-d protein_B
beta xxx protein_E
, , NE
and xxx NE
IL-6 XX-d protein
by xx NE
human xxx cell_type_B
peripheral xxx cell_type_M
blood xxx cell_type_M
mononuclear xxx cell_type_M
cells xxx cell_type_E
( ( NE
PBMC XXXX cell_type
) ) NE
stimulated xxx NE
by xx NE
lipopolysaccharide xxx NE
( ( NE
LPS XXX NE
) ) NE
( ( NE
IC50s XXddx NE
in xx NE
the xxx NE
low xxx NE
micromolar xxx NE
range) xxx) NE
. . NE

Inhibition Xxxx NE
of xx NE
cytokine xxx NE
production xxx NE
was xxx NE
gene xxx NE
selective xxx NE
and xxx NE
not xxx NE
due xxx NE
to xx NE
general xxx NE
effects xxx NE
on xx NE
protein xxx NE
synthesis xxx NE
. . NE

Inhibition Xxxx NE
of xx NE
cytokine xxx NE
production xxx NE
by xx NE
PBMC XXXX cell_type
was xxx NE
observed xxx NE
also xxx NE
when xxx NE
other xxx NE
inducers xxx NE
were xxx NE
used xxx NE
( ( NE
staphylococci xxx NE
, , NE
silica xxx NE
, , NE
zymosan xxx NE
) ) NE
. . NE

Much Xxxx NE
higher xxx NE
concentrations xxx NE
of xx NE
other xxx NE
antioxidants xxx NE
--including --xxx NE
ascorbic xxx NE
acid xxx NE
, , NE
trolox xxx NE
, , NE
alpha-tocopherol xxx-xxx NE
, , NE
butylated xxx NE
hydroxytoluene xxx NE
, , NE
and xxx NE
the xxx NE
5-lipoxygenase d-xxx NE
inhibitor xxx NE
zileuton xxx NE
--did --xxx NE
not xxx NE
affect xxx NE
the xxx NE
production xxx NE
of xx NE
these xxx NE
cytokines xxx protein
. . NE

The Xxx NE
active xxx NE
compounds xxx NE
did xxx NE
not xxx NE
inhibit xxx NE
IL-1 XX-d NE
-induced -xxx NE
production xxx NE
of xx NE
IL-6 XX-d NE
in xx NE
fibroblasts xxx NE
, , NE
showing xxx NE
the xxx NE
cell xxx NE
selectivity xxx NE
of xx NE
the xxx NE
effect xxx NE
. . NE

Antioxidant-mediated Xxxx-xxx NE
inhibition xxx NE
of xx NE
cytokine xxx NE
production xxx NE
was xxx NE
correlated xxx NE
with xxx NE
low xxx NE
levels xxx NE
of xx NE
the xxx NE
corresponding xxx NE
messenger xxx RNA_B
RNAs XXXx RNA_E
. . NE

Nuclear Xxxx NE
run-on xxx-xx NE
experiments xxx NE
showed xxx NE
that xxx NE
THP XXX NE
inhibited xxx NE
transcription xxx NE
of xx NE
the xxx NE
IL-1 XX-d DNA_B
beta xxx DNA_M
gene xxx DNA_E
. . NE

THP XXX NE
decreased xxx NE
the xxx NE
concentration xxx NE
of xx NE
the xxx NE
transcription xxx protein_B
factors xxx protein_E
NF-kappa XX-xxx protein_B
B X protein_E
and xxx NE
AP-1 XX-d protein
detected xxx NE
in xx NE
nuclear xxx NE
extracts xxx NE
of xx NE
PBMC XXXX cell_type
cultured xxx NE
in xx NE
the xxx NE
presence xxx NE
or xx NE
absence xxx NE
of xx NE
LPS XXX NE
. . NE

THP XXX NE
and xxx NE
DHA XXX NE
markedly xxx NE
decreased xxx NE
the xxx NE
levels xxx NE
of xx NE
TNF-alpha XXX-xxx protein
and xxx NE
IL-1 XX-d protein_B
beta xxx protein_E
in xx NE
the xxx NE
circulation xxx NE
of xx NE
mice xxx NE
following xxx NE
LPS XXX NE
injection xxx NE
. . NE

Thus Xxxx NE
antioxidants xxx NE
vary xxx NE
widely xxx NE
in xx NE
potency xxx NE
as xx NE
inhibitors xxx NE
of xx NE
the xxx NE
activation xxx NE
of xx NE
transcription xxx protein_B
factors xxx protein_E
and xxx NE
of xx NE
the xxx NE
transcription xxx NE
of xx NE
genes xxx DNA
for xxx NE
pro-inflammatory xxx-xxx protein_B
cytokines xxx protein_E
. . NE

Coordinate Xxxx NE
inhibition xxx NE
of xx NE
the xxx NE
transcription xxx NE
of xx NE
genes xxx NE
for xxx NE
inflammatory xxx NE
cytokines xxx protein
could xxx NE
provide xxx NE
a x NE
strategy xxx NE
for xxx NE
therapy xxx NE
of xx NE
diseases xxx NE
with xxx NE
inflammatory xxx NE
pathogenesis xxx NE
and xxx NE
for xxx NE
septic xxx NE
shock xxx NE
. . NE

An Xx NE
interleukin-4-induced xxx-d-xxx protein_B
transcription xxx protein_M
factor xxx protein_E
: : NE
IL-4 XX-d protein_B
Stat Xxxx protein_E
. . NE

Interleukin-4 Xxxx-d protein
( ( NE
IL-4 XX-d protein
) ) NE
is xx NE
an xx NE
immunomodulatory xxx NE
cytokine xxx NE
secreted xxx NE
by xx NE
activated xxx NE
T X cell_type_B
lymphocytes xxx cell_type_E
, , NE
basophils xxx cell_type
, , NE
and xxx NE
mast xxx cell_type_B
cells xxx cell_type_E
. . NE

It Xx NE
plays xxx NE
an xx NE
important xxx NE
role xxx NE
in xx NE
modulating xxx NE
the xxx NE
balance xxx NE
of xx NE
T X cell_type_B
helper xxx cell_type_M
(Th) (Xx) cell_type_M
cell xxx cell_type_M
subsets xxx cell_type_E
, , NE
favoring xxx NE
expansion xxx NE
of xx NE
the xxx NE
Th2 Xxd cell_type_B
lineage xxx cell_type_E
relative xxx NE
to xx NE
Th1 Xxd cell_type
. . NE

Imbalance Xxxx NE
of xx NE
these xxx NE
T X cell_type_B
lymphocyte xxx cell_type_M
subsets xxx cell_type_E
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
immunological xxx NE
diseases xxx NE
including xxx NE
allergy xxx NE
, , NE
inflammation xxx NE
, , NE
and xxx NE
autoimmune xxx NE
disease xxx NE
. . NE

IL-4 XX-d protein
may xxx NE
mediate xxx NE
its xxx NE
biological xxx NE
effects xxx NE
, , NE
at xx NE
least xxx NE
in xx NE
part xxx NE
, , NE
by xx NE
activating xxx NE
a x NE
tyrosine-phosphorylated xxx-xxx protein_B
DNA XXX protein_M
binding xxx protein_M
protein xxx protein_E
. . NE

This Xxxx NE
protein xxx NE
has xxx NE
now xxx NE
been xxx NE
purified xxx NE
and xxx NE
its xxx NE
encoding xxx NE
gene xxx NE
cloned xxx NE
. . NE

Examination Xxxx NE
of xx NE
the xxx NE
primary xxx protein_B
amino xxx protein_M
acid xxx protein_M
sequence xxx protein_E
of xx NE
this xxx NE
protein xxx NE
indicates xxx NE
that xxx NE
it xx NE
is xx NE
a x NE
member xxx NE
of xx NE
the xxx NE
signal xxx protein_B
transducers xxx protein_M
and xxx protein_M
activators xxx protein_M
of xx protein_M
transcription xxx protein_M
(Stat) (Xxxx) protein_M
family xxx protein_E
of xx NE
DNA XXX protein_B
binding xxx protein_M
proteins xxx protein_E
, , NE
hereby xxx NE
designated xxx NE
IL-4 XX-d protein_B
Stat Xxxx protein_E
. . NE

Study Xxxx NE
of xx NE
the xxx NE
inhibitory xxx NE
activities xxx NE
of xx NE
phosphotyrosine-containing xxx-xxx NE
peptides xxx NE
derived xxx NE
from xxx NE
the xxx NE
intracellular xxx protein_B
domain xxx protein_M
of xx protein_M
the xxx protein_M
IL-4 XX-d protein_M
receptor xxx protein_E
provided xxx NE
evidence xxx NE
for xxx NE
direct xxx NE
coupling xxx NE
of xx NE
receptor xxx protein
and xxx NE
transcription xxx protein_B
factor xxx protein_E
during xxx NE
the xxx NE
IL-4 XX-d NE
Stat Xxxx NE
activation xxx NE
cycle xxx NE
. . NE

Such Xxxx NE
observations xxx NE
indicate xxx NE
that xxx NE
IL-4 XX-d protein_B
Stat Xxxx protein_E
has xxx NE
the xxx NE
same xxx NE
functional xxx protein_B
domain xxx protein_E
for xxx NE
both xxx NE
receptor xxx NE
coupling xxx NE
and xxx NE
dimerization xxx NE
. . NE

Evaluation Xxxx NE
of xx NE
the xxx NE
respiratory xxx NE
epithelium xxx NE
of xx NE
normals xxx NE
and xxx NE
individuals xxx NE
with xxx NE
cystic xxx NE
fibrosis xxx NE
for xxx NE
the xxx NE
presence xxx NE
of xx NE
adenovirus xxx DNA_B
E1a Xdx DNA_M
sequences xxx DNA_E
relevant xxx NE
to xx NE
the xxx NE
use xxx NE
of xx NE
E1a- Xdx- NE
adenovirus xxx NE
vectors xxx NE
for xxx NE
gene xxx NE
therapy xxx NE
for xxx NE
the xxx NE
respiratory xxx NE
manifestations xxx NE
of xx NE
cystic xxx NE
fibrosis xxx NE
. . NE

Lung Xxxx NE
disease xxx NE
associated xxx NE
with xxx NE
disorders xxx NE
such xxx NE
as xx NE
cystic xxx NE
fibrosis xxx NE
(CF) (XX) NE
may xxx NE
be xx NE
amenable xxx NE
to xx NE
somatic xxx NE
gene xxx NE
therapy xxx NE
in xx NE
which xxx NE
there xxx NE
is xx NE
delivery xxx NE
of xx NE
the xxx NE
normal xxx DNA_B
gene xxx DNA_E
directly xxx NE
to xx NE
the xxx NE
respiratory xxx NE
epithelium xxx NE
using xxx NE
E1a- Xdx- NE
adenovirus xxx NE
(Ad) (Xx) NE
type xxx NE
2- d- NE
or xx NE
5-based d-xxx NE
vectors xxx NE
. . NE

For Xxx NE
safety xxx NE
reasons xxx NE
, , NE
the xxx NE
Ad Xx NE
vectors xxx NE
are xxx NE
rendered xxx NE
replication xxx NE
deficient xxx NE
by xx NE
deletion xxx NE
of xx NE
the xxx NE
E1a Xdx DNA_B
region xxx DNA_E
. . NE

Because Xxxx NE
there xxx NE
is xx NE
the xxx NE
theoretical xxx NE
possibility xxx NE
of xx NE
an xx NE
E1a- Xdx- NE
replication-deficient xxx-xxx NE
vector xxx NE
replicating xxx NE
as xx NE
a x NE
result xxx NE
of xx NE
recombination xxx NE
or xx NE
complementation xxx NE
with xxx NE
Ad Xx DNA_B
2/5 d/d DNA_M
E1a Xdx DNA_M
sequences xxx DNA_E
present xxx NE
in xx NE
the xxx NE
target xxx NE
cell xxx NE
, , NE
this xxx NE
study xxx NE
is xx NE
directed xxx NE
toward xxx NE
evaluating xxx NE
respiratory xxx NE
epithelium xxx NE
of xx NE
normals xxx NE
and xxx NE
individuals xxx NE
with xxx NE
CF XX NE
for xxx NE
the xxx NE
presence xxx NE
of xx NE
E1a Xdx NE
sequences xxx NE
. . NE

Using Xxxx NE
Ad Xx DNA_B
2/5 d/d DNA_M
E1a-specific Xdx-xxx DNA_M
primers xxx DNA_E
and xxx NE
the xxx NE
polymerase xxx NE
chain xxx NE
reaction xxx NE
to xx NE
evaluate xxx NE
DNA XXX NE
recovered xxx NE
from xxx NE
freshly xxx NE
isolated xxx NE
nasal xxx NE
epithelium xxx NE
and xxx NE
bronchial xxx NE
epithelium xxx NE
E1a Xdx NE
sequences xxx NE
were xxx NE
detected xxx NE
in xx NE
respiratory xxx NE
epithelium xxx NE
of xx NE
19 dd NE
of xx NE
91 dd NE
normals xxx NE
(21%) (dd%) NE
. . NE

In Xx NE
the xxx NE
E1a-positive Xdx-xxx NE
samples xxx NE
, , NE
the xxx NE
average xxx NE
of xx NE
E1a Xdx NE
copy xxx NE
number xxx NE
was xxx NE
55 dd NE
+/- +/- NE
18/10(3) dd/dd(d) NE
recovered xxx NE
cells xxx NE
. . NE

In Xx NE
CF XX NE
individuals xxx NE
, , NE
7 d NE
of xx NE
52 dd NE
(13%) (dd%) NE
had xxx NE
detectable xxx NE
E1a Xdx DNA_B
sequences xxx DNA_E
in xx NE
the xxx NE
respiratory xxx NE
epithelium xxx NE
, , NE
with xxx NE
E1a Xdx NE
copy xxx NE
number xxx NE
in xx NE
the xxx NE
positive xxx NE
samples xxx NE
of xx NE
80 dd NE
+/- +/- NE
21/10(3) dd/dd(d) NE
recovered xxx NE
cells xxx NE
. . NE

These Xxxx NE
results xxx NE
demonstrate xxx NE
that xxx NE
there xxx NE
are xxx NE
detectable xxx NE
Ad Xx DNA_B
2/5 d/d DNA_M
E1a Xdx DNA_M
sequences xxx DNA_E
in xx NE
the xxx NE
respiratory xxx NE
epithelium xxx NE
of xx NE
a x NE
small xxx NE
percentage xxx NE
of xx NE
normals xxx NE
and xxx NE
individuals xxx NE
with xxx NE
CF XX NE
. . NE

Because Xxxx NE
of xx NE
the xxx NE
theoretical xxx NE
potential xxx NE
of xx NE
such xxx NE
sequences xxx NE
supporting xxx NE
replication xxx NE
of xx NE
E1a- Xdx- NE
Ad Xx NE
vectors xxx NE
, , NE
human xxx NE
gene xxx NE
therapy xxx NE
protocols xxx NE
for xxx NE
CF XX NE
utilizing xxx NE
such xxx NE
vectors xxx NE
should xxx NE
consider xxx NE
evaluating xxx NE
study xxx NE
individuals xxx NE
for xxx NE
the xxx NE
presence xxx NE
of xx NE
Ad Xx DNA_B
2/5 d/d DNA_M
E1a Xdx DNA_M
sequences xxx DNA_E
in xx NE
the xxx NE
respiratory xxx NE
epithelium xxx NE
. . NE

Leiomyosarcoma Xxxx NE
of xx NE
the xxx NE
vulva xxx NE
: : NE
report xxx NE
of xx NE
a x NE
case xxx NE
. . NE

A X NE
52-year-old dd-xxx-xxx NE
female xxx NE
presented xxx NE
with xxx NE
a x NE
progressively xxx NE
enlarging xxx NE
vulvar xxx NE
mass xxx NE
. . NE

Pathological Xxxx NE
evaluation xxx NE
revealed xxx NE
a x NE
high-grade xxx-xxx NE
vulvar xxx NE
leiomyosarcoma xxx NE
. . NE

immunohistochemical xxx NE
study xxx NE
and xxx NE
ultrastructural xxx NE
study xxx NE
studies xxx NE
were xxx NE
performed xxx NE
to xx NE
support xxx NE
the xxx NE
diagnosis xxx NE
. . NE

In Xx NE
an xx NE
effort xxx NE
to xx NE
better xxx NE
understand xxx NE
the xxx NE
biology xxx NE
of xx NE
this xxx NE
tumor xxx NE
additional xxx NE
immunohistochemical xxx NE
studies xxx NE
for xxx NE
the xxx NE
protein xxx NE
product xxx NE
of xx NE
p53 xdd NE
tumor xxx NE
suppressor xxx NE
gene xxx NE
and xxx NE
estrogen xxx NE
receptor xxx NE
expression xxx NE
by xx NE
tumor xxx NE
cells xxx NE
, , NE
as xx NE
well xxx NE
as xx NE
the xxx NE
type xxx NE
of xx NE
immune xxx NE
cells xxx NE
infiltrating xxx NE
the xxx NE
tumor xxx NE
were xxx NE
performed xxx NE
. . NE

Tumor Xxxx cell_type_B
cells xxx cell_type_E
showed xxx NE
an xx NE
overexpression xxx NE
of xx NE
p53 xdd protein_B
protein xxx protein_E
and xxx NE
were xxx NE
estrogen xxx NE
receptor xxx NE
-positive -xxx NE
. . NE

Macrophages Xxxx cell_type
and xxx NE
T X cell_type_B
lymphocyte xxx cell_type_M
and xxx cell_type_M
B X cell_type_M
lymphocyte xxx cell_type_E
T X NE
infiltrated xxx NE
the xxx NE
tumor xxx NE
in xx NE
moderate xxx NE
numbers xxx NE
with xxx NE
occasional xxx NE
lymphoid xxx NE
aggregate xxx NE
formation xxx NE
. . NE

This Xxxx NE
study xxx NE
is xx NE
the xxx NE
first xxx NE
attempt xxx NE
to xx NE
better xxx NE
understand xxx NE
the xxx NE
biology xxx NE
of xx NE
these xxx NE
tumors xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
HIV XXX NE
replication xxx NE
in xx NE
mononuclear xxx cell_type_B
phagocytes xxx cell_type_E
by xx NE
leukemia xxx protein_B
inhibitory xxx protein_M
factor xxx protein_E
. . NE

This Xxxx NE
study xxx NE
examined xxx NE
the xxx NE
effects xxx NE
of xx NE
leukemia xxx protein_B
inhibitory xxx protein_M
factor xxx protein_E
( ( NE
LIF XXX protein
) ) NE
on xx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
( ( NE
HIV XXX NE
) ) NE
replication xxx NE
in xx NE
mononuclear xxx NE
phagocytes xxx NE
( ( NE
MNP XXX NE
) ) NE
. . NE

LIF XXX protein
induced xxx NE
a x NE
dose-dependent xxx-xxx NE
increase xxx NE
in xx NE
p24 xdd protein_B
antigen xxx protein_E
production xxx NE
in xx NE
the xxx NE
chronically xxx cell_line_B
infected xxx cell_line_M
promonocytic xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_M
U1 Xd cell_line_E
. . NE

The Xxx NE
magnitude xxx NE
and xxx NE
time xxx NE
kinetics xxx NE
of xx NE
the xxx NE
LIF XXX protein
effects xxx NE
were xxx NE
similar xxx NE
to xx NE
interleukin xxx protein_B
1 d protein_E
( ( NE
IL-1 XX-d protein
) ) NE
, , NE
IL-6 XX-d protein
, , NE
and xxx NE
tumor xxx protein_B
necrosis xxx protein_M
factor xxx protein_E
( ( NE
TNF XXX protein
) ) NE
, , NE
other xxx NE
cytokines xxx NE
known xxx NE
to xx NE
induce xxx NE
HIV XXX NE
replication xxx NE
in xx NE
this xxx NE
cell xxx NE
line xxx NE
. . NE

To Xx NE
characterize xxx NE
mechanisms xxx NE
responsible xxx NE
for xxx NE
these xxx NE
LIF XXX NE
effects xxx NE
, , NE
levels xxx NE
of xx NE
HIV XXX RNA_B
mRNA xXXX RNA_E
, , NE
activation xxx NE
of xx NE
the xxx NE
DNA XXX protein_B
binding xxx protein_M
protein xxx protein_M
nuclear xxx protein_M
factor xxx protein_E
(NF)-kB (XX)-xX protein
, , NE
signal xxx NE
transduction xxx NE
pathways xxx NE
, , NE
and xxx NE
potential xxx NE
interactions xxx NE
with xxx NE
other xxx NE
cytokines xxx protein
were xxx NE
analyzed xxx NE
. . NE

LIF XXX protein
increased xxx NE
steady-state xxx-xxx NE
levels xxx NE
of xx NE
HIV XXX RNA_B
mRNA xXXX RNA_E
at xx NE
2.0 d.d NE
, , NE
4.3 d.d NE
, , NE
and xxx NE
9.2 d.d NE
kB xX NE
. . NE

This Xxxx NE
was xxx NE
detectable xxx NE
by xx NE
24 dd NE
h x NE
and xxx NE
persisted xxx NE
until xxx NE
72 dd NE
h x NE
. . NE

The Xxx NE
DNA XXX protein_B
binding xxx protein_M
protein xxx protein_M
NF-kB XX-xX protein_E
is xx NE
a x NE
central xxx NE
mediator xxx NE
in xx NE
cytokine xxx NE
activation xxx NE
of xx NE
HIV XXX NE
transcription xxx NE
. . NE

NF-kB XX-xX NE
levels xxx NE
were xxx NE
higher xxx NE
in xx NE
unstimulated xxx cell_line_B
U1 Xd cell_line_M
cells xxx cell_line_E
as xx NE
compared xxx NE
to xx NE
the xxx NE
parent xxx cell_line_B
cell xxx cell_line_M
line xxx cell_line_E
U937 Xddd cell_line
. . NE

In Xx NE
both xxx NE
cell xxx NE
lines xxx NE
LIF XXX protein
increased xxx NE
NF-kB XX-xX NE
activity xxx NE
. . NE

Induction Xxxx NE
of xx NE
NF-kB XX-xX protein
and xxx NE
HIV XXX NE
replication xxx NE
by xx NE
cytokines xxx protein
are xxx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
dependent xxx NE
on xx NE
reactive xxx NE
oxygen xxx NE
intermediates xxx NE
. . NE

The Xxx NE
oxygen xxx NE
radical xxx NE
scavenger xxx NE
N-acetyl-L-cysteine X-xxx-X-xxx NE
, , NE
but xxx NE
not xxx NE
an xx NE
inhibitor xxx NE
of xx NE
nitric xxx protein_B
oxide xxx protein_M
synthase xxx protein_E
, , NE
inhibited xxx NE
LIF XXX NE
-induced -xxx NE
HIV XXX NE
replication xxx NE
. . NE

LIF XXX protein
induces xxx NE
the xxx NE
production xxx NE
of xx NE
other xxx NE
cytokines xxx protein
in xx NE
monocytes xxx NE
but xxx NE
its xxx NE
effects xxx NE
on xx NE
HIV XXX NE
replication xxx NE
were xxx NE
not xxx NE
inhibited xxx NE
by xx NE
antibodies xxx NE
to xx NE
IL-1 XX-d NE
, , NE
TNF XXX NE
, , NE
or xx NE
IL-6 XX-d NE
. . NE

These Xxxx NE
results xxx NE
identify xxx NE
LIF XXX protein
as xx NE
a x NE
stimulus xxx NE
of xx NE
HIV XXX NE
replication xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Mechanisms Xxxx NE
involved xxx NE
in xx NE
the xxx NE
inhibition xxx NE
of xx NE
growth xxx NE
of xx NE
a x NE
human xxx cell_line_B
B X cell_line_M
lymphoma xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
, , NE
B104 Xddd cell_line
, , NE
by xx NE
anti-MHC xxx-XXX NE
class xxx NE
II XX NE
antibodies xxx NE
. . NE

The Xxx NE
mechanisms xxx NE
involved xxx NE
in xx NE
the xxx NE
inhibition xxx NE
of xx NE
growth xxx NE
of xx NE
a x NE
human xxx cell_line_B
B X cell_line_M
lymphoma xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
, , NE
B104 Xddd cell_line
, , NE
by xx NE
anti-MHC xxx-XXX NE
class xxx NE
II XX NE
antibodies xxx NE
( ( NE
Ab Xx NE
) ) NE
were xxx NE
compared xxx NE
with xxx NE
those xxx NE
in xx NE
anti-IgM xxx-XxX NE
Ab Xx NE
-induced -xxx NE
B104 Xddd NE
growth xxx NE
inhibition xxx NE
. . NE

Two Xxx NE
anti-MHC xxx-XXX protein_B
class xxx protein_M
II XX protein_M
Ab Xx protein_E
, , NE
L227 Xddd protein
and xxx NE
2.06 d.dd protein
, , NE
inhibited xxx NE
the xxx NE
growth xxx NE
of xx NE
B104 Xddd cell_line_B
cells xxx cell_line_E
, , NE
although xxx NE
2.06 d.dd protein
, , NE
but xxx NE
not xxx NE
L227 Xddd protein
, , NE
needed xxx NE
to xx NE
be xx NE
further xxx NE
cross-linked xxx-xxx NE
with xxx NE
a x NE
goat xxx protein_B
anti-mouse xxx-xxx protein_M
IgG XxX protein_M
Ab Xx protein_E
( ( NE
GAM XXX protein
) ) NE
to xx NE
show xxx NE
the xxx NE
effect xxx NE
. . NE

L227 Xddd protein
induced xxx NE
an xx NE
increase xxx NE
in xx NE
intracellular xxx NE
free xxx NE
Ca2+ Xxd+ NE
concentration xxx NE
( ( NE
[ [ NE
Ca2+ Xxd+ NE
]i ]x NE
) ) NE
from xxx NE
the xxx NE
intracellular xxx NE
pool xxx NE
and xxx NE
little xxx NE
or xx NE
no xx NE
protein xxx NE
tyrosine xxx NE
phosphorylation xxx NE
, , NE
phosphatidyl xxx NE
inositol xxx NE
turnover xxx NE
, , NE
or xx NE
expression xxx NE
of xx NE
Egr-1 Xxx-d NE
mRNA xXXX NE
, , NE
whereas xxx NE
2.06 d.dd NE
plus xxx NE
GAM XXX NE
induced xxx NE
an xx NE
increase xxx NE
in xx NE
[ [ NE
Ca2+ Xxd+ NE
]i ]x NE
from xxx NE
both xxx NE
the xxx NE
intracellular xxx NE
and xxx NE
, , NE
in xx NE
particular xxx NE
, , NE
the xxx NE
extracellular xxx NE
pools xxx NE
. . NE

The Xxx NE
inhibition xxx NE
of xx NE
B104 Xddd NE
cell xxx NE
growth xxx NE
induced xxx NE
by xx NE
anti-MHC xxx-XXX protein_B
class xxx protein_M
II XX protein_M
Ab Xx protein_E
was xxx NE
Ca(2+) Xx(d+) NE
-independent -xxx NE
and xxx NE
not xxx NE
inhibited xxx NE
by xx NE
actinomycin xxx NE
D X NE
or xx NE
cyclosporin xxx NE
A X NE
, , NE
and xxx NE
cell xxx NE
cycle xxx NE
arrest xxx NE
at xx NE
the xxx NE
G2/M Xd/X NE
interphase xxx NE
was xxx NE
not xxx NE
observed xxx NE
. . NE

These Xxxx NE
features xxx NE
are xxx NE
very xxx NE
different xxx NE
from xxx NE
those xxx NE
observed xxx NE
in xx NE
B104 Xddd NE
cell xxx NE
death xxx NE
induced xxx NE
by xx NE
anti-IgM xxx-XxX protein_B
Ab Xx protein_E
. . NE

Neither Xxxx NE
DNA XXX NE
fragmentation xxx NE
nor xxx NE
the xxx NE
morphology xxx NE
of xx NE
apoptosis xxx NE
was xxx NE
observed xxx NE
. . NE

These Xxxx NE
findings xxx NE
demonstrate xxx NE
that xxx NE
cross-linking xxx-xxx NE
of xx NE
MHC XXX protein_B
class xxx protein_M
II XX protein_M
molecules xxx protein_E
transduced xxx NE
the xxx NE
negative xxx NE
signals xxx NE
through xxx NE
intracellular xxx NE
mechanisms xxx NE
different xxx NE
from xxx NE
those xxx NE
present xxx NE
in xx NE
the xxx NE
cross-linking xxx-xxx NE
of xx NE
surface xxx NE
IgM XxX protein
. . NE

Functional Xxxx NE
block xxx NE
for xxx NE
1 d NE
alpha,25-dihydroxyvitamin xxx,dd-xxx NE
D3 Xd NE
-mediated -xxx NE
gene xxx NE
regulation xxx NE
in xx NE
human xxx NE
B X NE
lymphocytes xxx NE
. . NE

Elements Xxxx NE
necessary xxx NE
for xxx NE
the xxx NE
steroid xxx NE
hormone xxx NE
1 d NE
alpha,25-dihydroxyvitamin xxx,dd-xxx NE
D3 Xd NE
( ( NE
1 d NE
alpha,25-(OH)2D3 xxx,dd-(XX)dXd NE
) ) NE
to xx NE
induce xxx NE
a x NE
biological xxx NE
response xxx NE
include xxx NE
the xxx NE
presence xxx NE
of xx NE
specific xxx NE
intracellular xxx protein_B
receptors xxx protein_E
( ( NE
vitamin xxx protein_B
D3 Xd protein_M
receptors xxx protein_E
( ( NE
VDR XXX protein
)) )) NE
and xxx NE
modulation xxx NE
of xx NE
gene xxx NE
expression xxx NE
via xxx NE
hormone-activated xxx-xxx NE
receptor xxx NE
binding xxx NE
to xx NE
regulatory xxx protein_B
regions xxx protein_E
of xx NE
target xxx DNA_B
genes xxx DNA_E
. . NE

These Xxxx NE
parameters xxx NE
were xxx NE
examined xxx NE
in xx NE
normal xxx NE
and xxx NE
Epstein-Barr Xxxx-Xxxx cell_line_B
virus-immortalized xxx-xxx cell_line_M
human xxx cell_line_M
B X cell_line_M
cells xxx cell_line_E
and xxx NE
compared xxx NE
with xxx NE
1 d cell_line_B
alpha,25-(OH)2D3 xxx,dd-(XX)dXd cell_line_E
-responsive -xxx NE
cells xxx NE
of xx NE
the xxx NE
T X cell_type_B
lineage xxx cell_type_M
and xxx cell_type_M
monocytic xxx cell_type_M
lineage xxx cell_type_E

Although Xxxx NE
resting xxx NE
tonsillar xxx NE
B X NE
cells xxx NE
did xxx NE
not xxx NE
express xxx NE
VDR XXX RNA_B
mRNA xXXX RNA_E
, , NE
activation xxx NE
of xx NE
these xxx NE
cells xxx NE
with xxx NE
interleukin-4 xxx-d protein
induced xxx NE
VDR XXX protein
in xx NE
the xxx NE
absence xxx NE
of xx NE
exogenously xxx NE
supplemented xxx NE
1 d NE
alpha,25-(OH)2D3 xxx,dd-(XX)dXd NE
. . NE

As Xx NE
indicators xxx NE
of xx NE
hormone-mediated xxx-xxx NE
gene xxx NE
regulation xxx NE
we xx NE
analyzed xxx NE
modulation xxx NE
of xx NE
CD23 XXdd protein
, , NE
a x NE
common xxx protein_B
B X protein_M
cell/monocyte xxx/xxx protein_M
surface xxx protein_M
antigen xxx protein_E
, , NE
and xxx NE
24-hydroxylase dd-xxx protein
. . NE

1 d NE
alpha,25-(OH)2D3 xxx,dd-(XX)dXd NE
inhibited xxx NE
CD23 XXdd protein
expression xxx NE
in xx NE
U937 Xddd cell_line_B
cells xxx cell_line_E
, , NE
yet xxx NE
failed xxx NE
to xx NE
modulate xxx NE
CD23 XXdd protein
expression xxx NE
in xx NE
B X cell_type_B
cells xxx cell_type_E
. . NE

Furthermore Xxxx NE
, , NE
1 d NE
alpha,25-(OH)2D3 xxx,dd-(XX)dXd NE
induced xxx NE
24-hydroxylase dd-xxx protein
mRNA xXXX NE
expression xxx NE
and xxx NE
metabolic xxx NE
activity xxx NE
in xx NE
both xxx NE
U937 Xddd cell_line_B
cells xxx cell_line_E
and xxx NE
lectin-activated xxx-xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
, , NE
yet xxx NE
failed xxx NE
to xx NE
induce xxx NE
24-hydroxylase dd-xxx RNA_B
mRNA xXXX RNA_E
or xx NE
its xxx NE
metabolic xxx NE
activity xxx NE
in xx NE
B X cell_type_B
cells xxx cell_type_E
. . NE

These Xxxx NE
findings xxx NE
suggest xxx NE
that xxx NE
although xxx NE
human xxx cell_type_B
B X cell_type_M
lymphocytes xxx cell_type_E
can xxx NE
express xxx NE
VDR XXX RNA_B
mRNA xXXX RNA_E
and xxx NE
protein xxx NE
, , NE
they xxx NE
exhibit xxx NE
a x NE
functional xxx NE
block xxx NE
for xxx NE
vitamin xxx NE
D X NE
-dependent -xxx NE
gene xxx NE
regulation xxx NE
. . NE

Positive Xxxx NE
and xxx NE
negative xxx NE
regulation xxx NE
of xx NE
IL-2 XX-d protein
gene xxx NE
expression xxx NE
: : NE
role xxx NE
of xx NE
multiple xxx NE
regulatory xxx NE
sites xxx NE
. . NE

Interleukin Xxxx protein_B
2 d protein_E
( ( NE
IL-2 XX-d protein
) ) NE
is xx NE
an xx NE
important xxx NE
lymphokine xxx protein
required xxx NE
in xx NE
the xxx NE
process xxx NE
of xx NE
T X NE
cell xxx NE
activation xxx NE
, , NE
proliferation xxx NE
, , NE
clonal xxx NE
expansion xxx NE
and xxx NE
differentiation xxx NE
. . NE

The Xxx NE
IL-2 XX-d DNA_B
gene xxx DNA_E
displays xxx NE
both xxx NE
T X NE
cell xxx NE
specific xxx NE
and xxx NE
inducible xxx NE
expression xxx NE
: : NE
it xx NE
is xx NE
only xxx NE
expressed xxx NE
in xx NE
CD4+ XXd+ cell_type_B
T X cell_type_M
cells xxx cell_type_E
after xxx NE
antigenic xxx NE
stimulation xxx NE
or xx NE
mitogenic xxx NE
stimulation xxx NE

Several Xxxx NE
cis-acting xxx-xxx DNA_B
regulatory xxx DNA_M
sites xxx DNA_E
are xxx NE
required xxx NE
for xxx NE
induction xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_B
gene xxx DNA_E
after xxx NE
stimulation xxx NE
. . NE

In Xx NE
this xxx NE
study xxx NE
, , NE
we xx NE
have xxx NE
analysed xxx NE
the xxx NE
function xxx NE
of xx NE
these xxx NE
cis-acting xxx-xxx DNA_B
regulatory xxx DNA_M
sites xxx DNA_E
in xx NE
the xxx NE
context xxx NE
of xx NE
the xxx NE
native xxx NE
IL-2 XX-d DNA_B
enhancer xxx DNA_E
and xxx NE
promoter xxx NE
sequence xxx NE
. . NE

The Xxx NE
results xxx NE
of xx NE
this xxx NE
study xxx NE
suggest xxx NE
that xxx NE
the xxx NE
NFAT XXXX protein
( ( NE
-276 -ddd DNA_B
to xx DNA_M
-261 -ddd DNA_E
) ) NE
, , NE
the xxx NE
distal xxx DNA_B
octamer xxx DNA_E
( ( NE
-256 -ddd DNA_B
to xx DNA_M
-248 -ddd DNA_E
) ) NE
and xxx NE
the xxx NE
proximal xxx DNA_B
octamer xxx DNA_E
( ( NE
-75 -dd DNA_B
to xx DNA_M
-66 -dd DNA_E
) ) NE
sites xxx NE
not xxx NE
only xxx NE
act xxx NE
as xx NE
enhancers xxx NE
of xx NE
IL-2 XX-d NE
gene xxx NE
transcription xxx NE
in xx NE
the xxx NE
presence xxx NE
of xx NE
cellular xxx NE
stimulation xxx NE
, , NE
but xxx NE
also xxx NE
have xxx NE
a x NE
silencing xxx NE
effect xxx NE
on xx NE
IL-2 XX-d NE
gene xxx NE
expression xxx NE
in xx NE
resting xxx NE
cells xxx NE
. . NE

Two Xxx NE
other xxx NE
sites xxx NE
display xxx NE
disparate xxx NE
effects xxx NE
on xx NE
IL-2 XX-d NE
gene xxx NE
expression xxx NE
in xx NE
different xxx NE
T X cell_line_B
leukemia xxx cell_line_M
cell xxx cell_line_M
lines xxx cell_line_E
: : NE
the xxx NE
distal xxx DNA_B
purine xxx DNA_M
box xxx DNA_E
( ( NE
-291 -ddd DNA_B
to xx DNA_M
-277 -ddd DNA_E
) ) NE
and xxx NE
the xxx NE
proximal xxx DNA_B
purine xxx DNA_M
box xxx DNA_M
sites xxx DNA_E
( ( NE
-145 -ddd DNA_B
to xx DNA_M
-128 -ddd DNA_E
) ) NE
. . NE

Finally Xxxx NE
, , NE
the xxx NE
AP-1 XX-d DNA_B
(-186 (-ddd DNA_M
to xx DNA_M
-176) -ddd) DNA_M
site xxx DNA_M
and xxx DNA_M
the xxx DNA_M
kappa xxx DNA_M
B X DNA_M
site xxx DNA_E
EL4 XXd NE
cells xxx NE
. . NE

The Xxx NE
AP-1 XX-d DNA_B
site xxx DNA_E
mediated xxx NE
the xxx NE
response xxx NE
to xx NE
PMA XXX NE
stimulation xxx NE
while xxx NE
the xxx NE
kappa xxx DNA_B
B X DNA_M
site xxx DNA_E
responded xxx NE
to xx NE
IL-1 XX-d NE
stimulation xxx NE
. . NE

These Xxxx NE
data xxx NE
suggest xxx NE
that xxx NE
the xxx NE
regulation xxx NE
of xx NE
IL-2 XX-d NE
gene xxx NE
expression xxx NE
is xx NE
a x NE
complex xxx NE
process xxx NE
and xxx NE
multiple xxx NE
cis-acting xxx-xxx DNA_B
regulatory xxx DNA_M
sites xxx DNA_E
interact xxx NE
to xx NE
exert xxx NE
different xxx NE
effects xxx NE
in xx NE
T X cell_type_B
cells xxx cell_type_E
representative xxx NE
of xx NE
alternative xxx NE
stages xxx NE
of xx NE
differentiation xxx NE
. . NE

Sp1 Xxd protein
is xx NE
a x NE
critical xxx NE
factor xxx NE
for xxx NE
the xxx NE
monocytic xxx NE
specific xxx NE
expression xxx NE
of xx NE
human xxx protein_B
CD14 XXdd protein_E
. . NE

CD14 XXdd protein
is xx NE
a x NE
membrane xxx protein_B
glycoprotein xxx protein_E
expressed xxx NE
specifically xxx NE
on xx NE
monocytes xxx cell_type
and xxx NE
macrophages xxx cell_type
, , NE
and xxx NE
its xxx NE
expression xxx NE
is xx NE
markedly xxx NE
increased xxx NE
during xxx NE
the xxx NE
process xxx NE
of xx NE
monocyte xxx NE
differentiation xxx NE
. . NE

In Xx NE
order xxx NE
to xx NE
study xxx NE
CD14 XXdd NE
gene xxx NE
regulation xxx NE
, , NE
the xxx NE
human xxx DNA_B
CD14 XXdd DNA_M
gene xxx DNA_E
was xxx NE
cloned xxx NE
from xxx NE
a x NE
partial xxx NE
EcoRI XxxXX DNA_B
digested xxx DNA_M
chromosome xxx DNA_M
5 d DNA_M
library xxx DNA_E
. . NE

A X NE
5.5-kilobase d.d-xxx DNA_B
genomic xxx DNA_M
clone xxx DNA_E
contained xxx NE
the xxx NE
full-length xxx-xxx NE
CD14 XXdd DNA_B
coding xxx DNA_M
sequence xxx DNA_E
and xxx NE
4.2 d.d DNA_B
kilobases xxx DNA_M
of xx DNA_M
5'-upstream d'-xxx DNA_M
sequence xxx DNA_E
. . NE

One Xxx NE
major xxx DNA_B
transcription xxx DNA_M
start xxx DNA_M
site xxx DNA_M
and xxx DNA_M
minor xxx DNA_M
transcription xxx DNA_M
start xxx DNA_M
site xxx DNA_E
were xxx NE
identified xxx NE
101 ddd DNA_B
and xxx DNA_M
130 ddd DNA_M
base xxx DNA_M
pairs xxx DNA_M
(bp) (xx) DNA_M
upstream xxx DNA_E
, , NE
respectively xxx NE
, , NE
from xxx NE
the xxx NE
protein xxx DNA_B
translation xxx DNA_M
start xxx DNA_M
ATG XXX DNA_E
. . NE

A X NE
DNA XXX DNA_B
fragment xxx DNA_E
containing xxx NE
128 ddd DNA_B
bp xx DNA_M
of xx DNA_M
upstream xxx DNA_M
sequence xxx DNA_E
had xxx NE
strong xxx NE
, , NE
monocyte-specific xxx-xxx NE
promoter xxx NE
activity xxx NE
in xx NE
the xxx NE
CD14 XXdd cell_line_B
positive xxx cell_line_M
monocytic xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
Mono Xxxx cell_line_B
Mac Xxx cell_line_M
6 d cell_line_E
as xx NE
compared xxx NE
to xx NE
the xxx NE
nonmonocytic xxx cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
HeLa XxXx cell_line
and xxx NE
REX XXX cell_line
. . NE

Four Xxxx NE
regions xxx NE
in xx NE
this xxx NE
DNA XXX DNA_B
fragment xxx DNA_E
interact xxx NE
with xxx NE
nuclear xxx protein_B
proteins xxx protein_E
isolated xxx NE
from xxx NE
monocytic xxx cell_type_B
cells xxx cell_type_E
. . NE

The Xxx NE
Sp1 Xxd protein
transcription xxx protein_B
factor xxx protein_E
bound xxx NE
to xx NE
three xxx NE
different xxx NE
regions xxx NE
in xx NE
the xxx NE
CD14 XXdd DNA_B
promoter xxx DNA_E
. . NE

Mutation Xxxx NE
of xx NE
the xxx NE
major xxx DNA_B
Sp1 Xxd DNA_M
binding xxx DNA_M
site xxx DNA_E
( ( NE
-110 -ddd DNA_B
bp xx DNA_E
) ) NE
decreased xxx NE
tissue-specific xxx-xxx NE
promoter xxx NE
activity xxx NE
, , NE
and xxx NE
these xxx NE
results xxx NE
, , NE
together xxx NE
with xxx NE
transactivation xxx NE
experiments xxx NE
, , NE
demonstrate xxx NE
that xxx NE
Sp1 Xxd protein
plays xxx NE
a x NE
critical xxx NE
role xxx NE
in xx NE
the xxx NE
tissue-specific xxx-xxx NE
expression xxx NE
of xx NE
CD14 XXdd protein
in xx NE
monocytic xxx cell_type_B
cells xxx cell_type_E
. . NE

CD14 XXdd protein
Sp1 Xxd NE
site xxx NE
oligonucleotides xxx NE
bound xxx NE
preferentially xxx NE
to xx NE
a x NE
105-kDa ddd-xXx protein_B
Sp1 Xxd protein_M
species xxx protein_E
, , NE
which xxx NE
is xx NE
present xxx NE
in xx NE
higher xxx NE
relative xxx NE
levels xxx NE
in xx NE
monocytic xxx NE
than xxx NE
non-monocytic xxx-xxx NE
cells xxx NE
, , NE
suggesting xxx NE
that xxx NE
modification xxx NE
of xx NE
Sp1 Xxd NE
, , NE
such xxx NE
as xx NE
phosphorylation xxx NE
, , NE
may xxx NE
explain xxx NE
how xxx NE
the xxx NE
Sp1 Xxd NE
site xxx NE
mediates xxx NE
monocytic xxx NE
specific xxx NE
promoter xxx NE
activity xxx NE
. . NE

The Xxx NE
interleukin-8 xxx-d DNA_B
AP-1 XX-d DNA_M
site xxx DNA_M
and xxx DNA_M
kappa xxx DNA_M
B-like X-xxx DNA_M
site xxx DNA_E
are xxx NE
genetic xxx NE
end xxx NE
targets xxx NE
of xx NE
FK506-sensitive XXddd-xxx NE
pathway xxx NE
accompanied xxx NE
by xx NE
calcium xxx NE
mobilization xxx NE
. . NE

FK506 XXddd NE
, , NE
an xx NE
immunosuppressant xxx NE
, , NE
inhibits xxx NE
the xxx NE
production xxx NE
of xx NE
several xxx NE
cytokines xxx protein
in xx NE
T X cell_type_B
lymphocytes xxx cell_type_E
. . NE

We Xx NE
observed xxx NE
that xxx NE
FK506 XXddd NE
suppressed xxx NE
the xxx NE
transcription xxx NE
of xx NE
a x NE
chemotactic xxx protein_B
cytokine xxx protein_E
, , NE
interleukin-8 xxx-d protein
( ( NE
IL-8 XX-d protein
) ) NE
in xx NE
a x NE
human xxx cell_line_B
T X cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
, , NE
Jurkat Xxxx cell_line_B
cells xxx cell_line_E
, , NE
activated xxx NE
by xx NE
phorbol xxx NE
12-myristate dd-xxx NE
13-acetate dd-xxx NE
( ( NE
PMA XXX NE
) ) NE
and xxx NE
calcium xxx NE
( ( NE
Ca2+ Xxd+ NE
) ) NE
ionophore xxx NE
( ( NE
ionomycin xxx NE
) ) NE
. . NE

By Xx NE
deleted xxx NE
and xxx NE
mutated xxx NE
analysis xxx NE
of xx NE
the xxx NE
IL-8 XX-d DNA_B
promoters xxx DNA_E
, , NE
the xxx NE
AP-1 XX-d DNA_B
and xxx DNA_M
kappa xxx DNA_M
B-like X-xxx DNA_M
sites xxx DNA_E
were xxx NE
identified xxx NE
as xx NE
the xxx NE
responsive xxx NE
elements xxx NE
for xxx NE
PMA XXX NE
and xxx NE
ionomycin xxx NE
. . NE

FK506 XXddd NE
suppressed xxx NE
the xxx NE
transcriptions xxx NE
through xxx NE
the xxx NE
AP-1 XX-d NE
or xx NE
kappa xxx NE
B-like X-xxx NE
sites xxx NE
induced xxx NE
by xx NE
PMA XXX NE
plus xxx NE
Ca(2+)-mobilizing Xx(d+)-xxx NE
agents xxx NE
, , NE
but xxx NE
not xxx NE
those xxx NE
induced xxx NE
by xx NE
Ca(2+)-independent Xx(d+)-xxx NE
stimuli xxx NE
. . NE

In Xx NE
gel xxx NE
retardation xxx NE
analysis xxx NE
, , NE
FK506 XXddd NE
had xxx NE
little xxx NE
effect xxx NE
on xx NE
the xxx NE
binding xxx NE
to xx NE
the xxx NE
AP-1 XX-d DNA_B
site xxx DNA_E
of xx NE
PMA XXX NE
/ / NE
ionomycin xxx NE
-induced -xxx NE
nuclear xxx NE
factors xxx NE
, , NE
which xxx NE
were xxx NE
recognized xxx NE
with xxx NE
anti-JunD xxx-XxxX protein
or xx NE
c-Fos x-Xxx protein_B
antibody xxx protein_E
. . NE

In Xx NE
contrast xxx NE
, , NE
FK506 XXddd NE
or xx NE
EGTA XXXX NE
( ( NE
Ca2+ Xxd+ NE
chelator xxx NE
) ) NE
similarly xxx NE
affected xxx NE
the xxx NE
formation xxx NE
of xx NE
kappa xxx NE
B-like X-xxx NE
site xxx NE
binding xxx NE
complexes xxx NE
, , NE
which xxx NE
were xxx NE
not xxx NE
recognized xxx NE
by xx NE
any xxx NE
antibodies xxx NE
against xxx NE
the xxx NE
human xxx NE
Rel Xxx NE
family xxx NE
proteins xxx NE
( ( NE
c-Rel x-Xxx NE
, , NE
p65 xdd NE
, , NE
p50 xdd NE
, , NE
and xxx NE
p49 xdd NE
) ) NE
. . NE

Furthermore Xxxx NE
, , NE
we xx NE
confirmed xxx NE
the xxx NE
previous xxx NE
report xxx NE
that xxx NE
FK506 XXddd NE
suppressed xxx NE
the xxx NE
PMA XXX NE
/ / NE
ionomycin xxx NE
-induced -xxx NE
activation xxx NE
through xxx NE
authentic xxx NE
kappa xxx DNA_B
B X DNA_M
site xxx DNA_E
of xx NE
immunoglobulin xxx DNA_B
(Ig) (Xx) DNA_M
gene xxx DNA_E
, , NE
to xx NE
which xxx NE
NF-kappa XX-xxx NE
B X NE
binding xxx NE
was xxx NE
also xxx NE
decreased xxx NE
by xx NE
FK506 XXddd NE
, , NE
indicating xxx NE
that xxx NE
both xxx NE
IL-8 XX-d DNA_B
kappa xxx DNA_M
B-like X-xxx DNA_M
site xxx DNA_E
and xxx NE
Ig Xx NE
kappa xxx DNA_B
B X DNA_M
site xxx DNA_E
are xxx NE
FK506 XXddd NE
-sensitive -xxx NE
in xx NE
spite xxx NE
of xx NE
the xxx NE
difference xxx NE
of xx NE
binding xxx NE
factors xxx NE
. . NE

Our Xxx NE
results xxx NE
indicate xxx NE
that xxx NE
not xxx NE
only xxx NE
the xxx NE
reported xxx NE
IL-2 XX-d DNA_B
NF-AT XX-XX DNA_M
site xxx DNA_M
and xxx DNA_M
NFIL-2A XXXX-dX DNA_M
site xxx DNA_E
kappa xxx NE
B X NE
site xxx NE
, , NE
but xxx NE
also xxx NE
the xxx NE
IL-8 XX-d protein
AP-1 XX-d NE
and xxx NE
kappa xxx DNA_B
B-like X-xxx DNA_M
sites xxx DNA_E
are xxx NE
terminals xxx NE
of xx NE
FK506 XXddd NE
-sensitive -xxx NE
pathway xxx NE
involving xxx NE
Ca2+ Xxd+ NE
mobilization xxx NE
. . NE

Androgen Xxxx protein_B
binding xxx protein_M
sites xxx protein_E
in xx NE
peripheral xxx cell_type_B
human xxx cell_type_M
mononuclear xxx cell_type_M
leukocytes xxx cell_type_E
of xx NE
healthy xxx NE
males xxx NE
and xxx NE
females xxx NE
. . NE

Androgen Xxxx protein_B
binding xxx protein_M
sites xxx protein_E
have xxx NE
been xxx NE
identified xxx NE
in xx NE
circulating xxx cell_type_B
human xxx cell_type_M
mononuclear xxx cell_type_M
leukocytes xxx cell_type_E
of xx NE
healthy xxx NE
donors xxx NE
of xx NE
both xxx NE
sexes xxx NE
. . NE

Cells Xxxx NE
were xxx NE
separated xxx NE
from xxx NE
blood xxx NE
samples xxx NE
on xx NE
a x NE
Ficoll Xxxx NE
gradient xxx NE
and xxx NE
incubated xxx NE
with xxx NE
different xxx NE
concentrations xxx NE
of xx NE
[3H]testosterone [dX]xxx NE
in xx NE
the xxx NE
presence xxx NE
or xx NE
absence xxx NE
of xx NE
a x NE
400-fold ddd-xxx NE
excess xxx NE
of xx NE
unlabelled xxx NE
testosterone xxx NE
. . NE

Binding Xxxx NE
data xxx NE
were xxx NE
derived xxx NE
from xxx NE
Scatchard Xxxx NE
analysis xxx NE
. . NE

The Xxx NE
binding xxx protein_B
sites xxx protein_E
fulfil xxx NE
the xxx NE
required xxx NE
criteria xxx NE
for xxx NE
specific xxx NE
steroid xxx protein_B
binding xxx protein_M
sites xxx protein_E
however xxx NE
differ xxx NE
somewhat xxx NE
from xxx NE
the xxx NE
classic xxx NE
androgen xxx protein_B
receptors xxx protein_E
from xxx NE
genital xxx cell_type_B
skin xxx cell_type_M
fibroblast xxx cell_type_E
: : NE
in xx NE
fertile xxx NE
adult xxx NE
males xxx NE
(n (x NE
= = NE
20) dd) NE
the xxx NE
binding xxx protein_B
sites xxx protein_E
showed xxx NE
(1) (d) NE
a x NE
high xxx NE
affinity xxx NE
for xxx NE
testosterone xxx NE
(1.32 (d.dd NE
+/- +/- NE
0.49 d.dd NE
nM xX NE
; ; NE
mean xxx NE
+/- +/- NE
SD) XX) NE
, , NE
(2) (d) NE
a x NE
saturable xxx NE
capacity xxx NE
(184 (ddd NE
+/- +/- NE
52 dd NE
binding xxx protein_B
sites xxx protein_E
per xxx NE
cell xxx NE
; ; NE
mean xxx NE
+/- +/- NE
SD) XX) NE
, , NE
and xxx NE
(3) (d) NE
a x NE
characteristic xxx NE
competitive xxx NE
binding xxx NE
profile xxx NE
for xxx NE
other xxx NE
steroid xxx NE
hormones xxx NE
(relative (xxx NE
binding xxx NE
affinities xxx NE
: : NE
testosterone xxx NE
= = NE
dihydrotestosterone xxx NE
> > NE
17 dd NE
beta-estradiol xxx-xxx NE
> > NE
progesterone xxx NE
, , NE
whereas xxx NE
aldosterone xxx NE
, , NE
17-hydroxy-progesterone dd-xxx-xxx NE
and xxx NE
cortisol xxx NE
did xxx NE
not xxx NE
compete xxx NE
appreciably) xxx) NE
. . NE

Furthermore Xxxx NE
the xxx NE
number xxx NE
of xx NE
binding xxx protein_B
sites xxx protein_E
determined xxx NE
using xxx NE
[3H]dihydrotestosterone [dX]xxx NE
, , NE
[3H]RU-1881 [dX]XX-dddd NE
, , NE
or xx NE
[3H] [dX] NE
testosterone xxx NE
were xxx NE
comparable xxx NE
. . NE

This Xxxx NE
raises xxx NE
the xxx NE
possibility xxx NE
that xxx NE
androgen xxx protein_B
receptors xxx protein_E
in xx NE
peripheral xxx cell_type_B
mononuclear xxx cell_type_M
leukocytes xxx cell_type_E
differ xxx NE
from xxx NE
those xxx NE
in xx NE
genital xxx cell_type_B
skin xxx cell_type_M
fibroblasts xxx cell_type_E
. . NE

There Xxxx NE
was xxx NE
no xx NE
apparent xxx NE
correlation xxx NE
between xxx NE
serum xxx NE
testosterone xxx NE
concentrations xxx NE
and xxx NE
androgen xxx protein_B
binding xxx protein_M
sites xxx protein_E
. . NE

In Xx NE
fertile xxx NE
women xxx NE
remarkable xxx NE
changes xxx NE
in xx NE
androgen xxx protein_B
binding xxx protein_M
sites xxx protein_E
were xxx NE
seen xxx NE
in xx NE
the xxx NE
course xxx NE
of xx NE
the xxx NE
menstrual xxx NE
cycle xxx NE
, , NE
with xxx NE
a x NE
significant xxx NE
increase xxx NE
in xx NE
the xxx NE
immediate xxx NE
preovulatory xxx NE
period xxx NE
. . NE

The Xxx NE
presence xxx NE
of xx NE
androgen xxx protein_B
receptors xxx protein_E
in xx NE
peripheral xxx cell_type_B
mononuclear xxx cell_type_M
leukocytes xxx cell_type_E
provides xxx NE
for xxx NE
the xxx NE
first xxx NE
time xxx NE
the xxx NE
experimental xxx NE
basis xxx NE
for xxx NE
an xx NE
hypothesis xxx NE
of xx NE
direct, xxx, NE
receptor-mediated xxx-xxx NE
effects xxx NE
of xx NE
androgens xxx NE
on xx NE
mature xxx cell_type_B
immunocompetent xxx cell_type_M
cells xxx cell_type_E
. . NE

The Xxx NE
immunological xxx NE
implications xxx NE
of xx NE
these xxx NE
results xxx NE
are xxx NE
discussed xxx NE
. . NE

Induction Xxxx NE
of xx NE
IL-8 XX-d NE
expression xxx NE
in xx NE
T X cell_type_B
cells xxx cell_type_E
uses xxx NE
the xxx NE
CD28 XXdd NE
costimulatory xxx NE
pathway xxx NE
. . NE

IL-8 XX-d protein
, , NE
a x NE
potent xxx NE
chemotactic xxx protein_B
factor xxx protein_E
for xxx NE
neutrophil xxx cell_type_B
granulocytes xxx cell_type_E
and xxx NE
lymphocytes xxx cell_type
, , NE
is xx NE
a x NE
proinflammatory xxx NE
cytokine xxx NE
secreted xxx NE
by xx NE
a x NE
variety xxx NE
of xx NE
cell xxx NE
types xxx NE
, , NE
including xxx NE
T X cell_type_B
cells xxx cell_type_E
. . NE

Stimulation Xxxx NE
of xx NE
the xxx NE
CD28 XXdd protein_B
cell xxx protein_M
surface xxx protein_M
molecule xxx protein_E
delivers xxx NE
costimulatory xxx NE
signals xxx NE
essential xxx NE
for xxx NE
lymphokine xxx NE
production xxx NE
in xx NE
activated xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
via xxx NE
a x NE
conserved xxx DNA_B
sequence xxx DNA_M
element xxx DNA_E
found xxx NE
in xx NE
the xxx NE
promoter xxx DNA
of xx NE
several xxx NE
lymphokine xxx DNA_B
genes xxx DNA_E
. . NE

Anti- Xxxx- NE
CD28 XXdd NE
-stimulated -xxx NE
T X NE
cells xxx NE
produced xxx NE
significant xxx NE
amounts xxx NE
of xx NE
IL-8 XX-d NE
; ; NE
additionally xxx NE
, , NE
costimulation xxx NE
with xxx NE
anti-CD3 xxx-XXd NE
and xxx NE
anti- xxx- NE
CD28 XXdd NE
Abs Xxx NE
resulted xxx NE
in xx NE
a x NE
synergistic xxx NE
induction xxx NE
of xx NE
IL-8 XX-d NE
secretion xxx NE
. . NE

Sequence Xxxx NE
homology xxx NE
, , NE
single xxx NE
nucleotide xxx NE
mutations xxx NE
, , NE
and xxx NE
anti- xxx- NE
CD28 XXdd NE
Ab Xx NE
stimulation xxx NE
studies xxx NE
established xxx NE
that xxx NE
the xxx NE
NF-kappa XX-xxx NE
B X NE
-like -xxx NE
sequence xxx NE
in xx NE
the xxx NE
promoter xxx NE
of xx NE
the xxx NE
IL-8 XX-d NE
gene xxx NE
functioned xxx NE
as xx NE
a x NE
CD28 XXdd NE
response xxx NE
element xxx NE
. . NE

Furthermore Xxxx NE
, , NE
cyclosporin xxx NE
A X NE
, , NE
but xxx NE
not xxx NE
rapamycin xxx NE
, , NE
blocked xxx NE
the xxx NE
synergistic xxx NE
induction xxx NE
of xx NE
IL-8 XX-d NE
expression xxx NE
achieved xxx NE
with xxx NE
anti-CD3 xxx-XXd protein
and xxx NE
anti- xxx- NE
CD28 XXdd NE
costimulation xxx NE
. . NE

The Xxx NE
involvement xxx NE
of xx NE
a x NE
CD28 XXdd DNA_B
response xxx DNA_M
element xxx DNA_E
in xx NE
the xxx NE
induction xxx NE
of xx NE
IL-8 XX-d NE
expression xxx NE
in xx NE
activated xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
may xxx NE
provide xxx NE
new xxx NE
insights xxx NE
into xxx NE
the xxx NE
pathogenesis xxx NE
and xxx NE
persistence xxx NE
of xx NE
immune xxx NE
disorders xxx NE
characterized xxx NE
by xx NE
increased xxx NE
levels xxx NE
of xx NE
IL-8 XX-d protein
, , NE
such xxx NE
as xx NE
psoriasis xxx NE
and xxx NE
rheumatoid xxx NE
arthritis xxx NE
. . NE

MHC XXX NE
class xxx NE
II XX NE
signaling xxx NE
in xx NE
B-cell X-xxx NE
activation xxx NE
[see [xxx NE
comments] xxx] NE

The Xxx NE
cognate xxx NE
interaction xxx NE
between xxx NE
T X cell_type_B
cells xxx cell_type_E
and xxx NE
antigen-presenting xxx-xxx cell_type_B
cells xxx cell_type_E
( ( NE
APCs XXXx cell_type
) ) NE
, , NE
mediated xxx NE
by xx NE
major xxx protein_B
histocompatibility xxx protein_M
complex xxx protein_M
(MHC) (XXX) protein_M
class xxx protein_M
II XX protein_M
molecules xxx protein_E
, , NE
results xxx NE
in xx NE
the xxx NE
delivery xxx NE
of xx NE
activation xxx NE
signals xxx NE
to xx NE
the xxx NE
APC XXX cell_type
. . NE

These Xxxx NE
signals xxx NE
contribute xxx NE
to xx NE
the xxx NE
expression xxx NE
of xx NE
co-stimulatory xx-xxx NE
activity xxx NE
by xx NE
APCs XXXx cell_type
and xxx NE
have xxx NE
important xxx NE
consequences xxx NE
for xxx NE
cell xxx NE
effector xxx NE
function xxx NE
. . NE

MHC XXX protein_B
class xxx protein_M
II XX protein_E
molecules xxx NE
also xxx NE
serve xxx NE
as xx NE
receptors xxx NE
for xxx NE
B-cell X-xxx NE
stimulation xxx NE
by xx NE
microbial xxx protein_B
superantigens xxx protein_E
. . NE

In Xx NE
this xxx NE
review xxx NE
, , NE
Paul Xxxx NE
Scholl Xxxx NE
and xxx NE
Raif Xxxx NE
Geha Xxxx NE
discuss xxx NE
recent xxx NE
advances xxx NE
in xx NE
our xxx NE
understanding xxx NE
of xx NE
mechanisms xxx NE
of xx NE
MHC XXX NE
class xxx NE
II XX NE
signaling xxx NE
and xxx NE
analyse xxx NE
their xxx NE
role xxx NE
in xx NE
human xxx NE
B-cell X-xxx NE
activation xxx NE
. . NE

Effects Xxxx NE
of xx NE
glucocorticoids xxx NE
in xx NE
rheumatoid xxx NE
arthritis xxx NE
. . NE

Diminished Xxxx NE
glucocorticoid xxx protein_B
receptors xxx protein_E
do xx NE
not xxx NE
result xxx NE
in xx NE
glucocorticoid xxx NE
resistance xxx NE
. . NE

OBJECTIVE XXXXXXXXX NE
. . NE

Lymphocytes Xxxx NE
of xx NE
patients xxx NE
with xxx NE
rheumatoid xxx NE
arthritis xxx NE
( ( NE
RA XX NE
) ) NE
have xxx NE
diminished xxx NE
receptor xxx NE
density xxx NE
; ; NE
thus xxx NE
, , NE
patients xxx NE
with xxx NE
RA XX NE
should xxx NE
show xxx NE
partial xxx NE
resistance xxx NE
to xx NE
glucocorticoids xxx NE
. . NE

We Xx NE
investigated xxx NE
the xxx NE
glucocorticoid xxx NE
sensitivity xxx NE
of xx NE
lymphocytes xxx cell_type
in xx NE
RA XX NE
patients xxx NE
compared xxx NE
with xxx NE
healthy xxx NE
subjects xxx NE
. . NE

METHODS XXXXXXX NE
. . NE

We Xx NE
determined xxx NE
the xxx NE
effects xxx NE
of xx NE
glucocorticoids xxx NE
on xx NE
lymphocyte xxx NE
proliferation xxx NE
and xxx NE
cytokine xxx NE
release xxx NE
. . NE

RESULTS XXXXXXX NE
. . NE

Proliferation Xxxx NE
and xxx NE
cytokine xxx NE
release xxx NE
were xxx NE
inhibited xxx NE
in xx NE
RA XX NE
patients xxx NE
to xx NE
the xxx NE
same xxx NE
extent xxx NE
as xx NE
in xx NE
healthy xxx NE
controls xxx NE
. . NE

CONCLUSION XXXXXXXXXX NE
. . NE

Diminished Xxxx NE
receptor xxx NE
density xxx NE
in xx NE
RA XX NE
patients xxx NE
does xxx NE
not xxx NE
result xxx NE
in xx NE
glucocorticoid xxx NE
resistance xxx NE
. . NE

Arrested Xxxx NE
development xxx NE
: : NE
understanding xxx NE
v-abl x-xxx DNA
. . NE

The Xxx NE
protein xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
of xx NE
the xxx NE
v-abl x-xxx DNA_B
oncogene xxx DNA_E
has xxx NE
been xxx NE
demonstrated xxx NE
to xx NE
subvert xxx NE
the xxx NE
normal xxx NE
second xxx NE
messenger xxx NE
systems xxx NE
used xxx NE
by xx NE
lymphoid xxx cell_type_B
cells xxx cell_type_E
for xxx NE
growth xxx NE
and xxx NE
differentiation xxx NE
. . NE

Transformation Xxxx NE
of xx NE
bone xxx NE
marrow xxx NE
with xxx NE
the xxx NE
Abelson Xxxx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
results xxx NE
in xx NE
the xxx NE
appearance xxx NE
of xx NE
B X cell_type_B
cell xxx cell_type_M
lineage xxx cell_type_M
cells xxx cell_type_E
arrested xxx NE
at xx NE
the xxx NE
pre-B xxx-X NE
cell xxx NE
stage xxx NE
. . NE

Recent Xxxx NE
reports xxx NE
have xxx NE
characterized xxx NE
these xxx NE
cells xxx NE
expressing xxx NE
high xxx NE
v-abl x-xxx NE
kinase xxx NE
activity xxx NE
as xx NE
deficient xxx NE
in xx NE
detectable xxx NE
NF-kappaB XX-xxxX NE
DNA XXX NE
binding xxx NE
activity xxx NE
and xxx NE
low xxx NE
level xxx NE
RAG XXX NE
gene xxx NE
expression xxx NE
. . NE

These Xxxx NE
observations xxx NE
suggest xxx NE
that xxx NE
v-abl x-xxx DNA
may xxx NE
be xx NE
inhibiting xxx NE
the xxx NE
differentiation xxx NE
of xx NE
B X cell_type_B
cells xxx cell_type_E
by xx NE
blocking xxx NE
these xxx NE
two xxx NE
crucial xxx NE
elements xxx NE
in xx NE
the xxx NE
maturation xxx NE
pathway xxx NE
. . NE

Corticosteroid Xxxx protein_B
receptors xxx protein_E
in xx NE
lymphocytes xxx cell_type
: : NE
a x NE
possible xxx NE
marker xxx NE
of xx NE
brain xxx NE
involution xxx NE
? ? NE

A X NE
similarity xxx NE
has xxx NE
recently xxx NE
been xxx NE
found xxx NE
between xxx NE
the xxx NE
regulation xxx NE
of xx NE
corticosteroid xxx protein_B
receptors xxx protein_E
in xx NE
brain xxx NE
and xxx NE
in xx NE
lymphoid xxx NE
tissue xxx NE
. . NE

We Xx NE
have xxx NE
studied xxx NE
the xxx NE
regulation xxx NE
of xx NE
corticosteroid xxx protein_B
receptors xxx protein_E
in xx NE
human xxx cell_type_B
mononuclear xxx cell_type_M
leukocytes xxx cell_type_E
as xx NE
a x NE
possible xxx NE
marker xxx NE
of xx NE
brain xxx NE
involution xxx NE
. . NE

Type Xxxx protein_B
I X protein_M
corticosteroid xxx protein_M
receptors xxx protein_E
are xxx NE
down xxx NE
regulated xxx NE
by xx NE
excess xxx NE
of xx NE
mineralocorticoids xxx NE
(primary (xxx NE
and xxx NE
secondary xxx NE
hyperaldosteronism xxx NE
, , NE
pseudohyperaldosteronism xxx NE
) ) NE
and xxx NE
of xx NE
glucocorticoids xxx NE
( ( NE
Cushing's Xxxx'x NE
syndrome xxx NE
) ) NE
. . NE
Type Xxxx protein_B
II XX protein_M
corticosteroid xxx protein_M
receptors xxx protein_E
are xxx NE
not xxx NE
reduced xxx NE
by xx NE
excess xxx NE
of xx NE
endogenous xxx NE
corticosteroids xxx NE
( ( NE
Cushing's Xxxx'x NE
syndrome xxx NE
) ) NE
. . NE

In Xx NE
normal xxx NE
adults xxx NE
there xxx NE
is xx NE
a x NE
direct xxx NE
significant xxx NE
correlation xxx NE
between xxx NE
plasma xxx NE
cortisol xxx NE
and xxx NE
Type Xxxx NE
I X NE
and xxx NE
between xxx NE
plasma xxx NE
cortisol xxx NE
and xxx NE
Type Xxxx NE
II XX NE
receptors xxx NE
in xx NE
mononuclear xxx NE
leukocytes xxx NE
, , NE
while xxx NE
in xx NE
Cushing's Xxxx'x NE
syndrome xxx NE
the xxx NE
correlation xxx NE
is xx NE
inverse xxx NE
between xxx NE
plasma xxx NE
cortisol xxx NE
at xx NE
8 d NE
a.m x.x NE
. . NE
and xxx NE
Type Xxxx NE
II XX NE
receptors xxx NE
. . NE

In Xx NE
an xx NE
aged xxx NE
population xxx NE
the xxx NE
mean xxx NE
numbers xxx NE
of xx NE
Type Xxxx NE
I X NE
and xxx NE
of xx NE
Type Xxxx NE
II XX NE
receptors xxx NE
are xxx NE
lower xxx NE
and xxx NE
plasma xxx NE
cortisol xxx NE
is xx NE
higher xxx NE
than xxx NE
in xx NE
adult xxx NE
controls xxx NE
, , NE
but xxx NE
the xxx NE
increase xxx NE
of xx NE
plasma xxx NE
cortisol xxx NE
is xx NE
not xxx NE
followed xxx NE
by xx NE
a x NE
clinical xxx NE
picture xxx NE
of xx NE
hypercorticism xxx NE
. . NE

corticosteroid xxx protein_B
Type Xxxx protein_M
I X protein_M
receptor xxx protein_M
and xxx protein_M
corticosteroid xxx protein_M
Type Xxxx protein_M
II XX protein_M
receptor xxx protein_E

After Xxxx NE
dexamethasone xxx NE
suppression xxx NE
(1 (d NE
mg xx NE
at xx NE
11 dd NE
p.m.) x.x.) NE
Type Xxxx protein_B
I X protein_M
receptors xxx protein_E
always xxx NE
decrease xxx NE
in xx NE
controls xxx NE
while xxx NE
the xxx NE
response xxx NE
of xx NE
Type Xxxx NE
II XX NE
is xx NE
not xxx NE
homogeneous xxx NE
. . NE

In Xx NE
an xx NE
aged xxx NE
group xxx NE
of xx NE
patients xxx NE
, , NE
both xxx NE
receptors xxx NE
are xxx NE
reduced xxx NE
by xx NE
dexamethasone xxx NE
. . NE

We Xx NE
conclude xxx NE
that xxx NE
the xxx NE
decrease xxx NE
with xxx NE
age xxx NE
of xx NE
corticosteroid xxx protein_B
receptors xxx protein_E
is xx NE
possibly xxx NE
related xxx NE
to xx NE
a x NE
physiological xxx NE
involution xxx NE
of xx NE
corticosteroid xxx protein_B
receptors xxx protein_E
and xxx NE
that xxx NE
this xxx NE
reduction xxx NE
does xxx NE
increase xxx NE
plasma xxx NE
cortisol xxx NE
concentration xxx NE
, , NE
without xxx NE
affecting xxx NE
the xxx NE
glucocorticoid xxx NE
effector xxx NE
mechanism xxx NE
. . NE

All-trans Xxx-xxx NE
retinoic xxx NE
acid xxx NE
and xxx NE
1 d NE
alpha,25-dihydroxyvitamin xxx,dd-xxx NE
D3 Xd NE
co-operate xx-xxx NE
to xx NE
promote xxx NE
differentiation xxx NE
of xx NE
the xxx NE
human xxx cell_line_B
promyeloid xxx cell_line_M
leukemia xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
HL60 XXdd cell_line
to xx NE
monocytes xxx cell_type
. . NE

A X NE
basis xxx NE
for xxx NE
differentiation xxx NE
therapy xxx NE
of xx NE
leukemias xxx NE
is xx NE
provided xxx NE
by xx NE
knowledge xxx NE
of xx NE
agents xxx NE
which xxx NE
induce xxx NE
specific xxx NE
lineage xxx NE
maturation xxx NE
. . NE

All-trans Xxx-xxx NE
retinoic xxx NE
acid xxx NE
( ( NE
RA XX NE
) ) NE
induces xxx NE
differentiation xxx NE
of xx NE
HL60 XXdd cell_line_B
cells xxx cell_line_E
to xx NE
neutrophils xxx cell_type
and xxx NE
is xx NE
used xxx NE
to xx NE
treat xxx NE
acute xxx NE
promyelocytic xxx NE
leukemia xxx NE
. . NE

We Xx NE
observed xxx NE
that xxx NE
RA XX NE
did xxx NE
not xxx NE
induced xxx NE
neutrophil xxx NE
differentiation xxx NE
in xx NE
serum-free xxx-xxx cell_line_B
grown xxx cell_line_M
HL60 XXdd cell_line_M
cells xxx cell_line_E
whereas xxx NE
50 dd NE
nM xX NE
1 d NE
alpha,25-dihydroxyvitamin xxx,dd-xxx NE
D3 Xd NE
( ( NE
D3 Xd NE
) ) NE
induced xxx NE
maximal xxx NE
monocyte xxx NE
differentiation xxx NE
. . NE

Increasing Xxxx NE
RA XX NE
concentrations xxx NE
reduced xxx NE
the xxx NE
D3 Xd NE
concentration xxx NE
required xxx NE
for xxx NE
monocyte xxx NE
differentiation xxx NE
. . NE

Cells Xxxx NE
treated xxx NE
with xxx NE
5 d NE
nM xX NE
D3 Xd NE
showed xxx NE
little xxx NE
response xxx NE
, , NE
but xxx NE
differentiated xxx NE
maximally xxx NE
with xxx NE
5 d NE
nM xX NE
D3 Xd NE
and xxx NE
10 dd NE
nM xX NE
RA XX NE
. . NE

The Xxx NE
D3 Xd NE
analogs xxx NE
MC903 XXddd NE
, , NE
EB1089 XXdddd NE
and xxx NE
KH1060 XXdddd NE
were xxx NE
more xxx NE
potent xxx NE
inducers xxx NE
of xx NE
monocyte xxx NE
differentiation xxx NE
. . NE

The Xxx NE
extent xxx NE
to xx NE
which xxx NE
analog xxx NE
activity xxx NE
was xxx NE
increased xxx NE
after xxx NE
cotreatment xxx NE
with xxx NE
RA XX NE
was xxx NE
inversely xxx NE
related xxx NE
to xx NE
potency xxx NE
. . NE

Twenty-four Xxxx-xxx NE
hour xxx NE
treatment xxx NE
with xxx NE
10 dd NE
nM xX NE
RA XX cell_line_B
primed xxx cell_line_M
cells xxx cell_line_E
for xxx NE
response xxx NE
to xx NE
5 d NE
nM xX NE
D3 Xd NE
; ; NE
the xxx NE
reverse xxx NE
sequence xxx NE
being xxx NE
ineffective xxx NE
. . NE

Priming Xxxx NE
with xxx NE
10 dd NE
nM xX NE
RA XX NE
, , NE
or xx NE
subsequent xxx NE
treatment xxx NE
with xxx NE
D3 Xd NE
(5 (d NE
nM) xX) NE
, , NE
did xxx NE
not xxx NE
alter xxx NE
expression xxx NE
of xx NE
mRNAs xXXXx RNA
encoding xxx NE
receptors xxx protein
for xxx NE
D3 Xd NE
( ( NE
VDR XXX protein
) ) NE
, , NE
RA XX NE
( ( NE
RAR XXX protein_B
alpha xxx protein_E
) ) NE
or xx NE
9-CIS d-XXX NE
RA XX NE
( ( NE
RXR XXX protein_B
alpha xxx protein_M
and xxx protein_M
RXR XXX protein_M
beta xxx protein_M
and xxx protein_M
RXR XXX protein_M
gamma xxx protein_E

That Xxxx NE
RA XX NE
promotes xxx NE
both xxx NE
neutrophil xxx NE
and xxx NE
monocyte xxx NE
differentiation xxx NE
has xxx NE
implications xxx NE
for xxx NE
the xxx NE
use xxx NE
of xx NE
RA XX NE
and xxx NE
D3 Xd NE
in xx NE
treatment xxx NE
of xx NE
leukemias xxx NE
and xxx NE
provides xxx NE
insight xxx NE
into xxx NE
mechanisms xxx NE
whereby xxx NE
RAR XXX NE
, , NE
VDR XXX NE
and xxx NE
RXR XXX NE
facilitate xxx NE
monocyte xxx NE
differentiation xxx NE
. . NE

[An [Xx NE
overexpression xxx NE
of xx NE
retinoic xxx protein_B
acid xxx protein_M
receptor xxx protein_M
alpha xxx protein_E
blocks xxx NE
myeloid xxx NE
cell xxx NE
differentiation xxx NE
at xx NE
the xxx NE
promyelocyte xxx NE
stage xxx NE
] ] NE

Retinoic Xxxx NE
acid xxx NE
( ( NE
RA XX NE
) ) NE
, , NE
a x NE
vitamin xxx NE
A X NE
derivative xxx NE
, , NE
exerts xxx NE
a x NE
wide xxx NE
range xxx NE
of xx NE
biological xxx NE
effects xxx NE
related xxx NE
to xx NE
cell xxx NE
proliferation xxx NE
and xxx NE
differentiation xxx NE
. . NE

The Xxx NE
pleiotropic xxx NE
effects xxx NE
of xx NE
RA XX NE
are xxx NE
thought xxx NE
to xx NE
be xx NE
mediated xxx NE
through xxx NE
specific xxx NE
nuclear xxx NE
RA XX protein_B
receptors xxx protein_E
( ( NE
RARs XXXx protein
) ) NE
. . NE

RARs XXXx protein
are xxx NE
members xxx NE
of xx NE
the xxx NE
steroid/thyroid xxx/xxx protein_B
hormone xxx protein_M
receptor xxx protein_M
superfamily xxx protein_E
and xxx NE
exhibit xxx NE
a x NE
molecular xxx NE
structure xxx NE
that xxx NE
possess xxx NE
discrete xxx NE
DNA-binding XXX-xxx NE
and xxx NE
RA XX protein_B
(ligand)-binding (xxx)-xxx protein_M
domains xxx protein_E
. . NE

In Xx NE
hematopoietic xxx NE
system xxx NE
, , NE
RA XX NE
and xxx NE
RARs XXXx protein
, , NE
predominantly xxx NE
RAR XXX protein_B
alpha xxx protein_E
may xxx NE
play xxx NE
key xxx NE
roles xxx NE
for xxx NE
the xxx NE
proliferation xxx NE
and xxx NE
differentiation xxx NE
of xx NE
hematopoietic xxx cell_type_B
progenitors xxx cell_type_E
. . NE

However Xxxx NE
, , NE
it xx NE
is xx NE
currently xxx NE
unknown xxx NE
how xxx NE
RA XX NE
and xxx NE
RARs XXXx protein
are xxx NE
involved xxx NE
in xx NE
regulating xxx NE
normal xxx NE
hematopoietic xxx NE
differentiation xxx NE
. . NE

To Xx NE
make xxx NE
clear xxx NE
the xxx NE
roles xxx NE
of xx NE
RA XX NE
and xxx NE
RAR XXX protein_B
alpha xxx protein_E
in xx NE
the xxx NE
normal xxx NE
hematopoiesis xxx NE
, , NE
I X NE
have xxx NE
introduced xxx NE
the xxx NE
construct xxx NE
of xx NE
human xxx protein_B
RAR XXX protein_M
alpha xxx protein_E
( ( NE
hRAR xXXX protein_B
alpha xxx protein_E
) ) NE
into xxx NE
murine xxx cell_type_B
bone xxx cell_type_M
marrow xxx cell_type_M
cells xxx cell_type_E
with xxx NE
retroviral xxx NE
vector xxx NE
, , NE
and xxx NE
selected xxx NE
infected xxx NE
cells xxx NE
with xxx NE
drug xxx DNA_B
resistant xxx DNA_M
marker xxx DNA_E
( ( NE
Neo(r) Xxx(x) DNA
) ) NE
cultured xxx NE
on xx NE
the xxx NE
stroma xxx cell_line_B
cell xxx cell_line_M
line xxx cell_line_E
( ( NE
PA6-neo XXd-xxx cell_line
) ) NE
, , NE
and xxx NE
analyzed xxx NE
the xxx NE
behavior xxx NE
of xx NE
infected xxx cell_type_B
cells xxx cell_type_E
. . NE

All Xxx NE
of xx NE
procedure xxx NE
were xxx NE
done xxx NE
in xx NE
vitro xxx NE
. . NE

Most Xxxx NE
cells xxx NE
infected xxx NE
with xxx NE
hRAR xXXX protein_B
alpha xxx protein_E
exhibited xxx NE
promyelocytic xxx cell_type_B
morphology xxx cell_type_E
and xxx NE
were xxx NE
thought xxx NE
to xx NE
be xx NE
blocked xxx NE
at xx NE
the xxx NE
promyelocytic xxx NE
stage xxx NE
in xx NE
their xxx NE
myeloid xxx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
these xxx NE
immature xxx cell_type_B
cells xxx cell_type_E
differentiated xxx NE
terminally xxx NE
into xxx NE
mature xxx NE
granulocytes xxx NE
by xx NE
adding xxx NE
with xxx NE
RA XX NE
(10(-6) (dd(-d) NE
M) X) NE
. . NE

RAR XXX protein_B
alpha xxx protein_E
infected xxx cell_type_B
cells xxx cell_type_E
were xxx NE
also xxx NE
able xxx NE
to xx NE
differentiate xxx NE
into xxx NE
mature xxx cell_type_B
macrophages xxx cell_type_E
in xx NE
the xxx NE
both xxx NE
of xx NE
long xxx NE
term xxx NE
culture xxx NE
and xxx NE
IL3 XXd cell_line_B
colony xxx cell_line_E
. . NE

These Xxxx NE
observations xxx NE
suggest xxx NE
that xxx NE
an xx NE
overexpression xxx NE
of xx NE
RAR XXX protein_B
alpha xxx protein_E
alone xxx NE
is xx NE
effective xxx NE
to xx NE
suppress xxx NE
myeloid xxx NE
cell xxx NE
differentiation xxx NE
and xxx NE
RAR XXX protein_B
alpha xxx protein_E
plays xxx NE
a x NE
crucial xxx NE
role xxx NE
in xx NE
the xxx NE
terminal xxx NE
differentiation xxx NE
of xx NE
myeloid xxx NE
precursors xxx NE
. . NE

The Xxx NE
system xxx NE
described xxx NE
here xxx NE
may xxx NE
serve xxx NE
as xx NE
a x NE
model xxx NE
for xxx NE
studying xxx NE
the xxx NE
the xxx NE
essential xxx DNA_B
genes xxx DNA_E
for xxx NE
differentiation xxx NE
of xx NE
normal xxx cell_type_B
bone xxx cell_type_M
marrow xxx cell_type_M
cells xxx cell_type_E
. . NE

Hypoxic Xxxx NE
induction xxx NE
of xx NE
interleukin-8 xxx-d NE
gene xxx NE
expression xxx NE
in xx NE
human xxx cell_type_B
endothelial xxx cell_type_M
cells xxx cell_type_E
. . NE

Because Xxxx NE
leukocyte-mediated xxx-xxx NE
tissue xxx NE
damage xxx NE
is xx NE
an xx NE
important xxx NE
component xxx NE
of xx NE
the xxx NE
pathologic xxx NE
picture xxx NE
in xx NE
ischemia/reperfusion xxx/xxx NE
, , NE
we xx NE
have xxx NE
sought xxx NE
mechanisms xxx NE
by xx NE
which xxx NE
PMNs XXXx cell_type
are xxx NE
directed xxx NE
into xxx NE
hypoxic xxx NE
tissue xxx NE
. . NE

Incubation Xxxx NE
of xx NE
human xxx cell_type_B
endothelial xxx cell_type_M
cells xxx cell_type_E
( ( NE
ECs XXx cell_type
) ) NE
in xx NE
hypoxia xxx NE
, , NE
PO2 XXd NE
approximately xxx NE
14-18 dd-dd NE
Torr Xxxx NE
, , NE
led xxx NE
to xx NE
time-dependent xxx-xxx NE
release xxx NE
of xx NE
IL-8 XX-d protein
antigen xxx NE
into xxx NE
the xxx NE
conditioned xxx NE
medium xxx NE
; ; NE
this xxx NE
was xxx NE
accompanied xxx NE
by xx NE
increased xxx NE
chemotactic xxx NE
activity xxx NE
for xxx NE
PMNs XXXx cell_type
, , NE
blocked xxx NE
by xx NE
antibody xxx NE
to xx NE
IL-8 XX-d protein
. . NE

Production Xxxx NE
of xx NE
IL-8 XX-d protein
by xx NE
hypoxic xxx NE
ECs XXx cell_type
occurred xxx NE
concomitantly xxx NE
with xxx NE
both xxx NE
increased xxx NE
levels xxx NE
of xx NE
IL-8 XX-d RNA_B
mRNA xXXX RNA_E
, , NE
based xxx NE
on xx NE
polymerase xxx NE
chain xxx NE
reaction xxx NE
analysis xxx NE
, , NE
and xxx NE
increased xxx NE
IL-8 XX-d NE
transcription xxx NE
, , NE
based xxx NE
on xx NE
nuclear xxx NE
run-on xxx-xx NE
assays xxx NE
. . NE

Northern Xxxx NE
analysis xxx NE
of xx NE
mRNA xXXX NE
from xxx NE
hypoxic xxx NE
ECs XXx cell_type
also xxx NE
demonstrated xxx NE
increased xxx NE
levels xxx NE
of xx NE
mRNA xXXX RNA
for xxx NE
macrophage xxx protein_B
chemotactic xxx protein_M
protein-1 xxx-d protein_E
, , NE
another xxx NE
member xxx NE
of xx NE
the xxx NE
chemokine xxx protein_B
superfamily xxx protein_E
of xx NE
proinflammatory xxx protein_B
cytokines xxx protein_E
. . NE

IL-8 XX-d DNA_B
gene xxx DNA_E
induction xxx NE
was xxx NE
associated xxx NE
with xxx NE
the xxx NE
presence xxx NE
of xx NE
increased xxx NE
binding xxx NE
activity xxx NE
in xx NE
nuclear xxx NE
extracts xxx NE
from xxx NE
hypoxic xxx cell_type_B
ECs XXx cell_type_E
for xxx NE
the xxx NE
NF-kB XX-xX NE
site xxx NE
. . NE

Studies Xxxx NE
with xxx NE
human xxx NE
umbilical xxx NE
vein xxx NE
segments xxx NE
exposed xxx NE
to xx NE
hypoxia xxx NE
also xxx NE
demonstrated xxx NE
increased xxx NE
elaboration xxx NE
of xx NE
IL-8 XX-d protein_B
antigen xxx protein_E
compared xxx NE
with xxx NE
normoxic xxx NE
controls xxx NE
. . NE

In Xx NE
mice xxx NE
exposed xxx NE
to xx NE
hypoxia xxx NE
(PO2 (XXd NE
approximately xxx NE
30-40 dd-dd NE
Torr) Xxxx) NE
, , NE
there xxx NE
was xxx NE
increased xxx NE
pulmonary xxx NE
leukostasis xxx NE
, , NE
as xx NE
evidenced xxx NE
by xx NE
increased xxx NE
myeloperoxidase xxx NE
activity xxx NE
in xx NE
tissue xxx NE
homogenates xxx NE
. . NE

In Xx NE
parallel xxx NE
, , NE
increased xxx NE
levels xxx NE
of xx NE
transcripts xxx NE
for xxx NE
IP-10 XX-dd protein
, , NE
a x NE
murine xxx NE
homologue xxx NE
in xx NE
the xxx NE
chemokine xxx protein_B
family xxx protein_E
related xxx NE
to xx NE
IL-8 XX-d protein
, , NE
were xxx NE
observed xxx NE
in xx NE
hypoxic xxx NE
lung xxx NE
tissue xxx NE
. . NE

Taken Xxxx NE
together xxx NE
, , NE
these xxx NE
data xxx NE
suggest xxx NE
that xxx NE
hypoxia xxx NE
constitutes xxx NE
a x NE
stimulus xxx NE
for xxx NE
leukocyte xxx NE
chemotaxis xxx NE
and xxx NE
tissue xxx NE
leukostasis xxx NE
. . NE

Thrombin Xxxx protein
and xxx NE
thrombin xxx NE
receptor xxx NE
agonist xxx NE
peptide xxx NE
induce xxx NE
early xxx NE
events xxx NE
of xx NE
T X NE
cell xxx NE
activation xxx NE
and xxx NE
synergize xxx NE
with xxx NE
TCR XXX NE
cross-linking xxx-xxx NE
for xxx NE
CD69 XXdd NE
expression xxx NE
and xxx NE
interleukin xxx NE
2 d NE
production xxx NE
. . NE

Thrombin Xxxx protein
stimulation xxx NE
of xx NE
the xxx NE
T X cell_line_B
leukemic xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_M
Jurkat Xxxx cell_line_E
induced xxx NE
a x NE
transient xxx NE
increase xxx NE
in xx NE
[ [ NE
Ca2+ Xxd+ NE
]i ]x NE
. . NE

Proteolytic Xxxx NE
activity xxx NE
of xx NE
the xxx NE
enzyme xxx protein
was xxx NE
required xxx NE
for xxx NE
this xxx NE
effect xxx NE
since xxx NE
diisopropyl xxx protein_B
fluorophosphate-thrombin xxx-xxx protein_E
failed xxx NE
to xx NE
increase xxx NE
[ [ NE
Ca2+ Xxd+ NE
]i ]x NE
. . NE

Furthermore Xxxx NE
, , NE
hirudin xxx NE
and xxx NE
anti-thrombin xxx-xxx protein_B
III XXX protein_E
inhibited xxx NE
the xxx NE
thrombin-induced xxx-xxx NE
[ [ NE
Ca2+ Xxd+ NE
]i ]x NE
rise xxx NE
in xx NE
Jurkat Xxxx NE
T X NE
cells xxx NE
. . NE

A X NE
synthetic xxx NE
thrombin xxx NE
receptor xxx NE
agonist xxx NE
peptide xxx NE
( ( NE
TRP XXX NE
) ) NE
of xx NE
7 d NE
residues xxx NE
( ( NE
SFLLRNP XXXXXXX NE
) ) NE
was xxx NE
found xxx NE
to xx NE
be xx NE
as xx NE
effective xxx NE
as xx NE
thrombin xxx protein
for xxx NE
[ [ NE
Ca2+ Xxd+ NE
]i ]x NE
mobilization xxx NE
, , NE
and xxx NE
both xxx NE
agonists xxx NE
induced xxx NE
Ca2+ Xxd+ NE
release xxx NE
exclusively xxx NE
from xxx NE
internal xxx NE
stores xxx NE
. . NE

Thrombin Xxxx protein
stimulated xxx NE
tyrosine xxx NE
phosphorylation xxx NE
of xx NE
several xxx NE
proteins xxx NE
of xx NE
molecular xxx protein_B
mass xxx protein_M
40 dd protein_M
kDa xXx protein_M
and xxx protein_M
molecular xxx protein_M
mass xxx protein_M
42 dd protein_M
kDa xXx protein_M
and xxx protein_M
molecular xxx protein_M
mass xxx protein_M
70 dd protein_M
kDa xXx protein_M
and xxx protein_M
molecular xxx protein_M
mass xxx protein_M
120 ddd protein_M
kDa xXx protein_M
and xxx protein_M
molecular xxx protein_M
mass xxx protein_M
130 ddd protein_M
kDa xXx protein_E

There Xxxx NE
was xxx NE
a x NE
good xxx NE
correlation xxx NE
between xxx NE
thrombin xxx NE
-induced -xxx NE
tyrosine xxx NE
phosphorylation xxx NE
of xx NE
the xxx NE
latter xxx NE
three xxx NE
proteins xxx NE
and xxx NE
Ca2+ Xxd+ NE
mobilization xxx NE
. . NE

Thrombin Xxxx protein
and xxx NE
TRP XXX NE
also xxx NE
caused xxx NE
translocation xxx NE
of xx NE
protein xxx protein_B
kinase xxx protein_M
C X protein_E
from xxx NE
the xxx NE
cytosol xxx NE
to xx NE
the xxx NE
plasma xxx NE
membrane xxx NE
. . NE

As Xx NE
a x NE
likely xxx NE
consequence xxx NE
of xx NE
these xxx NE
events xxx NE
, , NE
thrombin xxx protein
activated xxx NE
the xxx NE
nuclear xxx protein_B
factor xxx protein_M
NF-kB XX-xX protein_E
. . NE

Several Xxxx NE
cell xxx NE
lines xxx NE
of xx NE
hematopoietic xxx NE
origin xxx NE
including xxx NE
the xxx NE
leukemic xxx cell_line_B
T X cell_line_M
cell xxx cell_line_M
line xxx cell_line_M
HPB.ALL XXX.XXX cell_line_E
and xxx NE
the xxx NE
erythroleukemic xxx cell_line_B
cell xxx cell_line_M
line xxx cell_line_M
K562 Xddd cell_line_E
were xxx NE
responsive xxx NE
to xx NE
thrombin xxx protein
, , NE
whereas xxx NE
others xxx NE
such xxx NE
as xx NE
THP1 XXXd cell_line
, , NE
a x NE
myelomonocytic xxx cell_line_B
cell xxx cell_line_M
line xxx cell_line_E
, , NE
and xxx NE
BL2 XXd NE
, , NE
a x NE
Burkitt Xxxx NE
lymphoma xxx NE
were xxx NE
refractory xxx NE
to xx NE
thrombin xxx NE
or xx NE
TRP XXX NE
stimulation xxx NE
. . NE

The Xxx NE
magnitude xxx NE
of xx NE
the xxx NE
thrombin xxx protein
response xxx NE
in xx NE
the xxx NE
different xxx NE
cell xxx NE
types xxx NE
paralleled xxx NE
the xxx NE
expression xxx NE
of xx NE
the xxx NE
thrombin xxx RNA_B
receptor xxx RNA_M
mRNA xXXX RNA_E
. . NE

We Xx NE
found xxx NE
that xxx NE
activation xxx NE
of xx NE
Jurkat Xxxx cell_line_B
T X cell_line_M
cells xxx cell_line_E
by xx NE
a x NE
combination xxx NE
of xx NE
phytohemagglutinin xxx protein
and xxx NE
phorbol xxx NE
12-myristate dd-xxx NE
13-acetate dd-xxx NE
led xxx NE
to xx NE
a x NE
dramatic xxx NE
inhibition xxx NE
of xx NE
thrombin xxx NE
receptor xxx NE
mRNA xXXX NE
expression xxx NE
and xxx NE
to xx NE
a x NE
concomitant xxx NE
loss xxx NE
of xx NE
the xxx NE
thrombin xxx NE
response xxx NE
. . NE

Finally Xxxx NE
, , NE
we xx NE
demonstrate xxx NE
that xxx NE
thrombin xxx protein
and xxx NE
TRP XXX NE
enhanced xxx NE
CD69 XXdd NE
expression xxx NE
and xxx NE
interleukin xxx NE
2 d NE
production xxx NE
induced xxx NE
by xx NE
T X NE
cell xxx NE
receptor xxx NE
cross-linking xxx-xxx NE
in xx NE
both xxx NE
Jurkat Xxxx cell_line_B
T X cell_line_M
cells xxx cell_line_E
and xxx NE
peripheral xxx NE
blood xxx NE
lymphocytes xxx cell_type
. . NE

These Xxxx NE
findings xxx NE
highlight xxx NE
the xxx NE
role xxx NE
of xx NE
thrombin xxx protein
as xx NE
a x NE
potential xxx NE
regulator xxx NE
of xx NE
T X NE
lymphocyte xxx NE
activation xxx NE
. . NE

Stress Xxxx NE
response xxx NE
of xx NE
senescent xxx cell_type_B
T X cell_type_M
lymphocytes xxx cell_type_E
: : NE
reduced xxx NE
hsp70 xxxdd protein
is xx NE
independent xxx NE
of xx NE
the xxx NE
proliferative xxx NE
block xxx NE
. . NE

Senescent Xxxx cell_line_B
human xxx cell_line_M
T X cell_line_M
lymphocyte xxx cell_line_M
cultures xxx cell_line_E
are xxx NE
unable xxx NE
to xx NE
undergo xxx NE
proliferation xxx NE
, , NE
but xxx NE
show xxx NE
no xx NE
difference xxx NE
from xxx NE
early xxx cell_line_B
passage xxx cell_line_M
cells xxx cell_line_E
in xx NE
cytotoxic xxx NE
function xxx NE
or xx NE
surface xxx NE
antigenic xxx NE
profile xxx NE
. . NE

A X NE
second xxx NE
feature xxx NE
of xx NE
senescent xxx cell_line_B
T X cell_line_M
cells xxx cell_line_E
is xx NE
the xxx NE
dramatic xxx NE
reduction xxx NE
in xx NE
hsp70 xxxdd NE
production xxx NE
in xx NE
response xxx NE
to xx NE
heat xxx NE
shock xxx NE
. . NE

This Xxxx NE
decline xxx NE
is xx NE
associated xxx NE
with xxx NE
a x NE
decrease xxx NE
in xx NE
binding xxx NE
of xx NE
nuclear xxx NE
extracts xxx NE
to xx NE
the xxx NE
consensus xxx DNA_B
heat xxx DNA_M
shock xxx DNA_M
element xxx DNA_E
. . NE

Interestingly Xxxx NE
, , NE
the xxx NE
progressive xxx NE
decline xxx NE
in xx NE
the xxx NE
heat xxx NE
shock xxx NE
response xxx NE
of xx NE
cultured xxx cell_line_B
T X cell_line_M
cells xxx cell_line_E
correlates xxx NE
with xxx NE
the xxx NE
percent xxx NE
proliferative xxx NE
life xxx NE
span xxx NE
completed xxx NE
rather xxx NE
than xxx NE
with xxx NE
the xxx NE
actual xxx NE
proliferative xxx NE
activity xxx NE
at xx NE
the xxx NE
time xxx NE
of xx NE
heat xxx NE
shock xxx NE
. . NE

This Xxxx NE
suggests xxx NE
that xxx NE
for xxx NE
senescent xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
the xxx NE
reduced xxx NE
ability xxx NE
to xx NE
respond xxx NE
to xx NE
heat xxx NE
shock xxx NE
by xx NE
producing xxx NE
hsp70 xxxdd protein
, , NE
although xxx NE
possibly xxx NE
lying xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
transcriptional xxx NE
control xxx NE
, , NE
may xxx NE
nevertheless xxx NE
be xx NE
unrelated xxx NE
to xx NE
the xxx NE
reduced xxx NE
DNA XXX NE
synthesis xxx NE
or xx NE
the xxx NE
diminished xxx NE
proliferative xxx NE
activity xxx NE
also xxx NE
manifested xxx NE
by xx NE
these xxx NE
cells xxx NE
. . NE

Involvement Xxxx NE
of xx NE
phospholipase xxx protein_B
D X protein_E
in xx NE
the xxx NE
activation xxx NE
of xx NE
transcription xxx protein_B
factor xxx protein_M
AP-1 XX-d protein_E
in xx NE
human xxx cell_line_B
T X cell_line_M
lymphoid xxx cell_line_M
Jurkat Xxxx cell_line_M
cells xxx cell_line_E
. . NE

The Xxx NE
induction xxx NE
of xx NE
the xxx NE
AP-1 XX-d protein
transcription xxx protein_B
factor xxx protein_E
has xxx NE
been xxx NE
ascribed xxx NE
to xx NE
the xxx NE
early xxx NE
events xxx NE
leading xxx NE
to xx NE
T X NE
lymphocyte xxx NE
activation xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
possibility xxx NE
that xxx NE
stimulation xxx NE
of xx NE
phospholipase xxx protein_B
D X protein_E
( ( NE
PLD XXX protein
) ) NE
may xxx NE
regulate xxx NE
activation xxx NE
of xx NE
transcription xxx protein_B
factor xxx protein_M
AP-1 XX-d protein_E
in xx NE
human xxx NE
T X NE
cells xxx NE
by xx NE
transfecting xxx NE
human xxx NE
T X cell_line_B
lymphocyte xxx cell_line_M
Jurkat Xxxx cell_line_M
cells xxx cell_line_E
with xxx NE
a x NE
plasmid xxx NE
containing xxx NE
an xx NE
AP-1 XX-d DNA_B
enhancer xxx DNA_M
element xxx DNA_E
and xxx NE
a x NE
chloramphenicol xxx DNA_B
acetyltransferase xxx DNA_M
reporter xxx DNA_M
gene xxx DNA_E
. . NE

We Xx NE
have xxx NE
detected xxx NE
activatable xxx NE
PLD XXX protein
in xx NE
Jurkat Xxxx cell_line_B
cells xxx cell_line_E
, , NE
and xxx NE
we xx NE
have xxx NE
found xxx NE
that xxx NE
addition xxx NE
of xx NE
phosphatidic xxx NE
acid xxx NE
( ( NE
PA XX NE
) ) NE
, , NE
the xxx NE
physiologic xxx NE
product xxx NE
of xx NE
PLD XXX protein
action xxx NE
on xx NE
phospholipids xxx NE
, , NE
is xx NE
rapidly xxx NE
incorporated xxx NE
into xxx NE
Jurkat Xxxx cell_line_B
cells xxx cell_line_E
and xxx NE
leads xxx NE
to xx NE
activation xxx NE
of xx NE
transcription xxx protein_B
factor xxx protein_M
AP-1 XX-d protein_E
. . NE

Treatment Xxxx NE
of xx NE
Jurkat Xxxx cell_line_B
cells xxx cell_line_E
with xxx NE
anti-CD3 xxx-XXd protein_B
mAb xXx protein_E
activated xxx NE
both xxx NE
PLD XXX protein
and xxx NE
transcription xxx protein_B
factor xxx protein_M
AP-1 XX-d protein_E
. . NE

Wortmannin Xxxx NE
, , NE
an xx NE
inhibitor xxx NE
of xx NE
receptor-coupled xxx-xxx NE
PLD XXX protein
activation xxx NE
, , NE
blocked xxx NE
the xxx NE
anti-CD3 xxx-XXd NE
-induced -xxx NE
increases xxx NE
in xx NE
both xxx NE
PLD XXX NE
activity xxx NE
and xxx NE
AP-1 XX-d NE
enhancer xxx NE
activity xxx NE
. . NE

We Xx NE
found xxx NE
a x NE
good xxx NE
correlation xxx NE
in xx NE
the xxx NE
transfected xxx cell_line_B
cells xxx cell_line_E
between xxx NE
PLD XXX NE
activation xxx NE
and xxx NE
induction xxx NE
of xx NE
AP-1 XX-d NE
enhancer xxx NE
activity xxx NE
under xxx NE
different xxx NE
experimental xxx NE
conditions xxx NE
. . NE

Furthermore Xxxx NE
, , NE
ethanol xxx NE
, , NE
an xx NE
inhibitor xxx NE
of xx NE
the xxx NE
PLD XXX protein
pathway xxx NE
, , NE
blocked xxx NE
the xxx NE
anti-CD3-stimulated xxx-XXd-xxx NE
AP-1 XX-d NE
enhancer xxx NE
activity xxx NE
. . NE

However Xxxx NE
, , NE
this xxx NE
anti-CD3 xxx-XXd NE
-mediated -xxx NE
response xxx NE
was xxx NE
not xxx NE
inhibited xxx NE
by xx NE
neomycin xxx NE
, , NE
an xx NE
inhibitor xxx NE
of xx NE
phosphoinositide xxx NE
hydrolysis xxx NE
. . NE

The Xxx NE
increases xxx NE
in xx NE
AP-1 XX-d NE
enhancer xxx NE
activity xxx NE
induced xxx NE
by xx NE
PA XX NE
or xx NE
anti-CD3 xxx-XXd protein_B
mAb xXx protein_E
were xxx NE
efficiently xxx NE
abrogated xxx NE
by xx NE
the xxx NE
presence xxx NE
of xx NE
propranolol xxx NE
, , NE
an xx NE
inhibitor xxx NE
of xx NE
PA XX NE
phosphohydrolase xxx protein
and xxx NE
protein xxx protein_B
kinase xxx protein_M
C X protein_E
( ( NE
PKC XXX protein
) ) NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
PA XX NE
-and -xxx NE
the xxx NE
anti-CD3 xxx-XXd NE
-induced -xxx NE
increases xxx NE
in xx NE
AP-1 XX-d NE
enhancer xxx NE
activity xxx NE
were xxx NE
blocked xxx NE
by xx NE
the xxx NE
presence xxx NE
of xx NE
PKC XXX NE
inhibitors xxx NE
or xx NE
by xx NE
PKC XXX NE
down-regulation xxx-xxx NE
. . NE

These Xxxx NE
data xxx NE
indicate xxx NE
that xxx NE
PLD XXX NE
stimulation xxx NE
can xxx NE
activate xxx NE
the xxx NE
transcription xxx protein_B
factor xxx protein_M
AP-1 XX-d protein_E
in xx NE
T X cell_type_B
lymphocytes xxx cell_type_E
, , NE
and xxx NE
suggest xxx NE
that xxx NE
the xxx NE
induction xxx NE
of xx NE
AP-1 XX-d NE
enhancer xxx NE
factor xxx NE
activity xxx NE
by xx NE
PA XX NE
is xx NE
mediated xxx NE
via xxx NE
PKC XXX NE
stimulation xxx NE
, , NE
either xxx NE
through xxx NE
a x NE
direct xxx NE
activating xxx NE
effect xxx NE
of xx NE
PA XX NE
or xx NE
through xxx NE
PA XX NE
-derived -xxx NE
diacylglycerol xxx NE
formation xxx NE
. . NE

These Xxxx NE
data xxx NE
also xxx NE
provide xxx NE
evidence xxx NE
for xxx NE
a x NE
role xxx NE
of xx NE
PLD XXX NE
-derived -xxx NE
lipids xxx NE
in xx NE
the xxx NE
induction xxx NE
of xx NE
AP-1 XX-d NE
enhancer xxx NE
activity xxx NE
resulting xxx NE
from xxx NE
stimulation xxx NE
of xx NE
the xxx NE
TCR/CD3 XXX/XXd NE
complex xxx NE
, , NE
suggesting xxx NE
that xxx NE
increased xxx NE
PLD XXX NE
activity xxx NE
can xxx NE
play xxx NE
an xx NE
important xxx NE
role xxx NE
in xx NE
T X NE
lymphocyte xxx NE
activation xxx NE
. . NE

Upregulation Xxxx NE
of xx NE
bcl-2 xxx-d DNA
by xx NE
the xxx NE
Epstein-Barr Xxxx-Xxxx protein_B
virus xxx protein_M
latent xxx protein_M
membrane xxx protein_M
protein xxx protein_E
LMP1 XXXd protein
: : NE
a x NE
B-cell-specific X-xxx-xxx NE
response xxx NE
that xxx NE
is xx NE
delayed xxx NE
relative xxx NE
to xx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
and xxx NE
to xx NE
induction xxx NE
of xx NE
cell xxx protein_B
surface xxx protein_M
markers xxx protein_E
. . NE

An Xx NE
ability xxx NE
of xx NE
the xxx NE
Epstein-Barr Xxxx-Xxxx protein_B
virus xxx protein_M
latent xxx protein_M
membrane xxx protein_M
protein xxx protein_E
LMP1 XXXd protein
to xx NE
enhance xxx NE
the xxx NE
survival xxx NE
of xx NE
infected xxx cell_type_B
B X cell_type_M
cells xxx cell_type_E
through xxx NE
upregulation xxx NE
of xx NE
the xxx NE
bcl-2 xxx-d DNA_B
oncogene xxx DNA_E
was xxx NE
first xxx NE
suggested xxx NE
by xx NE
experiments xxx NE
involving xxx NE
gene xxx NE
transfection xxx NE
and xxx NE
the xxx NE
selection xxx NE
of xx NE
stable xxx NE
LMP1 XXXd NE
+ + NE
clones xxx NE
(S.Henderson (X.Xxxx NE
, , NE
M X NE
. . NE
Rowe Xxxx NE
, , NE
C.Gregory X.Xxxx NE
, , NE
F.Wang X.Xxxx NE
, , NE
E.Kieff X.Xxxx NE
, , NE
and xxx NE
A.Rickinson X.Xxxx NE
, , NE
Cell Xxxx NE
65:1107-1115 dd:dddd-dddd NE
, , NE
1991) dddd) NE
. . NE

However Xxxx NE
, , NE
it xx NE
was xxx NE
not xxx NE
possible xxx NE
to xx NE
ascertain xxx NE
whether xxx NE
Bcl-2 Xxx-d protein
upregulation xxx NE
was xxx NE
a x NE
specific xxx NE
consequence xxx NE
of xx NE
LMP1 XXXd protein
expression xxx NE
or xx NE
an xx NE
artifact xxx NE
of xx NE
the xxx NE
selection xxx NE
procedure xxx NE
whereby xxx NE
rare xxx NE
Bcl-2 Xxx-d NE
+ + NE
cells xxx NE
already xxx NE
present xxx NE
in xx NE
the xxx NE
starting xxx NE
population xxx NE
might xxx NE
best xxx NE
be xx NE
able xxx NE
to xx NE
tolerate xxx NE
the xxx NE
potentially xxx NE
toxic xxx NE
effects xxx NE
of xx NE
LMP1 XXXd NE
. . NE

We Xx NE
therefore xxx NE
reexamined xxx NE
this xxx NE
issue xxx NE
by xx NE
using xxx NE
two xxx NE
different xxx NE
experimental xxx NE
approaches xxx NE
that xxx NE
allowed xxx NE
LMP1 XXXd NE
-induced -xxx NE
effects xxx NE
to xx NE
be xx NE
monitored xxx NE
immediately xxx NE
following xxx NE
expression xxx NE
of xx NE
the xxx NE
viral xxx NE
protein xxx NE
and xxx NE
in xx NE
the xxx NE
absence xxx NE
of xx NE
selective xxx NE
pressures xxx NE
; ; NE
activation xxx NE
of xx NE
the xxx NE
NF-kappa XX-xxx NE
B X NE
transcription xxx NE
factor xxx NE
and xxx NE
upregulation xxx NE
of xx NE
the xxx NE
cell xxx NE
adhesion xxx NE
molecule xxx NE
ICAM-1 XXXX-d NE
were xxx NE
used xxx NE
as xx NE
early xxx NE
indices xxx NE
of xx NE
LMP1 XXXd NE
function xxx NE
. . NE

In Xx NE
the xxx NE
first xxx NE
approach xxx NE
, , NE
stable xxx NE
clones xxx NE
of xx NE
two xxx NE
B-cell X-xxx cell_line_B
lines xxx cell_line_E
carrying xxx NE
an xx NE
LMP1 XXXd protein
gene xxx NE
under xxx NE
the xxx NE
control xxx NE
of xx NE
an xx NE
inducible xxx NE
metallothionein xxx DNA_B
promoter xxx DNA_E
were xxx NE
induced xxx NE
to xx NE
express xxx NE
LMP1 XXXd protein
in xx NE
all xxx NE
cells xxx NE
. . NE

Activation Xxxx NE
of xx NE
NK-kappa XX-xxx protein_B
B X protein_E
and xxx NE
upregulation xxx NE
of xx NE
ICAM-1 XXXX-d protein
occurred xxx NE
within xxx NE
24 dd NE
h x NE
and xxx NE
were xxx NE
followed xxx NE
at xx NE
48 dd NE
to xx NE
72 dd NE
h x NE
by xx NE
upregulation xxx NE
of xx NE
Bcl-2 Xxx-d protein
. . NE

In Xx NE
the xxx NE
second xxx NE
approach xxx NE
, , NE
we xx NE
tested xxx NE
the xxx NE
generality xxx NE
of xx NE
this xxx NE
phenomenon xxx NE
by xx NE
transiently xxx NE
expressing xxx NE
LMP1 XXXd protein
from xxx NE
a x NE
strong xxx NE
constitutively xxx NE
active xxx NE
promoter xxx NE
in xx NE
a x NE
range xxx NE
of xx NE
different xxx NE
cell xxx NE
types xxx NE
. . NE

All Xxx NE
six xxx NE
B-cell X-xxx cell_line_B
lines xxx cell_line_E
tested xxx NE
showed xxx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
in xx NE
response xxx NE
to xx NE
LMP1 XXXd NE
expression xxx NE
, , NE
and xxx NE
this xxx NE
was xxx NE
followed xxx NE
in xx NE
five xxx NE
of xx NE
six xxx NE
lines xxx NE
by xx NE
expression xxx NE
of xx NE
ICAM-1 XXXX-d protein
and xxx NE
Bcl-2 Xxx-d protein
. . NE

In Xx NE
the xxx NE
same xxx NE
experiments xxx NE
, , NE
all xxx NE
three xxx NE
non- xxx- NE
B-cell X-xxx cell_line_B
lines xxx cell_line_E
showed xxx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
and xxx NE
ICAM-1 XXXX-d protein
upregulation xxx NE
but xxx NE
never xxx NE
any xxx NE
effect xxx NE
upon xxx NE
Bcl-2 Xxx-d protein
. . NE

We Xx NE
therefore xxx NE
conclude xxx NE
that xxx NE
Bcl-2 Xxx-d NE
upregulation xxx NE
is xx NE
part xxx NE
of xx NE
the xxx NE
panoply xxx NE
of xx NE
cellular xxx NE
changes xxx NE
induced xxx NE
by xx NE
LMP1 XXXd protein
but xxx NE
that xxx NE
the xxx NE
effect xxx NE
is xx NE
cell xxx NE
type xxx NE
specific xxx NE
. . NE

Our Xxx NE
data xxx NE
also xxx NE
suggest xxx NE
that xxx NE
whilst xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
may xxx NE
be xx NE
an xx NE
essential xxx NE
component xxx NE
of xx NE
LMP1 XXXd NE
signal xxx NE
transduction xxx NE
, , NE
other xxx NE
cell-specific xxx-xxx protein_B
factors xxx protein_E
may xxx NE
be xx NE
required xxx NE
to xx NE
effect xxx NE
some xxx NE
functions xxx NE
of xx NE
the xxx NE
viral xxx protein_B
protein xxx protein_E
. . NE

Long-term Xxxx-xxx NE
inositol xxx NE
phosphate xxx NE
release xxx NE
, , NE
but xxx NE
not xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
, , NE
correlates xxx NE
with xxx NE
IL-2 XX-d NE
secretion xxx NE
and xxx NE
NF-AT XX-XX NE
induction xxx NE
in xx NE
anti-CD3-activated xxx-XXd-xxx cell_line_B
peripheral xxx cell_line_M
human xxx cell_line_M
T X cell_line_M
lymphocytes xxx cell_line_E
. . NE

The Xxx NE
cascade xxx NE
of xx NE
events xxx NE
within xxx NE
the xxx NE
first xxx NE
few xxx NE
minutes xxx NE
of xx NE
T X NE
cell xxx NE
stimulation xxx NE
has xxx NE
been xxx NE
well xxx NE
characterized xxx NE
. . NE

Although Xxxx NE
many xxx NE
second xxx NE
messengers xxx NE
have xxx NE
been xxx NE
shown xxx NE
to xx NE
be xx NE
necessary xxx NE
and xxx NE
sufficient xxx NE
for xxx NE
T X NE
cell xxx NE
activation xxx NE
in xx NE
a x NE
number xxx NE
of xx NE
model xxx NE
systems xxx NE
, , NE
the xxx NE
rate-limiting xxx-xxx NE
step xxx NE
in xx NE
peripheral xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
has xxx NE
not xxx NE
been xxx NE
demonstrated xxx NE
. . NE

To Xx NE
model xxx NE
effective xxx NE
versus xxx NE
ineffective xxx NE
CD3 XXd NE
-mediated -xxx NE
stimulation xxx NE
in xx NE
peripheral xxx NE
T X NE
cells xxx NE
, , NE
we xx NE
used xxx NE
two xxx NE
anti-CD3 xxx-XXd NE
mAbs xXxx NE
that xxx NE
differ xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
stimulate xxx NE
purified xxx NE
T X NE
cells xxx NE
: : NE
OKT3 XXXd NE
, , NE
which xxx NE
causes xxx NE
early xxx NE
second xxx NE
messenger xxx NE
generation xxx NE
but xxx NE
is xx NE
unable xxx NE
to xx NE
activate xxx NE
T X NE
cells xxx NE
without xxx NE
a x NE
second xxx NE
signal xxx NE
, , NE
and xxx NE
64.1 dd.d NE
, , NE
which xxx NE
stimulates xxx NE
T X NE
cell xxx NE
proliferation xxx NE
on xx NE
its xxx NE
own xxx NE
. . NE

We Xx NE
found xxx NE
that xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
was xxx NE
similar xxx NE
for xxx NE
both xxx NE
mAbs xXxx protein
over xxx NE
a x NE
period xxx NE
of xx NE
hours xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
inositol xxx NE
phosphate xxx NE
response xxx NE
was xxx NE
stronger xxx NE
for xxx NE
64.1 dd.d protein
than xxx NE
for xxx NE
OKT3 XXXd protein
. . NE

To Xx NE
tie xxx NE
these xxx NE
events xxx NE
to xx NE
gene xxx NE
activation xxx NE
, , NE
we xx NE
measured xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
and xxx NE
NF-AT XX-XX NE
activity xxx NE
in xx NE
the xxx NE
nucleus xxx NE
after xxx NE
anti-CD3 xxx-XXd NE
stimulation xxx NE
. . NE

Both Xxxx NE
stimuli xxx NE
induced xxx NE
the xxx NE
appearance xxx NE
of xx NE
the xxx NE
NF-kappa XX-xxx protein_B
B X protein_M
components xxx protein_E
( ( NE
c-Rel x-Xxx protein
, , NE
p65 xdd protein
( ( NE
RelA XxxX protein
) ) NE
, , NE
and xxx NE
p50 xdd protein
( ( NE
NF-kappa XX-xxx protein_B
B1 Xd protein_E
)) )) NE
and xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
DNA XXX NE
binding xxx NE
activity xxx NE
in xx NE
the xxx NE
nucleus xxx NE
. . NE

However Xxxx NE
, , NE
only xxx NE
64.1 dd.d protein
induced xxx NE
NF-AT XX-XX protein
in xx NE
the xxx NE
nucleus xxx NE
, , NE
correlating xxx NE
with xxx NE
its xxx NE
ability xxx NE
to xx NE
activate xxx NE
T X cell_type_B
cells xxx cell_type_E
. . NE

Thus Xxxx NE
, , NE
NF-AT XX-XX NE
induction xxx NE
and xxx NE
IL-2 XX-d NE
secretion xxx NE
were xxx NE
correlated xxx NE
with xxx NE
the xxx NE
levels xxx NE
of xx NE
inositol xxx NE
phosphate xxx NE
release xxx NE
but xxx NE
not xxx NE
with xxx NE
gross xxx NE
levels xxx NE
of xx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
induced xxx NE
late xxx NE
following xxx NE
the xxx NE
response xxx NE
. . NE

On Xx NE
the xxx NE
other xxx NE
hand xxx NE
, , NE
NF-kappa XX-xxx protein_B
B X protein_E
induction xxx NE
and xxx NE
IL-2 XX-d protein
receptor xxx NE
expression xxx NE
occurred xxx NE
even xxx NE
with xxx NE
the xxx NE
smaller xxx NE
second xxx NE
messenger xxx NE
response xxx NE
generated xxx NE
by xx NE
OKT3 XXXd protein
. . NE

HLA-DR- XXX-XX- NE
myeloid/natural xxx/xxx NE
killer xxx NE
cell xxx NE
acute xxx NE
leukemia xxx NE
and xxx NE
CD33+ XXdd+ NE
myeloid/natural xxx/xxx NE
killer xxx NE
cell xxx NE
acute xxx NE
leukemia xxx NE
and xxx NE
CD56+ XXdd+ NE
myeloid/natural xxx/xxx NE
killer xxx NE
cell xxx NE
acute xxx NE
leukemia xxx NE
and xxx NE
CD16- XXdd- NE
myeloid/natural xxx/xxx NE
killer xxx NE
cell xxx NE
acute xxx NE
leukemia xxx NE
potentially xxx NE
misdiagnosed xxx NE
as xx NE
French-American-British Xxxx-Xxxx-Xxxx NE
acute xxx NE
myeloid xxx NE
leukemia-M3 xxx-Xd NE
[see [xxx NE
comments] xxx] NE

We Xx NE
have xxx NE
identified xxx NE
and xxx NE
characterized xxx NE
a x NE
previously xxx NE
unrecognized xxx NE
form xxx NE
of xx NE
acute xxx NE
leukemia xxx NE
that xxx NE
shares xxx NE
features xxx NE
of xx NE
both xxx NE
myeloid xxx cell_type_B
cell xxx cell_type_M
and xxx cell_type_M
natural xxx cell_type_M
killer xxx cell_type_M
(NK) (XX) cell_type_M
cell xxx cell_type_E

From Xxxx NE
a x NE
consecutive xxx NE
series xxx NE
of xx NE
350 ddd NE
cases xxx NE
of xx NE
adult xxx NE
de xx NE
novo xxx NE
acute xxx NE
myeloid xxx NE
leukemia xxx NE
( ( NE
AML XXX NE
) ) NE
, , NE
we xx NE
identified xxx NE
20 dd NE
cases xxx NE
(6%) (d%) NE
with xxx NE
a x NE
unique xxx NE
immunophenotype xxx NE
: : NE
CD33+ XXdd+ NE
, , NE
CD56+ XXdd+ NE
, , NE
CD11a+ XXddx+ NE
, , NE
CD13lo XXddxx NE
, , NE
CD15lo XXddxx NE
, , NE
CD34+/- XXdd+/- NE
, , NE
HLA-DR XXX-XX NE
- - NE
, , NE
CD16 XXdd NE
- - NE
. . NE

Multicolor Xxxx NE
flow xxx NE
cytometric xxx NE
assays xxx NE
confirmed xxx NE
the xxx NE
coexpression xxx NE
of xx NE
myeloid xxx protein_B
(CD33, (XXdd, protein_M
CD13, XXdd, protein_M
CD15) XXdd) protein_M
antigen xxx protein_M
and xxx protein_M
NK XX protein_M
cell-associated xxx-xxx protein_M
(CD56) (XXdd) protein_M
antigen xxx protein_E
confirmed xxx NE
the xxx NE
identity xxx NE
of xx NE
CD56 XXdd protein
( ( NE
neural xxx protein_B
cell xxx protein_M
adhesion xxx protein_M
molecule xxx protein_E
) ) NE
in xx NE
leukemic xxx cell_type_B
blasts xxx cell_type_E
. . NE

Although Xxxx NE
two xxx NE
cases xxx NE
expressed xxx NE
CD4 XXd protein
, , NE
no xx NE
case xxx NE
expressed xxx NE
CD2 XXd protein
, , NE
CD3 XXd protein
, , NE
or xx NE
CD8 XXd protein
and xxx NE
no xx NE
case xxx NE
showed xxx NE
clonal xxx NE
rearrangement xxx NE
of xx NE
genes xxx NE
encoding xxx NE
the xxx NE
T-cell X-xxx protein_B
receptor xxx protein_E
( ( NE
TCR XXX protein_B
beta xxx protein_M
and xxx protein_M
TCR XXX protein_M
gamma xxx protein_M
and xxx protein_M
TCR XXX protein_M
delta xxx protein_E

Leukemic Xxxx NE
blasts xxx NE
in xx NE
the xxx NE
majority xxx NE
of xx NE
cases xxx NE
shared xxx NE
unique xxx NE
morphologic xxx NE
features xxx NE
( ( NE
deeply xxx NE
invaginated xxx NE
nuclear xxx NE
membranes xxx NE
, , NE
scant xxx NE
cytoplasm xxx NE
with xxx NE
fine xxx NE
azurophilic xxx NE
granularity xxx NE
, , NE
and xxx NE
finely xxx NE
granular xxx NE
Sudan Xxxx NE
black xxx NE
B X NE
and xxx NE
myeloperoxidase xxx NE
cytochemical xxx NE
reactivity xxx NE
) ) NE
that xxx NE
were xxx NE
remarkably xxx NE
similar xxx NE
to xx NE
those xxx NE
of xx NE
acute xxx NE
promyelocytic xxx NE
leukemia xxx NE
( ( NE
APL XXX NE
) ) NE
; ; NE
particularly xxx NE
the xxx NE
microgranular xxx protein_B
variant xxx protein_E
( ( NE
FAB XXX NE
AML XXX NE
-M3v -Xdx NE
) ) NE
. . NE

However Xxxx NE
, , NE
all xxx NE
20 dd NE
cases xxx NE
lacked xxx NE
the xxx NE
t(15;17) x(dd;dd) NE
and xxx NE
17 dd NE
cases xxx NE
tested xxx NE
lacked xxx NE
the xxx NE
promyelocytic/retinoic xxx/xxx RNA_B
acid xxx RNA_M
receptor xxx RNA_M
alpha xxx RNA_M
( ( RNA_E
RAR XXX NE
alpha xxx NE
) ) NE
fusion xxx NE
transcript xxx NE
in xx RNA
RT-PCR XX-XXX NE
assays xxx NE
; ; NE
12 dd NE
cases xxx NE
had xxx NE
46,XX dd,XX NE
karyotype xxx NE
or xx NE
46,XY dd,XX NE
karyotype xxx NE
chromosome xxx NE
17q ddx NE
: : NE
1 d NE
with xxx NE
del(17)(q25) xxx(dd)(xdd) DNA
and xxx NE
the xxx NE
other xxx NE
with xxx NE
t(11;17)(q23;q21) x(dd;dd)(xdd;xdd) DNA
and xxx NE
the xxx NE
promyelocytic xxx NE
leukemia xxx NE
zinc xxx NE
finger xxx NE
/ / NE
RAR XXX NE
alpha xxx NE
fusion xxx NE
transcript xxx NE
. . NE

All Xxx NE
cases xxx NE
tested xxx NE
(6/20) (d/dd) NE
, , NE
including xxx NE
the xxx NE
case xxx NE
with xxx NE
t(11;17) x(dd;dd) DNA
, , NE
failed xxx NE
to xx NE
differentiate xxx NE
in xx NE
vitro xxx NE
in xx NE
response xxx NE
to xx NE
all-trans xxx-xxx NE
retinoic xxx NE
acid xxx NE
( ( NE
ATRA XXXX NE
) ) NE
, , NE
suggesting xxx NE
that xxx NE
these xxx NE
cases xxx NE
may xxx NE
account xxx NE
for xxx NE
some xxx NE
APLs XXXx NE
that xxx NE
have xxx NE
not xxx NE
shown xxx NE
a x NE
clinical xxx NE
response xxx NE
to xx NE
ATRA XXXX NE
. . NE

Four Xxxx NE
of xx NE
6 d NE
cases xxx NE
tested xxx NE
showed xxx NE
functional xxx NE
NK XX NE
cell-mediated xxx-xxx NE
cytotoxicity xxx NE
, , NE
suggesting xxx NE
a x NE
relationship xxx NE
between xxx NE
these xxx NE
unique xxx NE
CD33+ XXdd+ NE
, , NE
CD56+ XXdd+ NE
, , NE
CD16 XXdd NE
-acute -xxx NE
leukemias xxx NE
and xxx NE
normal xxx NE
CD56+ XXdd+ NE
, , NE
CD16- XXdd- NE
NK XX NE
precursor xxx NE
cells xxx NE
. . NE

Using Xxxx NE
a x NE
combination xxx NE
of xx NE
panning xxx NE
and xxx NE
multiparameter xxx NE
flow xxx NE
cytometric xxx NE
sorting xxx NE
, , NE
we xx NE
identified xxx NE
a x NE
normal xxx cell_type_B
CD56+, XXdd+, cell_type_M
CD33+, XXdd+, cell_type_M
CD16- XXdd- cell_type_M
counterpart xxx cell_type_M
cell xxx cell_type_E
at xx NE
a x NE
frequency xxx NE
of xx NE
1% d% NE
to xx NE
2% d% NE
in xx NE
the xxx NE
peripheral xxx NE
blood xxx NE
of xx NE
healthy xxx NE
individuals xxx NE
. . NE

Our Xxx NE
studies xxx NE
suggest xxx NE
that xxx NE
this xxx NE
form xxx NE
of xx NE
acute xxx NE
leukemia xxx NE
may xxx NE
arise xxx NE
from xxx NE
transformation xxx NE
of xx NE
a x NE
precursor xxx NE
cell xxx NE
common xxx NE
to xx NE
both xxx NE
the xxx NE
myeloid xxx cell_type_B
cell xxx cell_type_M
lineage xxx cell_type_M
and xxx cell_type_M
NK XX cell_type_M
cell xxx cell_type_M
lineage xxx cell_type_E
acute xxx NE
leukemia xxx NE
. . NE

Recognition Xxxx NE
of xx NE
this xxx NE
new xxx NE
leukemic xxx NE
entity xxx NE
will xxx NE
be xx NE
important xxx NE
in xx NE
distinguishing xxx NE
these xxx NE
ATRA XXXX NE
-nonresponsive -xxx NE
cases xxx NE
from xxx NE
ATRA XXXX NE
-responsive -xxx NE
true xxx NE
APL XXX NE
. . NE

IL-4 XX-d protein
down-regulates xxx-xxx NE
IL-2 XX-d protein
- - NE
, , NE
IL-3 XX-d protein
- - NE
, , NE
and xxx NE
GM-CSF XX-XXX protein
-induced -xxx NE
cytokine xxx NE
gene xxx NE
expression xxx NE
in xx NE
peripheral xxx NE
blood xxx NE
monocytes xxx NE
. . NE

IL-4 XX-d protein
, , NE
a x NE
product xxx NE
of xx NE
the xxx NE
T-helper X-xxx cell_type_B
0 d cell_type_M
(Th0) (Xxd) cell_type_M
subset xxx cell_type_M
and xxx cell_type_M
T-helper X-xxx cell_type_M
2 d cell_type_M
(Th2) (Xxd) cell_type_M
subset xxx cell_type_E
gene xxx NE
expression xxx NE
in xx NE
monocytes xxx cell_type
stimulated xxx NE
with xxx NE
LPS XXX NE
, , NE
and xxx NE
to xx NE
upregulate xxx NE
IL-1 XX-d NE
receptor xxx NE
antagonist xxx NE
(IL1-RA) (XXd-XX) NE
gene xxx NE
expression xxx NE
. . NE

In Xx NE
this xxx NE
study xxx NE
we xx NE
investigated xxx NE
the xxx NE
effect xxx NE
of xx NE
IL-4 XX-d protein
on xx NE
the xxx NE
expression xxx NE
of xx NE
cytokine xxx DNA_B
genes xxx DNA_E
in xx NE
monocytes xxx cell_type
evoked xxx NE
by xx NE
other xxx NE
T-helper X-xxx protein_B
cell xxx protein_M
cytokines xxx protein_E
: : NE
IL-2 XX-d protein
, , NE
IL-3 XX-d protein
, , NE
and xxx NE
GM-CSF XX-XXX protein
. . NE

IL-4 XX-d NE
down-regulated xxx-xxx NE
mRNA xXXX NE
accumulation xxx NE
of xx NE
the xxx NE
proinflammatory xxx protein_B
cytokines xxx protein_E
IL-1 XX-d protein_B
beta xxx protein_E
, , NE
IL-8 XX-d protein
, , NE
and xxx NE
TNF-alpha XXX-xxx protein
in xx NE
monocytes xxx cell_type
stimulated xxx NE
with xxx NE
IL-2 XX-d protein
, , NE
IL-3 XX-d protein
, , NE
and xxx NE
GM-CSF XX-XXX protein
. . NE

IL-4 XX-d protein
also xxx NE
suppressed xxx NE
the xxx NE
IL-2 XX-d NE
-induced -xxx NE
IL-6 XX-d NE
mRNA xXXX NE
expression xxx NE
. . NE

Temporal Xxxx NE
analysis xxx NE
of xx NE
the xxx NE
IL-4 XX-d NE
down-regulatory xxx-xxx NE
effect xxx NE
on xx NE
the xxx NE
IL-2-induced XX-d-xxx NE
proinflammatory xxx NE
cytokine xxx NE
gene xxx NE
expression xxx NE
or xx NE
IL-3-induced XX-d-xxx NE
proinflammatory xxx NE
cytokine xxx NE
gene xxx NE
expression xxx NE
or xx NE
GM-CSF-induced XX-XXX-xxx NE
proinflammatory xxx NE
cytokine xxx NE
gene xxx NE
expression xxx NE
monocytes xxx NE
provided xxx NE
evidence xxx NE
that xxx NE
IL-4 XX-d protein
acts xxx NE
predominantly xxx NE
on xx NE
the xxx NE
post-transcriptional xxx-xxx NE
level xxx NE
. . NE

This Xxxx NE
was xxx NE
supported xxx NE
by xx NE
the xxx NE
observation xxx NE
that xxx NE
the xxx NE
down-regulatory xxx-xxx NE
capacity xxx NE
of xx NE
IL-4 XX-d protein
appeared xxx NE
to xx NE
be xx NE
dependent xxx NE
on xx NE
de xx NE
novo xxx NE
protein xxx NE
synthesis xxx NE
. . NE

IL-4 XX-d protein
did xxx NE
not xxx NE
exert xxx NE
significant xxx NE
influence xxx NE
on xx NE
the xxx NE
induction xxx NE
of xx NE
expression xxx NE
of xx NE
IL-1-RA XX-d-XX protein
or xx NE
various xxx NE
CSFs XXXx protein
by xx NE
IL-2 XX-d protein
, , NE
IL-3 XX-d protein
, , NE
and xxx NE
GM-CSF XX-XXX protein
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Induction Xxxx NE
of xx NE
proto-oncogene xxx-xxx DNA
and xxx NE
cytokine xxx NE
expression xxx NE
in xx NE
human xxx NE
peripheral xxx NE
blood xxx NE
monocytes xxx cell_type
and xxx NE
the xxx NE
monocytic xxx cell_line_B
cell xxx cell_line_M
line xxx cell_line_E
THP-1 XXX-d cell_line
after xxx NE
stimulation xxx NE
with xxx NE
mycoplasma-derived xxx-xxx NE
material xxx NE
MDHM XXXX NE
. . NE

Mycoplasma Xxxx NE
fermentans-derived xxx-xxx NE
high-molecular-weight xxx-xxx-xxx NE
material xxx NE
( ( NE
MDHM XXXX NE
) ) NE
was xxx NE
originally xxx NE
described xxx NE
to xx NE
induce xxx NE
differentiation xxx NE
of xx NE
murine xxx cell_type_B
thymocytes xxx cell_type_E
to xx NE
cytolytic xxx cell_type_B
effector xxx cell_type_M
T-cells X-xxx cell_type_E
by xx NE
stimulating xxx NE
IL-6 XX-d protein
release xxx NE
from xxx NE
adherent xxx cell_type_B
cells xxx cell_type_E
. . NE

This Xxxx NE
study xxx NE
shows xxx NE
that xxx NE
human xxx NE
peripheral xxx NE
blood xxx NE
monocytes xxx cell_type
( ( NE
PBMo XXXx cell_type
) ) NE
also xxx NE
respond xxx NE
to xx NE
MDHM XXXX NE
with xxx NE
increases xxx NE
in xx NE
IL-1 XX-d protein_B
beta xxx protein_E
, , NE
IL-6 XX-d protein
and xxx NE
TNF XXX NE
alpha xxx NE
expression xxx NE
, , NE
both xxx NE
at xx NE
the xxx NE
mRNA xXXX NE
and xxx NE
protein xxx NE
level xxx NE
. . NE

The Xxx NE
induced xxx NE
expression xxx NE
of xx NE
IL-1 XX-d RNA_B
beta xxx RNA_M
mRNA xXXX RNA_M
and xxx RNA_M
TNF XXX RNA_M
alpha xxx RNA_M
mRNA xXXX RNA_E
in xx NE
the xxx NE
monocytic xxx NE
THP-1 XXX-d cell_line_B
cell xxx cell_line_M
line xxx cell_line_E
increased xxx NE
as xx NE
quickly xxx NE
as xx NE
in xx NE
primary xxx cell_type_B
cells xxx cell_type_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
PBMo XXXx cell_type
, , NE
THP-1 XXX-d cell_line
and xxx NE
14 dd NE
other xxx NE
monocytic/myeloid xxx/xxx cell_line_B
leukemia-derived xxx-xxx cell_line_M
cell xxx cell_line_M
lines xxx cell_line_E
did xxx NE
not xxx NE
secrete xxx NE
measurable xxx NE
amounts xxx NE
of xx NE
the xxx NE
cytokines xxx protein
upon xxx NE
treatment xxx NE
with xxx NE
MDHM XXXX NE
. . NE

IL-1 XX-d DNA_B
beta xxx DNA_M
and xxx DNA_M
IL-6 XX-d DNA_M
genes xxx DNA_E
contain xxx NE
AP-1 XX-d DNA_B
binding xxx DNA_M
sites xxx DNA_E
as xx NE
regulatory xxx DNA_B
elements xxx DNA_E
, , NE
the xxx NE
AP-1 XX-d protein
protein xxx NE
being xxx NE
composed xxx NE
of xx NE
c-jun x-xxx protein_B
gene xxx protein_M
product xxx protein_M
and xxx protein_M
c-fos x-xxx protein_M
gene xxx protein_M
product xxx protein_E

In Xx NE
THP-1 XXX-d cell_line_B
cells xxx cell_line_E
c-jun x-xxx NE
mRNA xXXX NE
expression xxx NE
increased xxx NE
after xxx NE
incubation xxx NE
with xxx NE
MDHM XXXX NE
while xxx NE
positive xxx NE
c-fos x-xxx NE
expression xxx NE
remained xxx NE
unaffected xxx NE
. . NE

Although Xxxx NE
these xxx NE
data xxx NE
suggest xxx NE
AP-1 XX-d protein
regulated xxx NE
cytokine xxx protein
mRNA xXXX NE
expression xxx NE
, , NE
results xxx NE
from xxx NE
PBMo XXXx cell_type
are xxx NE
not xxx NE
in xx NE
accordance xxx NE
with xxx NE
this xxx NE
notion xxx NE
. . NE

In Xx NE
the xxx NE
primary xxx cell_type_B
cells xxx cell_type_E
MDHM XXXX NE
-induced -xxx NE
elevation xxx NE
of xx NE
cytokine xxx NE
mRNA xXXX NE
levels xxx NE
was xxx NE
preceded xxx NE
by xx NE
a x NE
downregulation xxx NE
of xx NE
c-fos x-xxx NE
expression xxx NE
while xxx NE
positive xxx NE
c-jun x-xxx NE
expression xxx NE
was xxx NE
not xxx NE
modulated xxx NE
. . NE

c-myc x-xxx NE
mRNA xXXX NE
expression xxx NE
, , NE
constitutively xxx NE
high xxx NE
in xx NE
THP-1 XXX-d cell_line_B
cells xxx cell_line_E
, , NE
was xxx NE
induced xxx NE
in xx NE
MDHM XXXX NE
-stimulated -xxx NE
PBMo XXXx cell_type
. . NE

In Xx NE
conclusion xxx NE
, , NE
MDHM XXXX NE
-stimulated -xxx NE
induction xxx NE
of xx NE
cytokine xxx RNA_B
mRNA xXXX RNA_E
expression xxx NE
was xxx NE
accompanied xxx NE
by xx NE
different xxx NE
proto-oncogene xxx-xxx DNA
responses xxx NE
in xx NE
PBMo XXXx cell_type
and xxx NE
THP-1 XXX-d cell_line_B
cells xxx cell_line_E
. . NE

These Xxxx NE
differences xxx NE
may xxx NE
represent xxx NE
different xxx NE
regulatory xxx NE
pathways xxx NE
of xx NE
the xxx NE
two xxx NE
cell xxx NE
systems xxx NE
. . NE

Alternatively Xxxx NE
, , NE
these xxx NE
data xxx NE
support xxx NE
the xxx NE
notion xxx NE
that xxx NE
neither xxx NE
AP-1 XX-d protein
nor xxx NE
the xxx NE
c-myc x-xxx protein_B
protein xxx protein_E
are xxx NE
involved xxx NE
in xx NE
the xxx NE
MDHM XXXX NE
-induced -xxx NE
increase xxx NE
in xx NE
IL-1 XX-d NE
beta xxx NE
mRNA xXXX NE
level xxx NE
or xx NE
IL-6 XX-d NE
mRNA xXXX NE
level xxx NE
or xx NE
TNF XXX NE
alpha xxx NE
mRNA xXXX NE
level xxx NE

Furthermore Xxxx NE
, , NE
the xxx NE
present xxx NE
results xxx NE
demonstrate xxx NE
clearly xxx NE
that xxx NE
mycoplasma xxx protein_B
products xxx protein_E
can xxx NE
have xxx NE
a x NE
profound xxx NE
impact xxx NE
on xx NE
the xxx NE
activation xxx NE
status xxx NE
of xx NE
eukaryotic xxx cell_type_B
cells xxx cell_type_E
. . NE

Novel Xxxx protein_B
membrane xxx protein_M
receptors xxx protein_E
for xxx NE
aldosterone xxx NE
in xx NE
human xxx cell_type_B
lymphocytes xxx cell_type_E
: : NE
a x NE
50 dd protein_B
kDa xXx protein_M
protein xxx protein_E
on xx NE
SDS-PAGE XXX-XXXX NE
. . NE

Fast Xxxx NE
in xx NE
vitro xxx NE
effects xxx NE
of xx NE
aldosterone xxx NE
on xx NE
the xxx NE
Na+/H(+)-exchanger Xx+/X(+)-xxx protein
, , NE
inositoltrisphosphate xxx NE
generation xxx NE
and xxx NE
corresponding xxx NE
specific xxx NE
binding xxx NE
to xx NE
plasma xxx NE
membranes xxx NE
at xx NE
Kd-values Xx-xxx NE
of xx NE
approximately xxx NE
0.1 d.d NE
nM xX NE
have xxx NE
been xxx NE
found xxx NE
in xx NE
human xxx cell_type_B
mononuclear xxx cell_type_M
leukocytes xxx cell_type_E
and xxx NE
vascular xxx cell_type_B
smooth xxx cell_type_M
muscle xxx cell_type_M
cells xxx cell_type_E
. . NE

The Xxx NE
novel xxx NE
aldosterone xxx NE
membrane xxx NE
receptor xxx NE
was xxx NE
analyzed xxx NE
on xx NE
SDS-PAGE XXX-XXXX NE
after xxx NE
labeling xxx NE
of xx NE
microsomal xxx NE
membranes xxx NE
from xxx NE
human xxx cell_type_B
mononuclear xxx cell_type_M
leukocytes xxx cell_type_E
with xxx NE
a x NE
[125I]- [dddX]- NE
aldosterone xxx NE
-derivative -xxx NE
by xx NE
use xxx NE
of xx NE
BASED XXXXX NE
as xx NE
a x NE
photoactivatable xxx NE
crosslinker xxx NE
. . NE

Binding Xxxx NE
of xx NE
1 d NE
nM xX NE
[125I]- [dddX]- NE
aldosterone xxx NE
was xxx NE
found xxx NE
at xx NE
a x NE
molecular xxx NE
weight xxx NE
of xx NE
approximately xxx NE
50 dd NE
kDa xXx NE
which xxx NE
was xxx NE
absent xxx NE
with xxx NE
1 d NE
microM xxxX NE
cold xxx NE
aldosterone xxx NE
, , NE
but xxx NE
not xxx NE
cortisol xxx NE
in xx NE
the xxx NE
binding xxx NE
media xxx NE
. . NE

This Xxxx NE
aldosterone xxx NE
-selectivity -xxx NE
is xx NE
typical xxx NE
and xxx NE
discriminatory xxx NE
for xxx NE
the xxx NE
new xxx NE
aldosterone xxx protein_B
membrane xxx protein_M
receptor xxx protein_E
. . NE

Solubilization Xxxx NE
of xx NE
the xxx NE
receptor xxx protein_B
protein xxx protein_E
from xxx NE
membranes xxx NE
by xx NE
high xxx NE
salt xxx NE
concentrations xxx NE
(1 (d NE
M X NE
NaCl XxXx NE
, , NE
1 d NE
mM xX NE
EDTA XXXX NE
) ) NE
was xxx NE
not xxx NE
achieved xxx NE
. . NE

It Xx NE
, , NE
thus xxx NE
, , NE
appears xxx NE
as xx NE
an xx NE
integral xxx protein_B
membrane xxx protein_M
protein xxx protein_E
. . NE

Dithiothreitol Xxxx NE
, , NE
a x NE
sulfhydryl xxx NE
agent xxx NE
, , NE
does xxx NE
not xxx NE
reduce xxx NE
specific xxx NE
aldosterone xxx NE
binding xxx NE
indicating xxx NE
the xxx NE
absence xxx NE
of xx NE
SH-groups XX-xxx protein
in xx NE
the xxx NE
binding xxx protein_B
domain xxx protein_E
or xx NE
sensitive xxx NE
structures xxx NE
of xx NE
the xxx NE
receptors xxx NE
. . NE

The Xxx NE
results xxx NE
are xxx NE
the xxx NE
first xxx NE
to xx NE
characterize xxx NE
the xxx NE
novel xxx protein_B
membrane xxx protein_M
receptor xxx protein_E
for xxx NE
aldosterone xxx NE
with xxx NE
regard xxx NE
to xx NE
molecular xxx NE
weight xxx NE
and xxx NE
basic xxx NE
properties xxx NE
. . NE

These Xxxx NE
findings xxx NE
and xxx NE
other xxx NE
related xxx NE
results xxx NE
are xxx NE
reviewed xxx NE
here xxx NE
. . NE

A X NE
transcriptional xxx DNA_B
regulatory xxx DNA_M
element xxx DNA_E
is xx NE
associated xxx NE
with xxx NE
a x NE
nuclease-hypersensitive xxx-xxx DNA_B
site xxx DNA_E
in xx NE
the xxx NE
pol xxx DNA_B
gene xxx DNA_E
of xx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
. . NE

Analysis Xxxx NE
of xx NE
the xxx NE
chromatin xxx NE
organization xxx NE
of xx NE
the xxx NE
integrated xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
( ( NE
HIV-1 XXX-d NE
) ) NE
genome xxx NE
has xxx NE
previously xxx NE
revealed xxx NE
a x NE
major xxx NE
constitutive xxx NE
DNase XXxxx NE
I-hypersensitive X-xxx NE
site xxx NE
associated xxx NE
with xxx NE
the xxx NE
pol xxx NE
gene xxx NE
(E (X NE
. . NE
Verdin Xxxx NE
, , NE
J X NE
. . NE
Virol Xxxx NE
. . NE
65:6790-6799 dd:dddd-dddd NE
, , NE
1991) dddd) NE
. . NE

In Xx NE
the xxx NE
present xxx NE
report xxx NE
, , NE
high-resolution xxx-xxx NE
mapping xxx NE
of xx NE
this xxx NE
site xxx NE
with xxx NE
DNase XXxxx protein_B
I X protein_E
and xxx NE
micrococcal xxx protein_B
nuclease xxx protein_E
identified xxx NE
a x NE
nucleosome-free xxx-xxx DNA_B
region xxx DNA_E
centered xxx NE
around xxx NE
nucleotides xxx DNA_B
(nt) (xx) DNA_M
4490 dddd DNA_M
to xx DNA_M
4766 dddd DNA_E
. . NE

A X NE
500-bp ddd-xx DNA_B
fragment xxx DNA_E
encompassing xxx NE
this xxx NE
hypersensitive xxx DNA_B
site xxx DNA_E
( ( NE
nt xx DNA_B
4481 dddd DNA_M
to xx DNA_M
4982 dddd DNA_E
) ) NE
exhibited xxx NE
transcription-enhancing xxx-xxx NE
activity xxx NE
(two- (xxx- NE
to xx NE
threefold) xxx) NE
when xxx NE
it xx NE
was xxx NE
cloned xxx NE
in xx NE
its xxx NE
natural xxx NE
position xxx NE
with xxx NE
respect xxx NE
to xx NE
the xxx NE
HIV-1 XXX-d DNA_B
promoter xxx DNA_E
after xxx NE
transient xxx NE
transfection xxx NE
in xx NE
U937 Xddd cell_line
and xxx NE
CEM XXX cell_line_B
cells xxx cell_line_E
. . NE

Using Xxxx NE
in xx NE
vitro xxx NE
footprinting xxx NE
and xxx NE
gel xxx NE
shift xxx NE
assays xxx NE
, , NE
we xx NE
have xxx NE
identified xxx NE
four xxx NE
distinct xxx NE
binding xxx DNA_B
sites xxx DNA_E
for xxx NE
nuclear xxx protein_B
proteins xxx protein_E
within xxx NE
this xxx NE
positive xxx DNA_B
regulatory xxx DNA_M
element xxx DNA_E
. . NE

Site Xxxx DNA_B
B X DNA_E
( ( NE
nt xx DNA_B
4519 dddd DNA_M
to xx DNA_M
4545 dddd DNA_E
) ) NE
specifically xxx NE
bound xxx NE
four xxx NE
distinct xxx NE
nuclear xxx NE
protein xxx NE
complexes xxx NE
: : NE
a x NE
ubiquitous xxx NE
factor xxx NE
, , NE
a x NE
T-cell-specific X-xxx-xxx NE
factor xxx NE
, , NE
a x NE
B-cell-specific X-xxx-xxx NE
factor xxx NE
, , NE
and xxx NE
the xxx NE
monocyte/macrophage- xxx/xxx- NE
and xxx NE
B-cell-specific X-xxx-xxx NE
transcription xxx NE
factor xxx NE
PU.1/Spi-1 XX.d/Xxx-d NE
. . NE

In Xx NE
most xxx NE
HIV-1 XXX-d NE
isolates xxx NE
in xx NE
which xxx NE
this xxx NE
PU XX DNA_B
box xxx DNA_E
was xxx NE
not xxx NE
conserved xxx NE
, , NE
it xx NE
was xxx NE
replaced xxx NE
by xx NE
a x NE
binding xxx DNA_B
site xxx DNA_E
for xxx NE
the xxx NE
related xxx NE
factor xxx NE
Ets1 Xxxd protein
. . NE

Factors Xxxx NE
binding xxx NE
to xx NE
site xxx DNA_B
C X DNA_E
( ( NE
nt xx DNA_B
4681 dddd DNA_M
to xx DNA_M
4701 dddd DNA_E
) ) NE
had xxx NE
a x NE
DNA-binding XXX-xxx NE
specificity xxx NE
similar xxx NE
to xx NE
that xxx NE
of xx NE
factors xxx NE
binding xxx NE
to xx NE
site xxx DNA_B
B X DNA_E
, , NE
except xxx NE
for xxx NE
PU.1/Spi-1 XX.d/Xxx-d protein
. . NE

A X NE
GC XX DNA_B
box xxx DNA_E
containing xxx NE
a x NE
binding xxx DNA_B
site xxx DNA_E
for xxx NE
Sp1 Xxd protein
was xxx NE
identified xxx NE
( ( NE
nt xx DNA_B
4623 dddd DNA_M
to xx DNA_M
4631 dddd DNA_E
) ) NE
. . NE

Site Xxxx DNA_B
D X DNA_E
( ( NE
nt xx DNA_B
4816 dddd DNA_M
to xx DNA_M
4851 dddd DNA_E
) ) NE
specifically xxx NE
bound xxx NE
a x NE
ubiquitously xxx protein_B
expressed xxx protein_M
factor xxx protein_E
. . NE

These Xxxx NE
results xxx NE
identify xxx NE
a x NE
transcriptional xxx DNA_B
regulatory xxx DNA_M
element xxx DNA_E
associated xxx NE
with xxx NE
a x NE
nuclease- xxx- NE
hypersensitive xxx NE
site xxx NE
in xx NE
the xxx NE
pol xxx NE
gene xxx NE
of xx NE
HIV-1 XXX-d NE
and xxx NE
suggest xxx NE
that xxx NE
its xxx NE
activity xxx NE
may xxx NE
be xx NE
controlled xxx NE
by xx NE
a x NE
complex xxx NE
interplay xxx NE
of xx NE
cis- xxx- NE
regulatory xxx NE
elements xxx NE
. . NE

Expression Xxxx NE
of xx NE
v-src x-xxx DNA
in xx NE
T X cell_type_B
cells xxx cell_type_E
correlates xxx NE
with xxx NE
nuclear xxx NE
expression xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
. . NE

NF-kappa XX-xxx protein_B
B X protein_E
is xx NE
a x NE
rapidly xxx NE
inducible xxx NE
transcriptional xxx DNA_B
activator xxx DNA_E
that xxx NE
responds xxx NE
to xx NE
a x NE
variety xxx NE
of xx NE
signals xxx NE
and xxx NE
influences xxx NE
the xxx NE
expression xxx NE
of xx NE
many xxx NE
genes xxx NE
involved xxx NE
in xx NE
the xxx NE
immune xxx NE
response xxx NE
. . NE

Protein Xxxx NE
tyrosine xxx protein_B
kinases xxx protein_E
transmit xxx NE
signals xxx NE
from xxx NE
cytokine xxx protein_B
receptor xxx protein_M
and xxx protein_M
immune xxx protein_M
receptor xxx protein_E

Very Xxxx NE
little xxx NE
information xxx NE
exists xxx NE
linking xxx NE
these xxx NE
two xxx NE
important xxx NE
classes xxx NE
of xx NE
signaling xxx protein_B
molecules xxx protein_E
. . NE

We Xx NE
now xxx NE
demonstrate xxx NE
that xxx NE
v-src x-xxx NE
expression xxx NE
correlates xxx NE
with xxx NE
nuclear xxx NE
expression xxx NE
of xx NE
a x NE
kappa xxx protein_B
B X protein_M
binding xxx protein_M
complex xxx protein_E
similar xxx NE
to xx NE
that xxx NE
induced xxx NE
by xx NE
phorbol xxx NE
ester xxx NE
and xxx NE
ionomycin xxx NE
, , NE
as xx NE
detected xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
using xxx NE
a x NE
variety xxx NE
of xx NE
kappa xxx DNA_B
B X DNA_M
sites xxx DNA_E
. . NE

This Xxxx NE
complex xxx NE
was xxx NE
blocked xxx NE
by xx NE
the xxx NE
tyrosine xxx protein_B
kinase xxx protein_E
inhibitor xxx NE
, , NE
herbimycin xxx NE
A X NE
. . NE

The Xxx NE
v-src x-xxx protein
-induced -xxx NE
complex xxx NE
comprised xxx NE
the xxx NE
p50 xdd protein
and xxx NE
p65 xdd protein
components xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
, , NE
as xx NE
determined xxx NE
by xx NE
supershift xxx NE
analysis xxx NE
and xxx NE
immunoblot xxx NE
analysis xxx NE

As Xx NE
a x NE
functional xxx NE
correlate xxx NE
of xx NE
this xxx NE
finding xxx NE
, , NE
transient xxx NE
co-transfection xx-xxx NE
of xx NE
HIV-1 XXX-d DNA_B
LTR XXX DNA_M
reporter xxx DNA_M
constructs xxx DNA_E
in xx NE
a x NE
different xxx NE
T X cell_line_B
cell xxx cell_line_M
line xxx cell_line_E
demonstrated xxx NE
that xxx NE
v-src x-xxx DNA
activated xxx NE
this xxx NE
promoter xxx protein
in xx NE
a x NE
kappa xxx NE
B-dependent X-xxx NE
manner xxx NE
. . NE

We Xx NE
found xxx NE
that xxx NE
transactivation xxx NE
of xx NE
the xxx NE
HIV-1 XXX-d DNA_B
LTR XXX DNA_E
by xx NE
v-src x-xxx DNA
was xxx NE
more xxx NE
sensitive xxx NE
to xx NE
mutations xxx NE
of xx NE
the xxx NE
proximal xxx NE
, , NE
rather xxx NE
than xxx NE
the xxx NE
distal xxx NE
, , NE
kappa xxx DNA_B
B X DNA_M
element xxx DNA_E
. . NE

The Xxx NE
implications xxx NE
for xxx NE
T X NE
cell xxx NE
receptor xxx NE
signaling xxx NE
and xxx NE
HIV-1 XXX-d NE
gene xxx NE
expression xxx NE
are xxx NE
considered xxx NE
. . NE

trans-activation xxx-xxx NE
of xx NE
the xxx NE
HIV XXX DNA_B
promoter xxx DNA_E
by xx NE
a x NE
cDNA xXXX NE
and xxx NE
its xxx NE
genomic xxx NE
clones xxx NE
of xx NE
human xxx NE
herpesvirus-6 xxx-d NE
. . NE

Human Xxxx NE
herpesvirus xxx NE
6 d NE
( ( NE
HHV-6 XXX-d NE
) ) NE
is xx NE
a x NE
lymphotropic xxx NE
herpesvirus xxx NE
, , NE
and xxx NE
in xx NE
vitro xxx NE
, , NE
it xx NE
can xxx NE
productively xxx NE
infect xxx NE
human xxx NE
CD4+ XXd+ cell_line_B
T X cell_line_M
cells xxx cell_line_E
as xx NE
HIV-1 XXX-d NE
. . NE

Co-infection Xx-xxx NE
of xx NE
T X cell_type_B
cells xxx cell_type_E
by xx NE
HIV-1 XXX-d NE
and xxx NE
HHV-6 XXX-d NE
can xxx NE
lead xxx NE
to xx NE
both xxx NE
activation xxx NE
of xx NE
the xxx NE
HIV-1 XXX-d DNA_B
promoter xxx DNA_E
and xxx NE
acceleration xxx NE
of xx NE
the xxx NE
cytopathic xxx NE
effects xxx NE
. . NE

An Xx NE
HHV-6 XXX-d DNA_B
(GS) (XX) DNA_M
cDNA xXXX DNA_M
clone xxx DNA_E
, , NE
pCD41 xXXdd DNA
, , NE
encoding xxx NE
for xxx NE
a x NE
41-kDa dd-xXx protein_B
nuclear xxx protein_M
protein xxx protein_E
was xxx NE
identified xxx NE
and xxx NE
characterized xxx NE
previously xxx NE
(Chang (Xxxx NE
and xxx NE
Balachandran Xxxx NE
, , NE
J X NE
. . NE
Virol Xxxx NE
. . NE
65 dd NE
, , NE
2884-2894 dddd-dddd NE
and xxx NE
7085 dddd NE
, , NE
1991) dddd) NE
. . NE

Sequence Xxxx NE
analyses xxx NE
show xxx NE
that xxx NE
this xxx NE
protein xxx NE
has xxx NE
significant xxx NE
homology xxx NE
with xxx NE
the xxx NE
human xxx DNA_B
cytomegalovirus xxx DNA_M
UL44 XXdd DNA_M
gene xxx DNA_E
coding xxx NE
for xxx NE
the xxx NE
ICP36 XXXdd protein_B
family xxx protein_E
of xx NE
early-late-class xxx-xxx-xxx protein_B
phosphoprotein xxx protein_E
. . NE

Using Xxxx NE
this xxx NE
cDNA xXXX DNA
as xx NE
the xxx NE
probe xxx NE
, , NE
a x NE
3.8-kb d.d-xx DNA_B
EcoRI XxxXX DNA_M
genomic xxx DNA_M
fragment xxx DNA_E
encoding xxx NE
the xxx NE
HHV-6 XXX-d NE
(GS)P41 (XX)Xdd NE
was xxx NE
cloned xxx NE
and xxx NE
designated xxx NE
as xx NE
pGD41 xXXdd NE
. . NE

When Xxxx NE
cotransfected xxx NE
with xxx NE
the xxx NE
HIV XXX DNA_B
LTR XXX DNA_M
CAT XXX DNA_E
into xxx NE
CV-1 XX-d cell_line_B
cells xxx cell_line_E
, , NE
both xxx NE
the xxx NE
pCD41 xXXdd DNA
and xxx NE
pGD41 xXXdd DNA
clones xxx NE
trans-activated xxx-xxx NE
the xxx NE
HIV XXX DNA_B
LTR XXX DNA_E
. . NE

Sequence Xxxx NE
analyses xxx NE
of xx NE
pCD41 xXXdd DNA
indicate xxx NE
that xxx NE
there xxx NE
are xxx NE
two xxx NE
potential xxx NE
open xxx DNA_B
reading xxx DNA_M
frames xxx DNA_E
( ( NE
ORFs XXXx DNA
) ) NE
, , NE
A X DNA
and xxx NE
B X DNA
, , NE
which xxx NE
are xxx NE
homologous xxx NE
to xx NE
the xxx NE
ORFs XXXx DNA
found xxx NE
in xx NE
the xxx NE
genomic xxx NE
clone xxx NE
pGD41 xXXdd DNA
. . NE

Deletion Xxxx NE
constructs xxx NE
of xx NE
the xxx NE
pCD41 xXXdd DNA_B
clone xxx DNA_E
demonstrated xxx NE
that xxx NE
ORF-A XXX-X protein
was xxx NE
critical xxx NE
for xxx NE
the xxx NE
HIV XXX DNA_B
LTR XXX DNA_E
activation xxx NE
. . NE

Deletion Xxxx NE
analyses xxx NE
of xx NE
the xxx NE
pCD41 xXXdd DNA
ORF-A XXX-X protein
and xxx NE
the xxx NE
use xxx NE
of xx NE
promoter xxx DNA_B
constructs xxx DNA_E
further xxx NE
mapped xxx NE
an xx NE
internal xxx NE
functional xxx NE
promoter xxx NE
within xxx NE
the xxx NE
pCD41 xXXdd DNA
sequence xxx NE
that xxx NE
can xxx NE
direct xxx NE
the xxx NE
synthesis xxx NE
of xx NE
the xxx NE
trans-activating xxx-xxx protein_B
protein xxx protein_E
. . NE

By Xx NE
using xxx NE
HIV XXX DNA_B
LTR XXX DNA_M
deletion xxx DNA_M
mutants xxx DNA_E
, , NE
the xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
binding xxx DNA_B
sites xxx DNA_E
were xxx NE
found xxx NE
to xx NE
be xx NE
critical xxx NE
for xxx NE
response xxx NE
to xx NE
the xxx NE
pCD41 xXXdd NE
trans-activation xxx-xxx NE
. . NE

CD14 XXdd NE
-mediated -xxx NE
translocation xxx NE
of xx NE
nuclear xxx NE
factor-kappa xxx-xxx NE
B X NE
induced xxx NE
by xx NE
lipopolysaccharide xxx NE
does xxx NE
not xxx NE
require xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
. . NE

During Xxxx NE
the xxx NE
course xxx NE
of xx NE
serious xxx NE
bacterial xxx NE
infections xxx NE
, , NE
lipopolysaccharide xxx NE
( ( NE
LPS XXX NE
) ) NE
is xx NE
believed xxx NE
to xx NE
interact xxx NE
with xxx NE
macrophage xxx protein_B
receptors xxx protein_E
, , NE
resulting xxx NE
in xx NE
the xxx NE
generation xxx NE
of xx NE
inflammatory xxx NE
mediators xxx NE
and xxx NE
systemic xxx NE
symptoms xxx NE
including xxx NE
hemodynamic xxx NE
instability xxx NE
and xxx NE
shock xxx NE
. . NE

CD14 XXdd protein
, , NE
a x NE
glycosylphosphatidylinositol-linked xxx-xxx protein_B
antigen xxx protein_E
, , NE
functions xxx NE
as xx NE
an xx NE
LPS XXX protein_B
signaling xxx protein_M
receptor xxx protein_E
. . NE

A X NE
critical xxx NE
issue xxx NE
concerns xxx NE
the xxx NE
mechanism xxx NE
by xx NE
which xxx NE
CD14 XXdd protein
, , NE
which xxx NE
has xxx NE
no xx NE
transmembrane xxx protein_B
domain xxx protein_E
, , NE
transduces xxx NE
its xxx NE
signal xxx NE
following xxx NE
LPS XXX NE
binding xxx NE
. . NE

Recently Xxxx NE
, , NE
investigators xxx NE
have xxx NE
hypothesized xxx NE
that xxx NE
CD14 XXdd NE
-mediated -xxx NE
signaling xxx NE
is xx NE
effected xxx NE
through xxx NE
a x NE
receptor-associated xxx-xxx NE
tyrosine xxx NE
kinase xxx NE
(TK) (XX) NE
, , NE
suggesting xxx NE
a x NE
multicomponent xxx NE
receptor xxx NE
model xxx NE
of xx NE
LPS XXX NE
signaling xxx NE
. . NE

Wild-type Xxxx-xxx NE
Chinese Xxxx cell_line_B
hamster xxx cell_line_M
ovary xxx cell_line_M
(CHO)-K1 (XXX)-Xd cell_line_M
cells xxx cell_line_E
can xxx NE
be xx NE
activated xxx NE
by xx NE
endotoxin xxx NE
to xx NE
release xxx NE
arachidonate xxx NE
following xxx NE
transfection xxx NE
with xxx NE
human xxx NE
CD14 XXdd protein
( ( NE
CHO XXX NE
/ / NE
CD14 XXdd NE
) ) NE
. . NE

Nuclear Xxxx NE
translocation xxx NE
of xx NE
cytosolic xxx NE
NF-kappa XX-xxx NE
B X NE
is xx NE
correlated xxx NE
with xxx NE
a x NE
number xxx NE
of xx NE
LPS XXX NE
-inducible -xxx NE
responses xxx NE
. . NE

We Xx NE
sought xxx NE
to xx NE
determine xxx NE
if xx NE
this xxx NE
pathway xxx NE
were xxx NE
present xxx NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
and xxx NE
to xx NE
elucidate xxx NE
the xxx NE
relationship xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
to xx NE
the xxx NE
CD14 XXdd NE
receptor xxx NE
system xxx NE
. . NE

LPS XXX NE
-stimulated -xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd NE
cells xxx NE
resembled xxx NE
the xxx NE
same xxx NE
response xxx NE
in xx NE
the xxx NE
murine xxx NE
macrophage-like xxx-xxx NE
cell xxx NE
line xxx NE
RAW XXX NE
264.7 ddd.d NE
. . NE

Protein Xxxx NE
synthesis xxx NE
inhibitors xxx NE
and xxx NE
corticosteroids xxx NE
, , NE
which xxx NE
suppress xxx NE
arachidonate xxx NE
release xxx NE
and xxx NE
the xxx NE
synthesis xxx NE
of xx NE
proinflammatory xxx protein_B
cytokines xxx protein_E
, , NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
in xx NE
CHO XXX NE
/ / NE
CD14 XXdd protein
or xx NE
RAW XXX cell_line_B
264.7 ddd.d cell_line_M
cells xxx cell_line_E
, , NE
demonstrating xxx NE
that xxx NE
NF-kappa XX-xxx NE
B X NE
translocation xxx NE
is xx NE
an xx NE
early xxx NE
event xxx NE
. . NE

Although Xxxx NE
TK XX NE
activity xxx NE
was xxx NE
consistently xxx NE
observed xxx NE
by xx NE
immunoblotting xxx NE
extracts xxx NE
from xxx NE
activated xxx NE
RAW XXX cell_line_B
264.7 ddd.d cell_line_M
cells xxx cell_line_E
, , NE
LPS-induced XXX-xxx NE
phosphotyrosine xxx NE
residues xxx NE
were xxx NE
not xxx NE
observed xxx NE
from xxx NE
similarly xxx NE
treated xxx NE
CHO/CD14 XXX/XXdd cell_line_B
cells xxx cell_line_E
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
TK XX NE
inhibitors xxx NE
herbimycin xxx NE
A X NE
and xxx NE
genistein xxx NE
failed xxx NE
to xx NE
inhibit xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
in xx NE
CHO/CD14 XXX/XXdd NE
or xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
, , NE
although xxx NE
both xxx NE
of xx NE
these xxx NE
agents xxx NE
inhibited xxx NE
LPS XXX NE
-induced -xxx NE
TK XX NE
activity xxx NE
in xx NE
RAW XXX NE
264.7 ddd.d NE
cells xxx NE
. . NE

These Xxxx NE
results xxx NE
imply xxx NE
that xxx NE
TK XX NE
activity xxx NE
is xx NE
not xxx NE
obligatory xxx NE
for xxx NE
CD14 XXdd NE
-mediated -xxx NE
signal xxx NE
transduction xxx NE
to xx NE
occur xxx NE
in xx NE
response xxx NE
to xx NE
LPS XXX NE
. . NE

Signals Xxxx NE
transduced xxx NE
through xxx NE
the xxx NE
CD4 XXd protein_B
molecule xxx protein_E
on xx NE
T X cell_type_B
lymphocytes xxx cell_type_E
activate xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
. . NE

We Xx NE
have xxx NE
demonstrated xxx NE
that xxx NE
native xxx protein_B
envelope xxx protein_M
glycoproteins xxx protein_E
of xx NE
HIV-1 XXX-d NE
, , NE
gp160 xxddd NE
can xxx NE
induce xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx protein_B
factor xxx protein_E
, , NE
NF-kappa XX-xxx protein_B
B X protein_E
. . NE

The Xxx NE
stimulatory xxx NE
effects xxx NE
of xx NE
gp160 xxddd NE
are xxx NE
mediated xxx NE
through xxx NE
the xxx NE
CD4 XXd protein_B
molecule xxx protein_E
, , NE
since xxx NE
pretreatment xxx NE
with xxx NE
soluble xxx NE
CD4 XXd protein
abrogates xxx NE
its xxx NE
activity xxx NE
. . NE

The Xxx NE
gp160 xxddd NE
-induced -xxx NE
NF-kappa XX-xxx NE
B X NE
complex xxx NE
consists xxx NE
of xx NE
p65 xdd NE
, , NE
p50 xdd NE
and xxx NE
c-rel x-xxx NE
proteins xxx NE
. . NE

The Xxx NE
stimulatory xxx NE
effect xxx NE
of xx NE
gp160 xxddd NE
on xx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
is xx NE
protein xxx NE
synthesis xxx NE
independent xxx NE
, , NE
is xx NE
dependent xxx NE
upon xxx NE
protein xxx NE
tyrosine xxx NE
phosphorylation xxx NE
, , NE
and xxx NE
abrogated xxx NE
by xx NE
inhibitors xxx NE
of xx NE
protein xxx protein_B
kinase xxx protein_M
C X protein_E
. . NE

The Xxx NE
gp160 xxddd NE
-mediated -xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
in xx NE
CD4 XXd NE
positive xxx NE
T X NE
cells xxx NE
may xxx NE
be xx NE
involved xxx NE
in xx NE
biological xxx NE
effects xxx NE
, , NE
e.g. x.x. NE
, , NE
enhanced xxx NE
HIV XXX NE
replication xxx NE
, , NE
hypergammaglobulinemia xxx NE
, , NE
increased xxx NE
cytokine xxx NE
secretion xxx NE
, , NE
hypercellularity xxx NE
in xx NE
bone xxx NE
marrow xxx NE
and xxx NE
apoptosis xxx NE
. . NE

No Xx NE
evidence xxx NE
for xxx NE
the xxx NE
expression xxx NE
of xx NE
the xxx NE
progesterone xxx protein_B
receptor xxx protein_E
on xx NE
peripheral xxx cell_type_B
blood xxx cell_type_M
lymphocytes xxx cell_type_E
during xxx NE
pregnancy xxx NE
[see [xxx NE
comments] xxx] NE

The Xxx NE
expression xxx NE
of xx NE
the xxx NE
progesterone xxx protein_B
receptor xxx protein_E
in xx NE
human xxx cell_type_B
peripheral xxx cell_type_M
blood xxx cell_type_M
lymphocytes xxx cell_type_E
was xxx NE
analysed xxx NE
, , NE
using xxx NE
an xx NE
enzyme xxx NE
linked xxx NE
immunosorbent xxx NE
assay xxx NE
( ( NE
Abbott Xxxx NE
PgR-EIA XxX-XXX NE
monoclonal xxx NE
) ) NE
, , NE
in xx NE
order xxx NE
to xx NE
evaluate xxx NE
its xxx NE
prognostic xxx NE
character xxx NE
in xx NE
the xxx NE
context xxx NE
of xx NE
spontaneous xxx NE
abortion xxx NE
. . NE

Cytosols Xxxx NE
were xxx NE
prepared xxx NE
from xxx NE
lymphocytes xxx NE
of xx NE
24 dd NE
healthy xxx NE
pregnant xxx NE
women xxx NE
(11 (dd NE
first xxx NE
, , NE
10 dd NE
second xxx NE
and xxx NE
three xxx NE
third xxx NE
trimester) xxx) NE
, , NE
seven xxx NE
healthy xxx NE
non-pregnant xxx-xxx NE
women xxx NE
, , NE
nine xxx NE
women xxx NE
with xxx NE
recurrent xxx NE
spontaneous xxx NE
abortion xxx NE
, , NE
and xxx NE
six xxx NE
healthy xxx NE
men xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
a x NE
human xxx cell_line_B
breast xxx cell_line_M
carcinoma xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
( ( NE
ZR-75-1 XX-dd-d cell_line
) ) NE
, , NE
which xxx NE
expresses xxx NE
the xxx NE
progesterone xxx protein_B
receptor xxx protein_E
, , NE
was xxx NE
analysed xxx NE
throughout xxx NE
. . NE

The Xxx NE
ZR-75-1 XX-dd-d cell_line_B
cell xxx cell_line_M
line xxx cell_line_E
showed xxx NE
an xx NE
expression xxx NE
of xx NE
642 ddd NE
fmol/mg xxx/xx NE
whereas xxx NE
lymphocytes xxx NE
of xx NE
pregnant xxx NE
women xxx NE
showed xxx NE
an xx NE
expression xxx NE
< < NE
or xx NE
= = NE
4 d NE
fmol/mg xxx/xx NE
. . NE

Lymphocytes Xxxx cell_type
of xx NE
non-pregnant xxx-xxx NE
women xxx NE
, , NE
women xxx NE
with xxx NE
threatened xxx NE
pre-term xxx-xxx NE
delivery xxx NE
, , NE
and xxx NE
men xxx NE
showed xxx NE
equivalent xxx NE
levels xxx NE
: : NE
3 d NE
+/- +/- NE
1 d NE
, , NE
3 d NE
+/- +/- NE
2 d NE
and xxx NE
5 d NE
+/- +/- NE
4 d NE
fmol/mg xxx/xx NE
respectively xxx NE
. . NE

These Xxxx NE
results xxx NE
show xxx NE
that xxx NE
there xxx NE
is xx NE
no xx NE
evidence xxx NE
of xx NE
specific xxx NE
expression xxx NE
of xx NE
the xxx NE
progesterone xxx protein_B
receptor xxx protein_E
in xx NE
pregnancy xxx NE
and xxx NE
exclude xxx NE
any xxx NE
prognostic xxx NE
character xxx NE
in xx NE
spontaneous xxx NE
abortion xxx NE
. . NE

A X NE
role xxx NE
for xxx NE
the xxx NE
progesterone xxx protein_B
receptor xxx protein_E
in xx NE
the xxx NE
mechanism xxx NE
of xx NE
the xxx NE
known xxx NE
effect xxx NE
of xx NE
progesterone xxx NE
on xx NE
peripheral xxx cell_type_B
blood xxx cell_type_M
lymphocytes xxx cell_type_E
is xx NE
also xxx NE
excluded xxx NE
. . NE

Tolerance Xxxx NE
to xx NE
lipopolysaccharide xxx NE
involves xxx NE
mobilization xxx NE
of xx NE
nuclear xxx protein_B
factor xxx protein_M
kappa xxx protein_M
B X protein_E
with xxx NE
predominance xxx NE
of xx NE
p50 xdd protein
homodimers xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
the xxx NE
human xxx cell_line_B
monocytic xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
Mono Xxxx cell_line_B
Mac Xxx cell_line_M
6 d cell_line_E
with xxx NE
lipopolysaccharide xxx NE
( ( NE
LPS XXX NE
) ) NE
leads xxx NE
to xx NE
rapid xxx NE
and xxx NE
transient xxx NE
expression xxx NE
of xx NE
cytokines xxx protein
like xxx NE
tumor xxx protein_B
necrosis xxx protein_M
factor xxx protein_E
( ( NE
TNF XXX protein
) ) NE
. . NE

When Xxxx NE
such xxx NE
cells xxx NE
are xxx NE
precultured xxx NE
for xxx NE
2 d NE
days xxx NE
with xxx NE
a x NE
low xxx NE
dose xxx NE
of xx NE
LPS XXX NE
(20 (dd NE
ng/ml) xx/xx) NE
followed xxx NE
by xx NE
stimulation xxx NE
with xxx NE
a x NE
high xxx NE
dose xxx NE
of xx NE
LPS XXX NE
(1 (d NE
microgram/ml) xxx/xx) NE
, , NE
expression xxx NE
of xx NE
the xxx NE
TNF XXX DNA_B
gene xxx DNA_E
is xx NE
minimal xxx NE
, , NE
i.e x.x NE
. . NE
the xxx NE
cells xxx NE
are xxx NE
tolerant xxx NE
. . NE

In Xx NE
nuclear xxx NE
run-on xxx-xx NE
analysis xxx NE
, , NE
such xxx NE
tolerant xxx cell_type_B
cells xxx cell_type_E
show xxx NE
only xxx NE
a x NE
low xxx NE
degree xxx NE
of xx NE
transcription xxx NE
, , NE
indicating xxx NE
that xxx NE
tolerance xxx NE
operates xxx NE
at xx NE
or xx NE
upstream xxx NE
of xx NE
the xxx NE
transcription xxx NE
level xxx NE
. . NE

The Xxx NE
CD14 XXdd protein
LPS XXX NE
receptor xxx NE
is xx NE
, , NE
however xxx NE
, , NE
up-regulated xx-xxx NE
(not (xxx NE
down-regulated) xxx-xxx) NE
in xx NE
tolerant xxx cell_line_B
cells xxx cell_line_E
, , NE
and xxx NE
LPS XXX NE
can xxx NE
, , NE
in xx NE
fact xxx NE
, , NE
still xxx NE
lead xxx NE
to xx NE
activation xxx NE
of xx NE
tolerant xxx cell_line_B
cells xxx cell_line_E
as xx NE
evidenced xxx NE
by xx NE
mobilization xxx NE
of xx NE
the xxx NE
transcription xxx protein_B
factor xxx protein_E
nuclear xxx protein_B
factor xxx protein_M
kappa xxx protein_M
B X protein_E
( ( NE
NF-kappa XX-xxx protein_B
B X protein_E
) ) NE
. . NE

Resolution Xxxx NE
of xx NE
the xxx NE
NF-kappa XX-xxx protein_B
B X protein_M
complex xxx protein_E
in xx NE
gel xxx NE
shift xxx NE
analysis xxx NE
shows xxx NE
that xxx NE
the xxx NE
binding xxx protein_B
protein xxx protein_E
, , NE
mobilized xxx NE
in xx NE
naive xxx cell_line_B
Mono Xxxx cell_line_M
Mac Xxx cell_line_M
6 d cell_line_M
cells xxx cell_line_E
, , NE
consists xxx NE
mainly xxx NE
of xx NE
p50 xdd NE
-p65 -xdd NE
heterodimers xxx NE
, , NE
while xxx NE
in xx NE
tolerant xxx NE
cells xxx NE
, , NE
the xxx NE
p50 xdd NE
homodimer xxx NE
is xx NE
predominant xxx NE
. . NE

This Xxxx NE
increase xxx NE
in xx NE
p50 xdd protein_B
homodimers xxx protein_E
coincides xxx NE
with xxx NE
an xx NE
increase xxx NE
in xx NE
p105 xddd RNA_B
mRNA xXXX RNA_E
, , NE
suggestive xxx NE
of xx NE
a x NE
transcriptional xxx NE
up-regulation xx-xxx NE
of xx NE
p50 xdd protein
. . NE

Reporter Xxxx NE
gene xxx NE
analysis xxx NE
reveals xxx NE
that xxx NE
the xxx NE
NF-kappa XX-xxx protein_B
B X protein_M
complex xxx protein_E
mobilized xxx NE
in xx NE
tolerant xxx cell_line_B
cells xxx cell_line_E
is xx NE
functionally xxx NE
inactive xxx NE
in xx NE
that xxx NE
NF-kappa XX-xxx NE
B X NE
-dependent -xxx NE
luciferase xxx NE
constructs xxx NE
containing xxx NE
the xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
long xxx NE
terminal xxx NE
repeat xxx NE
or xx NE
the xxx NE
TNF XXX NE
5'-region d'-xxx NE
show xxx NE
only xxx NE
minimal xxx NE
transactivation xxx NE
after xxx NE
LPS XXX NE
stimulation xxx NE
. . NE

Similar Xxxx NE
to xx NE
Mono Xxxx cell_line_B
Mac Xxx cell_line_M
6 d cell_line_M
cells xxx cell_line_E
, , NE
primary xxx cell_type_B
blood xxx cell_type_M
monocytes xxx cell_type_E
, , NE
when xxx NE
precultured xxx NE
with xxx NE
a x NE
low xxx NE
dose xxx NE
of xx NE
LPS XXX NE
, , NE
also xxx NE
become xxx NE
tolerant xxx NE
and xxx NE
produce xxx NE
little xxx NE
TNF XXX protein
after xxx NE
LPS XXX NE
stimulation xxx NE
. . NE

The Xxx NE
tolerant xxx cell_type_B
blood xxx cell_type_M
monocytes xxx cell_type_E
also xxx NE
up-regulate xx-xxx NE
CD14 XXdd protein
, , NE
and xxx NE
they xxx NE
mobilize xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
with xxx NE
a x NE
predominance xxx NE
of xx NE
p50 xdd protein_B
homodimers xxx protein_E
. . NE

Taken Xxxx NE
together xxx NE
, , NE
these xxx NE
results xxx NE
demonstrate xxx NE
that xxx NE
tolerance xxx NE
to xx NE
LPS XXX NE
is xx NE
determined xxx NE
by xx NE
post-receptor xxx-xxx NE
mechanisms xxx NE
that xxx NE
involve xxx NE
an xx NE
altered xxx NE
composition xxx NE
of xx NE
the xxx NE
NF-kappa XX-xxx protein_B
B X protein_M
complex xxx protein_E
. . NE

Analysis Xxxx NE
of xx NE
Oct2-isoform Xxxd-xxx NE
expression xxx NE
in xx NE
lipopolysaccharide xxx NE
-stimulated -xxx NE
B X NE
lymphocytes xxx NE
. . NE

Oct2-isoform Xxxd-xxx NE
expression xxx NE
in xx NE
splenic xxx cell_type_B
B X cell_type_M
cells xxx cell_type_E
stimulated xxx NE
with xxx NE
lipopolysaccharide xxx NE
or xx NE
lipopolysaccharide xxx NE
plus xxx NE
phorbol-di-butyrate xxx-xx-xxx NE
was xxx NE
analysed xxx NE
by xx NE
cDNA xXXX NE
cloning xxx NE
. . NE

The Xxx NE
frequency xxx NE
of xx NE
Oct2-positive Xxxd-xxx cell_line_B
clones xxx cell_line_E
was xxx NE
1/15,000 d/dd,ddd NE
in xx NE
both xxx NE
libraries xxx NE
. . NE

Two Xxx NE
new xxx NE
isoforms xxx NE
were xxx NE
found xxx NE
that xxx NE
generate xxx NE
novel xxx NE
amino-terminal xxx-xxx protein_B
sequence xxx protein_M
or xx protein_M
carboxy-terminal xxx-xxx protein_M
sequence xxx protein_E

An Xx NE
isoform xxx NE
lacking xxx NE
exon xxx DNA_B
11 dd DNA_E
destroyed xxx NE
the xxx NE
carboxy-terminal xxx-xxx protein_B
leucin-zipper xxx-xxx protein_M
region xxx protein_E
and xxx NE
introduced xxx NE
a x NE
frame xxx NE
shift xxx NE
creating xxx NE
a x NE
novel xxx NE
, , NE
proline xxx NE
-rich -xxx NE
carboxy xxx NE
terminus xxx NE
. . NE

A X NE
new xxx NE
exon xxx DNA
containing xxx NE
a x NE
highly xxx NE
basic xxx NE
region xxx NE
(4c) (dx) NE
was xxx NE
characterized xxx NE
, , NE
between xxx DNA_B
exons xxx DNA_M
4 d DNA_M
and xxx DNA_M
5 d DNA_E
. . NE

This Xxxx NE
exon xxx NE
was xxx NE
inserted xxx NE
between xxx DNA_B
glutamine-rich xxx-xxx DNA_M
regions xxx DNA_M
2 d DNA_M
and xxx DNA_M
3 d DNA_E
, , NE
carboxy xxx protein_B
terminal xxx protein_E
of xx NE
a x NE
tentative xxx NE
leucine-zipper xxx-xxx protein_B
structure xxx protein_E
. . NE

In Xx NE
addition xxx NE
, , NE
a x NE
new xxx NE
combination xxx NE
isoform xxx NE
containing xxx NE
Oct2a Xxxdx NE
's 'x NE
amino xxx NE
terminal xxx NE
insert xxx NE
( ( NE
exon xxx NE
7a dx NE
) ) NE
and xxx NE
Oct2b Xxxdx NE
's 'x NE
carboxy xxx NE
terminal xxx NE
insert xxx NE
( ( NE
exon xxx NE
13 dd NE
) ) NE
was xxx NE
found xxx NE
that xxx NE
created xxx NE
a x NE
novel xxx NE
large xxx NE
isoform xxx NE
, , NE
Oct2ab Xxxdxx NE
. . NE

More Xxxx NE
frequent xxx NE
use xxx NE
of xx NE
the xxx NE
classical xxx NE
Oct2a Xxxdx protein
and xxx NE
Oct2b Xxxdx protein
isoforms xxx NE
was xxx NE
observed xxx NE
in xx NE
the xxx NE
lipopolysaccharide xxx NE
-stimulated -xxx NE
B X NE
cells xxx NE
, , NE
while xxx NE
a x NE
preference xxx NE
for xxx NE
the xxx NE
Oct2ab Xxxdxx NE
and xxx NE
Oct2ba Xxxdxx NE
isoforms xxx NE
was xxx NE
observed xxx NE
in xx NE
lipopolysaccharide xxx NE
plus xxx NE
phorbol-di-butyrate xxx-xx-xxx NE
-treated -xxx NE
cells xxx NE
. . NE

Positive Xxxx NE
regulators xxx NE
of xx NE
the xxx NE
lineage-specific xxx-xxx NE
transcription xxx protein_B
factor xxx protein_E
GATA-1 XXXX-d protein
in xx NE
differentiating xxx cell_type_B
erythroid xxx cell_type_M
cells xxx cell_type_E
. . NE

The Xxx NE
zinc xxx protein_B
finger xxx protein_M
transcription xxx protein_M
factor xxx protein_E
GATA-1 XXXX-d NE
is xx NE
a x NE
major xxx NE
regulator xxx NE
of xx NE
gene xxx NE
expression xxx NE
in xx NE
erythroid xxx cell_type_B
cell xxx cell_type_M
lineage xxx cell_type_M
and xxx cell_type_M
megakaryocyte xxx cell_type_M
cell xxx cell_type_M
lineage xxx cell_type_M
and xxx cell_type_M
mast xxx cell_type_M
cell xxx cell_type_M
lineage xxx cell_type_E

GATA-1 XXXX-d protein
binds xxx NE
to xx NE
WGATAR XXXXXX DNA_B
consensus xxx DNA_M
motifs xxx DNA_E
in xx NE
the xxx NE
regulatory xxx DNA_B
regions xxx DNA_E
of xx NE
virtually xxx NE
all xxx NE
erythroid xxx DNA_B
cell-specific xxx-xxx DNA_M
genes xxx DNA_E
. . NE

Analyses Xxxx NE
with xxx NE
cultured xxx cell_line_B
cells xxx cell_line_E
and xxx NE
cell-free xxx-xxx NE
systems xxx NE
have xxx NE
provided xxx NE
strong xxx NE
evidence xxx NE
that xxx NE
GATA-1 XXXX-d protein
is xx NE
involved xxx NE
in xx NE
control xxx NE
of xx NE
globin xxx NE
gene xxx NE
expression xxx NE
during xxx NE
erythroid xxx NE
differentiation xxx NE
. . NE

Targeted Xxxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
GATA-1 XXXX-d DNA_B
gene xxx DNA_E
in xx NE
embryonic xxx cell_type_B
stem xxx cell_type_M
cells xxx cell_type_E
has xxx NE
demonstrated xxx NE
its xxx NE
requirement xxx NE
in xx NE
normal xxx NE
erythroid xxx NE
development xxx NE
. . NE

Efficient Xxxx NE
rescue xxx NE
of xx NE
the xxx NE
defect xxx NE
requires xxx NE
an xx NE
intact xxx NE
GATA XXXX DNA_B
element xxx DNA_E
in xx NE
the xxx NE
distal xxx DNA_B
promoter xxx DNA_E
, , NE
suggesting xxx NE
autoregulatory xxx NE
control xxx NE
of xx NE
GATA-1 XXXX-d NE
transcription xxx NE
. . NE

To Xx NE
examine xxx NE
whether xxx NE
GATA-1 XXXX-d NE
expression xxx NE
involves xxx NE
additional xxx NE
regulatory xxx protein_B
factors xxx protein_E
or xx NE
is xx NE
maintained xxx NE
entirely xxx NE
by xx NE
an xx NE
autoregulatory xxx NE
loop xxx NE
, , NE
we xx NE
have xxx NE
used xxx NE
a x NE
transient xxx NE
heterokaryon xxx NE
system xxx NE
to xx NE
test xxx NE
the xxx NE
ability xxx NE
of xx NE
erythroid xxx protein_B
factors xxx protein_E
to xx NE
activate xxx NE
the xxx NE
GATA-1 XXXX-d DNA_B
gene xxx DNA_E
in xx NE
nonerythroid xxx NE
nuclei xxx NE
. . NE

We Xx NE
show xxx NE
here xxx NE
that xxx NE
proerythroblasts xxx cell_type
and xxx NE
mature xxx cell_type_B
erythroid xxx cell_type_M
cells xxx cell_type_E
contain xxx NE
a x NE
diffusible xxx NE
activity xxx NE
( ( NE
TAG XXX NE
) ) NE
capable xxx NE
of xx NE
transcriptional xxx NE
activation xxx NE
of xx NE
GATA-1 XXXX-d protein
and xxx NE
that xxx NE
this xxx NE
activity xxx NE
decreases xxx NE
during xxx NE
the xxx NE
terminal xxx NE
differentiation xxx NE
of xx NE
erythroid xxx cell_type_B
cells xxx cell_type_E
. . NE

Nuclei Xxxx NE
from xxx NE
GATA-1 XXXX-d NE
-mutant -xxx NE
embryonic xxx NE
stem xxx NE
cells xxx NE
can xxx NE
still xxx NE
be xx NE
reprogrammed xxx NE
to xx NE
express xxx NE
their xxx NE
globin xxx NE
genes xxx NE
in xx NE
erythroid xxx NE
heterokaryons xxx NE
, , NE
indicating xxx NE
that xxx NE
de xx NE
novo xxx NE
induction xxx NE
of xx NE
GATA-1 XXXX-d NE
is xx NE
not xxx NE
required xxx NE
for xxx NE
globin xxx NE
gene xxx NE
activation xxx NE
following xxx NE
cell xxx NE
fusion xxx NE
. . NE

Role Xxxx NE
of xx NE
HIV-1 XXX-d protein_B
Nef Xxx protein_E
expression xxx NE
in xx NE
activation xxx NE
pathways xxx NE
in xx NE
CD4 XXd protein
+ + NE
T X NE
cells xxx NE
. . NE

The Xxx NE
role xxx NE
of xx NE
the xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
( ( NE
HIV-1 XXX-d NE
) ) NE
Nef Xxx NE
protein xxx NE
in xx NE
T X NE
cell xxx NE
activation xxx NE
pathways xxx NE
was xxx NE
investigated xxx NE
using xxx NE
a x NE
Jurkat Xxxx NE
CD4 XXd NE
+ + NE
cell xxx NE
line xxx NE
stably xxx NE
transfected xxx NE
with xxx NE
a x NE
Nef Xxx NE
expression xxx NE
vector xxx NE
. . NE

Secretion Xxxx NE
of xx NE
IL-2 XX-d protein
and xxx NE
TNF-alpha XXX-xxx protein
, , NE
surface xxx NE
expression xxx NE
of xx NE
IL-2R XX-dX protein
, , NE
and xxx NE
DNA-binding XXX-xxx NE
activity xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
and xxx NE
AP-1 XX-d protein_B
(Fos/Jun) (Xxx/Xxx) protein_M
complex xxx protein_E
in xx NE
response xxx NE
to xx NE
phorbol xxx NE
myristate xxx NE
acetate xxx NE
, , NE
TNF-alpha XXX-xxx protein
, , NE
or xx NE
immobilized xxx NE
antibodies xxx NE
to xx NE
CD3 XXd protein
were xxx NE
monitored xxx NE
. . NE

These Xxxx NE
parameters xxx NE
were xxx NE
not xxx NE
modified xxx NE
by xx NE
Nef Xxx NE
expression xxx NE
in xx NE
Jurkat Xxxx cell_line_B
cells xxx cell_line_E
, , NE
whereas xxx NE
stimulation xxx NE
with xxx NE
the xxx NE
same xxx NE
stimuli xxx NE
resulted xxx NE
in xx NE
partial xxx NE
inhibition xxx NE
of xx NE
LTR XXX NE
activation xxx NE
in xx NE
Nef Xxx NE
+ + NE
Jurkat Xxxx NE
cells xxx NE
. . NE

This Xxxx NE
inhibition xxx NE
was xxx NE
not xxx NE
mediated xxx NE
through xxx NE
Nef Xxx NE
phosphorylation xxx NE
on xx NE
Thr-15 Xxx-dd NE
or xx NE
GTP XXX NE
-binding -xxx NE
activity xxx NE
because xxx NE
mutations xxx NE
in xx NE
critical xxx NE
sites xxx NE
did xxx NE
not xxx NE
alter xxx NE
this xxx NE
inhibition xxx NE
. . NE

Analysis Xxxx NE
of xx NE
truncated xxx NE
LTRs XXXx DNA
confirmed xxx NE
that xxx NE
inhibition xxx NE
of xx NE
LTR XXX NE
activation xxx NE
was xxx NE
not xxx NE
mediated xxx NE
through xxx NE
NF-kappa XX-xxx NE
B X NE
-binding -xxx NE
activity xxx NE
but xxx NE
through xxx NE
the xxx NE
region xxx NE
containing xxx NE
the xxx NE
negative xxx NE
responding xxx NE
elements xxx NE
( ( NE
NREs XXXx NE
) ) NE
. . NE

These Xxxx NE
results xxx NE
suggest xxx NE
that xxx NE
Nef Xxx protein
downmodulates xxx NE
LTR XXX DNA
activation xxx NE
without xxx NE
significantly xxx NE
inhibiting xxx NE
the xxx NE
capacity xxx NE
of xx NE
T X cell_type_B
cells xxx cell_type_E
to xx NE
respond xxx NE
to xx NE
immunological xxx NE
activations xxx NE
. . NE

Tat-binding Xxx-xxx protein_B
protein xxx protein_M
7 d protein_E
is xx NE
a x NE
subunit xxx NE
of xx NE
the xxx NE
26S ddX protein_B
protease xxx protein_E
. . NE

Subunit Xxxx protein_B
6 d protein_E
( ( NE
S6 Xd protein
) ) NE
, , NE
an xx NE
integral xxx NE
component xxx NE
of xx NE
the xxx NE
26S ddX protein_B
protease xxx protein_E
from xxx NE
human xxx cell_type_B
erythrocytes xxx cell_type_E
, , NE
has xxx NE
been xxx NE
studied xxx NE
by xx NE
SDS-PAGE XXX-XXXX NE
, , NE
peptide xxx NE
mapping xxx NE
and xxx NE
sequence xxx NE
analysis xxx NE
. . NE

S6 Xd protein
was xxx NE
cleaved xxx NE
with xxx NE
CNBr XXXx protein
and xxx NE
three xxx NE
internal xxx NE
peptides xxx NE
were xxx NE
sequenced xxx NE
. . NE

A X NE
comparison xxx NE
with xxx NE
known xxx NE
proteins xxx NE
in xx NE
Genbank Xxxx NE
revealed xxx NE
that xxx NE
all xxx NE
three xxx NE
S6 Xd NE
peptides xxx NE
match xxx NE
the xxx NE
predicted xxx NE
sequence xxx NE
of xx NE
TBP7 XXXd protein
, , NE
Tat-binding Xxx-xxx protein_B
protein xxx protein_M
7 d protein_E
. . NE

Based Xxxx NE
on xx NE
peptide xxx NE
matches xxx NE
covering xxx NE
more xxx NE
than xxx NE
10% dd% NE
of xx NE
the xxx NE
TBP7 XXXd protein_B
sequence xxx protein_E
, , NE
and xxx NE
the xxx NE
fact xxx NE
that xxx NE
the xxx NE
migration xxx NE
of xx NE
S6 Xd protein
on xx NE
SDS-PAGE XXX-XXXX NE
is xx NE
consistent xxx NE
with xxx NE
the xxx NE
estimated xxx NE
molecular xxx NE
mass xxx NE
for xxx NE
TBP7 XXXd protein
, , NE
we xx NE
conclude xxx NE
that xxx NE
subunit xxx protein_B
6 d protein_E
of xx NE
the xxx NE
26S ddX protein_B
protease xxx protein_E
is xx NE
TBP7 XXXd protein
. . NE

Hypoxia Xxxx NE
causes xxx NE
the xxx NE
activation xxx NE
of xx NE
nuclear xxx protein_B
factor xxx protein_M
kappa xxx protein_M
B X protein_E
through xxx NE
the xxx NE
phosphorylation xxx NE
of xx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
on xx NE
tyrosine xxx NE
residues xxx NE
. . NE

The Xxx NE
response xxx NE
of xx NE
mammalian xxx cell_type_B
cells xxx cell_type_E
to xx NE
stress xxx NE
is xx NE
controlled xxx NE
by xx NE
transcriptional xxx protein_B
regulatory xxx protein_M
proteins xxx protein_E
such xxx NE
as xx NE
nuclear xxx protein_B
factor xxx protein_M
kappa xxx protein_M
B X protein_E
( ( NE
NF-kappa XX-xxx protein_B
B X protein_E
) ) NE
to xx NE
induce xxx NE
a x NE
wide xxx NE
variety xxx NE
of xx NE
early xxx DNA_B
response xxx DNA_M
genes xxx DNA_E
. . NE

In Xx NE
this xxx NE
report xxx NE
, , NE
we xx NE
show xxx NE
that xxx NE
exposure xxx NE
of xx NE
cells xxx NE
to xx NE
hypoxia xxx NE
(0.02% (d.dd% NE
O2) Xd) NE
results xxx NE
in xx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
degradation xxx NE
, , NE
increased xxx NE
NF-kappa XX-xxx NE
B X NE
DNA XXX NE
binding xxx NE
activity xxx NE
, , NE
and xxx NE
transactivation xxx NE
of xx NE
a x NE
reporter xxx DNA_B
gene xxx DNA_M
construct xxx DNA_E
containing xxx NE
two xxx NE
NF-kappa XX-xxx DNA_B
B X DNA_M
DNA XXX DNA_M
binding xxx DNA_M
sites xxx DNA_E
. . NE

Pretreatment Xxxx NE
of xx NE
cells xxx NE
with xxx NE
protein xxx NE
tyrosine xxx NE
kinase xxx NE
inhibitors xxx NE
and xxx NE
the xxx NE
dominant xxx DNA_B
negative xxx DNA_M
allele xxx DNA_E
of xx NE
c-Raf-1 x-Xxx-d DNA
( ( NE
Raf Xxx protein_B
301 ddd protein_E
) ) NE
inhibited xxx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
degradation xxx NE
, , NE
NF-kappa XX-xxx NE
B X NE
binding xxx NE
, , NE
and xxx NE
transactivation xxx NE
of xx NE
kappa xxx DNA_B
B X DNA_M
reporter xxx DNA_M
constructs xxx DNA_E
by xx NE
hypoxia xxx NE
. . NE

To Xx NE
demonstrate xxx NE
a x NE
direct xxx NE
link xxx NE
between xxx NE
changes xxx NE
in xx NE
the xxx NE
phosphorylation xxx NE
pattern xxx NE
of xx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
with xxx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
, , NE
we xx NE
immunoprecipitated xxx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
after xxx NE
varying xxx NE
times xxx NE
of xx NE
hypoxic xxx NE
exposure xxx NE
and xxx NE
found xxx NE
that xxx NE
its xxx NE
tyrosine xxx NE
phosphorylation xxx NE
status xxx NE
increased xxx NE
during xxx NE
hypoxic xxx NE
exposure xxx NE
. . NE

Inhibition Xxxx NE
of xx NE
the xxx NE
transfer xxx NE
of xx NE
tyrosine xxx NE
phosphoryl xxx NE
groups xxx NE
onto xxx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
prevented xxx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
degradation xxx NE
and xxx NE
NF-kappa XX-xxx NE
B X NE
binding xxx NE
. . NE

In Xx NE
comparison xxx NE
to xx NE
other xxx NE
activators xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
such xxx NE
as xx NE
phorbol xxx NE
myristate xxx NE
acetate xxx NE
or xx NE
tumor xxx protein_B
necrosis xxx protein_M
factor xxx protein_E
, , NE
we xx NE
did xxx NE
not xxx NE
detect xxx NE
changes xxx NE
in xx NE
the xxx NE
tyrosine xxx NE
phosphorylation xxx NE
status xxx NE
of xx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
following xxx NE
treatment xxx NE
with xxx NE
either xxx NE
of xx NE
these xxx NE
agents xxx NE
. . NE

These Xxxx NE
results xxx NE
suggest xxx NE
that xxx NE
tyrosine xxx NE
phosphorylation xxx NE
of xx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
during xxx NE
hypoxia xxx NE
is xx NE
an xx NE
important xxx NE
proximal xxx NE
step xxx NE
which xxx NE
precedes xxx NE
its xxx NE
dissociation xxx NE
and xxx NE
degradation xxx NE
from xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
. . NE

Overproduction Xxxx NE
of xx NE
NFKB2 XXXXd protein
( ( NE
lyt-10 xxx-dd protein
) ) NE
and xxx NE
c-Rel x-Xxx protein
: : NE
a x NE
mechanism xxx NE
for xxx NE
HTLV-I XXXX-X NE
Tax Xxx NE
-mediated -xxx NE
trans-activation xxx-xxx NE
via xxx NE
the xxx NE
NF-kappa XX-xxx NE
B X NE
signalling xxx NE
pathway xxx NE
. . NE

Molecular Xxxx NE
, , NE
biochemical xxx NE
and xxx NE
epidemiological xxx NE
evidence xxx NE
implicate xxx NE
HTLV-I XXXX-X NE
as xx NE
an xx NE
etiologic xxx NE
agent xxx NE
of xx NE
adult xxx NE
T X NE
cell xxx NE
leukemia xxx NE
( ( NE
ATL XXX NE
) ) NE
. . NE

The Xxx NE
Tax Xxx protein_B
protein xxx protein_E
of xx NE
HTLV-I XXXX-X NE
, , NE
a x NE
positive xxx protein_B
transcriptional xxx protein_M
activator xxx protein_E
of xx NE
HTLV-I XXXX-X NE
gene xxx NE
expression xxx NE
, , NE
is xx NE
a x NE
viral xxx NE
oncogene xxx NE
that xxx NE
also xxx NE
increases xxx NE
transcription xxx NE
of xx NE
cellular xxx DNA_B
genes xxx DNA_E
including xxx NE
GM-CSF XX-XXX protein
, , NE
IL-2R XX-dX protein_B
alpha xxx protein_E
and xxx NE
IL-2 XX-d protein
. . NE

One Xxx NE
of xx NE
the xxx NE
cellular xxx NE
targets xxx NE
of xx NE
the xxx NE
trans-activating xxx-xxx NE
effects xxx NE
of xx NE
Tax Xxx NE
is xx NE
the xxx NE
NF-kappa XX-xxx protein_B
B X protein_M
/Rel /Xxx protein_M
family xxx protein_E
of xx NE
transcription xxx protein_B
factors xxx protein_E
, , NE
pleiotropic xxx protein_B
regulators xxx protein_E
of xx NE
immunoregulatory xxx NE
gene xxx NE
expression xxx NE
and xxx NE
cytokine xxx NE
gene xxx NE
expression xxx NE
and xxx NE
viral xxx NE
gene xxx NE
expression xxx NE

In Xx NE
this xxx NE
report xxx NE
, , NE
we xx NE
demonstrate xxx NE
that xxx NE
NFKB2 XXXXd protein
( ( NE
lyt-10 xxx-dd protein
) ) NE
and xxx NE
c-Rel x-Xxx protein
are xxx NE
overexpressed xxx NE
in xx NE
HTLV-I XXXX-X NE
infected xxx NE
and xxx NE
Tax-expressing Xxx-xxx cell_type_B
cells xxx cell_type_E
and xxx NE
, , NE
together xxx NE
, , NE
account xxx NE
for xxx NE
the xxx NE
majority xxx NE
of xx NE
the xxx NE
constitutive xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
binding xxx NE
activity xxx NE
in xx NE
these xxx NE
cells xxx NE
before xxx NE
and xxx NE
after xxx NE
PMA XXX NE
stimulation xxx NE
. . NE

Most Xxxx NE
importantly xxx NE
, , NE
we xx NE
show xxx NE
a x NE
Tax Xxx NE
-dependent -xxx NE
correlation xxx NE
between xxx NE
expression xxx NE
of xx NE
NFKB2 XXXXd NE
( ( NE
p100 xddd NE
) ) NE
and xxx NE
processing xxx NE
to xx NE
the xxx NE
DNA XXX NE
binding xxx NE
NFKB2 XXXXd NE
( ( NE
p52 xdd NE
) ) NE
form xxx NE
, , NE
induction xxx NE
of xx NE
c-Rel x-Xxx NE
, , NE
and xxx NE
trans-activation xxx-xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-mediated -xxx NE
gene xxx NE
expression xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
NFKB2 XXXXd protein
precursor xxx NE
is xx NE
physically xxx NE
associated xxx NE
with xxx NE
c-Rel x-Xxx protein
and xxx NE
with xxx NE
Tax Xxx protein
in xx NE
HTLV-I XXXX-X cell_type_B
infected xxx cell_type_M
cells xxx cell_type_E
. . NE

We Xx NE
propose xxx NE
that xxx NE
NFKB2 XXXXd NE
synthesis xxx NE
and xxx NE
processing xxx NE
allows xxx NE
continuous xxx NE
nuclear xxx NE
expression xxx NE
of xx NE
an xx NE
otherwise xxx NE
cytoplasmic xxx protein_B
protein xxx protein_E
and xxx NE
, , NE
in xx NE
conjunction xxx NE
with xxx NE
overexpression xxx NE
of xx NE
c-Rel x-Xxx protein
, , NE
NFKB2 XXXXd protein
alters xxx NE
the xxx NE
NF-kappa XX-xxx NE
B X NE
signalling xxx NE
pathway xxx NE
and xxx NE
contributes xxx NE
to xx NE
leukemic xxx NE
transformation xxx NE
of xx NE
T X cell_type_B
cells xxx cell_type_E
by xx NE
HTLV-I XXXX-X NE
. . NE

Retinoic Xxxx NE
acid xxx NE
downmodulates xxx NE
erythroid xxx NE
differentiation xxx NE
and xxx NE
GATA1 XXXXd NE
expression xxx NE
in xx NE
purified xxx cell_line_B
adult-progenitor xxx-xxx cell_line_M
culture xxx cell_line_E
. . NE

All-trans Xxx-xxx NE
retinoic xxx NE
acid xxx NE
( ( NE
RA XX NE
) ) NE
is xx NE
an xx NE
important xxx NE
morphogen xxx NE
in xx NE
vertebrate xxx NE
development xxx NE
, , NE
a x NE
normal xxx NE
constituent xxx NE
in xx NE
human xxx NE
adult xxx NE
blood xxx NE
and xxx NE
is xx NE
also xxx NE
involved xxx NE
in xx NE
the xxx NE
control xxx NE
of xx NE
cell xxx NE
growth xxx NE
and xxx NE
differentiation xxx NE
in xx NE
acute xxx NE
promyelocytic xxx NE
leukemia xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
effects xxx NE
of xx NE
RA XX NE
on xx NE
normal xxx NE
hematopoiesis xxx NE
by xx NE
using xxx NE
early xxx NE
hematopoietic xxx cell_type_B
progenitor xxx cell_type_M
cells xxx cell_type_E
( ( NE
HPC XXX cell_type
) ) NE
stringently xxx NE
purified xxx NE
from xxx NE
adult xxx NE
peripheral xxx NE
blood xxx NE
. . NE

In Xx protein
clonogenetic xxx NE
fetal xxx NE
calf xxx NE
serum xxx NE
clonogenetic xxx cell_line_B
fetal xxx cell_line_M
calf xxx cell_line_M
serum-supplemented xxx-xxx cell_line_M
(FCS+) (XXX+) cell_line_M
culture xxx cell_line_M
or xx cell_line_M
clonogenetic xxx cell_line_M
fetal xxx cell_line_M
calf xxx cell_line_M
serum-nonsupplemented xxx-xxx cell_line_M
(FCS-) (XXX-) cell_line_M
culture xxx cell_line_E
treated xxx NE
with xxx NE
saturating xxx NE
levels xxx NE
of xx NE
interleukin-3 xxx-d NE
( ( NE
IL-3 XX-d NE
) ) NE
granulocyte-macrophage xxx-xxx protein_B
colony-stimulating xxx-xxx protein_M
factor xxx protein_E
( ( NE
GM-CSF XX-XXX protein
) ) NE
and xxx NE
erythropoietin xxx protein
( ( NE
Ep Xx protein
) ) NE
(combined (xxx NE
with xxx NE
c-kit x-xxx NE
ligand xxx NE
in xx NE
FCS(-)-culture XXX(-)-xxx NE
conditions xxx NE
) ) NE
, , NE
RA XX NE
induces xxx NE
a x NE
dramatic xxx NE
dose-dependent xxx-xxx NE
shift xxx NE
from xxx NE
erythroid xxx NE
to xx NE
granulomonocytic xxx NE
colony xxx NE
formation xxx NE
, , NE
the xxx NE
latter xxx NE
colonies xxx NE
being xxx NE
essentially xxx NE
represented xxx NE
by xx NE
granulocytic xxx cell_line_B
clones xxx cell_line_E
. . NE

This Xxxx NE
shift xxx NE
is xx NE
apparently xxx NE
not xxx NE
caused xxx NE
by xx NE
a x NE
recruitment xxx NE
phenomenon xxx NE
, , NE
because xxx NE
in xx NE
FCS+ XXX+ cell_line_B
culture xxx cell_line_E
, , NE
the xxx NE
total xxx NE
number xxx NE
of xx NE
colonies xxx NE
is xx NE
not xxx NE
significantly xxx NE
modified xxx NE
by xx NE
RA XX NE
addition xxx NE
. . NE

In Xx NE
FCS- XXX- cell_line_B
liquid-suspension xxx-xxx cell_line_M
culture xxx cell_line_E
supplemented xxx NE
with xxx NE
saturating xxx NE
Ep Xx NE
level xxx NE
and xxx NE
low-dose xxx-xxx NE
IL-3 XX-d NE
/GM-CSF /XX-XXX NE
, , NE
adult xxx NE
HPC XXX NE
undergo xxx NE
unilineage xxx NE
erythropoietic xxx NE
differentiation xxx NE
: : NE
Here Xxxx NE
again xxx NE
, , NE
treatment xxx NE
with xxx NE
high-dose xxx-xxx NE
RA XX NE
induces xxx NE
a x NE
shift xxx NE
from xxx NE
the xxx NE
erythroid xxx NE
to xx NE
granulocytic xxx NE
differentiation xxx NE
pathway xxx NE
. . NE

Studies Xxxx NE
on xx NE
RA XX NE
time-response xxx-xxx NE
or xx NE
pulse xxx NE
treatment xxx NE
in xx NE
semisolid xxx NE
or xx NE
liquid xxx NE
culture xxx NE
show xxx NE
that xxx NE
early xxx NE
RA XX NE
addition xxx NE
is xx NE
most xxx NE
effective xxx NE
, , NE
thus xxx NE
indicating xxx NE
that xxx NE
early xxx NE
but xxx NE
not xxx NE
late xxx NE
HPC XXX cell_type
are xxx NE
sensitive xxx NE
to xx NE
its xxx NE
action xxx NE
. . NE

We Xx NE
then xxx NE
analyzed xxx NE
the xxx NE
expression xxx NE
of xx NE
the xxx NE
master xxx DNA_B
GATA1 XXXXd DNA_M
gene xxx DNA_E
, , NE
which xxx NE
encodes xxx NE
a x NE
finger xxx protein_B
transcription xxx protein_M
factor xxx protein_E
required xxx NE
for xxx NE
normal xxx NE
erythroid xxx NE
development xxx NE
; ; NE
addition xxx NE
of xx NE
RA XX NE
to xx NE
HPC XXX cell_type
stimulated xxx NE
into xxx NE
unilineage xxx NE
erythropoietic xxx NE
differentiation xxx NE
in xx NE
liquid xxx NE
culture xxx NE
caused xxx NE
a x NE
virtually xxx NE
complete xxx NE
inhibition xxx NE
of xx NE
GATA1 XXXXd NE
mRNA xXXX NE
induction xxx NE
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
RA XX NE
directly xxx NE
inhibits xxx NE
the xxx NE
erythroid xxx NE
differentiation xxx NE
program xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
early xxx NE
adult xxx NE
HPC XXX cell_type
, , NE
and xxx NE
may xxx NE
lead xxx NE
to xx NE
a x NE
shift xxx NE
from xxx NE
the xxx NE
erythroid xxx NE
to xx NE
granulocytic xxx NE
differentiation xxx NE
pathway xxx NE
. . NE

This Xxxx NE
phenomenon xxx NE
is xx NE
correlated xxx NE
with xxx NE
inhibition xxx NE
of xx NE
GATA1 XXXXd NE
induction xxx NE
in xx NE
the xxx NE
early xxx NE
stages xxx NE
of xx NE
erythropoietic xxx NE
differentiation xxx NE
. . NE

Induction Xxxx NE
of xx NE
phosphatidylinositol xxx NE
turnover xxx NE
and xxx NE
EGR-1 XXX-d NE
mRNA xXXX NE
expression xxx NE
by xx NE
crosslinking xxx NE
of xx NE
surface xxx NE
IgM XxX protein
and xxx NE
IgD XxX protein
in xx NE
the xxx NE
human xxx cell_line_B
B X cell_line_M
cell xxx cell_line_M
line xxx cell_line_M
B104 Xddd cell_line_E
. . NE

We Xx NE
have xxx NE
previously xxx NE
shown xxx NE
that xxx NE
a x NE
human xxx cell_line_B
B X cell_line_M
lymphoma xxx cell_line_M
cell xxx cell_line_M
line, xxx, cell_line_M
B104 Xddd cell_line_E
, , NE
expressed xxx NE
surface xxx protein_B
IgM XxX protein_E
( ( NE
sIgM xXxX protein
) ) NE
and xxx NE
surface xxx protein_B
IgD XxX protein_E
( ( NE
sIgD xXxX protein
) ) NE
, , NE
and xxx NE
that xxx NE
crosslinking xxx NE
of xx NE
sIgM xXxX protein
and xxx NE
sIgD xXxX protein
by xx NE
anti- xxx- NE
IgM XxX NE
antibody xxx NE
(Ab) (Xx) NE
and xxx NE
anti- xxx- NE
IgD XxX NE
Ab Xx NE
, , NE
respectively xxx NE
, , NE
induced xxx NE
Ca2+ Xxd+ NE
influx xxx NE
to xx NE
almost xxx NE
the xxx NE
same xxx NE
degree xxx NE
, , NE
whereas xxx NE
only xxx NE
sIgM xXxX NE
-crosslinking -xxx NE
caused xxx NE
B104 Xddd NE
cell xxx NE
death xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
investigated xxx NE
the xxx NE
accumulation xxx NE
of xx NE
cyclic xxx NE
AMP XXX NE
( ( NE
cAMP xXXX NE
) ) NE
, , NE
the xxx NE
hydrolysis xxx NE
of xx NE
inositol xxx NE
phosphates xxx NE
, , NE
protein xxx NE
kinase xxx NE
C X NE
( ( NE
PKC XXX NE
) ) NE
activity xxx NE
and xxx NE
the xxx NE
induction xxx NE
of xx NE
Egr-1 Xxx-d NE
mRNA xXXX NE
expression xxx NE
and xxx NE
c-fos x-xxx NE
mRNA xXXX NE
expression xxx NE
by xx NE
sIgM-crosslinking xXxX-xxx NE
and xxx NE
sIgD-crosslinking xXxX-xxx NE
to xx NE
examine xxx NE
differences xxx NE
in xx NE
the xxx NE
signals xxx NE
mediated xxx NE
through xxx NE
sIgM xXxX protein
and xxx NE
sIgD xXxX protein
in xx NE
B104 Xddd cell_line_B
cells xxx cell_line_E
. . NE

Both Xxxx NE
sIgM-crosslinking xXxX-xxx NE
and xxx NE
sIgD-crosslinking xXxX-xxx NE
sIgM- xXxX- NE
with xxx NE
antibodies xxx NE
induced xxx NE
elevation xxx NE
of xx NE
cAMP xXXX NE
levels xxx NE
, , NE
phosphatidylinositol xxx NE
turnover xxx NE
, , NE
PKC XXX NE
activation xxx NE
and xxx NE
expression xxx NE
of xx NE
Egr-1 Xxx-d RNA_B
mRNA xXXX RNA_M
and xxx RNA_M
c-fos x-xxx RNA_M
mRNA xXXX RNA_E
sIgM xXxX NE
-crosslinking -xxx NE
was xxx NE
more xxx NE
effective xxx NE
than xxx NE
sIgD xXxX protein
-crosslinking -xxx NE
, , NE
presumably xxx NE
due xxx NE
to xx NE
the xxx NE
higher xxx NE
expression xxx NE
of xx NE
sIgM xXxX protein
than xxx NE
of xx NE
sIgD xXxX NE
. . NE

Egr-1 Xxx-d NE
mRNA xXXX NE
expression xxx NE
induced xxx NE
by xx NE
sIgM-crosslinking xXxX-xxx NE
and xxx NE
sIgD-crosslinking xXxX-xxx NE
was xxx NE
inhibited xxx NE
by xx NE
H7 Xd protein
, , NE
erbstatin xxx NE
and xxx NE
genistein xxx NE
, , NE
but xxx NE
not xxx NE
by xx NE
HA1004 XXdddd NE
. . NE

Erbstatin Xxxx NE
and xxx NE
genistein xxx NE
inhibited xxx NE
the xxx NE
sIg-crosslinking-induced xXx-xxx-xxx NE
Egr-1 Xxx-d NE
mRNA xXXX NE
expression xxx NE
in xx NE
a x NE
dose-dependent xxx-xxx NE
manner xxx NE
parallel xxx NE
to xx NE
that xxx NE
observed xxx NE
in xx NE
the xxx NE
inhibition xxx NE
of xx NE
sIg-crosslinking-induced xXx-xxx-xxx NE
protein xxx NE
tyrosine xxx NE
phosphorylation xxx NE
. . NE

Phorbol Xxxx NE
myristate xxx NE
acetate xxx NE
induced xxx NE
Egr-1 Xxx-d NE
mRNA xXXX NE
expression xxx NE
but xxx NE
forskolin xxx NE
and xxx NE
dibutyryl xxx NE
cyclic xxx NE
AMP XXX NE
did xxx NE
not xxx NE
. . NE

These Xxxx NE
findings xxx NE
suggest xxx NE
that xxx NE
the xxx NE
Egr-1 Xxx-d RNA_B
mRNA xXXX RNA_E
activating xxx NE
signals xxx NE
through xxx NE
sIgM xXxX protein
and xxx NE
sIgD xXxX protein
are xxx NE
protein xxx NE
tyrosine xxx NE
kinase-dependent xxx-xxx NE
and xxx NE
PKC-dependent XXX-xxx NE
protein xxx NE
kinase xxx NE
A X NE
-independent -xxx NE
. . NE

Cyclosporin Xxxx NE
A X NE
( ( NE
CsA XxX NE
) ) NE
and xxx NE
FK506 XXddd NE
rescued xxx NE
B104 Xddd cell_line_B
cells xxx cell_line_E
from xxx NE
death xxx NE
induced xxx NE
by xx NE
anti-IgM xxx-XxX protein_B
Ab Xx protein_E
, , NE
but xxx NE
did xxx NE
not xxx NE
affect xxx NE
the xxx NE
expression xxx NE
of xx NE
Egr-1 Xxx-d protein
and xxx NE
c-fos x-xxx RNA_B
mRNA xXXX RNA_E
, , NE
showing xxx NE
that xxx NE
CsA XxX NE
and xxx NE
FK506 XXddd NE
affect xxx NE
signal xxx NE
transducers xxx NE
differently xxx NE
from xxx NE
or xx NE
downstream xxx NE
to xx NE
these xxx NE
molecules xxx NE
. . NE

The Xxx NE
difference xxx NE
in xx NE
signals xxx NE
transduced xxx NE
through xxx NE
sIgM xXxX protein
and xxx NE
sIgD xXxX protein
in xx NE
B104 Xddd cell_line_B
cells xxx cell_line_E
is xx NE
discussed xxx NE
. . NE

Direct Xxxx NE
exposure xxx NE
to xx NE
2,3,7,8-tetrachlorodibenzo-p-dioxin d,d,d,d-xxx-x-xxx NE
( ( NE
TCDD XXXX NE
) ) NE
increases xxx NE
infectivity xxx NE
of xx NE
human xxx cell_type_B
erythrocytes xxx cell_type_E
to xx NE
a x NE
malarial xxx NE
parasite xxx NE
. . NE

Direct Xxxx NE
exposure xxx NE
to xx NE
10 dd NE
nM xX NE
2,3,7,8-TCDD d,d,d,d-XXXX NE
caused xxx NE
a x NE
75% dd% NE
increase xxx NE
and xxx NE
a x NE
2-fold d-xxx NE
increase xxx NE
in xx NE
the xxx NE
infectivity xxx NE
of xx NE
isolated xxx NE
human xxx cell_type_B
erythrocytes xxx cell_type_E
to xx NE
P. X. NE
falciparum xxx NE
after xxx NE
48 dd NE
hours xxx NE
when xxx NE
the xxx NE
parasites xxx NE
were xxx NE
in xx NE
an xx NE
unsynchronized xxx NE
or xx NE
synchronized xxx NE
state xxx NE
of xx NE
growth xxx NE
, , NE
respectively xxx NE
. . NE

Treatment Xxxx NE
of xx NE
human xxx cell_type_B
erythrocytes xxx cell_type_E
with xxx NE
10 dd NE
microM xxxX NE
sodium xxx NE
orthovanadate xxx NE
( ( NE
NaOV XxXX NE
) ) NE
, , NE
an xx NE
inhibitor xxx NE
of xx NE
plasma xxx protein_B
membrane xxx protein_M
Ca-ATPase Xx-XXXxxx protein_E
and xxx NE
phosphotyrosine xxx protein_B
phosphatase xxx protein_E
, , NE
decreased xxx NE
parasitemia xxx NE
by xx NE
30% dd% NE
. . NE

Co-treatment Xx-xxx NE
of xx NE
RBCs XXXx cell_type
with xxx NE
TCDD XXXX NE
and xxx NE
NaOV XxXX NE
completely xxx NE
blocked xxx NE
the xxx NE
TCDD XXXX NE
-induced -xxx NE
increase xxx NE
in xx NE
parasitemia xxx NE
. . NE

Because Xxxx NE
erythrocytes xxx cell_type
are xxx NE
anucleated xxx NE
, , NE
these xxx NE
results xxx NE
are xxx NE
discussed xxx NE
as xx NE
evidence xxx NE
for xxx NE
biochemical xxx NE
changes xxx NE
by xx NE
TCDD XXXX NE
without xxx NE
requiring xxx NE
the xxx NE
activation xxx NE
of xx NE
gene xxx protein_B
products xxx protein_E
. . NE

Evidence Xxxx NE
for xxx NE
a x NE
trans-acting xxx-xxx protein_B
activator xxx protein_E
function xxx NE
regulating xxx NE
the xxx NE
expression xxx NE
of xx NE
the xxx NE
human xxx protein_B
CD5 XXd protein_M
antigen xxx protein_E
. . NE

Interspecies Xxxx NE
somatic xxx cell_line_B
cell xxx cell_line_M
hybrids xxx cell_line_E
were xxx NE
generated xxx NE
by xx NE
fusing xxx NE
the xxx NE
mouse xxx cell_line_B
T-lymphoma X-xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
, , NE
BW5147 XXdddd cell_line
, , NE
with xxx NE
normal xxx cell_type_B
human xxx cell_type_M
T X cell_type_M
lymphocytes xxx cell_type_E
at xx NE
different xxx NE
stages xxx NE
of xx NE
differentiation xxx NE
. . NE

Thymocytes Xxxx cell_type
, , NE
activated xxx cell_type_B
peripheral xxx cell_type_M
T X cell_type_M
lymphocytes xxx cell_type_E
, , NE
or xx NE
an xx NE
activated xxx cell_line_B
T-cell X-xxx cell_line_M
clone xxx cell_line_E
were xxx NE
used xxx NE
as xx NE
human xxx NE
partners xxx NE
, , NE
respectively xxx NE
, , NE
in xx NE
three xxx NE
independent xxx NE
fusions xxx NE
. . NE

Irrespective Xxxx NE
of xx NE
the xxx NE
human xxx NE
cell xxx NE
partner xxx NE
used xxx NE
for xxx NE
fusion xxx NE
, , NE
a x NE
certain xxx NE
number xxx NE
of xx NE
hybrids xxx cell_line
lost xxx NE
CD5 XXd NE
surface xxx NE
expression xxx NE
over xxx NE
a x NE
period xxx NE
of xx NE
time xxx NE
in xx NE
culture xxx NE
. . NE

Analysis Xxxx NE
at xx NE
the xxx NE
phenotype xxx NE
and xxx NE
genetic xxx NE
level xxx NE
showed xxx NE
that xxx NE
lack xxx NE
of xx NE
CD5 XXd NE
expression xxx NE
was xxx NE
due xxx NE
neither xxx NE
to xx NE
segregation xxx NE
of xx NE
human xxx DNA_B
autosome xxx DNA_M
11 dd DNA_E
, , NE
on xx NE
which xxx NE
the xxx NE
CD5 XXd DNA_B
gene xxx DNA_E
has xxx NE
been xxx NE
mapped xxx NE
, , NE
nor xxx NE
to xx NE
deletion xxx NE
of xx NE
the xxx NE
CD5 XXd DNA_B
structural xxx DNA_M
gene xxx DNA_E
. . NE

Furthermore Xxxx NE
, , NE
loss xxx NE
of xx NE
CD5 XXd NE
surface xxx NE
expression xxx NE
correlated xxx NE
with xxx NE
the xxx NE
absence xxx NE
of xx NE
specific xxx NE
mRNA xXXX RNA
. . NE

Since Xxxx NE
these xxx NE
hybrids xxx NE
preferentially xxx NE
segregate xxx NE
human xxx NE
chromosomes xxx NE
, , NE
these xxx NE
results xxx NE
indicate xxx NE
the xxx NE
existence xxx NE
of xx NE
a x NE
non-syntenic xxx-xxx DNA_B
trans-active xxx-xxx DNA_M
locus xxx DNA_E
, , NE
or xx NE
loci xxx NE
, , NE
positively xxx NE
controlling xxx NE
the xxx NE
expression xxx NE
of xx NE
the xxx NE
human xxx DNA_B
CD5 XXd DNA_M
gene xxx DNA_E
. . NE

Induction Xxxx NE
of xx NE
the xxx NE
CD11b XXddx DNA_B
gene xxx DNA_E
during xxx NE
activation xxx NE
of xx NE
the xxx NE
monocytic xxx cell_line_B
cell xxx cell_line_M
line xxx cell_line_M
U937 Xddd cell_line_E
requires xxx NE
a x NE
novel xxx NE
nuclear xxx protein_B
factor xxx protein_E
MS-2 XX-d protein
[published [xxx NE
erratum xxx NE
appears xxx NE
in xx NE
J X NE
Immunol Xxxx NE
1999 dddd NE
Jul Xxx NE
15;163(2):1091] dd;ddd(d):dddd] NE

The Xxx NE
differentiation xxx NE
of xx NE
myeloid xxx cell_type_B
precursors xxx cell_type_E
into xxx NE
mature xxx NE
myelomonocytic xxx cell_type_B
cells xxx cell_type_E
is xx NE
characterized xxx NE
by xx NE
the xxx NE
induction xxx NE
of xx NE
the xxx NE
gene xxx NE
encoding xxx NE
the xxx NE
beta2 xxxd protein_B
integrin xxx protein_E
CD11b XXddx protein
. . NE

The Xxx NE
transcription xxx protein_B
factors xxx protein_E
Sp1 Xxd protein
and xxx NE
PU.1 XX.d protein_B
prime xxx protein_E
the xxx NE
CD11b XXddx DNA_B
promoter xxx DNA_E
, , NE
but xxx NE
the xxx NE
nature xxx NE
of xx NE
the xxx NE
factors xxx NE
responsible xxx NE
for xxx NE
its xxx NE
inducible xxx NE
expression xxx NE
are xxx NE
unknown xxx NE
. . NE

In Xx NE
addition xxx NE
to xx NE
the xxx NE
CD11b XXddx DNA_B
gene xxx DNA_E
, , NE
the xxx NE
homologous xxx NE
genes xxx NE
encoding xxx NE
CD11a XXddx protein
and xxx NE
CD11c XXddx protein
also xxx NE
exhibit xxx NE
inducible xxx NE
expression xxx NE
during xxx NE
myeloid xxx NE
differentiation xxx NE
. . NE

Therefore Xxxx NE
, , NE
we xx NE
compared xxx NE
the xxx NE
nucleotide xxx DNA_B
sequences xxx DNA_E
of xx NE
the xxx NE
CD11a XXddx DNA_B
gene xxx DNA_M
promoter xxx DNA_M
and xxx DNA_M
CD11b XXddx DNA_M
gene xxx DNA_M
promoter xxx DNA_M
and xxx DNA_M
CD11c XXddx DNA_M
gene xxx DNA_M
promoter xxx DNA_E
to xx NE
identify xxx NE
common xxx NE
elements xxx NE
that xxx NE
might xxx NE
contribute xxx NE
to xx NE
inducible xxx NE
expression xxx NE
. . NE

This Xxxx NE
analysis xxx NE
identified xxx NE
one xxx NE
such xxx NE
element xxx NE
repeated xxx NE
four xxx NE
times xxx NE
within xxx NE
the xxx NE
CD11b XXddx DNA_B
promoter xxx DNA_E
. . NE

Mutation Xxxx NE
of xx NE
these xxx NE
elements xxx NE
indicated xxx NE
that xxx NE
two xxx NE
, , NE
MS-2beta XX-dxxx protein
and xxx NE
MS-2gamma XX-dxxx protein
, , NE
are xxx NE
critical xxx NE
to xx NE
the xxx NE
induction xxx NE
of xx NE
the xxx NE
CD11b XXddx DNA_B
gene xxx DNA_E
during xxx NE
differentiation xxx NE
of xx NE
the xxx NE
pro-monocytic xxx-xxx cell_line_B
cell xxx cell_line_M
line xxx cell_line_M
U937 Xddd cell_line_E
. . NE

Electrophoretic Xxxx NE
mobility xxx NE
shift xxx NE
assays xxx NE
indicate xxx NE
that xxx NE
MS-2beta XX-dxxx protein
and xxx NE
MS-2gamma XX-dxxx protein
interact xxx NE
with xxx NE
nuclear xxx protein_B
factors xxx protein_E
that xxx NE
are xxx NE
induced xxx NE
during xxx NE
U937 Xddd NE
differentiation xxx NE
. . NE

These Xxxx NE
factors xxx NE
are xxx NE
detected xxx NE
at xx NE
the xxx NE
time xxx NE
the xxx NE
CD11b XXddx DNA_B
promoter xxx DNA_E
is xx NE
activated xxx NE
. . NE

The Xxx NE
molecular xxx NE
mass xxx NE
of xx NE
these xxx NE
factors xxx NE
is xx NE
approximately xxx NE
28 dd NE
kDa xXx NE
, , NE
and xxx NE
their xxx NE
DNA XXX NE
binding xxx NE
characteristics xxx NE
are xxx NE
indistinguishable xxx NE
from xxx NE
those xxx NE
of xx NE
the xxx NE
novel xxx NE
nuclear xxx protein_B
factor xxx protein_E
MS-2 XX-d protein
. . NE

Taken Xxxx NE
together xxx NE
, , NE
our xxx NE
data xxx NE
indicate xxx NE
that xxx NE
MS-2 XX-d protein
mediates xxx NE
induction xxx NE
of xx NE
the xxx NE
CD11b XXddx DNA_B
gene xxx DNA_E
as xx NE
cells xxx NE
of xx NE
the xxx NE
monocytic xxx NE
lineage xxx NE
mature xxx NE
. . NE

The Xxx NE
presence xxx NE
of xx NE
multiple xxx NE
potential xxx NE
binding xxx NE
sites xxx NE
for xxx NE
MS-2 XX-d protein
in xx NE
the xxx NE
promoter xxx NE
regions xxx NE
of xx NE
a x NE
wide xxx NE
range xxx NE
of xx NE
genes xxx NE
expressed xxx NE
in xx NE
mature xxx cell_type_B
myeloid xxx cell_type_M
cells xxx cell_type_E
suggests xxx NE
this xxx NE
factor xxx NE
plays xxx NE
a x NE
general xxx NE
role xxx NE
in xx NE
myeloid xxx NE
differentiation xxx NE
. . NE

Acetylsalicylic Xxxx NE
acid xxx NE
and xxx NE
sodium xxx NE
salicylate xxx NE
inhibit xxx NE
LPS XXX NE
-induced -xxx NE
NF-kappa XX-xxx NE
B/c-Rel X/x-Xxx NE
nuclear xxx NE
translocation xxx NE
, , NE
and xxx NE
synthesis xxx NE
of xx NE
tissue xxx NE
factor xxx NE
( ( NE
TF XX NE
) ) NE
and xxx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
alfa xxx NE
( ( NE
TNF-alpha XXX-xxx NE
) ) NE
in xx NE
human xxx NE
monocytes xxx NE
. . NE

We Xx NE
have xxx NE
investigated xxx NE
the xxx NE
effects xxx NE
of xx NE
acetylsalicylic xxx NE
acid xxx NE
and xxx NE
sodium xxx NE
salicylate xxx NE
on xx NE
the xxx NE
LPS XXX NE
-induced -xxx NE
synthesis xxx NE
of xx NE
the xxx NE
pro-coagulant xxx-xxx NE
protein xxx NE
tissue xxx NE
factor xxx NE
(TF) (XX) NE
and xxx NE
the xxx NE
pro-inflammatory xxx-xxx NE
protein xxx NE
tumor xxx NE
necrosis xxx NE
factor-alpha xxx-xxx NE
( ( NE
TNF-alpha XXX-xxx protein
) ) NE
, , NE
as xx NE
well xxx NE
as xx NE
the xxx NE
prostaglandin xxx protein_B
PGE2 XXXd protein_E
in xx NE
human xxx cell_type_B
monocytes xxx cell_type_E
. . NE

Both Xxxx NE
drugs xxx NE
dose-dependently xxx-xxx NE
inhibited xxx NE
LPS XXX NE
-induced -xxx NE
TF XX NE
and xxx NE
TNF-alpha XXX-xxx NE
synthesis xxx NE
at xx NE
the xxx NE
mRNA xXXX NE
and xxx NE
the xxx NE
protein xxx NE
level xxx NE
, , NE
and xxx NE
reduced xxx NE
PGE2 XXXd NE
production xxx NE
. . NE

As Xx NE
evidenced xxx NE
by xx NE
electro xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
( ( NE
EMSA XXXX NE
) ) NE
and xxx NE
the xxx NE
use xxx NE
of xx NE
a x NE
NF-kappa XX-xxx DNA_B
B X DNA_M
prototypic xxx DNA_M
probe xxx DNA_E
, , NE
these xxx NE
drugs xxx NE
probably xxx NE
exert xxx NE
their xxx NE
inhibitory xxx NE
effects xxx NE
by xx NE
interference xxx NE
with xxx NE
the xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B/c-Rel X/x-Xxx protein_M
proteins xxx protein_E
. . NE

These Xxxx NE
data xxx NE
may xxx NE
expand xxx NE
the xxx NE
understanding xxx NE
of xx NE
the xxx NE
anti-thrombotic xxx-xxx NE
and xxx NE
anti-inflammatory xxx-xxx NE
effects xxx NE
of xx NE
these xxx NE
drugs xxx NE
when xxx NE
activation xxx NE
of xx NE
monocytes xxx NE
occurs xxx NE
. . NE

Interferon Xxxx NE
augments xxx NE
PML XXX protein
and xxx NE
PML/RAR XXX/XXX NE
alpha xxx NE
expression xxx NE
in xx NE
normal xxx NE
myeloid xxx NE
and xxx NE
acute xxx NE
promyelocytic xxx NE
cells xxx NE
and xxx NE
cooperates xxx NE
with xxx NE
all-trans xxx-xxx NE
retinoic xxx NE
acid xxx NE
to xx NE
induce xxx NE
maturation xxx NE
of xx NE
a x NE
retinoid-resistant xxx-xxx NE
promyelocytic xxx NE
cell xxx NE
line xxx NE
. . NE

The Xxx NE
PML XXX DNA_B
gene xxx DNA_E
is xx NE
fused xxx NE
to xx NE
the xxx NE
retinoic xxx DNA_B
acid xxx DNA_M
receptor xxx DNA_M
alpha xxx DNA_M
gene xxx DNA_E
( ( NE
RAR XXX DNA_B
alpha xxx DNA_E
) ) NE
in xx NE
the xxx NE
acute xxx NE
promyelocytic xxx NE
leukemia xxx NE
( ( NE
APL XXX NE
) ) NE
15 dd NE
; ; NE
17 dd NE
translocation xxx NE
. . NE

PML XXX protein
is xx NE
expressed xxx NE
in xx NE
diverse xxx NE
tissues xxx NE
and xxx NE
cell xxx NE
lines xxx NE
and xxx NE
localized xxx NE
in xx NE
the xxx NE
nucleus xxx NE
with xxx NE
a x NE
typical xxx NE
speckled xxx NE
pattern xxx NE
. . NE

In Xx NE
the xxx NE
bone xxx NE
marrow xxx NE
, , NE
it xx NE
is xx NE
preferentially xxx NE
expressed xxx NE
in xx NE
myeloid xxx cell_type_B
cells xxx cell_type_E
. . NE

PML XXX protein
appears xxx NE
to xx NE
be xx NE
transcriptionally xxx NE
regulated xxx NE
by xx NE
class xxx protein_B
I X protein_M
interferon xxx protein_M
and xxx protein_M
class xxx protein_M
II XX protein_M
interferon xxx protein_E
myeloid xxx NE
cells xxx NE
and xxx NE
precursors xxx NE
by xx NE
activating xxx NE
PML XXX NE
-dependent -xxx NE
pathways xxx NE
. . NE

Similarly Xxxx NE
, , NE
interferons xxx NE
could xxx NE
act xxx NE
on xx NE
APL XXX cell_type_B
cells xxx cell_type_E
, , NE
alone xxx NE
or xx NE
in xx NE
combination xxx NE
with xxx NE
all-trans xxx-xxx NE
retinoic xxx NE
acid xxx NE
( ( NE
RA XX NE
) ) NE
, , NE
especially xxx NE
if xx NE
the xxx NE
PML/RAR XXX/XXX RNA_B
alpha xxx RNA_M
fusion xxx RNA_M
transcript xxx RNA_E
that xxx NE
results xxx NE
from xxx NE
the xxx NE
t(15; x(dd; DNA_B
17) dd) DNA_E
is xx NE
induced xxx NE
by xx NE
interferon xxx protein
. . NE

We Xx NE
report xxx NE
here xxx NE
that xxx NE
PML XXX protein
is xx NE
expressed xxx NE
at xx NE
low xxx NE
levels xxx NE
or xx NE
not xxx NE
expressed xxx NE
in xx NE
normal xxx NE
circulating xxx NE
human xxx cell_type_B
monocytes xxx cell_type_E
, , NE
lymphocytes xxx cell_type
, , NE
and xxx NE
polymorphonucleate xxx cell_type_B
cells xxx cell_type_E
, , NE
but xxx NE
is xx NE
markedly xxx NE
induced xxx NE
by xx NE
interferon xxx protein
; ; NE
that xxx NE
PML XXX protein
and xxx NE
PML/RAR XXX/XXX NE
alpha xxx NE
expression xxx NE
is xx NE
augmented xxx NE
by xx NE
interferon xxx protein
in xx NE
the xxx NE
NB4 XXd cell_line_B
APL XXX cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
, , NE
which xxx NE
carries xxx NE
the xxx NE
t(15; x(dd; DNA_B
17) dd) DNA_E
, , NE
and xxx NE
in xx NE
APL XXX cell_type_B
blasts xxx cell_type_E
from xxx NE
patients xxx NE
; ; NE
that xxx NE
interferon xxx protein
inhibits xxx NE
growth xxx NE
and xxx NE
survival xxx NE
of xx NE
NB4 XXd NE
APL XXX cell_type_B
cells xxx cell_type_E
in xx NE
cooperation xxx NE
with xxx NE
RA XX NE
; ; NE
that xxx NE
interferons xxx NE
alone xxx NE
have xxx NE
minimal xxx NE
maturation xxx NE
effect xxx NE
on xx NE
NB4 XXd cell_line_B
cells xxx cell_line_E
; ; NE
and xxx NE
, , NE
finally xxx NE
, , NE
that xxx NE
interferon xxx protein_B
gamma xxx protein_M
but xxx protein_M
not xxx protein_M
(OR (XX protein_M
but xxx protein_M
not xxx protein_M
interferon xxx protein_M
alpha xxx protein_M
but xxx protein_M
not xxx protein_M
interferon xxx protein_M
beta) xxx) protein_E
or xx NE
beta xxx NE
, , NE
induces xxx NE
maturation xxx NE
and xxx NE
growth xxx NE
suppression xxx NE
of xx NE
NB4 XXd cell_line_B
cells xxx cell_line_E
with xxx NE
de xx NE
novo xxx NE
retinoid xxx NE
resistance xxx NE
, , NE
and xxx NE
partially xxx NE
restores xxx NE
RA XX NE
response xxx NE
. . NE

Effects Xxxx NE
of xx NE
Ara-C Xxx-X NE
on xx NE
neutral xxx protein_B
sphingomyelinase xxx protein_E
and xxx NE
mitogen- xxx- protein_B
activated xxx protein_M
protein xxx protein_M
kinase xxx protein_M
and xxx protein_M
stress- xxx- protein_M
activated xxx protein_M
protein xxx protein_M
kinase xxx protein_E

Neutral Xxxx protein_B
sphingomyelinase xxx protein_E
( ( NE
SMase XXxxx protein
) ) NE
can xxx NE
be xx NE
activated xxx NE
by xx NE
extracellular xxx NE
signals xxx NE
to xx NE
produce xxx NE
ceramide xxx NE
, , NE
which xxx NE
may xxx NE
affect xxx NE
mitogen-activated xxx-xxx NE
protein xxx NE
kinase xxx NE
( ( NE
MAPK XXXX NE
) ) NE
activities xxx NE
. . NE

Neutral Xxxx NE
SMase XXxxx NE
activity xxx NE
was xxx NE
assessed xxx NE
in xx NE
membranes xxx NE
from xxx NE
Jurkat Xxxx cell_line
, , NE
a x NE
human xxx cell_line_B
T-cell X-xxx cell_line_M
line xxx cell_line_E
, , NE
and xxx NE
EL4 XXd cell_line
, , NE
a x NE
murine xxx cell_line_B
T-cell X-xxx cell_line_M
line xxx cell_line_E
. . NE

Ara-C Xxx-X NE
activated xxx NE
SMase XXxxx protein
with xxx NE
10 dd NE
minutes xxx NE
in xx NE
both xxx NE
Jurkat Xxxx NE
and xxx NE
EL4 XXd cell_line_B
cells xxx cell_line_E
, , NE
while xxx NE
phorbol xxx NE
ester xxx NE
( ( NE
PMA XXX NE
) ) NE
had xxx NE
no xx NE
effect xxx NE
. . NE

PMA XXX NE
, , NE
but xxx NE
not xxx NE
Ara-C Xxx-X NE
or xx NE
ceramides xxx NE
, , NE
activated xxx NE
ERK XXX protein_B
MAPKS XXXXX protein_E
, , NE
in xx NE
Jurkat Xxxx cell_line
and xxx NE
EL4 XXd cell_line
. . NE

PMA XXX NE
acted xxx NE
synergistically xxx NE
with xxx NE
ionomycin xxx NE
to xx NE
activate xxx NE
JNK XXX protein_B
MAPKs XXXXx protein_E
in xx NE
Jurkat Xxxx cell_line
and xxx NE
EL4 XXd cell_line
within xxx NE
10 dd NE
minutes xxx NE
. . NE

Ara-C Xxx-X NE
activated xxx NE
JNKs XXXx protein
only xxx NE
after xxx NE
prolonged xxx NE
incubation xxx NE
(90-120 (dd-ddd NE
minutes) xxx) NE
. . NE

Thus Xxxx NE
, , NE
ceramide xxx NE
is xx NE
not xxx NE
a x NE
positive xxx NE
signal xxx NE
for xxx NE
ERK XXX NE
activation xxx NE
in xx NE
T-cell X-xxx cell_line_B
lines xxx cell_line_E
. . NE

The Xxx NE
effects xxx NE
of xx NE
Ara-C Xxx-X NE
on xx NE
JNK XXX NE
activity xxx NE
may xxx NE
be xx NE
mediated xxx NE
through xxx NE
secondary xxx NE
response xxx NE
pathways xxx NE
. . NE

Comparative Xxxx NE
analysis xxx NE
identifies xxx NE
conserved xxx NE
tumor xxx DNA_B
necrosis xxx DNA_M
factor xxx DNA_M
receptor xxx DNA_E
-associated -xxx NE
factor xxx NE
3 d NE
binding xxx NE
sites xxx NE
in xx NE
the xxx NE
human xxx DNA_B
Epstein-Barr Xxxx-Xxxx DNA_M
virus xxx DNA_M
oncogene xxx DNA_M
LMP1 XXXd DNA_M
and xxx DNA_M
simian xxx DNA_M
Epstein-Barr Xxxx-Xxxx DNA_M
virus xxx DNA_M
oncogene xxx DNA_M
LMP1 XXXd DNA_E

Nonhuman Xxxx NE
primates xxx NE
are xxx NE
naturally xxx NE
infected xxx NE
with xxx NE
a x NE
B-lymphotropic X-xxx NE
herpesvirus xxx NE
closely xxx NE
related xxx NE
to xx NE
Epstein-Barr Xxxx-Xxxx NE
virus xxx NE
( ( NE
EBV XXX NE
) ) NE
. . NE

These Xxxx NE
simian xxx NE
EBV XXX NE
share xxx NE
considerable xxx NE
genetic xxx NE
, , NE
biologic xxx NE
, , NE
and xxx NE
epidemiologic xxx NE
features xxx NE
with xxx NE
human xxx NE
EBV XXX NE
, , NE
including xxx NE
virus-induced xxx-xxx NE
tumorigenesis xxx NE
. . NE

However Xxxx NE
, , NE
latent xxx NE
, , NE
transformation-associated xxx-xxx NE
viral xxx NE
genes xxx NE
demonstrate xxx NE
marked xxx NE
sequence xxx NE
divergence xxx NE
among xxx NE
species xxx NE
despite xxx NE
the xxx NE
conserved xxx NE
functions xxx NE
. . NE

We Xx NE
have xxx NE
cloned xxx NE
the xxx NE
latent xxx NE
membrane xxx NE
protein xxx NE
1 d NE
( ( NE
LMP1 XXXd NE
) ) NE
homologs xxx NE
from xxx NE
the xxx NE
simian xxx NE
EBV XXX NE
naturally xxx NE
infecting xxx NE
baboons xxx NE
( ( NE
cercopithicine xxx NE
herpesvirus xxx NE
12 dd NE
, , NE
herpesvirus xxx NE
papio xxx NE
) ) NE
and xxx NE
rhesus xxx NE
monkeys xxx NE
( ( NE
cercopithicine xxx NE
herpesvirus xxx NE
15 dd NE
) ) NE
for xxx NE
a x NE
comparative xxx NE
study xxx NE
with xxx NE
the xxx NE
human xxx NE
EBV XXX NE
oncogene xxx NE
. . NE

The Xxx NE
transmembrane xxx NE
domains xxx NE
are xxx NE
well xxx NE
conserved xxx NE
, , NE
but xxx NE
there xxx NE
is xx NE
striking xxx NE
sequence xxx NE
divergence xxx NE
of xx NE
the xxx NE
carboxy-terminal xxx-xxx protein_B
cytoplasmic xxx protein_M
domain xxx protein_E
essential xxx NE
for xxx NE
B-cell X-xxx NE
immortalization xxx NE
and xxx NE
interaction xxx NE
with xxx NE
the xxx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor xxx NE
signaling xxx NE
pathway xxx NE
. . NE

Nevertheless Xxxx NE
, , NE
the xxx NE
simian xxx protein_B
EBV XXX protein_M
LMP1s XXXdx protein_E
retain xxx NE
most xxx NE
functions xxx NE
in xx NE
common xxx NE
with xxx NE
EBV XXX NE
LMP1 XXXd protein
, , NE
including xxx NE
the xxx NE
ability xxx NE
to xx NE
induce xxx NE
NF-(kappa)B XX-(xxx)X NE
activity xxx NE
in xx NE
human xxx NE
cells xxx NE
, , NE
to xx NE
bind xxx NE
the xxx NE
tumor xxx NE
necrosis xxx NE
factor-associated xxx-xxx NE
factor xxx NE
3 d NE
( ( NE
TRAF3 XXXXd NE
) ) NE
in xx NE
vitro xxx NE
, , NE
and xxx NE
to xx NE
induce xxx NE
expression xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor-responsive xxx-xxx NE
genes xxx NE
, , NE
such xxx NE
as xx NE
ICAM1 XXXXd NE
, , NE
in xx NE
human xxx NE
B X NE
lymphocytes xxx NE
. . NE

Multiple Xxxx NE
TRAF3 XXXXd DNA_B
binding xxx DNA_M
sites xxx DNA_E
containing xxx NE
a x NE
PXQXT/S XXXXX/X DNA_B
core xxx DNA_M
sequence xxx DNA_E
can xxx NE
be xx NE
identified xxx NE
in xx NE
the xxx NE
simian xxx protein_B
EBV XXX protein_M
LMP1s XXXdx protein_E
by xx NE
an xx NE
in xx NE
vitro xxx NE
binding xxx NE
assay xxx NE
. . NE

A X NE
PXQXT/S-containing XXXXX/X-xxx DNA_B
sequence xxx DNA_E
is xx NE
also xxx NE
present xxx NE
in xx NE
the xxx NE
cytoplasmic xxx protein_B
domain xxx protein_E
of xx NE
the xxx NE
Hodgkin's Xxxx'x NE
disease xxx NE
marker xxx NE
, , NE
CD30 XXdd protein
, , NE
and xxx NE
binds xxx NE
TRAF3 XXXXd protein
in xx NE
vitro xxx NE
. . NE

The Xxx NE
last xxx protein_B
13 dd protein_M
amino xxx protein_M
acids xxx protein_E
containing xxx NE
a x NE
PXQXT/S XXXXX/X DNA_B
sequence xxx DNA_E
are xxx NE
highly xxx NE
conserved xxx NE
in xx NE
human xxx NE
and xxx NE
simian xxx NE
EBV XXX NE
LMP1 XXXd protein
but xxx NE
do xx NE
not xxx NE
bind xxx NE
TRAF3 XXXXd protein
, , NE
suggesting xxx NE
a x NE
distinct xxx NE
role xxx NE
for xxx NE
this xxx NE
conserved xxx NE
region xxx NE
of xx NE
LMP1 XXXd protein
. . NE

The Xxx NE
conserved xxx NE
TRAF3 XXXXd DNA_B
binding xxx DNA_M
sites xxx DNA_E
in xx NE
LMP1 XXXd protein
and xxx NE
the xxx NE
CD30 XXdd protein_B
Hodgkin's Xxxx'x protein_M
disease xxx protein_M
marker xxx protein_E
provides xxx NE
further xxx NE
evidence xxx NE
that xxx NE
a x NE
TRAF3 XXXXd NE
-mediated -xxx NE
signal xxx NE
transduction xxx NE
pathway xxx NE
may xxx NE
be xx NE
important xxx NE
in xx NE
malignant xxx NE
transformation xxx NE
. . NE

Chromosome Xxxx NE
1 d NE
aneusomy xxx NE
with xxx NE
1p36 dxdd NE
under-representation xxx-xxx NE
is xx NE
related xxx NE
to xx NE
histologic xxx NE
grade xxx NE
, , NE
DNA XXX NE
aneuploidy xxx NE
, , NE
high xxx NE
c-erb x-xxx protein_B
B-2 X-d protein_E
and xxx NE
loss xxx NE
of xx NE
bcl-2 xxx-d NE
expression xxx NE
in xx NE
ductal xxx NE
breast xxx NE
carcinoma xxx NE
. . NE

Chromosome Xxxx DNA_B
1 d DNA_E
abnormalities xxx NE
with xxx NE
loss xxx NE
of xx NE
1p36 dxdd DNA
have xxx NE
been xxx NE
investigated xxx NE
in xx NE
95 dd NE
breast-cancer xxx-xxx NE
samples xxx NE
by xx NE
means xxx NE
of xx NE
a x NE
dual-target xxx-xxx NE
fluorescence xxx NE
in-situ xx-xxx NE
hybridization xxx NE
( ( NE
FISH XXXX NE
) ) NE
technique xxx NE
using xxx NE
the xxx NE
pUC xXX DNA_B
1.77 d.dd DNA_E
and xxx NE
p1-79 xd-dd DNA_B
probes xxx DNA_E
, , NE
specific xxx NE
for xxx NE
the xxx NE
1q12 dxdd DNA_B
region xxx DNA_M
and xxx DNA_M
1p36 dxdd DNA_M
region xxx DNA_E

Abnormalities Xxxx NE
for xxx NE
one xxx NE
or xx NE
both xxx NE
probes xxx NE
were xxx NE
detected xxx NE
in xx NE
83/95 dd/dd NE
samples xxx NE
. . NE

Relative Xxxx NE
1p36 dxdd DNA
under-representation xxx-xxx NE
was xxx NE
found xxx NE
in xx NE
79/95 dd/dd NE
. . NE

The Xxx NE
clinical xxx NE
relevance xxx NE
of xx NE
these xxx NE
alterations xxx NE
was xxx NE
studied xxx NE
by xx NE
comparing xxx NE
the xxx NE
FISH XXXX NE
results xxx NE
with xxx NE
several xxx NE
parameters xxx NE
currently xxx NE
used xxx NE
in xx NE
breast-cancer xxx-xxx NE
pathology xxx NE
. . NE

Distinct Xxxx NE
patterns xxx NE
of xx NE
chromosome xxx NE
1 d NE
abnormalities xxx NE
were xxx NE
found xxx NE
among xxx NE
the xxx NE
histologic xxx NE
types xxx NE
of xx NE
breast xxx NE
carcinoma xxx NE
. . NE

Lobular Xxxx NE
or xx NE
mucinous xxx NE
samples xxx NE
showed xxx NE
few xxx NE
or xx NE
no xx NE
alterations xxx NE
, , NE
whereas xxx NE
most xxx NE
ductal xxx NE
samples xxx NE
had xxx NE
high xxx NE
chromosome xxx NE
1 d NE
polysomy xxx NE
with xxx NE
under-representation xxx-xxx NE
of xx NE
1p36 dxdd DNA
. . NE

In Xx NE
ductal xxx NE
carcinomas xxx NE
, , NE
chromosome xxx DNA_B
1 d DNA_E
alterations xxx NE
increased xxx NE
with xxx NE
histologic xxx NE
grade xxx NE
, , NE
DNA XXX NE
aneuploidy xxx NE
, , NE
loss xxx NE
of xx NE
bcl-2 xxx-d NE
and xxx NE
high xxx NE
c-erb x-xxx protein_B
B-2 X-d protein_E
expression xxx NE
. . NE

These Xxxx NE
associations xxx NE
were xxx NE
found xxx NE
to xx NE
be xx NE
statistically xxx NE
significant xxx NE
. . NE

No Xx NE
correlation xxx NE
between xxx NE
chromosome xxx NE
1 d NE
alterations xxx NE
and xxx NE
nuclear xxx NE
grade xxx NE
, , NE
age xxx NE
, , NE
size xxx NE
, , NE
lymph-node xxx-xxx NE
involvement xxx NE
, , NE
hormonal xxx NE
receptor xxx NE
presence xxx NE
, , NE
proliferation xxx NE
activity xxx NE
or xx NE
p53 xdd NE
protein xxx NE
expression xxx NE
was xxx NE
detected xxx NE
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
the xxx NE
utility xxx NE
of xx NE
this xxx NE
FISH XXXX NE
technique xxx NE
for xxx NE
a x NE
better xxx NE
definition xxx NE
of xx NE
the xxx NE
biological xxx NE
characteristics xxx NE
of xx NE
ductal xxx NE
carcinomas xxx NE
. . NE

G(Anh)MTetra X(Xxx)XXxxx NE
, , NE
a x NE
natural xxx NE
bacterial xxx NE
cell xxx NE
wall xxx NE
breakdown xxx NE
product xxx NE
, , NE
induces xxx NE
interleukin-1 xxx-d protein_B
beta xxx protein_E
and xxx NE
interleukin-6 xxx-d NE
expression xxx NE
in xx NE
human xxx cell_type_B
monocytes xxx cell_type_E
. . NE

A X NE
study xxx NE
of xx NE
the xxx NE
molecular xxx NE
mechanisms xxx NE
involved xxx NE
in xx NE
inflammatory xxx NE
cytokine xxx NE
expression xxx NE
[published [xxx NE
erratum xxx NE
appears xxx NE
in xx NE
J X NE
Biol Xxxx NE
Chem Xxxx NE
1994 dddd NE
Jun Xxx NE
17;269(24):16983] dd;ddd(dd):ddddd] NE

It Xx NE
is xx NE
believed xxx NE
that xxx NE
induction xxx NE
of xx NE
cytokine xxx NE
expression xxx NE
by xx NE
bacterial xxx NE
cell xxx NE
wall xxx NE
components xxx NE
plays xxx NE
a x NE
role xxx NE
in xx NE
the xxx NE
development xxx NE
and xxx NE
course xxx NE
of xx NE
sepsis xxx NE
. . NE

However Xxxx NE
, , NE
most xxx NE
attention xxx NE
has xxx NE
been xxx NE
focused xxx NE
on xx NE
lipopolysaccharide xxx NE
( ( NE
LPS XXX NE
) ) NE
. . NE

We Xx NE
studied xxx NE
the xxx NE
ability xxx NE
of xx NE
N-acetylglucosaminyl-1,6-anhydro-N-acetylmuramyl-L-alanyl-D- X-xxx-d,d-xxx-X-xxx-X-xxx-X- NE
isoglutamyl-m-diaminopimelyl-D-alanine xxx-x-xxx-X-xxx NE
( ( NE
G(Anh)MTetra X(Xxx)XXxxx NE
) ) NE
, , NE
a x NE
naturally xxx NE
occurring xxx NE
breakdown xxx NE
product xxx NE
of xx NE
peptidoglycan xxx NE
that xxx NE
is xx NE
produced xxx NE
by xx NE
soluble xxx NE
lytic xxx protein_B
transglycosylase xxx protein_E
of xx NE
Escherichia Xxxx NE
coli xxx NE
, , NE
to xx NE
induce xxx NE
cytokine xxx NE
expression xxx NE
in xx NE
human xxx cell_type_B
monocytes xxx cell_type_E
. . NE

G(Anh)MTetra X(Xxx)XXxxx NE
was xxx NE
found xxx NE
to xx NE
strongly xxx NE
induce xxx NE
interleukin xxx protein_B
(IL)-1 (XX)-d protein_M
beta xxx protein_E
and xxx NE
IL-6 XX-d NE
mRNA xXXX NE
expression xxx NE
after xxx NE
2 d NE
h x NE
and xxx NE
IL-1 XX-d protein_B
beta xxx protein_E
and xxx NE
IL-6 XX-d NE
protein xxx NE
secretion xxx NE
after xxx NE
48 dd NE
h x NE
of xx NE
activation xxx NE
. . NE

The Xxx NE
increase xxx NE
in xx NE
mRNA xXXX NE
accumulation xxx NE
was xxx NE
at xx NE
least xxx NE
partly xxx NE
due xxx NE
to xx NE
an xx NE
increase xxx NE
in xx NE
the xxx NE
transcription xxx NE
rates xxx NE
of xx NE
the xxx NE
respective xxx NE
genes xxx DNA
and xxx NE
was xxx NE
accompanied xxx NE
by xx NE
a x NE
strong xxx NE
induction xxx NE
of xx NE
nuclear xxx NE
factor-kappa xxx-xxx NE
B X NE
transcription xxx NE
factor xxx NE
expression xxx NE
and xxx NE
activator xxx NE
protein-1 xxx-d NE
transcription xxx NE
factor xxx NE
expression xxx NE

Experiments Xxxx NE
using xxx NE
inhibitors xxx NE
of xx NE
protein xxx protein_B
kinase xxx protein_M
C X protein_E
, , NE
protein xxx protein_B
kinase xxx protein_M
A X protein_E
, , NE
and xxx NE
tyrosine xxx NE
kinase-dependent xxx-xxx NE
pathways xxx NE
revealed xxx NE
that xxx NE
G(Anh)MTetra X(Xxx)XXxxx NE
-induced -xxx NE
IL-1 XX-d protein_B
beta xxx protein_E
and xxx NE
IL-6 XX-d NE
mRNA xXXX NE
expression xxx NE
involves xxx NE
activation xxx NE
of xx NE
an xx NE
H7-inhibitable Xd-xxx NE
pathway xxx NE
. . NE

By Xx NE
using xxx NE
the xxx NE
protein xxx NE
synthesis xxx NE
inhibitor xxx NE
cycloheximide xxx NE
, , NE
it xx NE
was xxx NE
shown xxx NE
that xxx NE
G(Anh)MTetra X(Xxx)XXxxx NE
-induced -xxx NE
IL-6 XX-d NE
mRNA xXXX NE
expression xxx NE
depends xxx NE
on xx NE
the xxx NE
synthesis xxx NE
of xx NE
new xxx NE
protein xxx NE
, , NE
whereas xxx NE
G(Anh)MTetra X(Xxx)XXxxx NE
-induced -xxx NE
IL-1 XX-d NE
beta xxx NE
mRNA xXXX NE
accumulation xxx NE
does xxx NE
not xxx NE
. . NE

When Xxxx NE
responses xxx NE
to xx NE
G(Anh)MTetra X(Xxx)XXxxx NE
were xxx NE
compared xxx NE
with xxx NE
those xxx NE
to xx NE
LPS XXX NE
and xxx NE
muramyldipeptide xxx NE
( ( NE
MDP XXX NE
) ) NE
, , NE
it xx NE
was xxx NE
found xxx NE
that xxx NE
the xxx NE
optimal xxx NE
response xxx NE
to xx NE
G(Anh)MTetra X(Xxx)XXxxx NE
induction xxx NE
was xxx NE
similar xxx NE
to xx NE
that xxx NE
of xx NE
LPS XXX NE
but xxx NE
significantly xxx NE
higher xxx NE
than xxx NE
the xxx NE
response xxx NE
to xx NE
MDP XXX NE
. . NE

Furthermore Xxxx NE
, , NE
maximal xxx NE
G(Anh)MTetra X(Xxx)XXxxx NE
-induced -xxx NE
IL-1 XX-d NE
beta xxx NE
and xxx NE
IL-6 XX-d NE
mRNA xXXX NE
expression xxx NE
could xxx NE
be xx NE
enhanced xxx NE
by xx NE
co-stimulation xx-xxx NE
with xxx NE
LPS XXX NE
or xx NE
MDP XXX NE
, , NE
suggesting xxx NE
that xxx NE
different xxx NE
receptors xxx NE
and/or xxx/xx NE
transduction xxx NE
pathways xxx NE
were xxx NE
involved xxx NE
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
G(Anh)MTetra X(Xxx)XXxxx NE
induces xxx NE
IL-1 XX-d protein_B
beta xxx protein_E
and xxx NE
IL-6 XX-d protein
expression xxx NE
in xx NE
human xxx cell_type_B
monocytes xxx cell_type_E
suggesting xxx NE
a x NE
possible xxx NE
role xxx NE
for xxx NE
G(Anh)MTetra X(Xxx)XXxxx NE
in xx NE
the xxx NE
release xxx NE
of xx NE
cytokines xxx protein
during xxx NE
sepsis xxx NE
. . NE

Increased Xxxx NE
proliferation xxx NE
, , NE
cytotoxicity xxx NE
, , NE
and xxx NE
gene xxx NE
expression xxx NE
after xxx NE
stimulation xxx NE
of xx NE
human xxx cell_type_B
peripheral xxx cell_type_M
blood xxx cell_type_M
T X cell_type_M
lymphocytes xxx cell_type_E
through xxx NE
a x NE
surface xxx NE
ganglioside xxx NE
( ( NE
GD3 XXd NE
) ) NE
[published [xxx NE
erratum xxx NE
appears xxx NE
in xx NE
J X NE
Immunol Xxxx NE
1994 dddd NE
Jul Xxx NE
15;153(2):910] dd;ddd(d):ddd] NE

Previous Xxxx NE
studies xxx NE
have xxx NE
suggested xxx NE
that xxx NE
gangliosides xxx NE
have xxx NE
an xx NE
important xxx NE
role xxx NE
in xx NE
cell xxx NE
signaling xxx NE
and xxx NE
recognition xxx NE
. . NE

However Xxxx NE
, , NE
their xxx NE
specific xxx NE
function xxx NE
in xx NE
these xxx NE
processes xxx NE
has xxx NE
not xxx NE
been xxx NE
clearly xxx NE
defined xxx NE
. . NE

A X NE
mAb xXx protein
, , NE
R24 Xdd protein
, , NE
that xxx NE
reacts xxx NE
specifically xxx NE
with xxx NE
a x NE
cell xxx NE
surface xxx NE
ganglioside xxx NE
( ( NE
GD3 XXd NE
) ) NE
has xxx NE
been xxx NE
demonstrated xxx NE
to xx NE
stimulate xxx NE
proliferation xxx NE
of xx NE
T X cell_type_B
cells xxx cell_type_E
derived xxx NE
from xxx NE
human xxx NE
peripheral xxx NE
blood xxx NE
. . NE

In Xx NE
this xxx NE
study xxx NE
, , NE
we xx NE
have xxx NE
investigated xxx NE
the xxx NE
mechanisms xxx NE
by xx NE
which xxx NE
the xxx NE
R24 Xdd protein_B
mAb xXx protein_E
affects xxx NE
T X NE
cell xxx NE
functions xxx NE
. . NE

We Xx NE
have xxx NE
observed xxx NE
that xxx NE
the xxx NE
R24 Xdd protein_B
mAb xXx protein_E
stimulates xxx NE
GD3 XXd NE
+ + NE
T X NE
cell xxx NE
proliferation xxx NE
, , NE
cytotoxicity xxx NE
, , NE
and xxx NE
surface xxx NE
marker xxx NE
expression xxx NE
of xx NE
IL-2R XX-dX NE
alpha-chain xxx-xxx NE
, , NE
IL-2R XX-dX NE
beta-chain xxx-xxx NE
, , NE
HLA-DR XXX-XX NE
, , NE
CD11a XXddx NE
, , NE
and xxx NE
CD11c XXddx NE
. . NE

Additionally Xxxx NE
, , NE
IFN-gamma XXX-xxx NE
activity xxx NE
but xxx NE
not xxx NE
IL-1 XX-d NE
activity xxx NE
or xx NE
IL-2 XX-d NE
activity xxx NE
or xx NE
IL-4 XX-d NE
activity xxx NE
was xxx NE
present xxx NE
in xx NE
culture xxx NE
supernatants xxx NE
72 dd NE
h x NE
after xxx NE
R24 Xdd NE
stimulation xxx NE
. . NE

In Xx NE
some xxx NE
donors xxx NE
, , NE
increased xxx NE
IL-6 XX-d protein
and xxx NE
TNF-alpha XXX-xxx NE
activity xxx NE
also xxx NE
was xxx NE
detected xxx NE
after xxx NE
R24 Xdd NE
treatment xxx NE
. . NE

Furthermore Xxxx NE
, , NE
R24 Xdd protein
treatment xxx NE
resulted xxx NE
in xx NE
translocation xxx NE
of xx NE
c-rel x-xxx protein
, , NE
but xxx NE
little xxx NE
or xx NE
no xx NE
NF XX protein_B
kappa xxx protein_M
B X protein_M
p50 xdd protein_E
or xx NE
p65 xdd protein
, , NE
from xxx NE
the xxx NE
cytoplasm xxx NE
to xx NE
the xxx NE
nucleus xxx NE
and xxx NE
an xx NE
increase xxx NE
of xx NE
NF XX NE
kappa xxx NE
B X NE
binding xxx NE
complexes xxx NE
containing xxx NE
c-rel x-xxx NE
and xxx NE
p50 xdd NE
. . NE

This Xxxx NE
treatment xxx NE
also xxx NE
caused xxx NE
increased xxx NE
tyrosine xxx NE
phosphorylation xxx NE
of xx NE
specific xxx NE
protein xxx NE
substrates xxx NE
. . NE

R24 Xdd protein
-stimulated -xxx NE
increases xxx NE
in xx NE
proliferation xxx NE
, , NE
cytotoxicity xxx NE
, , NE
and xxx NE
cell xxx NE
surface xxx NE
protein xxx NE
expression xxx NE
could xxx NE
be xx NE
blocked xxx NE
by xx NE
cyclosporin xxx NE
and xxx NE
staurosporin xxx NE
, , NE
indicating xxx NE
that xxx NE
cyclophilin/calcineurin xxx/xxx protein
and xxx NE
protein xxx protein_B
kinase xxx protein_M
C X protein_E
may xxx NE
be xx NE
involved xxx NE
in xx NE
the xxx NE
R24 Xdd protein
signaling xxx NE
pathway xxx NE
. . NE

Additionally Xxxx NE
, , NE
herbimycin xxx NE
A X NE
, , NE
a x NE
tyrosine xxx NE
kinase xxx NE
inhibitor xxx NE
, , NE
blocked xxx NE
the xxx NE
R24 Xdd NE
-stimulated -xxx NE
increase xxx NE
in xx NE
proliferation xxx NE
but xxx NE
not xxx NE
cytotoxicity xxx NE
at xx NE
concentrations xxx NE
consistent xxx NE
with xxx NE
specificity xxx NE
for xxx NE
tyrosine xxx NE
kinases xxx NE
. . NE

These Xxxx NE
results xxx NE
suggest xxx NE
that xxx NE
multiple xxx NE
biochemical xxx NE
pathways xxx NE
are xxx NE
involved xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
human xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
by xx NE
R24 Xdd protein
. . NE

Genes Xxxx NE
encoding xxx NE
general xxx protein_B
initiation xxx protein_M
factors xxx protein_E
for xxx NE
RNA XXX NE
polymerase xxx NE
II XX NE
transcription xxx NE
are xxx NE
dispersed xxx NE
in xx NE
the xxx NE
human xxx DNA_B
genome xxx DNA_E
. . NE

General Xxxx protein_B
transcription xxx protein_M
factors xxx protein_E
are xxx NE
required xxx NE
for xxx NE
accurate xxx NE
initiation xxx NE
of xx NE
transcription xxx NE
by xx NE
RNA XXX protein_B
polymerase xxx protein_M
II XX protein_E
. . NE

Human Xxxx DNA_B
cDNAs xXXXx DNA_E
encoding xxx NE
subunits xxx NE
of xx NE
these xxx NE
factors xxx NE
have xxx NE
been xxx NE
cloned xxx NE
and xxx NE
sequenced xxx NE
. . NE

Using Xxxx NE
fluorescence xxx NE
in xx NE
situ xxx NE
hybridization xxx NE
( ( NE
FISH XXXX NE
) ) NE
, , NE
we xx NE
show xxx NE
here xxx NE
that xxx NE
the xxx NE
genes xxx DNA
encoding xxx NE
the xxx NE
TATA-box XXXX-xxx protein_B
binding xxx protein_M
protein xxx protein_E
( ( NE
TBP XXX protein
) ) NE
, , NE
TFIIB XXXXX protein
, , NE
TFIIE XXXXX protein_B
alpha xxx protein_E
, , NE
TFIIE XXXXX protein_B
beta xxx protein_E
, , NE
RAP30 XXXdd protein
, , NE
RAP74 XXXdd protein
and xxx NE
the xxx NE
62 dd protein_B
kDa xXx protein_M
subunit xxx protein_E
, , NE
of xx NE
TFIIH XXXXX protein
are xxx NE
located xxx NE
at xx NE
the xxx NE
human xxx NE
chromosomal xxx NE
bands xxx NE
human xxx DNA_B
chromosomal xxx DNA_M
band xxx DNA_M
6q26-27 dxdd-dd DNA_M
and xxx DNA_M
human xxx DNA_M
chromosomal xxx DNA_M
band xxx DNA_M
1p21-22 dxdd-dd DNA_M
and xxx DNA_M
human xxx DNA_M
chromosomal xxx DNA_M
band xxx DNA_M
3q21-24 dxdd-dd DNA_M
and xxx DNA_M
human xxx DNA_M
chromosomal xxx DNA_M
band xxx DNA_M
8p12 dxdd DNA_M
and xxx DNA_M
human xxx DNA_M
chromosomal xxx DNA_M
band xxx DNA_M
13q14 ddxdd DNA_M
and xxx DNA_M
human xxx DNA_M
chromosomal xxx DNA_M
band xxx DNA_M
19p13.3 ddxdd.d DNA_M
and xxx DNA_M
human xxx DNA_M
chromosomal xxx DNA_M
band xxx DNA_M
11p14-15.1 ddxdd-dd.d DNA_E

This Xxxx NE
dispersed xxx NE
localization xxx NE
of xx NE
a x NE
group xxx NE
of xx NE
functionally xxx NE
related xxx NE
gene xxx NE
provides xxx NE
insights xxx NE
into xxx NE
the xxx NE
molecular xxx NE
mechanism xxx NE
of xx NE
human xxx NE
genome xxx NE
evolution xxx NE
and xxx NE
their xxx NE
possible xxx NE
involvement xxx NE
in xx NE
human xxx NE
diseases xxx NE
. . NE

BCL-6 XXX-d protein
and xxx NE
the xxx NE
molecular xxx NE
pathogenesis xxx NE
of xx NE
B-cell X-xxx NE
lymphoma xxx NE
. . NE

The Xxx NE
results xxx NE
presented xxx NE
identify xxx NE
the xxx NE
first xxx NE
genetic xxx NE
lesion xxx NE
associated xxx NE
with xxx NE
DLCL XXXX NE
, , NE
the xxx NE
most xxx NE
clinically xxx NE
relevant xxx NE
form xxx NE
of xx NE
NHL XXX NE
. . NE

Although Xxxx NE
no xx NE
proof xxx NE
yet xxx NE
exists xxx NE
of xx NE
a x NE
role xxx NE
for xxx NE
these xxx NE
lesions xxx NE
in xx NE
DLCL XXXX NE
pathogenesis xxx NE
, , NE
the xxx NE
feature xxx NE
of xx NE
the xxx NE
BCL-6 XXX-d protein_B
gene xxx protein_M
product xxx protein_E
, , NE
its xxx NE
specific xxx NE
pattern xxx NE
of xx NE
expression xxx NE
in xx NE
B X cell_type_B
cells xxx cell_type_E
, , NE
and xxx NE
the xxx NE
clustering xxx NE
of xx NE
lesions xxx NE
disrupting xxx NE
its xxx NE
regulatory xxx NE
domain xxx NE
strongly xxx NE
suggest xxx NE
that xxx NE
deregulation xxx NE
of xx NE
BCL-6 XXX-d NE
expression xxx NE
may xxx NE
contribute xxx NE
to xx NE
DLCL XXXX NE
development xxx NE
. . NE

A X NE
more xxx NE
precise xxx NE
definition xxx NE
of xx NE
the xxx NE
role xxx NE
of xx NE
BCL-6 XXX-d protein
in xx NE
normal xxx NE
and xxx NE
neoplastic xxx NE
B-cell X-xxx NE
development xxx NE
is xx NE
the xxx NE
goal xxx NE
of xx NE
ongoing xxx NE
study xxx NE
of xx NE
transgenic xxx NE
mice xxx NE
engineered xxx NE
either xxx NE
to xx NE
express xxx NE
BCL-6 XXX-d NE
under xxx NE
heterologous xxx NE
promoters xxx NE
or xx NE
lacking xxx NE
BCL-6 XXX-d NE
function xxx NE
due xxx NE
to xx NE
targeted xxx NE
deletions xxx NE
. . NE

In Xx NE
addition xxx NE
to xx NE
contributing xxx NE
to xx NE
the xxx NE
understanding xxx NE
of xx NE
DLCL XXXX NE
pathogenesis xxx NE
, , NE
the xxx NE
identification xxx NE
of xx NE
BCL-6 XXX-d NE
lesions xxx NE
may xxx NE
have xxx NE
relevant xxx NE
clinical xxx NE
implications xxx NE
. . NE

DLCL XXXX NE
represent xxx NE
a x NE
heterogeneous xxx NE
group xxx NE
of xx NE
neoplasms xxx NE
which xxx NE
are xxx NE
treated xxx NE
homogeneously xxx NE
despite xxx NE
the xxx NE
fact xxx NE
that xxx NE
only xxx NE
50% dd% NE
of xx NE
patients xxx NE
experience xxx NE
long-term xxx-xxx NE
disease-free xxx-xxx NE
survival xxx NE
(Schneider (Xxxx NE
et xx NE
al xx NE
. . NE
1990) dddd) NE
. . NE

The Xxx NE
fact xxx NE
that xxx NE
BCL-6 XXX-d NE
rearrangements xxx NE
identify xxx NE
biologically xxx NE
and xxx NE
clinically xxx NE
distinct xxx NE
subsets xxx NE
of xx NE
DLCL XXXX NE
suggests xxx NE
that xxx NE
these xxx NE
lesions xxx NE
may xxx NE
be xx NE
useful xxx NE
as xx NE
markers xxx NE
in xx NE
selection xxx NE
of xx NE
differential xxx NE
therapeutic xxx NE
strategies xxx NE
based xxx NE
on xx NE
different xxx NE
risk xxx NE
groups xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
BCL-6 XXX-d NE
rearrangements xxx NE
can xxx NE
be xx NE
used xxx NE
to xx NE
identify xxx NE
and xxx NE
monitor xxx NE
the xxx NE
malignant xxx cell_type_B
clone xxx cell_type_E
with xxx NE
sensitive xxx NE
PCR-based XXX-xxx NE
techniques xxx NE
. . NE

Since Xxxx NE
clinical xxx NE
remission xxx NE
has xxx NE
been xxx NE
observed xxx NE
in xx NE
a x NE
significant xxx NE
fraction xxx NE
of xx NE
DLCL XXXX NE
cases xxx NE
, , NE
these xxx NE
markers xxx NE
may xxx NE
serve xxx NE
as xx NE
critical xxx NE
tools xxx NE
for xxx NE
sensitive xxx NE
monitoring xxx NE
of xx NE
minimal xxx NE
residual xxx NE
disease xxx NE
and xxx NE
early xxx NE
diagnosis xxx NE
of xx NE
relapse xxx NE
(Gribben (Xxxx NE
et xx NE
al xx NE
. . NE
1993) dddd) NE
. . NE

Pancreatic Xxxx NE
development xxx NE
and xxx NE
maturation xxx NE
of xx NE
the xxx NE
islet xxx cell_type_B
B X cell_type_M
cell xxx cell_type_E
. . NE

Studies Xxxx NE
of xx NE
pluripotent xxx cell_line_B
islet xxx cell_line_M
cultures xxx cell_line_E
. . NE

Pancreas Xxxx NE
organogenesis xxx NE
is xx NE
a x NE
highly xxx NE
regulated xxx NE
process xxx NE
, , NE
in xx NE
which xxx NE
two xxx NE
anlage xxx NE
evaginate xxx NE
from xxx NE
the xxx NE
primitive xxx NE
gut xxx NE
. . NE

They Xxxx NE
later xxx NE
fuse xxx NE
, , NE
and xxx NE
, , NE
under xxx NE
the xxx NE
influence xxx NE
of xx NE
the xxx NE
surrounding xxx NE
mesenchyme xxx NE
, , NE
the xxx NE
mature xxx NE
organ xxx NE
develops xxx NE
, , NE
being xxx NE
mainly xxx NE
composed xxx NE
of xx NE
ductal xxx NE
compartment xxx NE
and xxx NE
exocrine xxx NE
compartment xxx NE
and xxx NE
endocrine xxx NE
compartment xxx NE

Early Xxxx NE
buds xxx NE
are xxx NE
characterized xxx NE
by xx NE
a x NE
branching xxx NE
morphogenesis xxx NE
of xx NE
the xxx NE
ductal xxx NE
epithelium xxx NE
from xxx NE
which xxx NE
endocrine xxx cell_type_B
precursor xxx cell_type_M
cell xxx cell_type_M
and xxx cell_type_M
exocrine xxx cell_type_M
precursor xxx cell_type_M
cell xxx cell_type_E

The Xxx NE
three xxx NE
compartments xxx NE
are xxx NE
thought xxx NE
to xx NE
be xx NE
of xx NE
common xxx NE
endodermal xxx NE
origin xxx NE
; ; NE
in xx NE
contrast xxx NE
to xx NE
earlier xxx NE
hypotheses xxx NE
, , NE
which xxx NE
suggested xxx NE
that xxx NE
the xxx NE
endocrine xxx NE
compartment xxx NE
was xxx NE
of xx NE
neuroectodermal xxx NE
origin xxx NE
. . NE

It Xx NE
is xx NE
thus xxx NE
generally xxx NE
believed xxx NE
that xxx NE
the xxx NE
pancreatic xxx NE
endocrine-lineage xxx-xxx NE
possesses xxx NE
the xxx NE
ability xxx NE
to xx NE
mature xxx NE
along xxx NE
a x NE
differentiation xxx NE
pathway xxx NE
that xxx NE
shares xxx NE
many xxx NE
characteristics xxx NE
with xxx NE
those xxx NE
of xx NE
neuronal xxx NE
differentiation xxx NE
. . NE

During Xxxx NE
recent xxx NE
years xxx NE
, , NE
studies xxx NE
of xx NE
insulin-gene xxx-xxx NE
regulation xxx NE
and xxx NE
, , NE
in xx NE
particular xxx NE
, , NE
the xxx NE
tissue-specific xxx-xxx NE
transcriptional xxx NE
control xxx NE
of xx NE
insulin-gene xxx-xxx NE
activity xxx NE
have xxx NE
provided xxx NE
information xxx NE
on xx NE
pancreas xxx NE
development xxx NE
in xx NE
general xxx NE
. . NE

The Xxx NE
present xxx NE
review xxx NE
summarizes xxx NE
these xxx NE
findings xxx NE
, , NE
with xxx NE
a x NE
special xxx NE
focus xxx NE
on xx NE
our xxx NE
own xxx NE
studies xxx NE
on xx NE
pluripotent xxx cell_line_B
endocrine xxx cell_line_M
cultures xxx cell_line_E
of xx NE
rat xxx NE
pancreas xxx NE
. . NE

Octamer Xxxx NE
independent xxx NE
activation xxx NE
of xx NE
transcription xxx NE
from xxx NE
the xxx NE
kappa xxx DNA_B
immunoglobulin xxx DNA_M
germline xxx DNA_M
promoter xxx DNA_E
. . NE

Previous Xxxx NE
analyses xxx NE
of xx NE
immunoglobulin xxx DNA_B
V X DNA_M
region xxx DNA_M
promoters xxx DNA_E
has xxx NE
led xxx NE
to xx NE
the xxx NE
discovery xxx NE
of xx NE
a x NE
common xxx NE
octamer xxx DNA_B
motif xxx DNA_E
which xxx NE
is xx NE
functionally xxx NE
important xxx NE
in xx NE
the xxx NE
tissue-specific xxx-xxx NE
and xxx NE
developmentally xxx NE
regulated xxx NE
transcriptional xxx NE
activation xxx NE
of xx NE
immunoglobulin xxx DNA_B
genes xxx DNA_E
. . NE

The Xxx NE
germline xxx DNA_B
promoters xxx DNA_E
( ( NE
Ko Xx DNA
) ) NE
located xxx NE
upstream xxx NE
of xx NE
the xxx NE
J X DNA_B
region xxx DNA_M
gene xxx DNA_M
segments xxx DNA_E
of xx NE
the xxx NE
kappa xxx DNA_B
locus xxx DNA_E
also xxx NE
contain xxx NE
an xx NE
octamer xxx DNA_B
motif xxx DNA_E
(containing (xxx NE
a x NE
single xxx NE
base xxx DNA_B
pair xxx DNA_M
mutation xxx DNA_E
and xxx NE
referred xxx NE
to xx NE
as xx NE
the xxx NE
variant xxx NE
octamer) xxx) NE
which xxx NE
has xxx NE
been xxx NE
shown xxx NE
previously xxx NE
to xx NE
bind xxx NE
Oct-1 Xxx-d protein
and xxx NE
Oct-2 Xxx-d protein
transcription xxx protein_B
factors xxx protein_E
in xx NE
vitro xxx NE
. . NE

To Xx NE
further xxx NE
elucidate xxx NE
the xxx NE
role xxx NE
of xx NE
this xxx NE
variant xxx NE
octamer xxx DNA_B
motif xxx DNA_E
in xx NE
the xxx NE
regulation xxx NE
of xx NE
germline xxx NE
transcription xxx NE
from xxx NE
the xxx NE
unrearranged xxx NE
kappa xxx DNA_B
locus xxx DNA_E
, , NE
we xx NE
have xxx NE
quantitated xxx NE
the xxx NE
relative xxx NE
binding xxx NE
affinity xxx NE
of xx NE
Oct-1 Xxx-d protein
and xxx NE
Oct-2 Xxx-d protein
for xxx NE
the xxx NE
variant xxx NE
octamer xxx DNA_B
motif xxx DNA_E
and xxx NE
determined xxx NE
the xxx NE
functional xxx NE
role xxx NE
of xx NE
this xxx NE
octamer xxx DNA_B
motif xxx DNA_E
in xx NE
transcriptional xxx NE
activation xxx NE
. . NE

We Xx NE
find xxx NE
that xxx NE
, , NE
although xxx NE
the xxx NE
variant xxx NE
octamer xxx DNA_B
motif xxx DNA_E
binds xxx NE
Oct-1 Xxx-d protein
and xxx NE
Oct-2 Xxx-d protein
in xx NE
vitro xxx NE
with xxx NE
5-fold d-xxx NE
lower xxx NE
affinity xxx NE
than xxx NE
the xxx NE
consensus xxx DNA_B
octamer xxx DNA_M
motif xxx DNA_E
, , NE
mutation xxx NE
of xx NE
the xxx NE
variant xxx NE
octamer xxx DNA_B
motif xxx DNA_E
to xx NE
either xxx NE
a x NE
consensus xxx DNA_B
octamer xxx DNA_E
or xx NE
non- xxx- NE
octamer xxx NE
motif xxx NE
has xxx NE
no xx NE
effect xxx NE
on xx NE
transcriptional xxx NE
activation xxx NE
from xxx NE
the xxx NE
germline xxx NE
promoter xxx NE
. . NE

We Xx NE
also xxx NE
find xxx NE
significant xxx NE
differences xxx NE
in xx NE
activation xxx NE
of xx NE
germline xxx NE
and xxx NE
V X NE
region xxx NE
promoters xxx NE
by xx NE
kappa xxx NE
enhancers xxx NE
. . NE

Our Xxx NE
results xxx NE
suggest xxx NE
that xxx NE
the xxx NE
germline xxx DNA_B
promoters xxx DNA_E
and xxx NE
V X DNA_B
region xxx DNA_M
promoters xxx DNA_E
differ xxx NE
in xx NE
their xxx NE
dependence xxx NE
on xx NE
octamer xxx DNA
for xxx NE
activation xxx NE
and xxx NE
respond xxx NE
differently xxx NE
to xx NE
enhancer xxx NE
activation xxx NE
. . NE

These Xxxx NE
findings xxx NE
have xxx NE
important xxx NE
implications xxx NE
in xx NE
regulation xxx NE
of xx NE
germline xxx NE
transcription xxx NE
as xx NE
well xxx NE
as xx NE
concomitant xxx NE
activation xxx NE
of xx NE
the xxx NE
V-J X-X NE
recombination xxx NE
of xx NE
the xxx NE
kappa xxx DNA_B
light xxx DNA_M
chain xxx DNA_M
locus xxx DNA_E
. . NE

Generation Xxxx NE
of xx NE
CD1+RelB+ XXd+XxxX+ cell_type_B
dendritic xxx cell_type_M
cells xxx cell_type_E
and xxx NE
tartrate-resistant xxx-xxx cell_type_B
acid xxx cell_type_M
phosphatase-positive xxx-xxx cell_type_M
osteoclast-like xxx-xxx cell_type_M
multinucleated xxx cell_type_M
giant xxx cell_type_M
cells xxx cell_type_E
from xxx NE
human xxx cell_type_B
monocytes xxx cell_type_E
. . NE

We Xx NE
previously xxx NE
showed xxx NE
that xxx NE
granulocyte-macrophage xxx-xxx protein_B
colony-stimulating xxx-xxx protein_M
factor xxx protein_E
( ( NE
GM-CSF XX-XXX protein
) ) NE
and xxx NE
macrophage xxx protein_B
colony-stimulating xxx-xxx protein_M
factor xxx protein_E
( ( NE
M-CSF X-XXX protein
) ) NE
stimulate xxx NE
the xxx NE
differentiation xxx NE
of xx NE
human xxx cell_type_B
monocytes xxx cell_type_E
into xxx NE
two xxx NE
phenotypically xxx NE
distinct xxx NE
types xxx NE
of xx NE
macrophages xxx cell_type
. . NE

However Xxxx NE
, , NE
in xx NE
vivo xxx NE
, , NE
not xxx NE
only xxx NE
CSF XXX protein
but xxx NE
also xxx NE
many xxx NE
other xxx NE
cytokines xxx protein
are xxx NE
produced xxx NE
under xxx NE
various xxx NE
conditions xxx NE
. . NE

Those Xxxx NE
cytokines xxx protein
may xxx NE
modulate xxx NE
the xxx NE
differentiation xxx NE
of xx NE
monocytes xxx cell_type
by xx NE
CSFs XXXx protein
. . NE

In Xx NE
the xxx NE
present xxx NE
study xxx NE
, , NE
we xx NE
showed xxx NE
that xxx NE
CD14+ XXdd+ cell_type_B
adherent xxx cell_type_M
human xxx cell_type_M
monocytes xxx cell_type_E
can xxx NE
differentiate xxx NE
into xxx NE
CD1+relB+ XXd+xxxX+ cell_type_B
dendritic xxx cell_type_M
cells xxx cell_type_E
( ( NE
DC XX cell_type
) ) NE
by xx NE
the xxx NE
combination xxx NE
of xx NE
GM-CSF XX-XXX protein
plus xxx NE
interleukin-4 xxx-d protein
( ( NE
IL-4 XX-d protein
) ) NE
and xxx NE
that xxx NE
they xxx NE
differentiate xxx NE
into xxx NE
tartrate-resistant xxx-xxx cell_type_B
acid xxx cell_type_M
phosphatase xxx cell_type_M
(TRAP)-positive (XXXX)-xxx cell_type_M
osteoclast-like xxx-xxx cell_type_M
multinucleated xxx cell_type_M
giant xxx cell_type_M
cells xxx cell_type_E
( ( NE
MGC XXX cell_type
) ) NE
by xx NE
the xxx NE
combination xxx NE
of xx NE
M-CSF X-XXX protein
plus xxx NE
IL-4 XX-d protein
. . NE

However Xxxx NE
, , NE
the xxx NE
monocyte-derived xxx-xxx cell_line_B
DC XX cell_line_E
were xxx NE
not xxx NE
terminally xxx cell_line_B
differentiated xxx cell_line_M
cells xxx cell_line_E
; ; NE
they xxx NE
could xxx NE
still xxx NE
convert xxx NE
to xx NE
macrophages xxx cell_type
in xx NE
response xxx NE
to xx NE
M-CSF X-XXX protein
. . NE

Tumor Xxxx protein_B
necrosis xxx protein_M
factor-alpha xxx-xxx protein_E
( ( NE
TNF-alpha XXX-xxx protein
) ) NE
stimulated xxx NE
the xxx NE
terminal xxx NE
differentiation xxx NE
of xx NE
the xxx NE
DC XX cell_type
by xx NE
downregulating xxx NE
the xxx NE
expression xxx NE
of xx NE
the xxx NE
M-CSF X-XXX protein_B
receptor xxx protein_E
, , NE
cfms xxx RNA_B
mRNA xXXX RNA_E
, , NE
and xxx NE
aborting xxx NE
the xxx NE
potential xxx NE
to xx NE
convert xxx NE
to xx NE
macrophages xxx cell_type
. . NE

In Xx NE
contrast xxx NE
to xx NE
IL-4 XX-d protein
, , NE
interferon-gamma xxx-xxx protein
( ( NE
IFN-gamma XXX-xxx protein
) ) NE
had xxx NE
no xx NE
demonstrable xxx NE
effect xxx NE
on xx NE
the xxx NE
differentiation xxx NE
of xx NE
monocytes xxx cell_type
. . NE

Rather Xxxx NE
, , NE
IFN-gamma XXX-xxx protein
antagonized xxx NE
the xxx NE
effect xxx NE
of xx NE
IL-4 XX-d protein
and xxx NE
suppressed xxx NE
the xxx NE
DC XX NE
and xxx NE
MGC XXX NE
formation xxx NE
induced xxx NE
by xx NE
GM-CSF XX-XXX protein
+ + NE
IL-4 XX-d protein
and xxx NE
M-CSF X-XXX protein
+ + NE
IL-4 XX-d protein
, , NE
respectively xxx NE
. . NE

Taken Xxxx NE
together xxx NE
, , NE
these xxx NE
results xxx NE
provide xxx NE
a x NE
new xxx NE
aspect xxx NE
to xx NE
our xxx NE
knowledge xxx NE
of xx NE
monocyte xxx NE
differentiation xxx NE
and xxx NE
provide xxx NE
evidence xxx NE
that xxx NE
human xxx cell_type_B
monocytes xxx cell_type_E
are xxx NE
flexible xxx NE
in xx NE
their xxx NE
differentiation xxx NE
potential xxx NE
and xxx NE
are xxx NE
precursors xxx NE
not xxx NE
only xxx NE
of xx NE
macrophages xxx cell_type
but xxx NE
also xxx NE
of xx NE
CD1+relB+DC XXd+xxxX+XX cell_type
and xxx NE
TRAP-positive XXXX-xxx cell_type_B
MGC XXX cell_type_E
. . NE

Such Xxxx NE
a x NE
diverse xxx NE
pathway xxx NE
of xx NE
monocyte xxx NE
differentiation xxx NE
may xxx NE
constitute xxx NE
one xxx NE
of xx NE
the xxx NE
basic xxx NE
mechanisms xxx NE
of xx NE
immune xxx NE
regulation xxx NE
. . NE

The Xxx NE
NF-kappa XX-xxx NE
B X NE
inhibitor xxx NE
, , NE
tepoxalin xxx NE
, , NE
suppresses xxx NE
surface xxx NE
expression xxx NE
of xx NE
the xxx NE
cell xxx protein_B
adhesion xxx protein_M
molecules xxx protein_E
CD62E XXddX protein
, , NE
CD11b/CD18 XXddx/XXdd protein
and xxx NE
CD106 XXddd protein
. . NE

Tepoxalin Xxxx NE
, , NE
a x NE
dual xxx NE
enzyme xxx NE
inhibitor xxx NE
of xx NE
cyclooxygenase xxx protein
and xxx NE
5-lipoxygenase d-xxx protein
has xxx NE
been xxx NE
shown xxx NE
to xx NE
inhibit xxx NE
T-cell X-xxx NE
activation xxx NE
. . NE

Its Xxx NE
immunosuppressive xxx NE
property xxx NE
is xx NE
distinct xxx NE
from xxx NE
cyclosporin xxx NE
because xxx NE
only xxx NE
tepoxalin xxx NE
, , NE
but xxx NE
not xxx NE
cyclosporin xxx NE
, , NE
suppresses xxx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
. . NE

Here Xxxx NE
we xx NE
report xxx NE
that xxx NE
tepoxalin xxx NE
selectively xxx NE
inhibits xxx NE
intercellular xxx NE
adhesion xxx NE
molecule-1 xxx-d NE
( ( NE
ICAM-1 XXXX-d NE
, , NE
CD54 XXdd NE
)/MAC-1 )/XXX-d NE
( ( NE
CD11b/CD18 XXddx/XXdd NE
) ) NE
dependent xxx NE
adhesion xxx NE
of xx NE
polymorphonuclear xxx NE
cells xxx NE
to xx NE
IL-1 XX-d NE
activated xxx NE
human xxx NE
umbilical xxx NE
vein xxx NE
endothelial xxx NE
cells xxx NE
. . NE

The Xxx NE
mechanism xxx NE
of xx NE
inhibition xxx NE
is xx NE
related xxx NE
to xx NE
the xxx NE
surface xxx NE
expression xxx NE
of xx NE
several xxx NE
cell xxx NE
adhesion xxx protein_B
molecules xxx protein_E
. . NE

Flow Xxxx NE
cytometry xxx NE
analyses xxx NE
on xx NE
cultured xxx NE
cells xxx NE
that xxx NE
were xxx NE
treated xxx NE
with xxx NE
tepoxalin xxx NE
or xx NE
antisense xxx NE
oligonucleotides xxx NE
to xx NE
the xxx NE
P65/p50 Xdd/xdd NE
subunit xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
, , NE
and xxx NE
then xxx NE
stimulated xxx NE
with xxx NE
PMA XXX NE
, , NE
revealed xxx NE
a x NE
reduced xxx NE
expression xxx NE
of xx NE
CD11b/CD18 XXddx/XXdd NE
on xx NE
monocytic xxx NE
HL60 XXdd NE
cells xxx NE
, , NE
and xxx NE
endothelial xxx NE
adhesion xxx NE
molecule-1 xxx-d NE
( ( NE
CD62E XXddX NE
) ) NE
and xxx NE
vascular xxx NE
adhesion xxx NE
molecule-1 xxx-d NE
( ( NE
CD106 XXddd NE
) ) NE
on xx NE
human xxx NE
umbilical xxx NE
vein xxx NE
endothelial xxx NE
cells xxx NE
. . NE

Expression Xxxx NE
of xx NE
other xxx NE
adhesion xxx protein_B
molecules xxx protein_E
such xxx NE
as xx NE
lymphocyte xxx protein_B
function xxx protein_M
associated-antigen-1 xxx-xxx-d protein_E
( ( NE
CD11a XXddx NE
/CD18 /XXdd NE
) ) NE
and xxx NE
CD54 XXdd NE
were xxx NE
unaffected xxx NE
. . NE

Tepoxalin Xxxx NE
also xxx NE
inhibited xxx NE
the xxx NE
secretion xxx NE
of xx NE
a x NE
NF-kappa XX-xxx protein_B
B X protein_M
regulated xxx protein_M
chemokine xxx protein_E
, , NE
IL-8 XX-d protein
, , NE
a x NE
known xxx NE
inducer xxx NE
of xx NE
CD11b/CD18 XXddx/XXdd NE
expression xxx NE
. . NE

Thus Xxxx NE
the xxx NE
suppression xxx NE
of xx NE
CD11b/CD18 XXddx/XXdd protein
expression xxx NE
by xx NE
tepoxalin xxx NE
may xxx NE
involve xxx NE
IL-8 XX-d protein
. . NE

Our Xxx NE
results xxx NE
suggest xxx NE
that xxx NE
by xx NE
inhibiting xxx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
, , NE
surface xxx NE
expression xxx NE
of xx NE
several xxx NE
adhesion xxx protein_B
molecules xxx protein_E
can xxx NE
be xx NE
modulated xxx NE
and xxx NE
that xxx NE
tepoxalin xxx NE
may xxx NE
be xx NE
useful xxx NE
in xx NE
treating xxx NE
selected xxx NE
adhesion xxx NE
mediated xxx NE
events xxx NE
such xxx NE
as xx NE
leukocyte xxx NE
migration xxx NE
or xx NE
atherosclerotic xxx NE
plaque xxx NE
formation xxx NE
. . NE

Characterization Xxxx NE
of xx NE
a x NE
CD43/leukosialin XXdd/xxx NE
-mediated -xxx NE
pathway xxx NE
for xxx NE
inducing xxx NE
apoptosis xxx NE
in xx NE
human xxx NE
T-lymphoblastoid X-xxx NE
cells xxx NE
. . NE

The Xxx NE
monoclonal xxx protein_B
antibody xxx protein_E
( ( NE
mAb xXx protein
) ) NE
J393 Xddd protein
induces xxx NE
apoptosis xxx NE
in xx NE
Jurkat Xxxx cell_line_B
T-cells X-xxx cell_line_E
. . NE

NH2 XXd NE
-terminal -xxx NE
amino xxx NE
acid xxx NE
sequence xxx NE
analysis xxx NE
identified xxx NE
the xxx NE
140-kDa ddd-xXx NE
surface xxx NE
antigen xxx NE
for xxx NE
mAb xXx NE
J393 Xddd NE
as xx NE
CD43/leukosialin XXdd/xxx NE
, , NE
the xxx NE
major xxx NE
sialoglycoprotein xxx NE
of xx NE
leukocytes xxx NE
. . NE

While Xxxx NE
Jurkat Xxxx cell_line_B
cells xxx cell_line_E
co-expressed xx-xxx NE
two xxx NE
discrete xxx NE
cell-surface xxx-xxx protein_B
isoforms xxx protein_E
of xx NE
CD43 XXdd protein
, , NE
recognized xxx NE
by xx NE
mAb xXx protein_B
J393 Xddd protein_E
and xxx NE
mAb xXx protein_B
G10-2 Xdd-d protein_E
, , NE
respectively xxx NE
, , NE
only xxx NE
J393 Xddd NE
/ / NE
CD43 XXdd NE
signaled xxx NE
apoptosis xxx NE
. . NE

J393/ Xddd/ protein
CD43 XXdd NE
was xxx NE
found xxx NE
to xx NE
be xx NE
hyposialylated xxx NE
, , NE
bearing xxx NE
predominantly xxx NE
O-linked X-xxx NE
monosaccharide xxx NE
glycans xxx NE
, , NE
whereas xxx NE
G10-2/ Xdd-d/ protein
CD43 XXdd NE
bore xxx NE
complex xxx NE
sialylated xxx NE
tetra-chain xxx-xxx NE
and xxx NE
hexasaccharide xxx NE
chain xxx NE

Treatment Xxxx NE
with xxx NE
soluble xxx NE
, , NE
bivalent xxx NE
mAb xXx protein_B
J393 Xddd protein_E
killed xxx NE
25-50% dd-dd% NE
of xx NE
the xxx NE
cell xxx cell_line_B
population xxx cell_line_E
, , NE
while xxx NE
concomitant xxx NE
engagement xxx NE
of xx NE
either xxx NE
the xxx NE
CD3.TcR XXd.XxX protein_B
complex xxx protein_E
or xx NE
the xxx NE
integrins xxx protein
CD18 XXdd protein
and xxx NE
CD29 XXdd protein
significantly xxx NE
potentiated xxx NE
this xxx NE
effect xxx NE
. . NE

Treatment Xxxx NE
of xx NE
Jurkat Xxxx cell_line_B
cells xxx cell_line_E
with xxx NE
mAb xXx protein_B
J393 Xddd protein_E
induced xxx NE
tyrosine xxx NE
phosphorylation xxx NE
of xx NE
specific xxx NE
protein xxx protein_B
substrates xxx protein_E
that xxx NE
underwent xxx NE
hyperphosphorylation xxx NE
upon xxx NE
antigen xxx NE
receptor xxx NE
costimulation xxx NE
. . NE

Tyrosine Xxxx NE
kinase xxx NE
inhibition xxx NE
by xx NE
herbimycin xxx NE
A X NE
diminished xxx NE
J393 Xddd NE
/ / NE
CD43 XXdd NE
-mediated -xxx NE
apoptosis xxx NE
, , NE
whereas xxx NE
inhibition xxx NE
of xx NE
phosphotyrosine xxx NE
phosphatase xxx NE
activity xxx NE
by xx NE
bis(maltolato)oxovanadium-IV xxx(xxx)xxx-XX NE
enhanced xxx NE
cell xxx NE
death xxx NE
. . NE

Signal Xxxx NE
transduction xxx NE
through xxx NE
tyrosine xxx NE
kinase xxx NE
activation xxx NE
may xxx NE
lead xxx NE
to xx NE
altered xxx NE
gene xxx NE
expression xxx NE
, , NE
as xx NE
J393 Xddd NE
/ / NE
CD43 XXdd protein
ligation xxx NE
prompted xxx NE
decreases xxx NE
in xx NE
the xxx NE
nuclear xxx NE
localization xxx NE
of xx NE
the xxx NE
transcriptional xxx protein_B
regulatory xxx protein_M
protein xxx protein_E
NF-kappaB XX-xxxX protein
and xxx NE
proteins xxx NE
binding xxx NE
the xxx NE
interferon-inducible xxx-xxx DNA_B
regulatory xxx DNA_M
element xxx DNA_E
. . NE

Since Xxxx NE
peripheral xxx cell_type_B
blood xxx cell_type_M
T-lymphocytes X-xxx cell_type_E
express xxx NE
cryptic xxx protein_B
epitopes xxx protein_E
for xxx NE
mAb xXx protein_B
J393 Xddd protein_E
, , NE
these xxx NE
findings xxx NE
demonstrate xxx NE
the xxx NE
existence xxx NE
of xx NE
a x NE
tightly xxx NE
regulated xxx NE
CD43 XXdd NE
-mediated -xxx NE
pathway xxx NE
for xxx NE
inducing xxx NE
apoptosis xxx NE
in xx NE
human xxx NE
T-cell X-xxx NE
lineages xxx NE
. . NE

Sterol Xxxx NE
dependent xxx NE
LDL-receptor XXX-xxx NE
gene xxx NE
transcription xxx NE
in xx NE
lymphocytes xxx cell_type
from xxx NE
normal xxx NE
and xxx NE
CML XXX NE
patients xxx NE
. . NE

Sterol Xxxx DNA_B
regulatory xxx DNA_M
element xxx DNA_E
( ( NE
SRE XXX DNA
) ) NE
has xxx NE
been xxx NE
recognized xxx NE
to xx NE
regulate xxx NE
various xxx NE
key xxx NE
genes xxx DNA
coding xxx NE
for xxx NE
especially xxx NE
low xxx NE
density xxx NE
lipoprotein xxx NE
( ( NE
LDL XXX NE
)-receptor )-xxx NE
, , NE
3-hydroxy-3-methylglutaryl d-xxx-d-xxx NE
coenzyme xxx NE
A X NE
(HMG-CoA) (XXX-XxX) NE
reductase xxx NE
and xxx NE
HMG-CoA XXX-XxX NE
synthase xxx NE
known xxx NE
to xx NE
play xxx NE
a x NE
crucial xxx NE
role xxx NE
in xx NE
the xxx NE
cholesterol xxx NE
feedback xxx NE
mechanism xxx NE
. . NE

The Xxx NE
deranged xxx NE
cholesterol xxx NE
feedback xxx NE
mechanism xxx NE
has xxx NE
been xxx NE
widely xxx NE
recognised xxx NE
in xx NE
initiation xxx NE
as xx NE
well xxx NE
as xx NE
progression xxx NE
of xx NE
various xxx NE
types xxx NE
of xx NE
cancers xxx NE
including xxx NE
chronic xxx NE
myeloid xxx NE
leukaemia xxx NE
( ( NE
CML XXX NE
) ) NE
. . NE

Consequently Xxxx NE
, , NE
the xxx NE
present xxx NE
study xxx NE
was xxx NE
addressed xxx NE
to xx NE
understand xxx NE
this xxx NE
phenomenon xxx NE
and xxx NE
revealed xxx NE
the xxx NE
existence xxx NE
of xx NE
a x NE
unique xxx protein_B
47 dd protein_M
kDa xXx protein_M
protein xxx protein_M
factor xxx protein_E
having xxx NE
affinity xxx NE
for xxx NE
this xxx NE
SRE XXX DNA_B
sequence xxx DNA_E
in xx NE
lymphocytes xxx cell_type
from xxx NE
normal xxx NE
subjects xxx NE
as xx NE
well xxx NE
as xx NE
its xxx NE
absence xxx NE
in xx NE
lymphocytes xxx cell_type
from xxx NE
untreated xxx NE
CML XXX NE
patients xxx NE
. . NE

However Xxxx NE
, , NE
this xxx NE
factor xxx NE
appeared xxx NE
when xxx NE
the xxx NE
CML XXX NE
patients xxx NE
achieved xxx NE
complete xxx NE
haematological xxx NE
remission xxx NE
( ( NE
CHR XXX NE
) ) NE
through xxx NE
alpha-interferon xxx-xxx NE
therapy xxx NE
. . NE

Further Xxxx NE
, , NE
an xx NE
inverse xxx NE
relationship xxx NE
was xxx NE
also xxx NE
observed xxx NE
between xxx NE
sterol xxx NE
modulated xxx NE
LDL XXX NE
-receptor -xxx NE
gene xxx NE
transcription xxx NE
and xxx NE
the xxx NE
binding xxx NE
affinity xxx NE
of xx NE
this xxx NE
47 dd NE
kDa xXx NE
factor xxx NE
to xx NE
the xxx NE
SRE XXX NE
sequence xxx NE
. . NE

Based Xxxx NE
upon xxx NE
these xxx NE
results xxx NE
we xx NE
propose xxx NE
that xxx NE
alpha-interferon xxx-xxx protein
through xxx NE
its xxx NE
receptor xxx NE
initiates xxx NE
phosphatidic xxx NE
acid xxx NE
dependent xxx NE
signalling xxx NE
which xxx NE
in xx NE
turn xxx NE
regulates xxx NE
the xxx NE
affinity xxx NE
of xx NE
47 dd protein_B
kDa xXx protein_M
sterol xxx protein_M
regulatory xxx protein_M
element xxx protein_M
binding xxx protein_M
factor xxx protein_E
as xx NE
well xxx NE
as xx NE
LDL XXX NE
-receptor -xxx NE
gene xxx NE
transcription xxx NE
in xx NE
lymphocytes xxx NE
from xxx NE
CML XXX NE
patients xxx NE
. . NE

Multiple Xxxx NE
prolactin-responsive xxx-xxx DNA_B
elements xxx DNA_E
mediate xxx NE
G1 Xd NE
phase xxx NE
expression xxx NE
and xxx NE
S X NE
phase xxx NE
expression xxx NE
of xx NE
the xxx NE
interferon xxx DNA_B
regulatory xxx DNA_M
factor-1 xxx-d DNA_M
gene xxx DNA_E
. . NE

The Xxx NE
interferon xxx NE
regulatory xxx NE
factor-1 xxx-d NE
( ( NE
IRF-1 XXX-d NE
) ) NE
gene xxx NE
is xx NE
both xxx NE
an xx NE
immediate-early xxx-xxx NE
G1 Xd NE
phase xxx NE
gene xxx NE
and xxx NE
an xx NE
S X NE
phase xxx NE
gene xxx NE
inducible xxx NE
by xx NE
PRL XXX NE
in xx NE
rat xxx NE
Nb2 Xxd NE
T X NE
lymphocytes xxx NE
. . NE

To Xx NE
understand xxx NE
the xxx NE
mechanism xxx NE
by xx NE
which xxx NE
PRL XXX protein
regulates xxx NE
the xxx NE
biphasic xxx NE
expression xxx NE
of xx NE
IRF-1 XXX-d protein
, , NE
we xx NE
cloned xxx NE
the xxx NE
rat xxx DNA_B
IRF-1 XXX-d DNA_M
gene xxx DNA_E
and xxx NE
functionally xxx NE
characterized xxx NE
the xxx NE
IRF-1 XXX-d DNA_B
promoter xxx DNA_E
. . NE

Upon Xxxx NE
transfection xxx NE
into xxx NE
Nb2 Xxd cell_line_B
T X cell_line_M
cells xxx cell_line_E
, , NE
1.7 d.d NE
kilobases xxx NE
(kb) (xx) NE
of xx NE
IRF-1 XXX-d DNA_B
5'-flanking d'-xxx DNA_M
DNA XXX DNA_E
linked xxx NE
to xx NE
a x NE
chloramphenicol xxx NE
acetyl xxx NE
transferase xxx NE
( ( NE
CAT XXX NE
) ) NE
reporter xxx NE
gene xxx NE
mediated xxx NE
a x NE
30-fold dd-xxx NE
induction xxx NE
of xx NE
CAT XXX NE
enzyme xxx NE
activity xxx NE
in xx NE
response xxx NE
to xx NE
24 dd NE
h x NE
of xx NE
PRL XXX NE
stimulation xxx NE
. . NE

Deletion Xxxx NE
mutants xxx NE
containing xxx NE
1.3kb d.dxx DNA_B
5'-flanking d'-xxx DNA_M
DNA XXX DNA_M
and xxx DNA_M
0.6 d.d DNA_M
kb xx DNA_M
5'-flanking d'-xxx DNA_M
DNA XXX DNA_M
and xxx DNA_M
0.2 d.d DNA_M
kb xx DNA_M
5'-flanking d'-xxx DNA_M
DNA XXX DNA_E
PRL XXX NE
. . NE

The Xxx NE
sequence xxx NE
between xxx NE
-1.7 -d.d NE
and xxx NE
-0.2 -d.d NE
kb xx NE
linked xxx NE
to xx NE
a x NE
heterologous xxx DNA_B
thymidine xxx DNA_M
kinase xxx DNA_M
promoter xxx DNA_E
failed xxx NE
to xx NE
respond xxx NE
to xx NE
PRL XXX protein
stimulation xxx NE
, , NE
suggesting xxx NE
that xxx NE
the xxx NE
activity xxx NE
of xx NE
upstream xxx DNA_B
PRL XXX DNA_M
response xxx DNA_M
elements xxx DNA_E
may xxx NE
require xxx NE
an xx NE
interaction xxx NE
with xxx NE
promoter-proximal xxx-xxx DNA_B
elements xxx DNA_E
. . NE

By Xx NE
assaying xxx NE
CAT XXX NE
enzyme xxx NE
activity xxx NE
across xxx NE
a x NE
24-h dd-x NE
PRL XXX NE
induction xxx NE
time xxx NE
course xxx NE
, , NE
we xx NE
were xxx NE
able xxx NE
to xx NE
assign xxx NE
G1 Xd NE
vs xx NE
. . NE
S X NE
phase xxx NE
PRL XXX NE
responses xxx NE
of xx NE
the xxx NE
IRF-1 XXX-d DNA_B
gene xxx DNA_E
to xx NE
different xxx NE
regions xxx NE
of xx NE
the xxx NE
IRF-1 XXX-d protein
5'-flanking d'-xxx NE
and xxx NE
promoter xxx NE
DNA XXX NE
. . NE

The Xxx NE
0.2-kb d.d-xx NE
IRF- XXX- NE
CAT XXX NE
construct xxx NE
was xxx NE
induced xxx NE
by xx NE
PRL XXX NE
stimulation xxx NE
during xxx NE
the xxx NE
G1 Xd NE
phase xxx NE
of xx NE
the xxx NE
cell xxx NE
cycle xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
1.7-kb d.d-xx NE
IRF- XXX- NE
CAT XXX protein
construct xxx NE
was xxx NE
inducible xxx NE
by xx NE
PRL XXX protein
during xxx NE
both xxx NE
G1 Xd NE
phase xxx NE
and xxx NE
S X NE
phase xxx NE
of xx NE
the xxx NE
cell xxx NE
cycle xxx NE
. . NE

Hence Xxxx NE
, , NE
the xxx NE
PRL XXX protein
-induced -xxx NE
biphasic xxx NE
expression xxx NE
of xx NE
the xxx NE
IRF-1 XXX-d DNA_B
gene xxx DNA_E
appears xxx NE
to xx NE
be xx NE
controlled xxx NE
by xx NE
separate xxx NE
PRL XXX NE
-responsive -xxx NE
elements xxx NE
: : NE
elements xxx NE
in xx NE
the xxx NE
first xxx NE
0.2 d.d NE
kb xx NE
of xx NE
the xxx NE
IRF-1 XXX-d NE
promoter xxx NE
region xxx NE
act xxx NE
during xxx NE
early xxx NE
activation xxx NE
, , NE
and xxx NE
elements xxx NE
between xxx NE
0.2 d.d NE
and xxx NE
1.7 d.d NE
kb xx NE
act xxx NE
in xx NE
concert xxx NE
with xxx NE
the xxx NE
proximal xxx NE
0.2-kb d.d-xx NE
region xxx NE
during xxx NE
S X NE
phase xxx NE
progression xxx NE
. . NE

Regulation Xxxx NE
of xx NE
the xxx NE
BZLF1 XXXXd DNA_B
promoter xxx DNA_E
of xx NE
Epstein-Barr Xxxx-Xxxx NE
virus xxx NE
by xx NE
second xxx NE
messengers xxx NE
in xx NE
anti-immunoglobulin-treated xxx-xxx-xxx cell_line_B
B X cell_line_M
cells xxx cell_line_E
. . NE

Initiation Xxxx NE
of xx NE
the xxx NE
Epstein-Barr Xxxx-Xxxx NE
virus xxx NE
(EBV) (XXX) NE
lytic xxx NE
cycle xxx NE
is xx NE
dependent xxx NE
on xx NE
the xxx NE
transcription xxx NE
of xx NE
the xxx NE
BZLF1 XXXXd DNA_B
gene xxx DNA_E
. . NE

The Xxx NE
BZLF1 XXXXd DNA_B
gene xxx DNA_M
promoter xxx DNA_E
( ( NE
Zp Xx DNA
) ) NE
was xxx NE
activated xxx NE
by xx NE
crosslinking xxx NE
of xx NE
cell xxx protein_B
surface xxx protein_M
immunoglobulin xxx protein_E
( ( NE
Ig Xx protein
) ) NE
with xxx NE
anti-Ig xxx-Xx protein_B
antibody xxx protein_E
in xx NE
B X cell_type_B
cells xxx cell_type_E
, , NE
even xxx NE
in xx NE
the xxx NE
absence xxx NE
of xx NE
other xxx NE
viral xxx NE
genes xxx NE
. . NE

We Xx NE
identified xxx NE
several xxx NE
anti-Ig xxx-Xx NE
response xxx NE
elements xxx NE
within xxx NE
Zp Xx DNA
, , NE
which xxx NE
were xxx NE
originally xxx NE
defined xxx NE
as xx NE
12-O-tetradecanoylphorbol-13-acetate dd-X-xxx-dd-xxx NE
( ( NE
TPA XXX NE
) ) NE
response xxx NE
elements xxx NE
( ( NE
ZI XX NE
repeats xxx NE
and xxx NE
ZII XXX NE
, , NE
an xx NE
AP-1-like XX-d-xxx NE
domain xxx NE
) ) NE
. . NE

Since Xxxx NE
anti-Ig xxx-Xx NE
crosslinking xxx NE
leads xxx NE
to xx NE
activation xxx NE
of xx NE
protein xxx protein_B
kinase xxx protein_M
C X protein_E
( ( NE
PKC XXX protein
) ) NE
and xxx NE
an xx NE
increase xxx NE
in xx NE
intracellular xxx NE
calcium xxx NE
level xxx NE
, , NE
Zp Xx DNA
was xxx NE
tested xxx NE
for xxx NE
the xxx NE
response xxx NE
to xx NE
these xxx NE
cellular xxx protein_B
factors xxx protein_E
. . NE

Treatment Xxxx NE
with xxx NE
calcium xxx NE
ionophore xxx NE
A23187 Xddddd NE
increased xxx NE
Zp Xx NE
activity xxx NE
. . NE

When Xxxx NE
the xxx NE
calcium xxx NE
ionophore xxx NE
was xxx NE
used xxx NE
in xx NE
conjunction xxx NE
with xxx NE
TPA XXX NE
, , NE
a x NE
PKC XXX protein
activator xxx NE
, , NE
the xxx NE
Zp Xx DNA
induction xxx NE
was xxx NE
synergistically xxx NE
enhanced xxx NE
. . NE

1-(5-Isoquinolinyl d-(d-Xxxx NE
sulfonyl)-2-methylpiperazine xxx)-d-xxx NE
, , NE
an xx NE
inhibitor xxx NE
of xx NE
PKC XXX protein
, , NE
inhibited xxx NE
the xxx NE
anti-Ig xxx-Xx NE
inducibility xxx NE
of xx NE
Zp Xx DNA
. . NE

Calmodulin Xxxx NE
antagonists xxx NE
, , NE
compound xxx NE
R24571 Xddddd NE
and xxx NE
trifluoperazine xxx NE
, , NE
blocked xxx NE
the xxx NE
Zp Xx DNA
activation xxx NE
with xxx NE
anti-Ig xxx-Xx protein
. . NE

These Xxxx NE
findings xxx NE
suggest xxx NE
that xxx NE
Zp Xx DNA
responds xxx NE
directly xxx NE
to xx NE
changes xxx NE
in xx NE
the xxx NE
activity xxx NE
of xx NE
both xxx NE
PKC XXX protein
and xxx NE
calcium xxx NE
/calmodulin-dependent /xxx-xxx NE
protein xxx NE
kinase xxx NE
. . NE

Requirement Xxxx NE
of xx NE
tyrosine xxx NE
kinase xxx NE
activation xxx NE
for xxx NE
the xxx NE
anti-Ig xxx-Xx protein
-mediated -xxx NE
Zp Xx NE
activation xxx NE
was xxx NE
also xxx NE
demonstrated xxx NE
through xxx NE
the xxx NE
use xxx NE
of xx NE
the xxx NE
tyrosine xxx NE
kinase xxx NE
inhibitor xxx NE
herbimycin xxx NE
. . NE

These Xxxx NE
cellular xxx protein_B
gene xxx protein_M
regulatory xxx protein_M
molecules xxx protein_E
induced xxx NE
with xxx NE
anti-Ig xxx-Xx NE
may xxx NE
cooperatively xxx NE
play xxx NE
an xx NE
important xxx NE
part xxx NE
in xx NE
achieving xxx NE
efficient xxx NE
EBV XXX NE
activation xxx NE
as xx NE
seen xxx NE
with xxx NE
anti-Ig xxx-Xx NE
treatment xxx NE
in xx NE
B X cell_type_B
cells xxx cell_type_E
. . NE

The Xxx NE
SCL XXX protein_B
protein xxx protein_E
displays xxx NE
cell-specific xxx-xxx NE
heterogeneity xxx NE
in xx NE
size xxx NE
. . NE

SCL XXX protein_B
protein xxx protein_E
production xxx NE
was xxx NE
examined xxx NE
in xx NE
a x NE
variety xxx NE
of xx NE
hemopoietic xxx cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
by xx NE
immunoblotting xxx NE
using xxx NE
specific xxx NE
polyclonal xxx NE
antisera xxx NE
. . NE

SCL XXX protein_B
protein xxx protein_E
was xxx NE
detected xxx NE
in xx NE
erythroid xxx cell_line_B
cell xxx cell_line_M
line xxx cell_line_M
and xxx cell_line_M
megakaryocyte xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_M
and xxx cell_line_M
mast xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_M
and xxx cell_line_M
early xxx cell_line_M
myeloid xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
lymphoid xxx NE
leukemia xxx NE
cell xxx NE
lines xxx NE
which xxx NE
are xxx NE
known xxx NE
to xx NE
harbor xxx NE
SCL XXX DNA_B
gene xxx DNA_M
rearrangements xxx DNA_E
. . NE

In Xx NE
most xxx NE
cell xxx NE
lines xxx NE
, , NE
proteins xxx NE
of xx NE
molecular xxx protein_B
weight xxx protein_M
49 dd protein_M
and xxx protein_M
44 dd protein_M
kDa xXx protein_E
were xxx NE
found xxx NE
, , NE
however xxx NE
two xxx NE
myeloid xxx NE
cell xxx NE
lines xxx NE
expressed xxx NE
only xxx NE
lower xxx NE
molecular xxx protein_B
weight xxx protein_M
species xxx protein_M
of xx protein_M
24 dd protein_M
and xxx protein_M
22 dd protein_M
kDa xXx protein_E
. . NE

This Xxxx NE
size xxx NE
discrepancy xxx NE
appeared xxx NE
to xx NE
be xx NE
due xxx NE
to xx NE
cell-specific xxx-xxx NE
translational xxx NE
regulation xxx NE
, , NE
since xxx NE
overexpression xxx NE
of xx NE
a x NE
retrovirally xxx NE
transfected xxx NE
SCL XXX DNA_B
gene xxx DNA_E
yielded xxx NE
the xxx NE
higher xxx NE
molecular xxx NE
weight xxx NE
forms xxx NE
in xx NE
most xxx NE
cell xxx cell_line_B
lines xxx cell_line_E
( ( NE
GP+E-86 XX+X-dd cell_line
, , NE
AT2.5 XXd.d cell_line
, , NE
M1 Xd cell_line
) ) NE
but xxx NE
only xxx NE
the xxx NE
22 dd protein_B
kDa xXx protein_M
form xxx protein_E
in xx NE
the xxx NE
myeloid xxx cell_line_B
cell xxx cell_line_M
line xxx cell_line_E
, , NE
WEHI-3B/D+ XXXX-dX/X+ cell_line
. . NE

Overexpression Xxxx NE
of xx NE
full-length xxx-xxx NE
SCL XXX protein_B
protein xxx protein_E
in xx NE
the xxx NE
lymphoid xxx cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
, , NE
SupT1 XxxXd NE
and xxx NE
Raji Xxxx NE
, , NE
did xxx NE
not xxx NE
alter xxx NE
cell xxx NE
phenotype xxx NE
and xxx NE
there xxx NE
was xxx NE
no xx NE
evidence xxx NE
for xxx NE
autoregulation xxx NE
of xx NE
SCL XXX NE
transcription xxx NE
. . NE

The Xxx NE
restricted xxx NE
pattern xxx NE
of xx NE
SCL XXX NE
protein xxx NE
synthesis xxx NE
is xx NE
consistent xxx NE
with xxx NE
the xxx NE
restricted xxx NE
expression xxx NE
of xx NE
SCL XXX RNA_B
mRNA xXXX RNA_E
documented xxx NE
previously xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
the xxx NE
present xxx NE
results xxx NE
indicate xxx NE
that xxx NE
SCL XXX NE
protein xxx NE
size xxx NE
was xxx NE
determined xxx NE
by xx NE
regulation xxx NE
of xx NE
translation xxx NE
in xx NE
a x NE
cell-specific xxx-xxx NE
manner xxx NE
. . NE

Description Xxxx NE
and xxx NE
functional xxx NE
implications xxx NE
of xx NE
a x NE
novel xxx NE
mutation xxx NE
in xx NE
the xxx NE
sex-determining xxx-xxx DNA_B
gene xxx DNA_E
SRY XXX DNA
. . NE

The Xxx NE
sex-determining xxx-xxx NE
gene xxx NE
SRY XXX DNA
was xxx NE
screened xxx NE
for xxx NE
molecular xxx NE
alteration xxx NE
in xx NE
an xx NE
XY XX NE
sex-reversed xxx-xxx NE
female xxx NE
by xx NE
single-strand xxx-xxx NE
conformation xxx NE
polymorphism xxx NE
(SSCP) (XXXX) NE
technique xxx NE
. . NE

An Xx NE
A-to-G X-xx-X NE
transition xxx NE
was xxx NE
detected xxx NE
which xxx NE
leads xxx NE
to xx NE
an xx NE
exchange xxx NE
of xx NE
a x NE
tyrosine xxx NE
by xx NE
a x NE
cysteine xxx NE
in xx NE
the xxx NE
SRY XXX protein_B
protein xxx protein_E
. . NE

The Xxx NE
affected xxx NE
tyrosine xxx NE
residue xxx NE
located xxx NE
at xx NE
the xxx NE
C X protein_B
terminus xxx protein_E
of xx NE
the xxx NE
DNA XXX protein_B
binding xxx protein_M
protein xxx protein_E
is xx NE
evolutionarily xxx NE
strongly xxx NE
conserved xxx NE
among xxx NE
the xxx NE
members xxx NE
of xx NE
the xxx NE
HMG XXX protein_B
box xxx protein_M
containing xxx protein_M
proteins xxx protein_E
. . NE

Using Xxxx NE
gel xxx NE
shift xxx NE
assay xxx NE
and xxx NE
peptide xxx NE
synthesis xxx NE
such xxx NE
a x NE
mutation xxx NE
is xx NE
shown xxx NE
to xx NE
abolish xxx NE
the xxx NE
SRY XXX NE
protein xxx NE
DNA XXX NE
binding xxx NE
ability xxx NE
. . NE

The Xxx NE
involvement xxx NE
of xx NE
this xxx NE
particular xxx NE
amino xxx NE
acid xxx NE
in xx NE
the xxx NE
binding xxx NE
specificity xxx NE
is xx NE
also xxx NE
discussed xxx NE
. . NE

Induction Xxxx NE
of xx NE
tyrosine xxx NE
phosphorylation xxx NE
and xxx NE
T-cell X-xxx NE
activation xxx NE
by xx NE
vanadate xxx NE
peroxide xxx NE
, , NE
an xx NE
inhibitor xxx NE
of xx NE
protein xxx protein_B
tyrosine xxx protein_M
phosphatases xxx protein_E
. . NE

Rapid Xxxx NE
tyrosine xxx NE
phosphorylation xxx NE
of xx NE
key xxx NE
cellular xxx NE
proteins xxx NE
is xx NE
a x NE
crucial xxx NE
event xxx NE
in xx NE
the xxx NE
transduction xxx NE
of xx NE
activation xxx NE
signals xxx NE
to xx NE
T-lymphocytes X-xxx cell_type
. . NE

The Xxx NE
regulatory xxx NE
role xxx NE
of xx NE
protein xxx protein_B
tyrosine xxx protein_M
phosphatases xxx protein_E
( ( NE
PTPases XXXxxx protein
) ) NE
in xx NE
this xxx NE
process xxx NE
was xxx NE
explored xxx NE
by xx NE
studying xxx NE
the xxx NE
effects xxx NE
of xx NE
a x NE
powerful xxx NE
PTPase XXXxxx NE
inhibitor xxx NE
, , NE
vanadate xxx NE
peroxide xxx NE
( ( NE
pervanadate xxx NE
) ) NE
, , NE
on xx NE
the xxx NE
activation xxx NE
cascade xxx NE
of xx NE
Jurkat Xxxx cell_line_B
human xxx cell_line_M
leukaemic xxx cell_line_M
T-cells X-xxx cell_line_E
. . NE

Pervanadate Xxxx NE
induced xxx NE
activation xxx NE
of xx NE
the xxx NE
tyrosine xxx protein_B
kinases xxx protein_E
lck xxx protein
and xxx NE
fyn xxx protein
(4- (d- NE
and xxx NE
3-fold d-xxx NE
respectively) xxx) NE
and xxx NE
a x NE
dramatic xxx NE
increase xxx NE
in xx NE
tyrosine xxx NE
phosphorylation xxx NE
of xx NE
cellular xxx protein_B
proteins xxx protein_E
, , NE
notably xxx NE
phospholipase xxx protein_B
C X protein_M
gamma xxx protein_M
1 d protein_E
. . NE

After Xxxx NE
this xxx NE
event xxx NE
, , NE
we xx NE
observed xxx NE
a x NE
rise xxx NE
in xx NE
intracellular xxx NE
Ca2+ Xxd+ NE
concentration xxx NE
, , NE
corresponding xxx NE
to xx NE
an xx NE
influx xxx NE
. . NE

This Xxxx NE
effect xxx NE
required xxx NE
surface xxx NE
expression xxx NE
of xx NE
the xxx NE
CD45 XXdd protein_B
PTPase XXXxxx protein_E
and xxx NE
was xxx NE
not xxx NE
observed xxx NE
in xx NE
CD45-deficient XXdd-xxx cell_line_B
variants xxx cell_line_E
of xx NE
Jurkat Xxxx cell_line_B
cells xxx cell_line_E
. . NE

In Xx NE
the xxx NE
CD45-negative XXdd-xxx cell_line_B
variant xxx cell_line_E
, , NE
the xxx NE
effect xxx NE
of xx NE
pervanadate xxx NE
on xx NE
tyrosine xxx NE
phosphorylation xxx NE
was xxx NE
globally xxx NE
decreased xxx NE
and xxx NE
some xxx NE
phosphorylated xxx NE
substrates xxx NE
were xxx NE
specifically xxx NE
missing xxx NE
. . NE

Pervanadate Xxxx NE
also xxx NE
stimulated xxx NE
transcription xxx NE
of xx NE
the xxx NE
c-fos x-xxx DNA_B
gene xxx DNA_E
and xxx NE
accumulation xxx NE
of xx NE
its xxx NE
mRNA xXXX RNA
as xx NE
well xxx NE
as xx NE
several xxx NE
other xxx NE
hallmarks xxx NE
of xx NE
T-lymphocyte X-xxx NE
activation xxx NE
such xxx NE
as xx NE
surface xxx NE
expression xxx NE
of xx NE
the xxx NE
CD69 XXdd NE
antigen xxx NE
and xxx NE
the xxx NE
interleukin xxx NE
2 d NE
receptor xxx NE
alpha-chain xxx-xxx NE
(CD25) (XXdd) NE
. . NE

Pervanadate Xxxx NE
synergized xxx NE
with xxx NE
signals xxx NE
delivered xxx NE
by xx NE
T-cell X-xxx NE
antigen xxx NE
receptor xxx NE
engagement xxx NE
or xx NE
by xx NE
a x NE
phorbol xxx NE
ester xxx NE
to xx NE
induce xxx NE
interleukin xxx NE
2 d NE
production xxx NE
. . NE

Pervanadate Xxxx protein_B
activated xxx protein_M
NF-kappa XX-xxx protein_M
B X protein_E
, , NE
as xx NE
shown xxx NE
by xx NE
an xx NE
increase xxx NE
in xx NE
DNA-binding XXX-xxx NE
activity xxx NE
of xx NE
this xxx NE
transcription xxx protein_B
factor xxx protein_E
. . NE

We Xx NE
thus xxx NE
conclude xxx NE
that xxx NE
PTPases XXXxxx protein
play xxx NE
a x NE
crucial xxx NE
role xxx NE
in xx NE
the xxx NE
negative xxx NE
regulation xxx NE
of xx NE
signal xxx NE
transduction xxx NE
culminating xxx NE
in xx NE
T-lymphocyte X-xxx NE
activation xxx NE
. . NE

Moreover Xxxx NE
, , NE
induction xxx NE
of xx NE
tyrosine xxx NE
phosphorylation xxx NE
appears xxx NE
sufficient xxx NE
per xxx NE
se xx NE
to xx NE
initiate xxx NE
a x NE
complete xxx NE
activation xxx NE
programme xxx NE
. . NE

Activation Xxxx NE
of xx NE
nuclear xxx protein_B
factor-kappaB xxx-xxxX protein_E
via xxx NE
T X protein_B
cell xxx protein_M
receptor xxx protein_E
requires xxx NE
a x NE
Raf Xxx protein_B
kinase xxx protein_E
and xxx NE
Ca2+ Xxd+ NE
influx xxx NE
. . NE

Functional Xxxx NE
synergy xxx NE
between xxx NE
Raf Xxx protein
and xxx NE
calcineurin xxx protein
. . NE

Signals Xxxx NE
transduced xxx NE
via xxx NE
the xxx NE
TCR XXX protein
activate xxx NE
the xxx NE
transcription xxx protein_B
factor xxx protein_E
nuclear xxx protein_B
factor-kappaB xxx-xxxX protein_E
( ( NE
NF-kappaB XX-xxxX protein
) ) NE
, , NE
which xxx NE
, , NE
in xx NE
turn xxx NE
, , NE
is xx NE
critical xxx NE
to xx NE
the xxx NE
transcriptional xxx NE
induction xxx NE
of xx NE
many xxx NE
genes xxx NE
important xxx NE
for xxx NE
the xxx NE
proliferation xxx NE
and xxx NE
expression xxx NE
of xx NE
a x NE
differentiated xxx NE
phenotype xxx NE
. . NE

Treatment Xxxx NE
of xx NE
T X cell_type_B
cells xxx cell_type_E
with xxx NE
the xxx NE
protein xxx protein_B
kinase xxx protein_M
C X protein_E
activator xxx NE
PMA XXX NE
in xx NE
combination xxx NE
with xxx NE
Ca2+ Xxd+ NE
ionophores xxx NE
mimics xxx NE
this xxx NE
process xxx NE
, , NE
and xxx NE
the xxx NE
two xxx NE
agents xxx NE
are xxx NE
often xxx NE
substituted xxx NE
for xxx NE
TCR XXX NE
stimulation xxx NE
, , NE
bypassing xxx NE
the xxx NE
TCR XXX protein
. . NE

Here Xxxx NE
we xx NE
identify xxx NE
intracellular xxx NE
signaling xxx NE
components xxx NE
involved xxx NE
in xx NE
activation xxx NE
of xx NE
NF-kappaB XX-xxxX protein
following xxx NE
TCR XXX NE
stimulation xxx NE
. . NE

TCR XXX protein
signaling xxx NE
was xxx NE
triggered xxx NE
by xx NE
treating xxx NE
Jurkat Xxxx cell_line_B
T X cell_line_M
cells xxx cell_line_E
with xxx NE
PHA XXX protein
or xx NE
anti-CD3 xxx-XXd protein_B
Abs Xxx protein_E
, , NE
and xxx NE
NF-kappaB XX-xxxX protein
activation xxx NE
was xxx NE
monitored xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assays xxx NE
and/or xxx/xx NE
by xx NE
kappaB xxxX NE
-dependent -xxx NE
reporter xxx NE
assays xxx NE
. . NE

Contrary Xxxx NE
to xx NE
the xxx NE
idea xxx NE
that xxx NE
protein xxx protein_B
kinase xxx protein_M
C X protein_E
is xx NE
involved xxx NE
in xx NE
TCR XXX NE
-mediated -xxx NE
activation xxx NE
of xx NE
NF-kappaB XX-xxxX NE
, , NE
high xxx NE
doses xxx NE
of xx NE
staurosporine xxx NE
did xxx NE
not xxx NE
interfere xxx NE
with xxx NE
activation xxx NE
of xx NE
NF-kappaB XX-xxxX NE
by xx NE
PHA XXX NE
, , NE
while xxx NE
the xxx NE
same xxx NE
dose xxx NE
of xx NE
staurosporine xxx NE
completely xxx NE
blocked xxx NE
activation xxx NE
by xx NE
PMA XXX NE
. . NE

PHA XXX protein
-induced -xxx NE
kappaB-dependent xxxX-xxx NE
reporter xxx NE
activity xxx NE
was xxx NE
, , NE
however xxx NE
, , NE
effectively xxx NE
blocked xxx NE
by xx NE
a x NE
dominant xxx NE
negative xxx NE
form xxx NE
of xx NE
Raf-1 Xxx-d protein
, , NE
suggesting xxx NE
a x NE
critical xxx NE
role xxx NE
for xxx NE
a x NE
Raf Xxx protein_B
kinase xxx protein_E
. . NE

The Xxx NE
TCR XXX NE
-mediated -xxx NE
activation xxx NE
of xx NE
NF-kappaB XX-xxxX NE
was xxx NE
also xxx NE
dependent xxx NE
on xx NE
a x NE
Ca2+ Xxd+ NE
influx xxx NE
, , NE
because xxx NE
the xxx NE
Ca2+ Xxd+ NE
channel xxx NE
blocker xxx NE
, , NE
SK&F XX&X NE
96365 ddddd NE
, , NE
as xx NE
well xxx NE
as xx NE
other xxx NE
agents xxx NE
that xxx NE
prevented xxx NE
the xxx NE
Ca2+ Xxd+ NE
influx xxx NE
, , NE
inhibited xxx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Cotransfection Xxxx NE
of xx NE
a x NE
constitutively xxx NE
active xxx NE
form xxx NE
of xx NE
calcineurin xxx protein
largely xxx NE
substituted xxx NE
for xxx NE
the xxx NE
Ca2+ Xxd+ NE
requirement xxx NE
and xxx NE
reversed xxx NE
the xxx NE
blockade xxx NE
by xx NE
SK&F XX&X NE
96365 ddddd NE
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
observations xxx NE
, , NE
coexpression xxx NE
of xx NE
constitutively xxx NE
active xxx NE
forms xxx NE
of xx NE
Raf-1 Xxx-d protein
and xxx NE
calcineurin xxx protein
synergistically xxx NE
induced xxx NE
kappaB xxxX NE
-dependent -xxx NE
reporter xxx NE
activity xxx NE
, , NE
suggesting xxx NE
a x NE
physiologically xxx NE
relevant xxx NE
functional xxx NE
interaction xxx NE
between xxx NE
the xxx NE
kinase xxx NE
and xxx NE
the xxx NE
phosphatase xxx NE
. . NE

Synergistic Xxxx NE
interactions xxx NE
between xxx NE
overlapping xxx DNA_B
binding xxx DNA_M
sites xxx DNA_E
for xxx NE
the xxx NE
serum xxx protein_B
response xxx protein_M
factor xxx protein_E
and xxx NE
ELK-1 XXX-d protein_B
proteins xxx protein_E
mediate xxx NE
both xxx NE
basal xxx NE
enhancement xxx NE
and xxx NE
phorbol xxx NE
ester xxx NE
responsiveness xxx NE
of xx NE
primate xxx DNA_B
cytomegalovirus xxx DNA_M
major xxx DNA_M
immediate-early xxx-xxx DNA_M
promoters xxx DNA_E
in xx NE
monocyte xxx NE
and xxx NE
T-lymphocyte X-xxx cell_type
cell xxx NE
types xxx NE
. . NE

Cytomegalovirus Xxxx NE
(CMV) (XXX) NE
infection xxx NE
is xx NE
nonpermissive xxx NE
or xx NE
persistent xxx NE
in xx NE
many xxx NE
lymphoid xxx cell_type_B
cell xxx cell_type_M
type xxx cell_type_M
and xxx cell_type_M
myeloid xxx cell_type_M
cell xxx cell_type_M
type xxx cell_type_E
but xxx NE
can xxx NE
be xx NE
activated xxx NE
in xx NE
differentiated xxx cell_type_B
macrophages xxx cell_type_E
. . NE

We Xx NE
have xxx NE
shown xxx NE
elsewhere xxx NE
that xxx NE
both xxx NE
the xxx NE
major xxx DNA_B
immediate-early xxx-xxx DNA_M
gene xxx DNA_E
( ( NE
MIE XXX DNA
) ) NE
and xxx NE
lytic xxx NE
cycle xxx NE
infectious xxx NE
progeny xxx NE
virus xxx NE
expression xxx NE
can xxx NE
be xx NE
induced xxx NE
in xx NE
otherwise xxx NE
nonpermissive xxx NE
monocyte-like xxx-xxx cell_line_B
U-937 X-ddd cell_line_M
cell xxx cell_line_M
cultures xxx cell_line_E
infected xxx NE
with xxx NE
either xxx NE
human xxx NE
CMV XXX NE
( ( NE
HCMV XXXX NE
) ) NE
or xx NE
simian xxx NE
CMV XXX NE
( ( NE
SCMV XXXX NE
) ) NE
by xx NE
treatment xxx NE
with xxx NE
the xxx NE
phorbol xxx NE
ester xxx NE
12-O-tetradecanoylphorbol-13-acetate dd-X-xxx-dd-xxx NE
( ( NE
TPA XXX NE
) ) NE
. . NE

Two Xxx NE
multicopy xxx DNA_B
basal xxx DNA_M
enhancer xxx DNA_M
motifs xxx DNA_E
within xxx NE
the xxx NE
SCMV XXXX NE
MIE XXX NE
enhancer xxx DNA
, , NE
namely xxx NE
, , NE
11 dd NE
copies xxx NE
of xx NE
the xxx NE
16-bp dd-xx NE
cyclic xxx DNA_B
AMP XXX DNA_M
response xxx DNA_M
element xxx DNA_E
( ( NE
CRE XXX DNA
) ) NE
and xxx NE
3 d NE
copies xxx NE
of xx NE
novel xxx NE
17-bp dd-xx NE
serum xxx DNA_B
response xxx DNA_M
factor xxx DNA_M
( ( DNA_E
SRF XXX NE
) ) NE
binding xxx NE
sites xxx NE
referred xxx NE
to xx NE
as xx NE
the xxx NE
SNE XXX DNA
( ( NE
SRF/NFkappaB-like XXX/XXxxxX-xxx DNA_B
element xxx DNA_E
) ) NE
, , NE
as xx NE
well xxx NE
as xx NE
four xxx NE
classical xxx NE
NFkappaB XXxxxX DNA_B
sites xxx DNA_E
within xxx NE
the xxx NE
HCMV XXXX NE
version xxx NE
, , NE
contribute xxx NE
to xx NE
TPA XXX NE
responsiveness xxx NE
in xx NE
transient xxx NE
assays xxx NE
in xx NE
monocyte xxx cell_type_B
type xxx cell_type_M
and xxx cell_type_M
T-cell X-xxx cell_type_M
type xxx cell_type_E

The Xxx NE
SCMV XXXX DNA_B
SNE XXX DNA_M
sites xxx DNA_E
contain xxx NE
potential xxx NE
overlapping xxx NE
core xxx NE
recognition xxx NE
binding xxx NE
motifs xxx NE
for xxx NE
SRF XXX protein
, , NE
Rel/NFkappaB Xxx/XXxxxX protein
, , NE
ETS XXX protein
, , NE
and xxx NE
YY1 XXd protein_B
class xxx protein_M
transcription xxx protein_M
factors xxx protein_E
but xxx NE
fail xxx NE
to xx NE
respond xxx NE
to xx NE
either xxx NE
serum xxx protein_B
necrosis xxx protein_M
factor xxx protein_M
alpha xxx protein_M
or xx protein_M
tumor xxx protein_M
necrosis xxx protein_M
factor xxx protein_M
alpha xxx protein_E

Therefore Xxxx NE
, , NE
to xx NE
evaluate xxx NE
the xxx NE
mechanism xxx NE
of xx NE
TPA XXX NE
responsiveness xxx NE
of xx NE
the xxx NE
SNE XXX DNA_B
motifs xxx DNA_E
and xxx NE
of xx NE
a x NE
related xxx NE
16-bp dd-xx NE
SEE XXX DNA
( ( NE
SRF/ XXX/ DNA
ETS XXX NE
multimerized xxx DNA_B
wild-type xxx-xxx DNA_M
element xxx DNA_M
and xxx DNA_M
multimerized xxx DNA_M
mutant xxx DNA_M
element xxx DNA_E
HCMV XXXX NE
and xxx NE
HCMV XXXX DNA_B
MIE XXX DNA_M
enhancer xxx DNA_M
and xxx DNA_M
chimpanzee xxx DNA_M
CMV XXX DNA_M
MIE XXX DNA_M
enhancer xxx DNA_E
functional xxx NE
responses xxx NE
and xxx NE
protein xxx NE
binding xxx NE
properties xxx NE
of xx NE
multimerized xxx NE
wild-type xxx-xxx NE
and xxx NE
mutant xxx NE
elements xxx NE
added xxx NE
upstream xxx NE
to xx NE
the xxx NE
SCMV XXXX DNA_B
MIE XXX DNA_E
or xx NE
simian xxx DNA_B
virus xxx DNA_M
40 dd DNA_M
minimal xxx DNA_M
promoter xxx DNA_M
regions xxx DNA_E
in xx NE
the xxx NE
U-937 X-ddd cell_line
, , NE
K-562 X-ddd cell_line
, , NE
HL-60 XX-dd cell_line
, , NE
THP-1 XXX-d cell_line
, , NE
and xxx NE
Jurkat Xxxx cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
. . NE

Unlike Xxxx NE
classical xxx NE
NFkappaB XXxxxX DNA_B
sites xxx DNA_E
, , NE
neither xxx NE
the xxx NE
SNE XXX DNA
nor xxx NE
the xxx NE
SEE XXX DNA_B
motif xxx DNA_E
responded xxx NE
to xx NE
phosphatase xxx NE
inhibition xxx NE
by xx NE
okadaic xxx NE
acid xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
TPA XXX NE
responsiveness xxx NE
of xx NE
both xxx NE
CMV XXX DNA_B
elements xxx DNA_E
proved xxx NE
to xx NE
involve xxx NE
synergistic xxx NE
interactions xxx NE
between xxx NE
the xxx NE
core xxx NE
SRF XXX DNA_B
binding xxx DNA_M
site xxx DNA_E
( ( NE
CCATATATGG XXXXXXXXXX NE
) ) NE
and xxx NE
the xxx NE
adjacent xxx NE
inverted xxx NE
ETS XXX DNA_B
binding xxx DNA_M
motifs xxx DNA_E
( ( NE
TTCC XXXX NE
) ) NE
, , NE
which xxx NE
correlated xxx NE
directly xxx NE
with xxx NE
formation xxx NE
of xx NE
a x NE
bound xxx NE
tripartite xxx protein_B
complex xxx protein_E
containing xxx NE
both xxx NE
the xxx NE
cellular xxx NE
SRF XXX protein
and xxx NE
ELK-1 XXX-d protein_B
proteins xxx protein_E
. . NE

This Xxxx NE
protein xxx protein_B
complex xxx protein_E
was xxx NE
more xxx NE
abundant xxx NE
in xx NE
U-937 X-ddd NE
cell xxx NE
extract xxx NE
and xxx NE
K-562 X-ddd NE
cell xxx NE
extract xxx NE
and xxx NE
HeLa XxXx NE
cell xxx NE
extract xxx NE
than xxx NE
in xx NE
Raji Xxxx cell_line
, , NE
HF XX cell_line
, , NE
BALB/c XXXX/x cell_line_B
3T3 dXd cell_line_E
, , NE
or xx NE
HL-60 XX-dd cell_line_B
cells xxx cell_line_E
, , NE
but xxx NE
the xxx NE
binding xxx NE
activity xxx NE
was xxx NE
altered xxx NE
only xxx NE
twofold xxx NE
after xxx NE
TPA XXX NE
treatment xxx NE
. . NE

A X NE
40-fold dd-xxx NE
stimulation xxx NE
of xx NE
chloramphenicol xxx NE
acetyltransferase xxx NE
activity xxx NE
mediated xxx NE
by xx NE
four xxx NE
tandem xxx DNA_B
repeats xxx DNA_E
of xx NE
the xxx NE
SNE XXX DNA
could xxx NE
be xx NE
induced xxx NE
within xxx NE
2 d NE
h x NE
(and (xxx NE
up xx NE
to xx NE
250-fold ddd-xxx NE
within xxx NE
6 d NE
h) x) NE
after xxx NE
addition xxx NE
of xx NE
TPA XXX NE
in xx NE
DNA-transfected XXX-xxx cell_line_B
U-937 X-ddd cell_line_M
cells xxx cell_line_E
, , NE
indicating xxx NE
that xxx NE
the xxx NE
stimulation xxx NE
appeared xxx NE
likely xxx NE
to xx NE
be xx NE
a x NE
true xxx NE
protein xxx NE
kinase xxx NE
C X NE
-mediated -xxx NE
signal xxx NE
transduction xxx NE
event xxx NE
rather xxx NE
than xxx NE
a x NE
differentiation xxx NE
response xxx NE
. . NE

Slight Xxxx NE
differences xxx NE
in xx NE
the xxx NE
sequence xxx NE
of xx NE
the xxx NE
core xxx DNA_B
SRF XXX DNA_M
binding xxx DNA_M
site xxx DNA_E
compared xxx NE
with xxx NE
that xxx NE
of xx NE
the xxx NE
classical xxx NE
c-Fos x-Xxx DNA_B
promoter xxx DNA_M
serum xxx DNA_M
response xxx DNA_M
element xxx DNA_E
, , NE
together xxx NE
with xxx NE
differences xxx NE
in xx NE
the xxx NE
spacing xxx NE
between xxx NE
the xxx NE
SRF XXX DNA_B
motif xxx DNA_M
and xxx DNA_M
ETS XXX DNA_M
motif xxx DNA_E
SCMV XXXX NE
SNEs XXXx NE
to xx NE
respond xxx NE
to xx NE
serum xxx NE
induction xxx NE
. . NE

T-cell X-xxx NE
-directed -xxx NE
TAL-1 XXX-d NE
expression xxx NE
induces xxx NE
T-cell X-xxx NE
malignancies xxx NE
in xx NE
transgenic xxx NE
mice xxx NE
. . NE

The Xxx NE
TAL-1 XXX-d DNA_B
gene xxx DNA_E
specifies xxx NE
for xxx NE
a x NE
basic xxx NE
domain-helix-loop-helix xxx-xxx-xxx-xxx protein_B
protein xxx protein_E
, , NE
which xxx NE
is xx NE
involved xxx NE
in xx NE
the xxx NE
control xxx NE
of xx NE
normal xxx NE
hematopoiesis xxx NE
. . NE

In Xx NE
human xxx NE
pathology xxx NE
, , NE
the xxx NE
TAL-1 XXX-d protein_B
gene xxx protein_M
product xxx protein_E
is xx NE
expressed xxx NE
in xx NE
a x NE
high xxx NE
percentage xxx NE
of xx NE
T-cell X-xxx NE
acute xxx NE
lymphoblastic xxx NE
leukemias xxx NE
in xx NE
the xxx NE
pediatric xxx NE
age xxx NE
range xxx NE
; ; NE
however xxx NE
, , NE
it xx NE
has xxx NE
not xxx NE
been xxx NE
established xxx NE
whether xxx NE
the xxx NE
expression xxx NE
has xxx NE
a x NE
causal xxx NE
role xxx NE
in xx NE
oncogenesis xxx NE
. . NE

In Xx NE
this xxx NE
report xxx NE
, , NE
we xx NE
describe xxx NE
the xxx NE
phenotype xxx NE
of xx NE
mouse xxx cell_line_B
transgenic xxx cell_line_M
lines xxx cell_line_E
obtained xxx NE
by xx NE
inducing xxx NE
tal-1 xxx-d NE
protein xxx NE
expression xxx NE
in xx NE
lymphoid xxx NE
tissues xxx NE
using xxx NE
the xxx NE
LCK XXX DNA_B
promoter xxx DNA_E
. . NE

The Xxx NE
survival xxx NE
rate xxx NE
of xx NE
tal-1 xxx-d NE
transgenic xxx NE
animals xxx NE
was xxx NE
much xxx NE
lower xxx NE
as xx NE
compared xxx NE
with xxx NE
control xxx NE
mice xxx NE
. . NE

Histopathological Xxxx NE
analysis xxx NE
revealed xxx NE
lymphomas xxx NE
of xx NE
T-cell X-xxx NE
type xxx NE
, , NE
often xxx NE
comprising xxx NE
a x NE
minor xxx NE
B-cell X-xxx NE
component xxx NE
. . NE

Some Xxxx NE
mice xxx NE
showed xxx NE
marked xxx NE
splenic xxx NE
lymphocyte xxx NE
depletion xxx NE
. . NE

Primary Xxxx cell_line_B
lymphocyte xxx cell_line_M
cultures xxx cell_line_E
showed xxx NE
partial xxx NE
independence xxx NE
from xxx NE
exogenous xxx NE
growth xxx NE
stimuli xxx NE
and xxx NE
increased xxx NE
resistance xxx NE
to xx NE
low-serum xxx-xxx NE
apoptosis xxx NE
. . NE

To Xx NE
further xxx NE
unravel xxx NE
the xxx NE
tal-1 xxx-d NE
oncogenic xxx NE
potential xxx NE
, , NE
a x NE
strain xxx NE
of xx NE
tal-1 xxx-d DNA
transgenic xxx NE
mice xxx NE
was xxx NE
crossbred xxx NE
with xxx NE
p53-/- xdd-/- NE
mice xxx NE
; ; NE
the xxx NE
survival xxx NE
rate xxx NE
in xx NE
these xxx NE
animals xxx NE
was xxx NE
reduced xxx NE
by xx NE
more xxx NE
than xxx NE
one-half xxx-xxx NE
when xxx NE
compared xxx NE
with xxx NE
that xxx NE
of xx NE
tal-1 xxx-d NE
mice xxx NE
, , NE
and xxx NE
histopathological xxx NE
analysis xxx NE
revealed xxx NE
exclusively xxx NE
T-cell X-xxx NE
lymphomas xxx NE
. . NE

These Xxxx NE
data xxx NE
indicate xxx NE
that xxx NE
TAL-1 XXX-d protein
, , NE
expressed xxx NE
in xx NE
T X cell_type_B
cells xxx cell_type_E
, , NE
is xx NE
per xxx NE
se xx NE
a x NE
potent xxx NE
oncogene xxx NE
, , NE
which xxx NE
may xxx NE
exert xxx NE
a x NE
key xxx NE
leukemogenetic xxx NE
role xxx NE
in xx NE
the xxx NE
majority xxx NE
of xx NE
T-cell X-xxx NE
acute xxx NE
lymphoblastic xxx NE
leukemias xxx NE
. . NE

Tissue Xxxx NE
and xxx NE
cell-type xxx-xxx NE
specific xxx NE
expression xxx NE
of xx NE
the xxx NE
tuberous xxx DNA_B
sclerosis xxx DNA_M
gene xxx DNA_E
, , NE
TSC2 XXXd DNA
, , NE
in xx NE
human xxx NE
tissues xxx NE
. . NE

TSC2 XXXd DNA
is xx NE
a x NE
gene xxx NE
on xx NE
chromosome xxx DNA_B
16p13.3 ddxdd.d DNA_E
associated xxx NE
with xxx NE
the xxx NE
autosomal xxx NE
dominant xxx NE
neurocutaneous xxx NE
disorder xxx NE
, , NE
tuberous xxx NE
sclerosis xxx NE
complex xxx NE
( ( NE
TSC XXX NE
) ) NE
. . NE

By Xx NE
using xxx NE
a x NE
partial xxx DNA_B
nucleotide xxx DNA_M
sequence xxx DNA_E
from xxx NE
the xxx NE
cloned xxx NE
TSC2 XXXd DNA
and xxx NE
polymerase xxx NE
chain xxx NE
reaction xxx NE
methodology xxx NE
, , NE
we xx NE
constructed xxx NE
a x NE
digoxigenin-labeled xxx-xxx DNA_B
complementary xxx DNA_M
DNA XXX DNA_M
probe xxx DNA_E
to xx NE
examine xxx NE
TSC2 XXXd NE
gene xxx NE
expression xxx NE
in xx NE
autopsy- xxx- NE
or xx NE
biopsy-derived xxx-xxx NE
human xxx NE
tissues xxx NE
by xx NE
in xx NE
situ xxx NE
hybridization xxx NE
. . NE

TSC2 XXXd RNA_B
messenger xxx RNA_M
RNA XXX RNA_E
was xxx NE
widely xxx NE
expressed xxx NE
in xx NE
various xxx NE
cell xxx NE
types xxx NE
throughout xxx NE
the xxx NE
body xxx NE
, , NE
including xxx NE
epithelia xxx NE
, , NE
lymphocytes xxx cell_type
, , NE
and xxx NE
cells xxx NE
with xxx NE
endocrine xxx NE
functions xxx NE
, , NE
e.g. x.x. NE
, , NE
adrenal xxx NE
cortex xxx NE
and xxx NE
anterior xxx NE
pituitary xxx NE
. . NE

It Xx NE
was xxx NE
prominently xxx NE
and xxx NE
selectively xxx NE
(within (xxx NE
the xxx NE
central xxx NE
nervous xxx NE
system xxx NE
) ) NE
expressed xxx NE
in xx NE
pyramidal xxx cell_type_B
cells xxx cell_type_E
of xx NE
the xxx NE
cerebral xxx NE
cortex xxx NE
and xxx NE
other xxx NE
motor xxx cell_type_B
neurons xxx cell_type_E
, , NE
e.g. x.x. NE
, , NE
in xx NE
spinal xxx NE
cord xxx NE
and xxx NE
brainstem xxx NE
nuclei xxx NE
. . NE

Visceral Xxxx NE
TSC2 XXXd DNA
expression xxx NE
was xxx NE
comparable xxx NE
in xx NE
autopsy xxx NE
tissues xxx NE
from xxx NE
patients xxx NE
with xxx NE
and xxx NE
without xxx NE
TSC XXX NE
; ; NE
TSC2 XXXd DNA
messenger xxx NE
RNA XXX NE
expression xxx NE
was xxx NE
most xxx NE
prominent xxx NE
in xx NE
cells xxx NE
with xxx NE
a x NE
rapid xxx NE
mitotic xxx NE
rate xxx NE
and xxx NE
turnover xxx NE
, , NE
e.g. x.x. NE
, , NE
epithelia xxx NE
and xxx NE
lymphocytes xxx cell_type
, , NE
with xxx NE
central xxx NE
nervous xxx NE
system xxx NE
pyramidal xxx cell_type_B
cells xxx cell_type_E
and xxx NE
other xxx NE
neurons xxx NE
being xxx NE
an xx NE
obvious xxx NE
exception xxx NE
, , NE
and/or xxx/xx NE
in xx NE
cells xxx NE
with xxx NE
important xxx NE
secretory/transport xxx/xxx NE
functions xxx NE
. . NE

This Xxxx NE
widespread xxx NE
expression xxx NE
of xx NE
the xxx NE
TSC2 XXXd DNA_B
gene xxx DNA_E
supports xxx NE
the xxx NE
view xxx NE
that xxx NE
it xx NE
encodes xxx NE
a x NE
protein xxx NE
vital xxx NE
to xx NE
cell xxx NE
growth xxx NE
and xxx NE
metabolism xxx NE
or xx NE
one xxx NE
that xxx NE
functions xxx NE
as xx NE
a x NE
tumor/growth xxx/xxx NE
suppressor xxx NE
. . NE

Apoptosis Xxxx NE
signaling xxx NE
pathways xxx NE
in xx NE
normal xxx NE
T X cell_type_B
cells xxx cell_type_E
: : NE
differential xxx NE
activity xxx NE
of xx NE
Bcl-2 Xxx-d protein
and xxx NE
IL-1beta XX-dxxx NE
-converting -xxx NE
enzyme xxx NE
family xxx NE
protease xxx NE
inhibitors xxx NE
on xx NE
glucocorticoid-mediated xxx-xxx NE
cytotoxicity xxx NE
and xxx NE
Fas-mediated Xxx-xxx NE
cytotoxicity xxx NE

Fas Xxx NE
-mediated -xxx NE
apoptosis xxx NE
plays xxx NE
an xx NE
important xxx NE
role xxx NE
in xx NE
regulating xxx NE
the xxx NE
immune xxx NE
response xxx NE
in xx NE
peripheral xxx NE
T X NE
cells xxx NE
. . NE

Restimulation Xxxx NE
of xx NE
T X cell_type_B
cell xxx cell_type_M
blasts xxx cell_type_E
up-regulates xx-xxx NE
Fas Xxx protein
and xxx NE
Fas Xxx NE
ligand xxx NE
expression xxx NE
, , NE
with xxx NE
subsequent xxx NE
interaction xxx NE
leading xxx NE
to xx NE
cell xxx NE
death xxx NE
. . NE

Overexpression Xxxx NE
of xx NE
Bcl-2 Xxx-d protein
in xx NE
tumor xxx cell_type_B
cells xxx cell_type_E
blocks xxx NE
apoptosis xxx NE
induced xxx NE
by xx NE
many xxx NE
stimuli xxx NE
, , NE
but xxx NE
inhibition xxx NE
of xx NE
Fas Xxx NE
-mediated -xxx NE
killing xxx NE
has xxx NE
not xxx NE
been xxx NE
consistently xxx NE
observed xxx NE
. . NE

To Xx NE
examine xxx NE
the xxx NE
behavior xxx NE
of xx NE
Bcl-2 Xxx-d protein
in xx NE
normal xxx cell_type_B
cells xxx cell_type_E
, , NE
T X cell_type_B
cell xxx cell_type_M
blasts xxx cell_type_E
were xxx NE
transiently xxx NE
transfected xxx NE
with xxx NE
Bcl-2 Xxx-d protein
and xxx NE
related xxx NE
gene xxx protein_B
products xxx protein_E
to xx NE
determine xxx NE
the xxx NE
effect xxx NE
on xx NE
apoptotic xxx NE
signaling xxx NE
. . NE

Transient Xxxx NE
overexpression xxx NE
of xx NE
Bcl-2 Xxx-d protein
in xx NE
mouse xxx NE
and xxx NE
human xxx NE
T X cell_type_B
cell xxx cell_type_M
blasts xxx cell_type_E
did xxx NE
not xxx NE
block xxx NE
Fas Xxx NE
-mediated -xxx NE
apoptosis xxx NE
, , NE
whereas xxx NE
etoposide-induced xxx-xxx NE
cytotoxicity xxx NE
and xxx NE
glucocorticoid-induced xxx-xxx NE
cytotoxicity xxx NE

Expression Xxxx NE
of xx NE
Bcl-xL Xxx-xX protein
and xxx NE
adenovirus xxx protein_B
E1B XdX protein_M
19K ddX protein_E
did xxx NE
not xxx NE
interfere xxx NE
with xxx NE
anti- xxx- NE
Fas Xxx NE
killing xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
interleukin-1beta-converting xxx-dxxx-xxx NE
enzyme xxx NE
family xxx NE
protease xxx NE
inhibitors xxx NE
Ac-DEVD-CHO Xx-XXXX-XXX NE
and xxx NE
CrmA XxxX NE
blocked xxx NE
Fas Xxx NE
-mediated -xxx NE
apoptosis xxx NE
. . NE

These Xxxx NE
results xxx NE
suggest xxx NE
that xxx NE
peripheral xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
use xxx NE
distinct xxx NE
apoptosis xxx NE
signaling xxx NE
pathways xxx NE
with xxx NE
differential xxx NE
sensitivity xxx NE
to xx NE
Bcl-2 Xxx-d protein
and xxx NE
interleukin-1beta-converting xxx-dxxx-xxx NE
enzyme xxx NE
family xxx NE
protease xxx NE
inhibitors xxx NE
. . NE

Since Xxxx NE
T X cell_type_B
cells xxx cell_type_E
normally xxx NE
express xxx NE
Bcl-2 Xxx-d protein
and xxx NE
Bcl-xL Xxx-xX protein
following xxx NE
activation xxx NE
, , NE
their xxx NE
inability xxx NE
to xx NE
block xxx NE
Fas Xxx NE
-mediated -xxx NE
apoptosis xxx NE
may xxx NE
allow xxx NE
for xxx NE
the xxx NE
elimination xxx NE
of xx NE
self-reactive xxx-xxx NE
cells xxx NE
and xxx NE
the xxx NE
appropriate xxx NE
regulation xxx NE
of xx NE
immune xxx NE
responses xxx NE
. . NE

Increased Xxxx NE
interleukin xxx NE
2 d NE
transcription xxx NE
in xx NE
murine xxx cell_type_B
lymphocytes xxx cell_type_E
by xx NE
ciprofloxacin xxx NE
. . NE

The Xxx NE
fluoroquinolone xxx NE
antibiotic xxx NE
, , NE
ciprofloxacin xxx NE
( ( NE
cipro xxx NE
) ) NE
, , NE
induces xxx NE
hyperproduction xxx NE
of xx NE
interleukin xxx protein_B
2 d protein_E
( ( NE
IL-2 XX-d protein
) ) NE
and xxx NE
interferon-gamma xxx-xxx protein
( ( NE
IFN-gamma XXX-xxx protein
) ) NE
in xx NE
stimulated xxx NE
human xxx cell_type_B
peripheral xxx cell_type_M
blood xxx cell_type_M
lymphocytes xxx cell_type_E
. . NE

In Xx NE
this xxx NE
investigation xxx NE
an xx NE
enhanced xxx NE
and xxx NE
prolonged xxx NE
IL-2 XX-d protein
and xxx NE
IL-2 XX-d NE
mRNA xXXX NE
response xxx NE
was xxx NE
also xxx NE
detected xxx NE
in xx NE
both xxx NE
stimulated xxx NE
( ( NE
T X protein_B
cell xxx protein_M
mitogens xxx protein_E
or xx NE
alloantigens xxx protein
) ) NE
murine xxx cell_type_B
splenocytes xxx cell_type_E
and xxx NE
in xx NE
the xxx NE
stimulated xxx NE
murine xxx cell_line_B
T X cell_line_M
cell xxx cell_line_M
line xxx cell_line_M
EL-4 XX-d cell_line_E
in xx NE
the xxx NE
presence xxx NE
of xx NE
ciprofloxacin xxx NE
(5-80 (d-dd NE
micrograms/ml) xxx/xx) NE
as xx NE
compared xxx NE
to xx NE
control xxx NE
cells xxx NE
without xxx NE
antibiotics xxx NE
. . NE

However Xxxx NE
, , NE
in xx NE
contrast xxx NE
to xx NE
human xxx cell_type_B
lymphocytes xxx cell_type_E
, , NE
IFN-gamma XXX-xxx NE
production xxx NE
was xxx NE
inhibited xxx NE
and xxx NE
IFN-gamma XXX-xxx NE
mRNA xXXX NE
levels xxx NE
were xxx NE
unaffected xxx NE
at xx NE
24 dd NE
h x NE
and xxx NE
only xxx NE
slightly xxx NE
upregulated xxx NE
at xx NE
48 dd NE
and xxx NE
72 dd NE
h x NE
of xx NE
culture xxx NE
in xx NE
murine xxx cell_type_B
splenocytes xxx cell_type_E
incubated xxx NE
with xxx NE
cipro xxx NE
(20 (dd NE
micrograms/ml) xxx/xx) NE
. . NE

EL-4 XX-d cell_type_B
cells xxx cell_type_E
were xxx NE
transfected xxx NE
with xxx NE
a x NE
plasmid xxx NE
containing xxx NE
the xxx NE
IL-2 XX-d DNA_B
promoter xxx DNA_E
and xxx NE
enhancer xxx DNA_B
region xxx DNA_E
linked xxx NE
to xx NE
the xxx NE
chloramphenicol xxx NE
acetyltransferase xxx NE
( ( NE
CAT XXX NE
) ) NE
reporter xxx NE
gene xxx NE
. . NE

Analysis Xxxx NE
of xx NE
CAT XXX NE
activity xxx NE
revealed xxx NE
that xxx NE
cipro xxx NE
enhanced xxx NE
IL-2 XX-d NE
gene xxx NE
induction xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
EL-4 XX-d cell_type_B
cells xxx cell_type_E
incubated xxx NE
with xxx NE
ciprofloxacin xxx NE
showed xxx NE
an xx NE
early xxx NE
peak xxx NE
and xxx NE
more xxx NE
activated xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
( ( NE
NFAT-1 XXXX-d protein
) ) NE
as xx NE
compared xxx NE
to xx NE
control xxx NE
cells xxx NE
without xxx NE
antibiotics xxx NE
. . NE

Cipro Xxxx NE
did xxx NE
not xxx NE
affect xxx NE
the xxx NE
nuclear xxx protein_B
transcription xxx protein_M
factors xxx protein_E
AP-1 XX-d protein
or xx NE
NFIL-2A XXXX-dX protein
. . NE

Taken Xxxx NE
together xxx NE
, , NE
cipro xxx NE
inhibited xxx NE
IFN-gamma XXX-xxx NE
synthesis xxx NE
, , NE
but xxx NE
enhanced xxx NE
IL-2 XX-d protein
production xxx NE
in xx NE
murine xxx cell_type_B
lymphocytes xxx cell_type_E
by xx NE
means xxx NE
of xx NE
influencing xxx NE
NFAT-1 XXXX-d protein
and xxx NE
causing xxx NE
an xx NE
increased xxx NE
IL-2 XX-d NE
transcription xxx NE
. . NE

Human Xxxx NE
T-cell X-xxx NE
leukemia xxx NE
virus xxx NE
type xxx NE
I X NE
Tax Xxx protein
associates xxx NE
with xxx NE
and xxx NE
is xx NE
negatively xxx NE
regulated xxx NE
by xx NE
the xxx NE
NF-kappa XX-xxx protein_B
B2 Xd protein_M
p100 xddd protein_M
gene xxx protein_M
product xxx protein_E
: : NE
implications xxx NE
for xxx NE
viral xxx NE
latency xxx NE
. . NE

Human Xxxx NE
T-cell X-xxx NE
leukemia xxx NE
virus xxx NE
type xxx NE
I X NE
( ( NE
HTLV-I XXXX-X NE
) ) NE
is xx NE
the xxx NE
etiologic xxx NE
agent xxx NE
of xx NE
the xxx NE
adult xxx NE
T-cell X-xxx NE
leukemia xxx NE
, , NE
an xx NE
aggressive xxx NE
and xxx NE
often xxx NE
fatal xxx NE
malignancy xxx NE
of xx NE
activated xxx cell_line_B
human xxx cell_line_M
CD4 XXd cell_line_M
T X cell_line_M
cells xxx cell_line_E
. . NE

HTLV-I XXXX-X NE
encodes xxx NE
an xx NE
essential xxx NE
40-kDa dd-xXx protein_B
protein xxx protein_E
termed xxx NE
Tax Xxx protein
that xxx NE
not xxx NE
only xxx NE
transactivates xxx NE
the xxx NE
long xxx NE
terminal xxx NE
repeat xxx NE
of xx NE
this xxx NE
retrovirus xxx NE
but xxx NE
also xxx NE
induces xxx NE
an xx NE
array xxx NE
of xx NE
cellular xxx DNA_B
genes xxx DNA_E
. . NE

Tax Xxx NE
-mediated -xxx NE
transformation xxx NE
of xx NE
T X NE
cells xxx NE
likely xxx NE
involves xxx NE
the xxx NE
deregulated xxx NE
expression xxx NE
of xx NE
various xxx NE
cellular xxx NE
genes xxx NE
that xxx NE
normally xxx NE
regulate xxx NE
lymphocyte xxx NE
growth xxx NE
produced xxx NE
by xx NE
altered xxx NE
activity xxx NE
of xx NE
various xxx NE
endogenous xxx NE
host xxx NE
transcription xxx NE
factors xxx NE
. . NE

In Xx NE
particular xxx NE
, , NE
Tax Xxx protein
is xx NE
capable xxx NE
of xx NE
modulating xxx NE
the xxx NE
expression xxx NE
or xx NE
activity xxx NE
of xx NE
various xxx NE
host xxx NE
transcription xxx protein_B
factors xxx protein_E
, , NE
including xxx NE
members xxx NE
of xx NE
the xxx NE
NF-kappa XX-xxx protein_B
B/Rel X/Xxx protein_E
and xxx NE
CREB/ATF XXXX/XXX NE
families xxx NE
, , NE
as xx NE
well xxx NE
as xx NE
the xxx NE
cellular xxx NE
factors xxx NE
HEB-1 XXX-d NE
and xxx NE
p67SRF xddXXX NE
. . NE

An Xx NE
additional xxx NE
distinguishing xxx NE
characteristic xxx NE
of xx NE
HTLV-I XXXX-X NE
infection xxx NE
is xx NE
the xxx NE
profound xxx NE
state xxx NE
of xx NE
viral xxx NE
latency xxx NE
that xxx NE
is xx NE
present xxx NE
in xx NE
circulating xxx NE
primary xxx cell_type_B
leukemic xxx cell_type_M
T X cell_type_M
cells xxx cell_type_E
. . NE

In Xx NE
this xxx NE
study xxx NE
, , NE
we xx NE
demonstrate xxx NE
that xxx NE
HTLV-I XXXX-X NE
Tax Xxx protein
can xxx NE
physically xxx NE
associate xxx NE
with xxx NE
p100 xddd protein
, , NE
the xxx NE
product xxx NE
of xx NE
the xxx NE
Rel-related Xxx-xxx DNA_B
NF-kappa XX-xxx DNA_M
B2 Xd DNA_M
gene xxx DNA_E
, , NE
both xxx NE
in xx NE
transfected xxx cell_line_B
cells xxx cell_line_E
and xxx NE
in xx NE
HTLV-I XXXX-X NE
-infected -xxx NE
leukemic xxx NE
T-cell X-xxx NE
lines xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
physical xxx NE
interaction xxx NE
of xx NE
Tax Xxx protein
with xxx NE
p100 xddd protein
leads xxx NE
to xx NE
the xxx NE
inhibition xxx NE
of xx NE
Tax Xxx NE
-induced -xxx NE
activation xxx NE
of xx NE
the xxx NE
HTLV-I XXXX-X NE
and xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
long xxx NE
terminal xxx NE
repeats xxx NE
, , NE
reflecting xxx NE
p100 xddd NE
-mediated -xxx NE
cytoplasmic xxx NE
sequestration xxx NE
of xx NE
the xxx NE
normally xxx NE
nuclearly xxx NE
expressed xxx NE
Tax Xxx NE
protein xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
a x NE
mutant xxx NE
of xx NE
Tax Xxx protein
that xxx NE
selectively xxx NE
fails xxx NE
to xx NE
activate xxx NE
nuclear xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
expression xxx NE
does xxx NE
not xxx NE
associate xxx NE
with xxx NE
p100 xddd protein
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Rhabdomyosarcomas Xxxx NE
do xx NE
not xxx NE
contain xxx NE
mutations xxx NE
in xx NE
the xxx NE
DNA XXX NE
binding xxx NE
domains xxx NE
of xx NE
myogenic xxx NE
transcription xxx protein_B
factors xxx protein_E
. . NE

Skeletal Xxxx NE
myogenesis xxx NE
is xx NE
regulated xxx NE
by xx NE
a x NE
group xxx NE
of xx NE
transcription xxx protein_B
factors xxx protein_E
( ( NE
MyoD XxxX protein
, , NE
myogenin xxx protein
, , NE
myf5 xxxd protein
, , NE
and xxx NE
myf6 xxxd protein
) ) NE
that xxx NE
are xxx NE
"basic "xxx protein_B
helix-loop-helix" xxx-xxx-xxx" protein_M
proteins xxx protein_E
that xxx NE
bind xxx NE
to xx NE
the xxx NE
promoters xxx DNA
of xx NE
muscle-specific xxx-xxx DNA_B
genes xxx DNA_E
and xxx NE
promote xxx NE
their xxx NE
expression xxx NE
. . NE

We Xx NE
have xxx NE
previously xxx NE
shown xxx NE
that xxx NE
after xxx NE
a x NE
mutation xxx NE
of xx NE
Leu122 Xxxddd NE
to xx NE
Arg Xxx NE
the xxx NE
DNA XXX protein_B
binding xxx protein_M
basic xxx protein_M
domain xxx protein_E
of xx NE
MyoD XxxX protein
confers xxx NE
c-myc x-xxx NE
-like -xxx NE
functional xxx NE
characteristics xxx NE
to xx NE
the xxx NE
protein xxx NE
. . NE

In Xx NE
this xxx NE
study xxx NE
we xx NE
used xxx NE
single-strand xxx-xxx NE
conformation xxx NE
polymorphism xxx NE
analysis xxx NE
to xx NE
determine xxx NE
whether xxx NE
such xxx NE
mutations xxx NE
occur xxx NE
naturally xxx NE
in xx NE
rhabdomyosarcomas xxx NE
. . NE

We Xx NE
have xxx NE
found xxx NE
that xxx NE
the xxx NE
basic xxx protein_B
domains xxx protein_E
of xx NE
all xxx NE
the xxx NE
myogenic xxx protein_B
factors xxx protein_E
remain xxx NE
unaltered xxx NE
in xx NE
rhabdomyosarcomas xxx NE
. . NE

Selection Xxxx NE
against xxx NE
such xxx NE
mutations xxx NE
may xxx NE
be xx NE
the xxx NE
result xxx NE
of xx NE
functional xxx NE
redundancy xxx NE
of xx NE
these xxx NE
myogenic xxx protein_B
transcription xxx protein_M
factors xxx protein_E
. . NE

Function Xxxx NE
and xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
in xx NE
the xxx NE
immune xxx NE
system xxx NE
. . NE

NF-kappa XX-xxx protein_B
B X protein_E
is xx NE
a x NE
ubiquitous xxx protein_B
transcription xxx protein_M
factor xxx protein_E
. . NE

Nevertheless Xxxx NE
, , NE
its xxx NE
properties xxx NE
seem xxx NE
to xx NE
be xx NE
most xxx NE
extensively xxx NE
exploited xxx NE
in xx NE
cells xxx NE
of xx NE
the xxx NE
immune xxx NE
system xxx NE
. . NE

Among Xxxx NE
these xxx NE
properties xxx NE
are xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
's 'x NE
rapid xxx NE
posttranslational xxx NE
activation xxx NE
in xx NE
response xxx NE
to xx NE
many xxx NE
pathogenic xxx NE
signals xxx NE
, , NE
its xxx NE
direct xxx NE
participation xxx NE
in xx NE
cytoplasmic/nuclear xxx/xxx NE
signaling xxx NE
, , NE
and xxx NE
its xxx NE
potency xxx NE
to xx NE
activate xxx NE
transcription xxx NE
of xx NE
a x NE
great xxx NE
variety xxx NE
of xx NE
genes xxx NE
encoding xxx NE
immunologically xxx protein_B
relevant xxx protein_M
proteins xxx protein_E
. . NE

In Xx NE
vertebrates xxx NE
, , NE
five xxx NE
distinct xxx NE
DNA XXX protein_B
binding xxx protein_M
subunits xxx protein_E
are xxx NE
currently xxx NE
known xxx NE
which xxx NE
might xxx NE
extensively xxx NE
heterodimerize xxx NE
, , NE
thereby xxx NE
forming xxx NE
complexes xxx NE
with xxx NE
distinct xxx NE
transcriptional xxx NE
activity xxx NE
, , NE
DNA XXX NE
sequence xxx NE
specificity xxx NE
, , NE
and xxx NE
cell xxx NE
type- xxx- NE
and xxx NE
cell xxx NE
stage-specific xxx-xxx NE
distribution xxx NE
. . NE

The Xxx NE
activity xxx NE
of xx NE
DNA XXX protein_B
binding xxx protein_M
NF-kappa XX-xxx protein_M
B X protein_M
dimers xxx protein_E
is xx NE
tightly xxx NE
controlled xxx NE
by xx NE
accessory xxx protein_B
proteins xxx protein_E
called xxx NE
I X protein_B
kappa xxx protein_M
B X protein_M
subunits xxx protein_E
of xx NE
which xxx NE
there xxx NE
are xxx NE
also xxx NE
five xxx NE
different xxx NE
species xxx NE
currently xxx NE
known xxx NE
in xx NE
vertebrates xxx NE
. . NE

I X protein_B
kappa xxx protein_M
B X protein_M
proteins xxx protein_E
inhibit xxx NE
DNA XXX NE
binding xxx NE
and xxx NE
prevent xxx NE
nuclear xxx NE
uptake xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
complexes xxx NE
. . NE

An Xx NE
exception xxx NE
is xx NE
the xxx NE
Bcl-3 Xxx-d protein_B
protein xxx protein_E
which xxx NE
in xx NE
addition xxx NE
can xxx NE
function xxx NE
as xx NE
a x NE
transcription xxx protein_B
activating xxx protein_M
subunit xxx protein_E
in xx NE
th xx NE
nucleus xxx NE
. . NE

Other Xxxx NE
I X protein_B
kappa xxx protein_M
B X protein_M
proteins xxx protein_E
are xxx NE
rather xxx NE
involved xxx NE
in xx NE
terminating xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
's 'x NE
activity xxx NE
in xx NE
the xxx NE
nucleus xxx NE
. . NE

The Xxx NE
intracellular xxx NE
events xxx NE
that xxx NE
lead xxx NE
to xx NE
the xxx NE
inactivation xxx NE
of xx NE
I X protein_B
kappa xxx protein_M
B X protein_E
, , NE
i.e x.x NE
. . NE
the xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
, , NE
are xxx NE
complex xxx NE
. . NE

They Xxxx NE
involve xxx NE
phosphorylation xxx NE
and xxx NE
proteolytic xxx NE
reactions xxx NE
and xxx NE
seem xxx NE
to xx NE
be xx NE
controlled xxx NE
by xx NE
the xxx NE
cells' xxx' NE
redox xxx NE
status xxx NE
. . NE

Interference Xxxx NE
with xxx NE
the xxx NE
activation xxx NE
or xx NE
activity xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
may xxx NE
be xx NE
beneficial xxx NE
in xx NE
suppressing xxx NE
toxic/septic xxx/xxx NE
shock xxx NE
, , NE
graft-vs-host xxx-xx-xxx NE
reactions xxx NE
, , NE
acute xxx NE
inflammatory xxx NE
reactions xxx NE
, , NE
acute xxx NE
phase xxx NE
response xxx NE
, , NE
and xxx NE
radiation xxx NE
damage xxx NE
. . NE

The Xxx NE
inhibition xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
activation xxx NE
by xx NE
antioxidants xxx NE
and xxx NE
specific xxx NE
protease xxx NE
inhibitors xxx NE
may xxx NE
provide xxx NE
a x NE
pharmacological xxx NE
basis xxx NE
for xxx NE
interfering xxx NE
with xxx NE
these xxx NE
acute xxx NE
processes xxx NE
. . NE

Lack Xxxx NE
of xx NE
T-cell-mediated X-xxx-xxx NE
recognition xxx NE
of xx NE
the xxx NE
fusion xxx NE
region xxx NE
of xx NE
the xxx NE
pml/RAR-alpha xxx/XXX-xxx protein_B
hybrid xxx protein_M
protein xxx protein_E
by xx NE
lymphocytes xxx cell_type
of xx NE
acute xxx NE
promyelocytic xxx NE
leukemia xxx NE
patients xxx NE
. . NE

In Xx NE
previous xxx NE
studies xxx NE
, , NE
it xx NE
was xxx NE
shown xxx NE
that xxx NE
the xxx NE
fusion xxx NE
region xxx NE
of xx NE
the xxx NE
pml/RAR-alpha xxx/XXX-xxx protein_B
protein xxx protein_E
, , NE
expressed xxx NE
by xx NE
acute xxx cell_line_B
promyelocytic xxx cell_line_M
leukemia xxx cell_line_M
(APL) (XXX) cell_line_M
cells xxx cell_line_E
, , NE
can xxx NE
be xx NE
specifically xxx NE
recognized xxx NE
in xx NE
vitro xxx NE
by xx NE
donor xxx NE
(D (X NE
. . NE
E.) X.) NE
CD4 XXd cell_line_B
T X cell_line_M
cells xxx cell_line_E
in xx NE
a x NE
HLA XXX NE
class xxx NE
II XX NE
DR11-restricted XXdd-xxx NE
fashion xxx NE
. . NE

We Xx NE
present xxx NE
here xxx NE
the xxx NE
results xxx NE
on xx NE
the xxx NE
recognition xxx NE
of xx NE
several xxx NE
pml/RAR-alpha xxx/XXX-xxx NE
peptides xxx NE
by xx NE
APL XXX NE
patients xxx NE
expressing xxx NE
HLA XXX protein_B
DR11 XXdd protein_E
. . NE

The Xxx NE
in xx NE
vitro xxx NE
immunization xxx NE
of xx NE
peripheral xxx cell_type_B
blood xxx cell_type_M
lymphocytes xxx cell_type_E
from xxx NE
four xxx NE
patients xxx NE
in xx NE
remission xxx NE
(S.R. (X.X. NE
, , NE
F.R. X.X. NE
, , NE
M.M. X.X. NE
, , NE
P X NE
. . NE
G.) X.) NE
with xxx NE
BCR1/25 XXXd/dd NE
, , NE
a x NE
25-mer dd-xxx NE
pml xxx NE
/ / NE
RAR-alpha XXX-xxx protein
, , NE
did xxx NE
not xxx NE
elicit xxx NE
either xxx NE
a x NE
polyclonal xxx NE
or xx NE
a x NE
clonal xxx NE
immune xxx NE
response xxx NE
specific xxx NE
to xx NE
the xxx NE
peptide xxx NE
. . NE

We Xx NE
then xxx NE
generated xxx NE
new xxx NE
donor xxx NE
anti-pml xxx-xxx NE
/ / NE
RAR-alpha XXX-xxx NE
CD4(+) XXd(+) NE
T-cell X-xxx NE
clones xxx NE
. . NE

These Xxxx NE
clones xxx NE
were xxx NE
tested xxx NE
for xxx NE
their xxx NE
recognition xxx NE
of xx NE
BCR1/25 XXXd/dd NE
. . NE

One Xxx NE
clone xxx NE
( ( NE
C3/5, Xd/d, cell_line_B
CD3(+), XXd(+), cell_line_M
CD4(+), XXd(+), cell_line_M
CD8(-) XXd(-) cell_line_E
) ) NE
was xxx NE
selected xxx NE
for xxx NE
further xxx NE
analysis xxx NE
. . NE

Clone Xxxx cell_line_B
C3/5 Xd/d cell_line_E
showed xxx NE
specific xxx NE
proliferation xxx NE
, , NE
cytotoxicity xxx NE
, , NE
and xxx NE
cytokine xxx NE
( ( NE
tumor xxx protein_B
necrosis xxx protein_M
factor xxx protein_M
alpha xxx protein_E
, , NE
granulocyte-macrophage xxx-xxx protein_B
colony-stimulating xxx-xxx protein_M
factor xxx protein_E
) ) NE
production xxx NE
when xxx NE
challenged xxx NE
with xxx NE
autologous xxx cell_line_B
lymphoblastic xxx cell_line_M
cell xxx cell_line_M
lines xxx cell_line_E
pulsed xxx NE
with xxx NE
peptide xxx NE
BCR1/25 XXXd/dd NE
. . NE

C3/5 Xd/d cell_line_B
cells xxx cell_line_E
developed xxx NE
specific xxx NE
proliferation xxx NE
and xxx NE
cytotoxicity xxx NE
when xxx NE
challenged xxx NE
with xxx NE
peptide-pulsed xxx-xxx cell_line_B
lymphoblastic xxx cell_line_M
cell xxx cell_line_M
lines xxx cell_line_E
and xxx NE
peripheral xxx cell_type_B
blood xxx cell_type_M
lymphocytes xxx cell_type_E
from xxx NE
the xxx NE
four xxx NE
DR11(+) XXdd(+) NE
APL XXX NE
patients xxx NE
. . NE

APL XXX cell_type_B
blasts xxx cell_type_E
, , NE
available xxx NE
only xxx NE
from xxx NE
patients xxx NE
F.R X.X NE
. . NE
and xxx NE
P.G. X.X. NE
, , NE
were xxx NE
not xxx NE
lysed xxx NE
by xx NE
C3/5 Xd/d cell_line
and xxx NE
were xxx NE
unable xxx NE
to xx NE
present xxx NE
peptide xxx NE
BCR1/25 XXXd/dd NE
. . NE

Incubation Xxxx NE
of xx NE
APL XXX cell_line_B
cells xxx cell_line_E
with xxx NE
IFN-gamma XXX-xxx protein
failed xxx NE
to xx NE
induce xxx NE
HLA XXX protein_B
class xxx protein_M
II XX protein_M
molecules xxx protein_E
and xxx NE
recognition xxx NE
by xx NE
the xxx NE
C3/5 Xd/d cell_line_B
clone xxx cell_line_E
. . NE

Since Xxxx NE
APL XXX cell_line_B
cells xxx cell_line_E
do xx NE
not xxx NE
express xxx NE
HLA XXX protein_B
class xxx protein_M
II XX protein_M
molecules xxx protein_E
, , NE
we xx NE
tested xxx NE
in xx NE
two xxx NE
donors xxx NE
(D.E (X.X NE
. . NE
and xxx NE
C.H.R.) X.X.X.) NE
and xxx NE
in xx NE
patients xxx NE
S.R.and X.X.xxx NE
P.G.whether X.X.xxx NE
the xxx NE
use xxx NE
of xx NE
9-mer d-xxx NE
peptides xxx NE
( ( NE
BCR1/9 XXXd/d NE
) ) NE
would xxx NE
generate xxx NE
a x NE
CD8 XXd NE
/HLA /XXX NE
class xxx NE
I X NE
-restricted -xxx NE
response xxx NE
. . NE

No Xx NE
peptide-specific xxx-xxx cell_line_B
T-cell X-xxx cell_line_M
line xxx cell_line_E
or xx NE
clone xxx NE
could xxx NE
be xx NE
generated xxx NE
from xxx NE
both xxx NE
donors xxx NE
and xxx NE
patients xxx NE
. . NE

These Xxxx NE
findings xxx NE
are xxx NE
discussed xxx NE
in xx NE
relation xxx NE
to xx NE
possible xxx NE
therapeutic xxx NE
approaches xxx NE
to xx NE
the xxx NE
immunotherapy xxx NE
of xx NE
APL XXX NE
. . NE

The Xxx NE
proximal xxx NE
regulatory xxx NE
element xxx NE
of xx NE
the xxx NE
interferon-gamma xxx-xxx DNA_B
promoter xxx DNA_E
mediates xxx NE
selective xxx NE
expression xxx NE
in xx NE
T X cell_type_B
cells xxx cell_type_E
. . NE

Interferon-gamma Xxxx-xxx protein
( ( NE
IFN-gamma XXX-xxx protein
) ) NE
is xx NE
produced xxx NE
by xx NE
natural xxx cell_type_B
killer xxx cell_type_M
cells xxx cell_type_E
and xxx NE
certain xxx NE
subsets xxx NE
of xx NE
T X cell_type_B
cells xxx cell_type_E
, , NE
but xxx NE
the xxx NE
basis xxx NE
for xxx NE
its xxx NE
selective xxx NE
expression xxx NE
is xx NE
unknown xxx NE
. . NE

Within Xxxx NE
the xxx NE
region xxx NE
between xxx NE
-108 -ddd NE
and xxx NE
-40 -dd NE
base xxx NE
pairs xxx NE
of xx NE
the xxx NE
IFN-gamma XXX-xxx protein
promoter xxx NE
are xxx NE
two xxx NE
conserved xxx NE
and xxx NE
essential xxx NE
regulatory xxx DNA_B
elements xxx DNA_E
, , NE
which xxx NE
confer xxx NE
activation-specific xxx-xxx NE
expression xxx NE
in xx NE
T X cell_type_B
cells xxx cell_type_E
. . NE

This Xxxx NE
report xxx NE
describes xxx NE
studies xxx NE
indicating xxx NE
that xxx NE
the xxx NE
most xxx NE
proximal xxx NE
of xx NE
these xxx NE
two xxx NE
regulatory xxx DNA_B
elements xxx DNA_E
is xx NE
an xx NE
important xxx NE
determinant xxx NE
of xx NE
its xxx NE
restricted xxx NE
expression xxx NE
. . NE

The Xxx NE
proximal xxx NE
element xxx NE
is xx NE
a x NE
composite xxx NE
site xxx NE
that xxx NE
binds xxx NE
members xxx NE
of xx NE
the xxx NE
CREB/ATF XXXX/XXX protein
, , NE
AP-1 XX-d protein
, , NE
and xxx NE
octamer xxx NE
families xxx NE
of xx NE
transcription xxx NE
factors xxx NE
. . NE

Jun Xxx protein
is xx NE
essential xxx NE
for xxx NE
activation-induced xxx-xxx NE
transcription xxx NE
and xxx NE
binds xxx NE
preferably xxx NE
as xx NE
a x NE
heterodimer xxx NE
with xxx NE
ATF-2 XXX-d protein
. . NE

In Xx NE
contrast xxx NE
, , NE
CREB XXXX protein
appears xxx NE
to xx NE
dampen xxx NE
transcription xxx NE
from xxx NE
this xxx NE
element xxx NE
. . NE

The Xxx NE
CpG XxX NE
dinucleotide xxx NE
in xx NE
this xxx NE
element xxx DNA
is xx NE
selectively xxx NE
methylated xxx NE
in xx NE
Th2 Xxd cell_type_B
T X cell_type_M
cells xxx cell_type_E
and xxx NE
other xxx NE
cells xxx NE
that xxx NE
do xx NE
not xxx NE
express xxx NE
IFN-gamma XXX-xxx protein
, , NE
and xxx NE
methylation xxx NE
markedly xxx NE
reduces xxx NE
transcription xxx NE
factor xxx NE
binding xxx NE
. . NE

As Xx NE
a x NE
target xxx NE
for xxx NE
DNA XXX NE
methylation xxx NE
and xxx NE
for xxx NE
binding xxx NE
of xx NE
transcription xxx protein_B
factors xxx protein_E
that xxx NE
mediate xxx NE
or xx NE
impede xxx NE
transcription xxx NE
, , NE
this xxx NE
element xxx NE
appears xxx NE
to xx NE
play xxx NE
a x NE
central xxx NE
role xxx NE
in xx NE
controlling xxx NE
IFN-gamma XXX-xxx NE
expression xxx NE
. . NE

CD40 XXdd protein
, , NE
but xxx NE
not xxx NE
lipopolysaccharide xxx NE
and xxx NE
anti-IgM xxx-XxX NE
stimulation xxx NE
of xx NE
primary xxx cell_type_B
B X cell_type_M
lymphocytes xxx cell_type_E
, , NE
leads xxx NE
to xx NE
a x NE
persistent xxx NE
nuclear xxx NE
accumulation xxx NE
of xx NE
RelB XxxX protein
. . NE

In Xx NE
this xxx NE
study xxx NE
we xx NE
analyzed xxx NE
the xxx NE
effect xxx NE
of xx NE
CD40 XXdd NE
stimulation xxx NE
on xx NE
the xxx NE
activity xxx NE
and xxx NE
nuclear xxx NE
appearance xxx NE
of xx NE
Rel/nuclear Xxx/xxx NE
factor xxx NE
kappaB xxxX NE
( ( NE
NF-kappaB XX-xxxX NE
) ) NE
factors xxx NE
in xx NE
primary xxx NE
murine xxx NE
B X NE
lymphocytes xxx NE
. . NE

We Xx NE
show xxx NE
that xxx NE
triggering xxx NE
of xx NE
CD40 XXdd NE
signaling xxx NE
pathway xxx NE
(s) (x) NE
by xx NE
CD40 XXdd protein_B
ligands xxx protein_E
expressed xxx NE
on xx NE
L X cell_type_B
cells xxx cell_type_E
led xxx NE
to xx NE
strong xxx NE
activation xxx NE
of xx NE
an xx NE
NF-kappaB-controlled XX-xxxX-xxx DNA_B
beta-globin xxx-xxx DNA_M
reporter xxx DNA_M
gene xxx DNA_E
in xx NE
primary xxx cell_type_B
B X cell_type_M
lymphocytes xxx cell_type_E
from xxx NE
transgenic xxx NE
mice xxx NE
. . NE

Analyses Xxxx NE
of xx NE
nuclear xxx NE
translocation xxx NE
of xx NE
individual xxx NE
members xxx NE
of xx NE
Rel Xxx protein_B
proteins xxx protein_E
after xxx NE
CD40 XXdd protein
induction xxx NE
of xx NE
primary xxx cell_type_B
B X cell_type_M
cells xxx cell_type_E
showed xxx NE
a x NE
strong xxx NE
and xxx NE
long-lasting xxx-xxx NE
accumulation xxx NE
of xx NE
RelB XxxX protein
and xxx NE
, , NE
less xxx NE
pronounced xxx NE
, , NE
of xx NE
c-Rel x-Xxx protein
. . NE

LPS XXX NE
stimulation xxx NE
did xxx NE
not xxx NE
give xxx NE
rise xxx NE
to xx NE
a x NE
persistent xxx NE
nuclear xxx NE
accumulation xxx NE
of xx NE
RelB XxxX protein
and xxx NE
c-Rel x-Xxx protein
, , NE
whereas xxx NE
nuclear xxx NE
c-Rel x-Xxx protein
, , NE
but xxx NE
not xxx NE
RelB XxxX protein
, , NE
accumulated xxx NE
after xxx NE
B X NE
cell xxx NE
receptor xxx NE
stimulation xxx NE
. . NE

CD40 XXdd protein
induced xxx NE
not xxx NE
only xxx NE
nuclear xxx NE
translocation xxx NE
but xxx NE
also xxx NE
de xx NE
novo xxx NE
synthesis xxx NE
of xx NE
RelB XxxX RNA_B
RNA XXX RNA_E
and xxx NE
protein xxx NE
. . NE

S107 Xddd cell_line_B
plasmacytoma xxx cell_line_M
cells xxx cell_line_E
, , NE
which xxx NE
express xxx NE
CD40 XXdd protein
but xxx NE
are xxx NE
defective xxx NE
for xxx NE
the xxx NE
nuclear xxx NE
appearance xxx NE
of xx NE
p50/p65-NF-kappaB xdd/xdd-XX-xxxX protein
, , NE
do xx NE
not xxx NE
express xxx NE
RelB XxxX protein
after xxx NE
CD40 XXdd protein
stimulation xxx NE
. . NE

In Xx NE
S107 Xddd cell_line_B
cells xxx cell_line_E
stably xxx NE
transfected xxx NE
with xxx NE
relB xxxX DNA_B
genes xxx DNA_E
, , NE
stimulation xxx NE
of xx NE
nuclear xxx NE
RelB XxxX NE
translocation xxx NE
by xx NE
CD40 XXdd protein
was xxx NE
observed xxx NE
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
stimulation xxx NE
of xx NE
CD40 XXdd NE
signaling xxx NE
pathways xxx NE
exerts xxx NE
a x NE
long-lasting xxx-xxx NE
stimulatory xxx NE
effect xxx NE
on xx NE
both xxx NE
the xxx NE
transcription xxx NE
and xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
RelB XxxX protein
. . NE

Since Xxxx NE
LPS XXX NE
and xxx NE
anti-IgM xxx-XxX protein
were xxx NE
unable xxx NE
to xx NE
activate xxx NE
RelB XxxX protein
, , NE
CD40 XXdd protein
appears xxx NE
to xx NE
trigger xxx NE
a x NE
special xxx NE
program xxx NE
of xx NE
gene xxx NE
expression xxx NE
involved xxx NE
in xx NE
the xxx NE
proliferation xxx NE
and/or xxx/xx NE
differentiation xxx NE
of xx NE
B X cell_type_B
lymphocytes xxx cell_type_E
. . NE

Identification Xxxx NE
and xxx NE
characterization xxx NE
of xx NE
a x NE
leukocyte-specific xxx-xxx NE
component xxx NE
of xx NE
the xxx NE
nuclear xxx NE
body xxx NE
. . NE

The Xxx NE
nuclear xxx NE
body xxx NE
( ( NE
NB XX NE
) ) NE
is xx NE
a x NE
cellular xxx NE
organelle xxx NE
that xxx NE
is xx NE
involved xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
acute xxx NE
promyelocytic xxx NE
leukemia xxx NE
and xxx NE
viral xxx NE
infection xxx NE
. . NE

The Xxx NE
NB XX NE
is xx NE
also xxx NE
a x NE
target xxx NE
of xx NE
antibodies xxx NE
in xx NE
the xxx NE
serum xxx NE
of xx NE
patients xxx NE
with xxx NE
the xxx NE
autoimmune xxx NE
disease xxx NE
primary xxx NE
biliary xxx NE
cirrhosis xxx NE
. . NE

In Xx NE
this xxx NE
study xxx NE
, , NE
serum xxx NE
from xxx NE
a x NE
patient xxx NE
with xxx NE
primary xxx NE
biliary xxx NE
cirrhosis xxx NE
was xxx NE
used xxx NE
to xx NE
identify xxx NE
a x NE
cDNA xXXX NE
encoding xxx NE
a x NE
novel xxx NE
component xxx NE
of xx NE
the xxx NE
NB XX NE
, , NE
a x NE
140-kDa ddd-xXx protein_B
protein xxx protein_E
designated xxx NE
Sp140 Xxddd protein
. . NE

The Xxx NE
predicted xxx NE
amino xxx protein_B
acid xxx protein_M
sequence xxx protein_E
of xx NE
the xxx NE
amino-terminal xxx-xxx protein_B
portion xxx protein_E
of xx NE
Sp140 Xxddd protein
was xxx NE
similar xxx NE
to xx NE
Sp100 Xxddd protein
, , NE
a x NE
previously xxx NE
identified xxx NE
NB XX protein_B
protein xxx protein_E
. . NE

The Xxx NE
carboxyl xxx protein_B
portion xxx protein_E
of xx NE
Sp140 Xxddd protein
contained xxx NE
a x NE
zinc-finger xxx-xxx protein_B
domain xxx protein_E
and xxx NE
a x NE
bromodomain xxx protein
, , NE
motifs xxx NE
that xxx NE
are xxx NE
present xxx NE
in xx NE
proteins xxx NE
regulating xxx NE
gene xxx NE
transcription xxx NE
. . NE

High Xxxx NE
levels xxx NE
of xx NE
Sp140 Xxddd RNA_B
mRNA xXXX RNA_E
were xxx NE
detected xxx NE
in xx NE
human xxx NE
spleen xxx NE
and xxx NE
peripheral xxx cell_type_B
blood xxx cell_type_M
leukocytes xxx cell_type_E
, , NE
but xxx NE
not xxx NE
other xxx NE
human xxx NE
tissues xxx NE
. . NE

The Xxx NE
level xxx NE
of xx NE
SP140 XXddd RNA_B
mRNA xXXX RNA_E
in xx NE
myeloid xxx cell_line_B
precursor xxx cell_line_M
cell xxx cell_line_M
lines xxx cell_line_E
HL60 XXdd cell_line
and xxx NE
NB4 XXd cell_line
markedly xxx NE
increased xxx NE
in xx NE
response xxx NE
to xx NE
chemically xxx NE
induced xxx NE
cellular xxx NE
differentiation xxx NE
. . NE

Immunohistochemical Xxxx NE
techniques xxx NE
were xxx NE
used xxx NE
to xx NE
demonstrate xxx NE
that xxx NE
SP140 XXddd protein
localized xxx NE
to xx NE
the xxx NE
NB XX NE
in xx NE
differentiated xxx NE
HL60 XXdd cell_line
and xxx NE
NB4 XXd cell_line_B
cells xxx cell_line_E
. . NE

The Xxx NE
location xxx NE
of xx NE
Sp140 Xxddd protein
in xx NE
the xxx NE
NB XX NE
, , NE
and xxx NE
expression xxx NE
of xx NE
this xxx NE
gene xxx NE
in xx NE
cells xxx NE
involved xxx NE
in xx NE
host xxx NE
defense xxx NE
, , NE
suggest xxx NE
that xxx NE
Sp140 Xxddd protein
may xxx NE
be xx NE
involved xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
acute xxx NE
promyelocytic xxx NE
leukemia xxx NE
and xxx NE
viral xxx NE
infection xxx NE
. . NE

Regulation Xxxx NE
of xx NE
cytokine xxx protein
and xxx NE
cytokine xxx NE
receptor xxx NE
expression xxx NE
by xx NE
glucocorticoids xxx NE
. . NE

Glucocorticoids Xxxx NE
( ( NE
GCS XXX NE
) ) NE
profoundly xxx NE
inhibit xxx NE
several xxx NE
aspects xxx NE
of xx NE
T X NE
cell xxx NE
immunity xxx NE
largely xxx NE
through xxx NE
inhibition xxx NE
of xx NE
cytokine xxx NE
expression xxx NE
at xx NE
the xxx NE
transcriptional xxx NE
and xxx NE
posttranscriptional xxx NE
levels xxx NE
. . NE

GCS XXX NE
were xxx NE
also xxx NE
reported xxx NE
to xx NE
act xxx NE
indirectly xxx NE
by xx NE
inducing xxx NE
transforming xxx NE
growth xxx NE
factor-beta xxx-xxx NE
expression xxx NE
, , NE
which xxx NE
in xx NE
turn xxx NE
blocks xxx NE
T X NE
cell xxx NE
immunity xxx NE
. . NE

In Xx NE
exerting xxx NE
their xxx NE
antiproliferative xxx NE
effects xxx NE
, , NE
GCS XXX NE
diffuse xxx NE
into xxx NE
target xxx cell_type_B
cells xxx cell_type_E
where xxx NE
they xxx NE
bind xxx NE
their xxx NE
cytoplasmic xxx protein_B
receptor xxx protein_E
, , NE
which xxx NE
in xx NE
turn xxx NE
translocates xxx NE
to xx NE
the xxx NE
nucleus xxx NE
where xxx NE
it xx NE
inhibits xxx NE
transcription xxx NE
of xx NE
cytokine xxx DNA_B
genes xxx DNA_E
through xxx NE
direct xxx NE
binding xxx NE
to xx NE
the xxx NE
glucocorticoid xxx DNA_B
response xxx DNA_M
elements xxx DNA_E
( ( NE
GRE XXX DNA
) ) NE
, , NE
which xxx NE
are xxx NE
located xxx NE
in xx NE
the xxx NE
promoter xxx NE
region xxx NE
of xx NE
cytokine xxx DNA_B
genes xxx DNA_E
or xx NE
, , NE
alternatively xxx NE
, , NE
through xxx NE
antagonism xxx NE
of xx NE
the xxx NE
action xxx NE
of xx NE
transcription xxx protein_B
factors xxx protein_E
required xxx NE
for xxx NE
optimal xxx NE
transcriptional xxx NE
activation xxx NE
. . NE

In Xx NE
contrast xxx NE
to xx NE
their xxx NE
inhibitory xxx NE
effects xxx NE
on xx NE
cytokine xxx NE
expression xxx NE
, , NE
GCS XXX NE
up-regulate xx-xxx NE
cytokine xxx NE
receptor xxx NE
expression xxx NE
that xxx NE
correlates xxx NE
with xxx NE
enhanced xxx NE
cytokine xxx NE
effects xxx NE
on xx NE
target xxx cell_type_B
cells xxx cell_type_E
. . NE

In Xx NE
this xxx NE
review xxx NE
, , NE
we xx NE
summarize xxx NE
the xxx NE
current xxx NE
state xxx NE
of xx NE
knowledge xxx NE
of xx NE
the xxx NE
mechanism xxx NE
of xx NE
action xxx NE
of xx NE
GCS XXX NE
, , NE
including xxx NE
the xxx NE
phenomenon xxx NE
of xx NE
steroid-induced xxx-xxx NE
rebound xxx NE
, , NE
which xxx NE
ensues xxx NE
upon xxx NE
GCS XXX NE
withdrawal xxx NE
. . NE

Isolation Xxxx NE
and xxx NE
characterization xxx NE
of xx NE
murine xxx DNA_B
fra-1 xxx-d DNA_E
: : NE
induction xxx NE
mediated xxx NE
by xx NE
CD40 XXdd protein
and xxx NE
surface xxx protein_B
Ig Xx protein_E
is xx NE
protein xxx NE
kinase xxx NE
C X NE
dependent xxx NE
. . NE

The Xxx NE
murine xxx DNA_B
fra-1 xxx-d DNA_M
gene xxx DNA_E
, , NE
encoding xxx NE
Fos-related Xxx-xxx protein_B
Ag Xx protein_M
1 d protein_E
, , NE
was xxx NE
isolated xxx NE
from xxx NE
a x NE
splenic xxx DNA_B
cDNA xXXX DNA_M
library xxx DNA_E
and xxx NE
sequenced xxx NE
. . NE

Murine Xxxx DNA_B
fra-1 xxx-d DNA_E
was xxx NE
highly xxx NE
homologous xxx NE
to xx NE
rat xxx DNA_B
fra-1 xxx-d DNA_M
and xxx DNA_M
human xxx DNA_M
fra-1 xxx-d DNA_E

Oligonucleotide Xxxx NE
primers xxx NE
based xxx NE
on xx NE
the xxx NE
murine xxx DNA_B
sequence xxx DNA_E
were xxx NE
used xxx NE
to xx NE
construct xxx NE
a x NE
quantitative xxx NE
reverse xxx NE
transcription-PCR xxx-XXX NE
assay xxx NE
for xxx NE
gene xxx NE
expression xxx NE
. . NE

B X NE
lymphocyte xxx NE
stimulation xxx NE
via xxx NE
both xxx NE
CD40 XXdd protein
and xxx NE
surface xxx NE
Ig Xx NE
( ( NE
sIg xXx NE
) ) NE
receptors xxx NE
substantially xxx NE
induced xxx NE
fra-1 xxx-d NE
expression xxx NE
, , NE
and xxx NE
for xxx NE
both xxx NE
receptors xxx NE
, , NE
induction xxx NE
was xxx NE
protein xxx NE
kinase xxx NE
C X NE
( ( NE
PKC XXX NE
) ) NE
dependent xxx NE
. . NE

This Xxxx NE
contrasts xxx NE
with xxx NE
induction xxx NE
of xx NE
c-fos x-xxx DNA
by xx NE
both xxx NE
CD40 XXdd protein
and xxx NE
sIg xXx protein
, , NE
which xxx NE
is xx NE
PKC XXX protein
independent xxx NE
and xxx NE
indicates xxx NE
that xxx NE
CD40 XXdd protein
is xx NE
capable xxx NE
of xx NE
signaling xxx NE
through xxx NE
PKC XXX protein
or xx NE
a x NE
closely xxx NE
related xxx NE
kinase xxx protein
. . NE

Induction Xxxx NE
of xx NE
fra-1 xxx-d DNA
following xxx NE
engagement xxx NE
of xx NE
CD40 XXdd protein
did xxx NE
not xxx NE
require xxx NE
protein xxx NE
synthesis xxx NE
, , NE
suggesting xxx NE
that xxx NE
the xxx NE
PKC XXX NE
-dependent -xxx NE
linkage xxx NE
between xxx NE
CD40 XXdd NE
and xxx NE
fra-1 xxx-d NE
is xx NE
direct xxx NE
. . NE

CD40 XXdd protein
-mediated -xxx NE
fra-1 xxx-d NE
induction xxx NE
did xxx NE
require xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
. . NE

These Xxxx NE
results xxx NE
demonstrate xxx NE
that xxx NE
CD40 XXdd protein
, , NE
like xxx NE
sIg xXx protein
, , NE
may xxx NE
employ xxx NE
PKC XXX protein
in xx NE
producing xxx NE
select xxx NE
outcomes xxx NE
, , NE
that xxx NE
individual xxx NE
B X protein_B
cell xxx protein_M
receptors xxx protein_E
may xxx NE
signal xxx NE
downstream xxx NE
events xxx NE
via xxx NE
both xxx NE
PKC-dependent XXX-xxx NE
pathway xxx NE
and xxx NE
PKC-independent XXX-xxx NE
pathway xxx NE
multiple xxx NE
signal xxx NE
transduction xxx NE
pathways xxx NE
may xxx NE
be xx NE
used xxx NE
to xx NE
activate xxx NE
the xxx NE
expression xxx NE
of xx NE
closely xxx NE
related xxx NE
genes xxx DNA
. . NE

Pentoxifylline Xxxx NE
for xxx NE
the xxx NE
treatment xxx NE
of xx NE
infection xxx NE
with xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
. . NE

Cytokine Xxxx NE
dysregulation xxx NE
in xx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
( ( NE
HIV-1 XXX-d NE
) ) NE
infection xxx NE
has xxx NE
been xxx NE
documented xxx NE
in xx NE
numerous xxx NE
studies xxx NE
and xxx NE
has xxx NE
been xxx NE
cited xxx NE
as xx NE
an xx NE
important xxx NE
component xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
this xxx NE
retroviral xxx NE
infection xxx NE
. . NE

Pharmacological Xxxx NE
modification xxx NE
of xx NE
cytokine xxx NE
dysregulation xxx NE
, , NE
therefore xxx NE
, , NE
has xxx NE
been xxx NE
suggested xxx NE
as xx NE
a x NE
therapeutic xxx NE
modality xxx NE
for xxx NE
HIV-1 XXX-d NE
infection xxx NE
. . NE

Dr Xx NE
. . NE
Dezube Xxxx NE
of xx NE
Beth Xxxx NE
Israel Xxxx NE
Hospital Xxxx NE
(Boston) (Xxxx) NE
concisely xxx NE
reviews xxx NE
the xxx NE
state xxx NE
of xx NE
our xxx NE
knowledge xxx NE
regarding xxx NE
the xxx NE
effects xxx NE
of xx NE
pentoxifylline xxx NE
on xx NE
expression xxx NE
of xx NE
tumor xxx protein_B
necrosis xxx protein_M
factor-alpha xxx-xxx protein_E
, , NE
a x NE
cytokine xxx protein
known xxx NE
to xx NE
influence xxx NE
HIV-1 XXX-d NE
replication xxx NE
and xxx NE
to xx NE
play xxx NE
a x NE
possible xxx NE
role xxx NE
in xx NE
the xxx NE
clinical xxx NE
manifestations xxx NE
of xx NE
advanced xxx NE
infection xxx NE
with xxx NE
this xxx NE
virus xxx NE
. . NE

Pentoxifylline Xxxx NE
, , NE
a x NE
trisubstituted xxx NE
xanthine xxx NE
derivative xxx NE
, , NE
has xxx NE
been xxx NE
used xxx NE
to xx NE
decrease xxx NE
blood xxx NE
viscosity xxx NE
and xxx NE
is xx NE
reasonably xxx NE
well xxx NE
tolerated xxx NE
by xx NE
most xxx NE
recipients xxx NE
of xx NE
the xxx NE
drug xxx NE
. . NE

Results Xxxx NE
of xx NE
preliminary xxx NE
studies xxx NE
, , NE
many xxx NE
of xx NE
which xxx NE
were xxx NE
conducted xxx NE
by xx NE
Dr. Xx. NE
Dezube Xxxx NE
, , NE
suggest xxx NE
that xxx NE
use xxx NE
of xx NE
this xxx NE
agent xxx NE
in xx NE
combination xxx NE
with xxx NE
antiretroviral xxx NE
compounds xxx NE
may xxx NE
prove xxx NE
useful xxx NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
patients xxx NE
with xxx NE
HIV-1 XXX-d NE
infection xxx NE
. . NE

Activation Xxxx NE
of xx NE
the xxx NE
granulocyte-macrophage xxx-xxx DNA_B
colony-stimulating xxx-xxx DNA_M
factor xxx DNA_M
promoter xxx DNA_E
in xx NE
T X cell_type_B
cells xxx cell_type_E
requires xxx NE
cooperative xxx NE
binding xxx NE
of xx NE
Elf-1 Xxx-d protein
and xxx NE
AP-1 XX-d protein
transcription xxx protein_B
factors xxx protein_E
. . NE

The Xxx NE
granulocyte-macrophage xxx-xxx NE
colony-stimulating xxx-xxx NE
factor xxx NE
( ( NE
GM-CSF XX-XXX NE
) ) NE
gene xxx NE
has xxx NE
been xxx NE
studied xxx NE
extensively xxx NE
as xx NE
a x NE
model xxx NE
system xxx NE
of xx NE
transcriptional xxx NE
induction xxx NE
during xxx NE
T-lymphocyte X-xxx NE
activation xxx NE
. . NE

The Xxx NE
GM-CSF XX-XXX DNA_B
gene xxx DNA_E
is xx NE
not xxx NE
expressed xxx NE
in xx NE
resting xxx cell_type_B
peripheral xxx cell_type_M
blood xxx cell_type_M
T X cell_type_M
cells xxx cell_type_E
but xxx NE
is xx NE
rapidly xxx NE
induced xxx NE
at xx NE
the xxx NE
transcriptional xxx NE
level xxx NE
following xxx NE
activation xxx NE
through xxx NE
the xxx NE
cell xxx protein_B
surface xxx protein_M
T-cell X-xxx protein_M
receptor xxx protein_E
. . NE

A X NE
highly xxx NE
conserved xxx NE
19-bp dd-xx NE
element xxx NE
located xxx NE
immediately xxx NE
5' d' NE
of xx NE
the xxx NE
human xxx DNA_B
GM-CSF XX-XXX DNA_M
TATA XXXX DNA_M
box xxx DNA_E
( ( NE
bp xx DNA_B
-34 -dd DNA_M
to xx DNA_M
-52 -dd DNA_E
) ) NE
, , NE
herein xxx NE
called xxx NE
purine xxx DNA_B
box xxx DNA_M
1 d DNA_E
( ( NE
PB1 XXd DNA
) ) NE
, , NE
has xxx NE
been xxx NE
shown xxx NE
to xx NE
bind xxx NE
a x NE
T-cell X-xxx protein_B
nuclear xxx protein_M
protein xxx protein_M
complex xxx protein_E
and xxx NE
to xx NE
be xx NE
required xxx NE
for xxx NE
transcriptional xxx NE
induction xxx NE
of xx NE
the xxx NE
GM-CSF XX-XXX DNA_B
gene xxx DNA_E
following xxx NE
T-cell X-xxx NE
activation xxx NE
. . NE

The Xxx NE
PB1 XXd DNA
sequence xxx NE
motif xxx NE
is xx NE
highly xxx NE
conserved xxx NE
in xx NE
both xxx NE
human xxx DNA_B
GM-CSF XX-XXX DNA_M
gene xxx DNA_M
and xxx DNA_M
murine xxx DNA_M
GM-CSF XX-XXX DNA_M
gene xxx DNA_E

In Xx NE
this xxx NE
report xxx NE
, , NE
we xx NE
demonstrate xxx NE
that xxx NE
the xxx NE
PB1 XXd DNA_B
element xxx DNA_E
alone xxx NE
confers xxx NE
inducibility xxx NE
on xx NE
a x NE
heterologous xxx NE
promoter xxx NE
following xxx NE
transfection xxx NE
into xxx NE
human xxx cell_line_B
Jurkat Xxxx cell_line_M
T X cell_line_M
cells xxx cell_line_E
. . NE

In Xx NE
addition xxx NE
, , NE
we xx NE
identify xxx NE
a x NE
major xxx NE
PB1 XXd protein_B
nuclear xxx protein_M
protein-binding xxx-xxx protein_M
complex xxx protein_E
that xxx NE
is xx NE
not xxx NE
present xxx NE
in xx NE
resting xxx cell_type_B
peripheral xxx cell_type_M
blood xxx cell_type_M
T X cell_type_M
cells xxx cell_type_E
but xxx NE
is xx NE
rapidly xxx NE
induced xxx NE
following xxx NE
T-cell X-xxx NE
activation xxx NE
. . NE

Sequence Xxxx NE
analysis xxx NE
revealed xxx NE
that xxx NE
PB1 XXd DNA
is xx NE
composed xxx NE
of xx NE
adjacent xxx DNA_B
binding xxx DNA_M
sites xxx DNA_E
for xxx NE
Ets Xxx protein
and xxx NE
AP-1 XX-d protein
transcription xxx protein_B
factors xxx protein_E
. . NE

In Xx NE
vitro xxx NE
mutagenesis xxx NE
experiments xxx NE
demonstrated xxx NE
that xxx NE
both xxx NE
the xxx NE
Ets Xxx DNA_B
site xxx DNA_M
and xxx DNA_M
AP-1 XX-d DNA_M
site xxx DNA_E
are xxx NE
required xxx NE
for xxx NE
binding xxx NE
of xx NE
the xxx NE
inducible xxx NE
PB1 XXd protein_B
nuclear xxx protein_M
protein xxx protein_M
complex xxx protein_E
and xxx NE
for xxx NE
the xxx NE
transcriptional xxx NE
activity xxx NE
of xx NE
this xxx NE
element xxx NE
and xxx NE
the xxx NE
GM-CSF XX-XXX DNA_B
promoter xxx DNA_E
in xx NE
activated xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Steroid-resistant Xxxx-xxx NE
asthma xxx NE
. . NE

Cellular Xxxx NE
mechanisms xxx NE
contributing xxx NE
to xx NE
inadequate xxx NE
response xxx NE
to xx NE
glucocorticoid xxx NE
therapy xxx NE
. . NE

The Xxx NE
current xxx NE
study xxx NE
examined xxx NE
whether xxx NE
alterations xxx NE
in xx NE
glucocorticoid xxx protein_B
receptor xxx protein_E
( ( NE
GR XX protein
) ) NE
binding xxx NE
contribute xxx NE
to xx NE
poor xxx NE
response xxx NE
to xx NE
glucocorticoid xxx NE
therapy xxx NE
in xx NE
asthma xxx NE
. . NE

29 dd NE
asthma xxx NE
patients xxx NE
with xxx NE
forced xxx NE
expiratory xxx NE
volume xxx NE
in xx NE
1 d NE
s x NE
( ( NE
FEV1 XXXd NE
) ) NE
< < NE
70% dd% NE
predicted xxx NE
were xxx NE
studied xxx NE
. . NE

Patients Xxxx NE
were xxx NE
classified xxx NE
as xx NE
steroid xxx NE
sensitive xxx NE
( ( NE
SS XX NE
) ) NE
if xx NE
their xxx NE
morning xxx NE
FEV1 XXXd NE
increased xxx NE
> > NE
30% dd% NE
after xxx NE
a x NE
1-wk d-xx NE
course xxx NE
of xx NE
oral xxx NE
prednisone xxx NE
20 dd NE
mg xx NE
twice xxx NE
daily xxx NE
and xxx NE
steroid xxx NE
resistant xxx NE
( ( NE
SR XX NE
) ) NE
if xx NE
they xxx NE
failed xxx NE
to xx NE
increase xxx NE
> > NE
15% dd% NE
. . NE

PBMC XXXX NE
obtained xxx NE
from xxx NE
these xxx NE
two xxx NE
groups xxx NE
, , NE
17 dd NE
SR XX NE
and xxx NE
12 dd NE
SS XX NE
, , NE
as xx NE
well xxx NE
as xx NE
12 dd NE
normal xxx NE
controls xxx NE
were xxx NE
analyzed xxx NE
. . NE
SR XX NE
patients xxx NE
had xxx NE
two xxx NE
distinguishable xxx NE
GR XX NE
binding xxx NE
abnormalities xxx NE
: : NE
15 dd NE
of xx NE
the xxx NE
17 dd NE
SR XX NE
patients xxx NE
demonstrated xxx NE
a x NE
significantly xxx NE
reduced xxx NE
GR XX NE
binding xxx NE
affinity xxx NE
, , NE
as xx NE
compared xxx NE
with xxx NE
SS XX NE
patients xxx NE
(P (X NE
= = NE
0.0001) d.dddd) NE
and xxx NE
normal xxx NE
controls xxx NE
(P (X NE
= = NE
0.0001) d.dddd) NE
. . NE

This Xxxx NE
defect xxx NE
was xxx NE
localized xxx NE
to xx NE
T X cell_type_B
cells xxx cell_type_E
and xxx NE
reverted xxx NE
to xx NE
normal xxx NE
after xxx NE
48 dd NE
h x NE
in xx NE
culture xxx NE
media xxx NE
. . NE

However Xxxx NE
, , NE
incubation xxx NE
with xxx NE
a x NE
combination xxx NE
of xx NE
IL-2 XX-d protein
and xxx NE
IL-4 XX-d protein
sustained xxx NE
this xxx NE
abnormality xxx NE
. . NE

The Xxx NE
other xxx NE
two xxx NE
SR XX NE
patients xxx NE
had xxx NE
an xx NE
abnormally xxx NE
low xxx NE
GR XX protein
number xxx NE
with xxx NE
normal xxx NE
binding xxx NE
affinity xxx NE
that xxx NE
was xxx NE
not xxx NE
limited xxx NE
to xx NE
T X cell_type_B
cells xxx cell_type_E
. . NE

Furthermore Xxxx NE
, , NE
GR XX protein
number xxx NE
failed xxx NE
to xx NE
normalize xxx NE
after xxx NE
incubation xxx NE
in xx NE
media xxx NE
alone xxx NE
or xx NE
IL-2 XX-d protein
and xxx NE
IL-4 XX-d protein
. . NE

Therefore Xxxx NE
, , NE
SR XX NE
asthma xxx NE
may xxx NE
be xx NE
due xxx NE
to xx NE
more xxx NE
than xxx NE
one xxx NE
abnormality xxx NE
, , NE
the xxx NE
majority xxx NE
related xxx NE
to xx NE
a x NE
reversible xxx NE
cytokine xxx NE
-induced -xxx NE
reduction xxx NE
in xx NE
GR XX NE
binding xxx NE
affinity xxx NE
and xxx NE
the xxx NE
second xxx NE
related xxx NE
to xx NE
an xx NE
irreversible xxx NE
reduction xxx NE
in xx NE
GR XX NE
number xxx NE
. . NE

These Xxxx NE
findings xxx NE
may xxx NE
have xxx NE
important xxx NE
implications xxx NE
for xxx NE
the xxx NE
design xxx NE
of xx NE
alternative xxx NE
treatment xxx NE
approaches xxx NE
for xxx NE
recalcitrant xxx NE
asthma xxx NE
. . NE

Prevalence Xxxx NE
of xx NE
aneuploidy xxx NE
, , NE
overexpressed xxx NE
ER XX protein
, , NE
and xxx NE
overexpressed xxx NE
EGFR XXXX protein
in xx NE
random xxx NE
breast xxx NE
aspirates xxx NE
of xx NE
women xxx NE
at xx NE
high xxx NE
and xxx NE
low xxx NE
risk xxx NE
for xxx NE
breast xxx NE
cancer xxx NE
. . NE

Breast Xxxx NE
tissue xxx NE
biomarkers xxx NE
which xxx NE
accurately xxx NE
predict xxx NE
breast xxx NE
cancer xxx NE
development xxx NE
within xxx NE
a x NE
10 dd NE
year xxx NE
period xxx NE
in xx NE
high xxx NE
risk xxx NE
women xxx NE
are xxx NE
needed xxx NE
but xxx NE
currently xxx NE
not xxx NE
available xxx NE
. . NE

We Xx NE
initiated xxx NE
this xxx NE
study xxx NE
to xx NE
determine xxx NE
1) d) NE
the xxx NE
prevalence xxx NE
of xx NE
one xxx NE
or xx NE
more xxx NE
breast xxx NE
tissue xxx NE
abnormalities xxx NE
in xx NE
a x NE
group xxx NE
of xx NE
women xxx NE
at xx NE
high xxx NE
risk xxx NE
for xxx NE
breast xxx NE
cancer xxx NE
, , NE
and xxx NE
2) d) NE
if xx NE
the xxx NE
prevalence xxx NE
of xx NE
biomarker xxx NE
abnormalities xxx NE
is xx NE
greater xxx NE
in xx NE
high xxx NE
risk xxx NE
than xxx NE
in xx NE
low xxx NE
risk xxx NE
women xxx NE
. . NE

Eligible Xxxx NE
high xxx NE
risk xxx NE
women xxx NE
were xxx NE
those xxx NE
with xxx NE
a x NE
first xxx NE
degree xxx NE
relative xxx NE
with xxx NE
breast xxx NE
cancer xxx NE
, , NE
prior xxx NE
breast xxx NE
cancer xxx NE
, , NE
or xx NE
precancerous xxx NE
mastopathy xxx NE
. . NE

Low Xxx NE
risk xxx NE
women xxx NE
were xxx NE
those xxx NE
without xxx NE
these xxx NE
or xx NE
other xxx NE
major xxx NE
identifiable xxx NE
risk xxx NE
factors xxx NE
. . NE

Ductal Xxxx cell_type_B
cells xxx cell_type_E
were xxx NE
obtained xxx NE
via xxx NE
random xxx NE
fine xxx NE
needle xxx NE
aspirations xxx NE
and xxx NE
cytologically xxx NE
classified xxx NE
. . NE

Biomarkers Xxxx NE
included xxx NE
DNA XXX NE
ploidy xxx NE
, , NE
estrogen xxx protein_B
receptor xxx protein_E
( ( NE
ER XX protein
) ) NE
, , NE
and xxx NE
epidermal xxx protein_B
growth xxx protein_M
factor xxx protein_M
receptor xxx protein_E
( ( NE
EGFR XXXX protein
) ) NE
. . NE

The Xxx NE
prevalence xxx NE
of xx NE
DNA XXX NE
aneuploidy xxx NE
was xxx NE
30% dd% NE
, , NE
overexpression xxx NE
of xx NE
ER XX protein
10% dd% NE
, , NE
and xxx NE
overexpression xxx NE
of xx NE
EGFR XXXX protein
35% dd% NE
, , NE
in xx NE
the xxx NE
206 ddd NE
high xxx NE
risk xxx NE
women xxx NE
whose xxx NE
median xxx NE
10 dd NE
year xxx NE
Gail Xxxx NE
risk xxx NE
(projected (xxx NE
probability) xxx) NE
of xx NE
developing xxx NE
breast xxx NE
cancer xxx NE
was xxx NE
4.5% d.d% NE
. . NE

The Xxx NE
prevalence xxx NE
of xx NE
aneuploidy xxx NE
and xxx NE
overexpressed xxx NE
EGFR XXXX protein
was xxx NE
significantly xxx NE
higher xxx NE
in xx NE
the xxx NE
high xxx NE
risk xxx NE
women xxx NE
than xxx NE
in xx NE
the xxx NE
25 dd NE
low xxx NE
risk xxx NE
controls xxx NE
(p (x NE
< < NE
0.002) d.ddd) NE
, , NE
whose xxx NE
median xxx NE
10 dd NE
year xxx NE
Gail Xxxx NE
risk xxx NE
was xxx NE
0.7% d.d% NE
. . NE

The Xxx NE
difference xxx NE
in xx NE
the xxx NE
prevalence xxx NE
of xx NE
ER XX NE
overexpression xxx NE
between xxx NE
high xxx NE
and xxx NE
low xxx NE
risk xxx NE
groups xxx NE
was xxx NE
not xxx NE
statistically xxx NE
significant xxx NE
(p (x NE
= = NE
0.095) d.ddd) NE
. . NE

This Xxxx NE
may xxx NE
be xx NE
due xxx NE
to xx NE
the xxx NE
low xxx NE
prevalence xxx NE
of xx NE
overexpressed xxx NE
ER XX protein
and xxx NE
the xxx NE
small xxx NE
number xxx NE
of xx NE
controls xxx NE
. . NE

A X NE
significant xxx NE
difference xxx NE
was xxx NE
noted xxx NE
in xx NE
the xxx NE
prevalence xxx NE
of xx NE
one xxx NE
or xx NE
more xxx NE
abnormal xxx NE
biomarkers xxx NE
between xxx NE
the xxx NE
high xxx NE
risk xxx NE
and xxx NE
low xxx NE
risk xxx NE
women xxx NE
(p (x NE
< < NE
0.001) d.ddd) NE
. . NE

A X NE
large xxx NE
prospective xxx NE
trial xxx NE
is xx NE
needed xxx NE
to xx NE
determine xxx NE
if xx NE
one xxx NE
or xx NE
more xxx NE
of xx NE
these xxx NE
biomarkers xxx NE
, , NE
is xx NE
predictive xxx NE
of xx NE
breast xxx NE
cancer xxx NE
development xxx NE
. . NE

Inhibition Xxxx NE
of xx NE
nuclear xxx RNA_B
factor xxx RNA_M
kappa xxx RNA_M
B X RNA_M
subunit xxx RNA_M
p65 xdd RNA_M
mRNA xXXX RNA_E
accumulation xxx NE
in xx NE
lipopolysaccharide xxx NE
-stimulated -xxx NE
human xxx NE
monocytic xxx NE
cells xxx NE
treated xxx NE
with xxx NE
sodium xxx NE
salicylate xxx NE
. . NE

Lipopolysaccharide Xxxx NE
is xx NE
one xxx NE
of xx NE
the xxx NE
most xxx NE
potent xxx NE
trigger xxx NE
substances xxx NE
for xxx NE
monocytes xxx NE
and xxx NE
macrophages xxx NE
causing xxx NE
secretion xxx NE
of xx NE
inflammatory xxx protein_B
mediators xxx protein_E
such xxx NE
as xx NE
tumor xxx protein_B
necrosis xxx protein_M
factor xxx protein_E
and xxx NE
interleukin-1 xxx-d protein
. . NE

The Xxx NE
nature xxx NE
of xx NE
the xxx NE
nuclear xxx NE
factors xxx NE
involved xxx NE
in xx NE
regulation xxx NE
of xx NE
these xxx NE
cytokine xxx DNA_B
genes xxx DNA_E
is xx NE
still xxx NE
unknown xxx NE
. . NE

Nuclear Xxxx NE
factor xxx NE
kappa xxx NE
B X NE
( ( NE
NF-kappa XX-xxx NE
B X NE
; ; NE
heterodimer xxx NE
of xx NE
p50 xdd NE
and xxx NE
p65 xdd NE
) ) NE
proteins xxx NE
have xxx NE
been xxx NE
suggested xxx NE
to xx NE
play xxx NE
an xx NE
important xxx NE
role xxx NE
in xx NE
gene xxx NE
transcription xxx NE
of xx NE
inflammatory xxx NE
mediators xxx NE
when xxx NE
monocytes xxx NE
are xxx NE
stimulated xxx NE
with xxx NE
lipopolysaccharide xxx NE
. . NE

Nonsteroidal Xxxx NE
anti-inflammatory xxx-xxx NE
drugs xxx NE
such xxx NE
as xx NE
salicylates xxx NE
have xxx NE
been xxx NE
used xxx NE
to xx NE
treat xxx NE
symptoms xxx NE
of xx NE
inflammation xxx NE
, , NE
and xxx NE
a x NE
new xxx NE
mechanism xxx NE
of xx NE
drug xxx NE
action xxx NE
was xxx NE
suggested xxx NE
recently xxx NE
. . NE

Salicylates Xxxx NE
have xxx NE
been xxx NE
shown xxx NE
to xx NE
inhibit xxx NE
lipopolysaccharide xxx NE
-induced -xxx NE
gene xxx NE
transcription xxx NE
via xxx NE
inhibition xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
by xx NE
preventing xxx NE
the xxx NE
degradation xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_M
inhibitor xxx protein_E
" " NE
I X protein_B
kappa xxx protein_M
B X protein_E
" " NE
, , NE
blocking xxx NE
the xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
into xxx NE
the xxx NE
nuclear xxx NE
compartment xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
nature xxx NE
of xx NE
the xxx NE
subunit xxx NE
involved xxx NE
in xx NE
this xxx NE
mechanism xxx NE
has xxx NE
not xxx NE
been xxx NE
defined xxx NE
. . NE

To Xx NE
examine xxx NE
the xxx NE
mechanisms xxx NE
by xx NE
which xxx NE
salicylates xxx NE
affect xxx NE
cytokine xxx protein
gene xxx NE
transcription xxx NE
, , NE
the xxx NE
amount xxx NE
of xx NE
active xxx NE
and xxx NE
inactive xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
and xxx NE
NF-kappa XX-xxx RNA_B
B X RNA_M
mRNA xXXX RNA_E
, , NE
in xx NE
Porphyromonas Xxxx NE
gingivalis xxx NE
lipopolysaccharide xxx NE
-stimulated -xxx NE
human xxx NE
monocytic xxx NE
cells xxx NE
was xxx NE
assessed xxx NE
. . NE

High Xxxx NE
doses xxx NE
of xx NE
sodium xxx NE
salicylate xxx NE
suppressed xxx NE
NF-kappa XX-xxx NE
B X NE
p65 xdd NE
mRNA xXXX NE
accumulation xxx NE
, , NE
resulting xxx NE
in xx NE
suppression xxx NE
of xx NE
total xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
, , NE
p50 xdd protein
on xx NE
tissue xxx NE
oligonucleotide xxx NE
had xxx NE
no xx NE
effects xxx NE
on xx NE
lipopolysaccharide xxx NE
-induced -xxx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
. . NE

The Xxx NE
data xxx NE
demonstrate xxx NE
that xxx NE
the xxx NE
p65 xdd protein
subunit xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
is xx NE
inhibited xxx NE
by xx NE
salicylate xxx NE
treatment xxx NE
and xxx NE
highlight xxx NE
the xxx NE
role xxx NE
of xx NE
salicylate xxx NE
in xx NE
the xxx NE
control xxx NE
of xx NE
gene xxx NE
expression xxx NE
of xx NE
inflammatory xxx protein_B
mediators xxx protein_E
. . NE

Glucocorticoid Xxxx NE
-mediated -xxx NE
inhibition xxx NE
of xx NE
RANTES XXXXXX NE
expression xxx NE
in xx NE
human xxx NE
T X NE
lymphocytes xxx NE
. . NE

The Xxx NE
chemokine xxx protein
RANTES XXXXXX protein
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
pathogenesis xxx NE
of xx NE
allergic xxx NE
inflammatory xxx NE
diseases xxx NE
including xxx NE
asthma xxx NE
and xxx NE
rhinitis xxx NE
which xxx NE
are xxx NE
frequently xxx NE
treated xxx NE
with xxx NE
glucocorticoids xxx NE
. . NE

We Xx NE
observed xxx NE
that xxx NE
dexamethasone xxx NE
dramatically xxx NE
inhibited xxx NE
RANTES XXXXXX NE
mRNA xXXX NE
expression xxx NE
dose xxx NE
dependently xxx NE
in xx NE
anti-CD3 xxx-XXd cell_line_B
activated xxx cell_line_M
Hut-78 Xxx-dd cell_line_M
T X cell_line_M
cells xxx cell_line_E
and xxx NE
human xxx cell_type_B
PBMCs XXXXx cell_type_E
. . NE

Inhibition Xxxx NE
of xx NE
RANTES XXXXXX NE
expression xxx NE
did xxx NE
not xxx NE
appear xxx NE
to xx NE
be xx NE
secondary xxx NE
to xx NE
IL-2 XX-d NE
inhibition xxx NE
and xxx NE
required xxx NE
binding xxx NE
to xx NE
the xxx NE
intracellular xxx NE
glucocorticoid xxx protein_B
receptor xxx protein_E
. . NE

The Xxx NE
down-regulation xxx-xxx NE
of xx NE
RANTES XXXXXX NE
expression xxx NE
by xx NE
glucocorticoids xxx NE
in xx NE
T X cell_type_B
cells xxx cell_type_E
may xxx NE
directly xxx NE
contribute xxx NE
to xx NE
the xxx NE
efficacy xxx NE
of xx NE
these xxx NE
agents xxx NE
in xx NE
suppressing xxx NE
cellular xxx NE
infiltration xxx NE
and xxx NE
to xx NE
their xxx NE
anti-inflammatory xxx-xxx NE
properties xxx NE
. . NE

Association Xxxx NE
of xx NE
TRAF1 XXXXd protein
, , NE
TRAF2 XXXXd protein
, , NE
and xxx NE
TRAF3 XXXXd protein
with xxx NE
an xx NE
Epstein-Barr Xxxx-Xxxx DNA_B
virus xxx DNA_M
LMP1 XXXd DNA_M
domain xxx DNA_E
important xxx NE
for xxx NE
B-lymphocyte X-xxx NE
transformation xxx NE
: : NE
role xxx NE
in xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

The Xxx NE
Epstein-Barr Xxxx-Xxxx NE
virus xxx NE
( ( NE
EBV XXX NE
) ) NE
transforming xxx NE
protein xxx NE
LMP1 XXXd NE
appears xxx NE
to xx NE
be xx NE
a x NE
constitutively xxx NE
activated xxx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
receptor xxx NE
( ( NE
TNFR XXXX NE
) ) NE
on xx NE
the xxx NE
basis xxx NE
of xx NE
an xx NE
intrinsic xxx NE
ability xxx NE
to xx NE
aggregate xxx NE
in xx NE
the xxx NE
plasma xxx NE
membrane xxx NE
and xxx NE
an xx NE
association xxx NE
of xx NE
its xxx NE
cytoplasmic xxx NE
carboxyl xxx NE
terminus xxx NE
( ( NE
CT XX NE
) ) NE
with xxx NE
TNFR XXXX NE
-associated -xxx NE
factors xxx NE
( ( NE
TRAFs XXXXx NE
) ) NE
. . NE

We Xx NE
now xxx NE
show xxx NE
that xxx NE
in xx NE
EBV-transformed XXX-xxx cell_line_B
B X cell_line_M
lymphocytes xxx cell_line_E
most xxx NE
of xx NE
TRAF1 XXXXd protein
or xx NE
TRAF3 XXXXd protein
and xxx NE
5% d% NE
of xx NE
TRAF2 XXXXd protein
are xxx NE
associated xxx NE
with xxx NE
LMP1 XXXd protein
and xxx NE
that xxx NE
most xxx NE
of xx NE
LMP1 XXXd protein
is xx NE
associated xxx NE
with xxx NE
TRAF1 XXXXd protein
or xx NE
TRAF3 XXXXd protein
. . NE

TRAF1 XXXXd protein
, , NE
TRAF2 XXXXd protein
, , NE
and xxx NE
TRAF3 XXXXd protein
bind xxx NE
to xx NE
a x NE
single xxx NE
site xxx NE
in xx NE
the xxx NE
LMP1 XXXd protein_B
CT XX protein_E
corresponding xxx NE
to xx NE
amino xxx NE
acids xxx NE
(aa) (xx) NE
199 ddd NE
to xx NE
214 ddd NE
, , NE
within xxx NE
a x NE
domain xxx NE
which xxx NE
is xx NE
important xxx NE
for xxx NE
B-lymphocyte X-xxx NE
growth xxx NE
transformation xxx NE
(aa (xx NE
187 ddd NE
to xx NE
231) ddd) NE
. . NE

Further Xxxx NE
deletional xxx NE
mutagenesis xxx NE
and xxx NE
alanine xxx NE
mutagenesis xxx NE
TRAF XXXX NE
binding xxx DNA_B
sequences xxx DNA_E
in xx NE
CD40 XXdd NE
, , NE
in xx NE
CD30 XXdd NE
, , NE
and xxx NE
in xx NE
the xxx NE
LMP1 XXXd protein
of xx NE
other xxx NE
lymphycryptoviruses xxx NE
provide xxx NE
the xxx NE
first xxx NE
evidence xxx NE
that xxx NE
PXQXT/S XXXXX/X DNA
is xx NE
a x NE
core xxx NE
TRAF XXXX DNA_B
binding xxx DNA_M
motif xxx DNA_E
. . NE

The Xxx NE
negative xxx NE
effects xxx NE
of xx NE
point xxx NE
mutations xxx NE
in xx NE
the xxx NE
LMP1 XXXd NE
(1-231) (d-ddd) NE
core xxx NE
TRAF XXXX NE
binding xxx NE
motif xxx NE
on xx NE
TRAF XXXX NE
binding xxx NE
and xxx NE
NF-kappaB XX-xxxX NE
activation xxx NE
genetically xxx NE
link xxx NE
the xxx NE
TRAFs XXXXx NE
to xx NE
LMP1 XXXd NE
(1-231)-mediated (d-ddd)-xxx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

NF-kappaB XX-xxxX NE
activation xxx NE
by xx NE
LMP1 XXXd protein
(1-231) (d-ddd) NE
is xx NE
likely xxx NE
to xx NE
be xx NE
mediated xxx NE
by xx NE
TRAF1 XXXXd protein
/TRAF2 /XXXXd NE
heteroaggregates xxx NE
since xxx NE
TRAF1 XXXXd NE
is xx NE
unique xxx NE
among xxx NE
the xxx NE
TRAFs XXXXx NE
in xx NE
coactivating xxx NE
NF-kappaB XX-xxxX NE
with xxx NE
LMP1 XXXd NE
(1-231) (d-ddd) NE
, , NE
a x NE
TRAF2 XXXXd protein
dominant-negative xxx-xxx NE
mutant xxx NE
can xxx NE
block xxx NE
LMP1 XXXd NE
(1-231)-mediated (d-ddd)-xxx NE
NF-kappaB XX-xxxX NE
activation xxx NE
as xx NE
well xxx NE
as xx NE
TRAF1 XXXXd NE
coactivation xxx NE
, , NE
and xxx NE
30% dd% NE
of xx NE
TRAF2 XXXXd NE
is xx NE
associated xxx NE
with xxx NE
TRAF1 XXXXd protein
in xx NE
EBV-transformed XXX-xxx NE
B X NE
cells xxx NE
. . NE

TRAF3 XXXXd protein
is xx NE
a x NE
negative xxx NE
modulator xxx NE
of xx NE
LMP1 XXXd NE
(1-231)-mediated (d-ddd)-xxx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

Surprisingly Xxxx NE
, , NE
TRAF1 XXXXd protein_B
or xx protein_M
TRAF-2 XXXX-d protein_M
or xx protein_M
TRAF-3 XXXX-d protein_E
does xxx NE
not xxx NE
interact xxx NE
with xxx NE
the xxx NE
terminal xxx protein_B
LMP1 XXXd protein_M
CT XX protein_E
aa xx NE
333 ddd NE
to xx NE
386 ddd NE
which xxx NE
can xxx NE
independently xxx NE
mediate xxx NE
NF-kappaB XX-xxxX NE
activation xxx NE
. . NE

The Xxx NE
constitutive xxx NE
association xxx NE
of xx NE
TRAFs XXXXx protein
with xxx NE
LMP1 XXXd protein
through xxx NE
the xxx NE
aa xx protein_B
187 ddd protein_M
to xx protein_M
231 ddd protein_M
domain xxx protein_E
which xxx NE
is xx NE
important xxx NE
in xx NE
NF-kappaB XX-xxxX NE
activation xxx NE
and xxx NE
primary xxx NE
B-lymphocyte X-xxx NE
growth xxx NE
transformation xxx NE
implicates xxx NE
TRAF XXXX NE
aggregation xxx NE
in xx NE
LMP1 XXXd NE
signaling xxx NE
. . NE

Lack Xxxx NE
of xx NE
IL-12 XX-dd NE
signaling xxx NE
in xx NE
human xxx cell_line_B
allergen-specific xxx-xxx cell_line_M
Th2 Xxd cell_line_M
cells xxx cell_line_E
. . NE

IL-12 XX-dd protein
is xx NE
a x NE
powerful xxx NE
skewer xxx NE
of xx NE
CD4+ XXd+ NE
T X NE
cell xxx NE
responses xxx NE
toward xxx NE
the xxx NE
Th1 Xxd NE
phenotype xxx NE
by xx NE
inducing xxx NE
IFN-gamma XXX-xxx NE
production xxx NE
in xx NE
naive xxx cell_line_B
Th Xx cell_line_M
cells xxx cell_line_E
. . NE

In Xx NE
the xxx NE
present xxx NE
study xxx NE
we xx NE
addressed xxx NE
the xxx NE
question xxx NE
of xx NE
whether xxx NE
IL-12 XX-dd protein
can xxx NE
reverse xxx NE
established xxx NE
Th2 Xxd NE
responses xxx NE
into xxx NE
Th1/Th0 Xxd/Xxd NE
responses xxx NE
by xx NE
inducing xxx NE
IFN-gamma XXX-xxx NE
production xxx NE
in xx NE
memory xxx cell_line_B
Th2 Xxd cell_line_M
cells xxx cell_line_E
. . NE

To Xx NE
this xxx NE
aim xxx NE
, , NE
allergen-specific xxx-xxx cell_line_B
CD4+ XXd+ cell_line_M
T X cell_line_M
cell xxx cell_line_M
clones xxx cell_line_E
( ( NE
TCC XXX cell_line
) ) NE
were xxx NE
generated xxx NE
from xxx NE
the xxx NE
peripheral xxx NE
blood xxx NE
of xx NE
three xxx NE
atopic xxx NE
patients xxx NE
, , NE
and xxx NE
their xxx NE
cytokine xxx NE
profiles xxx NE
were xxx NE
analyzed xxx NE
. . NE

The Xxx NE
majority xxx NE
of xx NE
these xxx NE
TCC XXX cell_line
exhibited xxx NE
a x NE
strongly xxx NE
polarized xxx NE
Th2 Xxd NE
cytokine xxx NE
profile xxx NE
, , NE
and xxx NE
the xxx NE
production xxx NE
of xx NE
IFN-gamma XXX-xxx protein
could xxx NE
not xxx NE
be xx NE
induced xxx NE
by xx NE
exogenous xxx NE
IL-12 XX-dd protein
. . NE

Only Xxxx NE
those xxx NE
TCC XXX cell_line
with xxx NE
low xxx NE
IFN-gamma XXX-xxx NE
levels xxx NE
in xx NE
the xxx NE
absence xxx NE
of xx NE
IL-12 XX-dd NE
responded xxx NE
to xx NE
IL-12 XX-dd NE
by xx NE
additional xxx NE
enhancement xxx NE
of xx NE
IFN-gamma XXX-xxx NE
production xxx NE
. . NE

The Xxx NE
IL-12 XX-dd protein
nonresponsiveness xxx NE
of xx NE
the xxx NE
Th2 Xxd cell_line_B
clones xxx cell_line_E
was xxx NE
further xxx NE
evident xxx NE
by xx NE
the xxx NE
total xxx NE
lack xxx NE
of xx NE
IL-12 XX-dd NE
-induced -xxx NE
phosphorylation xxx NE
of xx NE
STAT4 XXXXd NE
( ( NE
signal xxx NE
transducer xxx NE
and xxx NE
activator xxx NE
of xx NE
transcription-4 xxx-d NE
) ) NE
, , NE
a x NE
transcription xxx NE
factor xxx NE
that xxx NE
is xx NE
typically xxx NE
involved xxx NE
in xx NE
IL-12 XX-dd NE
signaling xxx NE
. . NE

Consequently Xxxx NE
, , NE
IL-12 XX-dd protein
also xxx NE
failed xxx NE
to xx NE
induce xxx NE
the xxx NE
DNA-binding XXX-xxx NE
activity xxx NE
of xx NE
STAT4 XXXXd NE
-containing -xxx NE
complexes xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
these xxx NE
Th2 Xxd NE
clones xxx NE
. . NE

All Xxx NE
TCC XXX cell_line
expressed xxx NE
equal xxx NE
levels xxx NE
of xx NE
the xxx NE
low-affinity xxx-xxx protein_B
IL-12R XX-ddX protein_M
beta1 xxxd protein_M
subunit xxx protein_E
. . NE

Our Xxx NE
results xxx NE
indicate xxx NE
that xxx NE
human xxx NE
allergen-specific xxx-xxx NE
Th Xx NE
cells xxx NE
with xxx NE
strongly xxx NE
polarized xxx NE
Th2 Xxd NE
cytokine xxx NE
profiles xxx NE
do xx NE
not xxx NE
respond xxx NE
to xx NE
IL-12 XX-dd protein
and xxx NE
, , NE
therefore xxx NE
, , NE
cannot xxx NE
be xx NE
induced xxx NE
to xx NE
produce xxx NE
IFN-gamma XXX-xxx protein
. . NE

The Xxx NE
apparent xxx NE
high xxx NE
frequency xxx NE
of xx NE
IL-12 XX-dd NE
-nonresponsive -xxx NE
Th Xx NE
cells xxx NE
within xxx NE
the xxx NE
allergen-specific xxx-xxx NE
populations xxx NE
in xx NE
atopic xxx NE
patients xxx NE
predicts xxx NE
a x NE
limited xxx NE
skewing xxx NE
potential xxx NE
of xx NE
IL-12 XX-dd NE
in xx NE
the xxx NE
case xxx NE
of xx NE
established xxx NE
Th2 Xxd NE
responses xxx NE
, , NE
but xxx NE
only xxx NE
affecting xxx NE
newly xxx NE
recruited xxx NE
naive xxx NE
Th Xx NE
cells xxx NE
. . NE

Cloning Xxxx NE
and xxx NE
expression xxx NE
of xx NE
the xxx NE
Epstein-Barr Xxxx-Xxxx NE
virus xxx NE
-encoded -xxx NE
dUTPase xXXXxxx NE
: : NE
patients xxx NE
with xxx NE
acute xxx NE
, , NE
reactivated xxx NE
or xx NE
chronic xxx NE
virus xxx NE
infection xxx NE
develop xxx NE
antibodies xxx NE
against xxx NE
the xxx NE
enzyme xxx NE
. . NE

The Xxx NE
gene xxx NE
encoding xxx NE
the xxx NE
Epstein-Barr Xxxx-Xxxx NE
virus xxx NE
( ( NE
EBV XXX NE
)-specific )-xxx NE
dUTPase xXXXxxx NE
was xxx NE
amplified xxx NE
from xxx NE
virus xxx NE
DNA XXX NE
by xx NE
PCR XXX NE
. . NE

The Xxx NE
active xxx NE
enzyme xxx NE
was xxx NE
expressed xxx NE
in xx NE
Escherichia Xxxx NE
coli xxx NE
and xxx NE
in xx NE
insect xxx cell_type_B
cells xxx cell_type_E
as xx NE
a x NE
non-fusion xxx-xxx protein_B
protein xxx protein_E
. . NE

The Xxx NE
protein xxx NE
from xxx NE
E. X. NE
coli xxx NE
specifically xxx NE
converted xxx NE
dUTP xXXX NE
to xx NE
dUMP xXXX NE
and xxx NE
did xxx NE
not xxx NE
react xxx NE
with xxx NE
other xxx NE
dNTPs xXXXx NE
or xx NE
NTPs XXXx NE
. . NE

Preliminary Xxxx NE
experiments xxx NE
yielded xxx NE
a x NE
Km Xx NE
value xxx NE
of xx NE
about xxx NE
0.8 d.d NE
microM xxxX NE
for xxx NE
dUTP xXXX NE
. . NE

MAbs XXxx NE
against xxx NE
the xxx NE
dUTPase xXXXxxx protein
reacted xxx NE
with xxx NE
a x NE
protein xxx NE
of xx NE
approximately xxx NE
31 dd NE
kDa xXx NE
in xx NE
12-O-tetradecanoyl-phorbol-13-acetate dd-X-xxx-xxx-dd-xxx cell_line_B
( ( cell_line_E
TPA XXX NE
)-stimulated )-xxx NE
B X NE
cells xxx NE
harbouring xxx NE
either xxx NE
type xxx NE
1 d NE
EBV XXX NE
or xx NE
type xxx NE
2 d NE
EBV XXX NE

The Xxx NE
protein xxx NE
was xxx NE
found xxx NE
in xx NE
untreated xxx cell_type_B
cells xxx cell_type_E
at xx NE
low xxx NE
levels xxx NE
, , NE
whereas xxx NE
induction xxx NE
of xx NE
the xxx NE
lytic xxx NE
replication xxx NE
cycle xxx NE
by xx NE
TPA XXX NE
treatment xxx NE
or xx NE
by xx NE
providing xxx NE
the xxx NE
immediate xxx protein_B
early xxx protein_M
transactivator xxx protein_E
BZLF1 XXXXd protein
in xx NE
trans xxx NE
resulted xxx NE
in xx NE
increased xxx NE
expression xxx NE
. . NE

We Xx NE
demonstrated xxx NE
that xxx NE
the xxx NE
virus xxx protein_B
dUTPase xXXXxxx protein_E
isolated xxx NE
from xxx NE
EBV XXX NE
-infected -xxx NE
cells xxx NE
is xx NE
a x NE
phosphoprotein xxx NE
. . NE

The Xxx NE
protein xxx NE
expressed xxx NE
in xx NE
insect xxx cell_type_B
cells xxx cell_type_E
was xxx NE
used xxx NE
to xx NE
test xxx NE
for xxx NE
the xxx NE
presence xxx NE
of xx NE
specific xxx NE
antibodies xxx NE
in xx NE
sera xxx NE
from xxx NE
normal xxx NE
, , NE
healthy xxx NE
carriers xxx NE
and xxx NE
from xxx NE
patients xxx NE
with xxx NE
various xxx NE
diseases xxx NE
. . NE

While Xxxx NE
the xxx NE
sera xxx NE
of xx NE
EBV XXX NE
-negative -xxx NE
individuals xxx NE
(0/3) (d/d) NE
or xx NE
healthy xxx NE
carriers xxx NE
(0/33) (d/dd) NE
did xxx NE
not xxx NE
contain xxx NE
detectable xxx NE
levels xxx NE
of xx NE
antibodies xxx NE
, , NE
patients xxx NE
with xxx NE
mononucleosis xxx NE
(5/18) (d/dd) NE
, , NE
chronic xxx NE
EBV XXX NE
infection xxx NE
(2/7) (d/d) NE
, , NE
EBV XXX NE
reactivation xxx NE
(7/20) (d/dd) NE
and xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
infection xxx NE
(5/24) (d/dd) NE
showed xxx NE
elevated xxx NE
antibody xxx NE
titres xxx NE
against xxx NE
the xxx NE
enzyme xxx NE
. . NE

This Xxxx NE
indicated xxx NE
that xxx NE
the xxx NE
dUTPase xXXXxxx NE
is xx NE
expressed xxx NE
during xxx NE
EBV XXX NE
replication xxx NE
and xxx NE
reactivation xxx NE
. . NE

The Xxx NE
enzyme xxx NE
might xxx NE
therefore xxx NE
be xx NE
a x NE
potential xxx NE
target xxx NE
for xxx NE
drug xxx NE
therapy xxx NE
under xxx NE
conditions xxx NE
of xx NE
active xxx NE
DNA XXX NE
replication xxx NE
. . NE

The Xxx NE
catalytic xxx protein_B
domain xxx protein_E
of xx NE
pp56(lck) xxdd(xxx) protein
, , NE
but xxx NE
not xxx NE
its xxx NE
regulatory xxx protein_B
domain xxx protein_E
, , NE
is xx NE
sufficient xxx NE
for xxx NE
inducing xxx NE
IL-2 XX-d NE
production xxx NE
. . NE

The Xxx NE
lymphoid xxx protein_B
src xxx protein_M
kinase xxx protein_E
pp56(lck) xxdd(xxx) protein
has xxx NE
been xxx NE
shown xxx NE
to xx NE
be xx NE
essential xxx NE
for xxx NE
the xxx NE
induction xxx NE
of xx NE
different xxx NE
T X NE
lymphocyte xxx NE
responses xxx NE
, , NE
including xxx NE
CD4 XXd NE
-mediated -xxx NE
enhancement xxx NE
of xx NE
Ag-induced Xx-xxx NE
T X NE
cell xxx NE
activation xxx NE
, , NE
early xxx NE
T X NE
cell xxx NE
differentiation xxx NE
, , NE
induction xxx NE
of xx NE
IL-2 XX-d NE
production xxx NE
, , NE
and xxx NE
cytotoxicity xxx NE
. . NE

It Xx NE
is xx NE
assumed xxx NE
that xxx NE
pp56(lck) xxdd(xxx) protein
acts xxx NE
on xx NE
these xxx NE
processes xxx NE
by xx NE
phosphorylating xxx NE
substrates xxx NE
. . NE

However Xxxx NE
, , NE
it xx NE
has xxx NE
been xxx NE
recently xxx NE
reported xxx NE
that xxx NE
the xxx NE
NH2 XXd protein
regulatory xxx protein_B
domain xxx protein_E
is xx NE
sufficient xxx NE
to xx NE
mediate xxx NE
CD4 XXd NE
accessory xxx NE
function xxx NE
. . NE

In Xx NE
this xxx NE
report xxx NE
we xx NE
address xxx NE
the xxx NE
contribution xxx NE
of xx NE
the xxx NE
regulatory xxx protein_B
domain xxx protein_M
and xxx protein_M
catalytic xxx protein_M
domain xxx protein_E
of xx NE
pp56(lck) xxdd(xxx) protein
to xx NE
another xxx NE
function xxx NE
of xx NE
this xxx NE
enzyme xxx NE
independent xxx NE
of xx NE
CD4 XXd protein
: : NE
TCR-induced XXX-xxx NE
IL-2 XX-d NE
production xxx NE
. . NE

Two Xxx NE
pp56(lck) xxdd(xxx) protein_B
mutants xxx protein_E
lacking xxx NE
either xxx NE
the xxx NE
entire xxx NE
catalytic xxx protein_B
domain xxx protein_E
or xx NE
the xxx NE
entire xxx NE
NH2 XXd protein
regulatory xxx protein_B
domain xxx protein_E
were xxx NE
generated xxx NE
, , NE
and xxx NE
their xxx NE
abilities xxx NE
to xx NE
trigger xxx NE
transactivation xxx NE
of xx NE
the xxx NE
TCR-regulated XXX-xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
( ( NE
NF-AT XX-XX NE
) ) NE
region xxx NE
of xx NE
the xxx NE
IL-2 XX-d NE
promoter xxx NE
were xxx NE
compared xxx NE
. . NE

Only Xxxx NE
the xxx NE
catalytic xxx NE
, , NE
but xxx NE
not xxx NE
the xxx NE
NH2 XXd protein
regulatory xxx NE
, , NE
domain xxx NE
of xx NE
pp56(lck) xxdd(xxx) protein
was xxx NE
able xxx NE
to xx NE
induce xxx NE
NF-AT XX-XX NE
region xxx NE
transactivation xxx NE
on xx NE
its xxx NE
own xxx NE
and xxx NE
to xx NE
cooperate xxx NE
with xxx NE
other xxx NE
intracellular xxx NE
signals xxx NE
to xx NE
trigger xxx NE
this xxx NE
response xxx NE
. . NE

Moreover Xxxx NE
, , NE
the xxx NE
catalytic xxx protein_B
domain xxx protein_E
of xx NE
pp56(lck) xxdd(xxx) protein
was xxx NE
able xxx NE
to xx NE
induce xxx NE
IL-2 XX-d protein
cytokine xxx protein
production xxx NE
to xx NE
an xx NE
extent xxx NE
similar xxx NE
to xx NE
that xxx NE
of xx NE
wild-type xxx-xxx NE
pp56(lck) xxdd(xxx) protein
. . NE

We Xx NE
conclude xxx NE
that xxx NE
different xxx NE
domains xxx NE
of xx NE
the xxx NE
pp56(lck) xxdd(xxx) protein
molecule xxx NE
contribute xxx NE
to xx NE
regulate xxx NE
distinct xxx NE
biologic xxx NE
functions xxx NE
. . NE

In Xx NE
fact xxx NE
, , NE
while xxx NE
the xxx NE
NH2 XXd protein
regulatory xxx protein_B
domain xxx protein_E
is xx NE
sufficient xxx NE
to xx NE
mediate xxx NE
CD4 XXd NE
accessory xxx NE
function xxx NE
, , NE
we xx NE
show xxx NE
here xxx NE
that xxx NE
the xxx NE
catalytic xxx NE
domain xxx NE
of xx NE
pp56(lck) xxdd(xxx) NE
is xx NE
sufficient xxx NE
for xxx NE
induction xxx NE
of xx NE
IL-2 XX-d NE
production xxx NE
, , NE
mimicking xxx NE
TCR XXX NE
ligation xxx NE
. . NE

[The [Xxx NE
changes xxx NE
in xx NE
glucocorticoid xxx NE
receptors xxx NE
in xx NE
peripheral xxx cell_type_B
leukocytes xxx cell_type_E
in xx NE
asthmatic xxx NE
subjects xxx NE
] ] NE

The Xxx NE
number xxx NE
of xx NE
glucocorticoid xxx protein_B
receptors xxx protein_E
( ( NE
GCR XXX protein
) ) NE
in xx NE
peripheral xxx cell_type_B
leukocytes xxx cell_type_E
was xxx NE
determined xxx NE
by xx NE
radioligand-binding xxx-xxx NE
assay xxx NE
in xx NE
extrinsic xxx NE
and xxx NE
intrinsic xxx NE
asthmatics xxx NE
. . NE

Their Xxxx NE
corresponding xxx NE
plasma xxx NE
cortisol xxx NE
levels xxx NE
were xxx NE
assessed xxx NE
. . NE

The Xxx NE
results xxx NE
showed xxx NE
that xxx NE
the xxx NE
average xxx NE
number xxx NE
of xx NE
GCR XXX protein
in xx NE
asthmatics xxx NE
was xxx NE
significantly xxx NE
lower xxx NE
than xxx NE
that xxx NE
in xx NE
healthy xxx NE
subjects xxx NE
(P (X NE
< < NE
0.01) d.dd) NE
, , NE
and xxx NE
there xxx NE
was xxx NE
a x NE
linear xxx NE
correlation xxx NE
between xxx NE
the xxx NE
number xxx NE
of xx NE
GCR XXX protein
and xxx NE
the xxx NE
course xxx NE
of xx NE
asthma xxx NE
. . NE

Besides Xxxx NE
, , NE
there xxx NE
was xxx NE
also xxx NE
a x NE
linear xxx NE
correlation xxx NE
between xxx NE
the xxx NE
number xxx NE
of xx NE
GCR XXX protein
and xxx NE
the xxx NE
age xxx NE
of xx NE
the xxx NE
initial xxx NE
attack xxx NE
of xx NE
asthma xxx NE
. . NE

No Xx NE
difference xxx NE
in xx NE
plasma xxx NE
cortisol xxx NE
level xxx NE
was xxx NE
found xxx NE
between xxx NE
asthmatics xxx NE
and xxx NE
healthy xxx NE
subjects xxx NE
. . NE

These Xxxx NE
findings xxx NE
suggest xxx NE
that xxx NE
there xxx NE
is xx NE
no xx NE
primary xxx NE
and xxx NE
general xxx NE
impairment xxx NE
of xx NE
glucocorticoid xxx NE
metabolism xxx NE
in xx NE
the xxx NE
asthmatics xxx NE
, , NE
but xxx NE
the xxx NE
number xxx NE
of xx NE
GCR XXX protein
in xx NE
the xxx NE
asthmatics xxx NE
is xx NE
lower xxx NE
than xxx NE
that xxx NE
in xx NE
healthy xxx NE
controls xxx NE
. . NE

The Xxx NE
decrease xxx NE
of xx NE
the xxx NE
number xxx NE
of xx NE
GCR XXX protein
in xx NE
asthmatics xxx NE
, , NE
we xx NE
think xxx NE
, , NE
is xx NE
related xxx NE
to xx NE
heredity xxx NE
and xxx NE
repeated xxx NE
attacks xxx NE
of xx NE
asthma xxx NE
. . NE

Novel Xxxx NE
aldosterone xxx protein_B
receptors xxx protein_E
: : NE
specificity-conferring xxx-xxx NE
mechanism xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
the xxx NE
cell xxx NE
membrane xxx NE
. . NE

Functional Xxxx NE
studies xxx NE
in xx NE
extra-renal, xxx-xxx, cell_type_B
nonepithelial xxx cell_type_M
cells xxx cell_type_E
such xxx NE
as xx NE
smooth xxx cell_type_B
muscle xxx cell_type_M
cells xxx cell_type_E
and xxx NE
more xxx NE
recently xxx NE
circulating xxx NE
human xxx cell_type_B
lymphocytes xxx cell_type_E
have xxx NE
provided xxx NE
increasing xxx NE
evidence xxx NE
that xxx NE
aldosterone xxx NE
produces xxx NE
not xxx NE
only xxx NE
classical xxx NE
genomic xxx NE
effects xxx NE
, , NE
but xxx NE
also xxx NE
rapid xxx NE
non-genomic xxx-xxx NE
effects xxx NE
on xx NE
transmembrane xxx NE
electrolyte xxx NE
movements xxx NE
. . NE

These Xxxx NE
involve xxx NE
activation xxx NE
of xx NE
the xxx NE
sodium/proton-exchanger xxx/xxx-xxx protein
of xx NE
the xxx NE
cell xxx NE
membrane xxx NE
at xx NE
very xxx NE
low xxx NE
, , NE
physiological xxx NE
concentrations xxx NE
of xx NE
aldosterone xxx NE
with xxx NE
an xx NE
acute xxx NE
onset xxx NE
within xxx NE
1-2 d-d NE
minutes xxx NE
. . NE

A X NE
second xxx NE
messenger xxx NE
cascade xxx NE
involved xxx NE
is xx NE
the xxx NE
inositol-1,4,5-trisphosphate xxx-d,d,d-xxx NE
/calcium /xxx NE
pathway xxx NE
which xxx NE
responds xxx NE
over xxx NE
the xxx NE
same xxx NE
rapid xxx NE
time xxx NE
course xxx NE
. . NE

Such Xxxx NE
changes xxx NE
clearly xxx NE
cannot xxx NE
be xx NE
explained xxx NE
by xx NE
genomic xxx NE
mechanisms xxx NE
, , NE
which xxx NE
are xxx NE
responsible xxx NE
for xxx NE
later xxx NE
effects xxx NE
than xxx NE
the xxx NE
membrane-related xxx-xxx NE
rapid xxx NE
responses xxx NE
. . NE

In Xx NE
addition xxx NE
to xx NE
its xxx NE
rapid xxx NE
time xxx NE
course xxx NE
the xxx NE
unique xxx NE
characteristics xxx NE
of xx NE
this xxx NE
new xxx NE
pathway xxx NE
for xxx NE
steroid xxx NE
action xxx NE
include xxx NE
a x NE
10000-fold ddddd-xxx NE
selectivity xxx NE
for xxx NE
aldosterone xxx NE
over xxx NE
cortisol xxx NE
and xxx NE
the xxx NE
ineffectiveness xxx NE
of xx NE
spironolactones xxx NE
, , NE
classical xxx NE
mineralocorticoid xxx NE
antagonists xxx NE
, , NE
as xx NE
antagonists xxx NE
of xx NE
the xxx NE
response xxx NE
. . NE

Subsequently Xxxx NE
binding xxx NE
sites xxx NE
have xxx NE
been xxx NE
demonstrated xxx NE
in xx NE
the xxx NE
plasma xxx NE
membrane xxx NE
of xx NE
human xxx cell_type_B
lymphocytes xxx cell_type_E
which xxx NE
show xxx NE
pharmacological xxx NE
( ( NE
aldosterone xxx NE
specificity) xxx) NE
and xxx NE
kinetic xxx NE
(high (xxx NE
turnover) xxx) NE
properties xxx NE
identical xxx NE
with xxx NE
those xxx NE
of xx NE
the xxx NE
rapid xxx NE
aldosterone xxx NE
effects xxx NE
in xx NE
the xxx NE
same xxx NE
cells xxx NE
. . NE

SDS-PAGE XXX-XXXX NE
analysis xxx NE
of xx NE
the xxx NE
receptor xxx protein_B
protein xxx protein_E
has xxx NE
shown xxx NE
a x NE
molecular xxx NE
weight xxx NE
of xx NE
approximately xxx NE
50 dd NE
kD xX NE
. . NE

The Xxx NE
present xxx NE
paper xxx NE
reviews xxx NE
the xxx NE
data xxx NE
supporting xxx NE
a x NE
new xxx NE
, , NE
two-step xxx-xxx NE
model xxx NE
for xxx NE
non-genomic xxx-xxx NE
and xxx NE
genomic xxx NE
aldosterone xxx NE
effects xxx NE
. . NE

It Xx NE
also xxx NE
suggests xxx NE
a x NE
novel xxx NE
specificity-conferring xxx-xxx NE
mechanism xxx NE
for xxx NE
mineralocorticoid xxx NE
action xxx NE
at xx NE
the xxx NE
membrane xxx NE
level xxx NE
. . NE

The Xxx NE
macrophage xxx protein_B
transcription xxx protein_M
factor xxx protein_E
PU.1 XX.d protein
directs xxx NE
tissue-specific xxx-xxx NE
expression xxx NE
of xx NE
the xxx NE
macrophage xxx protein_B
colony-stimulating xxx-xxx protein_M
factor xxx protein_M
receptor xxx protein_E
. . NE

The Xxx NE
macrophage xxx NE
colony-stimulating xxx-xxx NE
factor xxx NE
( ( NE
M-CSF X-XXX NE
) ) NE
receptor xxx NE
is xx NE
expressed xxx NE
in xx NE
a x NE
tissue-specific xxx-xxx NE
fashion xxx NE
from xxx NE
two xxx NE
distinct xxx NE
promoters xxx NE
in xx NE
monocytes/macrophages xxx/xxx NE
and xxx NE
the xxx NE
placenta xxx NE
. . NE

In Xx NE
order xxx NE
to xx NE
further xxx NE
understand xxx NE
the xxx NE
transcription xxx NE
factors xxx NE
which xxx NE
play xxx NE
a x NE
role xxx NE
in xx NE
the xxx NE
commitment xxx NE
of xx NE
multipotential xxx cell_type_B
progenitors xxx cell_type_E
to xx NE
the xxx NE
monocyte/macrophage xxx/xxx NE
lineage xxx NE
, , NE
we xx NE
have xxx NE
initiated xxx NE
an xx NE
investigation xxx NE
of xx NE
the xxx NE
factors xxx NE
which xxx NE
activate xxx NE
the xxx NE
M-CSF X-XXX protein_B
receptor xxx protein_E
very xxx NE
early xxx NE
during xxx NE
the xxx NE
monocyte xxx NE
differentiation xxx NE
process xxx NE
. . NE

Here Xxxx NE
we xx NE
demonstrate xxx NE
that xxx NE
the xxx NE
human xxx DNA_B
monocytic xxx DNA_M
M-CSF X-XXX DNA_M
receptor xxx DNA_M
promoter xxx DNA_E
directs xxx NE
reporter xxx NE
gene xxx NE
activity xxx NE
in xx NE
a x NE
tissue-specific xxx-xxx NE
fashion xxx NE
. . NE

Since Xxxx NE
one xxx NE
of xx NE
the xxx NE
few xxx NE
transcription xxx protein_B
factors xxx protein_E
which xxx NE
have xxx NE
been xxx NE
implicated xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
monocyte xxx DNA_B
genes xxx DNA_E
is xx NE
the xxx NE
macrophage- xxx- protein_B
and xxx protein_M
B-cell-specific X-xxx-xxx protein_M
PU.1 XX.d protein_E
transcription xxx protein_B
factor xxx protein_E
, , NE
we xx NE
investigated xxx NE
whether xxx NE
PU.1 XX.d protein
binds xxx NE
and xxx NE
activates xxx NE
the xxx NE
M-CSF X-XXX DNA_B
receptor xxx DNA_M
promoter xxx DNA_E
. . NE

Here Xxxx NE
we xx NE
demonstrate xxx NE
that xxx NE
both xxx NE
in xx NE
vitro-translated xxx-xxx protein_B
PU.1 XX.d protein_E
and xxx NE
PU.1 XX.d protein
from xxx NE
nuclear xxx NE
extracts xxx NE
bind xxx NE
to xx NE
a x NE
specific xxx NE
site xxx NE
in xx NE
the xxx NE
M-CSF X-XXX DNA_B
receptor xxx DNA_M
promoter xxx DNA_E
just xxx NE
upstream xxx NE
from xxx NE
the xxx NE
major xxx DNA_B
transcription xxx DNA_M
initiation xxx DNA_M
site xxx DNA_E
. . NE

Mutations Xxxx NE
in xx NE
this xxx NE
site xxx NE
which xxx NE
eliminate xxx NE
PU.1 XX.d protein
binding xxx NE
decrease xxx NE
M-CSF X-XXX protein_B
receptor xxx protein_E
promoter xxx NE
activity xxx NE
significantly xxx NE
in xx NE
macrophage xxx cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
only xxx NE
. . NE

Furthermore Xxxx NE
, , NE
PU.1 XX.d protein
transactivates xxx NE
the xxx NE
M-CSF X-XXX DNA_B
receptor xxx DNA_M
promoter xxx DNA_E
in xx NE
nonmacrophage xxx cell_type_B
cells xxx cell_type_E
. . NE

These Xxxx NE
results xxx NE
suggest xxx NE
that xxx NE
PU.1 XX.d protein
plays xxx NE
a x NE
major xxx NE
role xxx NE
in xx NE
macrophage xxx NE
gene xxx NE
regulation xxx NE
and xxx NE
development xxx NE
by xx NE
directing xxx NE
the xxx NE
expression xxx NE
of xx NE
a x NE
receptor xxx NE
for xxx NE
a x NE
key xxx protein_B
macrophage xxx protein_M
growth xxx protein_M
factor xxx protein_E
. . NE

Increased Xxxx NE
natural xxx NE
killer xxx NE
cell xxx NE
activity xxx NE
correlates xxx NE
with xxx NE
low xxx NE
or xx NE
negative xxx NE
expression xxx NE
of xx NE
the xxx NE
HER-2/neu XXX-d/xxx DNA_B
oncogene xxx DNA_E
in xx NE
patients xxx NE
with xxx NE
breast xxx NE
cancer xxx NE
. . NE

BACKGROUND XXXXXXXXXX NE
. . NE

Increased Xxxx NE
expression xxx NE
of xx NE
the xxx NE
HER-2/neu XXX-d/xxx DNA_B
oncogene xxx DNA_E
in xx NE
breast xxx NE
cancer xxx NE
correlates xxx NE
with xxx NE
decreased xxx NE
estrogen xxx NE
receptor xxx NE
concentration xxx NE
and xxx NE
seems xxx NE
to xx NE
be xx NE
an xx NE
important xxx NE
prognostic xxx NE
factor xxx NE
. . NE

The Xxx NE
authors xxx NE
investigated xxx NE
whether xxx NE
there xxx NE
is xx NE
a x NE
correlation xxx NE
between xxx NE
HER-2/neu XXX-d/xxx NE
expression xxx NE
and xxx NE
immunologic xxx NE
parameters xxx NE
representing xxx NE
tumor xxx NE
defense xxx NE
in xx NE
patients xxx NE
with xxx NE
breast xxx NE
cancer xxx NE
. . NE

METHOD XXXXXX NE
. . NE

A X NE
Western Xxxx NE
blot xxx NE
analysis xxx NE
was xxx NE
used xxx NE
to xx NE
investigate xxx NE
HER-2/neu XXX-d/xxx NE
expression xxx NE
, , NE
whereas xxx NE
a x NE
chromium-release xxx-xxx NE
assay xxx NE
using xxx NE
the xxx NE
K562 Xddd cell_line_B
cell xxx cell_line_M
line xxx cell_line_E
as xx NE
target xxx NE
was xxx NE
used xxx NE
to xx NE
measure xxx NE
natural xxx NE
killer xxx NE
(NK) (XX) NE
cell xxx NE
activity xxx NE
. . NE

RESULTS XXXXXXX NE
. . NE

In Xx NE
patients xxx NE
with xxx NE
breast xxx NE
cancer xxx NE
, , NE
NK XX NE
cell xxx NE
activity xxx NE
was xxx NE
significantly xxx NE
higher xxx NE
compared xxx NE
with xxx NE
patients xxx NE
with xxx NE
benign xxx cell_type_B
tumors xxx cell_type_E
(P (X NE
= = NE
0.006) d.ddd) NE
or xx NE
healthy xxx NE
control xxx NE
subjects xxx NE
(P (X NE
= = NE
0.002) d.ddd) NE
. . NE

Moreover Xxxx NE
, , NE
23.3% dd.d% NE
of xx NE
patients xxx NE
with xxx NE
breast xxx NE
cancer xxx NE
showed xxx NE
an xx NE
overexpression xxx NE
of xx NE
HER-2/neu XXX-d/xxx protein_B
protein xxx protein_E
. . NE

Within Xxxx NE
this xxx NE
group xxx NE
of xx NE
patients xxx NE
, , NE
NK XX NE
cell xxx NE
activity xxx NE
was xxx NE
significantly xxx NE
lower xxx NE
(45.6 (dd.d NE
+/- +/- NE
16.1%) dd.d%) NE
compared xxx NE
with xxx NE
the xxx NE
group xxx NE
with xxx NE
no xx NE
HER-2/neu XXX-d/xxx protein
overexpression xxx NE
(57.3 (dd.d NE
+/- +/- NE
11.0%) dd.d%) NE
. . NE

NK XX NE
cell xxx NE
activity xxx NE
did xxx NE
not xxx NE
increase xxx NE
in xx NE
patients xxx NE
with xxx NE
HER-2/neu XXX-d/xxx NE
overexpression xxx NE
. . NE

Thus Xxxx NE
, , NE
there xxx NE
was xxx NE
a x NE
statistically xxx NE
significant xxx NE
correlation xxx NE
of xx NE
cytolytic xxx NE
effector xxx NE
cell xxx NE
function xxx NE
with xxx NE
HER-2/neu XXX-d/xxx NE
expression xxx NE
of xx NE
the xxx NE
tumor xxx NE
(P (X NE
= = NE
0.003) d.ddd) NE
, , NE
and xxx NE
HER-2/neu XXX-d/xxx NE
overexpression xxx NE
correlated xxx NE
with xxx NE
a x NE
negative xxx NE
estrogen xxx protein_B
receptor xxx protein_E
status xxx NE
(P (X NE
= = NE
0.005) d.ddd) NE
. . NE

CONCLUSION XXXXXXXXXX NE
. . NE

These Xxxx NE
data xxx NE
add xxx NE
further xxx NE
evidence xxx NE
to xx NE
previous xxx NE
observations xxx NE
from xxx NE
the xxx NE
authors' xxx' NE
laboratory xxx NE
that xxx NE
certain xxx NE
tumor xxx NE
characteristics xxx NE
may xxx NE
be xx NE
associated xxx NE
with xxx NE
reactions xxx NE
of xx NE
the xxx NE
host xxx NE
with xxx NE
breast xxx NE
cancer xxx NE
. . NE

[The [Xxx NE
value xxx NE
of xx NE
the xxx NE
clinical xxx NE
test xxx NE
of xx NE
glucocorticoid xxx protein_B
receptors xxx protein_E
of xx NE
peripheral xxx cell_type_B
blood xxx cell_type_M
leukocytes xxx cell_type_E
in xx NE
patients xxx NE
with xxx NE
chronic xxx NE
pulmonary xxx NE
heart xxx NE
disease xxx NE
] ] NE

In Xx NE
order xxx NE
to xx NE
inquire xxx NE
into xxx NE
the xxx NE
functional xxx NE
state xxx NE
of xx NE
adrenal xxx NE
cortex xxx NE
in xx NE
patients xxx NE
with xxx NE
pulmonary xxx NE
heart xxx NE
disease xxx NE
, , NE
the xxx NE
number xxx NE
of xx NE
glucocorticoid xxx protein_B
receptors xxx protein_E
( ( NE
GCR XXX protein
) ) NE
of xx NE
peripheral xxx cell_type_B
blood xxx cell_type_M
leukocytes xxx cell_type_E
in xx NE
patients xxx NE
with xxx NE
chronic xxx NE
pulmonary xxx NE
heart xxx NE
disease xxx NE
was xxx NE
determined xxx NE
with xxx NE
radioligand-binding xxx-xxx NE
assay xxx NE
and xxx NE
the xxx NE
corresponding xxx NE
plasma xxx NE
cortisol xxx NE
levels xxx NE
were xxx NE
assessed xxx NE
with xxx NE
radioimmune xxx NE
assays xxx NE
. . NE

The Xxx NE
results xxx NE
showed xxx NE
that xxx NE
the xxx NE
number xxx NE
of xx NE
GCR XXX protein
in xx NE
the xxx NE
patients xxx NE
was xxx NE
significantly xxx NE
reduced xxx NE
(P (X NE
< < NE
0.01) d.dd) NE
and xxx NE
it xx NE
was xxx NE
increased xxx NE
when xxx NE
their xxx NE
health xxx NE
state xxx NE
was xxx NE
improved xxx NE
. . NE

However Xxxx NE
, , NE
it xx NE
was xxx NE
still xxx NE
lower xxx NE
than xxx NE
that xxx NE
in xx NE
healthy xxx NE
subjects xxx NE
(P (X NE
< < NE
0.01) d.dd) NE
. . NE

The Xxx NE
number xxx NE
of xx NE
GCR XXX protein
in xx NE
the xxx NE
patients xxx NE
was xxx NE
greatly xxx NE
increased xxx NE
when xxx NE
these xxx NE
patients xxx NE
were xxx NE
treated xxx NE
with xxx NE
oxygen xxx NE
(P (X NE
< < NE
0.01) d.dd) NE
. . NE

No Xx NE
difference xxx NE
in xx NE
plasma xxx NE
cortisol xxx NE
was xxx NE
found xxx NE
between xxx NE
the xxx NE
patients xxx NE
and xxx NE
the xxx NE
healthy xxx NE
subjects xxx NE
(P (X NE
> > NE
0.05) d.dd) NE
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
the xxx NE
function xxx NE
of xx NE
adrenal xxx NE
cortex xxx NE
may xxx NE
be xx NE
improved xxx NE
by xx NE
the xxx NE
compensation xxx NE
mechanism xxx NE
of xx NE
the xxx NE
patients xxx NE
, , NE
but xxx NE
the xxx NE
lower xxx NE
GCR XXX protein
number xxx NE
was xxx NE
the xxx NE
result xxx NE
of xx NE
lacking xxx NE
of xx NE
oxygen xxx NE
in xx NE
the xxx NE
patients xxx NE
. . NE

The Xxx NE
number xxx NE
of xx NE
GCR XXX protein
may xxx NE
be xx NE
improved xxx NE
by xx NE
inhalation xxx NE
of xx NE
oxygen xxx NE
. . NE

Therefore Xxxx NE
oxygen xxx NE
therapy xxx NE
is xx NE
helpful xxx NE
in xx NE
raising xxx NE
the xxx NE
activity xxx NE
of xx NE
glucocorticoid xxx protein_B
receptors xxx protein_E
and xxx NE
controlling xxx NE
the xxx NE
development xxx NE
of xx NE
the xxx NE
disease xxx NE
. . NE

Signaling Xxxx NE
via xxx NE
IL-2 XX-d protein
and xxx NE
IL-4 XX-d protein
in xx NE
JAK3 XXXd NE
-deficient -xxx NE
severe xxx NE
combined xxx NE
immunodeficiency xxx NE
lymphocytes xxx NE
: : NE
JAK3 XXXd NE
-dependent -xxx NE
and xxx NE
independent xxx NE
pathways xxx NE
. . NE

Both Xxxx NE
IL-2 XX-d protein
and xxx NE
IL-4 XX-d protein
bind xxx NE
to xx NE
receptors xxx NE
containing xxx NE
the xxx NE
common xxx protein_B
gamma xxx protein_M
chain xxx protein_E
and xxx NE
JAK3 XXXd protein
. . NE

Although Xxxx NE
JAK3 XXXd protein
is xx NE
required xxx NE
for xxx NE
proper xxx NE
lymphoid xxx NE
development xxx NE
, , NE
the xxx NE
precise xxx NE
roles xxx NE
of xx NE
this xxx NE
kinase xxx NE
in xx NE
IL-2 XX-d protein
and xxx NE
IL-4 XX-d protein
signaling xxx NE
in xx NE
lymphocytes xxx cell_type
have xxx NE
not xxx NE
been xxx NE
defined xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
have xxx NE
studied xxx NE
IL-2 XX-d protein
and xxx NE
IL-4 XX-d protein
signaling xxx NE
in xx NE
B X cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
lacking xxx NE
JAK3 XXXd protein
. . NE

Although Xxxx NE
IL-2 XX-d NE
-induced -xxx NE
phosphorylation xxx NE
of xx NE
IL-2R XX-dX NE
beta xxx NE
, , NE
JAK1 XXXd NE
, , NE
and xxx NE
STAT5 XXXXd NE
all xxx NE
required xxx NE
the xxx NE
presence xxx NE
of xx NE
JAK3 XXXd NE
, , NE
IL-4 XX-d NE
-mediated -xxx NE
phosphorylation xxx NE
of xx NE
JAK1 XXXd NE
, , NE
STAT6 XXXXd NE
, , NE
and xxx NE
insulin xxx NE
receptor xxx NE
substrates xxx NE
1 d NE
and xxx NE
2 d NE
did xxx NE
not xxx NE
. . NE

However Xxxx NE
, , NE
IL-4 XX-d NE
-induced -xxx NE
effects xxx NE
were xxx NE
clearly xxx NE
improved xxx NE
following xxx NE
JAK3 XXXd NE
expression xxx NE
. . NE

These Xxxx NE
data xxx NE
indicate xxx NE
that xxx NE
IL-4 XX-d protein
signaling xxx NE
occurs xxx NE
in xx NE
the xxx NE
absence xxx NE
of xx NE
of xx NE
JAK3 XXXd protein
, , NE
but xxx NE
is xx NE
comparatively xxx NE
inefficient xxx NE
. . NE

These Xxxx NE
findings xxx NE
may xxx NE
help xxx NE
in xx NE
understanding xxx NE
the xxx NE
pathogenesis xxx NE
of xx NE
the xxx NE
immunodeficiency xxx NE
that xxx NE
occurs xxx NE
with xxx NE
mutations xxx NE
of xx NE
JAK3 XXXd protein
and xxx NE
may xxx NE
suggest xxx NE
a x NE
mechanism xxx NE
for xxx NE
the xxx NE
pleiotropic xxx NE
effects xxx NE
of xx NE
IL-4 XX-d protein
. . NE

Elf-1 Xxx-d protein
and xxx NE
Stat5 Xxxxd protein
bind xxx NE
to xx NE
a x NE
critical xxx NE
element xxx NE
in xx NE
a x NE
new xxx NE
enhancer xxx NE
of xx NE
the xxx NE
human xxx DNA_B
interleukin-2 xxx-d DNA_M
receptor xxx DNA_M
alpha xxx DNA_M
gene xxx DNA_E
[published [xxx NE
erratum xxx NE
appears xxx NE
in xx NE
Mol Xxx NE
Cell Xxxx NE
Biol Xxxx NE
1997 dddd NE
Apr;17(4):2351] Xxx;dd(d):dddd] NE

The Xxx NE
interleukin xxx NE
2 d NE
receptor xxx NE
alpha-chain xxx-xxx NE
( ( NE
IL-2R XX-dX NE
alpha xxx NE
) ) NE
gene xxx NE
is xx NE
a x NE
key xxx NE
regulator xxx NE
of xx NE
lymphocyte xxx NE
proliferation xxx NE
. . NE

IL-2R XX-dX protein_B
alpha xxx protein_E
is xx NE
rapidly xxx NE
and xxx NE
potently xxx NE
induced xxx NE
in xx NE
T X cell_type_B
cells xxx cell_type_E
in xx NE
response xxx NE
to xx NE
mitogenic xxx NE
stimuli xxx NE
. . NE

Interleukin Xxxx protein_B
2 d protein_E
( ( NE
IL-2 XX-d protein
) ) NE
stimulates xxx NE
IL-2R XX-dX protein_B
alpha xxx protein_E
. . NE

transcription xxx NE
, , NE
thereby xxx NE
amplifying xxx NE
expression xxx NE
of xx NE
its xxx NE
own xxx NE
high-affinity xxx-xxx protein_B
receptor xxx protein_E
. . NE

IL-2R XX-dX NE
alpha xxx NE
transcription xxx NE
is xx NE
at xx NE
least xxx NE
in xx NE
part xxx NE
controlled xxx NE
by xx NE
two xxx NE
positive xxx protein_B
regulatory xxx protein_M
regions xxx protein_E
, , NE
PRRI XXXX DNA
and xxx NE
PRRII XXXXX DNA
. . NE

PRRI XXXX DNA
is xx NE
an xx NE
inducible xxx DNA_B
proximal xxx DNA_M
enhancer xxx DNA_E
, , NE
located xxx NE
between xxx DNA_B
nucleotides xxx DNA_M
-276 -ddd DNA_M
and xxx DNA_M
-244 -ddd DNA_E
, , NE
which xxx NE
contains xxx NE
NF-kappaB XX-xxxX DNA_B
motif xxx DNA_M
and xxx DNA_M
SRE/CArG XXX/XXxX DNA_M
motif xxx DNA_E

PRRII XXXXX DNA
is xx NE
a x NE
T-cell-specific X-xxx-xxx DNA_B
enhancer xxx DNA_E
, , NE
located xxx NE
between xxx NE
nucleotides xxx NE
-137 -ddd NE
and xxx NE
-64 -dd NE
, , NE
which xxx NE
binds xxx NE
the xxx NE
T-cell-specific X-xxx-xxx protein_B
Ets Xxx protein_M
protein xxx protein_E
Elf-1 Xxx-d protein
and xxx NE
HMG-I(Y) XXX-X(X) protein_B
proteins xxx protein_E
. . NE

However Xxxx NE
, , NE
none xxx NE
of xx NE
these xxx NE
proximal xxx NE
regions xxx NE
account xxx NE
for xxx NE
the xxx NE
induction xxx NE
of xx NE
IL-2R XX-dX NE
alpha xxx NE
transcription xxx NE
by xx NE
IL-2 XX-d protein
. . NE

To Xx NE
find xxx NE
new xxx NE
regulatory xxx DNA_B
regions xxx DNA_E
of xx NE
the xxx NE
IL-2R XX-dX DNA_B
alpha xxx DNA_M
gene xxx DNA_E
, , NE
8.5 d.d NE
kb xx NE
of xx NE
the xxx NE
5' d' NE
end xxx NE
noncoding xxx NE
sequence xxx NE
of xx NE
the xxx NE
IL-2R XX-dX DNA_B
alpha xxx DNA_M
gene xxx DNA_E
have xxx NE
been xxx NE
sequenced xxx NE
. . NE

We Xx NE
identified xxx NE
an xx NE
86-nucleotide dd-xxx NE
fragment xxx NE
that xxx NE
is xx NE
90% dd% NE
identical xxx NE
to xx NE
the xxx NE
recently xxx NE
characterized xxx NE
murine xxx NE
IL-2 XX-d NE
-responsive -xxx NE
element xxx NE
( ( NE
mIL-2rE xXX-dxX NE
) ) NE
. . NE

This Xxxx NE
putative xxx NE
human xxx DNA_B
IL-2rE XX-dxX DNA_E
, , NE
designated xxx NE
PRRIII XXXXXX DNA
, , NE
confers xxx NE
IL-2 XX-d protein
responsiveness xxx NE
on xx NE
a x NE
heterologous xxx DNA_B
promoter xxx DNA_E
. . NE

PRRIII XXXXXX DNA
contains xxx NE
a x NE
Stat Xxxx DNA_B
protein xxx DNA_M
binding xxx DNA_M
site xxx DNA_E
that xxx NE
overlaps xxx NE
with xxx NE
an xx NE
EBS XXX DNA_B
motif xxx DNA_E
( ( NE
GASd/EBSd XXXx/XXXx DNA
) ) NE
. . NE

These Xxxx NE
are xxx NE
essential xxx NE
for xxx NE
IL-2 XX-d NE
inducibility xxx NE
of xx NE
PRRIII XXXXXX NE
/CAT /XXX NE
reporter xxx NE
constructs xxx NE
. . NE

IL-2 XX-d protein
induced xxx NE
the xxx NE
binding xxx NE
of xx NE
Stat5a Xxxxdx protein_B
protein xxx protein_M
and xxx protein_M
Stat5b Xxxxdx protein_M
protein xxx protein_E
to xx NE
the xxx NE
human xxx DNA_B
GASd XXXx DNA_M
element xxx DNA_E
. . NE

To Xx NE
confirm xxx NE
the xxx NE
physiological xxx NE
relevance xxx NE
of xx NE
these xxx NE
findings xxx NE
, , NE
we xx NE
carried xxx NE
out xxx NE
in xx NE
vivo xxx NE
footprinting xxx NE
experiments xxx NE
which xxx NE
showed xxx NE
that xxx NE
stimulation xxx NE
of xx NE
IL-2R XX-dX NE
alpha xxx NE
expression xxx NE
correlated xxx NE
with xxx NE
occupancy xxx NE
of xx NE
the xxx NE
GASd XXXx DNA_B
element xxx DNA_E
. . NE

Our Xxx NE
data xxx NE
demonstrate xxx NE
a x NE
major xxx NE
role xxx NE
of xx NE
the xxx NE
GASd/EBSd XXXx/XXXx DNA_B
element xxx DNA_E
in xx NE
IL-2R XX-dX NE
alpha xxx NE
regulation xxx NE
and xxx NE
suggest xxx NE
that xxx NE
the xxx NE
T-cell-specific X-xxx-xxx protein_B
Elf-1 Xxx-d protein_M
factor xxx protein_E
can xxx NE
serve xxx NE
as xx NE
a x NE
transcriptional xxx protein_B
repressor xxx protein_E
. . NE

Signal Xxxx NE
transduction xxx NE
by xx NE
DR3 XXd protein
, , NE
a x NE
death xxx NE
domain xxx NE
-containing -xxx NE
receptor xxx NE
related xxx NE
to xx NE
TNFR-1 XXXX-d NE
and xxx NE
CD95 XXdd NE
. . NE

Tumor Xxxx protein_B
necrosis xxx protein_M
factor xxx protein_M
receptor-1 xxx-d protein_E
( ( NE
TNFR-1 XXXX-d protein
) ) NE
and xxx NE
CD95 XXdd protein
(also (xxx NE
called xxx NE
Fas Xxx protein
or xx NE
APO-1 XXX-d protein
) ) NE
are xxx NE
cytokine xxx protein_B
receptors xxx protein_E
that xxx NE
engage xxx NE
the xxx NE
apoptosis xxx NE
pathway xxx NE
through xxx NE
a x NE
region xxx NE
of xx NE
intracellular xxx NE
homology xxx NE
, , NE
designated xxx NE
the xxx NE
" " NE
death xxx protein_B
domain xxx protein_E
." ." NE
Another Xxxx NE
death xxx NE
domain xxx NE
-containing -xxx NE
member xxx NE
of xx NE
the xxx NE
TNFR XXXX NE
family xxx NE
, , NE
death xxx NE
receptor xxx NE
3 d NE
( ( NE
DR3 XXd NE
) ) NE
, , NE
was xxx NE
identified xxx NE
and xxx NE
was xxx NE
shown xxx NE
to xx NE
induce xxx NE
both xxx NE
apoptosis xxx NE
and xxx NE
activation xxx NE
of xx NE
nuclear xxx NE
factor xxx NE
kappaB xxxX NE
. . NE

Expression Xxxx NE
of xx NE
DR3 XXd protein
appears xxx NE
to xx NE
be xx NE
restricted xxx NE
to xx NE
tissues xxx NE
enriched xxx NE
in xx NE
lymphocytes xxx cell_type
. . NE

DR3 XXd NE
signal xxx NE
transduction xxx NE
is xx NE
mediated xxx NE
by xx NE
a x NE
complex xxx NE
of xx NE
intracellular xxx protein_B
signaling xxx protein_M
molecules xxx protein_E
including xxx NE
TRADD XXXXX protein
, , NE
TRAF2 XXXXd protein
, , NE
FADD XXXX protein
, , NE
and xxx NE
FLICE XXXXX protein
. . NE

Thus Xxxx NE
, , NE
DR3 XXd protein
likely xxx NE
plays xxx NE
a x NE
role xxx NE
in xx NE
regulating xxx NE
lymphocyte xxx NE
homeostasis xxx NE
. . NE

Differential Xxxx NE
nuclear xxx NE
localization xxx NE
of xx NE
p50 xdd protein
, , NE
p52 xdd protein
, , NE
and xxx NE
RelB XxxX protein
proteins xxx NE
in xx NE
human xxx cell_type_B
accessory xxx cell_type_M
cells xxx cell_type_E
of xx NE
the xxx NE
immune xxx NE
response xxx NE
in xx NE
situ xxx NE
. . NE

The Xxx NE
Rel/NF-kappa Xxx/XX-xxx protein_B
B X protein_M
proteins xxx protein_E
, , NE
p50 xdd protein
, , NE
p52 xdd protein
, , NE
p65 xdd protein
, , NE
c-Rel x-Xxx protein
, , NE
and xxx NE
RelB XxxX protein
, , NE
constitute xxx NE
a x NE
family xxx NE
of xx NE
transcription xxx protein_B
factors xxx protein_E
involved xxx NE
in xx NE
the xxx NE
positive xxx NE
regulation xxx NE
of xx NE
a x NE
variety xxx NE
of xx NE
genes xxx NE
during xxx NE
the xxx NE
immune xxx NE
response xxx NE
. . NE

Recently Xxxx NE
, , NE
it xx NE
has xxx NE
been xxx NE
shown xxx NE
that xxx NE
RelB XxxX NE
knockout xxx NE
mice xxx NE
have xxx NE
no xx NE
dendritic xxx cell_type_B
cells xxx cell_type_E
( ( NE
DC XX cell_type
) ) NE
. . NE

An Xx NE
overexpression xxx NE
of xx NE
p50 xdd protein
has xxx NE
been xxx NE
described xxx NE
in xx NE
follicular xxx cell_type_B
dendritic xxx cell_type_M
cells xxx cell_type_E
( ( NE
FDC XXX cell_type
) ) NE
. . NE

A X NE
constitutive xxx NE
NF-kappa XX-xxx NE
B X NE
activity xxx NE
has xxx NE
been xxx NE
reported xxx NE
in xx NE
mature xxx cell_type_B
macrophages xxx cell_type_E
. . NE

This Xxxx NE
led xxx NE
to xx NE
the xxx NE
hypothesis xxx NE
that xxx NE
some xxx NE
of xx NE
the xxx NE
Rel Xxx NE
/ / NE
NF-kappa XX-xxx NE
B X NE
proteins xxx NE
were xxx NE
key xxx NE
nuclear xxx NE
factors xxx NE
in xx NE
functions xxx NE
of xx NE
accessory xxx NE
cells xxx NE
of xx NE
the xxx NE
immune xxx NE
response xxx NE
. . NE

Therefore Xxxx NE
, , NE
we xx NE
investigated xxx NE
in xx NE
situ xxx NE
the xxx NE
nuclear xxx NE
localization xxx NE
of xx NE
Rel Xxx NE
/ / NE
NF-kappa XX-xxx NE
B X NE
proteins xxx NE
in xx NE
accessory xxx NE
cells xxx NE
of xx NE
the xxx NE
immune xxx NE
system xxx NE
by xx NE
immunohistochemistry xxx NE
and xxx NE
double xxx NE
labeling xxx NE
by xx NE
immunofluorescence xxx NE
from xxx NE
five xxx NE
normal xxx NE
human xxx NE
tonsils xxx NE
and xxx NE
five xxx NE
lymph xxx NE
nodes xxx NE
with xxx NE
follicular xxx NE
hyperplasia xxx NE
. . NE

Nuclear Xxxx NE
p65 xdd protein
and xxx NE
c-Rel x-Xxx protein
proteins xxx NE
were xxx NE
found xxx NE
in xx NE
all xxx NE
cell xxx NE
types xxx NE
including xxx NE
lymphocytes xxx cell_type
. . NE

In Xx NE
germinal xxx NE
centers xxx NE
GC XX NE
, , NE
p50 xdd protein
, , NE
p52 xdd protein
, , NE
and xxx NE
RelB XxxX protein
were xxx NE
found xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
FDC XXX cell_type
only xxx NE
and xxx NE
were xxx NE
not xxx NE
detected xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
CD68+ XXdd+ cell_line_B
cells xxx cell_line_E
. . NE

In Xx NE
T X NE
cell xxx NE
areas xxx NE
, , NE
p50 xdd protein
, , NE
p52 xdd protein
, , NE
and xxx NE
RelB XxxX protein
were xxx NE
found xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
HLA-DR+ XXX-XX+ cell_line_B
cells xxx cell_line_E
with xxx NE
an xx NE
antigen-presenting xxx-xxx NE
cell xxx NE
(APC) (XXX) NE
morphology xxx NE
. . NE

p52 xdd protein
and xxx NE
RelB XxxX protein
were xxx NE
detected xxx NE
in xx NE
the xxx NE
nuclei xxx NE
in xx NE
both xxx NE
CD1a+ XXdx+ cell_line
and xxx NE
CD68+ XXdd+ cell_line_B
cells xxx cell_line_E
from xxx NE
the xxx NE
T X NE
cell xxx NE
area xxx NE
, , NE
whereas xxx NE
p50 xdd protein
was xxx NE
found xxx NE
only xxx NE
in xx NE
CD68- XXdd- cell_line_B
cell xxx cell_line_M
and xxx cell_line_M
CD1a- XXdx- cell_line_M
cell xxx cell_line_E

Cells Xxxx NE
with xxx NE
nuclear xxx NE
p50 xdd protein
were xxx NE
negative xxx NE
for xxx NE
the xxx NE
CD38 XXdd protein
, , NE
CD20 XXdd protein
and xxx NE
CD2 XXd protein_B
markers xxx protein_E
. . NE

These Xxxx NE
results xxx NE
show xxx NE
that xxx NE
, , NE
physiologically xxx NE
, , NE
high xxx NE
levels xxx NE
of xx NE
nuclear xxx NE
of xx NE
p50 xdd protein
, , NE
p52 xdd protein
and xxx NE
RelB XxxX protein
are xxx NE
restricted xxx NE
to xx NE
accessory xxx cell_type_B
cells xxx cell_type_E
of xx NE
the xxx NE
immune xxx NE
system xxx NE
, , NE
which xxx NE
include xxx NE
FDC XXX cell_type
in xx NE
GC XX NE
, , NE
and xxx NE
DC XX cell_type
and xxx NE
macrophages xxx NE
in xx NE
the xxx NE
T X NE
cell xxx NE
zone xxx NE
, , NE
that xxx NE
specialized xxx NE
scavenger xxx cell_type_B
macrophages xxx cell_type_E
from xxx NE
GC XX cell_type
do xx NE
not xxx NE
have xxx NE
detectable xxx NE
levels xxx NE
of xx NE
p52 xdd protein
and xxx NE
RelB XxxX protein
, , NE
whereas xxx NE
macrophages xxx cell_type
from xxx NE
the xxx NE
T X NE
cell xxx NE
area xxx NE
, , NE
known xxx NE
to xx NE
present xxx NE
the xxx NE
antigen xxx NE
to xx NE
T X cell_type_B
cells xxx cell_type_E
, , NE
do xx NE
have xxx NE
both xxx NE
nuclear xxx NE
p52 xdd protein
and xxx NE
RelB XxxX protein
, , NE
and xxx NE
that xxx NE
in xx NE
the xxx NE
T X NE
cell xxx NE
zone xxx NE
, , NE
p52 xdd protein
and xxx NE
RelB XxxX protein
are xxx NE
located xxx NE
in xx NE
nuclei xxx NE
of xx NE
both xxx NE
CD1a+ XXdx+ NE
, , NE
CD68+ XXdd+ NE
or xx NE
both xxx NE
, , NE
cells xxx NE
APC XXX NE
, , NE
whereas xxx NE
p50 xdd NE
is xx NE
restricted xxx NE
to xx NE
CD1a- XXdx- NE
and xxx NE
CD68- XXdd- NE
APC XXX NE
. . NE

The Xxx NE
different xxx NE
patterns xxx NE
of xx NE
p50 xdd protein
, , NE
p52 xdd protein
and xxx NE
RelB XxxX protein
protein xxx NE
nuclear xxx NE
localization xxx NE
may xxx NE
provide xxx NE
insight xxx NE
into xxx NE
their xxx NE
different xxx NE
roles xxx NE
during xxx NE
the xxx NE
immune xxx NE
response xxx NE
in xx NE
vivo xxx NE
. . NE

Tyrosines Xxxx NE
tyrosine xxx NE
113 ddd NE
and xxx NE
tyrosine xxx NE
128 ddd NE
and xxx NE
tyrosine xxx NE
145 ddd NE
of xx NE
SLP-76 XXX-dd protein
are xxx NE
required xxx NE
for xxx NE
optimal xxx NE
augmentation xxx NE
of xx NE
NFAT XXXX NE
promoter xxx NE
activity xxx NE
. . NE

SLP-76 XXX-dd protein
( ( NE
SH2 XXd protein_B
domain xxx protein_M
leukocyte xxx protein_M
protein xxx protein_E
of xx NE
76 dd NE
kDa) xXx) NE
is xx NE
a x NE
recently xxx NE
identified xxx NE
substrate xxx NE
of xx NE
the xxx NE
TCR-stimulated XXX-xxx protein_B
protein xxx protein_E
tyrosine xxx protein_B
kinases xxx protein_E
that xxx NE
functions xxx NE
in xx NE
the xxx NE
signal xxx NE
transduction xxx NE
cascade xxx NE
linking xxx NE
the xxx NE
TCR XXX protein
with xxx NE
IL-2 XX-d NE
gene xxx NE
expression xxx NE
. . NE

In Xx NE
this xxx NE
report xxx NE
, , NE
we xx NE
demonstrate xxx NE
that xxx NE
engagement xxx NE
of xx NE
the xxx NE
TCR XXX protein
results xxx NE
in xx NE
tyrosine xxx NE
phosphorylation xxx NE
of xx NE
SLP-76 XXX-dd protein
in xx NE
its xxx NE
amino-terminal xxx-xxx protein_B
acidic xxx protein_M
region xxx protein_E
. . NE

Two Xxx NE
tyrosines xxx NE
( ( NE
Y113 Xddd NE
and xxx NE
Y128 Xddd NE
) ) NE
fall xxx NE
within xxx NE
an xx NE
identical xxx NE
five xxx NE
amino-acid xxx-xxx NE
motif xxx NE
and xxx NE
are xxx NE
shown xxx NE
to xx NE
be xx NE
phosphorylated xxx NE
upon xxx NE
TCR XXX NE
ligation xxx NE
. . NE

Although Xxxx NE
mutation xxx NE
of xx NE
either xxx NE
Y113 Xddd NE
and xxx NE
Y128 Xddd NE
has xxx NE
a x NE
minimal xxx NE
effect xxx NE
on xx NE
SLP-76 XXX-dd NE
function xxx NE
, , NE
mutation xxx NE
of xx NE
both xxx NE
residues xxx NE
decreases xxx NE
significantly xxx NE
the xxx NE
ability xxx NE
of xx NE
SLP-76 XXX-dd protein
to xx NE
promote xxx NE
T X NE
cell xxx NE
activation xxx NE
. . NE

A X NE
third xxx NE
tyrosine xxx NE
within xxx NE
the xxx NE
amino-terminal xxx-xxx protein_B
region xxx protein_E
( ( NE
Y145 Xddd NE
) ) NE
appears xxx NE
to xx NE
be xx NE
the xxx NE
most xxx NE
important xxx NE
for xxx NE
optimal xxx NE
SLP-76 XXX-dd protein
function xxx NE
, , NE
as xx NE
altering xxx NE
it xx NE
alone xxx NE
to xx NE
phenylalanine xxx NE
has xxx NE
a x NE
potent xxx NE
impact xxx NE
on xx NE
SLP-76 XXX-dd NE
augmentation xxx NE
of xx NE
NFAT XXXX NE
promoter xxx NE
activity xxx NE
. . NE

Human Xxxx DNA_B
interferon xxx DNA_M
regulatory xxx DNA_M
factor xxx DNA_M
2 d DNA_M
gene xxx DNA_E
. . NE

Intron-exon Xxxx-xxx NE
organization xxx NE
and xxx NE
functional xxx NE
analysis xxx NE
of xx NE
5'-flanking d'-xxx DNA_B
region xxx DNA_E
. . NE

Interferon Xxxx protein_B
regulatory xxx protein_M
factor xxx protein_M
2 d protein_E
( ( NE
IRF-2 XXX-d protein
) ) NE
is xx NE
a x NE
transcriptional xxx protein_B
regulatory xxx protein_M
protein xxx protein_E
that xxx NE
terminates xxx NE
interferon xxx NE
beta xxx NE
expression xxx NE
initiated xxx NE
by xx NE
interferon xxx protein_B
regulatory xxx protein_M
factor xxx protein_M
1 d protein_E
. . NE

In Xx NE
this xxx NE
study xxx NE
, , NE
we xx NE
isolated xxx NE
the xxx NE
genomic xxx DNA_B
DNA XXX DNA_E
for xxx NE
human xxx DNA_B
IRF-2 XXX-d DNA_M
gene xxx DNA_E
, , NE
determined xxx NE
the xxx NE
intron-exon xxx-xxx DNA_B
structure xxx DNA_E
of xx NE
the xxx NE
human xxx DNA_B
IRF-2 XXX-d DNA_M
gene xxx DNA_E
, , NE
mapped xxx NE
the xxx NE
major xxx DNA_B
transcription xxx DNA_M
initiation xxx DNA_M
site xxx DNA_E
, , NE
identified xxx NE
a x NE
number xxx NE
of xx NE
potential xxx NE
regulatory xxx NE
elements xxx NE
in xx NE
the xxx NE
5'-flanking d'-xxx DNA_B
region xxx DNA_E
, , NE
and xxx NE
localized xxx NE
the xxx NE
IRF-2 XXX-d DNA_B
gene xxx DNA_E
on xx NE
human xxx DNA_B
chromosome xxx DNA_M
4 d DNA_E
. . NE

The Xxx NE
IRF-2 XXX-d protein
promoter xxx DNA_B
region xxx DNA_E
contains xxx NE
a x NE
CpG XxX DNA_B
island xxx DNA_E
, , NE
with xxx NE
several xxx NE
GC XX NE
boxes xxx NE
, , NE
a x NE
putative xxx NE
NF-kappa XX-xxx NE
B X NE
-binding -xxx NE
site xxx NE
, , NE
and xxx NE
a x NE
CAAT XXXX NE
box xxx NE
, , NE
but xxx NE
no xx NE
TATA XXXX NE
box xxx NE
. . NE

When Xxxx NE
the xxx NE
promoter xxx DNA_B
region xxx DNA_E
was xxx NE
linked xxx NE
with xxx NE
a x NE
heterologous xxx DNA_B
reporter xxx DNA_M
gene xxx DNA_E
, , NE
we xx NE
found xxx NE
that xxx NE
the xxx NE
promoter xxx DNA_B
region xxx DNA_E
is xx NE
inducible xxx NE
by xx NE
both xxx NE
interferons xxx protein
( ( NE
interferon-alpha xxx-xxx protein_B
and xxx protein_M
interferon-gamma xxx-xxx protein_E
interferon xxx NE
regulatory xxx NE
factor xxx NE
1 d NE
. . NE

The Xxx NE
region xxx NE
which xxx NE
induced xxx NE
these xxx NE
inductions xxx NE
was xxx NE
identified xxx NE
as xx NE
being xxx NE
confined xxx NE
to xx NE
40 dd DNA_B
nucleotides xxx DNA_M
5' d' DNA_E
to xx NE
the xxx NE
major xxx DNA_B
transcriptional xxx DNA_M
initiation xxx DNA_M
site xxx DNA_E
by xx NE
testing xxx NE
a x NE
series xxx NE
of xx NE
clones xxx NE
with xxx NE
truncated xxx DNA_B
promoter xxx DNA_E
of xx NE
IRF-2 XXX-d protein
. . NE

This Xxxx NE
region xxx NE
contains xxx NE
elements xxx NE
which xxx NE
are xxx NE
shared xxx NE
with xxx NE
the xxx NE
transcriptional xxx DNA_B
enhancers xxx DNA_E
of xx NE
other xxx NE
genes xxx NE
including xxx NE
interferon xxx protein_B
regulatory xxx protein_M
factor xxx protein_M
1 d protein_E
, , NE
interferon xxx protein_B
beta xxx protein_E
, , NE
and xxx NE
interferon-inducible xxx-xxx DNA_B
genes xxx DNA_E
. . NE

These Xxxx NE
data xxx NE
suggest xxx NE
that xxx NE
interferon xxx protein_B
regulatory xxx protein_M
factor xxx protein_M
1 d protein_E
not xxx NE
only xxx NE
triggers xxx NE
the xxx NE
activation xxx NE
of xx NE
the xxx NE
interferon xxx NE
signal xxx NE
transduction xxx NE
pathway xxx NE
, , NE
but xxx NE
also xxx NE
may xxx NE
play xxx NE
a x NE
role xxx NE
in xx NE
limiting xxx NE
the xxx NE
duration xxx NE
of xx NE
this xxx NE
response xxx NE
by xx NE
activating xxx NE
the xxx NE
transcription xxx NE
of xx NE
IRF-2 XXX-d protein
. . NE

Interferon Xxxx protein_B
alpha xxx protein_E
selectively xxx NE
affects xxx NE
expression xxx NE
of xx NE
the xxx NE
human xxx protein_B
myeloid xxx protein_M
cell xxx protein_M
nuclear xxx protein_M
differentiation xxx protein_M
antigen xxx protein_E
in xx NE
late xxx cell_type_B
stage xxx cell_type_M
cells xxx cell_type_E
in xx NE
the xxx NE
monocytic xxx NE
but xxx NE
not xxx NE
the xxx NE
granulocytic xxx NE
lineage xxx NE
. . NE

The Xxx NE
human xxx protein_B
myeloid xxx protein_M
cell xxx protein_M
nuclear xxx protein_M
differentiation xxx protein_M
antigen xxx protein_E
( ( NE
MNDA XXXX protein
) ) NE
is xx NE
expressed xxx NE
constitutively xxx NE
in xx NE
cells xxx NE
of xx NE
the xxx NE
myeloid xxx cell_type_B
lineage xxx cell_type_E
, , NE
appearing xxx NE
in xx NE
myeloblast xxx cell_type_B
cells xxx cell_type_E
in xx NE
some xxx NE
cases xxx NE
of xx NE
acute xxx NE
myeloid xxx NE
leukemia xxx NE
and xxx NE
consistently xxx NE
being xxx NE
detected xxx NE
in xx NE
promyelocyte xxx cell_type_B
stage xxx cell_type_M
cells xxx cell_type_E
as xx NE
well xxx NE
as xx NE
in xx NE
all xxx NE
later xxx cell_type_B
stage xxx cell_type_M
cells xxx cell_type_E
including xxx NE
peripheral xxx cell_type_B
blood xxx cell_type_M
monocytes xxx cell_type_E
and xxx NE
granulocytes xxx cell_type
. . NE

The Xxx NE
human xxx cell_line_B
myeloid xxx cell_line_M
leukemia xxx cell_line_M
cell xxx cell_line_M
lines xxx cell_line_E
, , NE
HL-60 XX-dd cell_line
, , NE
U937 Xddd cell_line
, , NE
and xxx NE
THP-1 XXX-d cell_line
, , NE
express xxx NE
similar xxx NE
levels xxx NE
of xx NE
immunochemically xxx NE
detectable xxx NE
MNDA XXXX protein
. . NE

Although Xxxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
MNDA XXXX RNA_B
mRNA xXXX RNA_E
in xx NE
primary xxx cell_type_B
monocytes xxx cell_type_E
is xx NE
very xxx NE
low xxx NE
it xx NE
was xxx NE
up-regulated xx-xxx NE
at xx NE
6 d NE
h x NE
following xxx NE
the xxx NE
addition xxx NE
of xx NE
interferon xxx protein_B
alpha xxx protein_E
. . NE

The Xxx NE
effect xxx NE
of xx NE
interferon xxx protein_B
alpha xxx protein_E
on xx NE
the xxx NE
MNDA XXXX RNA_B
mRNA xXXX RNA_E
is xx NE
also xxx NE
observed xxx NE
in xx NE
the xxx NE
cell xxx cell_line_B
lines xxx cell_line_E
HL-60 XX-dd cell_line
, , NE
U937 Xddd cell_line
, , NE
and xxx NE
THP-1 XXX-d cell_line
. . NE

The Xxx NE
MNDA XXXX NE
mRNA xXXX NE
level xxx NE
in xx NE
primary xxx cell_type_B
granulocytes xxx cell_type_E
was xxx NE
unaffected xxx NE
by xx NE
addition xxx NE
of xx NE
interferon xxx protein_B
alpha xxx protein_E
and xxx NE
other xxx NE
agents xxx NE
including xxx NE
interferon xxx protein_B
gamma xxx protein_E
, , NE
endotoxin xxx protein
, , NE
poly xxx protein_B
(I).poly (X).xxx protein_M
(C) (X) protein_E
, , NE
and xxx NE
FMLP XXXX protein
. . NE

The Xxx NE
MNDA XXXX NE
mRNA xXXX NE
level xxx NE
in xx NE
the xxx NE
myeloid xxx cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
was xxx NE
also xxx NE
unaffected xxx NE
by xx NE
the xxx NE
latter xxx NE
four xxx NE
agents xxx NE
. . NE

Induction Xxxx NE
of xx NE
differentiation xxx NE
in xx NE
the xxx NE
myeloid xxx cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
with xxx NE
phorbol xxx NE
ester xxx NE
induces xxx NE
monocyte xxx NE
differentiation xxx NE
which xxx NE
was xxx NE
accompanied xxx NE
by xx NE
a x NE
decrease xxx NE
in xx NE
MNDA XXXX NE
mRNA xXXX NE
level xxx NE
. . NE

This Xxxx NE
reduced xxx NE
level xxx NE
of xx NE
mRNA xXXX RNA
could xxx NE
then xxx NE
be xx NE
elevated xxx NE
with xxx NE
subsequent xxx NE
interferon xxx protein_B
alpha xxx protein_E
treatment xxx NE
. . NE

The Xxx NE
effects xxx NE
of xx NE
phorbol xxx NE
ester xxx NE
on xx NE
MNDA XXXX RNA_B
mRNA xXXX RNA_E
appeared xxx NE
to xx NE
be xx NE
associated xxx NE
with xxx NE
induced xxx NE
differentiation xxx NE
since xxx NE
inhibiting xxx NE
cell xxx NE
proliferation xxx NE
did xxx NE
not xxx NE
alter xxx NE
the xxx NE
level xxx NE
of xx NE
MNDA XXXX RNA_B
mRNA xXXX RNA_E
and xxx NE
cell xxx NE
cycle xxx NE
variation xxx NE
in xx NE
MNDA XXXX NE
mRNA xXXX NE
levels xxx NE
were xxx NE
not xxx NE
observed xxx NE
. . NE

The Xxx NE
ability xxx NE
of xx NE
interferon xxx protein_B
alpha xxx protein_E
to xx NE
up-regulate xx-xxx NE
MNDA XXXX RNA_B
mRNA xXXX RNA_E
in xx NE
phorbol xxx NE
ester xxx NE
treated xxx NE
myeloid xxx cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
is xx NE
consistent xxx NE
with xxx NE
the xxx NE
observations xxx NE
made xxx NE
in xx NE
primary xxx cell_type_B
monocytes xxx cell_type_E
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Involvement Xxxx NE
of xx NE
transcription xxx protein_B
factor xxx protein_E
YB-1 XX-d protein
in xx NE
human xxx NE
T-cell X-xxx NE
lymphotropic xxx NE
virus xxx NE
type xxx NE
I X NE
basal xxx NE
gene xxx NE
expression xxx NE
. . NE

Sequences Xxxx NE
which xxx NE
control xxx NE
basal xxx NE
human xxx NE
T-cell X-xxx NE
lymphotropic xxx NE
virus xxx NE
type xxx NE
I X NE
( ( NE
HTLV-I XXXX-X NE
) ) NE
transcription xxx NE
likely xxx NE
play xxx NE
an xx NE
important xxx NE
role xxx NE
in xx NE
initiation xxx NE
and xxx NE
maintenance xxx NE
of xx NE
virus xxx NE
replication xxx NE
. . NE

We Xx NE
previously xxx NE
identified xxx NE
and xxx NE
analyzed xxx NE
a x NE
45-nucleotide dd-xxx DNA_B
sequence xxx DNA_E
( ( NE
downstream xxx DNA_B
regulatory xxx DNA_M
element xxx DNA_M
1 d DNA_E
[ [ NE
DRE XXX DNA_B
1 d DNA_E
]) ]) NE
, , NE
+195 +ddd DNA_B
to xx DNA_M
+240 +ddd DNA_E
, , NE
at xx NE
the xxx NE
boundary xxx NE
of xx NE
the xxx NE
R/U5 X/Xd DNA_B
region xxx DNA_E
of xx NE
the xxx NE
long xxx DNA_B
terminal xxx DNA_M
repeat xxx DNA_E
which xxx NE
is xx NE
required xxx NE
for xxx NE
HTLV-I XXXX-X NE
basal xxx NE
transcription xxx NE
. . NE

We Xx NE
identified xxx NE
a x NE
protein xxx NE
, , NE
p37 xdd NE
, , NE
which xxx NE
specifically xxx NE
bound xxx NE
to xx NE
DRE XXX DNA_B
1 d DNA_E
. . NE

An Xx NE
affinity xxx NE
column xxx NE
fraction xxx NE
, , NE
containing xxx NE
p37 xdd protein
, , NE
stimulated xxx NE
HTLV-I XXXX-X NE
transcription xxx NE
approximately xxx NE
12-fold dd-xxx NE
in xx NE
vitro xxx NE
. . NE

We Xx NE
now xxx NE
report xxx NE
the xxx NE
identification xxx NE
of xx NE
a x NE
cDNA xXXX DNA_B
clone xxx DNA_E
( ( NE
15B-7 ddX-d DNA
) ) NE
, , NE
from xxx NE
a x NE
Jurkat Xxxx DNA_B
expression xxx DNA_M
library xxx DNA_E
, , NE
that xxx NE
binds xxx NE
specifically xxx NE
to xx NE
the xxx NE
DRE XXX DNA_B
1 d DNA_M
regulatory xxx DNA_M
sequence xxx DNA_E
. . NE

Binding Xxxx NE
of xx NE
the xxx NE
cDNA xXXX protein_B
fusion xxx protein_M
protein xxx protein_E
, , NE
similarly xxx NE
to xx NE
the xxx NE
results xxx NE
obtained xxx NE
with xxx NE
purified xxx NE
Jurkat Xxxx NE
protein xxx NE
, , NE
was xxx NE
decreased xxx NE
by xx NE
introduction xxx NE
of xx NE
site-specific xxx-xxx NE
mutations xxx NE
in xx NE
the xxx NE
DRE XXX DNA_B
1 d DNA_M
regulatory xxx DNA_M
sequence xxx DNA_E
. . NE

In Xx NE
vitro xxx NE
transcription xxx NE
and xxx NE
translation xxx NE
of xx NE
15B-7 ddX-d DNA_B
cDNA xXXX DNA_E
produced xxx NE
a x NE
fusion xxx protein_B
protein xxx protein_E
which xxx NE
bound xxx NE
specifically xxx NE
to xx NE
the xxx NE
HTLV-I XXXX-X NE
+195 +ddd NE
to xx NE
+240 +ddd NE
oligonucleotide xxx NE
. . NE

The Xxx NE
partial xxx DNA_B
cDNA xXXX DNA_E
encodes xxx NE
a x NE
protein xxx NE
which xxx NE
is xx NE
homologous xxx NE
to xx NE
the xxx NE
C-terminal X-xxx protein_B
196 ddd protein_M
amino xxx protein_M
acids xxx protein_E
of xx NE
the xxx NE
36-kDa dd-xXx protein_B
transcription xxx protein_M
factor xxx protein_E
, , NE
YB-1 XX-d protein
. . NE

Cotransfection Xxxx NE
of xx NE
a x NE
YB-1 XX-d DNA_B
expression xxx DNA_M
plasmid xxx DNA_E
increases xxx NE
HTLV-I XXXX-X NE
basal xxx NE
transcription xxx NE
approximately xxx NE
14-fold dd-xxx NE
in xx NE
Jurkat Xxxx cell_line_B
T X cell_line_M
lymphocytes xxx cell_line_E
. . NE

On Xx NE
the xxx NE
basis xxx NE
of xx NE
the xxx NE
molecular xxx NE
weight xxx NE
, , NE
DNA-binding XXX-xxx NE
characteristics xxx NE
, , NE
and xxx NE
in xx NE
vivo xxx NE
transactivation xxx NE
activity xxx NE
, , NE
we xx NE
suggest xxx NE
that xxx NE
the xxx NE
previously xxx NE
identified xxx NE
DRE XXX DNA_B
1 d DNA_E
-binding -xxx NE
protein xxx NE
, , NE
p37 xdd protein
, , NE
is xx NE
YB-1 XX-d protein
. . NE

Changes Xxxx NE
in xx NE
triiodothyronine xxx NE
( ( NE
T3 Xd NE
) ) NE
mononuclear xxx NE
leukocyte xxx NE
receptor xxx NE
kinetics xxx NE
after xxx NE
T3 Xd NE
administration xxx NE
and xxx NE
multiple xxx NE
cold-air xxx-xxx NE
exposures xxx NE
. . NE

Repeated Xxxx NE
cold-air xxx-xxx NE
exposures xxx NE
increase xxx NE
human xxx NE
triiodothyronine xxx NE
( ( NE
T3 Xd NE
) ) NE
plasma xxx NE
clearance xxx NE
rates xxx NE
. . NE

To Xx NE
study xxx NE
the xxx NE
response xxx NE
of xx NE
the xxx NE
nuclear xxx protein_B
T3 Xd protein_M
receptor xxx protein_E
( ( NE
NT3R XXdX protein
) ) NE
in xx NE
this xxx NE
condition xxx NE
, , NE
binding xxx NE
characteristics xxx NE
were xxx NE
analyzed xxx NE
in xx NE
human xxx cell_type_B
mononuclear xxx cell_type_M
leukocytes xxx cell_type_E
( ( NE
MNL XXX cell_type
) ) NE
. . NE

In Xx NE
addition xxx NE
, , NE
we xx NE
supplemented xxx NE
one xxx NE
group xxx NE
of xx NE
individuals xxx NE
with xxx NE
a x NE
daily xxx NE
oral xxx NE
replacement xxx NE
dose xxx NE
of xx NE
T3 Xd NE
to xx NE
isolate xxx NE
the xxx NE
influence xxx NE
of xx NE
serum xxx NE
thyroxine xxx NE
(T4) (Xd) NE
level xxx NE
and xxx NE
serum xxx NE
thyrotropin xxx NE
(TSH) (XXX) NE
level xxx NE

The Xxx NE
subjects xxx NE
were xxx NE
exposed xxx NE
to xx NE
cold xxx NE
air xxx NE
(4 (d NE
degrees xxx NE
C) X) NE
twice/d xxx/x NE
, , NE
30 dd NE
min/exposure xxx/xxx NE
, , NE
for xxx NE
a x NE
total xxx NE
of xx NE
80 dd NE
exposures xxx NE
. . NE

The Xxx NE
T3 Xd NE
-subjects -xxx NE
received xxx NE
placebo xxx NE
[n [x NE
= = NE
8] d] NE
and xxx NE
the xxx NE
T3 Xd NE
+ + NE
subjects xxx NE
received xxx NE
T3 Xd NE
(30 (dd NE
micrograms/d) xxx/x) NE
[n [x NE
= = NE
8] d] NE
in xx NE
a x NE
double-blind xxx-xxx NE
fashion xxx NE
. . NE

Mononuclear Xxxx cell_type_B
leukocytes xxx cell_type_E
were xxx NE
isolated xxx NE
from xxx NE
peripheral xxx NE
blood xxx NE
before xxx NE
the xxx NE
cold xxx NE
exposure xxx NE
and xxx NE
drug xxx NE
regimen xxx NE
began xxx NE
, , NE
and xxx NE
then xxx NE
after xxx NE
every xxx NE
20 dd NE
exposures xxx NE
. . NE

The Xxx NE
dissociation xxx NE
constant xxx NE
( ( NE
Kd Xx NE
) ) NE
and xxx NE
maximum xxx NE
binding xxx NE
capacity xxx NE
( ( NE
MBC XXX NE
) ) NE
of xx NE
the xxx NE
NT3R XXdX protein
values xxx NE
were xxx NE
log xxx NE
transformed xxx NE
to xx NE
minimize xxx NE
between-subject xxx-xxx NE
variability xxx NE
. . NE

In Xx NE
the xxx NE
T3 Xd NE
+ + NE
group xxx NE
, , NE
serum xxx NE
total xxx NE
thyroxine xxx NE
( ( NE
TT4 XXd NE
) ) NE
, , NE
free xxx NE
T4 Xd NE
( ( NE
FT4 XXd NE
) ) NE
, , NE
and xxx NE
TSH XXX NE
were xxx NE
approx xxx NE
50% dd% NE
lower xxx NE
than xxx NE
both xxx NE
basal-value xxx-xxx NE
and xxx NE
T3-value Xd-xxx NE

The Xxx NE
log10Kd xxxddXx NE
increased xxx NE
0.304 d.ddd NE
+/- +/- NE
0.139 d.ddd NE
(p (x NE
< < NE
0.04) d.dd) NE
and xxx NE
the xxx NE
log10MBC xxxddXXX NE
increased xxx NE
0.49 d.dd NE
+/- +/- NE
0.10 d.dd NE
(p (x NE
< < NE
0.001) d.ddd) NE
in xx NE
the xxx NE
T3 Xd NE
+ + NE
subjects xxx NE
compared xxx NE
to xx NE
baseline xxx NE
. . NE

This Xxxx NE
change xxx NE
in xx NE
MBC XXX NE
represents xxx NE
a x NE
311% ddd% NE
increase xxx NE
in xx NE
the xxx NE
MBC XXX NE
over xxx NE
baseline xxx NE
and xxx NE
a x NE
fivefold xxx NE
increase xxx NE
over xxx NE
placebo-treated xxx-xxx NE
subjects xxx NE
. . NE

The Xxx NE
T3 Xd NE
-group -xxx NE
showed xxx NE
no xx NE
change xxx NE
in xx NE
MBC XXX NE
over xxx NE
the xxx NE
study xxx NE
. . NE

These Xxxx NE
results xxx NE
describe xxx NE
for xxx NE
the xxx NE
first xxx NE
time xxx NE
the xxx NE
rapid xxx NE
modulation xxx NE
of xx NE
the xxx NE
NT3R XXdX protein
in xx NE
response xxx NE
to xx NE
the xxx NE
combined xxx NE
influence xxx NE
of xx NE
cold xxx NE
exposure xxx NE
and xxx NE
reduced xxx NE
circulating xxx NE
T4 Xd NE
and xxx NE
TSH XXX NE
. . NE

HIV-1 XXX-d NE
LTR XXX NE
activity xxx NE
in xx NE
human xxx cell_line_B
CD40-activated XXdd-xxx cell_line_M
B X cell_line_M
lymphocytes xxx cell_line_E
is xx NE
dependent xxx NE
on xx NE
NF-kappaB XX-xxxX protein
. . NE

CD40-stimulated XXdd-xxx cell_line_B
human xxx cell_line_M
B X cell_line_M
lymphocytes xxx cell_line_E
are xxx NE
highly xxx NE
permissive xxx NE
to xx NE
a x NE
productive xxx NE
infection xxx NE
by xx NE
the xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
. . NE

In Xx NE
these xxx NE
cells xxx NE
, , NE
nuclear xxx protein_B
factors xxx protein_E
involved xxx NE
in xx NE
activation xxx NE
of xx NE
the xxx NE
HIV-1 XXX-d DNA_B
LTR XXX DNA_E
, , NE
which xxx NE
contains xxx NE
the xxx NE
transcriptional xxx DNA_B
control xxx DNA_M
elements xxx DNA_E
of xx NE
the xxx NE
virus xxx NE
, , NE
are xxx NE
unknown xxx NE
. . NE

Transient Xxxx NE
expression xxx NE
assays xxx NE
with xxx NE
plasmids xxx NE
containing xxx NE
deleted xxx NE
parts xxx NE
of xx NE
the xxx NE
LTR XXX DNA_B
region xxx DNA_E
linked xxx NE
to xx NE
a x NE
reporter xxx NE
gene xxx NE
showed xxx NE
that xxx NE
the xxx NE
NF-kappaB XX-xxxX DNA_B
binding xxx DNA_M
site xxx DNA_E
was xxx NE
essential xxx NE
for xxx NE
HIV-1 XXX-d NE
LTR XXX NE
activity xxx NE
in xx NE
CD40-stimulated XXdd-xxx cell_line_B
B X cell_line_M
lymphocytes xxx cell_line_E
. . NE

In Xx NE
addition xxx NE
, , NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
and xxx NE
supershift xxx NE
assays xxx NE
revealed xxx NE
that xxx NE
important xxx NE
NF-kappaB XX-xxxX NE
binding xxx NE
activity xxx NE
composed xxx NE
of xx NE
at xx NE
least xxx NE
p50 xdd protein
, , NE
p65 xdd protein
, , NE
and xxx NE
c-Rel x-Xxx protein
NF-kappaB XX-xxxX protein_B
subunits xxx protein_E
was xxx NE
present xxx NE
in xx NE
nuclei xxx NE
of xx NE
CD40-stimulated XXdd-xxx NE
B X NE
cells xxx NE
. . NE

These Xxxx NE
results xxx NE
confirm xxx NE
at xx NE
a x NE
molecular xxx NE
level xxx NE
the xxx NE
ability xxx NE
of xx NE
HIV-1 XXX-d NE
to xx NE
replicate xxx NE
in xx NE
B X cell_type_B
cells xxx cell_type_E
and xxx NE
that xxx NE
this xxx NE
activity xxx NE
is xx NE
strongly xxx NE
associated xxx NE
with xxx NE
NF-kappaB XX-xxxX protein
. . NE

Sequence Xxxx NE
analysis xxx NE
and xxx NE
expression xxx NE
in xx NE
cultured xxx cell_type_B
lymphocytes xxx cell_type_E
of xx NE
the xxx NE
human xxx NE
FOSB XXXX DNA_B
gene xxx DNA_E
( ( NE
G0S3 XdXd DNA
) ) NE
. . NE

G0S3 XdXd DNA
is xx NE
a x NE
member xxx NE
of xx NE
a x NE
set xxx NE
of xx NE
putative xxx DNA_B
G0/G1 Xd/Xd DNA_M
switch xxx DNA_M
regulatory xxx DNA_M
genes xxx DNA_E
( ( NE
G0S XdX DNA_B
genes xxx DNA_E
) ) NE
selected xxx NE
by xx NE
screening xxx NE
cDNA xXXX NE
libraries xxx NE
prepared xxx NE
from xxx NE
human xxx NE
blood xxx NE
mononuclear xxx NE
cells xxx NE
cultured xxx NE
for xxx NE
2 d NE
hr xx NE
with xxx NE
lectin xxx NE
and xxx NE
cycloheximide xxx NE
. . NE

The Xxx NE
sequence xxx NE
shows xxx NE
high xxx NE
homology xxx NE
with xxx NE
the xxx NE
murine xxx DNA_B
FOSB XXXX DNA_M
gene xxx DNA_E
, , NE
which xxx NE
encodes xxx NE
a x NE
component xxx NE
of xx NE
the xxx NE
AP1 XXd protein_B
transcriptional xxx protein_M
regulator xxx protein_E
. . NE

Comparison Xxxx NE
of xx NE
cDNA xXXX DNA
and xxx NE
genomic xxx DNA_B
sequences xxx DNA_E
reveals xxx NE
a x NE
4-exon d-xxx DNA_B
structure xxx DNA_E
characteristic xxx NE
of xx NE
the xxx NE
FOS XXX DNA_B
family xxx DNA_M
of xx DNA_M
genes xxx DNA_E
. . NE

Freshly Xxxx NE
isolated xxx NE
cells xxx NE
show xxx NE
high xxx NE
levels xxx NE
of xx NE
FOSB/G0S3 XXXX/XdXd RNA_B
mRNA xXXX RNA_M
and xxx RNA_M
FOS/G0S7 XXX/XdXd RNA_M
mRNA xXXX RNA_E
culture xxx NE
medium xxx NE
. . NE

The Xxx NE
kinetics xxx NE
of xx NE
expression xxx NE
suggest xxx NE
that xxx NE
the xxx NE
high xxx NE
initial xxx NE
levels xxx NE
are xxx NE
caused xxx NE
by xx NE
the xxx NE
isolation xxx NE
procedure xxx NE
, , NE
and xxx NE
do xx NE
not xxx NE
reflect xxx NE
constitutive xxx NE
expression xxx NE
. . NE

In Xx NE
cells xxx NE
preincubated xxx NE
for xxx NE
a x NE
day xxx NE
, , NE
levels xxx NE
of xx NE
FOS XXX RNA_B
mRNA xXXX RNA_E
reach xxx NE
a x NE
maximum xxx NE
20 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx protein
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
3 d NE
hr xx NE
. . NE

Levels Xxxx NE
of xx NE
FOSB XXXX RNA_B
mRNA xXXX RNA_E
reach xxx NE
a x NE
maximum xxx NE
40 dd NE
min xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
lectin xxx protein
and xxx NE
decline xxx NE
to xx NE
control xxx NE
levels xxx NE
over xxx NE
the xxx NE
next xxx NE
6 d NE
hr xx NE
. . NE

In Xx NE
freshly xxx NE
isolated xxx NE
cells xxx NE
, , NE
both xxx NE
FOS XXX RNA_B
mRNA xXXX RNA_M
and xxx RNA_M
FOSB XXXX RNA_M
mRNA xXXX RNA_E
increase xxx NE
dramatically xxx NE
in xx NE
response xxx NE
to xx NE
the xxx NE
protein xxx NE
synthesis xxx NE
inhibitor xxx NE
cycloheximide xxx NE
. . NE

In Xx NE
preincubated xxx NE
cells xxx NE
, , NE
the xxx NE
cycloheximide xxx NE
response xxx NE
is xx NE
decreased xxx NE
, , NE
especially xxx NE
in xx NE
the xxx NE
case xxx NE
of xx NE
FOSB XXXX DNA
. . NE

These Xxxx NE
differences xxx NE
in xx NE
expression xxx NE
of xx NE
FOS XXX DNA
and xxx NE
FOSB XXXX DNA
suggest xxx NE
different xxx NE
roles xxx NE
and xxx NE
regulation xxx NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
base xxx NE
order-dependent xxx-xxx NE
stem-loop xxx-xxx NE
potential xxx NE
in xx NE
the xxx NE
region xxx NE
of xx NE
the xxx NE
gene xxx NE
are xxx NE
defined xxx NE
. . NE

These Xxxx NE
indicate xxx NE
where xxx NE
base xxx NE
order xxx NE
has xxx NE
been xxx NE
adapted xxx NE
for xxx NE
purposes xxx NE
other xxx NE
than xxx NE
stem-loop xxx-xxx NE
stability xxx NE
(e.g. (x.x. NE
, , NE
encoding xxx NE
proteins xxx NE
or xx NE
gene xxx NE
regulation xxx NE
) ) NE
. . NE

Regions Xxxx NE
of xx NE
low xxx NE
potential xxx NE
in xx NE
a x NE
68.5-kb dd.d-xx NE
genomic xxx NE
segment xxx NE
containing xxx NE
the xxx NE
FOSB XXXX DNA_B
gene xxx DNA_E
suggest xxx NE
that xxx NE
the xxx NE
potential xxx NE
may xxx NE
help xxx NE
locate xxx NE
genes xxx NE
in xx NE
uncharted xxx DNA_B
DNA XXX DNA_M
sequences xxx DNA_E
. . NE

Susceptibility Xxxx NE
to xx NE
natural xxx cell_type_B
killer xxx cell_type_M
cells xxx cell_type_E
and xxx NE
down xxx NE
regulation xxx NE
of xx NE
MHC XXX NE
class xxx NE
I X NE
expression xxx NE
in xx NE
adenovirus xxx cell_line_B
12 dd cell_line_M
transformed xxx cell_line_M
cells xxx cell_line_E
are xxx NE
regulated xxx NE
by xx NE
different xxx NE
E1A XdX DNA_B
domains xxx DNA_E
. . NE

All Xxx NE
human xxx NE
adenoviruses xxx NE
transform xxx NE
rodent xxx cell_type_B
cells xxx cell_type_E
in xx NE
vitro xxx NE
, , NE
but xxx NE
only xxx NE
cells xxx NE
transformed xxx NE
by xx NE
serotypes xxx NE
belonging xxx NE
to xx NE
subgroups xxx NE
subgroup xxx NE
A X NE
(Ad12) (Xxdd) NE
and xxx NE
subgroup xxx NE
B X NE
(Ad3) (Xxd) NE
are xxx NE
tumorigenic xxx NE
for xxx NE
immunocompetent xxx NE
animals xxx NE
. . NE

In Xx NE
these xxx NE
cells xxx NE
, , NE
the xxx NE
expression xxx NE
of xx NE
MHC-class XXX-xxx protein_B
I X protein_M
antigens xxx protein_E
is xx NE
repressed xxx NE
and xxx NE
might xxx NE
allow xxx NE
them xxx NE
to xx NE
escape xxx NE
from xxx NE
recognition xxx NE
by xx NE
cytotoxic xxx cell_type_B
T X cell_type_M
lymphocytes xxx cell_type_E
( ( NE
CTL XXX cell_type
) ) NE
and xxx NE
to xx NE
develop xxx NE
in xx NE
tumor xxx NE
. . NE

Furthermore Xxxx NE
, , NE
these xxx NE
cell xxx cell_line_B
lines xxx cell_line_E
appear xxx NE
resistant xxx NE
to xx NE
lysis xxx NE
by xx NE
natural xxx cell_type_B
killer xxx cell_type_M
(NK) (XX) cell_type_M
cells xxx cell_type_E
. . NE

To Xx NE
determine xxx NE
the xxx NE
E1A XdX DNA_B
domain xxx DNA_E
(s) (x) NE
responsible xxx NE
for xxx NE
these xxx NE
properties xxx NE
several xxx NE
cell xxx cell_line_B
lines xxx cell_line_E
were xxx NE
created xxx NE
by xx NE
transforming xxx NE
baby xxx cell_line_B
rat xxx cell_line_M
kidney xxx cell_line_M
(BRK) (XXX) cell_line_M
cells xxx cell_line_E
with xxx NE
a x NE
set xxx NE
of xx NE
plasmids xxx DNA
expressing xxx NE
different xxx NE
Ad2/Ad12 Xxd/Xxdd protein_B
hybrid xxx protein_M
E1A XdX protein_M
gene xxx protein_M
products xxx protein_E
. . NE

The Xxx NE
MHC XXX NE
class xxx NE
1 d NE
gene xxx NE
expression xxx NE
was xxx NE
inhibited xxx NE
in xx NE
cells xxx NE
expressing xxx NE
the xxx NE
Ad12 Xxdd protein_B
13S ddX protein_M
mRNA xXXX protein_M
product xxx protein_E
and xxx NE
in xx NE
cells xxx NE
transformed xxx NE
with xxx NE
Ad2/Ad12 Xxd/Xxdd protein_B
hybrid xxx protein_M
E1A XdX protein_M
gene xxx protein_M
product xxx protein_E
harboring xxx NE
the xxx NE
C-terminal X-xxx protein_B
part xxx protein_E
of xx NE
the xxx NE
conserved xxx DNA_B
region xxx DNA_M
(CR) (XX) DNA_M
3 d DNA_E
of xx NE
Ad12 Xxdd NE
. . NE

Susceptibility Xxxx NE
of xx NE
these xxx NE
transformed xxx NE
cell xxx cell_line_B
lines xxx cell_line_E
to xx NE
NK XX cell_type_B
cells xxx cell_type_E
was xxx NE
determined xxx NE
by xx NE
cytolytic xxx NE
assays xxx NE
. . NE

The Xxx NE
results xxx NE
obtained xxx NE
suggest xxx NE
that xxx NE
two xxx NE
Ad12 Xxdd DNA_B
E1A XdX DNA_M
domains xxx DNA_E
are xxx NE
required xxx NE
to xx NE
induce xxx NE
resistance xxx NE
of xx NE
the xxx NE
cell xxx cell_line_B
lines xxx cell_line_E
to xx NE
NK XX cell_type_B
cells xxx cell_type_E
. . NE

Cell Xxxx NE
specific xxx NE
expression xxx NE
of xx NE
human xxx DNA_B
Bruton's Xxxx'x DNA_M
agammaglobulinemia xxx DNA_M
tyrosine xxx DNA_M
kinase xxx DNA_M
gene xxx DNA_E
( ( NE
Btk Xxx protein
) ) NE
is xx NE
regulated xxx NE
by xx NE
Sp1- Xxd- protein
and xxx NE
Spi-1/PU.1-family Xxx-d/XX.d-xxx protein_B
members xxx protein_E
. . NE

Bruton's Xxxx'x protein_B
agammaglobulinemia xxx protein_M
tyrosine xxx protein_M
kinase xxx protein_E
( ( NE
Btk Xxx protein
) ) NE
is xx NE
a x NE
cytoplasmic xxx protein_B
tyrosine xxx protein_M
kinase xxx protein_E
involved xxx NE
in xx NE
the xxx NE
human xxx NE
disease xxx NE
X-linked X-xxx NE
agammaglobulinemia xxx NE
( ( NE
XLA XXX NE
) ) NE
. . NE

The Xxx NE
gene xxx NE
is xx NE
expressed xxx NE
in xx NE
all xxx NE
hematopoietic xxx cell_type_B
cells xxx cell_type_E
with xxx NE
the xxx NE
exception xxx NE
of xx NE
T-cells X-xxx cell_type
and xxx NE
plasma xxx cell_type_B
cells xxx cell_type_E
. . NE

For Xxx NE
this xxx NE
expression xxx NE
pattern xxx NE
the xxx NE
first xxx NE
280 ddd DNA_B
bp xx DNA_M
upstream xxx DNA_E
of xx NE
the xxx NE
major xxx DNA_B
transcriptional xxx DNA_M
start xxx DNA_M
site xxx DNA_E
seems xxx NE
to xx NE
be xx NE
sufficient xxx NE
. . NE

In Xx NE
vitro xxx NE
footprinting xxx NE
analysis xxx NE
within xxx NE
this xxx NE
part xxx NE
of xx NE
the xxx NE
promoter xxx DNA
revealed xxx NE
two xxx NE
Sp1 Xxd DNA_B
binding xxx DNA_M
sites xxx DNA_E
as xx NE
well xxx NE
as xx NE
a x NE
PU-box XX-xxx DNA
. . NE

The Xxx NE
transcription xxx protein_B
factor xxx protein_E
Spi-1/PU.1 Xxx-d/XX.d protein
as xx NE
well xxx NE
as xx NE
the xxx NE
closely xxx NE
related xxx NE
factor xxx NE
Spi-B Xxx-X protein
bound xxx NE
to xx NE
the xxx NE
PU-box XX-xxx DNA
in xx NE
B-cells X-xxx NE
. . NE

In Xx NE
the xxx NE
erythroleukemia xxx cell_line_B
cell xxx cell_line_M
line xxx cell_line_M
K562 Xddd cell_line_E
, , NE
due xxx NE
to xx NE
the xxx NE
absence xxx NE
of xx NE
Spi-B Xxx-X protein
, , NE
only xxx NE
PU.1 XX.d protein
bound xxx NE
to xx NE
the xxx NE
Btk Xxx DNA_B
promoter xxx DNA_E
. . NE

Mutation Xxxx NE
of xx NE
either xxx NE
site xxx NE
reduced xxx NE
the xxx NE
expression xxx NE
in xx NE
transient xxx NE
transfection xxx NE
experiments xxx NE
. . NE

However Xxxx NE
, , NE
mutation xxx NE
of xx NE
the xxx NE
PU XX DNA_B
box xxx DNA_E
had xxx NE
no xx NE
effect xxx NE
in xx NE
the xxx NE
T-cell X-xxx cell_line_B
line xxx cell_line_M
Jurkat Xxxx cell_line_E
, , NE
where xxx NE
none xxx NE
of xx NE
the xxx NE
Spi-1 Xxx-d protein_B
family xxx protein_M
members xxx protein_E
is xx NE
expressed xxx NE
. . NE

In Xx NE
addition xxx NE
Spi-B Xxx-X protein
as xx NE
well xxx NE
as xx NE
PU.1 XX.d protein
were xxx NE
able xxx NE
to xx NE
transactivate xxx NE
Btk Xxx NE
expression xxx NE
. . NE

In Xx NE
fetal xxx NE
liver xxx NE
of xx NE
PU.1-/- XX.d-/- NE
mice xxx NE
, , NE
which xxx NE
lack xxx NE
lymphoid xxx cell_type_B
cell xxx cell_type_M
and xxx cell_type_M
myeloid xxx cell_type_M
cell xxx cell_type_E
Btk Xxx NE
was xxx NE
reduced xxx NE
two- xxx- NE
to xx NE
threefold xxx NE
but xxx NE
not xxx NE
abolished xxx NE
. . NE

Collectively Xxxx NE
this xxx NE
study xxx NE
shows xxx NE
that xxx NE
expression xxx NE
of xx NE
the xxx NE
Btk Xxx DNA_B
gene xxx DNA_E
is xx NE
regulated xxx NE
by xx NE
the xxx NE
combined xxx NE
action xxx NE
of xx NE
Sp1-family Xxd-xxx protein_B
member xxx protein_M
and xxx protein_M
PU.1-family XX.d-xxx protein_M
member xxx protein_E

T X NE
cell xxx NE
response xxx NE
to xx NE
Epstein-Barr Xxxx-Xxxx protein_B
virus xxx protein_M
transactivators xxx protein_E
in xx NE
chronic xxx NE
rheumatoid xxx NE
arthritis xxx NE
. . NE

Rheumatoid Xxxx NE
arthritis xxx NE
is xx NE
a x NE
multistep xxx NE
disorder xxx NE
associated xxx NE
with xxx NE
autoimmune xxx NE
features xxx NE
of xx NE
yet xxx NE
unknown xxx NE
etiology xxx NE
. . NE

Implication Xxxx NE
of xx NE
viruses xxx NE
such xxx NE
as xx NE
Epstein-Barr Xxxx-Xxxx NE
virus xxx NE
( ( NE
EBV XXX NE
) ) NE
in xx NE
rheumatoid xxx NE
arthritis xxx NE
pathogenesis xxx NE
has xxx NE
been xxx NE
suspected xxx NE
on xx NE
the xxx NE
basis xxx NE
of xx NE
several xxx NE
indirect xxx NE
observations xxx NE
, , NE
but xxx NE
thus xxx NE
far xxx NE
, , NE
a x NE
direct xxx NE
link xxx NE
between xxx NE
EBV XXX NE
and xxx NE
rheumatoid xxx NE
arthritis xxx NE
has xxx NE
not xxx NE
been xxx NE
provided xxx NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
a x NE
large xxx NE
fraction xxx NE
of xx NE
T X cell_type_B
cells xxx cell_type_E
infiltrating xxx NE
affected xxx NE
joints xxx NE
from xxx NE
a x NE
patient xxx NE
with xxx NE
chronic xxx NE
rheumatoid xxx NE
arthritis xxx NE
recognizes xxx NE
two xxx NE
EBV XXX protein_B
transactivators xxx protein_E
( ( NE
BZLF1 XXXXd protein
and xxx NE
BMLF1 XXXXd protein
) ) NE
in xx NE
a x NE
major xxx NE
histocompatibility xxx NE
complex xxx NE
-restricted -xxx NE
fashion xxx NE
. . NE

Responses Xxxx NE
to xx NE
these xxx NE
EBV XXX protein_B
antigens xxx protein_E
by xx NE
synovial xxx NE
lymphocytes xxx NE
from xxx NE
several xxx NE
other xxx NE
chronic xxx NE
rheumatoid xxx NE
arthritis xxx NE
patients xxx NE
were xxx NE
readily xxx NE
detectable xxx NE
. . NE

Thus Xxxx NE
these xxx NE
results xxx NE
suggest xxx NE
a x NE
direct xxx NE
contribution xxx NE
of xx NE
EBV XXX NE
to xx NE
chronic xxx NE
rheumatoid xxx NE
arthritis xxx NE
pathogenesis xxx NE
. . NE

They Xxxx NE
also xxx NE
demonstrate xxx NE
for xxx NE
the xxx NE
first xxx NE
time xxx NE
the xxx NE
occurrence xxx NE
of xx NE
T X NE
cell xxx NE
responses xxx NE
against xxx NE
EBV XXX protein_B
transactivating xxx protein_M
factors xxx protein_E
, , NE
which xxx NE
might xxx NE
be xx NE
central xxx NE
in xx NE
the xxx NE
control xxx NE
of xx NE
virus xxx NE
reactivation xxx NE
. . NE

CD14 XXdd NE
-mediated -xxx NE
signal xxx NE
pathway xxx NE
of xx NE
Porphyromonas Xxxx NE
gingivalis xxx NE
lipopolysaccharide xxx NE
in xx NE
human xxx NE
gingival xxx NE
fibroblasts xxx NE
. . NE

Lipopolysaccharide Xxxx NE
( ( NE
LPS XXX NE
) ) NE
induces xxx NE
expression xxx NE
of xx NE
inflammatory xxx protein_B
cytokines xxx protein_E
in xx NE
monocytes/macrophages xxx/xxx cell_type
via xxx NE
CD14 XXdd protein
, , NE
one xxx NE
of xx NE
the xxx NE
LPS XXX protein_B
receptors xxx protein_E
, , NE
which xxx NE
is xx NE
expressed xxx NE
predominantly xxx NE
in xx NE
these xxx NE
cells xxx NE
. . NE

It Xx NE
has xxx NE
been xxx NE
demonstrated xxx NE
that xxx NE
Porphyromonas Xxxx NE
gingivalis xxx NE
LPS XXX NE
( ( NE
P- X- NE
LPS XXX NE
) ) NE
also xxx NE
is xx NE
able xxx NE
to xx NE
induce xxx NE
inflammatory xxx NE
cytokines xxx NE
in xx NE
human xxx NE
gingival xxx NE
fibroblasts xxx NE
. . NE

Therefore Xxxx NE
, , NE
it xx NE
is xx NE
important xxx NE
to xx NE
determine xxx NE
whether xxx NE
CD14 XXdd protein
is xx NE
expressed xxx NE
in xx NE
gingival xxx cell_type_B
fibroblasts xxx cell_type_E
and xxx NE
to xx NE
define xxx NE
the xxx NE
P- X- NE
LPS XXX NE
-mediated -xxx NE
signal-transducing xxx-xxx NE
mechanism xxx NE
in xx NE
the xxx NE
cells xxx NE
. . NE

In Xx NE
this xxx NE
study xxx NE
, , NE
we xx NE
observed xxx NE
unexpectedly xxx NE
by xx NE
immunohistochemical, xxx, NE
Western Xxxx NE
blotting xxx NE
( ( NE
immunoblotting xxx NE
) ) NE
, , NE
and xxx NE
Northern Xxxx NE
(RNA) (XXX) NE
blotting xxx NE
assays xxx NE
that xxx NE
CD14 XXdd protein
is xx NE
expressed xxx NE
at xx NE
high xxx NE
density xxx NE
in xx NE
human xxx cell_type_B
gingival xxx cell_type_M
fibroblasts xxx cell_type_E
. . NE

P- X- NE
LPS XXX NE
-induced -xxx NE
expression xxx NE
of xx NE
the xxx NE
monocyte xxx NE
chemoattractant xxx NE
protein xxx NE
1 d NE
( ( NE
MCP-1 XXX-d NE
) ) NE
gene xxx NE
in xx NE
the xxx NE
cells xxx NE
was xxx NE
inhibited xxx NE
markedly xxx NE
by xx NE
treatment xxx NE
with xxx NE
anti-human xxx-xxx NE
CD14 XXdd NE
antibody xxx NE
and xxx NE
was xxx NE
completely xxx NE
inhibited xxx NE
by xx NE
herbimycin xxx NE
A X NE
, , NE
a x NE
potent xxx NE
inhibitor xxx NE
of xx NE
tyrosine xxx NE
kinase xxx NE
. . NE

The Xxx NE
inhibitor xxx NE
also xxx NE
dramatically xxx NE
inhibited xxx NE
monocyte xxx NE
chemotactic xxx NE
activity xxx NE
of xx NE
and xxx NE
MCP-1 XXX-d NE
production xxx NE
by xx NE
the xxx NE
cells xxx NE
. . NE

Furthermore Xxxx NE
, , NE
P- X- NE
LPS XXX NE
-induced -xxx NE
expression xxx NE
of xx NE
the xxx NE
MCP-1 XXX-d NE
gene xxx NE
in xx NE
the xxx NE
cells xxx NE
also xxx NE
was xxx NE
blocked xxx NE
by xx NE
inhibitors xxx NE
of xx NE
two xxx NE
transcription xxx NE
factors xxx NE
, , NE
i.e. x.x. NE
, , NE
curcumin xxx NE
, , NE
an xx NE
inhibitor xxx NE
of xx NE
AP-1 XX-d NE
, , NE
and xxx NE
pyrolidine xxx NE
dithiocarbamate xxx NE
, , NE
an xx NE
inhibitor xxx NE
of xx NE
NF-kappaB XX-xxxX NE
. . NE

Both Xxxx NE
inhibitors xxx NE
inhibited xxx NE
monocyte xxx NE
chemotactic xxx NE
activity xxx NE
in xx NE
the xxx NE
culture xxx NE
supernatant xxx NE
of xx NE
P- X- NE
LPS XXX NE
-treated -xxx NE
cells xxx NE
. . NE

Gel Xxx NE
shift xxx NE
mobility xxx NE
assay xxx NE
showed xxx NE
stimulation xxx NE
of xx NE
the xxx NE
AP-1 XX-d protein
and xxx NE
NF-kappaB XX-xxxX protein
contents xxx NE
in xx NE
P- X- NE
LPS XXX NE
-treated -xxx NE
cells xxx NE
. . NE

This Xxxx NE
study xxx NE
is xx NE
the xxx NE
first xxx NE
to xx NE
demonstrate xxx NE
the xxx NE
expression xxx NE
of xx NE
CD14 XXdd protein
in xx NE
human xxx cell_type_B
gingival xxx cell_type_M
fibroblasts xxx cell_type_E
and xxx NE
to xx NE
show xxx NE
that xxx NE
the xxx NE
signal-transducing xxx-xxx NE
pathway xxx NE
of xx NE
P- X- NE
LPS XXX NE
in xx NE
the xxx NE
cells xxx NE
is xx NE
mediated xxx NE
by xx NE
CD14 XXdd protein
. . NE

rel xxx protein
Is Xx NE
rapidly xxx NE
tyrosine-phosphorylated xxx-xxx NE
following xxx NE
granulocyte-colony xxx-xxx NE
stimulating xxx NE
factor xxx NE
treatment xxx NE
of xx NE
human xxx NE
neutrophils xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
neutrophils xxx cell_type
with xxx NE
granulocyte-colony xxx-xxx protein_B
stimulating xxx protein_M
factor xxx protein_E
( ( NE
G-CSF X-XXX protein
) ) NE
results xxx NE
in xx NE
an xx NE
enhanced xxx NE
respiratory xxx NE
burst xxx NE
, , NE
prolonged xxx NE
survival xxx NE
, , NE
and xxx NE
increased xxx NE
tumor xxx NE
cell xxx NE
killing xxx NE
. . NE

The Xxx NE
effects xxx NE
of xx NE
G-CSF X-XXX protein
are xxx NE
mediated xxx NE
by xx NE
binding xxx NE
to xx NE
specific xxx NE
, , NE
high xxx NE
affinity xxx protein_B
receptors xxx protein_E
. . NE

G-CSF X-XXX protein_B
receptors xxx protein_E
lack xxx NE
intrinsic xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
, , NE
but xxx NE
activation xxx NE
of xx NE
the xxx NE
receptor xxx NE
results xxx NE
in xx NE
the xxx NE
rapid xxx NE
induction xxx NE
of xx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
. . NE

Antiphosphotyrosine Xxxx NE
immunoblots xxx NE
of xx NE
whole xxx NE
cell xxx NE
lysates xxx NE
prepared xxx NE
from xxx NE
neutrophils xxx cell_type
show xxx NE
that xxx NE
the xxx NE
G-CSF X-XXX protein
rapidly xxx NE
induces xxx NE
prominent xxx NE
tyrosine xxx NE
phosphorylation xxx NE
of xx NE
a x NE
protein xxx NE
of xx NE
a x NE
relative xxx NE
molecular xxx NE
mass xxx NE
of xx NE
80 dd NE
kDa xXx NE
. . NE

Using Xxxx NE
monospecific xxx NE
antibodies xxx NE
, , NE
the xxx NE
80-kDa dd-xXx NE
tyrosine xxx NE
-phosphorylated -xxx NE
protein xxx NE
has xxx NE
been xxx NE
shown xxx NE
to xx NE
be xx NE
p80c-rel xddx-xxx NE
, , NE
a x NE
proto-oncogene xxx-xxx NE
belonging xxx NE
to xx NE
a x NE
family xxx NE
of xx NE
transcriptional xxx NE
regulators xxx NE
which xxx NE
include xxx NE
NF-kB XX-xX NE
. . NE

The Xxx NE
induction xxx NE
of xx NE
tyrosine xxx NE
phosphorylation xxx NE
of xx NE
p80c-rel xddx-xxx protein
was xxx NE
unique xxx NE
to xx NE
G-CSF X-XXX protein
in xx NE
that xxx NE
granulocyte-macrophage xxx-xxx protein_B
colony xxx protein_M
stimulating xxx protein_M
factor xxx protein_E
which xxx NE
also xxx NE
stimulates xxx NE
neutrophils xxx cell_type
and xxx NE
induces xxx NE
tyrosine xxx NE
phosphorylation xxx NE
does xxx NE
not xxx NE
result xxx NE
in xx NE
tyrosine xxx NE
phosphorylation xxx NE
of xx NE
p80c-rel xddx-xxx protein
. . NE

The Xxx NE
consequences xxx NE
of xx NE
p80c-rel xddx-xxx protein
tyrosine xxx NE
phosphorylation xxx NE
are xxx NE
not xxx NE
yet xxx NE
known xxx NE
; ; NE
however xxx NE
, , NE
tyrosine xxx NE
-phosphorylated -xxx NE
p80c-rel xddx-xxx protein
is xx NE
capable xxx NE
of xx NE
binding xxx NE
to xx NE
DNA XXX NE
, , NE
and xxx NE
G-CSF X-XXX NE
stimulation xxx NE
results xxx NE
in xx NE
an xx NE
increase xxx NE
in xx NE
the xxx NE
amount xxx NE
of xx NE
p80c-rel xddx-xxx protein
which xxx NE
binds xxx NE
to xx NE
DNA XXX NE
. . NE

These Xxxx NE
results xxx NE
demonstrate xxx NE
that xxx NE
one xxx NE
of xx NE
the xxx NE
first xxx NE
biochemical xxx NE
events xxx NE
which xxx NE
occurs xxx NE
in xx NE
neutrophils xxx cell_type
following xxx NE
G-CSF X-XXX NE
stimulation xxx NE
, , NE
activation xxx NE
of xx NE
a x NE
tyrosine xxx protein_B
kinase xxx protein_E
, , NE
leads xxx NE
directly xxx NE
to xx NE
the xxx NE
tyrosine xxx NE
phosphorylation xxx NE
of xx NE
p80c-rel xddx-xxx protein
. . NE

Thus Xxxx NE
, , NE
the xxx NE
tyrosine xxx protein_B
kinase xxx protein_E
activated xxx NE
by xx NE
G-CSF X-XXX protein
appears xxx NE
to xx NE
directly xxx NE
transduce xxx NE
a x NE
signal xxx NE
to xx NE
a x NE
protein xxx NE
which xxx NE
functions xxx NE
as xx NE
a x NE
transcriptional xxx protein_B
regulator xxx protein_E
. . NE

Patterns Xxxx NE
of xx NE
Pan Xxx NE
expression xxx NE
and xxx NE
role xxx NE
of xx NE
Pan Xxx protein_B
proteins xxx protein_E
in xx NE
endocrine xxx NE
cell xxx NE
type-specific xxx-xxx NE
complex xxx NE
formation xxx NE
. . NE

The Xxx NE
Pan Xxx DNA_B
gene xxx DNA_E
encodes xxx NE
at xx NE
least xxx NE
two xxx NE
distinct xxx NE
transcripts xxx NE
, , NE
Pan-1 Xxx-d protein
and xxx NE
Pan-2 Xxx-d protein
(also (xxx NE
known xxx NE
as xx NE
E47 Xdd protein
and xxx NE
E12 Xdd protein
, , NE
respectively) xxx) NE
, , NE
by xx NE
the xxx NE
mechanism xxx NE
of xx NE
alternative xxx NE
RNA XXX NE
splicing xxx NE
. . NE

Northern Xxxx NE
blot xxx NE
analyses xxx NE
performed xxx NE
on xx NE
rat xxx NE
tissue xxx NE
and xxx NE
mouse xxx NE
tissue xxx NE
Pan Xxx NE
proteins xxx NE
have xxx NE
not xxx NE
been xxx NE
clearly xxx NE
defined xxx NE
. . NE

Studies Xxxx NE
of xx NE
cell xxx cell_line_B
lines xxx cell_line_E
representing xxx NE
endocrine xxx cell_type_B
lineage xxx cell_type_M
and xxx cell_type_M
fibroblast xxx cell_type_M
lineage xxx cell_type_M
and xxx cell_type_M
lymphoid xxx cell_type_M
lineage xxx cell_type_E
using xxx NE
polyclonal xxx NE
antisera xxx NE
to xx NE
detect xxx NE
E2A XdX protein_B
proteins xxx protein_E
have xxx NE
suggested xxx NE
that xxx NE
significant xxx NE
E2A XdX NE
protein xxx NE
expression xxx NE
is xx NE
restricted xxx NE
to xx NE
B-lymphocytes X-xxx cell_type
. . NE

We Xx NE
have xxx NE
developed xxx NE
a x NE
monoclonal xxx protein_B
antibody xxx protein_E
, , NE
Yae Xxx protein
, , NE
which xxx NE
is xx NE
specific xxx NE
for xxx NE
Pan/ Xxx/ protein
E2A XdX NE
proteins xxx NE
, , NE
and xxx NE
have xxx NE
used xxx NE
the xxx NE
Yae Xxx protein_B
antibody xxx protein_E
to xx NE
examine xxx NE
a x NE
variety xxx NE
of xx NE
endocrine xxx cell_type_B
cell xxx cell_type_M
lineage xxx cell_type_M
and xxx cell_type_M
nonendocrine xxx cell_type_M
cell xxx cell_type_M
lineage xxx cell_type_E
E2A XdX NE
protein xxx NE
expression xxx NE
, , NE
subcellular xxx NE
localization xxx NE
, , NE
and xxx NE
heteromeric xxx NE
complex xxx NE
formation xxx NE
. . NE

In Xx NE
contrast xxx NE
to xx NE
previous xxx NE
results xxx NE
obtained xxx NE
using xxx NE
polyclonal xxx NE
antiseras xxx NE
to xx NE
detect xxx NE
Pan Xxx NE
/ / NE
E2A XdX protein_B
proteins xxx protein_E
, , NE
we xx NE
report xxx NE
comparable xxx NE
levels xxx NE
of xx NE
Pan Xxx protein_B
proteins xxx protein_E
in xx NE
GH/PRL-producing XX/XXX-xxx cell_line_B
lymphocyte xxx cell_line_M
cell xxx cell_line_M
and xxx cell_line_M
insulin-producing xxx-xxx cell_line_M
lymphocyte xxx cell_line_M
cell xxx cell_line_M
and xxx cell_line_M
B-lymphocyte X-xxx cell_line_M
cell xxx cell_line_M
and xxx cell_line_M
T-lymphocyte X-xxx cell_line_M
cell xxx cell_line_E

IEF-1 XXX-d protein
, , NE
a x NE
pancreatic xxx NE
beta-cell xxx-xxx NE
type-specific xxx-xxx NE
complex xxx NE
believed xxx NE
to xx NE
regulate xxx NE
insulin xxx NE
expression xxx NE
, , NE
is xx NE
demonstrated xxx NE
to xx NE
consist xxx NE
of xx NE
at xx NE
least xxx NE
two xxx NE
distinct xxx NE
species xxx NE
, , NE
one xxx NE
of xx NE
which xxx NE
does xxx NE
not xxx NE
contain xxx NE
Pan Xxx protein_B
molecules xxx protein_E
. . NE

Although Xxxx NE
it xx NE
has xxx NE
been xxx NE
postulated xxx NE
that xxx NE
pituitary xxx cell_type_B
endocrine xxx cell_type_M
cells xxx cell_type_E
and xxx NE
pancreatic xxx cell_type_B
endocrine xxx cell_type_M
beta-cells xxx-xxx cell_type_E
share xxx NE
identical xxx NE
Pan/E2A Xxx/XdX NE
complexes xxx NE
, , NE
native-Western xxx-Xxxx NE
analyses xxx NE
of xx NE
pituitary xxx NE
and xxx NE
endocrine xxx NE
beta-cells xxx-xxx NE
detect xxx NE
Pan Xxx NE
proteins xxx NE
in xx NE
distinct xxx NE
cell xxx NE
type-specific xxx-xxx NE
complexes xxx NE
. . NE

Visualization Xxxx NE
of xx NE
the xxx NE
endogenous xxx protein_B
NF-kappa XX-xxx protein_M
B X protein_M
p50 xdd protein_M
subunit xxx protein_E
in xx NE
the xxx NE
nucleus xxx NE
of xx NE
follicular xxx cell_type_B
dendritic xxx cell_type_M
cells xxx cell_type_E
in xx NE
germinal xxx NE
centers xxx NE
. . NE

NF-kappa XX-xxx protein_B
B X protein_E
, , NE
a x NE
50 dd protein_B
kDa/65 xXx/dd protein_M
kDa xXx protein_M
(p50/p65) (xdd/xdd) protein_M
heterodimer xxx protein_E
, , NE
is xx NE
a x NE
ubiquitous xxx protein_B
transcription xxx protein_M
factor xxx protein_E
involved xxx NE
in xx NE
the xxx NE
positive xxx NE
regulation xxx NE
of xx NE
various xxx NE
immune xxx DNA_B
genes xxx DNA_E
. . NE

The Xxx NE
aim xxx NE
of xx NE
this xxx NE
study xxx NE
was xxx NE
to xx NE
determine xxx NE
whether xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
is xx NE
related xxx NE
to xx NE
a x NE
particular xxx NE
cell xxx NE
type xxx NE
and/or xxx/xx NE
differentiation xxx NE
step xxx NE
during xxx NE
immunopoiesis xxx NE
. . NE

Using Xxxx NE
in xx NE
situ xxx NE
hybridization xxx NE
on xx NE
sections xxx NE
from xxx NE
non xxx NE
HIV XXX NE
hyperplastic xxx NE
lymph xxx NE
nodes xxx NE
, , NE
we xx NE
found xxx NE
that xxx NE
the xxx NE
gene xxx NE
of xx NE
the xxx NE
105 ddd protein_B
kDa xXx protein_M
precursor xxx protein_E
of xx NE
p50 xdd protein
was xxx NE
overexpressed xxx NE
in xx NE
the xxx NE
light xxx NE
zone xxx NE
of xx NE
germinal xxx NE
centers xxx NE
, , NE
with xxx NE
a x NE
network xxx NE
aspect xxx NE
, , NE
which xxx NE
suggested xxx NE
the xxx NE
involvement xxx NE
of xx NE
follicular xxx cell_type_B
dendritic xxx cell_type_M
cells xxx cell_type_E
( ( NE
FDC XXX cell_type
) ) NE
. . NE

By Xx NE
immunohistochemistry xxx NE
, , NE
p50 xdd protein
protein xxx NE
was xxx NE
detected xxx NE
in xx NE
the xxx NE
cytoplasm xxx NE
and xxx NE
nucleus xxx NE
of xx NE
FDC XXX cell_type
, , NE
confirming xxx NE
the xxx NE
involvement xxx NE
of xx NE
FDC XXX cell_type
. . NE

Furthermore Xxxx NE
, , NE
p50 xdd protein
protein xxx NE
was xxx NE
detected xxx NE
in xx NE
the xxx NE
cytoplasm xxx NE
of xx NE
all xxx NE
lymphocytes xxx cell_type
. . NE

Thus Xxxx NE
, , NE
we xx NE
focused xxx NE
our xxx NE
study xxx NE
on xx NE
isolated xxx NE
FDC XXX cell_type
clusters xxx NE
from xxx NE
normal xxx NE
tonsils xxx NE
. . NE

As Xx NE
showed xxx NE
on xx NE
tissue xxx NE
sections xxx NE
, , NE
we xx NE
detected xxx NE
the xxx NE
p50 xdd protein
in xx NE
both xxx NE
cytoplasm xxx NE
and xxx NE
nucleus xxx NE
of xx NE
FDC XXX cell_type
. . NE

Nuclei Xxxx NE
of xx NE
lymphocytes xxx cell_type
from xxx NE
FDC XXX cell_type
clusters xxx NE
were xxx NE
negative xxx NE
. . NE

We Xx NE
next xxx NE
studied xxx NE
p65 xdd NE
protein xxx NE
expression xxx NE
and xxx NE
c-Rel x-Xxx NE
protein xxx NE
expression xxx NE
FDC XXX NE
clusters xxx NE
. . NE

p65 xdd protein
was xxx NE
detected xxx NE
in xx NE
the xxx NE
cytoplasm xxx NE
of xx NE
FDC XXX cell_type
, , NE
whereas xxx NE
nuclei xxx NE
were xxx NE
negative xxx NE
. . NE

Furthermore Xxxx NE
, , NE
p65 xdd protein
was xxx NE
detected xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
some xxx NE
lymphocytes xxx NE
. . NE

c-Rel x-Xxx protein_B
protein xxx protein_E
was xxx NE
detected xxx NE
only xxx NE
in xx NE
the xxx NE
cytoplasm xxx NE
of xx NE
lymphocytes xxx cell_type
and xxx NE
not xxx NE
in xx NE
the xxx NE
nucleus xxx NE
and xxx NE
cytoplasm xxx NE
of xx NE
FDC XXX cell_type
. . NE

Our Xxx NE
results xxx NE
indicated xxx NE
that xxx NE
, , NE
in xx NE
the xxx NE
context xxx NE
of xx NE
T X NE
cell-dependent xxx-xxx NE
B X NE
cell xxx NE
immunopoiesis xxx NE
occurring xxx NE
in xx NE
FDC XXX cell_type
clusters xxx NE
, , NE
p50 xdd protein
is xx NE
mainly xxx NE
related xxx NE
to xx NE
FDC XXX cell_type
with xxx NE
a x NE
massive xxx NE
overexpression xxx NE
in xx NE
the xxx NE
nuclei xxx NE
, , NE
whereas xxx NE
p65 xdd NE
is xx NE
expressed xxx NE
in xx NE
a x NE
scattered xxx NE
manner xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
lymphocytes xxx NE
and xxx NE
c-Rel x-Xxx NE
protein xxx NE
exclusively xxx NE
in xx NE
the xxx NE
cytoplasm xxx NE
of xx NE
lymphocytes xxx NE
from xxx NE
FDC XXX NE
clusters xxx NE
. . NE

These Xxxx NE
results xxx NE
suggested xxx NE
that xxx NE
the xxx NE
two xxx NE
subunits xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
and xxx NE
the xxx NE
c-Rel x-Xxx protein_B
protein xxx protein_E
have xxx NE
different xxx NE
roles xxx NE
in xx NE
different xxx NE
cell xxx NE
types xxx NE
during xxx NE
B X NE
cell xxx NE
immunopoiesis xxx NE
. . NE

Cloning Xxxx NE
and xxx NE
characterization xxx NE
of xx NE
NF-ATc XX-XXx protein
and xxx NE
NF-ATp XX-XXx protein
: : NE
the xxx NE
cytoplasmic xxx NE
components xxx NE
of xx NE
NF-AT XX-XX NE
. . NE

Present Xxxx NE
evidence xxx NE
indicates xxx NE
a x NE
pathway xxx NE
of xx NE
signal xxx NE
transmission xxx NE
in xx NE
T X cell_type_B
cells xxx cell_type_E
that xxx NE
is xx NE
outlined xxx NE
in xx NE
figure xxx NE
1 d NE
. . NE

The Xxx NE
elevation xxx NE
in xx NE
intracellular xxx NE
calcium xxx NE
that xxx NE
is xx NE
induced xxx NE
by xx NE
interactions xxx NE
at xx NE
the xxx NE
antigen xxx protein_B
receptor xxx protein_E
leads xxx NE
to xx NE
the xxx NE
activation xxx NE
of xx NE
the xxx NE
calcium-dependent xxx-xxx protein_B
phosphatase xxx protein_E
calcineurin xxx protein
. . NE

This Xxxx NE
in xx NE
turn xxx NE
leads xxx NE
to xx NE
the xxx NE
nuclear xxx NE
association xxx NE
of xx NE
the xxx NE
cytosolic xxx protein_B
component xxx protein_E
of xx NE
NF-ATc XX-XXx protein
. . NE

The Xxx NE
activation xxx NE
of xx NE
calcineurin xxx protein
and xxx NE
the xxx NE
nuclear xxx NE
import xxx NE
of xx NE
NF-ATc XX-XXx protein
can xxx NE
both xxx NE
be xx NE
blocked xxx NE
by xx NE
cyclosporin xxx NE
A X NE
or xx NE
FK506 XXddd NE
in xx NE
complex xxx NE
with xxx NE
their xxx NE
respective xxx NE
immunophilins xxx protein
. . NE

Once Xxxx NE
in xx NE
the xxx NE
nucleus xxx NE
, , NE
NF-ATc XX-XXx protein
interacts xxx NE
with xxx NE
NF-ATn XX-XXx protein
to xx NE
form xxx NE
an xx NE
active xxx protein_B
transcriptional xxx protein_M
complex xxx protein_E
. . NE

NF-ATn XX-XXx protein
is xx NE
a x NE
ubiquitous xxx NE
protein xxx NE
, , NE
can xxx NE
be xx NE
synthesized xxx NE
in xx NE
response xxx NE
to xx NE
PMA XXX NE
, , NE
and xxx NE
has xxx NE
many xxx NE
similarities xxx NE
to xx NE
AP-1 XX-d protein
. . NE

The Xxx NE
mechanism xxx NE
by xx NE
which xxx NE
NF-ATc XX-XXx protein
enters xxx NE
the xxx NE
nucleus xxx NE
is xx NE
unknown xxx NE
, , NE
and xxx NE
although xxx NE
it xx NE
appears xxx NE
to xx NE
require xxx NE
calcineurin xxx protein
, , NE
NF-ATc XX-XXx protein
has xxx NE
not xxx NE
yet xxx NE
been xxx NE
shown xxx NE
to xx NE
be xx NE
an xx NE
in xx NE
vivo xxx NE
substrate xxx NE
of xx NE
calcineurin xxx protein
. . NE

Alternative Xxxx NE
mechanisms xxx NE
include xxx NE
the xxx NE
possibility xxx NE
that xxx NE
NF-ATc XX-XXx protein
operates xxx NE
on xx NE
some xxx NE
cytoplasmic xxx protein_B
anchor xxx protein_E
or xx NE
that xxx NE
other xxx NE
proteins xxx NE
that xxx NE
are xxx NE
controlled xxx NE
by xx NE
calcineurin xxx protein
carry xxx NE
out xxx NE
the xxx NE
nuclear xxx NE
import xxx NE
of xx NE
NF-ATc XX-XXx protein
. . NE

Although Xxxx NE
NF-ATp XX-XXx protein
copurifies xxx NE
with xxx NE
NF-ATc XX-XXx protein
, , NE
there xxx NE
is xx NE
as xx NE
yet xxx NE
no xx NE
understanding xxx NE
of xx NE
how xxx NE
NF-ATp XX-XXx protein
is xx NE
functioning xxx NE
in xx NE
vivo xxx NE
. . NE

Now Xxx NE
that xxx NE
these xxx NE
proteins xxx NE
are xxx NE
purified xxx NE
and xxx NE
cloned xxx NE
, , NE
the xxx NE
major xxx NE
goals xxx NE
will xxx NE
be xx NE
to xx NE
understand xxx NE
their xxx NE
role xxx NE
and xxx NE
the xxx NE
roles xxx NE
of xx NE
other xxx NE
family xxx NE
members xxx NE
in xx NE
thymic xxx NE
development xxx NE
. . NE

Induction Xxxx NE
of xx NE
vascular xxx protein_B
cell xxx protein_M
adhesion xxx protein_M
molecule-1 xxx-d protein_E
by xx NE
low-density xxx-xxx protein_B
lipoprotein xxx protein_E
. . NE

Low-density Xxx-xxx protein_B
lipoprotein xxx protein_E
( ( NE
LDL XXX protein
) ) NE
is xx NE
a x NE
well-established xxx-xxx NE
risk xxx NE
factor xxx NE
for xxx NE
atherosclerosis xxx NE
. . NE

When Xxxx NE
endothelial xxx NE
cells xxx NE
are xxx NE
incubated xxx NE
with xxx NE
this xxx NE
lipoprotein xxx NE
in xx NE
pathophysiologic xxx NE
amounts xxx NE
, , NE
the xxx NE
cells xxx NE
are xxx NE
activated xxx NE
. . NE

Among Xxxx NE
the xxx NE
documented xxx NE
cellular xxx NE
responses xxx NE
to xx NE
LDL XXX protein
is xx NE
increased xxx NE
recruitment xxx NE
of xx NE
monocytes xxx cell_type
, , NE
which xxx NE
are xxx NE
believed xxx NE
to xx NE
play xxx NE
a x NE
major xxx NE
role xxx NE
in xx NE
promoting xxx NE
intimal xxx NE
plaque xxx NE
formation xxx NE
. . NE

The Xxx NE
findings xxx NE
presented xxx NE
here xxx NE
link xxx NE
an xx NE
atheogenic xxx protein_B
lipoprotein xxx protein_E
, , NE
LDL XXX protein
, , NE
with xxx NE
the xxx NE
induction xxx NE
of xx NE
an xx NE
adhesion xxx NE
molecule xxx NE
important xxx NE
in xx NE
atherogenesis xxx NE
Human Xxxx NE
LDL XXX protein
induces xxx NE
the xxx NE
vascular xxx protein_B
cell xxx protein_M
adhesion xxx protein_M
molecule-1 xxx-d protein_E
( ( NE
VCAM-1 XXXX-d protein
) ) NE
transcriptionally xxx NE
with xxx NE
an xx NE
increase xxx NE
in xx NE
mRNA xXXX NE
levels xxx NE
through xxx NE
activation xxx NE
of xx NE
the xxx NE
VCAM XXXX DNA_B
promoter xxx DNA_E
. . NE

This Xxxx NE
effect xxx NE
is xx NE
blocked xxx NE
by xx NE
anti-VCAM xxx-XXXX NE
antibodies xxx NE
. . NE

After Xxxx NE
a x NE
2-day d-xxx NE
incubation xxx NE
in xx NE
LDL XXX protein
, , NE
the xxx NE
binding xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
, , NE
which xxx NE
is xx NE
believed xxx NE
to xx NE
be xx NE
a x NE
key xxx NE
oxidative-stress xxx-xxx NE
sensor xxx NE
for xxx NE
VCAM XXXX NE
regulation xxx NE
, , NE
remains xxx NE
at xx NE
basal xxx NE
level xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
binding xxx NE
activities xxx NE
of xx NE
AP-1 XX-d protein
and xxx NE
GATA XXXX protein
, , NE
on xx NE
the xxx NE
other xxx NE
hand xxx NE
, , NE
are xxx NE
increased xxx NE
by xx NE
LDL XXX protein
. . NE

Thus Xxxx NE
, , NE
a x NE
component xxx NE
of xx NE
LDL XXX NE
-enhanced -xxx NE
endothelial xxx NE
recruitment xxx NE
of xx NE
monocytes xxx NE
is xx NE
attributed xxx NE
to xx NE
VCAM-1 XXXX-d NE
expression xxx NE
, , NE
which xxx NE
appears xxx NE
to xx NE
be xx NE
mediated xxx NE
through xxx NE
AP-1 XX-d NE
and xxx NE
GATA XXXX NE
. . NE

These Xxxx NE
data xxx NE
identify xxx NE
LDL XXX protein
as xx NE
a x NE
VCAM XXXX NE
-inducer -xxx NE
possibly xxx NE
distinct xxx NE
from xxx NE
cytokines xxx NE
and xxx NE
endotoxin xxx NE
. . NE

Involvement Xxxx NE
of xx NE
nuclear xxx NE
factor-kappa xxx-xxx NE
B X NE
activation xxx NE
in xx NE
IgE XxX NE
synthesis xxx NE
in xx NE
human xxx cell_type_B
B X cell_type_M
cells xxx cell_type_E
. . NE

Nuclear Xxxx protein_B
factor-kappa xxx-xxx protein_M
B X protein_E
( ( NE
NF-kappa XX-xxx protein_B
B X protein_E
) ) NE
is xx NE
a x NE
transcription xxx NE
factor xxx NE
that xxx NE
binds xxx NE
to xx NE
the xxx NE
consensus xxx DNA_B
DNA XXX DNA_M
sequence xxx DNA_E
in xx NE
the xxx NE
cis-acting xxx-xxx DNA_B
elements xxx DNA_E
of xx NE
various xxx DNA_B
genes xxx DNA_E
. . NE

Although Xxxx NE
NF-kappa XX-xxx protein_B
B X protein_E
activates xxx NE
the xxx NE
expression xxx NE
of xx NE
many xxx NE
genes xxx NE
involved xxx NE
in xx NE
immune xxx NE
response xxx NE
and xxx NE
inflammatory xxx NE
response xxx NE
activation xxx NE
in xx NE
the xxx NE
induction xxx NE
of xx NE
IgE XxX NE
synthesis xxx NE
in xx NE
human xxx cell_type_B
B X cell_type_M
cells xxx cell_type_E
. . NE

Therefore Xxxx NE
we xx NE
first xxx NE
examined xxx NE
the xxx NE
participation xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
in xx NE
germline xxx NE
C X NE
epsilon xxx NE
transcription xxx NE
in xx NE
a x NE
human xxx cell_line_B
Burkitt Xxxx cell_line_M
lymphoma xxx cell_line_M
B X cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
, , NE
DND39 XXXdd cell_line
. . NE

Stimulation Xxxx NE
of xx NE
DND39 XXXdd cell_line_B
cells xxx cell_line_E
with xxx NE
IL-4 XX-d protein
or xx NE
anti-CD40 xxx-XXdd protein_B
monoclonal xxx protein_M
antibody xxx protein_E
( ( NE
mAb xXx protein
) ) NE
activated xxx NE
phosphatidylinositol xxx protein_B
3-kinase d-xxx protein_E
and xxx NE
subsequently xxx NE
induced xxx NE
nuclear xxx NE
expression xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
, , NE
which xxx NE
was xxx NE
identified xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assays xxx NE
. . NE

n-Acetyl-L-cysteine x-Xxxx-X-xxx NE
( ( NE
NAC XXX NE
) ) NE
, , NE
a x NE
potent xxx NE
antioxidant xxx NE
, , NE
blocked xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
activation xxx NE
caused xxx NE
by xx NE
IL-4 XX-d protein
and xxx NE
by xx NE
anti-CD40 xxx-XXdd protein_B
mAb xXx protein_E
. . NE

Although Xxxx NE
inhibition xxx NE
of xx NE
IL-4 XX-d NE
-driven -xxx NE
germline xxx NE
C X NE
epsilon xxx NE
transcription xxx NE
by xx NE
NAC XXX NE
was xxx NE
not xxx NE
sufficient xxx NE
, , NE
the xxx NE
agent xxx NE
remarkably xxx NE
diminished xxx NE
anti-CD40 xxx-XXdd NE
mAb xXx NE
-mediated -xxx NE
up-regulation xx-xxx NE
of xx NE
germline xxx NE
C X NE
epsilon xxx NE
transcription xxx NE
. . NE

Second Xxxx NE
, , NE
we xx NE
studied xxx NE
the xxx NE
effect xxx NE
of xx NE
NAC XXX NE
on xx NE
IgE XxX NE
synthesis xxx NE
in xx NE
human xxx NE
normal xxx NE
B X NE
cells xxx NE
costimulated xxx NE
with xxx NE
IL-4 XX-d protein
and xxx NE
anti-CD40 xxx-XXdd protein_B
mAb xXx protein_E
. . NE

NAC XXX NE
was xxx NE
effective xxx NE
in xx NE
inhibiting xxx NE
mature xxx NE
C X NE
epsilon xxx NE
transcription xxx NE
and xxx NE
IgE XxX NE
synthesis xxx NE
in xx NE
the xxx NE
T X NE
cell-independent xxx-xxx NE
culture xxx NE
system xxx NE
. . NE

However Xxxx NE
, , NE
NAC XXX NE
did xxx NE
not xxx NE
significantly xxx NE
affect xxx NE
the xxx NE
spontaneous xxx NE
production xxx NE
of xx NE
IgE XxX protein
by xx NE
atopic xxx cell_type_B
B X cell_type_M
cells xxx cell_type_E
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
activity xxx NE
is xx NE
commonly xxx NE
inducible xxx NE
in xx NE
DND39 XXXdd cell_line_B
cells xxx cell_line_E
by xx NE
IL-4 XX-d protein
and xxx NE
anti-CD40 xxx-XXdd protein_B
mAb xXx protein_E
and xxx NE
suggest xxx NE
that xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
sensitive xxx NE
to xx NE
NAC XXX NE
may xxx NE
play xxx NE
a x NE
role xxx NE
in xx NE
regulating xxx NE
IgE XxX NE
synthesis xxx NE
in xx NE
B X cell_type_B
cells xxx cell_type_E
. . NE

Prostaglandin Xxxx NE
E2 Xd NE
induction xxx NE
of xx NE
binding xxx NE
activity xxx NE
to xx NE
CRE XXX DNA
and xxx NE
AP-2 XX-d DNA_B
elements xxx DNA_E
in xx NE
human xxx cell_type_B
T X cell_type_M
lymphocytes xxx cell_type_E
. . NE

Prostaglandins Xxxx NE
of xx NE
the xxx NE
E X NE
series xxx NE
are xxx NE
immunomodulatory xxx NE
agents xxx NE
which xxx NE
exert xxx NE
inhibitory xxx NE
as xx NE
well xxx NE
as xx NE
stimulatory xxx NE
effects xxx NE
on xx NE
a x NE
variety xxx NE
of xx NE
immune xxx NE
responses xxx NE
. . NE

Since Xxxx NE
it xx NE
is xx NE
known xxx NE
that xxx NE
PGE2 XXXd NE
is xx NE
able xxx NE
to xx NE
increase xxx NE
cAMP xXXX NE
levels xxx NE
, , NE
we xx NE
investigated xxx NE
whether xxx NE
it xx NE
can xxx NE
affect xxx NE
gene xxx NE
expression xxx NE
through xxx NE
the xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx protein_B
factors xxx protein_E
which xxx NE
bind xxx NE
enhancer xxx NE
elements xxx NE
in xx NE
the xxx NE
promoter xxx NE
regions xxx NE
of xx NE
cAMP xXXX NE
-regulated -xxx NE
genes xxx NE
. . NE

Using Xxxx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
, , NE
we xx NE
demonstrated xxx NE
that xxx NE
a x NE
short xxx NE
treatment xxx NE
of xx NE
human xxx cell_type_B
T X cell_type_M
lymphocytes xxx cell_type_E
with xxx NE
PGE2 XXXd NE
induces xxx NE
specific xxx NE
binding xxx NE
activity xxx NE
to xx NE
CRE XXX DNA
and xxx NE
AP-2 XX-d NE
, , NE
but xxx NE
not xxx NE
AP-1 XX-d NE
, , NE
DNA XXX NE
elements xxx NE
. . NE

Since Xxxx NE
the xxx NE
okadaic xxx NE
acid xxx NE
, , NE
a x NE
potent xxx NE
protein xxx NE
phosphatase xxx NE
inhibitor xxx NE
, , NE
prolongs xxx NE
the xxx NE
induction xxx NE
of xx NE
the xxx NE
binding xxx NE
activity xxx NE
, , NE
phosphorylation xxx NE
events xxx NE
are xxx NE
likely xxx NE
to xx NE
occur xxx NE
. . NE

This Xxxx NE
activity xxx NE
seems xxx NE
to xx NE
be xx NE
due xxx NE
to xx NE
increased xxx NE
cAMP xXXX NE
levels xxx NE
because xxx NE
forskolin xxx NE
and xxx NE
IBMX XXXX NE
mimic xxx NE
the xxx NE
effects xxx NE
of xx NE
PGE2 XXXd NE
. . NE

More Xxxx NE
interestingly xxx NE
, , NE
transfection xxx NE
experiments xxx NE
with xxx NE
CRE XXX NE
-CAT -XXX NE
plasmide xxx NE
show xxx NE
that xxx NE
PGE2 XXXd NE
activates xxx NE
the xxx NE
transcription xxx NE
of xx NE
a x NE
CRE XXX NE
-containing -xxx NE
promoter xxx NE
. . NE

These Xxxx NE
data xxx NE
support xxx NE
the xxx NE
positive xxx NE
role xxx NE
for xxx NE
PGE2 XXXd NE
on xx NE
some xxx NE
immune xxx NE
functions xxx NE
. . NE

Nasal Xxxx cell_type_B
NK-cell XX-xxx cell_type_M
lymphoma xxx cell_type_M
and xxx cell_type_M
T-cell X-xxx cell_type_M
lymphoma xxx cell_type_E
share xxx NE
the xxx NE
same xxx NE
type xxx NE
of xx NE
Epstein-Barr Xxxx-Xxxx NE
virus xxx NE
latency xxx NE
as xx NE
nasopharyngeal xxx NE
carcinoma xxx NE
and xxx NE
Hodgkin's Xxxx'x NE
disease xxx NE
. . NE

Nasal Xxxx cell_type_B
T/NK-cell X/XX-xxx cell_type_M
lymphomas xxx cell_type_E
can xxx NE
be xx NE
further xxx NE
separated xxx NE
into xxx NE
those xxx NE
of xx NE
natural xxx cell_type_B
killer xxx cell_type_M
(NK) (XX) cell_type_M
cell xxx cell_type_M
lineage xxx cell_type_E
or xx NE
of xx NE
T-cell X-xxx cell_type_B
lineage xxx cell_type_E
, , NE
with xxx NE
differences xxx NE
in xx NE
cellular xxx NE
phenotype xxx NE
, , NE
T-cell X-xxx NE
receptor xxx NE
(TcR) (XxX) NE
gene xxx NE
rearrangement xxx NE
and xxx NE
TcR XxX NE
transcript xxx NE
expression xxx NE
. . NE

Both Xxxx NE
NK-cell XX-xxx cell_type_B
subtype xxx cell_type_M
and xxx cell_type_M
T-cell X-xxx cell_type_M
subtype xxx cell_type_E
are xxx NE
closely xxx NE
associated xxx NE
with xxx NE
Epstein-Barr Xxxx-Xxxx NE
virus xxx NE
( ( NE
EBV XXX NE
) ) NE
. . NE

In Xx NE
this xxx NE
study xxx NE
, , NE
EBV XXX NE
gene xxx NE
expression xxx NE
was xxx NE
determined xxx NE
in xx NE
23 dd NE
cases xxx NE
of xx NE
nasal xxx NE
lymphoma xxx NE
( ( NE
NL XX NE
) ) NE
by xx NE
in xx NE
situ xxx NE
hybridisation xxx NE
( ( NE
ISH XXX NE
) ) NE
, , NE
reverse xxx NE
transcriptase xxx NE
-polymerase -xxx NE
chain xxx NE
reaction xxx NE
( ( NE
RT-PCR XX-XXX NE
) ) NE
and xxx NE
immunohistochemistry xxx NE
( ( NE
IH XX NE
) ) NE
. . NE

Of Xx NE
the xxx NE
23 dd NE
cases xxx NE
, , NE
19 dd NE
were xxx NE
classified xxx NE
as xx NE
NK-cell XX-xxx NE
and xxx NE
4 d NE
as xx NE
T-cell X-xxx NE
tumours xxx NE
. . NE

ISH XXX NE
for xxx NE
EBV XXX NE
-encoded -xxx NE
small xxx NE
non-polyadenylated xxx-xxx NE
RNAs XXXx NE
showed xxx NE
that xxx NE
all xxx NE
cases xxx NE
, , NE
whether xxx NE
NK XX NE
or xx NE
T X NE
, , NE
harboured xxx NE
EBV XXX NE
in xx NE
virtually xxx NE
all xxx NE
tumour xxx NE
cells xxx NE
. . NE

RT-PCR XX-XXX NE
demonstrated xxx NE
that xxx NE
NL XX cell_type
of xx NE
both xxx NE
subtypes xxx NE
expressed xxx NE
EBNAI XXXXX protein
of xx NE
the xxx NE
QUK XXX NE
splice xxx NE
pattern xxx NE
, , NE
the xxx NE
latent xxx protein_B
membrane xxx protein_M
proteins xxx protein_E
, , NE
LMP1 XXXd protein_B
and xxx protein_M
LMP2 XXXd protein_E
BamHI XxxXX NE
A X NE
rightward xxx NE
transcripts xxx NE
in xx NE
the xxx NE
absence xxx NE
of xx NE
EBNA2 XXXXd RNA_B
mRNAs xXXXx RNA_E
, , NE
compatible xxx NE
with xxx NE
the xxx NE
latency xxx NE
type xxx NE
II XX NE
pattern xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
analysis xxx NE
of xx NE
EBV XXX NE
protein xxx NE
expression xxx NE
by xx NE
IH XX NE
revealed xxx NE
a x NE
heterogeneous xxx NE
pattern xxx NE
of xx NE
EBV XXX NE
gene xxx NE
expression xxx NE
at xx NE
the xxx NE
single-cell xxx-xxx NE
level xxx NE
consisting xxx NE
of xx NE
both xxx NE
LMP1+ XXXd+ cell_type_B
tumour xxx cell_type_M
cell xxx cell_type_M
and xxx cell_type_M
LMP1- XXXd- cell_type_M
tumour xxx cell_type_M
cell xxx cell_type_E

Although Xxxx NE
2 d NE
early xxx protein_B
lytic xxx protein_M
transcripts xxx protein_E
, , NE
BZLF1 XXXXd protein
and xxx NE
BHRF1 XXXXd protein
, , NE
were xxx NE
also xxx NE
detected xxx NE
in xx NE
13 dd NE
and xxx NE
10 dd NE
cases xxx NE
, , NE
respectively xxx NE
, , NE
the xxx NE
lack xxx NE
of xx NE
ZEBRA XXXXX NE
staining xxx NE
in xx NE
any xxx NE
case xxx NE
indicates xxx NE
that xxx NE
these xxx NE
lytic xxx NE
transcripts xxx NE
are xxx NE
most xxx NE
likely xxx NE
expressed xxx NE
by xx NE
rare xxx NE
cells xxx NE
in xx NE
the xxx NE
biopsies xxx NE
entering xxx NE
lytic xxx NE
cycle xxx NE
. . NE

The Xxx NE
viral xxx NE
transcriptional xxx NE
pattern xxx NE
similar xxx NE
to xx NE
that xxx NE
of xx NE
nasopharyngeal xxx NE
carcinoma xxx NE
and xxx NE
Hodgkin's Xxxx'x NE
disease xxx NE
suggests xxx NE
that xxx NE
EBV XXX NE
can xxx NE
exploit xxx NE
common xxx NE
regulatory xxx NE
mechanisms xxx NE
for xxx NE
gene xxx NE
transcription xxx NE
in xx NE
diverse xxx NE
host xxx NE
cell xxx NE
types xxx NE
. . NE

Down-regulation Xxxx-xxx NE
of xx NE
immunogenic xxx protein_B
proteins xxx protein_E
( ( NE
EBNA2-EBNA6 XXXXd-XXXXd protein
) ) NE
in xx NE
nasal xxx NE
lymphoma xxx NE
may xxx NE
enable xxx NE
tumour xxx cell_type_B
cells xxx cell_type_E
to xx NE
evade xxx NE
host xxx NE
cytotoxic xxx NE
T-cell X-xxx NE
surveillance xxx NE
. . NE

Potent Xxxx NE
gene xxx NE
regulatory xxx NE
and xxx NE
antiproliferative xxx NE
activities xxx NE
of xx NE
20-methyl dd-xxx NE
analogues xxx NE
of xx NE
1,25 d,dd NE
dihydroxyvitamin xxx NE
D3 Xd NE
. . NE

The Xxx NE
biological xxx NE
active xxx NE
form xxx NE
of xx NE
vitamin xxx NE
D3 Xd NE
, , NE
1,25-dihydroxyvitamin d,dd-xxx NE
D3 Xd NE
( ( NE
VD XX NE
) ) NE
, , NE
regulates xxx NE
cellular xxx NE
growth xxx NE
and xxx NE
differentiation xxx NE
. . NE

This Xxxx NE
provides xxx NE
the xxx NE
hormone xxx NE
with xxx NE
an xx NE
interesting xxx NE
therapeutic xxx NE
potential xxx NE
. . NE

However Xxxx NE
, , NE
hypercalcemia xxx NE
is xx NE
a x NE
side xxx NE
effect xxx NE
, , NE
which xxx NE
is xx NE
caused xxx NE
by xx NE
VD XX NE
's 'x NE
classical xxx NE
action xxx NE
, , NE
the xxx NE
regulation xxx NE
of xx NE
calcium xxx NE
homeostasis xxx NE
. . NE

This Xxxx NE
made xxx NE
the xxx NE
need xxx NE
for xxx NE
VD XX NE
analogues xxx NE
with xxx NE
selectively xxx NE
increased xxx NE
cell xxx NE
regulatory xxx NE
properties xxx NE
. . NE

Studies Xxxx NE
with xxx NE
20-epi dd-xxx NE
analogues xxx NE
pointed xxx NE
out xxx NE
the xxx NE
importance xxx NE
of xx NE
the xxx NE
carbon-20 xxx-dd NE
position xxx NE
and xxx NE
led xxx NE
to xx NE
the xxx NE
development xxx NE
of xx NE
20-methyl dd-xxx NE
derivatives xxx NE
of xx NE
VD XX NE
. . NE

In Xx NE
this xxx NE
report xxx NE
the xxx NE
biological xxx NE
properties xxx NE
of xx NE
the xxx NE
compounds xxx NE
ZK161422 XXdddddd NE
and xxx NE
ZK157202 XXdddddd NE
, , NE
which xxx NE
are xxx NE
20-methyl-eneanalogue dd-xxx-xxx NE
and xxx NE
20-methyl-23-eneanalogue dd-xxx-dd-xxx NE
VD XX NE
. . NE

Both Xxxx NE
compounds xxx NE
show xxx NE
about xxx NE
2-fold d-xxx NE
lower xxx NE
affinity xxx NE
to xx NE
the xxx NE
VD XX NE
receptor xxx NE
(VDR) (XXX) NE
than xxx NE
VD XX NE
. . NE

However Xxxx NE
, , NE
compared xxx NE
to xx NE
VD XX NE
, , NE
their xxx NE
antiproliferative xxx NE
effect xxx NE
is xx NE
up xx NE
to xx NE
30-fold dd-xxx NE
higher xxx NE
on xx NE
human xxx cell_type_B
peripheral xxx cell_type_M
blood xxx cell_type_M
mononuclear xxx cell_type_M
cells xxx cell_type_E
and xxx NE
even xxx NE
up xx NE
to xx NE
300-fold ddd-xxx NE
higher xxx NE
on xx NE
human xxx cell_line_B
breast xxx cell_line_M
cancer xxx cell_line_M
MCF-7 XXX-d cell_line_M
cells xxx cell_line_E
. . NE

Whereas Xxxx NE
the xxx NE
hypercalcemic xxx NE
effect xxx NE
for xxx NE
ZK157202 XXdddddd NE
is xx NE
also xxx NE
increased xxx NE
10-fold dd-xxx NE
, , NE
ZK161422 XXdddddd NE
has xxx NE
the xxx NE
same xxx NE
calcium xxx NE
-mobilizing -xxx NE
potency xxx NE
as xx NE
VD XX NE
. . NE

Moreover Xxxx NE
, , NE
ZK161422 XXdddddd NE
, , NE
but xxx NE
not xxx NE
ZK157202 XXdddddd NE
, , NE
showed xxx NE
preference xxx NE
for xxx NE
gene xxx NE
activation xxx NE
from xxx NE
a x NE
promoter xxx DNA
carrying xxx NE
a x NE
VD XX DNA_B
response xxx DNA_M
element xxx DNA_E
with xxx NE
a x NE
palindromic xxx DNA_B
arrangement xxx DNA_E
of xx NE
two xxx NE
hexameric xxx DNA_B
receptor xxx DNA_M
binding xxx DNA_M
sites xxx DNA_E
spaced xxx NE
by xx NE
9 d NE
nucleotides xxx NE
( ( NE
IP9 XXd NE
) ) NE
rather xxx NE
than xxx NE
for xxx NE
activation xxx NE
from xxx NE
a x NE
response xxx DNA_B
element xxx DNA_E
formed xxx NE
by xx NE
a x NE
direct xxx NE
repeat xxx NE
spaced xxx NE
by xx NE
3 d NE
nucleotides xxx NE
( ( NE
DR3 XXd NE
) ) NE
. . NE

This Xxxx NE
observation xxx NE
supports xxx NE
a x NE
model xxx NE
, , NE
in xx NE
which xxx NE
promoter xxx NE
selectivity xxx NE
reflects xxx NE
the xxx NE
selectively xxx NE
increased xxx NE
antiproliferative xxx NE
effect xxx NE
of xx NE
VD XX NE
analogues xxx NE
. . NE

Calcium Xxxx NE
-dependent -xxx NE
immediate-early xxx-xxx NE
gene xxx NE
induction xxx NE
in xx NE
lymphocytes xxx NE
is xx NE
negatively xxx NE
regulated xxx NE
by xx NE
p21Ha-ras xddXx-xxx NE
. . NE

The Xxx NE
induction xxx NE
of xx NE
immediate-early xxx-xxx DNA_B
(IE) (XX) DNA_M
response xxx DNA_M
genes xxx DNA_E
, , NE
such xxx NE
as xx NE
egr-1 xxx-d DNA
, , NE
c-fos x-xxx DNA
, , NE
and xxx NE
c-jun x-xxx DNA
, , NE
occurs xxx NE
rapidly xxx NE
after xxx NE
the xxx NE
activation xxx NE
of xx NE
T X cell_type_B
lymphocytes xxx cell_type_E
. . NE

The Xxx NE
process xxx NE
of xx NE
activation xxx NE
involves xxx NE
calcium xxx NE
mobilization xxx NE
, , NE
activation xxx NE
of xx NE
protein xxx protein_B
kinase xxx protein_M
C X protein_E
( ( NE
PKC XXX protein
) ) NE
, , NE
and xxx NE
phosphorylation xxx NE
of xx NE
tyrosine xxx protein_B
kinases xxx protein_E
. . NE

p21(ras) xdd(xxx) protein
, , NE
a x NE
guanine xxx protein_B
nucleotide xxx protein_M
binding xxx protein_M
factor xxx protein_E
, , NE
mediates xxx NE
T-cell X-xxx NE
signal xxx NE
transduction xxx NE
through xxx NE
PKC XXX NE
-dependent -xxx NE
and xxx NE
PKC XXX NE
-independent -xxx NE
pathways xxx NE
. . NE

The Xxx NE
involvement xxx NE
of xx NE
p21(ras) xdd(xxx) protein
in xx NE
the xxx NE
regulation xxx NE
of xx NE
calcium xxx NE
-dependent -xxx NE
signals xxx NE
has xxx NE
been xxx NE
suggested xxx NE
through xxx NE
analysis xxx NE
of xx NE
its xxx NE
role xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
NF-AT XX-XX NE
. . NE

We Xx NE
have xxx NE
investigated xxx NE
the xxx NE
inductions xxx NE
of xx NE
the xxx NE
IE XX DNA_B
genes xxx DNA_E
in xx NE
response xxx NE
to xx NE
calcium xxx NE
signals xxx NE
in xx NE
Jurkat Xxxx cell_line_B
cells xxx cell_line_E
(in (xx NE
the xxx NE
presence xxx NE
of xx NE
activated xxx NE
p21(ras) xdd(xxx) protein
) ) NE
and xxx NE
their xxx NE
correlated xxx NE
consequences xxx NE
. . NE

The Xxx NE
expression xxx NE
of xx NE
activated xxx NE
p21(ras) xdd(xxx) protein
negatively xxx NE
regulated xxx NE
the xxx NE
induction xxx NE
of xx NE
IE XX DNA_B
genes xxx DNA_E
by xx NE
calcium xxx NE
ionophore xxx NE
. . NE

This Xxxx NE
inhibition xxx NE
of xx NE
calcium xxx NE
-activated -xxx NE
IE XX NE
gene xxx NE
induction xxx NE
was xxx NE
reversed xxx NE
by xx NE
treatment xxx NE
with xxx NE
cyclosporin xxx NE
A X NE
, , NE
suggesting xxx NE
the xxx NE
involvement xxx NE
of xx NE
calcineurin xxx NE
in xx NE
this xxx NE
regulation xxx NE
. . NE

A X NE
later xxx NE
result xxx NE
of xx NE
inhibition xxx NE
of xx NE
this xxx NE
activation xxx NE
pathway xxx NE
by xx NE
p21(ras) xdd(xxx) protein
was xxx NE
down-regulation xxx-xxx NE
of xx NE
the xxx NE
activity xxx NE
of xx NE
the xxx NE
transcription xxx protein_B
factor xxx protein_E
AP-1 XX-d protein
and xxx NE
subsequent xxx NE
coordinate xxx NE
reductions xxx NE
in xx NE
IL-2 XX-d NE
gene xxx NE
expression xxx NE
and xxx NE
protein xxx NE
production xxx NE
. . NE

These Xxxx NE
results xxx NE
suggest xxx NE
that xxx NE
p2l(ras) xdx(xxx) protein
is xx NE
an xx NE
essential xxx NE
mediator xxx NE
in xx NE
generating xxx NE
not xxx NE
only xxx NE
positive xxx NE
but xxx NE
also xxx NE
negative xxx NE
modulatory xxx NE
mechanisms xxx NE
controlling xxx NE
the xxx NE
competence xxx NE
of xx NE
T X cell_type_B
cells xxx cell_type_E
in xx NE
response xxx NE
to xx NE
inductive xxx NE
stimulations xxx NE
. . NE

Calcineurin Xxxx protein
acts xxx NE
in xx NE
synergy xxx NE
with xxx NE
PMA XXX NE
to xx NE
inactivate xxx NE
I X protein_B
kappa xxx protein_M
B/MAD3 X/XXXd protein_E
, , NE
an xx NE
inhibitor xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
. . NE

The Xxx NE
interleukin-2 xxx-d NE
( ( NE
IL-2 XX-d NE
) ) NE
promoter xxx NE
consists xxx NE
of xx NE
several xxx NE
independent xxx NE
T X NE
cell xxx NE
receptor xxx NE
( ( NE
TcR XxX NE
) ) NE
responsive xxx NE
elements xxx NE
. . NE

The Xxx NE
induction xxx NE
of xx NE
promoters xxx DNA
dependent xxx NE
on xx NE
these xxx NE
elements xxx NE
is xx NE
inhibitable xxx NE
by xx NE
the xxx NE
immunosuppressants xxx NE
cyclosporin xxx NE
A X NE
( ( NE
CsA XxX NE
) ) NE
and xxx NE
tacrolimus xxx NE
( ( NE
FK-506 XX-ddd NE
) ) NE
. . NE

Calcineurin Xxxx protein
, , NE
a x NE
Ca2+ Xxd+ NE
/calmodulin-dependent /xxx-xxx NE
protein xxx NE
phosphatase xxx NE
, , NE
is xx NE
the xxx NE
FK-506 XX-ddd NE
-and -xxx NE
CsA XxX NE
-sensitive -xxx NE
enzyme xxx NE
required xxx NE
for xxx NE
TcR XxX NE
mediated xxx NE
activation xxx NE
of xx NE
the xxx NE
IL-2 XX-d NE
promoter xxx NE
. . NE

We Xx NE
report xxx NE
that xxx NE
a x NE
constitutively xxx NE
active xxx NE
form xxx NE
of xx NE
calcineurin xxx protein
partially xxx NE
substitutes xxx NE
for xxx NE
the xxx NE
Ca2+ Xxd+ NE
co-stimulus xx-xxx NE
required xxx NE
to xx NE
activate xxx NE
the xxx NE
IL-2 XX-d DNA_B
promoter xxx DNA_M
elements xxx DNA_E
IL-2A XX-dX DNA
(which (xxx NE
binds xxx NE
the xxx NE
factors xxx NE
OAP XXX protein
and xxx NE
Oct-1 Xxx-d protein
) ) NE
and xxx NE
IL-2E XX-dX DNA
(which (xxx NE
binds xxx NE
NF-AT XX-XX protein
) ) NE
, , NE
and xxx NE
completely xxx NE
substitutes xxx NE
for xxx NE
the xxx NE
Ca2+ Xxd+ NE
co-stimulus xx-xxx NE
required xxx NE
to xx NE
stimulate xxx NE
an xx NE
NF-kappa XX-xxx protein_B
B X protein_E
-dependent -xxx NE
element xxx NE
. . NE

Calcineurin Xxxx protein
stimulates xxx NE
the xxx NE
NF-kappa XX-xxx DNA_B
B X DNA_M
element xxx DNA_E
by xx NE
enhancing xxx NE
inactivation xxx NE
of xx NE
I X protein_B
kappa xxx protein_M
B/MAD3 X/XXXd protein_E
, , NE
an xx NE
inhibitor xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
, , NE
thereby xxx NE
increasing xxx NE
the xxx NE
amount xxx NE
of xx NE
nuclear xxx NE
NF-kappa XX-xxx NE
B X NE
DNA XXX NE
binding xxx NE
activity xxx NE
. . NE

These Xxxx NE
data xxx NE
provide xxx NE
the xxx NE
first xxx NE
demonstration xxx NE
in xx NE
vivo xxx NE
that xxx NE
activation xxx NE
of xx NE
a x NE
protein xxx protein_B
phosphatase xxx protein_E
can xxx NE
inactivate xxx NE
I X protein_B
kappa xxx protein_M
B X protein_E
, , NE
and xxx NE
suggest xxx NE
one xxx NE
possible xxx NE
explanation xxx NE
for xxx NE
mechanism-based xxx-xxx NE
toxicities xxx NE
associated xxx NE
with xxx NE
FK-506 XX-ddd NE
and xxx NE
CsA XxX NE
by xx NE
demonstrating xxx NE
that xxx NE
these xxx NE
drugs xxx NE
can xxx NE
inhibit xxx NE
the xxx NE
calcineurin xxx NE
-dependent -xxx NE
activation xxx NE
of xx NE
a x NE
virtually xxx NE
ubiquitous xxx NE
transcription xxx NE
factor xxx NE
. . NE

Detection Xxxx NE
of xx NE
minimal xxx NE
residual xxx NE
disease xxx NE
in xx NE
a x NE
patient xxx NE
with xxx NE
acute xxx NE
promyelocytic xxx NE
leukemia xxx NE
by xx NE
RT-PCR XX-XXX NE
: : NE
necessity xxx NE
of xx NE
chemotherapy xxx NE
following xxx NE
ATRA XXXX NE
therapy xxx NE
. . NE

The Xxx NE
PML/RAR XXX/XXX DNA_B
alpha xxx DNA_M
fusion xxx DNA_M
gene xxx DNA_E
resulting xxx NE
from xxx NE
the xxx NE
t x DNA_B
(15;17) (dd;dd) DNA_M
translocation xxx DNA_E
is xx NE
a x NE
specific xxx NE
marker xxx NE
for xxx NE
acute xxx NE
promyelocytic xxx NE
leukemia xxx NE
( ( NE
APL XXX NE
) ) NE
. . NE

We Xx NE
examined xxx NE
bone xxx NE
marrow xxx NE
cells xxx NE
by xx NE
reverse xxx NE
transcriptase-polymerase xxx-xxx NE
chain xxx NE
reaction xxx NE
( ( NE
RT-PCR XX-XXX NE
) ) NE
to xx NE
detect xxx NE
residual xxx NE
PML/RAR XXX/XXX NE
alpha xxx NE
mRNA xXXX NE
-containing -xxx NE
cells xxx NE
following xxx NE
treatment xxx NE
with xxx NE
all-trans xxx-xxx NE
retinoic xxx NE
acid xxx NE
( ( NE
ATRA XXXX NE
) ) NE
and xxx NE
cytotoxic xxx NE
chemotherapy xxx NE
in xx NE
a x NE
patient xxx NE
with xxx NE
APL XXX NE
. . NE

This Xxxx NE
RT-PCR XX-XXX NE
assay xxx NE
can xxx NE
detect xxx NE
one xxx NE
leukemic xxx cell_type_B
cell xxx cell_type_E
in xx NE
10(2) dd(d) NE
normal xxx cell_type_B
cells xxx cell_type_E
in xx NE
vitro xxx NE
. . NE

We Xx NE
show xxx NE
that xxx NE
PML/RAR XXX/XXX RNA_B
alpha xxx RNA_M
mRNA xXXX RNA_E
was xxx NE
still xxx NE
detectable xxx NE
despite xxx NE
clinical xxx NE
remission xxx NE
following xxx NE
ATRA XXXX NE
treatment xxx NE
, , NE
but xxx NE
undetectable xxx NE
following xxx NE
consolidation xxx NE
with xxx NE
chemotherapy xxx NE
. . NE

These Xxxx NE
data xxx NE
show xxx NE
that xxx NE
this xxx NE
technique xxx NE
is xx NE
useful xxx NE
for xxx NE
the xxx NE
identification xxx NE
of xx NE
minimal xxx NE
residual xxx NE
disease xxx NE
in xx NE
patients xxx NE
with xxx NE
APL XXX NE
and xxx NE
that xxx NE
cytotoxic xxx NE
chemotherapy xxx NE
following xxx NE
ATRA XXXX NE
therapy xxx NE
is xx NE
required xxx NE
for xxx NE
the xxx NE
elimination xxx NE
of xx NE
APL XXX cell_type_B
cells xxx cell_type_E
. . NE

Glucocorticoid Xxxx NE
-mediated -xxx NE
inhibition xxx NE
of xx NE
interleukin-2 xxx-d NE
receptor xxx NE
alpha xxx NE
subunit xxx NE
expression xxx NE
and xxx NE
interleukin-2 xxx-d NE
receptor xxx NE
-beta -xxx NE
subunit xxx NE
expression xxx NE

To Xx NE
determine xxx NE
the xxx NE
mechanism xxx NE
of xx NE
glucocorticoid xxx NE
( ( NE
GC XX NE
)-mediated )-xxx NE
inhibition xxx NE
of xx NE
T X NE
cell xxx NE
functions xxx NE
, , NE
the xxx NE
effect xxx NE
of xx NE
dexamethasone xxx NE
( ( NE
DM XX NE
) ) NE
on xx NE
T X NE
cell xxx NE
proliferation xxx NE
and xxx NE
interleukin-2 xxx-d NE
receptor xxx NE
( ( NE
IL-2R XX-dX NE
) ) NE
generation xxx NE
were xxx NE
studied xxx NE
. . NE

Dexamethasone Xxxx NE
inhibited xxx NE
IL-2 XX-d NE
-induced -xxx NE
T X NE
cell xxx NE
proliferation xxx NE
by xx NE
30%-88% dd%-dd% NE
, , NE
relative xxx NE
to xx NE
its xxx NE
concentration xxx NE
within xxx NE
the xxx NE
cultures xxx NE
. . NE

The Xxx NE
effect xxx NE
of xx NE
DM XX NE
on xx NE
expression xxx NE
of xx NE
IL-2R XX-dX protein_B
alpha xxx protein_E
( ( NE
Tac Xxx protein
, , NE
p55 xdd protein
, , NE
CD25 XXdd protein
) ) NE
and xxx NE
beta xxx DNA_B
(p75) (xdd) DNA_M
genes xxx DNA_E
in xx NE
activated xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
was xxx NE
examined xxx NE
next xxx NE
. . NE

In Xx NE
T X cell_type_B
cells xxx cell_type_E
stimulated xxx NE
with xxx NE
purified xxx NE
phytohemagglutinin xxx protein
( ( NE
PHA-p XXX-x protein
) ) NE
and xxx NE
4 d NE
beta-phorbol xxx-xxx NE
12-myristate dd-xxx NE
13-acetate dd-xxx NE
( ( NE
PMA XXX NE
) ) NE
addition xxx NE
of xx NE
DM XX NE
to xx NE
the xxx NE
cultures xxx NE
resulted xxx NE
in xx NE
a x NE
60% dd% NE
reduction xxx NE
in xx NE
IL-2R XX-dX protein_B
alpha xxx protein_E
and xxx NE
a x NE
30% dd% NE
reduction xxx NE
in xx NE
IL-2R XX-dX NE
beta xxx NE
membrane xxx NE
expression xxx NE
compared xxx NE
to xx NE
T X cell_type_B
cells xxx cell_type_E
cultured xxx NE
in xx NE
the xxx NE
absence xxx NE
of xx NE
DM XX NE
(p (x NE
< < NE
0.01) d.dd) NE
. . NE

Inhibition Xxxx NE
of xx NE
membrane xxx NE
IL-2R XX-dX protein_B
alpha xxx protein_E
and xxx NE
IL-2R XX-dX protein_B
beta xxx protein_E
expression xxx NE
by xx NE
10(-6) dd(-d) NE
M X NE
DM XX NE
was xxx NE
partially xxx NE
reversible xxx NE
by xx NE
recombinant xxx protein_B
human xxx protein_M
IL-2 XX-d protein_E
( ( NE
rhIL-2 xxXX-d protein
) ) NE
. . NE

By Xx NE
Northern Xxxx NE
blot xxx NE
analysis xxx NE
, , NE
DM XX NE
caused xxx NE
a x NE
comparable xxx NE
decrease xxx NE
in xx NE
IL-2R XX-dX protein_B
alpha xxx protein_E
and xxx NE
in xx NE
IL-2R XX-dX NE
beta xxx NE
mRNA xXXX NE
levels xxx NE
to xx NE
membrane xxx NE
receptor xxx NE
expression xxx NE
in xx NE
mitogen-stimulated xxx-xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
. . NE

By Xx NE
in xx NE
vitro xxx NE
transcription xxx NE
assays xxx NE
, , NE
DM XX NE
regulated xxx NE
IL-2R XX-dX NE
alpha xxx NE
gene xxx NE
expression xxx NE
at xx NE
a x NE
transcriptional xxx NE
level xxx NE
while xxx NE
transcription xxx NE
of xx NE
IL-2R XX-dX DNA_B
beta xxx DNA_M
gene xxx DNA_E
was xxx NE
unaffected xxx NE
by xx NE
DM XX NE
. . NE

The Xxx NE
mechanism xxx NE
of xx NE
action xxx NE
of xx NE
DM XX NE
on xx NE
IL-2R XX-dX NE
alpha xxx NE
transcription xxx NE
was xxx NE
examined xxx NE
by xx NE
determining xxx NE
the xxx NE
mRNA xXXX NE
levels xxx NE
of xx NE
the xxx NE
p50 xdd NE
subunit xxx NE
of xx NE
nuclear xxx NE
factor xxx NE
kappa xxx NE
B X NE
( ( NE
NF-kappa XX-xxx protein_B
B X protein_E
) ) NE
, , NE
a x NE
transcription xxx protein_B
factor xxx protein_E
that xxx NE
stimulates xxx NE
IL-2R XX-dX NE
alpha xxx NE
gene xxx NE
expression xxx NE
. . NE

The Xxx NE
data xxx NE
indicate xxx NE
that xxx NE
10(-6) dd(-d) NE
M X NE
DM XX NE
increased xxx NE
T X cell_type_B
cell xxx cell_type_E
p50 xdd NE
NF-kappa XX-xxx NE
B X NE
mRNA xXXX NE
levels xxx NE
by xx NE
four-fold xxx-xxx NE
compared xxx NE
to xx NE
the xxx NE
levels xxx NE
obtained xxx NE
in xx NE
the xxx NE
absence xxx NE
of xx NE
DM XX NE
. . NE

Further Xxxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
nuclear xxx protein_B
proteins xxx protein_E
capable xxx NE
of xx NE
binding xxx NE
to xx NE
the xxx NE
NF-kappa XX-xxx DNA_B
B X DNA_M
sites xxx DNA_E
in xx NE
activated xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
increased xxx NE
in xx NE
response xxx NE
to xx NE
DM XX NE
. . NE

In Xx NE
sum xxx NE
, , NE
DM XX NE
regulates xxx NE
T X cell_type_B
cell xxx cell_type_E
membrane xxx NE
expression xxx NE
of xx NE
IL-2R XX-dX protein
by xx NE
more xxx NE
than xxx NE
one xxx NE
molecular xxx NE
mechanism xxx NE
. . NE

Alteration Xxxx NE
of xx NE
structural xxx NE
order xxx NE
of xx NE
human xxx NE
erythrocyte xxx NE
ghost xxx NE
membrane xxx NE
by xx NE
glucocorticoids xxx NE
and xxx NE
the xxx NE
influence xxx NE
of xx NE
the xxx NE
glucocorticoid xxx NE
receptor xxx NE
antagonist xxx NE
RU XX NE
486 ddd NE
. . NE

High-dose Xxxx-xxx NE
pulse xxx NE
glucocorticoid xxx NE
therapy xxx NE
has xxx NE
been xxx NE
used xxx NE
successfully xxx NE
in xx NE
the xxx NE
clinic xxx NE
in xx NE
severe xxx NE
pathological xxx NE
conditions xxx NE
for xxx NE
about xxx NE
20 dd NE
years xxx NE
. . NE

The Xxx NE
mode xxx NE
of xx NE
glucocorticoid xxx NE
action xxx NE
after xxx NE
administration xxx NE
of xx NE
such xxx NE
megadoses xxx NE
is xx NE
inexplicable xxx NE
up xx NE
to xx NE
now xxx NE
. . NE

It Xx NE
is xx NE
supposed xxx NE
that xxx NE
some xxx NE
effects xxx NE
may xxx NE
be xx NE
due xxx NE
to xx NE
membrane xxx NE
alterations xxx NE
. . NE

In Xx NE
the xxx NE
present xxx NE
in-vitro xx-xxx NE
experiments xxx NE
the xxx NE
effect xxx NE
of xx NE
dexamethasone xxx NE
, , NE
of xx NE
further xxx NE
glucocorticoids xxx NE
, , NE
and xxx NE
of xx NE
the xxx NE
glucocorticoid xxx NE
receptor xxx NE
antagonist xxx NE
RU XX NE
486 ddd NE
, , NE
on xx NE
structural xxx NE
order xxx NE
of xx NE
human xxx NE
erythrocyte xxx NE
ghost xxx NE
membranes xxx NE
was xxx NE
investigated xxx NE
by xx NE
determining xxx NE
the xxx NE
steady-state xxx-xxx NE
fluorescence xxx NE
anisotropy xxx NE
of xx NE
diphenylhexatriene xxx NE
( ( NE
DPH XXX NE
) ) NE
. . NE

Dexamethasone Xxxx NE
was xxx NE
found xxx NE
to xx NE
induce xxx NE
a x NE
significant xxx NE
decrease xxx NE
in xx NE
membrane xxx NE
structural xxx NE
order xxx NE
at xx NE
concentrations xxx NE
of xx NE
about xxx NE
10(-6) dd(-d) NE
M X NE
in xx NE
a x NE
concentration-dependent xxx-xxx NE
manner xxx NE
. . NE

We Xx NE
found xxx NE
a x NE
correlation xxx NE
between xxx NE
the xxx NE
uptake xxx NE
of xx NE
dexamethasone xxx NE
by xx NE
the xxx NE
ghost xxx NE
membranes xxx NE
and xxx NE
the xxx NE
decrease xxx NE
in xx NE
the xxx NE
structural xxx NE
order xxx NE
. . NE

The Xxx NE
other xxx NE
glucocorticoids xxx NE
tested xxx NE
, , NE
methylprednisolone xxx NE
and xxx NE
corticosterone xxx NE
, , NE
were xxx NE
also xxx NE
effective xxx NE
at xx NE
concentrations xxx NE
of xx NE
10(-5) dd(-d) NE
M X NE
or xx NE
greater xxx NE
. . NE

We Xx NE
observed xxx NE
no xx NE
change xxx NE
in xx NE
membrane xxx NE
structural xxx NE
order xxx NE
with xxx NE
RU XX NE
486 ddd NE
up xx NE
to xx NE
a x NE
concentration xxx NE
of xx NE
10(-4) dd(-d) NE
M X NE
. . NE

However Xxxx NE
, , NE
simultaneous xxx NE
incubation xxx NE
of xx NE
RU XX NE
486 ddd NE
with xxx NE
dexamethasone xxx NE
caused xxx NE
a x NE
distinct xxx NE
interference xxx NE
of xx NE
RU XX NE
486 ddd NE
with xxx NE
dexamethasone xxx NE
. . NE

Thus Xxxx NE
, , NE
the xxx NE
glucocorticoid xxx NE
-induced -xxx NE
membrane xxx NE
perturbation xxx NE
, , NE
the xxx NE
possibility xxx NE
to xx NE
inhibit xxx NE
it xx NE
by xx NE
RU XX NE
486 ddd NE
, , NE
and xxx NE
the xxx NE
inactivity xxx NE
of xx NE
the xxx NE
structurally xxx NE
related xxx NE
progesterone xxx NE
, , NE
refer xxx NE
to xx NE
relatively xxx NE
specific xxx NE
binding xxx NE
sites xxx NE
for xxx NE
the xxx NE
glucocorticoids xxx NE
in xx NE
the xxx NE
membrane xxx NE
of xx NE
erythrocyte xxx NE
ghosts xxx NE
. . NE

Mutation Xxxx NE
of xx NE
tyrosines xxx NE
492/493 ddd/ddd NE
in xx NE
the xxx NE
kinase xxx protein_B
domain xxx protein_E
of xx NE
ZAP-70 XXX-dd protein
affects xxx NE
multiple xxx NE
T-cell X-xxx NE
receptor xxx NE
signaling xxx NE
pathways xxx NE
. . NE

The Xxx NE
protein-tyrosine xxx-xxx protein_B
kinase xxx protein_E
ZAP-70 XXX-dd protein
is xx NE
implicated xxx NE
, , NE
together xxx NE
with xxx NE
the xxx NE
Src Xxx protein_B
kinase xxx protein_E
p56(lck) xdd(xxx) protein
, , NE
in xx NE
controlling xxx NE
the xxx NE
early xxx NE
steps xxx NE
of xx NE
the xxx NE
T-cell X-xxx NE
antigen xxx NE
receptor xxx NE
( ( NE
TCR XXX NE
) ) NE
signaling xxx NE
cascade xxx NE
. . NE

To Xx NE
help xxx NE
elucidate xxx NE
further xxx NE
the xxx NE
mechanism xxx NE
by xx NE
which xxx NE
ZAP-70 XXX-dd protein
regulates xxx NE
these xxx NE
initial xxx NE
events xxx NE
, , NE
we xx NE
used xxx NE
a x NE
dominant-negative xxx-xxx NE
mutant xxx NE
approach xxx NE
. . NE

We Xx NE
overexpressed xxx NE
in xx NE
the xxx NE
Jurkat Xxxx cell_line_B
T-cell X-xxx cell_line_M
line xxx cell_line_E
ZAP-70 XXX-dd protein
mutated xxx NE
on xx NE
Tyr-492 Xxx-ddd NE
and xxx NE
Tyr-493 Xxx-ddd NE
in xx NE
the xxx NE
putative xxx NE
regulatory xxx NE
loop xxx NE
of xx NE
its xxx NE
kinase xxx protein_B
domain xxx protein_E
. . NE

This Xxxx NE
mutant xxx NE
inhibited xxx NE
TCR XXX NE
-induced -xxx NE
activation xxx NE
of xx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
by xx NE
interfering xxx NE
with xxx NE
both xxx NE
intracellular xxx NE
calcium xxx NE
increase xxx NE
and xxx NE
Ras Xxx NE
-regulated -xxx NE
activation xxx NE
of xx NE
extracellular xxx NE
signal-regulated xxx-xxx NE
kinases xxx NE
. . NE

Moreover Xxxx NE
, , NE
TCR XXX NE
-induced -xxx NE
phosphorylation xxx NE
of xx NE
pp36-38 xxdd-dd NE
, , NE
thought xxx NE
to xx NE
play xxx NE
a x NE
role xxx NE
upstream xxx NE
of xx NE
these xxx NE
pathways xxx NE
, , NE
was xxx NE
found xxx NE
to xx NE
be xx NE
reduced xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
overexpression xxx NE
of xx NE
wild-type xxx-xxx protein_B
ZAP-70 XXX-dd protein_E
induced xxx NE
constitutive xxx NE
activation xxx NE
of xx NE
nuclear xxx protein_B
factor xxx protein_M
of xx protein_M
activated xxx protein_M
T X protein_M
cells xxx protein_E
. . NE

The Xxx NE
ZAP-70 XXX-dd protein
mutant xxx NE
studied xxx NE
here xxx NE
could xxx NE
be xx NE
phosphorylated xxx NE
on xx NE
tyrosine xxx NE
when xxx NE
associated xxx NE
to xx NE
the xxx NE
TCR XXX protein_B
zeta xxx protein_M
chain xxx protein_E
and xxx NE
was xxx NE
able xxx NE
to xx NE
bind xxx NE
p56(lck) xdd(xxx) protein
. . NE

This Xxxx NE
result xxx NE
demonstrates xxx NE
that xxx NE
Tyr-492 Xxx-ddd NE
and xxx NE
Tyr-493 Xxx-ddd NE
are xxx NE
not xxx NE
responsible xxx NE
for xxx NE
the xxx NE
Src Xxx NE
homology xxx NE
domain xxx NE
2-mediated d-xxx NE
association xxx NE
of xx NE
p56(lck) xdd(xxx) protein
with xxx NE
ZAP-70 XXX-dd protein
. . NE

Our Xxx NE
data xxx NE
are xxx NE
most xxx NE
consistent xxx NE
with xxx NE
a x NE
model xxx NE
in xx NE
which xxx NE
recruitment xxx NE
to xx NE
the xxx NE
TCR XXX protein
allows xxx NE
ZAP-70 XXX-dd NE
autophosphorylation xxx NE
and xxx NE
binding xxx NE
to xx NE
p56(lck) xdd(xxx) protein
, , NE
which xxx NE
in xx NE
turn xxx NE
phosphorylates xxx NE
Tyr-492 Xxx-ddd NE
and/or xxx/xx NE
Tyr-493 Xxx-ddd NE
with xxx NE
consequent xxx NE
up-regulation xx-xxx NE
of xx NE
the xxx NE
ZAP-70 XXX-dd NE
kinase xxx NE
activity xxx NE
. . NE

ZAP-70 XXX-dd protein
will xxx NE
then xxx NE
be xx NE
able xxx NE
to xx NE
effectively xxx NE
control xxx NE
phosphorylation xxx NE
of xx NE
its xxx NE
substrates xxx NE
and xxx NE
lead xxx NE
to xx NE
gene xxx NE
activation xxx NE
. . NE

Effects Xxxx NE
of xx NE
glucocorticoids xxx NE
on xx NE
lymphocyte xxx NE
activation xxx NE
in xx NE
patients xxx NE
with xxx NE
steroid-sensitive xxx-xxx NE
asthma xxx NE
and xxx NE
steroid-resistant xxx-xxx NE
asthma xxx NE

BACKGROUND XXXXXXXXXX NE
: : NE
Glucocorticoids Xxxx NE
are xxx NE
important xxx NE
medications xxx NE
used xxx NE
to xx NE
control xxx NE
the xxx NE
airway xxx NE
inflammation xxx NE
associated xxx NE
with xxx NE
asthma xxx NE
. . NE

Synthetic Xxxx NE
glucocorticoids xxx NE
vary xxx NE
in xx NE
their xxx NE
binding xxx NE
affinity xxx NE
for xxx NE
the xxx NE
glucocorticoid xxx NE
receptor xxx NE
(GCR) (XXX) NE
. . NE

METHODS XXXXXXX NE
: : NE
We Xx NE
compared xxx NE
hydrocortisone xxx NE
, , NE
beclomethasone xxx NE
dipropionate xxx NE
, , NE
triamcinolone xxx NE
acetonide xxx NE
, , NE
flunisolide xxx NE
, , NE
and xxx NE
budesonide xxx NE
with xxx NE
regard xxx NE
to xx NE
their xxx NE
capacity xxx NE
to xx NE
inhibit xxx NE
phytohemagglutinin xxx NE
-induced -xxx NE
peripheral xxx NE
blood xxx NE
mononuclear xxx NE
cell xxx NE
proliferation xxx NE
from xxx NE
six xxx NE
patients xxx NE
with xxx NE
steroid-sensitive xxx-xxx NE
asthma xxx NE
and xxx NE
seven xxx NE
patients xxx NE
with xxx NE
steroid-resistant xxx-xxx NE
asthma xxx NE
. . NE

Peripheral Xxxx NE
blood xxx NE
mononuclear xxx NE
cell xxx NE
GCR XXX NE
binding xxx NE
affinities xxx NE
for xxx NE
dexamethasone xxx NE
and xxx NE
budesonide xxx NE
were xxx NE
also xxx NE
determined xxx NE
for xxx NE
both xxx NE
patient xxx NE
groups xxx NE
by xx NE
using xxx NE
a x NE
radioligand xxx NE
binding xxx NE
assay xxx NE
and xxx NE
Scatchard Xxxx NE
analysis xxx NE
. . NE

RESULTS XXXXXXX NE
: : NE
Dose-dependent Xxxx-xxx NE
inhibition xxx NE
was xxx NE
demonstrated xxx NE
for xxx NE
all xxx NE
glucocorticoids xxx NE
in xx NE
both xxx NE
patient xxx NE
groups xxx NE
, , NE
with xxx NE
the xxx NE
steroid-resistant xxx-xxx NE
group xxx NE
requiring xxx NE
approximately xxx NE
2 d NE
log-fold xxx-xxx NE
more xxx NE
glucocorticoids xxx NE
for xxx NE
an xx NE
equivalent xxx NE
degree xxx NE
of xx NE
inhibition xxx NE
. . NE

The Xxx NE
mean xxx NE
concentrations xxx NE
necessary xxx NE
to xx NE
cause xxx NE
50% dd% NE
inhibition xxx NE
of xx NE
lymphocyte xxx NE
proliferation xxx NE
( ( NE
IC50s XXddx NE
) ) NE
for xxx NE
the xxx NE
steroid-sensitive xxx-xxx NE
group xxx NE
ranged xxx NE
from xxx NE
2 d NE
x x NE
10(-10) dd(-dd) NE
mol/L xxx/X NE
for xxx NE
budesonide xxx NE
to xx NE
7 d NE
x x NE
10(-8) dd(-d) NE
mol/L xxx/X NE
for xxx NE
hydrocortisone xxx NE
, , NE
whereas xxx NE
the xxx NE
mean xxx NE
IC50s XXddx NE
for xxx NE
the xxx NE
steroid-resistant xxx-xxx NE
group xxx NE
ranged xxx NE
from xxx NE
approximately xxx NE
2 d NE
x x NE
10(-8) dd(-d) NE
mol/L xxx/X NE
for xxx NE
budesonide xxx NE
to xx NE
greater xxx NE
than xxx NE
10(-6) dd(-d) NE
mol/L xxx/X NE
for xxx NE
hydrocortisone xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
a x NE
significant xxx NE
correlation xxx NE
was xxx NE
noted xxx NE
between xxx NE
the xxx NE
degree xxx NE
of xx NE
inhibition xxx NE
of xx NE
lymphocyte xxx NE
proliferation xxx NE
( ( NE
IC50 XXdd NE
) ) NE
and xxx NE
the xxx NE
binding xxx NE
affinity xxx NE
of xx NE
dexamethasone xxx NE
to xx NE
the xxx NE
GCR XXX protein
. . NE

Patients Xxxx NE
with xxx NE
steroid-resistant xxx-xxx NE
asthma xxx NE
have xxx NE
been xxx NE
shown xxx NE
to xx NE
have xxx NE
a x NE
reduced xxx NE
GCR XXX NE
binding xxx NE
affinity xxx NE
. . NE

The Xxx NE
GCR XXX NE
binding xxx NE
affinity xxx NE
for xxx NE
budesonide xxx NE
was xxx NE
significantly xxx NE
higher xxx NE
in xx NE
both xxx NE
groups xxx NE
(i.e. (x.x. NE
, , NE
lower xxx NE
dissociation xxx NE
constant xxx NE
) ) NE
than xxx NE
that xxx NE
obtained xxx NE
for xxx NE
dexamethasone xxx NE
. . NE

CONCLUSION XXXXXXXXXX NE
: : NE
These Xxxx NE
data xxx NE
suggest xxx NE
that xxx NE
glucocorticoids xxx NE
such xxx NE
as xx NE
budesonide xxx NE
, , NE
by xx NE
virtue xxx NE
of xx NE
their xxx NE
high xxx NE
GCR XXX NE
binding xxx NE
affinities xxx NE
and xxx NE
greater xxx NE
ability xxx NE
to xx NE
suppress xxx NE
lymphocyte xxx NE
proliferation xxx NE
, , NE
may xxx NE
therefore xxx NE
be xx NE
beneficial xxx NE
in xx NE
the xxx NE
management xxx NE
of xx NE
difficult-to-control xxx-xx-xxx NE
asthma xxx NE
. . NE

Characterization Xxxx NE
of xx NE
the xxx NE
murine xxx DNA_B
cyclin-dependent xxx-xxx DNA_M
kinase xxx DNA_M
inhibitor xxx DNA_M
gene xxx DNA_E
p27Kip1 xddXxxd DNA
. . NE

The Xxx NE
cyclin-dependent xxx-xxx DNA_B
kinase xxx DNA_M
inhibitor xxx DNA_E
p27Kip1 xddXxxd DNA
plays xxx NE
an xx NE
important xxx NE
role xxx NE
in xx NE
regulating xxx NE
cell-cycle xxx-xxx NE
progression xxx NE
. . NE

p27Kip1 xddXxxd DNA
directly xxx NE
inhibits xxx NE
the xxx NE
catalytic xxx NE
activity xxx NE
of xx NE
cyclin/cdks xxx/xxx NE
( ( NE
cyclin-dependent xxx-xxx NE
kinase xxx NE
) ) NE
complexes xxx NE
and/or xxx/xx NE
interferes xxx NE
physically xxx NE
with xxx NE
cyclin/cdks xxx/xxx NE
activation xxx NE
by xx NE
CAK XXX NE
. . NE

Interestingly Xxxx NE
, , NE
the xxx NE
expression xxx NE
level xxx NE
of xx NE
p27Kip1 xddXxxd RNA_B
mRNA xXXX RNA_E
was xxx NE
maximal xxx NE
in xx NE
resting xxx cell_type_B
Go Xx cell_type_M
T-cells X-xxx cell_type_E
and xxx NE
rapidly xxx NE
declined xxx NE
following xxx NE
anti-CD3 xxx-XXd NE
activation xxx NE
. . NE

We Xx NE
report xxx NE
here xxx NE
the xxx NE
cloning xxx NE
of xx NE
p27Kip1 xddXxxd DNA_B
gene xxx DNA_E
from xxx NE
murine xxx DNA_B
genomic xxx DNA_M
DNA XXX DNA_E
and xxx NE
the xxx NE
functional xxx NE
analysis xxx NE
of xx NE
the xxx NE
promoter xxx NE
of xx NE
the xxx NE
p27Kip1 xddXxxd DNA
gene xxx NE
. . NE

The Xxx NE
gene xxx NE
consists xxx NE
of xx NE
at xx NE
least xxx NE
three xxx NE
exons xxx NE
and xxx NE
spans xxx NE
more xxx NE
than xxx NE
5.6 d.d DNA_B
kb xx DNA_M
of xx DNA_M
DNA XXX DNA_E
. . NE

Primer Xxxx NE
extension xxx NE
and xxx NE
nuclease xxx NE
S1 Xd NE
protection xxx NE
analysis xxx NE
revealed xxx NE
two xxx NE
major xxx NE
transcription xxx DNA_B
initiation xxx DNA_M
sites xxx DNA_E
. . NE

The Xxx NE
promoter xxx DNA_B
region xxx DNA_E
lacked xxx NE
a x NE
TATA XXXX DNA_B
box xxx DNA_E
but xxx NE
contained xxx NE
potential xxx NE
binding xxx NE
sites xxx NE
for xxx NE
the xxx NE
transcriptional xxx protein_B
factors xxx protein_E
including xxx NE
two xxx NE
Sp1 Xxd protein
, , NE
CRE XXX protein
, , NE
Myb Xxx protein
and xxx NE
NFkB XXxX protein
located xxx NE
at xx NE
positions xxx NE
position xxx DNA_B
-153 -ddd DNA_M
and xxx DNA_M
position xxx DNA_M
-178 -ddd DNA_M
and xxx DNA_M
position xxx DNA_M
-286 -ddd DNA_M
and xxx DNA_M
position xxx DNA_M
-875 -ddd DNA_M
and xxx DNA_M
position xxx DNA_M
-1011 -dddd DNA_E

To Xx NE
analyze xxx NE
the xxx NE
regulatory xxx NE
mechanisms xxx NE
controlling xxx NE
p27Kip1 xddXxxd DNA
gene xxx NE
expression xxx NE
, , NE
we xx NE
characterized xxx NE
the xxx NE
5'-flanking d'-xxx DNA_B
region xxx DNA_E
from xxx NE
nt xx DNA_B
-1609 -dddd DNA_M
to xx DNA_M
+178 +ddd DNA_E
. . NE

The Xxx NE
-326 -ddd DNA_B
to xx DNA_M
-615 -ddd DNA_M
region xxx DNA_E
contained xxx NE
positive xxx DNA_B
regulatory xxx DNA_M
elements xxx DNA_E
. . NE

Nuclear Xxxx protein_B
NF-ATp XX-XXx protein_E
is xx NE
a x NE
hallmark xxx NE
of xx NE
unstimulated xxx cell_type_B
B X cell_type_M
cells xxx cell_type_E
from xxx NE
B-CLL X-XXX NE
patients xxx NE
. . NE

B X cell_type_B
lymphocytes xxx cell_type_E
from xxx NE
the xxx NE
peripheral xxx NE
blood xxx NE
of xx NE
patients xxx NE
with xxx NE
chronic xxx NE
lymphocytic xxx NE
leukaemia xxx NE
( ( NE
CLL XXX NE
) ) NE
were xxx NE
analysed xxx NE
for xxx NE
the xxx NE
nuclear xxx NE
presence xxx NE
and xxx NE
DNA XXX NE
binding xxx NE
of xx NE
a x NE
panel xxx NE
of xx NE
transcription xxx protein_B
factors xxx protein_E
which xxx NE
are xxx NE
involved xxx NE
in xx NE
the xxx NE
gene xxx NE
control xxx NE
of xx NE
lymphoid xxx cell_type_B
cells xxx cell_type_E
. . NE

The Xxx NE
following xxx NE
transcription xxx protein_B
factors xxx protein_E
were xxx NE
studied xxx NE
: : NE
the xxx NE
Octamer Xxxx protein_B
factors xxx protein_E
Oct-1 Xxx-d protein
and xxx NE
Oct-2 Xxx-d protein
, , NE
members xxx NE
of xx NE
the xxx NE
AP-1 XX-d protein_B
factor xxx protein_M
family xxx protein_E
, , NE
NF-AT XX-XX protein_B
factors xxx protein_E
, , NE
in xx NE
particular xxx NE
NF-ATp XX-XXx protein
, , NE
and xxx NE
members xxx NE
of xx NE
the xxx NE
Rel/NF-kB Xxx/XX-xX protein_B
family xxx protein_E
. . NE

We Xx NE
show xxx NE
that xxx NE
the xxx NE
constitutive xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
NF-ATp XX-XXx protein
, , NE
a x NE
member xxx NE
of xx NE
the xxx NE
growing xxx NE
family xxx NE
of xx NE
NF-AT XX-XX protein_B
factors xxx protein_E
, , NE
is xx NE
a x NE
hallmark xxx NE
of xx NE
nonstimulated xxx cell_type_B
B X cell_type_M
cells xxx cell_type_E
from xxx NE
CLL XXX NE
patients xxx NE
that xxx NE
distinguishes xxx NE
B-CLL X-XXX cell_type_B
cells xxx cell_type_E
from xxx NE
'normal' 'xxx' cell_type_B
B X cell_type_M
lymphocytes xxx cell_type_E
. . NE

Constitutive Xxxx NE
nuclear xxx NE
appearance xxx NE
was xxx NE
also xxx NE
observed xxx NE
for xxx NE
NF-kB2/p52 XX-xXd/xdd NE
. . NE

Constitutive Xxxx NE
binding xxx NE
of xx NE
further xxx NE
factor xxx protein_B
proteins xxx protein_E
to xx NE
DNA XXX NE
, , NE
such xxx NE
as xx NE
JunD XxxX protein
, , NE
c-Fos x-Xxx protein
and xxx NE
FosB XxxX protein
, , NE
was xxx NE
detected xxx NE
in xx NE
several xxx NE
patients xxx NE
whereas xxx NE
the xxx NE
localisation xxx NE
and xxx NE
DNA XXX NE
binding xxx NE
of xx NE
other xxx NE
factors xxx NE
such xxx NE
as xx NE
c-Jun x-Xxx protein
, , NE
RelA/p65 XxxX/xdd protein
and xxx NE
c-Rel x-Xxx protein
was xxx NE
unaltered xxx NE
. . NE

It Xx NE
is xx NE
remarkable xxx NE
that xxx NE
in xx NE
B-CLL X-XXX cell_type_B
cells xxx cell_type_E
the xxx NE
nuclear xxx NE
appearance xxx NE
and xxx NE
DNA XXX NE
binding xxx NE
of xx NE
specific xxx NE
transcription xxx protein_B
factors xxx protein_E
is xx NE
dramatically xxx NE
affected xxx NE
whereas xxx NE
other xxx NE
members xxx NE
of xx NE
the xxx NE
same xxx NE
factor xxx protein_B
family xxx protein_E
remained xxx NE
unaltered xxx NE
in xx NE
these xxx NE
leukemic xxx NE
cells xxx NE
. . NE

It Xx NE
remains xxx NE
to xx NE
be xx NE
shown xxx NE
which xxx NE
molecular xxx NE
events xxx NE
lead xxx NE
to xx NE
the xxx NE
specific xxx NE
'pre-activation' 'xxx-xxx' NE
, , NE
i.e x.x NE
. . NE

constitutive xxx NE
nuclear xxx NE
translocation xxx NE
and xxx NE
DNA XXX NE
binding xxx NE
, , NE
of xx NE
these xxx NE
members xxx NE
of xx NE
NF-AT XX-XX protein
, , NE
NF-kB XX-xX protein
and xxx NE
AP-1 XX-d NE
factor xxx NE
families xxx NE
. . NE

Naive Xxxx cell_type_B
(CD45RA+) (XXddXX+) cell_type_M
T X cell_type_M
lymphocytes xxx cell_type_E
are xxx NE
more xxx NE
sensitive xxx NE
to xx NE
oxidative xxx NE
stress-induced xxx-xxx NE
signals xxx NE
than xxx NE
memory xxx cell_type_B
(CD45RO+) (XXddXX+) cell_type_M
cells xxx cell_type_E
. . NE

Formation Xxxx NE
of xx NE
reactive xxx NE
oxygen xxx NE
intermediates xxx NE
( ( NE
ROI XXX NE
) ) NE
after xxx NE
oxidative xxx NE
stress xxx NE
has xxx NE
been xxx NE
shown xxx NE
to xx NE
be xx NE
an xx NE
activation xxx NE
signal xxx NE
for xxx NE
T X cell_type_B
lymphocytes xxx cell_type_E
, , NE
e.g. x.x. NE
, , NE
expression xxx NE
of xx NE
IL-2 XX-d protein
and xxx NE
its xxx NE
receptor xxx NE
are xxx NE
induced xxx NE
. . NE

These Xxxx NE
ROI XXX NE
-induced -xxx NE
effects xxx NE
can xxx NE
, , NE
to xx NE
a x NE
large xxx NE
extent xxx NE
, , NE
be xx NE
attributed xxx NE
to xx NE
the xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappaB XX-xxxX NE
. . NE

Now Xxx NE
we xx NE
have xxx NE
examined xxx NE
whether xxx NE
naive xxx cell_type_B
T X cell_type_M
lymphocyte xxx cell_type_M
and xxx cell_type_M
memory xxx cell_type_M
T X cell_type_M
lymphocyte xxx cell_type_E
differ xxx NE
in xx NE
their xxx NE
sensitivity xxx NE
to xx NE
ROI XXX NE
-mediated -xxx NE
signals xxx NE
. . NE

When Xxxx NE
CD45RA+ XXddXX+ NE
(naive) (xxx) NE
and xxx NE
CD45RO+ XXddXX+ NE
(memory) (xxx) NE
T X NE
lymphocytes xxx NE
were xxx NE
directly xxx NE
stimulated xxx NE
with xxx NE
H2O2 XdXd NE
, , NE
NF-kappaB XX-xxxX NE
nuclear xxx NE
translocation xxx NE
was xxx NE
stronger xxx NE
in xx NE
naive xxx NE
cells xxx NE
than xxx NE
in xx NE
memory xxx NE
cells xxx NE
and xxx NE
it xx NE
could xxx NE
be xx NE
induced xxx NE
with xxx NE
lower xxx NE
doses xxx NE
. . NE

The Xxx NE
composition xxx NE
of xx NE
the xxx NE
induced xxx NE
nuclear xxx protein_B
NF-kappaB XX-xxxX protein_E
(levels (xxx NE
of xx NE
p50 xdd protein
and xxx NE
RelA XxxX protein_B
proteins xxx protein_E
) ) NE
was xxx NE
similar xxx NE
in xx NE
these xxx NE
cell xxx NE
types xxx NE
. . NE

The Xxx NE
magnitude xxx NE
and xxx NE
kinetics xxx NE
of xx NE
intracellular xxx NE
ROI XXX NE
were xxx NE
similar xxx NE
, , NE
suggesting xxx NE
that xxx NE
there xxx NE
were xxx NE
no xx NE
differences xxx NE
in xx NE
ROI XXX NE
-forming -xxx NE
mechanisms xxx NE
or xx NE
antioxidative xxx NE
capacities xxx NE
. . NE

The Xxx NE
probable xxx NE
regulatory xxx NE
point xxx NE
was xxx NE
the xxx NE
cytoplasmic xxx NE
IkappaB XxxxX NE
inhibitor xxx NE
: : NE
in xx NE
CD45RA+ XXddXX+ NE
cells xxx NE
, , NE
H2O2 XdXd NE
caused xxx NE
a x NE
more xxx NE
profound xxx NE
depression xxx NE
in xx NE
the xxx NE
levels xxx NE
of xx NE
IkappaB XxxxX protein_B
alpha xxx protein_E
. . NE

These Xxxx NE
findings xxx NE
indicate xxx NE
that xxx NE
T X cell_type_B
cells xxx cell_type_E
representing xxx NE
different xxx NE
activation xxx NE
and/or xxx/xx NE
differentiation xxx NE
stages xxx NE
can xxx NE
be xx NE
differentially xxx NE
responsive xxx NE
to xx NE
ROI XXX NE
-mediated -xxx NE
signals xxx NE
. . NE

Rapid Xxxx NE
shuttling xxx NE
of xx NE
NF-AT XX-XX protein
in xx NE
discrimination xxx NE
of xx NE
Ca2+ Xxd+ NE
signals xxx NE
and xxx NE
immunosuppression xxx NE
. . NE

Cells Xxxx NE
need xxx NE
to xx NE
distinguish xxx NE
between xxx NE
transient xxx NE
Ca2+ Xxd+ NE
signals xxx NE
that xxx NE
induce xxx NE
events xxx NE
such xxx NE
as xx NE
muscle xxx NE
contraction xxx NE
, , NE
secretion xxx NE
, , NE
adhesion xxx NE
and xxx NE
synaptic xxx NE
transmission xxx NE
, , NE
and xxx NE
sustained xxx NE
Ca2+ Xxd+ NE
signals xxx NE
that xxx NE
are xxx NE
involved xxx NE
in xx NE
cell xxx NE
proliferation xxx NE
and xxx NE
differentiation xxx NE
. . NE

The Xxx NE
latter xxx NE
class xxx NE
of xx NE
events xxx NE
is xx NE
blocked xxx NE
in xx NE
lymphocytes xxx cell_type
by xx NE
the xxx NE
immunosuppressive xxx NE
drugs xxx NE
cyclosporin xxx NE
A X NE
and xxx NE
FK506 XXddd NE
, , NE
which xxx NE
inhibit xxx NE
calcineurin xxx protein
, , NE
a x NE
Ca2+ Xxd+ NE
-activated -xxx NE
serine/threonine xxx/xxx NE
phosphatase xxx NE
necessary xxx NE
for xxx NE
the xxx NE
nuclear xxx NE
import xxx NE
of xx NE
NF-AT XX-XX NE
transcription xxx NE
factors xxx NE
. . NE

Here Xxxx NE
we xx NE
report xxx NE
that xxx NE
sustained xxx NE
high xxx NE
concentrations xxx NE
of xx NE
Ca2+ Xxd+ NE
, , NE
but xxx NE
not xxx NE
transient xxx NE
pulses xxx NE
, , NE
are xxx NE
required xxx NE
to xx NE
maintain xxx NE
NF-AT XX-XX protein
transcription xxx protein_B
factors xxx protein_E
in xx NE
the xxx NE
nucleus xxx NE
, , NE
where xxx NE
they xxx NE
participate xxx NE
in xx NE
Ca2+ Xxd+ NE
-dependent -xxx NE
induction xxx NE
of xx NE
genes xxx NE
required xxx NE
for xxx NE
lymphocyte xxx NE
activation xxx NE
and xxx NE
proliferation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
overexpression xxx NE
and xxx NE
constitutive xxx NE
nuclear xxx NE
localization xxx NE
of xx NE
NF-AT XX-XX protein
, , NE
but xxx NE
not xxx NE
Jun Xxx protein_B
family xxx protein_M
member xxx protein_M
or xx protein_M
Fos Xxx protein_M
family xxx protein_M
member xxx protein_M
or xx protein_M
NF-kappaB XX-xxxX protein_M
family xxx protein_M
member xxx protein_M
or xx protein_M
Oct Xxx protein_M
family xxx protein_M
member xxx protein_M
or xx protein_M
Ets Xxx protein_M
family xxx protein_M
member xxx protein_E
in xx NE
Jurkat Xxxx cell_line_B
T X cell_line_M
lymphocytes xxx cell_line_E
resistant xxx NE
to xx NE
FK506 XXddd NE
and xxx NE
cyclosporin xxx NE
A X NE
. . NE

Thus Xxxx NE
a x NE
primary xxx NE
effect xxx NE
of xx NE
these xxx NE
immunosuppressive xxx NE
reagents xxx NE
is xx NE
to xx NE
control xxx NE
the xxx NE
subcellular xxx NE
localization xxx NE
of xx NE
the xxx NE
NF-AT XX-XX protein
family xxx NE
of xx NE
transcription xxx protein_B
factors xxx protein_E
. . NE

Autoregulation Xxxx NE
of xx NE
the xxx NE
NF-kappa XX-xxx protein_B
B X protein_M
transactivator xxx protein_E
RelA XxxX protein
( ( NE
p65 xdd protein
) ) NE
by xx NE
multiple xxx NE
cytoplasmic xxx protein_B
inhibitors xxx protein_E
containing xxx NE
ankyrin xxx protein_B
motifs xxx protein_E
. . NE

RelA XxxX protein
( ( NE
p65 xdd protein
) ) NE
functions xxx NE
as xx NE
the xxx NE
critical xxx NE
transactivating xxx NE
component xxx NE
of xx NE
the xxx NE
heterodimeric xxx NE
p50- xdd- NE
p65 xdd NE
NF-kappa XX-xxx NE
B X NE
complex xxx NE
and xxx NE
contains xxx NE
a x NE
high-affinity xxx-xxx NE
binding xxx NE
site xxx NE
for xxx NE
its xxx NE
cytoplasmic xxx NE
inhibitor xxx NE
, , NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
. . NE

After Xxxx NE
cellular xxx NE
activation xxx NE
, , NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
is xx NE
rapidly xxx NE
degraded xxx NE
in xx NE
concert xxx NE
with xxx NE
the xxx NE
induced xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
. . NE

The Xxx NE
present xxx NE
study xxx NE
demonstrates xxx NE
that xxx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
alpha xxx NE
-induced -xxx NE
degradation xxx NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
in xx NE
human xxx NE
T X NE
cells xxx NE
is xx NE
preceded xxx NE
by xx NE
its xxx NE
rapid xxx NE
phosphorylation xxx NE
in xx NE
vivo xxx NE
. . NE

However Xxxx NE
, , NE
these xxx NE
effects xxx NE
on xx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
result xxx NE
in xx NE
nuclear xxx NE
mobilization xxx NE
of xx NE
only xxx NE
a x NE
fraction xxx NE
of xx NE
the xxx NE
entire xxx NE
cytoplasmic xxx NE
pool xxx NE
of xx NE
RelA XxxX protein
. . NE

Subsequent Xxxx NE
studies xxx NE
have xxx NE
revealed xxx NE
that xxx NE
(i) (x) NE
cytoplasmic xxx protein_B
RelA XxxX protein_E
is xx NE
stably xxx NE
associated xxx NE
not xxx NE
only xxx NE
with xxx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
but xxx NE
also xxx NE
with xxx NE
other xxx NE
ankyrin xxx protein_B
motif-rich xxx-xxx protein_M
proteins xxx protein_E
including xxx NE
the xxx NE
products xxx NE
of xx NE
the xxx NE
NF-kappa XX-xxx DNA_B
B2 Xd DNA_M
(p100) (xddd) DNA_M
genes xxx DNA_M
and xxx DNA_M
NF-kappa XX-xxx DNA_M
B1 Xd DNA_M
(p105) (xddd) DNA_M
genes xxx DNA_E
RelA XxxX NE
-I -X NE
kappa xxx NE
B X NE
alpha xxx NE
, , NE
RelA XxxX protein
-p100 -xddd NE
cytoplasmic xxx NE
complexes xxx NE
are xxx NE
not xxx NE
dissociated xxx NE
following xxx NE
tumor xxx protein_B
necrosis xxx protein_M
factor xxx protein_M
alpha xxx protein_E
activation xxx NE
; ; NE
(iii) (xxx) NE
p100 xddd protein
functions xxx NE
as xx NE
a x NE
potent xxx NE
inhibitor xxx NE
of xx NE
RelA XxxX NE
-mediated -xxx NE
transcription xxx NE
in xx NE
vivo xxx NE
; ; NE
(iv) (xx) NE
the xxx NE
interaction xxx NE
of xx NE
RelA XxxX protein
and xxx NE
p100 xddd protein
involves xxx NE
the xxx NE
conserved xxx protein_B
Rel Xxx protein_M
homology xxx protein_M
domain xxx protein_E
of xx NE
both xxx NE
proteins xxx NE
but xxx NE
not xxx NE
the xxx NE
nuclear xxx protein_B
localization xxx protein_M
signal xxx protein_E
of xx NE
RelA XxxX protein
, , NE
which xxx NE
is xx NE
required xxx NE
for xxx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
binding xxx NE
; ; NE
(v) (x) NE
p100 xddd protein
inhibition xxx NE
of xx NE
RelA XxxX protein
function xxx NE
requires xxx NE
the xxx NE
C-terminal X-xxx protein_B
ankyrin xxx protein_M
motif xxx protein_M
domain xxx protein_E
, , NE
which xxx NE
mediates xxx NE
cytoplasmic xxx NE
retention xxx NE
of xx NE
RelA XxxX protein
; ; NE
and xxx NE
(vi) (xx) NE
as xx NE
observed xxx NE
with xxx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
, , NE
nuclear xxx NE
RelA XxxX protein
stimulates xxx NE
p100 xddd protein
mRNA xXXX NE
and xxx NE
protein xxx NE
expression xxx NE
. . NE

These Xxxx NE
findings xxx NE
thus xxx NE
reveal xxx NE
the xxx NE
presence xxx NE
of xx NE
a x NE
second xxx NE
inducible xxx NE
autoregulated xxx NE
inhibitory xxx NE
pathway xxx NE
that xxx NE
helps xxx NE
ensure xxx NE
the xxx NE
rapid xxx NE
but xxx NE
transient xxx NE
action xxx NE
of xx NE
nuclear xxx protein_B
NF-kappa XX-xxx protein_M
B X protein_E
. . NE

Effects Xxxx NE
of xx NE
CD45 XXdd protein
on xx NE
NF-kappa XX-xxx protein_B
B X protein_E
. . NE

Implications Xxxx NE
for xxx NE
replication xxx NE
of xx NE
HIV-1 XXX-d NE
. . NE

Increased Xxxx NE
levels xxx NE
of xx NE
replication xxx NE
of xx NE
the xxx NE
HIV XXX NE
type xxx NE
1 d NE
are xxx NE
observed xxx NE
after xxx NE
the xxx NE
activation xxx NE
of xx NE
infected xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
through xxx NE
the xxx NE
TCR XXX protein
. . NE

However Xxxx NE
, , NE
anti- xxx- NE
CD45 XXdd protein
antibodies xxx NE
inhibit xxx NE
these xxx NE
effects xxx NE
in xx NE
cells xxx NE
from xxx NE
infected xxx NE
individuals xxx NE
. . NE

In Xx NE
this xxx NE
study xxx NE
, , NE
we xx NE
examined xxx NE
interrelationships xxx NE
between xxx NE
CD45 XXdd protein
and xxx NE
HIV-1 XXX-d NE
further xxx NE
. . NE

We Xx NE
measured xxx NE
effects xxx NE
on xx NE
the xxx NE
HIV-1 XXX-d DNA_B
LTR XXX DNA_E
in xx NE
T X cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
that xxx NE
were xxx NE
stimulated xxx NE
with xxx NE
antibodies xxx NE
against xxx NE
CD45 XXdd protein
and xxx NE
in xx NE
those xxx NE
that xxx NE
lacked xxx NE
the xxx NE
expression xxx NE
of xx NE
CD45 XXdd protein
on xx NE
their xxx NE
surfaces xxx NE
. . NE

First Xxxx NE
, , NE
anti- xxx- NE
CD45 XXdd NE
antibodies xxx NE
did xxx NE
not xxx NE
affect xxx NE
basal xxx NE
but xxx NE
decreased xxx NE
activated xxx NE
levels xxx NE
of xx NE
expression xxx NE
from xxx NE
the xxx NE
HIV-1 XXX-d NE
LTR XXX NE
. . NE

Second Xxxx NE
, , NE
T X cell_type_B
cells xxx cell_type_E
, , NE
which xxx NE
lack xxx NE
CD45 XXdd protein
and xxx NE
cannot xxx NE
signal xxx NE
via xxx NE
the xxx NE
TCR XXX protein
, , NE
supported xxx NE
higher xxx NE
levels xxx NE
of xx NE
viral xxx NE
replication xxx NE
and xxx NE
gene xxx NE
expression xxx NE
. . NE

This Xxxx NE
was xxx NE
due xxx NE
to xx NE
the xxx NE
presence xxx NE
of xx NE
active xxx NE
NF-kappa XX-xxx NE
B X NE
complexes xxx NE
in xx NE
the xxx NE
nucleus xxx NE
of xx NE
CD45 XXdd NE
-T -X NE
cells xxx NE
. . NE

Additionally Xxxx NE
, , NE
infected xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
displayed xxx NE
lower xxx NE
levels xxx NE
of xx NE
CD45 XXdd protein
on xx NE
their xxx NE
surfaces xxx NE
. . NE

Thus Xxxx NE
, , NE
CD45 XXdd protein
plays xxx NE
an xx NE
active xxx NE
role xxx NE
in xx NE
the xxx NE
physiology xxx NE
of xx NE
T X cell_type_B
cells xxx cell_type_E
and xxx NE
in xx NE
the xxx NE
replication xxx NE
of xx NE
HIV-1 XXX-d NE
. . NE

Calcineurin Xxxx protein
potentiates xxx NE
activation xxx NE
of xx NE
the xxx NE
granulocyte-macrophage xxx-xxx DNA_B
colony-stimulating xxx-xxx DNA_M
factor xxx DNA_M
gene xxx DNA_E
in xx NE
T X cell_type_B
cells xxx cell_type_E
: : NE
involvement xxx NE
of xx NE
the xxx NE
conserved xxx DNA_B
lymphokine xxx DNA_M
element xxx DNA_M
0 d DNA_E
. . NE

Granulocyte-macrophage Xxxx-xxx protein_B
colony-stimulating xxx-xxx protein_M
factor xxx protein_E
( ( NE
GM-CSF XX-XXX protein
) ) NE
and xxx NE
interleukin-2 xxx-d protein
( ( NE
IL-2 XX-d protein
) ) NE
are xxx NE
produced xxx NE
by xx NE
stimulation xxx NE
with xxx NE
phorbol-12-myristate xxx-dd-xxx NE
acetate xxx NE
( ( NE
PMA XXX NE
) ) NE
and xxx NE
calcium xxx NE
ionophore xxx NE
(A23187) (Xddddd) NE
in xx NE
human xxx cell_line_B
T X cell_line_M
cell xxx cell_line_M
leukemia xxx cell_line_M
Jurkat Xxxx cell_line_M
cells xxx cell_line_E
. . NE

The Xxx NE
expression xxx NE
of xx NE
GM-CSF XX-XXX protein
and xxx NE
IL-2 XX-d protein
is xx NE
inhibited xxx NE
by xx NE
immunosuppressive xxx NE
drugs xxx NE
such xxx NE
as xx NE
cyclosporin xxx NE
A X NE
( ( NE
CsA XxX NE
) ) NE
and xxx NE
FK506 XXddd NE
. . NE

Earlier Xxxx NE
studies xxx NE
on xx NE
the xxx NE
IL-2 XX-d NE
gene xxx NE
expression xxx NE
showed xxx NE
that xxx NE
overexpression xxx NE
of xx NE
calcineurin xxx protein
( ( NE
CN XX protein
) ) NE
, , NE
a x NE
Ca2+/calmodulin-dependent Xxd+/xxx-xxx protein_B
protein xxx protein_M
phosphatase xxx protein_E
, , NE
can xxx NE
stimulate xxx NE
transcription xxx NE
from xxx NE
the xxx NE
IL-2 XX-d DNA_B
promoter xxx DNA_E
through xxx NE
the xxx NE
NF-AT-binding XX-XX-xxx DNA_B
site xxx DNA_E
. . NE

In Xx NE
this xxx NE
study xxx NE
, , NE
we xx NE
obtained xxx NE
evidence xxx NE
that xxx NE
transfection xxx NE
of xx NE
the xxx NE
cDNAs xXXXx DNA
for xxx NE
CN XX protein_B
A X protein_M
(catalytic) (xxx) protein_M
subunit xxx protein_M
and xxx protein_M
CN XX protein_M
B X protein_M
(regulatory) (xxx) protein_M
subunit xxx protein_E
also xxx NE
augments xxx NE
transcription xxx NE
from xxx NE
the xxx NE
GM-CSF XX-XXX DNA_B
promoter xxx DNA_E
and xxx NE
recovers xxx NE
the xxx NE
transcription xxx NE
inhibited xxx NE
by xx NE
CsA XxX NE
. . NE

The Xxx NE
constitutively xxx NE
active xxx NE
type xxx NE
of xx NE
the xxx NE
CN XX protein_B
A X protein_M
subunit xxx protein_E
, , NE
which xxx NE
lacks xxx NE
the xxx NE
auto-inhibitory xxx-xxx NE
and xxx NE
calmodulin-binding xxx-xxx NE
domains xxx NE
, , NE
acts xxx NE
in xx NE
synergy xxx NE
with xxx NE
PMA XXX NE
to xx NE
activate xxx NE
transcription xxx NE
from xxx NE
the xxx NE
GM-CSF XX-XXX NE
promoter xxx NE
. . NE

We Xx NE
also xxx NE
found xxx NE
that xxx NE
the xxx NE
active xxx NE
CN XX protein
partially xxx NE
replaces xxx NE
calcium xxx NE
ionophore xxx NE
in xx NE
synergy xxx NE
with xxx NE
PMA XXX NE
to xx NE
induce xxx NE
expression xxx NE
of xx NE
endogenous xxx NE
GM-CSF XX-XXX protein
and xxx NE
IL-2 XX-d protein
. . NE

By Xx NE
multimerizing xxx NE
the xxx NE
regulatory xxx DNA_B
elements xxx DNA_E
of xx NE
the xxx NE
GM-CSF XX-XXX DNA_B
promoter xxx DNA_E
, , NE
we xx NE
found xxx NE
that xxx NE
one xxx NE
of xx NE
the xxx NE
target xxx DNA_B
sites xxx DNA_E
for xxx NE
the xxx NE
CN XX protein
action xxx NE
is xx NE
the xxx NE
conserved xxx DNA_B
lymphokine xxx DNA_M
element xxx DNA_M
0 d DNA_E
( ( NE
CLE0 XXXd DNA
) ) NE
, , NE
located xxx NE
at xx NE
positions xxx NE
between xxx NE
-54 -dd DNA_B
and xxx DNA_M
-40 -dd DNA_E
. . NE

Mobility Xxxx NE
shift xxx NE
assays xxx NE
showed xxx NE
that xxx NE
the xxx NE
CLE0 XXXd DNA
sequence xxx NE
has xxx NE
an xx NE
AP1-binding XXd-xxx DNA_B
site xxx DNA_E
and xxx NE
is xx NE
associated xxx NE
with xxx NE
an xx NE
NF-AT-like XX-XX-xxx protein_B
factor xxx protein_E
, , NE
termed xxx NE
NF- XX- NE
CLE0 XXXd NE
gamma xxx NE
. . NE

NF- XX- NE
CLE0 XXXd DNA
gamma xxx NE
binding xxx NE
is xx NE
induced xxx NE
by xx NE
PMA XXX NE
/A23187 /Xddddd NE
and xxx NE
is xx NE
inhibited xxx NE
by xx NE
treatment xxx NE
with xxx NE
CsA XxX NE
. . NE

These Xxxx NE
results xxx NE
suggest xxx NE
that xxx NE
CN XX protein
is xx NE
involved xxx NE
in xx NE
the xxx NE
coordinated xxx NE
induction xxx NE
of xx NE
the xxx NE
GM-CSF XX-XXX DNA_B
gene xxx DNA_M
and xxx DNA_M
IL-2 XX-d DNA_M
gene xxx DNA_E
GM-CSF XX-XXX DNA
CLE0 XXXd NE
sequence xxx DNA
of xx NE
the xxx NE
GM-CSF XX-XXX NE
gene xxx NE
is xx NE
a x NE
functional xxx NE
analogue xxx NE
of xx NE
the xxx NE
NF-AT-binding XX-XX-xxx DNA_B
site xxx DNA_E
in xx NE
the xxx NE
IL-2 XX-d DNA_B
promoter xxx DNA_E
, , NE
which xxx NE
mediates xxx NE
signals xxx NE
downstream xxx NE
of xx NE
T X NE
cell xxx NE
activation xxx NE
. . NE

Alternate Xxxx NE
immune xxx NE
system xxx NE
targets xxx NE
for xxx NE
TCDD XXXX NE
: : NE
lymphocyte xxx cell_type_B
stem xxx cell_type_M
cells xxx cell_type_E
and xxx NE
extrathymic xxx NE
T-cell X-xxx NE
development xxx NE
. . NE

We Xx NE
here xxx NE
summarize xxx NE
evidence xxx NE
that xxx NE
thymic xxx NE
atrophy xxx NE
induced xxx NE
by xx NE
2,3,7,8-tetrachlorodibenzo-p-dioxin d,d,d,d-xxx-x-xxx NE
( ( NE
TCDD XXXX NE
) ) NE
can xxx NE
be xx NE
mediated xxx NE
, , NE
at xx NE
least xxx NE
in xx NE
part xxx NE
, , NE
by xx NE
damage xxx NE
to xx NE
extrathymic xxx cell_type_B
T-cell X-xxx cell_type_M
precursors xxx cell_type_E
in xx NE
bone xxx NE
marrow xxx NE
and xxx NE
fetal xxx NE
liver xxx NE
. . NE

This Xxxx NE
atrophy xxx NE
induction xxx NE
does xxx NE
not xxx NE
involve xxx NE
apoptotic xxx NE
mechanisms xxx NE
in xx NE
thymocytes xxx cell_type
affected xxx NE
by xx NE
the xxx NE
bcl-2 xxx-d DNA_B
proto-oncogene xxx-xxx DNA_E
. . NE

TCDD XXXX NE
mediates xxx NE
atrophy xxx NE
induction xxx NE
through xxx NE
its xxx NE
specific xxx NE
receptor xxx NE
(the (xxx NE
AhR XxX protein
) ) NE
and xxx NE
not xxx NE
through xxx NE
effects xxx NE
on xx NE
the xxx NE
estrogen xxx NE
receptor xxx NE
. . NE

Both Xxxx NE
TCDD XXXX NE
and xxx NE
estradiol xxx NE
induce xxx NE
extrathymic xxx NE
T-cell X-xxx NE
differentiation xxx NE
in xx NE
the xxx NE
liver xxx NE
. . NE

These Xxxx NE
extrathymic xxx cell_type_B
T-cell X-xxx cell_type_M
populations xxx cell_type_E
include xxx NE
cells xxx NE
expressing xxx NE
elevated xxx NE
levels xxx NE
of xx NE
V X protein_B
beta xxx protein_M
T-cell X-xxx protein_M
receptors xxx protein_E
that xxx NE
are xxx NE
normally xxx NE
deleted xxx NE
in xx NE
thymic xxx NE
development xxx NE
. . NE

Identification Xxxx NE
of xx NE
Bcd Xxx DNA
, , NE
a x NE
novel xxx NE
proto-oncogene xxx-xxx DNA
expressed xxx NE
in xx NE
B-cells X-xxx cell_type
. . NE

A X NE
novel xxx cell_type_B
B-cell X-xxx cell_type_E
derived xxx NE
( ( NE
Bcd Xxx DNA
) ) NE
oncogene xxx DNA
has xxx NE
been xxx NE
isolated xxx NE
from xxx NE
the xxx NE
peripheral xxx NE
blood xxx NE
lymphocytes xxx NE
of xx NE
one xxx NE
B-cell X-xxx NE
chronic xxx NE
lymphocytic xxx NE
leukemia xxx NE
( ( NE
B-CLL X-XXX NE
) ) NE
patient xxx NE
using xxx NE
DNA XXX NE
transfer xxx NE
and xxx NE
a x NE
mouse xxx NE
tumorigenicity xxx NE
assay xxx NE
. . NE

The Xxx NE
Bcd Xxx DNA
proto-oncogene xxx-xxx DNA
was xxx NE
activated xxx NE
by xx NE
a x NE
truncation xxx NE
in xx NE
the xxx NE
5' d' DNA_B
UTR XXX DNA_E
. . NE

It Xx NE
predicts xxx NE
for xxx NE
two xxx NE
open xxx DNA_B
reading xxx DNA_M
frames xxx DNA_E
( ( NE
ORFs XXXx DNA
) ) NE
. . NE

ORF1 XXXd DNA
consists xxx NE
of xx NE
240 ddd NE
bp xx NE
that xxx NE
would xxx NE
encode xxx NE
80 dd NE
amino xxx NE
acids xxx NE
, , NE
while xxx NE
the xxx NE
major xxx DNA_B
ORF2 XXXd DNA_E
consists xxx NE
of xx NE
648 ddd NE
bp xx NE
capable xxx NE
of xx NE
coding xxx NE
for xxx NE
216 ddd NE
amino xxx NE
acids xxx NE
. . NE

Predicted Xxxx protein_B
peptide xxx protein_M
sequence xxx protein_E
of xx NE
ORF2 XXXd DNA
contained xxx NE
a x NE
zinc xxx protein_B
finger xxx protein_M
domain xxx protein_E
which xxx NE
showed xxx NE
significant xxx NE
homology xxx NE
to xx NE
GC XX protein_B
box xxx protein_M
binding xxx protein_M
proteins xxx protein_E
BTEB2 XXXXd protein
and xxx NE
SP1 XXd protein
. . NE

Transfection Xxxx NE
of xx NE
an xx NE
expression xxx DNA_B
vector xxx DNA_E
containing xxx NE
ORF2 XXXd DNA
but xxx NE
not xxx NE
full xxx DNA_B
length xxx DNA_M
cDNA xXXX DNA_E
was xxx NE
able xxx NE
to xx NE
transform xxx NE
NIH3T3 XXXdXd cell_line_B
cells xxx cell_line_E
and xxx NE
induce xxx NE
tumors xxx NE
in xx NE
nude xxx NE
mice xxx NE
. . NE

Bcd Xxx RNA_B
mRNA xXXX RNA_M
transcripts xxx RNA_E
of xx NE
< < NE
or xx NE
= = NE
2.6 d.d NE
kb xx NE
were xxx NE
selectively xxx NE
expressed xxx NE
in xx NE
PBL XXX cell_line
and xxx NE
testis xxx NE
of xx NE
healthy xxx NE
individuals xxx NE
. . NE

Within Xxxx NE
the xxx NE
PBL XXX cell_type
, , NE
Bcd Xxx NE
gene xxx NE
expression xxx NE
was xxx NE
restricted xxx NE
to xx NE
CD19+ XXdd+ cell_type_B
B-cells X-xxx cell_type_E
and xxx NE
absent xxx NE
from xxx NE
CD14+ XXdd+ cell_type_B
monocytes xxx cell_type_E
and xxx NE
T-cells X-xxx cell_type
. . NE

Bcd Xxx DNA
transcripts xxx NE
were xxx NE
detected xxx NE
in xx NE
all xxx NE
normal xxx NE
PBL XXX cell_type
samples xxx NE
tested xxx NE
but xxx NE
not xxx NE
in xx NE
several xxx NE
malignant xxx cell_line_B
human xxx cell_line_M
B-cell X-xxx cell_line_M
lines xxx cell_line_E
and xxx NE
not xxx NE
in xx NE
50% dd% NE
of xx NE
B-cells X-xxx cell_type
from xxx NE
B-CLL X-XXX NE
patients xxx NE
. . NE

However Xxxx NE
, , NE
stimulation xxx NE
of xx NE
B-cells X-xxx cell_type
from xxx NE
B-CLL X-XXX NE
patients xxx NE
under xxx NE
conditions xxx NE
which xxx NE
induced xxx NE
differentiation xxx NE
into xxx NE
plasma xxx cell_type_B
cells xxx cell_type_E
was xxx NE
associated xxx NE
with xxx NE
induction xxx NE
of xx NE
Bcd Xxx NE
gene xxx NE
expression xxx NE
. . NE

The Xxx NE
Bcd Xxx DNA_B
gene xxx DNA_E
may xxx NE
therefore xxx NE
play xxx NE
an xx NE
important xxx NE
role xxx NE
in xx NE
B-cell X-xxx NE
growth xxx NE
and xxx NE
B-cell X-xxx NE
development xxx NE

A X NE
novel xxx DNA_B
SP-1 XX-d DNA_M
site xxx DNA_E
in xx NE
the xxx NE
human xxx DNA_B
interleukin-1 xxx-d DNA_M
beta xxx DNA_M
promoter xxx DNA_E
confers xxx NE
preferential xxx NE
transcriptional xxx NE
activity xxx NE
in xx NE
keratinocytes xxx cell_type
. . NE

To Xx NE
investigate xxx NE
the xxx NE
mechanisms xxx NE
of xx NE
transcriptional xxx NE
activation xxx NE
of xx NE
interleukin-1beta xxx-dxxx protein
( ( NE
IL-1beta XX-dxxx protein
) ) NE
in xx NE
non-monocytic xxx-xxx NE
cells xxx NE
, , NE
we xx NE
constructed xxx NE
a x NE
series xxx NE
of xx NE
reporter xxx NE
plasmids xxx NE
with xxx NE
the xxx NE
bacterial xxx NE
chloramphenicol xxx NE
acetyltransferase xxx NE
gene xxx NE
linked xxx NE
to xx NE
various xxx NE
parts xxx NE
of xx NE
the xxx NE
human xxx DNA_B
IL-1beta XX-dxxx DNA_M
promoter xxx DNA_E
and xxx NE
performed xxx NE
transient xxx NE
transfection xxx NE
experiments xxx NE
. . NE

We Xx NE
identified xxx NE
a x NE
promoter xxx NE
segment xxx NE
that xxx NE
activates xxx NE
transcription xxx NE
most xxx NE
efficiently xxx NE
in xx NE
keratinocytes xxx cell_type
. . NE

Electrophoretic Xxxx NE
mobility xxx NE
shift xxx NE
assays xxx NE
( ( NE
EMSA XXXX NE
) ) NE
with xxx NE
a x NE
43-mer dd-xxx DNA_B
oligonucleotide xxx DNA_E
derived xxx NE
from xxx NE
the xxx NE
functionally xxx NE
identified xxx NE
cis-acting xxx-xxx DNA_B
element xxx DNA_E
revealed xxx NE
specific xxx NE
complexes xxx NE
. . NE

By Xx NE
competition xxx NE
analysis xxx NE
with xxx NE
transcription xxx DNA_B
factor xxx DNA_M
consensus xxx DNA_M
sequence xxx DNA_M
oligonucleotides xxx DNA_E
and xxx NE
by xx NE
immunosupershift xxx NE
, , NE
transcription xxx protein_B
factor xxx protein_M
SP-1 XX-d protein_E
or xx NE
a x NE
closely xxx NE
related xxx NE
protein xxx NE
was xxx NE
shown xxx NE
to xx NE
bind xxx NE
to xx NE
this xxx NE
regulatory xxx DNA_B
element xxx DNA_E
. . NE

The Xxx NE
closest xxx NE
match xxx NE
to xx NE
the xxx NE
known xxx NE
SP-1 XX-d DNA_B
consensus xxx DNA_M
sequence xxx DNA_E
within xxx NE
the xxx NE
respective xxx NE
region xxx NE
is xx NE
a x NE
TCCCCTCCCCT XXXXXXXXXXX DNA_B
motif xxx DNA_E
. . NE

Mutation Xxxx NE
of xx NE
this xxx NE
motif xxx NE
almost xxx NE
completely xxx NE
, , NE
and xxx NE
specifically xxx NE
, , NE
abolished xxx NE
the xxx NE
binding xxx NE
of xx NE
two xxx NE
low-mobility xxx-xxx NE
complexes xxx NE
and xxx NE
led xxx NE
to xx NE
a x NE
95% dd% NE
decrease xxx NE
of xx NE
constitutive xxx NE
transcriptional xxx NE
activation xxx NE
of xx NE
a x NE
reporter xxx NE
construct xxx NE
IL-1beta XX-dxxx NE
(-170/+108) (-ddd/+ddd) NE
. . NE

Likewise Xxxx NE
, , NE
activation xxx NE
of xx NE
this xxx NE
reporter xxx NE
construct xxx NE
by xx NE
tumor xxx protein_B
necrosis xxx protein_M
factor-alpha xxx-xxx protein_E
depended xxx NE
on xx NE
the xxx NE
SP-1 XX-d DNA_B
site xxx DNA_E
. . NE

These Xxxx NE
observations xxx NE
suggest xxx NE
that xxx NE
a x NE
so-far-unrecognized xx-xxx-xxx NE
SP-1 XX-d DNA_B
site xxx DNA_E
in xx NE
the xxx NE
human xxx DNA_B
IL-1beta XX-dxxx DNA_M
promoter xxx DNA_E
may xxx NE
participate xxx NE
in xx NE
the xxx NE
transcriptional xxx NE
regulation xxx NE
of xx NE
this xxx NE
gene xxx NE
in xx NE
keratinocytes xxx cell_type
. . NE

Expression Xxxx NE
of xx NE
Egr-1 Xxx-d protein
correlates xxx NE
with xxx NE
the xxx NE
transformed xxx NE
phenotype xxx NE
and xxx NE
the xxx NE
type xxx NE
of xx NE
viral xxx NE
latency xxx NE
in xx NE
EBV XXX cell_line_B
genome xxx cell_line_M
positive xxx cell_line_M
lymphoid xxx cell_line_M
cell xxx cell_line_M
lines xxx cell_line_E
. . NE

In Xx NE
this xxx NE
paper xxx NE
we xx NE
have xxx NE
investigated xxx NE
the xxx NE
role xxx NE
of xx NE
Egr-1 Xxx-d protein
in xx NE
B X NE
cell xxx NE
growth xxx NE
regulation xxx NE
by xx NE
examining xxx NE
the xxx NE
gene xxx NE
expression xxx NE
in xx NE
a x NE
panel xxx NE
of xx NE
B X cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
, , NE
including xxx NE
both xxx NE
EBV XXX DNA_B
genome xxx DNA_E
negative xxx NE
and xxx NE
EBV XXX cell_line_B
carrying xxx cell_line_M
cell xxx cell_line_M
lines xxx cell_line_E
. . NE

Egr-1 Xxx-d protein
expression xxx NE
correlates xxx NE
with xxx NE
the xxx NE
cellular xxx NE
phenotype xxx NE
and xxx NE
the xxx NE
specific xxx NE
pattern xxx NE
of xx NE
viral xxx NE
latency xxx NE
established xxx NE
within xxx NE
the xxx NE
individual xxx cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
. . NE

Thus Xxxx NE
, , NE
constitutive xxx NE
activation xxx NE
of xx NE
Egr-1 Xxx-d protein
gene xxx NE
is xx NE
invariably xxx NE
associated xxx NE
with xxx NE
unrestricted xxx NE
expression xxx NE
of xx NE
viral xxx NE
latent xxx NE
genes xxx NE
in xx NE
all xxx NE
group xxx cell_line_B
III XXX cell_line_M
EBV XXX cell_line_M
genome xxx cell_line_M
carrying xxx cell_line_M
cell xxx cell_line_M
lines xxx cell_line_E
. . NE

In Xx NE
contrast xxx NE
, , NE
Egr-1 Xxx-d NE
expression xxx NE
is xx NE
abrogated xxx NE
in xx NE
group xxx cell_line_B
I X cell_line_M
Burkitt Xxxx cell_line_M
tumor xxx cell_line_M
cells xxx cell_line_E
, , NE
irrespective xxx NE
of xx NE
the xxx NE
EBV XXX DNA_B
genome xxx DNA_E
carrying xxx NE
status xxx NE
. . NE

Activated Xxxx NE
viral xxx NE
gene xxx NE
expression xxx NE
associated xxx NE
with xxx NE
phenotypic xxx NE
conversion xxx NE
of xx NE
group xxx cell_line_B
I X cell_line_M
cell xxx cell_line_M
lines xxx cell_line_E
in xx NE
to xx NE
group xxx cell_line_B
II XX cell_line_E
or xx NE
III XXX NE
restores xxx NE
the xxx NE
Egr-1 Xxx-d NE
gene xxx NE
expression xxx NE
. . NE

Several Xxxx NE
forms xxx NE
of xx NE
EGR-1 XXX-d protein_B
protein xxx protein_E
are xxx NE
found xxx NE
within xxx NE
the xxx NE
different xxx NE
groups xxx NE
of xx NE
cell xxx NE
lines xxx NE
, , NE
and xxx NE
the xxx NE
binding xxx NE
activity xxx NE
to xx NE
DNA XXX DNA_B
consensus xxx DNA_M
sequences xxx DNA_E
was xxx NE
investigated xxx NE
. . NE

Finally Xxxx NE
, , NE
time xxx NE
course xxx NE
analysis xxx NE
of xx NE
Egr-1 Xxx-d NE
expression xxx NE
during xxx NE
the xxx NE
early xxx NE
steps xxx NE
of xx NE
EBV XXX NE
infection xxx NE
in xx NE
vitro xxx NE
demonstrated xxx NE
that xxx NE
Egr-1 Xxx-d protein
is xx NE
upregulated xxx NE
within xxx NE
minutes xxx NE
from xxx NE
the xxx NE
initial xxx NE
interaction xxx NE
with xxx NE
the xxx NE
B X cell_type_B
lymphocyte xxx cell_type_E
. . NE

Expression Xxxx NE
of xx NE
erythroid-specific xxx-xxx DNA_B
genes xxx DNA_E
in xx NE
megakaryoblastic xxx NE
disorders xxx NE
. . NE

Currently Xxxx NE
available xxx NE
data xxx NE
indicate xxx NE
that xxx NE
erythroid xxx NE
differentiation xxx NE
pathway xxx NE
and xxx NE
megakaryocytic xxx NE
differentiation xxx NE
pathway xxx NE
progenitor xxx NE
cells xxx NE
common xxx NE
to xx NE
those xxx NE
two xxx NE
lineages xxx NE
may xxx NE
exist xxx NE
. . NE

Acute Xxxx NE
megakaryoblastic xxx NE
leukemia xxx NE
( ( NE
AML-M7 XXX-Xd NE
) ) NE
and xxx NE
transient xxx NE
myeloproliferative xxx NE
disorder xxx NE
in xx NE
Down's Xxxx'x NE
syndrome xxx NE
( ( NE
TMD XXX NE
) ) NE
are xxx NE
characterized xxx NE
by xx NE
rapid xxx NE
growth xxx NE
of xx NE
abnormal xxx cell_type_B
blast xxx cell_type_M
cells xxx cell_type_E
which xxx NE
express xxx NE
megakaryocytic xxx protein_B
markers xxx protein_E
. . NE

These Xxxx NE
blast xxx cell_type_B
cells xxx cell_type_E
express xxx NE
lineage-specific xxx-xxx protein_B
transcription xxx protein_M
factors xxx protein_E
such xxx NE
as xx NE
GATA-1 XXXX-d protein
common xxx NE
to xx NE
these xxx NE
lineages xxx NE
and xxx NE
frequently xxx NE
express xxx NE
erythroid-specific xxx-xxx RNA_B
mRNAs xXXXx RNA_E
such xxx NE
as xx NE
gamma-globin xxx-xxx protein
and xxx NE
erythroid xxx protein_B
delta-aminolevulinate xxx-xxx protein_M
synthase xxx protein_E
( ( NE
ALAS-E XXXX-X protein
) ) NE
, , NE
indicating xxx NE
that xxx NE
most xxx NE
of xx NE
the xxx NE
blasts xxx NE
in xx NE
M7 Xd NE
case xxx NE
and xxx NE
TMD XXX NE
case xxx NE
have xxx NE
erythroid xxx NE
phenotype xxx NE
and xxx NE
megakaryocytic xxx NE
phenotype xxx NE

These Xxxx NE
results xxx NE
suggest xxx NE
that xxx NE
blasts xxx cell_type
in xx NE
M7 Xd NE
and xxx NE
TMD XXX NE
may xxx NE
correspond xxx NE
to xx NE
progenitors xxx cell_type
of xx NE
both xxx NE
erythroid xxx cell_type_B
lineage xxx cell_type_M
and xxx cell_type_M
megakaryocytic xxx cell_type_M
lineage xxx cell_type_E

Stat3 Xxxxd protein
recruitment xxx NE
by xx NE
two xxx NE
distinct xxx NE
ligand-induced, xxx-xxx, protein_B
tyrosine-phosphorylated xxx-xxx protein_M
docking xxx protein_M
sites xxx protein_E
in xx NE
the xxx NE
interleukin-10 xxx-dd protein_B
receptor xxx protein_M
intracellular xxx protein_M
domain xxx protein_E
. . NE

Recent Xxxx NE
work xxx NE
has xxx NE
shown xxx NE
that xxx NE
IL-10 XX-dd protein
induces xxx NE
activation xxx NE
of xx NE
the xxx NE
JAK XXX NE
-STAT -XXXX NE
signaling xxx NE
pathway xxx NE
. . NE

To Xx NE
define xxx NE
the xxx NE
mechanism xxx NE
underlying xxx NE
signal xxx protein_B
transducer xxx protein_M
and xxx protein_M
activator xxx protein_M
of xx protein_M
transcription xxx protein_M
(STAT) (XXXX) protein_M
protein xxx protein_E
recruitment xxx NE
to xx NE
the xxx NE
interleukin xxx NE
10 dd NE
( ( NE
IL-10 XX-dd NE
) ) NE
receptor xxx NE
, , NE
the xxx NE
STAT XXXX NE
proteins xxx NE
activated xxx NE
by xx NE
IL-10 XX-dd NE
in xx NE
different xxx NE
cell xxx NE
populations xxx NE
were xxx NE
first xxx NE
defined xxx NE
using xxx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assays xxx NE
. . NE

In Xx NE
all xxx NE
cells xxx NE
tested xxx NE
, , NE
IL-10 XX-dd protein
activated xxx NE
Stat1 Xxxxd protein
and xxx NE
Stat3 Xxxxd protein
and xxx NE
induced xxx NE
the xxx NE
formation xxx NE
of xx NE
three xxx NE
distinct xxx NE
DNA XXX NE
binding xxx NE
complexes xxx NE
that xxx NE
contained xxx NE
different xxx NE
combinations xxx NE
of xx NE
these xxx NE
two xxx NE
transcription xxx NE
factors xxx NE
. . NE

IL-10 XX-dd protein
also xxx NE
activated xxx NE
Stat5 Xxxxd protein
in xx NE
Ba/F3 Xx/Xd cell_line_B
cells xxx cell_line_E
that xxx NE
stably xxx NE
expressed xxx NE
the xxx NE
murine xxx NE
IL-10 XX-dd protein_B
receptor xxx protein_E
. . NE

Using Xxxx NE
a x NE
structure-function xxx-xxx NE
mutagenesis xxx NE
approach xxx NE
, , NE
two xxx NE
tyrosine xxx NE
residues xxx NE
( ( NE
Tyr427 Xxxddd NE
and xxx NE
Tyr477 Xxxddd NE
) ) NE
in xx NE
the xxx NE
intracellular xxx protein_B
domain xxx protein_E
of xx NE
the xxx NE
murine xxx NE
IL-10 XX-dd protein
receptor xxx NE
were xxx NE
found xxx NE
to xx NE
be xx NE
redundantly xxx NE
required xxx NE
for xxx NE
receptor xxx NE
function xxx NE
and xxx NE
for xxx NE
activation xxx NE
of xx NE
Stat3 Xxxxd protein
but xxx NE
not xxx NE
for xxx NE
Stat1 Xxxxd protein
or xx NE
Stat5 Xxxxd protein
. . NE

Twelve Xxxx NE
amino xxx NE
acid xxx NE
peptides xxx NE
encompassing xxx NE
either xxx NE
of xx NE
these xxx NE
two xxx NE
tyrosine xxx NE
residues xxx NE
in xx NE
phosphorylated xxx protein_B
form xxx protein_E
coprecipitated xxx NE
Stat3 Xxxxd protein
but xxx NE
not xxx NE
Stat1 Xxxxd protein
and xxx NE
blocked xxx NE
IL-10 XX-dd NE
-induced -xxx NE
Stat3 Xxxxd NE
phosphorylation xxx NE
in xx NE
a x NE
cell-free xxx-xxx NE
system xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
tyrosine-phosphorylated xxx-xxx NE
peptides xxx NE
containing xxx NE
Tyr374 Xxxddd NE
or xx NE
Tyr396 Xxxddd NE
did xxx NE
not xxx NE
interact xxx NE
with xxx NE
Stat3 Xxxxd protein
or xx NE
block xxx NE
Stat3 Xxxxd protein
activation xxx NE
. . NE

These Xxxx NE
data xxx NE
demonstrate xxx NE
that xxx NE
Stat3 Xxxxd protein
but xxx NE
not xxx NE
Stat1 Xxxxd protein
or xx NE
Stat5 Xxxxd protein
is xx NE
directly xxx NE
recruited xxx NE
to xx NE
the xxx NE
ligand-activated xxx-xxx protein_B
IL-10 XX-dd protein_M
receptor xxx protein_E
by xx NE
binding xxx NE
to xx NE
specific xxx NE
but xxx NE
redundant xxx NE
receptor xxx protein_B
intracellular xxx protein_M
domain xxx protein_M
sequences xxx protein_E
containing xxx NE
phosphotyrosine xxx NE
. . NE

This Xxxx NE
study xxx NE
thus xxx NE
supports xxx NE
the xxx NE
concept xxx NE
that xxx NE
utilization xxx NE
of xx NE
distinct xxx NE
STAT XXXX protein_B
proteins xxx protein_E
by xx NE
different xxx NE
cytokine xxx protein_B
receptors xxx protein_E
is xx NE
dependent xxx NE
on xx NE
the xxx NE
expression xxx NE
of xx NE
particular xxx NE
ligand-activatable xxx-xxx NE
, , NE
tyrosine-containing xxx-xxx protein_B
STAT XXXX protein_M
docking xxx protein_M
sites xxx protein_E
in xx NE
receptor xxx protein_B
intracellular xxx protein_M
domains xxx protein_E
. . NE

Silencing Xxxx NE
of xx NE
human xxx NE
fetal xxx NE
globin xxx NE
expression xxx NE
is xx NE
impaired xxx NE
in xx NE
the xxx NE
absence xxx NE
of xx NE
the xxx NE
adult xxx protein_B
beta-globin xxx-xxx protein_M
gene xxx protein_M
activator xxx protein_M
protein xxx protein_E
EKLF XXXX protein
. . NE

Globin Xxxx DNA_B
genes xxx DNA_E
are xxx NE
subject xxx NE
to xx NE
tissue-specific xxx-xxx NE
regulation xxx NE
and xxx NE
developmental xxx NE
stage-specific xxx-xxx NE
regulation xxx NE

A X NE
switch xxx NE
from xxx NE
human xxx NE
fetal xxx NE
(gamma) (xxx) NE
-to -xx NE
adult xxx NE
(beta)-globin (xxx)-xxx NE
expression xxx NE
occurs xxx NE
within xxx NE
erythroid xxx NE
precursor xxx NE
cells xxx NE
of xx NE
the xxx NE
adult xxx NE
lineage xxx NE
. . NE

Previously Xxxx NE
we xx NE
and xxx NE
others xxx NE
showed xxx NE
by xx NE
targeted xxx NE
gene xxx NE
disruption xxx NE
that xxx NE
the xxx NE
zinc xxx DNA_B
finger xxx DNA_M
gene xxx DNA_E
, , NE
erythroid xxx protein_B
Kruppel-like Xxxx-xxx protein_M
factor xxx protein_E
( ( NE
EKLF XXXX protein
) ) NE
, , NE
is xx NE
required xxx NE
for xxx NE
expression xxx NE
of xx NE
the xxx NE
beta-globin xxx-xxx DNA_B
gene xxx DNA_E
in xx NE
mice xxx NE
, , NE
presumably xxx NE
through xxx NE
interaction xxx NE
with xxx NE
a x NE
high-affinity xxx-xxx NE
binding xxx NE
site xxx NE
in xx NE
the xxx NE
proximal xxx NE
promoter xxx NE
. . NE

To Xx NE
examine xxx NE
the xxx NE
role xxx NE
of xx NE
EKLF XXXX protein
in xx NE
the xxx NE
developmental xxx NE
regulation xxx NE
of xx NE
the xxx NE
human xxx DNA_B
gamma-globin xxx-xxx DNA_M
gene xxx DNA_E
we xx NE
interbred xxx NE
EKLF XXXX protein_B
heterozygotes xxx protein_E
(+/-) (+/-) NE
with xxx NE
mice xxx NE
harboring xxx NE
a x NE
human xxx NE
beta-globin xxx-xxx NE
yeast xxx NE
artificial xxx NE
chromosome xxx NE
transgene xxx NE
. . NE

We Xx NE
find xxx NE
that xxx NE
in xx NE
the xxx NE
absence xxx NE
of xx NE
EKLF XXXX protein
, , NE
while xxx NE
human xxx NE
beta-globin xxx-xxx NE
expression xxx NE
is xx NE
dramatically xxx NE
reduced xxx NE
, , NE
gamma-globin xxx-xxx RNA_B
transcripts xxx RNA_E
are xxx NE
elevated xxx NE
approximately xxx NE
5-fold d-xxx NE
. . NE

Impaired Xxxx NE
silencing xxx NE
of xx NE
gamma-globin xxx-xxx NE
expression xxx NE
identifies xxx NE
EKLF XXXX protein
as xx NE
the xxx NE
first xxx NE
transcription xxx protein_B
factor xxx protein_E
participating xxx NE
quantitatively xxx NE
in xx NE
the xxx NE
gamma-globin xxx-xxx NE
to xx NE
beta-globin xxx-xxx NE
switch xxx NE
. . NE

Our Xxx NE
findings xxx NE
are xxx NE
compatible xxx NE
with xxx NE
a x NE
competitive xxx NE
model xxx NE
of xx NE
switching xxx NE
in xx NE
which xxx NE
EKLF XXXX protein
mediates xxx NE
an xx NE
adult xxx NE
stage-specific xxx-xxx NE
interaction xxx NE
between xxx NE
the xxx NE
beta-globin xxx-xxx DNA_B
gene xxx DNA_M
promoter xxx DNA_E
and xxx NE
the xxx NE
locus xxx DNA_B
control xxx DNA_M
region xxx DNA_E
that xxx NE
excludes xxx NE
the xxx NE
gamma-globin xxx-xxx DNA_B
gene xxx DNA_E
. . NE

Stimulation Xxxx NE
of xx NE
human xxx cell_type_B
peripheral xxx cell_type_M
blood xxx cell_type_M
mononuclear xxx cell_type_M
cells xxx cell_type_E
by xx NE
zinc xxx NE
and xxx NE
related xxx NE
cations xxx NE
. . NE

Zinc Xxxx NE
is xx NE
an xx NE
important xxx NE
trace xxx NE
element xxx NE
for xxx NE
immune xxx NE
function xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
show xxx NE
that xxx NE
zinc xxx NE
addition xxx NE
in xx NE
a x NE
serum- xxx- NE
and xxx NE
lipopolysaccharide-free xxx-xxx NE
cell xxx NE
culture xxx NE
system xxx NE
leads xxx NE
to xx NE
significantly xxx NE
enhanced xxx NE
levels xxx NE
of xx NE
interleukin xxx protein_B
1 d protein_M
beta xxx protein_E
( ( NE
IL-1 XX-d protein_B
beta xxx protein_E
) ) NE
and xxx NE
tumour xxx protein_B
necrosis xxx protein_M
factor xxx protein_M
alpha xxx protein_E
( ( NE
TNF-alpha XXX-xxx protein
) ) NE
and xxx NE
to xx NE
expression xxx NE
of xx NE
the xxx NE
corresponding xxx NE
mRNA xXXX RNA
in xx NE
human xxx cell_type_B
peripheral xxx cell_type_M
blood xxx cell_type_M
mononuclear xxx cell_type_M
cells xxx cell_type_E
( ( NE
PBMC XXXX cell_type
) ) NE
. . NE

Structurally Xxxx NE
related xxx NE
divalent xxx NE
cations xxx NE
like xxx NE
cobalt xxx NE
, , NE
nickel xxx NE
, , NE
and xxx NE
mercury xxx NE
also xxx NE
partially xxx NE
increase xxx NE
monokine xxx NE
secretion xxx NE
but xxx NE
to xx NE
a x NE
much xxx NE
lower xxx NE
and xxx NE
thus xxx NE
insignificant xxx NE
extent xxx NE
. . NE

They Xxxx NE
fail xxx NE
to xx NE
induce xxx NE
mRNA xXXX RNA
of xx NE
TNF-alpha XXX-xxx protein
after xxx NE
3 d NE
h x NE
of xx NE
culture xxx NE
. . NE

Therefore Xxxx NE
, , NE
monokine xxx NE
induction xxx NE
is xx NE
a x NE
zinc xxx NE
-specific -xxx NE
effect xxx NE
influenced xxx NE
by xx NE
the xxx NE
physicochemical xxx NE
properties xxx NE
of xx NE
the xxx NE
ion xxx NE
. . NE

Confirmation Xxxx NE
of xx NE
the xxx NE
unique xxx NE
significance xxx NE
of xx NE
zinc xxx NE
for xxx NE
immune xxx NE
function xxx NE
provides xxx NE
a x NE
better xxx NE
understanding xxx NE
of xx NE
the xxx NE
mechanisms xxx NE
of xx NE
specific xxx NE
zinc xxx NE
-mediated -xxx NE
immune xxx NE
modulation xxx NE
. . NE

E3 Xd protein
, , NE
a x NE
hematopoietic-specific xxx-xxx protein_B
transcript xxx protein_E
directly xxx NE
regulated xxx NE
by xx NE
the xxx NE
retinoic xxx protein_B
acid xxx protein_M
receptor xxx protein_M
alpha xxx protein_E
. . NE

Retinoic Xxxx NE
acid xxx NE
( ( NE
RA XX NE
)-induced )-xxx NE
maturation xxx NE
mediated xxx NE
by xx NE
the xxx NE
retinoic xxx NE
acid xxx NE
receptor xxx NE
alpha xxx NE
( ( NE
RAR XXX NE
alpha xxx NE
) ) NE
has xxx NE
been xxx NE
implicated xxx NE
in xx NE
myeloid xxx NE
development xxx NE
. . NE

We Xx NE
have xxx NE
used xxx NE
differential xxx NE
hybridization xxx NE
analysis xxx NE
of xx NE
a x NE
cDNA xXXX DNA_B
library xxx DNA_E
constructed xxx NE
from xxx NE
the xxx NE
murine xxx NE
RA XX NE
-inducible -xxx NE
MPRO XXXX NE
promyelocyte xxx NE
cell xxx NE
line xxx NE
to xx NE
identify xxx NE
immediate-early xxx-xxx NE
genes xxx NE
induced xxx NE
by xx NE
RA XX NE
during xxx NE
granulocytic xxx NE
differentiation xxx NE
. . NE

E3 Xd protein
, , NE
one xxx NE
of xx NE
nine xxx NE
sequences xxx NE
identified xxx NE
, , NE
was xxx NE
upregulated xxx NE
in xx NE
an xx NE
immediate-early xxx-xxx NE
manner xxx NE
, , NE
with xxx NE
transcript xxx NE
levels xxx NE
peaking xxx NE
after xxx NE
60 dd NE
minutes xxx NE
exposure xxx NE
to xx NE
RA XX NE
. . NE

E3 Xd protein_B
transcripts xxx protein_E
were xxx NE
RA XX NE
-inducible -xxx NE
in xx NE
HL60 XXdd NE
cells xxx NE
, , NE
but xxx NE
not xxx NE
in xx NE
an xx NE
RA XX NE
-resistant -xxx NE
subclone xxx NE
, , NE
HL60R XXddX NE
, , NE
that xxx NE
harbors xxx NE
a x NE
mutated xxx NE
RAR XXX NE
alpha xxx NE
gene xxx NE
. . NE

However Xxxx NE
, , NE
when xxx NE
HL60R XXddX cell_line_B
cells xxx cell_line_E
were xxx NE
transduced xxx NE
with xxx NE
a x NE
functional xxx NE
copy xxx NE
of xx NE
the xxx NE
RAR XXX DNA_B
alpha xxx DNA_M
gene xxx DNA_E
, , NE
RA XX NE
induced xxx NE
a x NE
10-fold dd-xxx NE
increase xxx NE
in xx NE
E3 Xd NE
mRNA xXXX NE
levels xxx NE
. . NE

E3 Xd protein_B
transcripts xxx protein_E
are xxx NE
present xxx NE
in xx NE
the xxx NE
myeloid xxx cell_type_B
lineage xxx cell_type_M
and xxx cell_type_M
B-lymphoid X-xxx cell_type_M
lineage xxx cell_type_M
and xxx cell_type_M
erythroid xxx cell_type_M
lineage xxx cell_type_E
myeloid xxx cell_type
nonhematopoietic xxx NE
cells xxx NE
, , NE
and xxx NE
encode xxx NE
a x NE
highly xxx NE
hydrophobic, xxx, NE
potentially xxx NE
phosphorylated xxx NE
polypeptide xxx NE
of xx NE
unknown xxx NE
function xxx NE
with xxx NE
significant xxx NE
homology xxx NE
to xx NE
a x NE
putative xxx NE
protein xxx NE
expressed xxx NE
in xx NE
myeloid xxx NE
cells xxx NE
. . NE

The Xxx NE
murine xxx NE
E3 Xd DNA_B
promoter xxx DNA_E
harbors xxx NE
a x NE
single xxx NE
bipartite xxx DNA_B
retinoic xxx DNA_M
acid xxx DNA_M
response xxx DNA_M
element xxx DNA_E
which xxx NE
in xx NE
transient xxx NE
transfection xxx NE
assays xxx NE
conferred xxx NE
RA XX NE
sensitivity xxx NE
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
E3 Xd protein
is xx NE
a x NE
hematopoietic-specific xxx-xxx DNA_B
gene xxx DNA_E
that xxx NE
is xx NE
an xx NE
immediate xxx NE
target xxx NE
for xxx NE
the xxx NE
activated xxx NE
RAR XXX protein_B
alpha xxx protein_E
during xxx NE
myelopoiesis xxx NE
. . NE

Multifactor Xxxx NE
cis-dominant xxx-xxx NE
negative xxx NE
regulation xxx NE
of xx NE
IL-2 XX-d NE
gene xxx NE
expression xxx NE
in xx NE
anergized xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
. . NE

The Xxx NE
molecular xxx NE
mechanism xxx NE
underlying xxx NE
IL-2 XX-d NE
transcriptional xxx NE
blockade xxx NE
in xx NE
anergic xxx cell_line_B
T X cell_line_M
cell xxx cell_line_M
clones xxx cell_line_E
is xx NE
not xxx NE
fully xxx NE
understood xxx NE
. . NE

To Xx NE
examine xxx NE
whether xxx NE
an xx NE
active xxx NE
negative xxx NE
regulatory xxx NE
process xxx NE
occurs xxx NE
, , NE
we xx NE
created xxx NE
a x NE
reporter xxx DNA_B
construct xxx DNA_E
containing xxx NE
as xx NE
an xx NE
enhancer xxx DNA
four xxx NE
copies xxx NE
of xx NE
the xxx NE
NF-AT XX-XX DNA_B
site xxx DNA_E
and xxx NE
one xxx NE
copy xxx NE
of xx NE
the xxx NE
octamer xxx DNA_B
site xxx DNA_E
( ( NE
4X dX DNA_B
NF-AT-Oct XX-XX-Xxx DNA_E
) ) NE
. . NE

This Xxxx NE
construct xxx NE
was xxx NE
only xxx NE
slightly xxx NE
reduced xxx NE
(1.3-fold) (d.d-xxx) NE
in xx NE
its xxx NE
expression xxx NE
when xxx NE
stimulated xxx NE
under xxx NE
anergic xxx NE
conditions xxx NE
, , NE
while xxx NE
a x NE
whole xxx NE
mouse xxx NE
IL-2 XX-d DNA_B
enhancer xxx DNA_M
construct xxx DNA_E
showed xxx NE
a x NE
reduction xxx NE
of xx NE
4.3-fold d.d-xxx NE
. . NE

Addition Xxxx NE
of xx NE
the xxx NE
-176 -ddd DNA_B
to xx DNA_M
-96 -dd DNA_M
sequence xxx DNA_E
to xx NE
the xxx NE
4X dX DNA_B
NF-AT-Oct XX-XX-Xxx DNA_M
construct xxx DNA_E
did xxx NE
not xxx NE
impart xxx NE
the xxx NE
ability xxx NE
to xx NE
be xx NE
affected xxx NE
by xx NE
anergy xxx NE
, , NE
but xxx NE
addition xxx NE
of xx NE
the xxx NE
-236 -ddd DNA_B
to xx DNA_M
-96 -dd DNA_M
sequence xxx DNA_E
did xxx NE
, , NE
demonstrating xxx NE
that xxx NE
anergy xxx NE
is xx NE
an xx NE
active xxx NE
inhibitory xxx NE
process xxx NE
and xxx NE
that xxx NE
more xxx NE
than xxx NE
the xxx NE
presence xxx NE
of xx NE
the xxx NE
-150 -ddd DNA_B
AP-1 XX-d DNA_M
binding xxx DNA_M
site xxx DNA_E
( ( NE
-152 -ddd DNA_B
to xx DNA_M
-147 -ddd DNA_E
) ) NE
is xx NE
required xxx NE
to xx NE
mediate xxx NE
the xxx NE
effect xxx NE
. . NE

Mutational Xxxx NE
studies xxx NE
of xx NE
the xxx NE
-236 -ddd NE
to xx NE
-96 -dd NE
sequence xxx NE
indicated xxx NE
that xxx NE
the xxx NE
presence xxx NE
of xx NE
both xxx NE
the xxx NE
-130 -ddd NE
AP-1-like XX-d-xxx NE
site xxx NE
( ( NE
-187 -ddd NE
to xx NE
-181 -ddd NE
) ) NE
and xxx NE
the xxx NE
-150 -ddd NE
proximal xxx NE
AP-1 XX-d NE
site xxx NE
were xxx NE
necessary xxx NE
to xx NE
observe xxx NE
anergy xxx NE
. . NE

Because Xxxx NE
the xxx NE
-180 -ddd DNA_B
site xxx DNA_E
is xx NE
not xxx NE
required xxx NE
for xxx NE
trans-activation xxx-xxx NE
, , NE
it xx NE
was xxx NE
possible xxx NE
to xx NE
confirm xxx NE
by xx NE
mutation xxx NE
in xx NE
the xxx NE
normal xxx NE
mouse xxx DNA_B
IL-2 XX-d DNA_M
enhancer xxx DNA_E
that xxx NE
this xxx NE
site xxx NE
is xx NE
absolutely xxx NE
essential xxx NE
for xxx NE
anergy xxx NE
induction xxx NE
. . NE

The Xxx NE
simplest xxx NE
model xxx NE
to xx NE
explain xxx NE
these xxx NE
results xxx NE
is xx NE
that xxx NE
anergy xxx NE
is xx NE
mediated xxx NE
by xx NE
a x NE
complex xxx NE
of xx NE
multiple xxx NE
transcription xxx protein_B
factors xxx protein_E
that xxx NE
exert xxx NE
a x NE
cis-acting xxx-xxx NE
dominant xxx NE
negative xxx NE
regulatory xxx NE
effect xxx NE
on xx NE
the xxx NE
trans-activation xxx-xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_B
gene xxx DNA_E
. . NE

Severe Xxxx NE
combined xxx NE
immunodeficiency xxx NE
due xxx NE
to xx NE
defective xxx NE
binding xxx NE
of xx NE
the xxx NE
nuclear xxx protein_B
factor xxx protein_M
of xx protein_M
activated xxx protein_M
T X protein_M
cells xxx protein_E
in xx NE
T X cell_type_B
lymphocytes xxx cell_type_E
of xx NE
two xxx NE
male xxx NE
siblings xxx NE
. . NE

Peripheral Xxxx cell_type_B
blood xxx cell_type_M
lymphocytes xxx cell_type_E
( ( NE
PBL XXX cell_type
) ) NE
and xxx NE
alloreactive xxx cell_line_B
T X cell_line_M
cell xxx cell_line_M
lines xxx cell_line_E
of xx NE
two xxx NE
male xxx NE
infants xxx NE
born xxx NE
to xx NE
consanguinous xxx NE
parents xxx NE
and xxx NE
presenting xxx NE
with xxx NE
severe xxx NE
combined xxx NE
immunodeficiency xxx NE
( ( NE
SCID XXXX NE
) ) NE
showed xxx NE
a x NE
pronounced xxx NE
deficiency xxx NE
in xx NE
T X NE
cell xxx NE
activation xxx NE
. . NE

Although Xxxx NE
phenotypically xxx NE
normal xxx NE
, , NE
the xxx NE
proliferative xxx NE
response xxx NE
of xx NE
the xxx NE
childrens' xxx' NE
T X cell_type_B
cells xxx cell_type_E
was xxx NE
strongly xxx NE
reduced xxx NE
but xxx NE
could xxx NE
be xx NE
improved xxx NE
by xx NE
the xxx NE
addition xxx NE
of xx NE
interleukin-2 xxx-d protein
( ( NE
IL-2 XX-d protein
) ) NE
. . NE

Furthermore Xxxx NE
both xxx NE
childrens' xxx' NE
T X cell_type_B
cells xxx cell_type_E
were xxx NE
unable xxx NE
to xx NE
produce xxx NE
the xxx NE
cytokines xxx protein
IL-2 XX-d protein
, , NE
interferon-gamma xxx-xxx protein
( ( NE
IFN-gamma XXX-xxx protein
) ) NE
, , NE
IL-4 XX-d protein
and xxx NE
tumor xxx protein_B
necrosis xxx protein_M
factor-alpha xxx-xxx protein_E
( ( NE
TNF-alpha XXX-xxx protein
) ) NE
. . NE

This Xxxx NE
multiple xxx NE
cytokine xxx NE
production xxx NE
deficiency xxx NE
could xxx NE
not xxx NE
be xx NE
restored xxx NE
by xx NE
IL-2 XX-d protein
or xx NE
co-stimulatory xx-xxx NE
signals xxx NE
provided xxx NE
by xx NE
antigen-presenting xxx-xxx cell_type_B
cells xxx cell_type_E
( ( NE
APC XXX cell_type
) ) NE
. . NE

Moreover Xxxx NE
, , NE
mRNA xXXX RNA
for xxx NE
IL-2 XX-d protein
and xxx NE
IFN-gamma XXX-xxx protein
could xxx NE
not xxx NE
be xx NE
detected xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
expression xxx NE
of xx NE
the xxx NE
activation-dependent xxx-xxx protein_B
cell xxx protein_M
surface xxx protein_M
markers xxx protein_E
CD25 XXdd protein
and xxx NE
CD69 XXdd protein
was xxx NE
within xxx NE
normal xxx NE
limits xxx NE
. . NE

To Xx NE
determine xxx NE
whether xxx NE
the xxx NE
functional xxx NE
defect xxx NE
of xx NE
the xxx NE
patients' xxx' NE
T X cell_type_B
cells xxx cell_type_E
was xxx NE
due xxx NE
to xx NE
the xxx NE
absence xxx NE
or xx NE
abnormal xxx NE
binding xxx NE
of xx NE
transcription xxx protein_B
factors xxx protein_E
involved xxx NE
in xx NE
cytokine xxx NE
gene xxx NE
expression xxx NE
, , NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assays xxx NE
were xxx NE
used xxx NE
to xx NE
examine xxx NE
the xxx NE
DNA XXX NE
binding xxx NE
of xx NE
AP-1 XX-d protein
, , NE
Oct Xxx protein
, , NE
CREB XXXX protein
, , NE
SP1 XXd protein
, , NE
NF-kappa XX-xxx protein_B
B X protein_E
and xxx NE
the xxx NE
nuclear xxx protein_B
factor xxx protein_M
of xx protein_M
activated xxx protein_M
T X protein_M
cells xxx protein_E
( ( NE
NF-AT XX-XX protein
) ) NE
to xx NE
their xxx NE
respective xxx NE
response xxx DNA_B
elements xxx DNA_E
in xx NE
the xxx NE
promoter xxx DNA
of xx NE
the xxx NE
IL-2 XX-d DNA_B
gene xxx DNA_E
. . NE

Whereas Xxxx NE
AP-1 XX-d protein
, , NE
NF-kappa XX-xxx NE
B X NE
, , NE
Oct Xxx protein
, , NE
CREB XXXX protein
and xxx NE
SP1 XXd protein
displayed xxx NE
normal xxx NE
binding xxx NE
activities xxx NE
in xx NE
nuclear xxx NE
extracts xxx NE
, , NE
the xxx NE
binding xxx NE
of xx NE
NF-AT XX-XX NE
to xx NE
its xxx NE
IL-2 XX-d NE
promoter xxx NE
response xxx NE
element xxx NE
was xxx NE
barely xxx NE
detectable xxx NE
both xxx NE
before xxx NE
and xxx NE
after xxx NE
T X NE
cell xxx NE
stimulation xxx NE
. . NE

Our Xxx NE
results xxx NE
strongly xxx NE
suggest xxx NE
that xxx NE
this xxx NE
NF-AT XX-XX NE
/DNA /XXX NE
binding xxx NE
defect xxx NE
is xx NE
responsible xxx NE
for xxx NE
the xxx NE
multiple xxx NE
cytokine xxx NE
deficiency xxx NE
and xxx NE
the xxx NE
SCID XXXX NE
phenotype xxx NE
observed xxx NE
in xx NE
the xxx NE
two xxx NE
infant xxx NE
brothers xxx NE
. . NE

oriP xxxX DNA
is xx NE
essential xxx NE
for xxx NE
EBNA XXXX NE
gene xxx NE
promoter xxx NE
activity xxx NE
in xx NE
Epstein-Barr Xxxx-Xxxx cell_line_B
virus-immortalized xxx-xxx cell_line_M
lymphoblastoid xxx cell_line_M
cell xxx cell_line_M
lines xxx cell_line_E
. . NE

During Xxxx NE
Epstein-Barr Xxxx-Xxxx NE
virus xxx NE
latent xxx NE
infection xxx NE
of xx NE
B X cell_type_B
lymphocytes xxx cell_type_E
in xx NE
vitro xxx NE
, , NE
six xxx NE
viral xxx protein_B
nuclear xxx protein_M
antigens xxx protein_E
( ( NE
EBNAs XXXXx protein
) ) NE
are xxx NE
expressed xxx NE
from xxx NE
one xxx NE
of xx NE
two xxx NE
promoters xxx DNA
, , NE
Cp Xx DNA
or xx NE
Wp Xx DNA
, , NE
whose xxx NE
activities xxx NE
are xxx NE
mutually xxx NE
exclusive xxx NE
. . NE

Upon Xxxx NE
infection xxx NE
, , NE
Wp Xx DNA
is xx NE
initially xxx NE
active xxx NE
, , NE
followed xxx NE
by xx NE
a x NE
switch xxx NE
to xx NE
Cp Xx DNA
for xxx NE
the xxx NE
duration xxx NE
of xx NE
latency xxx NE
. . NE

In Xx NE
this xxx NE
study xxx NE
, , NE
the xxx NE
region xxx NE
upstream xxx NE
of xx NE
Cp Xx DNA
was xxx NE
analyzed xxx NE
for xxx NE
the xxx NE
presence xxx NE
of xx NE
cis xxx NE
elements xxx NE
involved xxx NE
in xx NE
regulating xxx NE
the xxx NE
activities xxx NE
of xx NE
the xxx NE
EBNA XXXX DNA_B
gene xxx DNA_M
promoters xxx DNA_E
in xx NE
established xxx NE
in xx cell_line_B
vitro xxx cell_line_M
immortalized xxx cell_line_M
lymphoblastoid xxx cell_line_M
cell xxx cell_line_M
lines xxx cell_line_E
( ( NE
LCLs XXXx cell_line
) ) NE
. . NE

It Xx NE
was xxx NE
determined xxx NE
that xxx NE
oriP xxxX DNA
, , NE
the xxx NE
origin xxx NE
for xxx NE
episomal xxx NE
maintenance xxx NE
during xxx NE
latency xxx NE
, , NE
is xx NE
essential xxx NE
for xxx NE
efficient xxx NE
transcription xxx NE
initiation xxx NE
from xxx NE
either xxx NE
Cp Xx DNA
or xx NE
Wp Xx DNA
in xx NE
LCLs XXXx cell_line
, , NE
as xx NE
well xxx NE
as xx NE
in xx NE
some xxx NE
Burkitt's Xxxx'x cell_line_B
lymphoma xxx cell_line_M
cell xxx cell_line_M
lines xxx cell_line_E
. . NE

Deletion Xxxx NE
of xx NE
the xxx NE
EBNA2-dependent XXXXd-xxx DNA_B
enhancer xxx DNA_E
located xxx NE
upstream xxx NE
of xx NE
Cp Xx DNA
resulted xxx NE
in xx NE
a x NE
ca xx NE
. . NE
two- xxx- NE
to xx NE
fivefold xxx NE
reduction xxx NE
in xx NE
Cp Xx NE
activity xxx NE
in xx NE
the xxx NE
LCLs XXXx cell_line
assayed xxx NE
. . NE

More Xxxx NE
extensive xxx NE
deletion xxx NE
of xx NE
sequences xxx NE
upstream xxx NE
of xx NE
Cp Xx DNA
, , NE
including xxx NE
the xxx NE
EBNA2-dependent XXXXd-xxx DNA_B
enhancer xxx DNA_E
, , NE
resulted xxx NE
in xx NE
nearly xxx NE
complete xxx NE
loss xxx NE
of xx NE
Cp Xx NE
activity xxx NE
. . NE

This Xxxx NE
loss xxx NE
of xx NE
activity xxx NE
was xxx NE
shown xxx NE
to xx NE
correlate xxx NE
with xxx NE
deletion xxx NE
of xx NE
two xxx NE
CCAAT XXXXX NE
boxes xxx NE
, , NE
a x NE
proximal xxx NE
CCAAT XXXXX NE
box xxx NE
located xxx NE
at xx NE
bp xx NE
-61 -dd NE
to xx NE
-65 -dd NE
and xxx NE
a x NE
distal xxx NE
CCAAT XXXXX DNA_B
box xxx DNA_E
located xxx NE
at xx NE
bp xx NE
-253 -ddd NE
to xx NE
-257 -ddd NE
, , NE
upstream xxx NE
of xx NE
Cp Xx NE
. . NE

Site-directed Xxxx-xxx NE
mutagenesis xxx NE
of xx NE
these xxx NE
cis xxx DNA_B
elements xxx DNA_E
demonstrated xxx NE
that xxx NE
Cp Xx NE
activity xxx NE
is xx NE
highly xxx NE
dependent xxx NE
on xx NE
the xxx NE
presence xxx NE
of xx NE
a x NE
properly xxx NE
positioned xxx NE
CCAAT XXXXX DNA_B
box xxx DNA_E
, , NE
with xxx NE
the xxx NE
dependence xxx NE
on xx NE
the xxx NE
distal xxx DNA_B
CCAAT XXXXX DNA_M
box xxx DNA_E
apparent xxx NE
only xxx NE
when xxx NE
the xxx NE
proximal xxx DNA_B
CCAAT XXXXX DNA_M
box xxx DNA_E
was xxx NE
deleted xxx NE
or xx NE
mutated xxx NE
. . NE

Deletion Xxxx NE
of xx NE
the xxx NE
glucocorticoid xxx NE
response xxx NE
elements xxx NE
located xxx NE
at xx NE
ca. xx. DNA_B
bp xx DNA_M
-850 -ddd DNA_E
upstream xxx NE
of xx NE
Cp Xx DNA
did xxx NE
not xxx NE
result xxx NE
in xx NE
a x NE
significant xxx NE
loss xxx NE
in xx NE
activity xxx NE
. . NE

In Xx NE
general xxx NE
, , NE
deletions xxx NE
which xxx NE
diminished xxx NE
Cp Xx DNA
activity xxx NE
resulted xxx NE
in xx NE
induction xxx NE
of xx NE
Wp Xx NE
activity xxx NE
, , NE
consistent xxx NE
with xxx NE
suppression xxx NE
of xx NE
Wp Xx DNA
activity xxx NE
by xx NE
transcriptional xxx NE
interference xxx NE
from xxx NE
Cp Xx DNA
. . NE

The Xxx NE
identification xxx NE
of xx NE
oriP xxxX DNA
and xxx NE
the xxx NE
EBNA2-dependent XXXXd-xxx DNA_B
enhancer xxx DNA_E
as xx NE
the xxx NE
major xxx NE
positive xxx NE
cis xxx DNA_B
elements xxx DNA_E
involved xxx NE
in xx NE
regulating xxx NE
Cp Xx DNA
activity xxx NE
in xx NE
LCL XXX cell_line
suggests xxx NE
that xxx NE
EBNA XXXX NE
gene xxx NE
transcription xxx NE
is xx NE
largely xxx NE
autoregulated xxx NE
by xx NE
EBNA XXXX protein_B
1 d protein_E
and xxx NE
EBNA XXXX protein_B
2 d protein_E
. . NE

Protein-tyrosine Xxxx-xxx NE
kinase xxx NE
activation xxx NE
is xx NE
required xxx NE
for xxx NE
lipopolysaccharide xxx NE
induction xxx NE
of xx NE
interleukin xxx protein_B
1beta dxxx protein_E
and xxx NE
NFkappaB XXxxxX NE
activation xxx NE
, , NE
but xxx NE
not xxx NE
NFkappaB XXxxxX NE
nuclear xxx NE
translocation xxx NE
. . NE

In Xx NE
human xxx cell_type_B
monocytes xxx cell_type_E
, , NE
interleukin xxx NE
1beta dxxx NE
protein xxx NE
production xxx NE
and xxx NE
steady xxx NE
state xxx NE
mRNA xXXX NE
levels xxx NE
are xxx NE
increased xxx NE
in xx NE
response xxx NE
to xx NE
lipopolysaccharide xxx NE
, , NE
predominantly xxx NE
as xx NE
a x NE
result xxx NE
of xx NE
increased xxx NE
transcription xxx NE
of xx NE
the xxx NE
interleukin xxx protein_B
1beta dxxx protein_E
gene xxx NE
. . NE

Expression Xxxx NE
of xx NE
interleukin xxx protein_B
1beta dxxx protein_E
and xxx NE
other xxx NE
cytokines xxx protein
, , NE
such xxx NE
as xx NE
interleukin xxx protein_B
6 d protein_E
and xxx NE
tumor xxx protein_B
necrosis xxx protein_M
factor xxx protein_M
alpha xxx protein_E
, , NE
has xxx NE
been xxx NE
shown xxx NE
to xx NE
be xx NE
dependent xxx NE
on xx NE
the xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx protein_B
factor xxx protein_E
, , NE
NFkappaB XXxxxX protein
. . NE

Since Xxxx NE
recent xxx NE
studies xxx NE
have xxx NE
shown xxx NE
that xxx NE
lipopolysaccharide xxx NE
-induced -xxx NE
tyrosine xxx NE
kinase xxx NE
activation xxx NE
is xx NE
not xxx NE
required xxx NE
for xxx NE
NFkappaB XXxxxX NE
nuclear xxx NE
translocation xxx NE
, , NE
we xx NE
sought xxx NE
to xx NE
determine xxx NE
whether xxx NE
NFkappaB XXxxxX NE
translocated xxx NE
in xx NE
the xxx NE
absence xxx NE
of xx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
was xxx NE
active xxx NE
in xx NE
stimulating xxx NE
transcription xxx NE
. . NE

We Xx NE
have xxx NE
found xxx NE
that xxx NE
, , NE
in xx NE
the xxx NE
human xxx NE
pro-monocytic xxx-xxx cell_line_B
cell xxx cell_line_M
line xxx cell_line_E
, , NE
THP-1 XXX-d cell_line
, , NE
the xxx NE
lipopolysaccharide xxx NE
-induced -xxx NE
expression xxx NE
of xx NE
interleukin xxx NE
1beta dxxx NE
is xx NE
dependent xxx NE
on xx NE
tyrosine xxx NE
kinase xxx NE
activation xxx NE
. . NE

Tyrosine Xxxx NE
kinases xxx NE
are xxx NE
not xxx NE
required xxx NE
for xxx NE
lipopolysaccharide xxx NE
-mediated -xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
NFkappaB XXxxxX protein
. . NE

However Xxxx NE
, , NE
in xx NE
the xxx NE
absence xxx NE
of xx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
, , NE
the xxx NE
ability xxx NE
of xx NE
NFkappaB XXxxxX protein
to xx NE
stimulate xxx NE
transcription xxx NE
is xx NE
impaired xxx NE
. . NE

This Xxxx NE
inhibition xxx NE
of xx NE
transcription xxx NE
is xx NE
specific xxx NE
for xxx NE
NFkappaB XXxxxX protein
; ; NE
in xx NE
the xxx NE
absence xxx NE
of xx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
, , NE
AP-1 XX-d NE
-dependent -xxx NE
transcription xxx NE
is xx NE
enhanced xxx NE
. . NE

These Xxxx NE
results xxx NE
suggest xxx NE
that xxx NE
, , NE
while xxx NE
lipopolysaccharide xxx NE
-induced -xxx NE
expression xxx NE
of xx NE
inflammatory xxx NE
mediators xxx NE
requires xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
, , NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
is xx NE
not xxx NE
obligatory xxx NE
for xxx NE
lipopolysaccharide xxx NE
signal xxx NE
transduction xxx NE
. . NE

Chronic Xxxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
infection xxx NE
of xx NE
myeloid xxx cell_type_B
cells xxx cell_type_E
disrupts xxx NE
the xxx NE
autoregulatory xxx NE
control xxx NE
of xx NE
the xxx NE
NF-kappaB/Rel XX-xxxX/Xxx NE
pathway xxx NE
via xxx NE
enhanced xxx NE
IkappaBalpha XxxxXxxx NE
degradation xxx NE
. . NE

Productive Xxxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
(HIV-1) (XXX-d) NE
infection xxx NE
causes xxx NE
sustained xxx NE
NF-kappaB XX-xxxX NE
DNA-binding XXX-xxx NE
activity xxx NE
in xx NE
chronically xxx NE
infected xxx NE
monocytic xxx NE
cells xxx NE
. . NE

A X NE
direct xxx NE
temporal xxx NE
correlation xxx NE
exists xxx NE
between xxx NE
HIV XXX NE
infection xxx NE
and xxx NE
the xxx NE
appearance xxx NE
of xx NE
NF-kappaB XX-xxxX NE
DNA-binding XXX-xxx NE
activity xxx NE
in xx NE
myelomonoblastic xxx cell_line_B
PLB-985 XXX-ddd cell_line_M
cells xxx cell_line_E
. . NE

To Xx NE
examine xxx NE
the xxx NE
molecular xxx NE
basis xxx NE
of xx NE
constitutive xxx NE
NF-kappaB XX-xxxX NE
DNA-binding XXX-xxx NE
activity xxx NE
in xx NE
HIV1 XXXd cell_type_B
-infected -xxx cell_type_M
cells xxx cell_type_E
, , NE
we xx NE
analyzed xxx NE
the xxx NE
phosphorylation xxx NE
and xxx NE
turnover xxx NE
of xx NE
IkappaBalpha XxxxXxxx protein
protein xxx NE
, , NE
the xxx NE
activity xxx NE
of xx NE
the xxx NE
double-stranded xxx-xxx protein_B
RNA-dependent XXX-xxx protein_M
protein xxx protein_M
kinase xxx protein_E
( ( NE
PKR XXX protein
) ) NE
and xxx NE
the xxx NE
intracellular xxx NE
levels xxx NE
of xx NE
NF-kappaB XX-xxxX protein_B
subunits xxx protein_E
in xx NE
the xxx NE
PLB-985 XXX-ddd cell_line
and xxx NE
U937 Xddd cell_line_B
myeloid xxx cell_line_M
cell xxx cell_line_M
models xxx cell_line_E
. . NE

HIV-1 XXX-d NE
infection xxx NE
resulted xxx NE
in xx NE
constitutive xxx NE
, , NE
low-level xxx-xxx NE
expression xxx NE
of xx NE
type xxx protein_B
1 d protein_M
interferon xxx protein_E
( ( NE
IFN XXX protein
) ) NE
at xx NE
the xxx NE
mRNA xXXX NE
level xxx NE
. . NE

Constitutive Xxxx NE
PKR XXX NE
activity xxx NE
was xxx NE
also xxx NE
detected xxx NE
in xx NE
HIV-1 XXX-d NE
-infected -xxx NE
cells xxx NE
as xx NE
a x NE
result xxx NE
of xx NE
low-level xxx-xxx NE
IFN XXX NE
production xxx NE
, , NE
since xxx NE
the xxx NE
addition xxx NE
of xx NE
anti-IFN-alpha/beta xxx-XXX-xxx/xxx NE
antibody xxx NE
to xx NE
the xxx NE
cells xxx NE
decreased xxx NE
PKR XXX NE
expression xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
analysis xxx NE
of xx NE
IkappaBalpha XxxxXxxx protein
turnover xxx NE
demonstrated xxx NE
an xx NE
increased xxx NE
degradation xxx NE
of xx NE
IkappaBalpha XxxxXxxx protein
in xx NE
HIV-1 XXX-d NE
-infected -xxx NE
cells xxx NE
that xxx NE
may xxx NE
account xxx NE
for xxx NE
the xxx NE
constitutive xxx NE
DNA XXX NE
binding xxx NE
activity xxx NE
. . NE

A X NE
dramatic xxx NE
increase xxx NE
in xx NE
the xxx NE
intracellular xxx NE
levels xxx NE
of xx NE
NF-kappaB XX-xxxX protein
subunits xxx NE
c-Rel x-Xxx protein
and xxx NE
NF-kappaB2 XX-xxxXd protein_B
p100 xddd protein_E
and xxx NE
a x NE
moderate xxx NE
increase xxx NE
in xx NE
NF-kappaB2 XX-xxxXd protein_B
p52 xdd protein_E
and xxx NE
RelA(p65) XxxX(xdd) protein
were xxx NE
detected xxx NE
in xx NE
HIV-1 XXX-d NE
-infected -xxx NE
cells xxx NE
, , NE
whereas xxx NE
NF-kappaB1 XX-xxxXd NE
p105/p50 xddd/xdd NE
levels xxx NE
were xxx NE
not xxx NE
altered xxx NE
relative xxx NE
to xx NE
the xxx NE
levels xxx NE
in xx NE
uninfected xxx NE
cells xxx NE
. . NE

We Xx NE
suggest xxx NE
that xxx NE
HIV-1 XXX-d NE
infection xxx NE
of xx NE
myeloid xxx cell_type_B
cells xxx cell_type_E
induces xxx NE
IFN XXX NE
production xxx NE
and xxx NE
PKR XXX protein
activity xxx NE
, , NE
which xxx NE
in xx NE
turn xxx NE
contribute xxx NE
to xx NE
enhanced xxx NE
IkappaBalpha XxxxXxxx protein
phosphorylation xxx NE
and xxx NE
subsequent xxx NE
degradation xxx NE
. . NE

Nuclear Xxxx NE
translocation xxx NE
of xx NE
NF-kappaB XX-xxxX protein_B
subunits xxx protein_E
may xxx NE
ultimately xxx NE
increase xxx NE
the xxx NE
intracellular xxx NE
pool xxx NE
of xx NE
NF-kappaB XX-xxxX NE
/IkappaBalpha /XxxxXxxx NE
by xx NE
an xx NE
autoregulatory xxx NE
mechanism xxx NE
. . NE

Enhanced Xxxx NE
turnover xxx NE
of xx NE
IkappaBalpha XxxxXxxx protein
and xxx NE
the xxx NE
accumulation xxx NE
of xx NE
NF-kappaB XX-xxxX NE
/Rel /Xxx NE
proteins xxx NE
may xxx NE
contribute xxx NE
to xx NE
the xxx NE
chronically xxx NE
activated xxx NE
state xxx NE
of xx NE
HIV-1 XXX-d NE
-infected -xxx NE
cells xxx NE
. . NE

The Xxx NE
c-Jun x-Xxx protein_B
delta-domain xxx-xxx protein_E
inhibits xxx NE
neuroendocrine xxx NE
promoter xxx NE
activity xxx NE
in xx NE
a x NE
DNA XXX NE
sequence-specific xxx-xxx NE
manner xxx NE
and xxx NE
pituitary-specific xxx-xxx NE
manner xxx NE

The Xxx NE
transcription xxx NE
and xxx NE
transformation xxx NE
activity xxx NE
of xx NE
c-Jun x-Xxx protein
is xx NE
governed xxx NE
by xx NE
a x NE
27-amino dd-xxx protein_B
acid xxx protein_M
regulatory xxx protein_M
motif xxx protein_E
, , NE
labeled xxx NE
the xxx NE
delta-domain xxx-xxx protein
, , NE
which xxx NE
is xx NE
deleted xxx NE
in xx NE
v-Jun x-Xxx protein
. . NE

We Xx NE
have xxx NE
previously xxx NE
shown xxx NE
that xxx NE
c-Jun x-Xxx protein
is xx NE
a x NE
potent xxx NE
inhibitor xxx NE
of xx NE
the xxx NE
rat xxx NE
prolactin xxx NE
(rPRL) (xXXX) NE
promoter xxx NE
activity xxx NE
induced xxx NE
by xx NE
either xxx NE
oncogenic xxx protein_B
Ras Xxx protein_E
or xx NE
phorbol xxx NE
esters xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
have xxx NE
characterized xxx NE
the xxx NE
structural xxx NE
and xxx NE
cell-specific xxx-xxx NE
requirements xxx NE
for xxx NE
this xxx NE
c-Jun x-Xxx protein
inhibitory xxx NE
response xxx NE
, , NE
and xxx NE
we xx NE
show xxx NE
that xxx NE
this xxx NE
c-Jun x-Xxx NE
inhibitory xxx NE
response xxx NE
mapped xxx NE
to xx NE
the xxx NE
rPRL xXXX DNA_B
footprint xxx DNA_M
II XX DNA_M
repressor xxx DNA_M
site xxx DNA_E
, , NE
was xxx NE
pituitary-specific xxx-xxx NE
and xxx NE
required xxx NE
the xxx NE
c-Jun x-Xxx protein_B
delta-domain xxx-xxx protein_E
. . NE

Moreover Xxxx NE
, , NE
alteration xxx NE
of xx NE
any xxx NE
one xxx NE
of xx NE
these xxx NE
features xxx NE
(e.g. (x.x. NE
, , NE
cis-element xxx-xxx DNA
, , NE
trans-factor xxx-xxx DNA
, , NE
or xx NE
cell-specific xxx-xxx NE
background xxx NE
) ) NE
switched xxx NE
c-Jun x-Xxx protein
to xx NE
a x NE
transcriptional xxx protein_B
activator xxx protein_E
of xx NE
the xxx NE
rPRL xXXX DNA_B
promoter xxx DNA_E
. . NE

In Xx NE
HeLa XxXx cell_line_B
nonpituitary xxx cell_line_M
cells xxx cell_line_E
, , NE
c-Jun x-Xxx protein
alone xxx NE
activated xxx NE
the xxx NE
rPRL xXXX DNA_B
promoter xxx DNA_E
via xxx NE
the xxx NE
most xxx NE
proximal xxx NE
GHF-1/Pit-1 XXX-d/Xxx-d DNA_B
binding xxx DNA_M
site xxx DNA_E
, , NE
footprint xxx DNA_B
I X DNA_E
, , NE
and xxx NE
synergized xxx NE
with xxx NE
GHF-1 XXX-d protein
. . NE

Finally Xxxx NE
, , NE
recombinant xxx NE
GHF-1 XXX-d protein
interacted xxx NE
directly xxx NE
with xxx NE
c-Jun x-Xxx protein
but xxx NE
not xxx NE
c-Fos x-Xxx protein_B
proteins xxx protein_E
. . NE

These Xxxx NE
data xxx NE
provide xxx NE
important xxx NE
fundamental xxx NE
insights xxx NE
into xxx NE
the xxx NE
molecular xxx NE
mechanisms xxx NE
by xx NE
which xxx NE
the xxx NE
c-Jun x-Xxx protein_B
delta-domain xxx-xxx protein_E
functions xxx NE
as xx NE
a x NE
modulatory xxx NE
switch xxx NE
and xxx NE
further xxx NE
imply xxx NE
that xxx NE
the xxx NE
functional xxx NE
role xxx NE
of xx NE
c-Jun x-Xxx protein
is xx NE
dictated xxx NE
by xx NE
cell-specific xxx-xxx NE
influences xxx NE
and xxx NE
the xxx NE
delta-domain xxx-xxx protein_B
motif xxx protein_E
. . NE

Retinoic Xxxx NE
acid xxx NE
activates xxx NE
interferon xxx NE
regulatory xxx NE
factor-1 xxx-d NE
gene xxx NE
expression xxx NE
in xx NE
myeloid xxx cell_type_B
cells xxx cell_type_E
. . NE

All-trans-retinoic Xxx-xxx-xxx NE
acid xxx NE
( ( NE
ATRA XXXX NE
) ) NE
is xx NE
the xxx NE
drug xxx NE
of xx NE
choice xxx NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
acute xxx NE
promyelocytic xxx NE
leukemia xxx NE
( ( NE
APL XXX NE
) ) NE
. . NE

ATRA XXXX NE
induces xxx NE
both xxx NE
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
differentiation xxx NE
of xx NE
APL XXX cell_line_B
cells xxx cell_line_E
into xxx NE
mature xxx cell_type_B
granulocytes xxx cell_type_E
. . NE

However Xxxx NE
, , NE
the xxx NE
molecular xxx NE
mechanisms xxx NE
involved xxx NE
in xx NE
ATRA XXXX NE
-dependent -xxx NE
growth xxx NE
inhibition xxx NE
and xxx NE
cellular xxx NE
differentiation xxx NE
are xxx NE
not xxx NE
presently xxx NE
understood xxx NE
. . NE

The Xxx NE
NB4 XXd cell_line_B
cell xxx cell_line_M
line xxx cell_line_E
, , NE
which xxx NE
is xx NE
derived xxx NE
from xxx NE
the xxx NE
bone xxx NE
marrow xxx NE
of xx NE
a x NE
patient xxx NE
with xxx NE
APL XXX NE
during xxx NE
relapse xxx NE
, , NE
can xxx NE
be xx NE
used xxx NE
as xx NE
a x NE
model xxx NE
system xxx NE
to xx NE
study xxx NE
the xxx NE
growth xxx NE
and xxx NE
differentiation xxx NE
of xx NE
APL XXX cell_line_B
cells xxx cell_line_E
. . NE

Because Xxxx NE
interferon xxx protein_B
(IFN) (XXX) protein_M
regulatory xxx protein_M
factors xxx protein_E
( ( NE
IRF-1 XXX-d protein
and xxx NE
IRF-2 XXX-d protein
) ) NE
and xxx NE
other xxx NE
IFN-inducible XXX-xxx protein_B
gene xxx protein_M
products xxx protein_E
regulate xxx NE
cell xxx NE
growth xxx NE
, , NE
we xx NE
analyzed xxx NE
the xxx NE
effects xxx NE
of xx NE
ATRA XXXX NE
on xx NE
the xxx NE
expression xxx NE
of xx NE
these xxx NE
genes xxx NE
. . NE

